{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "b5aff476-ef0e-4f8a-b00f-2a1a79f39c25",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[FileInfo(path='dbfs:/FileStore/tables/Occupancy_Detection_Data.csv', name='Occupancy_Detection_Data.csv', size=50968, modificationTime=1709127648000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/TS021_2021_2.csv', name='TS021_2021_2.csv', size=497239, modificationTime=1710943982000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/account-models/', name='account-models/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/accounts/', name='accounts/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/activations/', name='activations/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/activations.zip', name='activations.zip', size=8411369, modificationTime=1706707428000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020/', name='clinicaltrial_2020/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1714415966000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.zip', name='clinicaltrial_2020.zip', size=10599182, modificationTime=1714411719000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021/', name='clinicaltrial_2021/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1714416256000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.zip', name='clinicaltrial_2021.zip', size=11508457, modificationTime=1714411730000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714632087000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.zip', name='clinicaltrial_2023.zip', size=57166668, modificationTime=1714411746000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood-1.zip', name='flood-1.zip', size=52053, modificationTime=1707924329000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood.csv', name='flood.csv', size=128984, modificationTime=1707924425000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood.zip', name='flood.zip', size=52053, modificationTime=1707924049000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/iotstream/', name='iotstream/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/iotstream.zip', name='iotstream.zip', size=43891, modificationTime=1708527872000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/logs/', name='logs/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/movies.csv', name='movies.csv', size=494431, modificationTime=1709732964000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/myratings_1_.csv', name='myratings_1_.csv', size=10683, modificationTime=1709733189000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma/', name='pharma/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1714415333000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma.zip', name='pharma.zip', size=109982, modificationTime=1714411917000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/ratings.csv', name='ratings.csv', size=2483723, modificationTime=1709732964000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/steam_200k.csv', name='steam_200k.csv', size=8059447, modificationTime=1713602057000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/test.json', name='test.json', size=17958, modificationTime=1706103845000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage/', name='webpage/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-1.zip', name='webpage-1.zip', size=1582, modificationTime=1707315353000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-2.zip', name='webpage-2.zip', size=1582, modificationTime=1707315630000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-3.zip', name='webpage-3.zip', size=1582, modificationTime=1707316481000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1707313841000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage_files_all/', name='webpage_files_all/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage_files_jpg/', name='webpage_files_jpg/', size=0, modificationTime=0)]"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.ls(\"/FileStore/tables\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1d502425-cc0c-40ce-af49-83edc01f9e0f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "fileroot = \"clinicaltrial_2023\"\n",
    "\n",
    "import os\n",
    "os.environ['fileroot'] = fileroot\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "ea26ae61-cf46-4b4c-85c5-330bb3b6698e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.cp(\"/FileStore/tables/\" + fileroot + \".zip\", \"file:/tmp/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "3c3c3fa6-e1e6-4120-b963-7ee9e62e5949",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Archive:  /tmp/clinicaltrial_2023.zip\n  inflating: /tmp/clinicaltrial_2023.csv  \n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "unzip -d /tmp /tmp/$fileroot.zip"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "cb9305e9-50b6-4cba-bdb1-b21f374ac83c",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rserv\nRtmp3geQ0C\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2023.csv\nclinicaltrial_2023.zip\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\npython_lsp_logs\nsystemd-private-84b1983c03394d87a86ac831aba0fc00-systemd-logind.service-HIOlWG\nsystemd-private-84b1983c03394d87a86ac831aba0fc00-systemd-resolved.service-BF0h4r\ntmp.xyzSa9H5ws\n"
     ]
    }
   ],
   "source": [
    "%sh\n",
    "ls /tmp/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "89177fe1-ce2c-4d5c-8685-25a3ea449284",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.mkdirs(\"/FileStore/tables/\" + fileroot)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "fedf78c2-938f-464d-a541-0cc4084c13be",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.mv(\"file:/tmp/\"+fileroot+\".csv\",\"/FileStore/tables/\",True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "afaf5317-fddd-4d5e-9a51-fe0518b6311f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714638714000)]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.ls(\"/FileStore/tables/\" + fileroot +\".csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "8ce34fbe-6729-4df4-af8a-909096fd3c8f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[FileInfo(path='dbfs:/FileStore/tables/Occupancy_Detection_Data.csv', name='Occupancy_Detection_Data.csv', size=50968, modificationTime=1709127648000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/TS021_2021_2.csv', name='TS021_2021_2.csv', size=497239, modificationTime=1710943982000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/account-models/', name='account-models/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/accounts/', name='accounts/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/activations/', name='activations/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/activations.zip', name='activations.zip', size=8411369, modificationTime=1706707428000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020/', name='clinicaltrial_2020/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1714415966000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.zip', name='clinicaltrial_2020.zip', size=10599182, modificationTime=1714411719000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021/', name='clinicaltrial_2021/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1714416256000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.zip', name='clinicaltrial_2021.zip', size=11508457, modificationTime=1714411730000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.csv', name='clinicaltrial_2023.csv', size=292436366, modificationTime=1714638714000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023.zip', name='clinicaltrial_2023.zip', size=57166668, modificationTime=1714411746000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood-1.zip', name='flood-1.zip', size=52053, modificationTime=1707924329000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood.csv', name='flood.csv', size=128984, modificationTime=1707924425000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/flood.zip', name='flood.zip', size=52053, modificationTime=1707924049000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/iotstream/', name='iotstream/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/iotstream.zip', name='iotstream.zip', size=43891, modificationTime=1708527872000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/logs/', name='logs/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/movies.csv', name='movies.csv', size=494431, modificationTime=1709732964000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/myratings_1_.csv', name='myratings_1_.csv', size=10683, modificationTime=1709733189000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma/', name='pharma/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1714415333000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma.zip', name='pharma.zip', size=109982, modificationTime=1714411917000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/ratings.csv', name='ratings.csv', size=2483723, modificationTime=1709732964000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/steam_200k.csv', name='steam_200k.csv', size=8059447, modificationTime=1713602057000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/test.json', name='test.json', size=17958, modificationTime=1706103845000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage/', name='webpage/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-1.zip', name='webpage-1.zip', size=1582, modificationTime=1707315353000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-2.zip', name='webpage-2.zip', size=1582, modificationTime=1707315630000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage-3.zip', name='webpage-3.zip', size=1582, modificationTime=1707316481000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1707313841000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage_files_all/', name='webpage_files_all/', size=0, modificationTime=0),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage_files_jpg/', name='webpage_files_jpg/', size=0, modificationTime=0)]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.ls(\"/FileStore/tables\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1c4f96fb-ba13-4030-b5dd-3a276b3fdbf7",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Truncated to first 65536 bytes]\n"
     ]
    },
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "'\"Id\\tStudy Title\\tAcronym\\tStatus\\tConditions\\tInterventions\\tSponsor\\tCollaborators\\tEnrollment\\tFunder Type\\tType\\tStudy Design\\tStart\\tCompletion\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03630471\\tEffectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India\\tPRIDE\\tCOMPLETED\\tMental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)\\tBEHAVIORAL: PRIDE \\'Step 1\\' problem-solving intervention|BEHAVIORAL: Enhanced usual care\\tSangath\\tHarvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine\\t250.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-08-20\\t2019-02-28\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05992571\\tOral Ketone Monoester Supplementation and Resting-state Brain Connectivity\\t\\tRECRUITING\\tCerebrovascular Function|Cognition\\tOTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB\\tMcMaster University\\tAlzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE\\t2023-10-25\\t2024-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00237471\\tImpact of Tight Glycaemic Control in Acute Myocardial Infarction\\t\\tTERMINATED\\tMyocardial Infarct|Hyperglycemia\\tDRUG: Insulin (tight blood glucose control)\\tMelbourne Health\\tNational Health and Medical Research Council\",\" Australia|Bristol-Myers Squibb\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2005-10\\t2006-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03820271\\tNew Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation\\tSUPERMELD\\tRECRUITING\\tDecompensated Cirrhosis|Liver Transplantation\\tOTHER: SuperMELD\\tAssistance Publique - Hôpitaux de Paris\\t\\t500.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-10-01\\t2023-10-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06229171\\tInTake Care: Development and Validation of an Innovative\",\" Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention\\tInTakeCare\\tNOT_YET_RECRUITING\\tHypertension|Treatment Adherence and Compliance|Digital Health\\tOTHER: adherence support system based on a vocal assistant\\tIstituto Auxologico Italiano\\tIstituti Clinici Scientifici Maugeri SpA|Politecnico di Milano\\t206.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER\\t2024-10-01\\t2026-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02945371\\tTailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life\\tREV\\tCOMPLETED\\tSmoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced\\tBEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training\\tUniversity of Oregon\\t\\t103.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2014-09\\t2016-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01055171\\tNeuromodulation of Trauma Memories in PTSD & Alcohol Dependence\\t\\tCOMPLETED\\tAlcohol Dependence|PTSD\\tDRUG: Propranolol|DRUG: Placebo\\tMedical University of South Carolina\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2010-01\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01125371\\tComputerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women\\t\\tCOMPLETED\\tAlcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection\\tBEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control\\tJohns Hopkins University\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t439.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2016-06-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02554071\\tManitoba Pharmacist Initiated Smoking Cessation Pilot Project\\t\\tCOMPLETED\\tSmoking Cessation\\tOTHER: Pharmacist - Smoking Cessation Support\\tUniversity of Manitoba\\tGovenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada\\t119.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2014-01\\t2014-11\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01772771\\tMolecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program\\t\\tRECRUITING\\tGlioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma\\tPROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review\\tM.D. Anderson Cancer Center\\tNational Cancer Institute (NCI)\\t12000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2012-03-01\\t2033-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02633371\\tA Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults\\t\\tCOMPLETED\\tHyperhidrosis\\tDRUG: Oxybutynin 3% gel\\tUniversity of Colorado\",\" Denver\\tSociety for Pediatric Dermatology\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-02\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03400371\\tBiology of Juvenile Myoclonic Epilepsy\\tBIOJUME\\tRECRUITING\\tJuvenile Myoclonic Epilepsy\\tOTHER: Blood draw|OTHER: Existing samples\\tKing\\'s College London\\tKing\\'s College Hospital NHS Trust|Charles University\",\" Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-07-13\\t2026-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00120471\\tSafety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies\\t\\tCOMPLETED\\tHIV Infections\\tDRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate\\tNational Institute of Allergy and Infectious Diseases (NIAID)\\tEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)\\t122.0\\tNIH\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2006-11\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04784871\\tPromoting Wellbeing: The Five Ways to All Intervention\\t5WaysA\\tCOMPLETED\\tWellbeing|Health Attitude|Quality of Life\\tBEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control\\tUniversity of Oslo\\tNorwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation\\t970.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2021-03-04\\t2023-02-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02383771\\tReversal of the Anti-platelet Effects of Ticagrelor\\tREVERSAL\\tCOMPLETED\\tCoronary Artery Disease\\tDRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor\\tThe First Affiliated Hospital with Nanjing Medical University\\tNational Natural Science Foundation of China\\t64.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-03\\t2016-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03269071\\tNeural Stem Cell Transplantation in Multiple Sclerosis Patients\\tSTEMS\\tCOMPLETED\\tProgressive Multiple Sclerosis\\tDRUG: human fetal-derived Neural Stem Cells (hNSCs)\\tIRCCS San Raffaele\\tFondazione Italiana Sclerosi Multipla\\t4.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT\\t2017-05-17\\t2021-07-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01659671\\tRCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea\\tSKUP3\\tCOMPLETED\\tObstructive Sleep Apnea Syndrome\\tPROCEDURE: Uvulopalatopharyngoplasty\\tKarolinska University Hospital\\tKarolinska Institutet\\t65.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-06\\t2014-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04765371\\tComparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy\",\" With CoViD-19\\tCOPreDex\\tCOMPLETED\\tCoronavirus Infection\\tDRUG: DEXAMETHASONE|DRUG: PREDNISOLONE\\tHôpital NOVO\\t\\t89.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-03-03\\t2022-05-13\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02830971\\tDeveloping a Standardized Learning Curve\\t\\tCOMPLETED\\tRegistered Nurses|Nursing Personnel|Motor Skills\\tPROCEDURE: Doing Different ICU techniques and skills\\tBaqiyatallah Medical Sciences University\\tShahid Beheshti University|Tehran University of Medical Sciences\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2016-07\\t2021-04-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00416871\\tInterleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer\\t\\tCOMPLETED\\tKidney Cancer\\tBIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa\\tCentre Leon Berard\\t\\t220.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT\\t\\t2006-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05900271\\tDutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS\\tDDOT\\tACTIVE_NOT_RECRUITING\\tTreatment Resistant Depression\\tDEVICE: rTMS|DEVICE: iTBS\\tAmsterdam UMC\",\" location VUmc\\tRadboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\\t108.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-11-15\\t2027-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02469571\\tModulation of Gut Microbiota in Early Sepsis: A Pilot Study\\tMGM-sepsis\\tCOMPLETED\\tSepsis\\tDIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo\\tMedical University of Graz\\t\\t15.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2015-09-01\\t2018-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05807971\\tAssessment of Safety\", Tolerability, Pharmacokinetics,\" and Pharmacodynamics of ATH-063 in Healthy Subjects\\t\\tRECRUITING\\tInflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases\\tDRUG: ATH-063|DRUG: Placebo\\tAthos Therapeutics Inc\\tSyneos Health|Athos Therapeutics Australia Pty Ltd\\t76.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-04-06\\t2024-02-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02083471\\tCow\\'s Milk and Hen\\'s Egg Hyposensitization in Adults\\t\\tUNKNOWN\\tEgg Allergy|Cow\\'s Milk Allergy\\tDIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow\\'s milk\\tTurku University Hospital\\t\\t40.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2015-04\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01062971\\tClinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide\\t\\tCOMPLETED\\tPrimary Open Angle Glaucoma|Ocular Hypertension\\tDRUG: dorzolamide-timolol-brimonidine\\tLaboratorios Sophia S.A de C.V.\\t\\t124.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2006-02\\t2008-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03928171\\tThe Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery\\tPERFUSION\\tCOMPLETED\\tLaparoscopic Surgery|Pneumoperitoneum\\tOTHER: Intra-abdominal pressure during laparoscopy\\tRadboud University Medical Center\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-06-13\\t2018-12-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00897871\\tEvaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer\\t\\tUNKNOWN\\tUnspecified Childhood Solid Tumor\",\" Protocol Specific\\tDRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study\\tChildren\\'s Cancer and Leukaemia Group\\t\\t60.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2007-02\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00848471\\tValidation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)\\tProtocol Quark\\tUNKNOWN\\tHealthy|Obesity\\tDEVICE: Quark RMR|DEVICE: Deltatrac II\\tHospices Civils de Lyon\\tCentre de Recherche en Nutrition Humaine Rhone-Alpe\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2009-01\\t2009-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06135571\\tStudy on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer\\t\\tRECRUITING\\tColorectal Cancer|Lymph Node Metastasis\\tPROCEDURE: Laparoscopic colorectal surgery\\tCancer Institute and Hospital\",\" Chinese Academy of Medical Sciences\\tPeking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital\\t3000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-09-01\\t2026-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01189071\\tPreoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain\\t\\tTERMINATED\\tOveractive Bladder|Renal Colic|Pain\",\" Postoperative\\tDRUG: Darifenacin\\tUniversity of Missouri-Columbia\\t\\t3.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2009-08\\t2011-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00728871\\tThe Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis\\t\\tUNKNOWN\\tCervical Cancer|Cervical Intraepithelial Neoplasia\\tPROCEDURE: peripheral blood isolation\\tNational Taiwan University Hospital\\t\\t600.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2005-12\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05592171\\tOcclusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC\\tSEASON-HCC\\tRECRUITING\\tHCC\\tPROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE\\tUniversity of Pisa\\tAzienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero\",\" Universitaria Pisana\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2022-10-17\\t2025-10-17\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00520871\\tThe Water-Blueberry Study\\t\\tCOMPLETED\\tCardiovascular Disease\\tDRUG: Blueberry juice\\tUniversity of Oslo\\tUllevaal University Hospital\\t62.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION\\t2003-03\\t2004-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05913271\\tStudy on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure\\t\\tRECRUITING\\tHeart Failure|Levosimendan|Efficacy|Safety\\t\\tYi Han\\tQianfoshan Hospital\\t352.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-05-30\\t2025-05-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04006171\\tComparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women\\tCNP\\tCOMPLETED\\tPolycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism\\tDIAGNOSTIC_TEST: C type natriuretic peptide\\tNear East University\",\" Turkey\\t\\t90.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-07-15\\t2020-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04370171\\tManagement of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic\\tTeleCoviDiab\\tCOMPLETED\\tDiabetes|Covid-19\\tOTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation\\tUniversity Hospital\", Strasbourg,\" France\\t\\t610.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-05-04\\t2020-05-29\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04340271\\tThe Clinical Utility of Extracorporeal Shock Wave Therapy on Burns\\t\\tCOMPLETED\\tBurn Scar\\tOTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy\\tHangang Sacred Heart Hospital\\t\\t48.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2020-04-15\\t2020-05-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03075371\\tHomeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa\\t\\tCOMPLETED\\tAnorexia Nervosa|Healthy\\tOTHER: Glucose|OTHER: Placebo\\tUniversity of Heidelberg Medical Center\\tGerman Research Foundation\\t85.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE\\t2014-09\\t2019-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05966571\\tOvarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)\\t\\tRECRUITING\\tPolycystic Ovary Syndrome\\tPROCEDURE: Ovary Biopsie\\tAlbanian University\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-07-01\\t2024-12-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03313271\\tChina Lymphoma Patient Registry Study\\tCLAP\\tRECRUITING\\tLymphoma\\t\\tJun Zhu\\tPeking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd\\t5000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-05-17\\t2027-08-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03490071\\tLong-term Follow up of Patients With Longstanding Hip and Groin Pain\\tLund LHGP\\tRECRUITING\\tHip Pain Chronic\\t\\tLund University\\t\\t81.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2018-01-01\\t2024-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05801471\\tClinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression\\t\\tRECRUITING\\tGlaucoma\\t\\tCentervue SpA\\t\\t200.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-05-06\\t2025-11-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00266071\\tStudy of the Cutaneous Microcirculation in Elderly People\\t\\tUNKNOWN\\tElderly People\\tBEHAVIORAL: Cutaneous response\\tUniversity Hospital\",\" Angers\\t\\t\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2005-12\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04405271\\tTAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)\\t\\tUNKNOWN\\tHealthcare Workers|COVID-19|SARS-CoV 2\\tDRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo\\tHospital Italiano de Buenos Aires\\tSociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)\\t1378.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2020-07-31\\t2020-11-15\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02121171\\tCombined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma\\t\\tUNKNOWN\\tCongenital Glaucoma\\tDEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy\\tNational Centre of Ophthalmology named after academician Zarifa Aliyeva\\tAeon Astron Europe B.V.\\t40.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2010-09\\t2015-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01068171\\tDeveloping a Diabetic Foot Ulcer Protocol\\t\\tWITHDRAWN\\tDiabetic Foot Ulcers\\tOTHER: type of footwear|OTHER: collagen dressing with and without silver\\tThe University of Texas Health Science Center\",\" Houston\\tHarris County Hospital District|Baylor College of Medicine\\t0.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2010-05\\t2012-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04875871\\tParticle-based Partial Tumor Irradiation of Unresectable Bulky Tumors\\tPARTICLE-PATHY\\tRECRUITING\\tCancer\\tRADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling\\tEBG MedAustron GmbH\\tCW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring\\t22.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-11-11\\t2024-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00553371\\tFollow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer\\t\\tUNKNOWN\\tTesticular Germ Cell Tumor\\tOTHER: biomarker analysis|PROCEDURE: computed tomography\\tRoyal Marsden NHS Foundation Trust\\t\\t300.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2006-04\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04674371\\tGerman Point Prevalence Study on CVC\\t\\tCOMPLETED\\tData Collection\\tOTHER: central venous catheter insertion\\tWolfram Schummer\", MD,\" PhD\\t\\t537.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-05-17\\t2022-05-20\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02321371\\tEffect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.\\t\\tCOMPLETED\\tAcute-On-Chronic Liver Failure\\tDRUG: Lactulose + Rifaximin|DRUG: Lactulose\\tInstitute of Liver and Biliary Sciences\",\" India\\t\\t73.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2014-10-19\\t2016-01-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02344771\\tPerioperative Endothelial Dysfunction\\t\\tCOMPLETED\\tMyocardial Injury\\tPROCEDURE: Elective colon cancer surgery\\tZealand University Hospital\\t\\t31.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2015-03\\t2015-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03354871\\tDeveloping Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables\\tIoT4Resident\\tUNKNOWN\\tFatigue\\t\\tHillel Yaffe Medical Center\\tInternational Business Machines (IBM)\\t6.0\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-11\\t2018-02-28\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02804971\\tCardiovascular Comorbidities and Bronchiectasis\\tBRONCOCA\\tACTIVE_NOT_RECRUITING\\tBronchiectasis\\t\\tCentre Hospitalier Intercommunal Creteil\\t\\t200.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2016-10-25\\t2023-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04591171\\tAssessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease\\t\\tCOMPLETED\\tHypertension|Chronic Kidney Diseases\\tPROCEDURE: n-of-1 trial guided clinical decision making\\tThe University of Texas Health Science Center\",\" Houston\\tChildren\\'s Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\\t9.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2021-01-25\\t2022-02-18\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04814771\\tMass Balance Study of TS-142 in Healthy Adult Subjects.\\t\\tCOMPLETED\\tHealthy Male Subjects\\tDRUG: [14C] TS-142\\tTaisho Pharmaceutical Co.\",\" Ltd.\\t\\t6.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2021-04-19\\t2021-05-19\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00991471\\tThe Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times\\tMDRNSTAT\\tCOMPLETED\\tEmergencies\\tBEHAVIORAL: Interaction with MDRN STAT|BEHAVIORAL: No MDRNSTAT\\tSunnybrook Health Sciences Centre\\t\\t6300.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2009-09\\t2010-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05702671\\tKenota 1 CWS Method Comparison Validation Study\\t\\tCOMPLETED\\tAllergy|Immunoglobulin E-Mediated Allergic Disorder\\tDIAGNOSTIC_TEST: Total Immunoglobulin E\",\" Obtained From Fingerstick Sample\\tKenota Inc.\\t\\t411.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-01-27\\t2023-04-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02069171\\tCross-sectional and Questionnaire Study for Leg Lymphedema\\t\\tCOMPLETED\\tGynecologic Cancer\\t\\tNational Cancer Center\",\" Korea\\t\\t333.0\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2012-06\\t2012-11\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00474071\\tOptimum Dose of Remifentanil for Intubation in Small Children\\t\\tCOMPLETED\\tEndotracheal Intubation\\tDRUG: Remifentanil\\tUniversity of British Columbia\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2007-03\\t2008-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02022371\\tProstate Cancer Genomic Heterogeneity\\tPROGENY\\tCOMPLETED\\tPROSTATE CANCER\\tPROCEDURE: Targeted biopsies of the prostate\\tUniversity College London Hospitals\\t\\t50.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2014-09\\t2016-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04585971\\tA Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of Brain Magnetic Resonance Imaging\",\" and Carotid Doppler Ultrasound\\t\\tUNKNOWN\\tCerebral Blood Flow\\tDIAGNOSTIC_TEST: Signal intensity gradient\\tChonbuk National University Hospital\\tMedi Image\",\" Inc\\t30.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-09-03\\t2021-01-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05473871\\tEnhancing Capacity in Churches to Implement PA Programs\\t\\tRECRUITING\\tCardiovascular Diseases\\tBEHAVIORAL: Faith in Action|BEHAVIORAL: Faith in Action+|BEHAVIORAL: Faith in Action++\\tSan Diego State University\\tWashington University School of Medicine|University of California\", Berkeley|University of California,\" San Diego\\t812.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2022-11-15\\t2026-10-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01523171\\tPhase II\", Open Label,\" Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib\\tJAKARTA2\\tCOMPLETED\\tHematopoietic Neoplasm\\tDRUG: SAR302503\\tSanofi\\t\\t97.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2012-04\\t2014-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00000571\\tTrial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease\\t\\tCOMPLETED\\tLung Diseases|Lung Diseases\",\" Obstructive|Chronic Obstructive Pulmonary Disease\\tDEVICE: ventilators\",\" negative pressure\\tMcGill University\\tNational Heart\", Lung,\" and Blood Institute (NHLBI)\\t\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT\\t1986-02\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01053871\\tPropofol Versus Midazolam With Fentanyl for EGD Endomicroscopy\\t\\tCOMPLETED\\tGastritis|Functional Dyspepsia\\tDRUG: propofol|DRUG: midazolam with fentanyl\\tShandong University\\t\\t104.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: \\t2010-01\\t2010-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02370771\\tProteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis\\tPASEO\\tCOMPLETED\\tErosive Hand Osteoarthritis\\tPROCEDURE: Biological sampling|DEVICE: Radiographic evaluation\\tUniversity Hospital\",\" Rouen\\t\\t32.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2015-06-09\\t2019-11-17\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05974371\\tEpisodic Memory Integration and Interference\\t\\tNOT_YET_RECRUITING\\tEpisodic Memory\\tOTHER: emotional context similarity\\tBoston College\\t\\t150.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2024-08\\t2027-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03713671\\tGait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism\\t\\tCOMPLETED\\tPrimary Hyperparathyroidism\\tDIAGNOSTIC_TEST: gait analysis\\tRecep Tayyip Erdogan University Training and Research Hospital\\tHacettepe University|Ankara Education and Research Hospital\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING\\t2021-10-17\\t2023-08-27\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02645071\\tBrief Program in Reducing Sedentary Behavior and Promoting Physical Exercise\\t\\tCOMPLETED\\tPhysical Activity\\tBEHAVIORAL: Physical Activity\\tThe University of Hong Kong\\tHong Kong Jockey Club Charities Trust\\t141.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION\\t2015-07\\t2017-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04004871\\tInduction Chemotherapy With Nab-paclitaxel\",\" Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma\\t\\tUNKNOWN\\tNasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer\\tDRUG: Nab-paclitaxel\",\" Cisplatin and Fluorouracil|RADIATION: concurrent chemoradiotherapy\\tGuangxi Medical University\\tSecond Affiliated Hospital of Guangxi Medical University|Guilin Medical University\",\" China|Liuzhou Workers Hospital|Wuzhou Red Cross Hospital\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2019-07-05\\t2022-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05953571\\tLaparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics\\t\\tCOMPLETED\\tUretro-pelvic Junction Obstruction|Poorly Function Kidney\\tPROCEDURE: Dismembered Pyeloplasty\\tAl-Azhar University\\tUniversity Hospital Fattouma Bourguiba\\t65.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-01-08\\t2023-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02570971\\tMannitol Versus Supportive Care in Ciguatera Fish Poisoning\\t\\tUNKNOWN\\tCiguatoxin\\tDRUG: Mannitol\\tUniversity of South Florida\\tFlorida Poison Control Center\\t200.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-10\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03987971\\tAcupuncture on GB26 to Treat Chronic Low Back Pain\\t\\tUNKNOWN\\tChronic Low-back Pain\\tOTHER: acupuncture\\tWenzhou Medical University\\tQingtian People\\'s hospital\\t114.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2020-01\\t2021-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01425671\\tNeural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States\\t\\tACTIVE_NOT_RECRUITING\\tSchizophrenia|Schizoaffective Disorder|Schizophreniform Disorder\\t\\tUniversity of Maryland\",\" Baltimore\\tNational Institute of Mental Health (NIMH)\\t800.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2010-11-30\\t2024-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04962971\\tComparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women\\t\\tCOMPLETED\\tRecurrent Cystitis\\tDIETARY_SUPPLEMENT: X|DIETARY_SUPPLEMENT: Y|DIETARY_SUPPLEMENT: Z\\tCEN Biotech\\tNexira|CEN Nutriment\\t216.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-09-01\\t2022-02-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02827071\\tOcular Imaging Study Using Advanced OCT\\t\\tUNKNOWN\\tRetinal Vascular Disorder|Macular Degeneration\\t\\tUniversity of California\",\" Los Angeles\\t\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2016-07\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04236271\\tTELEsurveillance of Patients in PostopErative Bridge surgeryAge CoronairE\\tTELE-PEACE\\tCOMPLETED\\tCoronary Artery Bypass\\tDEVICE: connected objects\\tAssistance Publique - Hôpitaux de Paris\\tGFI\\t33.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-03-13\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01780571\\tCPAP/PSV Preoxygenation in Obese Patients\\t\\tCOMPLETED\\tObesity|Anaesthesia\\tPROCEDURE: CPAP 5 cm H2O + PSV 5 cm H2O\\tKarolinska Institutet\\t\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2009-05\\t2012-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05078671\\tPharmacokinetic Boosting of Olaparib to Improve Exposure\",\" Tolerance and Cost-effectiveness\\tPROACTIVE\\tRECRUITING\\tCancer\\tDRUG: Olaparib|DRUG: Cobicistat\\tRadboud University Medical Center\\t\\t160.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-12-15\\t2025-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02529371\\tPre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients\\t\\tUNKNOWN\\tUrinary Incontinence\\tDEVICE: UriCap-RM\\tG.R. Dome Medical Ltd.\\t\\t30.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2015-09\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02309671\\tA Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment\\t\\tCOMPLETED\\tInfertility\\tDRUG: FE 999049|DRUG: follitropin beta\\tFerring Pharmaceuticals\\t\\t159.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2014-12\\t2016-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03876171\\tCulturally Modified Family Based Therapy for Haitian Youth in South Florida\\t\\tCOMPLETED\\tProblem Behavior\\tBEHAVIORAL: Haitian youth and family intervention study: family functioning|BEHAVIORAL: Haitian youth intervention study: youth psychoeducational|BEHAVIORAL: Haitian family intervention study: family psychoeducational|BEHAVIORAL: Diversion Programs\\tUniversity of Miami\\tNational Institute on Drug Abuse (NIDA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT\\t2019-04-01\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05031871\\tPharmacokinetics of HR17031 Injection in Healthy Subjects\\t\\tCOMPLETED\\tType 2 Diabetes Mellitus\\tDRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection\\tJiangsu HengRui Medicine Co.\",\" Ltd.\\t\\t24.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT\\t2021-09-02\\t2021-11-19\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04769271\\tIntra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis\\t\\tCOMPLETED\\tPeriodontitis\\tPROCEDURE: Scaling and Root Planing|DRUG: Scaling and Root Planing with tea tree oil\\tAlexandria University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-11-10\\t2020-08-25\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06044571\\tOptimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults\\t\\tNOT_YET_RECRUITING\\tObesity|Multiple Chronic Conditions\\tOTHER: Prescriptive|BEHAVIORAL: Behavioral\\tUniversity of North Carolina\",\" Chapel Hill\\tNational Institute on Aging (NIA)\\t180.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT\\t2024-03-01\\t2027-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01889771\\tA Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline\\t\\tCOMPLETED\\tSmoking Cessation\\tDRUG: Nicotine Patch\\tUniversity of Colorado\",\" Denver\\t\\t1495.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2010-03\\t2012-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03077971\\tEffectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis\\t\\tUNKNOWN\\tCarer Stress Syndrome\\tBEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support\\tUniversity of Nottingham\\t\\t24.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2016-12-01\\t2018-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02912871\\tSubthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson\\'s Disease\\t\\tCOMPLETED\\tParkinson\\'s Disease\\tOTHER: MRIgHIFU unilateral subthalamotomy\\tFundación de investigación HM\\tInsightech\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-04\\t2017-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03548571\\tDendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy\\tDEN-STEM\\tACTIVE_NOT_RECRUITING\\tGlioblastoma\\tBIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide\\tOslo University Hospital\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2018-04-26\\t2025-05-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01449071\\tStudy Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)\\t\\tCOMPLETED\\tSystemic Lupus Erythematosus\\tBIOLOGICAL: Placebo|BIOLOGICAL: Epratuzumab 400 mg|BIOLOGICAL: Epratuzumab 1200 mg|BIOLOGICAL: Epratuzumab 100 mg|BIOLOGICAL: Epratuzumab 600 mg\\tUCB Pharma\\t\\t20.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2013-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03530371\\tIntranasal Dexmedetomidine for Sedated Hearing Testing\\t\\tCOMPLETED\\tAuditory Brainstem Response\\tDRUG: Dexmedetomidine Hydrochloride\\tFondation Lenval\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-05-02\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05921071\\tDo Patients Who Received Tranexamic Acid in Vaginal Hysterectomy Loose Les Blood\",\" Comparing to Patients Who Did Not?\\t\\tRECRUITING\\tVaginal Hysterectomy\\tDRUG: Tranexamic acid|DRUG: Placebo\\tWolfson Medical Center\\t\\t150.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2023-01-22\\t2025-01-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04974671\\tTrial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma\\t\\tRECRUITING\\tRenal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Oligoprogressive|Progression\\tRADIATION: Stereotactic Body Radiation Therapy\\tYale University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2022-08-08\\t2027-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00080171\\tOsteoarthritis Initiative (OAI): A Knee Health Study\\t\\tCOMPLETED\\tOsteoarthritis|Knee Osteoarthritis\\t\\tNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\\tGlaxoSmithKline|Merck Sharp & Dohme LLC|Novartis|Pfizer\\t4796.0\\tNIH\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2004-02\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00368771\\tA Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome\\t\\tCOMPLETED\\tIrritable Bowel Syndrome\\tBEHAVIORAL: IBS Stress Management|BEHAVIORAL: IBS Symptom Management|BEHAVIORAL: IBS Educational Training\\tUniversity of California\",\" Los Angeles\\tNational Institute of Nursing Research (NINR)\\t163.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2002-07\\t2010-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04979871\\tSARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19\\tDER-CoV2-001\\tCOMPLETED\\tVaccine Reaction\\tPROCEDURE: Venous bleeding\\tUniversity of Zurich\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2021-07-22\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04097171\\tThe Effect of Diet Composition on Performance\", Expenditure, Blood Lipids,\" and Appetite Hormones in Highly Trained Cyclists\\tDCAP\\tCOMPLETED\\tEndurance Cycling Performance\\tOTHER: Diet\\tTexas Christian University\\t\\t34.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2019-11-11\\t2020-03-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06199271\\tNeoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma\\t\\tNOT_YET_RECRUITING\\tHead and Neck Squamous Cell Carcinoma\\tDRUG: Adebrelimab and dalpiciclib\\tZhongzheng Xiang\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2024-01-31\\t2026-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04032171\\tStudy of Evobrutinib in Participants With RMS\\t\\tTERMINATED\\tRelapsing-remitting Multiple Sclerosis\\tDRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo\\tEMD Serono Research & Development Institute\",\" Inc.\\tMerck KGaA\", Darmstadt,\" Germany\\t1.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-09-10\\t2020-05-20\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05674071\\tApplying an Osteopathic Intervention to Improve Mental Health Symptoms: a Mixed-methods Feasibility Study Protocol.\\t\\tCOMPLETED\\tMental Health Issue\\tBEHAVIORAL: Articulation/HVT|BEHAVIORAL: Soft-tissue massage|BEHAVIORAL: Craniosacral techniques|BEHAVIORAL: Combination of the three interventions: HVT\",\" soft-tissue and craniosacral techniques\\tSwansea University\\tOsteopathic Foundation|University College of Osteopathy\\t32.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2022-12-20\\t2023-08-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00858871\\tFirst Line Hepato Cellular Carcinoma (HCC)\\tBRISK FL\\tCOMPLETED\\tHepato Cellular Carcinoma (HCC)\\tDRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo\\tBristol-Myers Squibb\\t\\t1714.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2009-05\\t2013-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01776671\\tOnce Daily Gabapentin in the Treatment of Post Amputation Pain\\t\\tUNKNOWN\\tPain|Quality of Life\\tDRUG: Gralise\\tChicago Anesthesia Pain Specialists\\t\\t16.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2013-02\\t2018-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01363271\\tCost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients\\t\\tCOMPLETED\\tComplicated Skin and Structure Infection|Nosocomial Pneumonia\\tDRUG: Linezolid|DRUG: Vancomycin|DRUG: Linezolid|DRUG: Vancomycin\\tPfizer\\tUniversity of Maryland|Lodise & Lodise\",\" LLC\\t7260.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2011-05\\t2012-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01282671\\tEffects of Deep Breathing Exercises Two Months After Cardiac Surgery\\t\\tCOMPLETED\\tCABG|Valve Surgery\\tOTHER: Breathing exercises\\tUppsala University\\tThe Swedish Research Council|Örebro County Council\\t357.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-09\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05683171\\tA Phase 1/2\",\" Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma\\t\\tRECRUITING\\tLymphoma\\tDRUG: Rituximab|DRUG: Lenalidomide|DRUG: Valemetostat\\tM.D. Anderson Cancer Center\\tDaiichi Sankyo\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2023-05-19\\t2027-09-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05334771\\tEarly Detection of Endolymphatic Hydrops in Hypothyroid Patients\\t\\tNOT_YET_RECRUITING\\tHypothyroidism\\tDEVICE: Dual band pure tune audiometer\\tAssiut University\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-09\\t2025-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04718571\\tAn Ecological Analysis of Nontuberculous Mycobacteria in the Geneva Area (2015-2020)\\t\\tCOMPLETED\\tEcology of Nontubercuous Mycobacteria|Geneva Area\\t\\tUniversity Hospital\",\" Geneva\\t\\t231.0\\tOTHER\\tOBSERVATI'"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dbutils.fs.head(\"/FileStore/tables/\"+fileroot+\".csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "e2096ddf-0a56-41a8-9a69-59ab5a58d6c9",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "# introducing Reusability and defining Filepath\n",
    "\n",
    "clincaltrial_2023 = (\"/FileStore/tables/\"+fileroot+\".csv\")\n",
    "pharma = ('/FileStore/tables/pharma.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "1348f34f-ec35-45e0-ac67-0de831d29f8f",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "Load the Clinicaltrial  CSV fILE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "966e16b4-6847-48cd-b817-be90dd88940b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "#load the csv using spark content\n",
    "clinicaltrial_2023rdd = sc.textFile(clincaltrial_2023)\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "3b5b395c-a68c-4008-9c0c-a1dac050d932",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#Cleaning the dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "78f5cbc3-2f62-4f35-9b52-5e7cbc8b8a49",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "['\"Id\\tStudy Title\\tAcronym\\tStatus\\tConditions\\tInterventions\\tSponsor\\tCollaborators\\tEnrollment\\tFunder Type\\tType\\tStudy Design\\tStart\\tCompletion\"',\n",
       " '\"NCT03630471\\tEffectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India\\tPRIDE\\tCOMPLETED\\tMental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)\\tBEHAVIORAL: PRIDE \\'Step 1\\' problem-solving intervention|BEHAVIORAL: Enhanced usual care\\tSangath\\tHarvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine\\t250.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-08-20\\t2019-02-28\",',\n",
       " '\"NCT05992571\\tOral Ketone Monoester Supplementation and Resting-state Brain Connectivity\\t\\tRECRUITING\\tCerebrovascular Function|Cognition\\tOTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB\\tMcMaster University\\tAlzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE\\t2023-10-25\\t2024-08\"']"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#clean  the dataset\n",
    "clinicaltrial_2023rdd1 = clinicaltrial_2023rdd.map(lambda row: row.replace(',,', ''))\n",
    "\n",
    "\n",
    "clinicaltrial_2023rdd1.take(3)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "4ae5830e-17ec-43f6-8882-4b02222ba121",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[['NCT03630471',\n",
       "  'Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India',\n",
       "  'PRIDE',\n",
       "  'COMPLETED',\n",
       "  'Mental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)',\n",
       "  \"BEHAVIORAL: PRIDE 'Step 1' problem-solving intervention|BEHAVIORAL: Enhanced usual care\",\n",
       "  'Sangath',\n",
       "  'Harvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine',\n",
       "  '250.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-20',\n",
       "  '2019-02-28'],\n",
       " ['NCT05992571',\n",
       "  'Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cerebrovascular Function|Cognition',\n",
       "  'OTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB',\n",
       "  'McMaster University',\n",
       "  'Alzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2023-10-25',\n",
       "  '2024-08'],\n",
       " ['NCT00237471',\n",
       "  'Impact of Tight Glycaemic Control in Acute Myocardial Infarction',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Myocardial Infarct|Hyperglycemia',\n",
       "  'DRUG: Insulin (tight blood glucose control)',\n",
       "  'Melbourne Health',\n",
       "  'National Health and Medical Research Council\",\" Australia|Bristol-Myers Squibb',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2006-05'],\n",
       " ['NCT03820271',\n",
       "  'New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation',\n",
       "  'SUPERMELD',\n",
       "  'RECRUITING',\n",
       "  'Decompensated Cirrhosis|Liver Transplantation',\n",
       "  'OTHER: SuperMELD',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '500.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-10-01',\n",
       "  '2023-10-01'],\n",
       " ['NCT06229171',\n",
       "  'InTake Care: Development and Validation of an Innovative\",\" Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention',\n",
       "  'InTakeCare',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Hypertension|Treatment Adherence and Compliance|Digital Health',\n",
       "  'OTHER: adherence support system based on a vocal assistant',\n",
       "  'Istituto Auxologico Italiano',\n",
       "  'Istituti Clinici Scientifici Maugeri SpA|Politecnico di Milano',\n",
       "  '206.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2024-10-01',\n",
       "  '2026-04-01'],\n",
       " ['NCT02945371',\n",
       "  'Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life',\n",
       "  'REV',\n",
       "  'COMPLETED',\n",
       "  'Smoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced',\n",
       "  'BEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training',\n",
       "  'University of Oregon',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2014-09',\n",
       "  '2016-05'],\n",
       " ['NCT01055171',\n",
       "  'Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Dependence|PTSD',\n",
       "  'DRUG: Propranolol|DRUG: Placebo',\n",
       "  'Medical University of South Carolina',\n",
       "  'National Institute on Alcohol Abuse and Alcoholism (NIAAA)',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-01',\n",
       "  '2012-08'],\n",
       " ['NCT01125371',\n",
       "  'Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection',\n",
       "  'BEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Alcohol Abuse and Alcoholism (NIAAA)',\n",
       "  '439.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-10',\n",
       "  '2016-06-07'],\n",
       " ['NCT02554071',\n",
       "  'Manitoba Pharmacist Initiated Smoking Cessation Pilot Project',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking Cessation',\n",
       "  'OTHER: Pharmacist - Smoking Cessation Support',\n",
       "  'University of Manitoba',\n",
       "  'Govenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada',\n",
       "  '119.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2014-01',\n",
       "  '2014-11'],\n",
       " ['NCT01772771',\n",
       "  'Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma',\n",
       "  'PROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '12000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-03-01',\n",
       "  '2033-03-01'],\n",
       " ['NCT02633371',\n",
       "  'A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hyperhidrosis',\n",
       "  'DRUG: Oxybutynin 3% gel',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  'Society for Pediatric Dermatology',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-02',\n",
       "  '2017-05'],\n",
       " ['NCT03400371',\n",
       "  'Biology of Juvenile Myoclonic Epilepsy',\n",
       "  'BIOJUME',\n",
       "  'RECRUITING',\n",
       "  'Juvenile Myoclonic Epilepsy',\n",
       "  'OTHER: Blood draw|OTHER: Existing samples',\n",
       "  \"King's College London\",\n",
       "  'King\\'s College Hospital NHS Trust|Charles University\",\" Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-07-13',\n",
       "  '2026-06-30'],\n",
       " ['NCT00120471',\n",
       "  'Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)',\n",
       "  '122.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2006-11',\n",
       "  '2011-12'],\n",
       " ['NCT04784871',\n",
       "  'Promoting Wellbeing: The Five Ways to All Intervention',\n",
       "  '5WaysA',\n",
       "  'COMPLETED',\n",
       "  'Wellbeing|Health Attitude|Quality of Life',\n",
       "  'BEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control',\n",
       "  'University of Oslo',\n",
       "  'Norwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation',\n",
       "  '970.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-03-04',\n",
       "  '2023-02-24'],\n",
       " ['NCT02383771',\n",
       "  'Reversal of the Anti-platelet Effects of Ticagrelor',\n",
       "  'REVERSAL',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor',\n",
       "  'The First Affiliated Hospital with Nanjing Medical University',\n",
       "  'National Natural Science Foundation of China',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-03',\n",
       "  '2016-12'],\n",
       " ['NCT03269071',\n",
       "  'Neural Stem Cell Transplantation in Multiple Sclerosis Patients',\n",
       "  'STEMS',\n",
       "  'COMPLETED',\n",
       "  'Progressive Multiple Sclerosis',\n",
       "  'DRUG: human fetal-derived Neural Stem Cells (hNSCs)',\n",
       "  'IRCCS San Raffaele',\n",
       "  'Fondazione Italiana Sclerosi Multipla',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-05-17',\n",
       "  '2021-07-31'],\n",
       " ['NCT01659671',\n",
       "  'RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea',\n",
       "  'SKUP3',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea Syndrome',\n",
       "  'PROCEDURE: Uvulopalatopharyngoplasty',\n",
       "  'Karolinska University Hospital',\n",
       "  'Karolinska Institutet',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-06',\n",
       "  '2014-05'],\n",
       " ['NCT04765371',\n",
       "  'Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy\",\" With CoViD-19',\n",
       "  'COPreDex',\n",
       "  'COMPLETED',\n",
       "  'Coronavirus Infection',\n",
       "  'DRUG: DEXAMETHASONE|DRUG: PREDNISOLONE',\n",
       "  'Hôpital NOVO',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-03-03',\n",
       "  '2022-05-13'],\n",
       " ['NCT02830971',\n",
       "  'Developing a Standardized Learning Curve',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Registered Nurses|Nursing Personnel|Motor Skills',\n",
       "  'PROCEDURE: Doing Different ICU techniques and skills',\n",
       "  'Baqiyatallah Medical Sciences University',\n",
       "  'Shahid Beheshti University|Tehran University of Medical Sciences',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2016-07',\n",
       "  '2021-04-12'],\n",
       " ['NCT00416871',\n",
       "  'Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Kidney Cancer',\n",
       "  'BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa',\n",
       "  'Centre Leon Berard',\n",
       "  '',\n",
       "  '220.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  '2006-02'],\n",
       " ['NCT05900271',\n",
       "  'Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS',\n",
       "  'DDOT',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Treatment Resistant Depression',\n",
       "  'DEVICE: rTMS|DEVICE: iTBS',\n",
       "  'Amsterdam UMC\",\" location VUmc',\n",
       "  'Radboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-15',\n",
       "  '2027-12'],\n",
       " ['NCT02469571',\n",
       "  'Modulation of Gut Microbiota in Early Sepsis: A Pilot Study',\n",
       "  'MGM-sepsis',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  'DIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo',\n",
       "  'Medical University of Graz',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-09-01',\n",
       "  '2018-03-01'],\n",
       " ['NCT05807971',\n",
       "  'Assessment of Safety\", Tolerability, Pharmacokinetics,\" and Pharmacodynamics of ATH-063 in Healthy Subjects',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases',\n",
       "  'DRUG: ATH-063|DRUG: Placebo',\n",
       "  'Athos Therapeutics Inc',\n",
       "  'Syneos Health|Athos Therapeutics Australia Pty Ltd',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-06',\n",
       "  '2024-02-08'],\n",
       " ['NCT02083471',\n",
       "  \"Cow's Milk and Hen's Egg Hyposensitization in Adults\",\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  \"Egg Allergy|Cow's Milk Allergy\",\n",
       "  \"DIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow's milk\",\n",
       "  'Turku University Hospital',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2017-05'],\n",
       " ['NCT01062971',\n",
       "  'Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Open Angle Glaucoma|Ocular Hypertension',\n",
       "  'DRUG: dorzolamide-timolol-brimonidine',\n",
       "  'Laboratorios Sophia S.A de C.V.',\n",
       "  '',\n",
       "  '124.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-02',\n",
       "  '2008-06'],\n",
       " ['NCT03928171',\n",
       "  'The Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery',\n",
       "  'PERFUSION',\n",
       "  'COMPLETED',\n",
       "  'Laparoscopic Surgery|Pneumoperitoneum',\n",
       "  'OTHER: Intra-abdominal pressure during laparoscopy',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-06-13',\n",
       "  '2018-12-24'],\n",
       " ['NCT00897871',\n",
       "  'Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Unspecified Childhood Solid Tumor\",\" Protocol Specific',\n",
       "  'DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study',\n",
       "  \"Children's Cancer and Leukaemia Group\",\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-02',\n",
       "  ''],\n",
       " ['NCT00848471',\n",
       "  'Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)',\n",
       "  'Protocol Quark',\n",
       "  'UNKNOWN',\n",
       "  'Healthy|Obesity',\n",
       "  'DEVICE: Quark RMR|DEVICE: Deltatrac II',\n",
       "  'Hospices Civils de Lyon',\n",
       "  'Centre de Recherche en Nutrition Humaine Rhone-Alpe',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2009-01',\n",
       "  '2009-12'],\n",
       " ['NCT06135571',\n",
       "  'Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Cancer|Lymph Node Metastasis',\n",
       "  'PROCEDURE: Laparoscopic colorectal surgery',\n",
       "  'Cancer Institute and Hospital\",\" Chinese Academy of Medical Sciences',\n",
       "  'Peking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital',\n",
       "  '3000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-09-01',\n",
       "  '2026-09-01'],\n",
       " ['NCT01189071',\n",
       "  'Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Overactive Bladder|Renal Colic|Pain\",\" Postoperative',\n",
       "  'DRUG: Darifenacin',\n",
       "  'University of Missouri-Columbia',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2011-07'],\n",
       " ['NCT00728871',\n",
       "  'The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cervical Cancer|Cervical Intraepithelial Neoplasia',\n",
       "  'PROCEDURE: peripheral blood isolation',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2005-12',\n",
       "  '2011-12'],\n",
       " ['NCT05592171',\n",
       "  'Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC',\n",
       "  'SEASON-HCC',\n",
       "  'RECRUITING',\n",
       "  'HCC',\n",
       "  'PROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE',\n",
       "  'University of Pisa',\n",
       "  'Azienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero\",\" Universitaria Pisana',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-10-17',\n",
       "  '2025-10-17'],\n",
       " ['NCT00520871',\n",
       "  'The Water-Blueberry Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cardiovascular Disease',\n",
       "  'DRUG: Blueberry juice',\n",
       "  'University of Oslo',\n",
       "  'Ullevaal University Hospital',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION',\n",
       "  '2003-03',\n",
       "  '2004-04'],\n",
       " ['NCT05913271',\n",
       "  'Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Heart Failure|Levosimendan|Efficacy|Safety',\n",
       "  '',\n",
       "  'Yi Han',\n",
       "  'Qianfoshan Hospital',\n",
       "  '352.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-05-30',\n",
       "  '2025-05-30'],\n",
       " ['NCT04006171',\n",
       "  'Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women',\n",
       "  'CNP',\n",
       "  'COMPLETED',\n",
       "  'Polycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism',\n",
       "  'DIAGNOSTIC_TEST: C type natriuretic peptide',\n",
       "  'Near East University\",\" Turkey',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-07-15',\n",
       "  '2020-09-01'],\n",
       " ['NCT04370171',\n",
       "  'Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic',\n",
       "  'TeleCoviDiab',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Covid-19',\n",
       "  'OTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation',\n",
       "  'University Hospital\", Strasbourg,\" France',\n",
       "  '',\n",
       "  '610.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-05-04',\n",
       "  '2020-05-29'],\n",
       " ['NCT04340271',\n",
       "  'The Clinical Utility of Extracorporeal Shock Wave Therapy on Burns',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Burn Scar',\n",
       "  'OTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy',\n",
       "  'Hangang Sacred Heart Hospital',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-15',\n",
       "  '2020-05-31'],\n",
       " ['NCT03075371',\n",
       "  'Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anorexia Nervosa|Healthy',\n",
       "  'OTHER: Glucose|OTHER: Placebo',\n",
       "  'University of Heidelberg Medical Center',\n",
       "  'German Research Foundation',\n",
       "  '85.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2014-09',\n",
       "  '2019-02'],\n",
       " ['NCT05966571',\n",
       "  'Ovarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Polycystic Ovary Syndrome',\n",
       "  'PROCEDURE: Ovary Biopsie',\n",
       "  'Albanian University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-07-01',\n",
       "  '2024-12-01'],\n",
       " ['NCT03313271',\n",
       "  'China Lymphoma Patient Registry Study',\n",
       "  'CLAP',\n",
       "  'RECRUITING',\n",
       "  'Lymphoma',\n",
       "  '',\n",
       "  'Jun Zhu',\n",
       "  'Peking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-05-17',\n",
       "  '2027-08-30'],\n",
       " ['NCT03490071',\n",
       "  'Long-term Follow up of Patients With Longstanding Hip and Groin Pain',\n",
       "  'Lund LHGP',\n",
       "  'RECRUITING',\n",
       "  'Hip Pain Chronic',\n",
       "  '',\n",
       "  'Lund University',\n",
       "  '',\n",
       "  '81.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT05801471',\n",
       "  'Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Glaucoma',\n",
       "  '',\n",
       "  'Centervue SpA',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-06',\n",
       "  '2025-11-06'],\n",
       " ['NCT00266071',\n",
       "  'Study of the Cutaneous Microcirculation in Elderly People',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Elderly People',\n",
       "  'BEHAVIORAL: Cutaneous response',\n",
       "  'University Hospital\",\" Angers',\n",
       "  '',\n",
       "  '',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-12',\n",
       "  ''],\n",
       " ['NCT04405271',\n",
       "  'TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthcare Workers|COVID-19|SARS-CoV 2',\n",
       "  'DRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo',\n",
       "  'Hospital Italiano de Buenos Aires',\n",
       "  'Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)',\n",
       "  '1378.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-07-31',\n",
       "  '2020-11-15'],\n",
       " ['NCT02121171',\n",
       "  'Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Congenital Glaucoma',\n",
       "  'DEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy',\n",
       "  'National Centre of Ophthalmology named after academician Zarifa Aliyeva',\n",
       "  'Aeon Astron Europe B.V.',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-09',\n",
       "  '2015-09'],\n",
       " ['NCT01068171',\n",
       "  'Developing a Diabetic Foot Ulcer Protocol',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Diabetic Foot Ulcers',\n",
       "  'OTHER: type of footwear|OTHER: collagen dressing with and without silver',\n",
       "  'The University of Texas Health Science Center\",\" Houston',\n",
       "  'Harris County Hospital District|Baylor College of Medicine',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-05',\n",
       "  '2012-06'],\n",
       " ['NCT04875871',\n",
       "  'Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors',\n",
       "  'PARTICLE-PATHY',\n",
       "  'RECRUITING',\n",
       "  'Cancer',\n",
       "  'RADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling',\n",
       "  'EBG MedAustron GmbH',\n",
       "  'CW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring',\n",
       "  '22.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-11-11',\n",
       "  '2024-12'],\n",
       " ['NCT00553371',\n",
       "  'Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Testicular Germ Cell Tumor',\n",
       "  'OTHER: biomarker analysis|PROCEDURE: computed tomography',\n",
       "  'Royal Marsden NHS Foundation Trust',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2006-04',\n",
       "  ''],\n",
       " ['NCT04674371',\n",
       "  'German Point Prevalence Study on CVC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Data Collection',\n",
       "  'OTHER: central venous catheter insertion',\n",
       "  'Wolfram Schummer\", MD,\" PhD',\n",
       "  '',\n",
       "  '537.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-17',\n",
       "  '2022-05-20'],\n",
       " ['NCT02321371',\n",
       "  'Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute-On-Chronic Liver Failure',\n",
       "  'DRUG: Lactulose + Rifaximin|DRUG: Lactulose',\n",
       "  'Institute of Liver and Biliary Sciences\",\" India',\n",
       "  '',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-10-19',\n",
       "  '2016-01-31'],\n",
       " ['NCT02344771',\n",
       "  'Perioperative Endothelial Dysfunction',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myocardial Injury',\n",
       "  'PROCEDURE: Elective colon cancer surgery',\n",
       "  'Zealand University Hospital',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2015-06'],\n",
       " ['NCT03354871',\n",
       "  'Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables',\n",
       "  'IoT4Resident',\n",
       "  'UNKNOWN',\n",
       "  'Fatigue',\n",
       "  '',\n",
       "  'Hillel Yaffe Medical Center',\n",
       "  'International Business Machines (IBM)',\n",
       "  '6.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-11',\n",
       "  '2018-02-28'],\n",
       " ['NCT02804971',\n",
       "  'Cardiovascular Comorbidities and Bronchiectasis',\n",
       "  'BRONCOCA',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Bronchiectasis',\n",
       "  '',\n",
       "  'Centre Hospitalier Intercommunal Creteil',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-10-25',\n",
       "  '2023-12'],\n",
       " ['NCT04591171',\n",
       "  'Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension|Chronic Kidney Diseases',\n",
       "  'PROCEDURE: n-of-1 trial guided clinical decision making',\n",
       "  'The University of Texas Health Science Center\",\" Houston',\n",
       "  \"Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\",\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-01-25',\n",
       "  '2022-02-18'],\n",
       " ['NCT04814771',\n",
       "  'Mass Balance Study of TS-142 in Healthy Adult Subjects.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Male Subjects',\n",
       "  'DRUG: [14C] TS-142',\n",
       "  'Taisho Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2021-04-19',\n",
       "  '2021-05-19'],\n",
       " ['NCT00991471',\n",
       "  'The Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times',\n",
       "  'MDRNSTAT',\n",
       "  'COMPLETED',\n",
       "  'Emergencies',\n",
       "  'BEHAVIORAL: Interaction with MDRN STAT|BEHAVIORAL: No MDRNSTAT',\n",
       "  'Sunnybrook Health Sciences Centre',\n",
       "  '',\n",
       "  '6300.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2009-09',\n",
       "  '2010-02'],\n",
       " ['NCT05702671',\n",
       "  'Kenota 1 CWS Method Comparison Validation Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergy|Immunoglobulin E-Mediated Allergic Disorder',\n",
       "  'DIAGNOSTIC_TEST: Total Immunoglobulin E\",\" Obtained From Fingerstick Sample',\n",
       "  'Kenota Inc.',\n",
       "  '',\n",
       "  '411.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-01-27',\n",
       "  '2023-04-07'],\n",
       " ['NCT02069171',\n",
       "  'Cross-sectional and Questionnaire Study for Leg Lymphedema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gynecologic Cancer',\n",
       "  '',\n",
       "  'National Cancer Center\",\" Korea',\n",
       "  '',\n",
       "  '333.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-06',\n",
       "  '2012-11'],\n",
       " ['NCT00474071',\n",
       "  'Optimum Dose of Remifentanil for Intubation in Small Children',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Endotracheal Intubation',\n",
       "  'DRUG: Remifentanil',\n",
       "  'University of British Columbia',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-03',\n",
       "  '2008-04'],\n",
       " ['NCT02022371',\n",
       "  'Prostate Cancer Genomic Heterogeneity',\n",
       "  'PROGENY',\n",
       "  'COMPLETED',\n",
       "  'PROSTATE CANCER',\n",
       "  'PROCEDURE: Targeted biopsies of the prostate',\n",
       "  'University College London Hospitals',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-09',\n",
       "  '2016-06'],\n",
       " ['NCT04585971',\n",
       "  'A Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of Brain Magnetic Resonance Imaging\",\" and Carotid Doppler Ultrasound',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cerebral Blood Flow',\n",
       "  'DIAGNOSTIC_TEST: Signal intensity gradient',\n",
       "  'Chonbuk National University Hospital',\n",
       "  'Medi Image\",\" Inc',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-03',\n",
       "  '2021-01-31'],\n",
       " ['NCT05473871',\n",
       "  'Enhancing Capacity in Churches to Implement PA Programs',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cardiovascular Diseases',\n",
       "  'BEHAVIORAL: Faith in Action|BEHAVIORAL: Faith in Action+|BEHAVIORAL: Faith in Action++',\n",
       "  'San Diego State University',\n",
       "  'Washington University School of Medicine|University of California\", Berkeley|University of California,\" San Diego',\n",
       "  '812.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-11-15',\n",
       "  '2026-10-31'],\n",
       " ['NCT01523171',\n",
       "  'Phase II\", Open Label,\" Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib',\n",
       "  'JAKARTA2',\n",
       "  'COMPLETED',\n",
       "  'Hematopoietic Neoplasm',\n",
       "  'DRUG: SAR302503',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-04',\n",
       "  '2014-04'],\n",
       " ['NCT00000571',\n",
       "  'Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lung Diseases|Lung Diseases\",\" Obstructive|Chronic Obstructive Pulmonary Disease',\n",
       "  'DEVICE: ventilators\",\" negative pressure',\n",
       "  'McGill University',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1986-02',\n",
       "  ''],\n",
       " ['NCT01053871',\n",
       "  'Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastritis|Functional Dyspepsia',\n",
       "  'DRUG: propofol|DRUG: midazolam with fentanyl',\n",
       "  'Shandong University',\n",
       "  '',\n",
       "  '104.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: ',\n",
       "  '2010-01',\n",
       "  '2010-05'],\n",
       " ['NCT02370771',\n",
       "  'Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis',\n",
       "  'PASEO',\n",
       "  'COMPLETED',\n",
       "  'Erosive Hand Osteoarthritis',\n",
       "  'PROCEDURE: Biological sampling|DEVICE: Radiographic evaluation',\n",
       "  'University Hospital\",\" Rouen',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-06-09',\n",
       "  '2019-11-17'],\n",
       " ['NCT05974371',\n",
       "  'Episodic Memory Integration and Interference',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Episodic Memory',\n",
       "  'OTHER: emotional context similarity',\n",
       "  'Boston College',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2024-08',\n",
       "  '2027-08'],\n",
       " ['NCT03713671',\n",
       "  'Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Hyperparathyroidism',\n",
       "  'DIAGNOSTIC_TEST: gait analysis',\n",
       "  'Recep Tayyip Erdogan University Training and Research Hospital',\n",
       "  'Hacettepe University|Ankara Education and Research Hospital',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING',\n",
       "  '2021-10-17',\n",
       "  '2023-08-27'],\n",
       " ['NCT02645071',\n",
       "  'Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Activity',\n",
       "  'BEHAVIORAL: Physical Activity',\n",
       "  'The University of Hong Kong',\n",
       "  'Hong Kong Jockey Club Charities Trust',\n",
       "  '141.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2015-07',\n",
       "  '2017-07'],\n",
       " ['NCT04004871',\n",
       "  'Induction Chemotherapy With Nab-paclitaxel\",\" Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Nasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer',\n",
       "  'DRUG: Nab-paclitaxel\",\" Cisplatin and Fluorouracil|RADIATION: concurrent chemoradiotherapy',\n",
       "  'Guangxi Medical University',\n",
       "  'Second Affiliated Hospital of Guangxi Medical University|Guilin Medical University\",\" China|Liuzhou Workers Hospital|Wuzhou Red Cross Hospital',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-05',\n",
       "  '2022-06-30'],\n",
       " ['NCT05953571',\n",
       "  'Laparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Uretro-pelvic Junction Obstruction|Poorly Function Kidney',\n",
       "  'PROCEDURE: Dismembered Pyeloplasty',\n",
       "  'Al-Azhar University',\n",
       "  'University Hospital Fattouma Bourguiba',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01-08',\n",
       "  '2023-06-30'],\n",
       " ['NCT02570971',\n",
       "  'Mannitol Versus Supportive Care in Ciguatera Fish Poisoning',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ciguatoxin',\n",
       "  'DRUG: Mannitol',\n",
       "  'University of South Florida',\n",
       "  'Florida Poison Control Center',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-10',\n",
       "  ''],\n",
       " ['NCT03987971',\n",
       "  'Acupuncture on GB26 to Treat Chronic Low Back Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Low-back Pain',\n",
       "  'OTHER: acupuncture',\n",
       "  'Wenzhou Medical University',\n",
       "  \"Qingtian People's hospital\",\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2021-07'],\n",
       " ['NCT01425671',\n",
       "  'Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder',\n",
       "  '',\n",
       "  'University of Maryland\",\" Baltimore',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '800.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-11-30',\n",
       "  '2024-06'],\n",
       " ['NCT04962971',\n",
       "  'Comparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Recurrent Cystitis',\n",
       "  'DIETARY_SUPPLEMENT: X|DIETARY_SUPPLEMENT: Y|DIETARY_SUPPLEMENT: Z',\n",
       "  'CEN Biotech',\n",
       "  'Nexira|CEN Nutriment',\n",
       "  '216.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-01',\n",
       "  '2022-02-01'],\n",
       " ['NCT02827071',\n",
       "  'Ocular Imaging Study Using Advanced OCT',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Retinal Vascular Disorder|Macular Degeneration',\n",
       "  '',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  ''],\n",
       " ['NCT04236271',\n",
       "  'TELEsurveillance of Patients in PostopErative Bridge surgeryAge CoronairE',\n",
       "  'TELE-PEACE',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Bypass',\n",
       "  'DEVICE: connected objects',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  'GFI',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-03-13',\n",
       "  '2022-12-31'],\n",
       " ['NCT01780571',\n",
       "  'CPAP/PSV Preoxygenation in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Anaesthesia',\n",
       "  'PROCEDURE: CPAP 5 cm H2O + PSV 5 cm H2O',\n",
       "  'Karolinska Institutet',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2009-05',\n",
       "  '2012-12'],\n",
       " ['NCT05078671',\n",
       "  'Pharmacokinetic Boosting of Olaparib to Improve Exposure\",\" Tolerance and Cost-effectiveness',\n",
       "  'PROACTIVE',\n",
       "  'RECRUITING',\n",
       "  'Cancer',\n",
       "  'DRUG: Olaparib|DRUG: Cobicistat',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-12-15',\n",
       "  '2025-12-31'],\n",
       " ['NCT02529371',\n",
       "  'Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Urinary Incontinence',\n",
       "  'DEVICE: UriCap-RM',\n",
       "  'G.R. Dome Medical Ltd.',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-09',\n",
       "  '2015-10'],\n",
       " ['NCT02309671',\n",
       "  'A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infertility',\n",
       "  'DRUG: FE 999049|DRUG: follitropin beta',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '159.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-12',\n",
       "  '2016-09'],\n",
       " ['NCT03876171',\n",
       "  'Culturally Modified Family Based Therapy for Haitian Youth in South Florida',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Problem Behavior',\n",
       "  'BEHAVIORAL: Haitian youth and family intervention study: family functioning|BEHAVIORAL: Haitian youth intervention study: youth psychoeducational|BEHAVIORAL: Haitian family intervention study: family psychoeducational|BEHAVIORAL: Diversion Programs',\n",
       "  'University of Miami',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2019-04-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT05031871',\n",
       "  'Pharmacokinetics of HR17031 Injection in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection',\n",
       "  'Jiangsu HengRui Medicine Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-09-02',\n",
       "  '2021-11-19'],\n",
       " ['NCT04769271',\n",
       "  'Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis',\n",
       "  'PROCEDURE: Scaling and Root Planing|DRUG: Scaling and Root Planing with tea tree oil',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-11-10',\n",
       "  '2020-08-25'],\n",
       " ['NCT06044571',\n",
       "  'Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Obesity|Multiple Chronic Conditions',\n",
       "  'OTHER: Prescriptive|BEHAVIORAL: Behavioral',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute on Aging (NIA)',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2024-03-01',\n",
       "  '2027-09-01'],\n",
       " ['NCT01889771',\n",
       "  'A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking Cessation',\n",
       "  'DRUG: Nicotine Patch',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '',\n",
       "  '1495.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2010-03',\n",
       "  '2012-03'],\n",
       " ['NCT03077971',\n",
       "  'Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Carer Stress Syndrome',\n",
       "  'BEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support',\n",
       "  'University of Nottingham',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2016-12-01',\n",
       "  '2018-06'],\n",
       " ['NCT02912871',\n",
       "  \"Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  \"Parkinson's Disease\",\n",
       "  'OTHER: MRIgHIFU unilateral subthalamotomy',\n",
       "  'Fundación de investigación HM',\n",
       "  'Insightech',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-04',\n",
       "  '2017-01'],\n",
       " ['NCT03548571',\n",
       "  'Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy',\n",
       "  'DEN-STEM',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Glioblastoma',\n",
       "  'BIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-04-26',\n",
       "  '2025-05-01'],\n",
       " ['NCT01449071',\n",
       "  'Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Systemic Lupus Erythematosus',\n",
       "  'BIOLOGICAL: Placebo|BIOLOGICAL: Epratuzumab 400 mg|BIOLOGICAL: Epratuzumab 1200 mg|BIOLOGICAL: Epratuzumab 100 mg|BIOLOGICAL: Epratuzumab 600 mg',\n",
       "  'UCB Pharma',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-10',\n",
       "  '2013-03'],\n",
       " ['NCT03530371',\n",
       "  'Intranasal Dexmedetomidine for Sedated Hearing Testing',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Auditory Brainstem Response',\n",
       "  'DRUG: Dexmedetomidine Hydrochloride',\n",
       "  'Fondation Lenval',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-05-02',\n",
       "  '2021-12-31'],\n",
       " ['NCT05921071',\n",
       "  'Do Patients Who Received Tranexamic Acid in Vaginal Hysterectomy Loose Les Blood\",\" Comparing to Patients Who Did Not?',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Vaginal Hysterectomy',\n",
       "  'DRUG: Tranexamic acid|DRUG: Placebo',\n",
       "  'Wolfson Medical Center',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-01-22',\n",
       "  '2025-01-01'],\n",
       " ['NCT04974671',\n",
       "  'Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Oligoprogressive|Progression',\n",
       "  'RADIATION: Stereotactic Body Radiation Therapy',\n",
       "  'Yale University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-08',\n",
       "  '2027-04-01'],\n",
       " ['NCT00080171',\n",
       "  'Osteoarthritis Initiative (OAI): A Knee Health Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Knee Osteoarthritis',\n",
       "  '',\n",
       "  'National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)',\n",
       "  'GlaxoSmithKline|Merck Sharp & Dohme LLC|Novartis|Pfizer',\n",
       "  '4796.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-02',\n",
       "  '2015-10'],\n",
       " ['NCT00368771',\n",
       "  'A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Irritable Bowel Syndrome',\n",
       "  'BEHAVIORAL: IBS Stress Management|BEHAVIORAL: IBS Symptom Management|BEHAVIORAL: IBS Educational Training',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  'National Institute of Nursing Research (NINR)',\n",
       "  '163.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2002-07',\n",
       "  '2010-05'],\n",
       " ['NCT04979871',\n",
       "  'SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19',\n",
       "  'DER-CoV2-001',\n",
       "  'COMPLETED',\n",
       "  'Vaccine Reaction',\n",
       "  'PROCEDURE: Venous bleeding',\n",
       "  'University of Zurich',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-07-22',\n",
       "  '2021-12-31'],\n",
       " ['NCT04097171',\n",
       "  'The Effect of Diet Composition on Performance\", Expenditure, Blood Lipids,\" and Appetite Hormones in Highly Trained Cyclists',\n",
       "  'DCAP',\n",
       "  'COMPLETED',\n",
       "  'Endurance Cycling Performance',\n",
       "  'OTHER: Diet',\n",
       "  'Texas Christian University',\n",
       "  '',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-11-11',\n",
       "  '2020-03-30'],\n",
       " ['NCT06199271',\n",
       "  'Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Head and Neck Squamous Cell Carcinoma',\n",
       "  'DRUG: Adebrelimab and dalpiciclib',\n",
       "  'Zhongzheng Xiang',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01-31',\n",
       "  '2026-12-31'],\n",
       " ['NCT04032171',\n",
       "  'Study of Evobrutinib in Participants With RMS',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Relapsing-remitting Multiple Sclerosis',\n",
       "  'DRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo',\n",
       "  'EMD Serono Research & Development Institute\",\" Inc.',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '1.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-09-10',\n",
       "  '2020-05-20'],\n",
       " ['NCT05674071',\n",
       "  'Applying an Osteopathic Intervention to Improve Mental Health Symptoms: a Mixed-methods Feasibility Study Protocol.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Health Issue',\n",
       "  'BEHAVIORAL: Articulation/HVT|BEHAVIORAL: Soft-tissue massage|BEHAVIORAL: Craniosacral techniques|BEHAVIORAL: Combination of the three interventions: HVT\",\" soft-tissue and craniosacral techniques',\n",
       "  'Swansea University',\n",
       "  'Osteopathic Foundation|University College of Osteopathy',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-20',\n",
       "  '2023-08-01'],\n",
       " ['NCT00858871',\n",
       "  'First Line Hepato Cellular Carcinoma (HCC)',\n",
       "  'BRISK FL',\n",
       "  'COMPLETED',\n",
       "  'Hepato Cellular Carcinoma (HCC)',\n",
       "  'DRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '',\n",
       "  '1714.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-05',\n",
       "  '2013-09'],\n",
       " ['NCT01776671',\n",
       "  'Once Daily Gabapentin in the Treatment of Post Amputation Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pain|Quality of Life',\n",
       "  'DRUG: Gralise',\n",
       "  'Chicago Anesthesia Pain Specialists',\n",
       "  '',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-02',\n",
       "  '2018-12'],\n",
       " ['NCT01363271',\n",
       "  'Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Complicated Skin and Structure Infection|Nosocomial Pneumonia',\n",
       "  'DRUG: Linezolid|DRUG: Vancomycin|DRUG: Linezolid|DRUG: Vancomycin',\n",
       "  'Pfizer',\n",
       "  'University of Maryland|Lodise & Lodise\",\" LLC',\n",
       "  '7260.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-05',\n",
       "  '2012-05'],\n",
       " ['NCT01282671',\n",
       "  'Effects of Deep Breathing Exercises Two Months After Cardiac Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'CABG|Valve Surgery',\n",
       "  'OTHER: Breathing exercises',\n",
       "  'Uppsala University',\n",
       "  'The Swedish Research Council|Örebro County Council',\n",
       "  '357.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2012-08'],\n",
       " ['NCT05683171',\n",
       "  'A Phase 1/2\",\" Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Lymphoma',\n",
       "  'DRUG: Rituximab|DRUG: Lenalidomide|DRUG: Valemetostat',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'Daiichi Sankyo',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-05-19',\n",
       "  '2027-09-30'],\n",
       " ['NCT05334771',\n",
       "  'Early Detection of Endolymphatic Hydrops in Hypothyroid Patients',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Hypothyroidism',\n",
       "  'DEVICE: Dual band pure tune audiometer',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-09',\n",
       "  '2025-04'],\n",
       " ['NCT04718571',\n",
       "  'An Ecological Analysis of Nontuberculous Mycobacteria in the Geneva Area (2015-2020)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ecology of Nontubercuous Mycobacteria|Geneva Area',\n",
       "  '',\n",
       "  'University Hospital\",\" Geneva',\n",
       "  '',\n",
       "  '231.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-01',\n",
       "  '2020-12-01'],\n",
       " ['NCT05072171',\n",
       "  'Evidence of Myogenic Growth Factors in 3D Dynamic Inguinal Hernia Scaffold ProFlor',\n",
       "  'HERNIA',\n",
       "  'UNKNOWN',\n",
       "  'Inguinal Hernia',\n",
       "  'PROCEDURE: Inguinal hernia repair with dynamic prosthesis',\n",
       "  'University of Palermo',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01-01',\n",
       "  '2021-12-31'],\n",
       " ['NCT05638971',\n",
       "  'Optical Detection Infiltration/Extravasation in Neonates (ODINE)',\n",
       "  'ODINE',\n",
       "  'COMPLETED',\n",
       "  'Extravasation Injury|Infant\", Premature,\" Diseases',\n",
       "  'DEVICE: ivWatch',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-08-01',\n",
       "  '2022-07-12'],\n",
       " ['NCT05138471',\n",
       "  'Addition of Transcranial Direct Current Stimulation and Transcutaneous Electrical Nerve Stimulation to an Education and Exercise Program in Subjects With Chronic Pain Due to Knee Osteoarthritis',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Osteo Arthritis Knee|Chronic Pain',\n",
       "  'DEVICE: transcranial direct current stimulation (tDCS)|DEVICE: TENS|BEHAVIORAL: Exercise and General Education',\n",
       "  'Universidad de Murcia',\n",
       "  '',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2021-11-17',\n",
       "  '2024-03-01'],\n",
       " ['NCT00961571',\n",
       "  'Sunitinib and Capecitabine for First Line Colon Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: sunitinib and capecitabine',\n",
       "  'Georgetown University',\n",
       "  'Pfizer',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2011-03'],\n",
       " ['NCT03635671',\n",
       "  'Diabetic Retinopathy and Subclinical Signs of Disease Transition',\n",
       "  'DIRECTION',\n",
       "  'TERMINATED',\n",
       "  'Diabetic Retinopathy',\n",
       "  'DIAGNOSTIC_TEST: Optical Coherence Tomography Angiography',\n",
       "  'University of British Columbia',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-01',\n",
       "  '2019-07-15'],\n",
       " ['NCT01143571',\n",
       "  'Evaluation of Skin\", Colonic,\" and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'BMI|General Demographics Characteristics',\n",
       "  '',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-11-20',\n",
       "  ''],\n",
       " ['NCT02240771',\n",
       "  'Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: Transarterial chemotherapy|DRUG: Oral chemotherapy',\n",
       "  'All India Institute of Medical Sciences\",\" New Delhi',\n",
       "  'Indian Council of Medical Research',\n",
       "  '124.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2015-03'],\n",
       " ['NCT03365271',\n",
       "  'The Post-operative Effect of Applying Drainage on Total Knee Arthroplasty',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Knee Osteoarthritis',\n",
       "  'PROCEDURE: drainage|PROCEDURE: non-drainage',\n",
       "  \"Peking University People's Hospital\",\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-02',\n",
       "  '2019-02'],\n",
       " ['NCT06183671',\n",
       "  'A Study to Evaluate Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics of JX09 in Healthy Subjects.',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Resistant Hypertension',\n",
       "  'DRUG: JX09 or placebo SAD|DRUG: JX09 or placebo MAD|DRUG: JX09',\n",
       "  'Ji Xing Pharmaceuticals Australia Pty Ltd',\n",
       "  'Novotech (Australia) Pty Limited',\n",
       "  '92.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT02781571',\n",
       "  'Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C Virus Infection',\n",
       "  'DRUG: SOF/VEL',\n",
       "  'Gilead Sciences',\n",
       "  '',\n",
       "  '79.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-07-27',\n",
       "  '2017-07-28'],\n",
       " ['NCT03956771',\n",
       "  'Neurofeedback for Treatment-resistant Obsessive-compulsive Disorder (OCD)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Obsessive-Compulsive Disorder|OCD',\n",
       "  'BEHAVIORAL: Real neurofeedback|BEHAVIORAL: Sham neurofeedback',\n",
       "  'Pedro Morgado',\n",
       "  'Hospital de Braga|Clinical Academic Center (2CA)',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-04-05',\n",
       "  '2021-08-31'],\n",
       " ['NCT03737071',\n",
       "  'The Effects of Low Carbohydrate Diet on Liver Fat Content and Mitochondrial Fluxes',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Fatty Liver',\n",
       "  'BEHAVIORAL: Low Carbohydrate Diet',\n",
       "  'Helsinki University Central Hospital',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-11-15',\n",
       "  '2022-11'],\n",
       " ['NCT05661071',\n",
       "  'Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor Functions',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Duchenne Muscular Dystrophy',\n",
       "  \"OTHER: Modified Mini Mental Test:|OTHER: The Controlled Oral Word Association Test|OTHER: The Central Nervous System Vital Signs|OTHER: Conners' Parent Rating Scale-48 (Parent Report)|OTHER: Child Behavior Checklist 6-18 ages (Parent Report)|OTHER: Strengths and Difficulties Questionnaire (Self-Reported)|OTHER: Brooke Lower Extremity Functional Classification|OTHER: Motor Function Measurement-32 Items|OTHER: Four Square Step Test|OTHER: Six Minutes Walk Test|OTHER: Timed Performance Test\",\n",
       "  'Hacettepe University',\n",
       "  '',\n",
       "  '74.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-11',\n",
       "  '2023-03-01'],\n",
       " ['NCT03439371',\n",
       "  'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia',\n",
       "  'MTSA',\n",
       "  'RECRUITING',\n",
       "  'Acute Myeloid Leukemia',\n",
       "  'OTHER: HLA-mismatched micro-transplantation after induction chemotherapy',\n",
       "  'Centre Hospitalier Universitaire de Saint Etienne',\n",
       "  'Institut de Cancérologie de la Loire',\n",
       "  '21.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-08',\n",
       "  '2025-12-31'],\n",
       " ['NCT03257371',\n",
       "  'A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Post-traumatic Osteoarthritis',\n",
       "  '',\n",
       "  'James Stannard',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12-30',\n",
       "  '2019-07'],\n",
       " ['NCT06103071',\n",
       "  'Role of Membrane Sweeping on Initiation of Labor and Vaginal Birth in Previous Cesarean Section',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Vaginal Birth After Cesarean Section',\n",
       "  'PROCEDURE: Sweeping of membranes',\n",
       "  'HITEC-Institute of Medical Sciences',\n",
       "  '',\n",
       "  '384.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2023-01-15',\n",
       "  '2024-08-01'],\n",
       " ['NCT05924971',\n",
       "  'Aspirin for Postpartum Patients With Preeclampsia',\n",
       "  'ASAPP',\n",
       "  'RECRUITING',\n",
       "  'Preeclampsia Postpartum',\n",
       "  'DRUG: Aspirin 81Mg Ec Tab',\n",
       "  'MemorialCare Health System',\n",
       "  'University of California\",\" Irvine',\n",
       "  '86.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-26',\n",
       "  '2024-09'],\n",
       " ['NCT04242771',\n",
       "  'Mindfulness Meditation for Insomnia',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Insomnia',\n",
       "  'BEHAVIORAL: Mindfulness',\n",
       "  'Beth Israel Deaconess Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2022-12-02',\n",
       "  '2023-12-01'],\n",
       " ['NCT05121571',\n",
       "  'The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: HAIC|DRUG: Sorafenib',\n",
       "  'Sun Yat-sen University',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-04-21',\n",
       "  '2021-05-01'],\n",
       " ['NCT01740271',\n",
       "  'A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Neoplasms',\n",
       "  'DRUG: Epirubicin',\n",
       "  'AHS Cancer Control Alberta',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-12',\n",
       "  '2025-06'],\n",
       " ['NCT00912171',\n",
       "  'Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children',\n",
       "  'SB-OSAS',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea Syndrome',\n",
       "  'DRUG: budesonide (Aircort 50 nasal spray)|DRUG: montelukast (Singulair)',\n",
       "  'University of Bologna',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  '2010-06'],\n",
       " ['NCT01640171',\n",
       "  'Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Age-related Macular Degeneration|Central Retinal Vein Occlusion|Diabetic Macular Edema',\n",
       "  'PROCEDURE: Xylocaine 2% Injectable Anesthetic|DRUG: Proparacaine Hydrochloride 0.5% Drop|DRUG: Tetravisc 0.5% Gel|DRUG: Acuvail|DRUG: Intra-vitreal Anti-VEGF Drug',\n",
       "  'Retina Vitreous Associates of Florida',\n",
       "  '',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-07',\n",
       "  '2013-10'],\n",
       " ['NCT00507871',\n",
       "  'Transmission and the Respiratory Tract in Cryptosporidiosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cryptosporidiosis',\n",
       "  '',\n",
       "  'Tufts University',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '480.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2009-01'],\n",
       " ['NCT03128671',\n",
       "  'Family Automated Voice Reorientation Study',\n",
       "  'FAVoR',\n",
       "  'COMPLETED',\n",
       "  'Delirium|Cognitive Impairment|Health\",\" Subjective|Sleep',\n",
       "  'BEHAVIORAL: FAVoR Intervention',\n",
       "  'University of Miami',\n",
       "  'University of South Florida|National Institute of Nursing Research (NINR)',\n",
       "  '178.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-05-19',\n",
       "  '2021-05-17'],\n",
       " ['NCT00672971',\n",
       "  'Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Head Lice',\n",
       "  'OTHER: 4% dimethicone foam|OTHER: 1% permethrin',\n",
       "  'Oystershell NV',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2007-11'],\n",
       " ['NCT04852471',\n",
       "  'Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gynecologic Cancer',\n",
       "  'BEHAVIORAL: Standard Post-Operative Counseling + FACT-G|BEHAVIORAL: PROM symptom tracker',\n",
       "  'University of Michigan Rogel Cancer Center',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-01-05',\n",
       "  '2023-05-02'],\n",
       " ['NCT02960971',\n",
       "  'Neuropathic Pain After Lung Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Neuropathic Pain\", Postoperative|Chronic Pain,\" Postoperative|Chronic Chemotherapy-induced Neuropathic Pain|Chronic Chemotherapy-induced Pain|Chronic Chemotherapy-induced Peripheral Neuropathy',\n",
       "  'PROCEDURE: Thoracic surgery for lung cancer',\n",
       "  'Danish Pain Research Center',\n",
       "  'DOLORisk Consortium|Aarhus University Hospital',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-02',\n",
       "  '2021-06-16'],\n",
       " ['NCT02352571',\n",
       "  'Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Neoplasm Metastasis|Gastric Cancer|Colorectal Cancer',\n",
       "  'BIOLOGICAL: GC1118',\n",
       "  'Green Cross Corporation',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2017-06'],\n",
       " ['NCT00611871',\n",
       "  'The Use of Propranolol to Block Memory Reconsolidation in PTSD',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Posttraumatic Stress Disorders',\n",
       "  'DRUG: Propranolol|DRUG: Placebo',\n",
       "  'Wayne State University',\n",
       "  'John D. Dingell VA Medical Center|New York University',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2015-09'],\n",
       " ['NCT04676971',\n",
       "  'Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'DRUG: hzVSF-v13|DRUG: Placebo (Normal saline solution)',\n",
       "  'ImmuneMed\",\" Inc.',\n",
       "  '',\n",
       "  '115.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-12-11',\n",
       "  '2021-10-28'],\n",
       " ['NCT01191671',\n",
       "  'Language and Deglutition in Children',\n",
       "  'LDC',\n",
       "  'COMPLETED',\n",
       "  'Child|Development',\n",
       "  '',\n",
       "  'Fortaleza University',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-05',\n",
       "  '2009-12'],\n",
       " ['NCT01909271',\n",
       "  'Tailored Approaches to Stroke Health Education',\n",
       "  'TASHE',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'BEHAVIORAL: Stroke Education Film Viewing|OTHER: Stroke Education Pamphlet Exposure',\n",
       "  'Columbia University',\n",
       "  'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
       "  '290.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2014-04-16',\n",
       "  '2019-12'],\n",
       " ['NCT03673371',\n",
       "  \"Women's-Specific Footwear With Prosthetic Feet\",\n",
       "  'WSF',\n",
       "  'COMPLETED',\n",
       "  'Lower Limb Amputation Below Knee (Injury)|Lower Limb Amputation Above Knee (Injury)',\n",
       "  'OTHER: Questionnaire',\n",
       "  'Minneapolis Veterans Affairs Medical Center',\n",
       "  'United States Department of Defense',\n",
       "  '100.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-03-04',\n",
       "  '2023-01-06'],\n",
       " ['NCT05503771',\n",
       "  'Improving Pediatrician Counseling About Infant Safe Sleep Using the Electronic Medical Record',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Sudden Infant Death|Sudden Unexplained Infant Death',\n",
       "  'BEHAVIORAL: ISA-MI|OTHER: Standard of Care (SOC)',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Minority Health and Health Disparities (NIMHD)',\n",
       "  '470.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-10-10',\n",
       "  '2026-02-28'],\n",
       " ['NCT05898971',\n",
       "  'Robotic Hand on Hand Functions in Strokes',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'CVA (Cerebrovascular Accident)',\n",
       "  'OTHER: Robotic|OTHER: Mirror|OTHER: Traditional Physical Therapy',\n",
       "  'Cairo University',\n",
       "  'Batterjee Medical College',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-12',\n",
       "  '2023-10-11'],\n",
       " ['NCT04429971',\n",
       "  'Pre-Exposure Prophylaxis in the Emergency Department',\n",
       "  'PrEPPED',\n",
       "  'COMPLETED',\n",
       "  'HIV/AIDS|PrEP',\n",
       "  'OTHER: PrEP screening program|OTHER: PrEP starter pack',\n",
       "  'Icahn School of Medicine at Mount Sinai',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2020-03-18',\n",
       "  '2023-07-31'],\n",
       " ['NCT02626871',\n",
       "  'Atrial Fibrillation\", Stroke,\" and Bleeding in Patients Undergoing Aortic Biovalve Implantation',\n",
       "  'CAREAVR',\n",
       "  'COMPLETED',\n",
       "  'Atrial Fibrillation|Stroke|Transient Ischemic Attack|Bleeding|Aortic Stenosis',\n",
       "  '',\n",
       "  'University of Turku',\n",
       "  'Helsinki University Central Hospital|Oulu University Hospital|Kuopio University Hospital',\n",
       "  '850.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2002-01',\n",
       "  '2015-12'],\n",
       " ['NCT00932971',\n",
       "  'HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis',\n",
       "  'HIDIT-II',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis D',\n",
       "  'DRUG: PEG-IFN alfa-2a\", Tenofovir|DRUG: PEG-IFN alfa-2a,\" placebo',\n",
       "  'HepNet Study House\",\" German Liverfoundation',\n",
       "  'Hannover Medical School|Hoffmann-La Roche|Gilead Sciences',\n",
       "  '70.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2017-08-02'],\n",
       " ['NCT02528071',\n",
       "  'Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis',\n",
       "  'SLA',\n",
       "  'TERMINATED',\n",
       "  'ALS (Amyotrophic Lateral Sclerosis)',\n",
       "  'OTHER: Diaphragmatic endurance test',\n",
       "  'Centre Hospitalier Universitaire de Saint Etienne',\n",
       "  '',\n",
       "  '136.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-09-29',\n",
       "  '2020-10-28'],\n",
       " ['NCT04840771',\n",
       "  'Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pituitary Adenoma',\n",
       "  'PROCEDURE: Endoscopic Endonasal Pituitary Surgery',\n",
       "  'Federico II University',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-01',\n",
       "  '2020-07-31'],\n",
       " ['NCT06155071',\n",
       "  'Effects of 8 Week Plyometric Training on Physical Fitness and Technical Skills of Domestic Cricket Players',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Fitness|Technical Skills',\n",
       "  'OTHER: Plyometric Training|OTHER: Conventional Exercises',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-08-14',\n",
       "  '2024-01-10'],\n",
       " ['NCT03170271',\n",
       "  'A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.',\n",
       "  'ANDHI',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: Benralizumab (Medi-563)|DRUG: Placebo',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '660.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-07-07',\n",
       "  '2020-10-21'],\n",
       " ['NCT01982071',\n",
       "  'A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Candidemia|Candidiasis',\n",
       "  'DRUG: Micafungin',\n",
       "  'Astellas Pharma China\",\" Inc.',\n",
       "  '',\n",
       "  '59.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-09-26',\n",
       "  '2015-08-28'],\n",
       " ['NCT03016871',\n",
       "  'Nivolumab\", Ifosfamide, Carboplatin,\" and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma',\n",
       "  'DRUG: Carboplatin|DRUG: Etoposide|DRUG: Ifosfamide|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab',\n",
       "  'City of Hope Medical Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-24',\n",
       "  '2026-01-30'],\n",
       " ['NCT05313971',\n",
       "  'Impact of Self-awareness in Medical Students',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Burnout\", Student|Stress,\" Psychological|Compassion|Self-Perception',\n",
       "  'OTHER: Self knowledge course',\n",
       "  'University of Coimbra',\n",
       "  '',\n",
       "  '46.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-10-01',\n",
       "  '2020-12-31'],\n",
       " ['NCT02732171',\n",
       "  'PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  'OTHER: Research Blood Collection',\n",
       "  'Abramson Cancer Center at Penn Medicine',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2016-04',\n",
       "  '2026-04'],\n",
       " ['NCT00510471',\n",
       "  'Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  \"Non-Hodgkin's Lymphoma\",\n",
       "  'DRUG: autologous immunoglobulin idiotype-KLH conjugate vaccine',\n",
       "  'Genitope Corporation',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2007-05',\n",
       "  ''],\n",
       " ['NCT04856371',\n",
       "  'Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+\",\" HER2- Advanced Breast Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Advanced Breast Cancer',\n",
       "  'DRUG: CYH33|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib',\n",
       "  'Haihe Biopharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '228.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04',\n",
       "  '2022-12'],\n",
       " ['NCT00769171',\n",
       "  'Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)',\n",
       "  'DRAGON',\n",
       "  'COMPLETED',\n",
       "  'Infection\",\" Intra-abdominal',\n",
       "  'DRUG: Avelox (Moxifloxacin\",\" BAY12-8039)|DRUG: Ceftriaxone + Metronidazole',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '364.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2007-01'],\n",
       " ['NCT03522571',\n",
       "  'Experimental Gingivitis in Patients With Altered Passive Eruption',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Altered Passive Eruption of Teeth',\n",
       "  'BEHAVIORAL: Experimental gingivitis',\n",
       "  'Rustam Aghazada',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2017-02-21',\n",
       "  '2017-07-19'],\n",
       " ['NCT00116571',\n",
       "  'Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostatic Hyperplasia',\n",
       "  'DRUG: Lemuteporfin for injection|DEVICE: Transurethral drug delivery system|DEVICE: Transurethral light delivery system',\n",
       "  'QLT Inc.',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2006-12'],\n",
       " ['NCT00782171',\n",
       "  'Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Partial Edentulism',\n",
       "  'DEVICE: SLActive dental implant',\n",
       "  'Institut Straumann AG',\n",
       "  '',\n",
       "  '266.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-07',\n",
       "  '2010-02'],\n",
       " ['NCT05982171',\n",
       "  'Transcutaneous Spinal Cord Stimulation to Promote Walking Recovery After Spinal Cord Injury',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Spinal Cord Injuries',\n",
       "  'DEVICE: Exo + TSCS|DEVICE: Exo + Sham',\n",
       "  'Craig Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-15',\n",
       "  '2024-09-15'],\n",
       " ['NCT00376571',\n",
       "  'Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?',\n",
       "  'BIFI',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Disease',\n",
       "  'PROCEDURE: Percutaneous coronary intervention',\n",
       "  'Aarhus University Hospital Skejby',\n",
       "  'Johnson & Johnson',\n",
       "  '413.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-10',\n",
       "  '2011-03'],\n",
       " ['NCT00410371',\n",
       "  'Study to Compare Two Formulations of Lamotrigine in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Disorders',\n",
       "  'DRUG: Lamotrigine|DRUG: GI267119',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '96.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-12-28',\n",
       "  '2007-01-25'],\n",
       " ['NCT03066271',\n",
       "  'Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer',\n",
       "  'PRIME',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Non-Small Cell Lung Cancer Stage|Chemoradiation',\n",
       "  'OTHER: Exercise +|OTHER: Control +',\n",
       "  'Rigshospitalet\",\" Denmark',\n",
       "  'University of Copenhagen',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-04-03',\n",
       "  '2023-12-31'],\n",
       " ['NCT02125071',\n",
       "  'Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation',\n",
       "  'LT',\n",
       "  'COMPLETED',\n",
       "  'Liver Cirrhosis|Chronic Hepatitis B',\n",
       "  'OTHER: Blood Sample Collection',\n",
       "  'Dong-Gu Kim',\n",
       "  'Green Cross Corporation',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-11',\n",
       "  '2015-09'],\n",
       " ['NCT02869971',\n",
       "  'Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia',\n",
       "  'PARTEM',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostatic Hyperplasia',\n",
       "  'DEVICE: Embosphere® (Prostatic Arteries Embolization)|DRUG: Drug therapy',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  'Ministry of Health\",\" France',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2022-03-25'],\n",
       " ['NCT01801371',\n",
       "  '68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma',\n",
       "  'GRGDG',\n",
       "  'UNKNOWN',\n",
       "  'Glioma',\n",
       "  'DRUG: 68Ga-BNOTA-PRGD2',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  'Beijing Tiantan Hospital',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-10',\n",
       "  '2017-12'],\n",
       " ['NCT05800171',\n",
       "  'Efficacy of Single Use Disposable Elevator Cap (DEC) Duodenoscopy',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cholangitis',\n",
       "  '',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-04-24',\n",
       "  '2025-02-21'],\n",
       " ['NCT04293471',\n",
       "  'Prediction of Outcome by Echocardiography in Left Bundle Branch Block',\n",
       "  'EchoLBBB',\n",
       "  'RECRUITING',\n",
       "  'Left Bundle-Branch Block',\n",
       "  '',\n",
       "  'University Hospital of North Norway',\n",
       "  'Oslo University Hospital|University of Bergen|Norwegian University of Science and Technology|University of Tromso|KU Leuven',\n",
       "  '2000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-15',\n",
       "  '2036-12-31'],\n",
       " ['NCT05973071',\n",
       "  'Clinical Use of a Contraceptive Decision Aid and Patient Outcomes',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Contraceptive Usage',\n",
       "  'BEHAVIORAL: Tuune Supplemented Contraceptive Visit|BEHAVIORAL: Traditional Contraceptive Visit',\n",
       "  'Texas Christian University',\n",
       "  'Oklahoma State University',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2024-01-01',\n",
       "  '2025-12-30'],\n",
       " ['NCT03118271',\n",
       "  'Comparison of the Effect of Lumbar Traction\", Spinal Manipulation,\" and Surgery in the Treatment of Lumbar Disc Herniation',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lumbar Disc Herniation|Lumbar Traction|Spinal Manipulation|Lumbar Surgery',\n",
       "  'DEVICE: lumbar traction|PROCEDURE: spinal manipulation|PROCEDURE: surgery',\n",
       "  'Shin Kong Wu Ho-Su Memorial Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-01',\n",
       "  '2019-12'],\n",
       " ['NCT00708071',\n",
       "  'Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin\", Vapor Heated,\" Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Facial Rhytidectomy (Face-lift)',\n",
       "  'BIOLOGICAL: Fibrin Sealant with 4 IU/ml Thrombin\", Vapor-Heated,\" Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)',\n",
       "  'Baxter Healthcare Corporation',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-06',\n",
       "  '2008-09'],\n",
       " ['NCT01875471',\n",
       "  'Clinical Evaluation of Two Daily Disposable Contact Lenses',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Refractive Error',\n",
       "  'DEVICE: delefilcon A|DEVICE: narafilcon A',\n",
       "  'Johnson & Johnson Vision Care\",\" Inc.',\n",
       "  '',\n",
       "  '279.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER',\n",
       "  '2013-06',\n",
       "  '2013-08'],\n",
       " ['NCT01637571',\n",
       "  'Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain',\n",
       "  'Dexilant',\n",
       "  'WITHDRAWN',\n",
       "  'Chest Pain|Gastrointestinal Reflux Disease',\n",
       "  'DRUG: Dexilant|DRUG: Dexilant Placebo',\n",
       "  'University of Iowa',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT01216371',\n",
       "  'Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)',\n",
       "  'SMAT',\n",
       "  'UNKNOWN',\n",
       "  'Renal Cell Carcinoma|Pulmonary Metastases',\n",
       "  'DRUG: Sunitinib|DRUG: Placebo',\n",
       "  'Association of Urologic Oncology (AUO)',\n",
       "  'University Hospital\",\" Essen',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-10',\n",
       "  '2015-10'],\n",
       " ['NCT00021671',\n",
       "  'Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Erythromycin|DRUG: Nevirapine|DRUG: Ampicillin sodium|DRUG: Metronidazole',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)',\n",
       "  '3720.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '',\n",
       "  '2004-11'],\n",
       " ['NCT05610371',\n",
       "  'Intrauterine Anesthesia in Operative\", Awake,\" Office Hysteroscopy. A Randomized Double-blind Placebo-controlled Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia\",\" Local|Office Hysteroscopy',\n",
       "  'DRUG: Lidocaine|DRUG: Saline',\n",
       "  'Assuta Ashdod Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-01',\n",
       "  '2022-05-01'],\n",
       " ['NCT00172471',\n",
       "  'The Relationship Between Sleep Disorders and Cytokine Levels Among Hemodialysis and Peritoneal Dialysis Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Renal Failure|Sleep Disorder|Hemodialysis|Peritoneal Dialysis',\n",
       "  '',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT03237871',\n",
       "  'The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Feasibility',\n",
       "  'BEHAVIORAL: Text-message survey and informational text messages',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '17.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2017-07-07',\n",
       "  '2017-09-19'],\n",
       " ['NCT04039971',\n",
       "  'Tendon-Bone Versus All-Soft-Tissue for ACL Reconstruction: A Patient-Blinded Randomized Clinical Trial',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Anterior Cruciate Ligament Injuries|Anterior Cruciate Ligament Rupture|Anterior Cruciate Ligament Tear',\n",
       "  'PROCEDURE: ACL Reconstruction',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  \"Children's Hospital Colorado\",\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2020-08-01',\n",
       "  '2029-08-31'],\n",
       " ['NCT01558271',\n",
       "  'A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: LY2189265|DRUG: Placebo|DRUG: Liraglutide',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '492.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2014-05'],\n",
       " ['NCT04597671',\n",
       "  'Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)',\n",
       "  'NVALT28',\n",
       "  'RECRUITING',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Durvalumab|RADIATION: low-dose PCI',\n",
       "  'Association NVALT Studies',\n",
       "  '',\n",
       "  '170.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-12-06',\n",
       "  '2032-12'],\n",
       " ['NCT03994471',\n",
       "  'Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.',\n",
       "  'ELIXIR',\n",
       "  'RECRUITING',\n",
       "  'End Stage Renal Disease',\n",
       "  'DRUG: XyloCore Low Strenght\", XyloCore Medium Strenght, XyloCore High Strenght|DRUG: 1.36%,1.50%,2.27%,2.50%,3.86%,\" 2.25% Glucose PD Solution',\n",
       "  'Iperboreal Pharma Srl',\n",
       "  '',\n",
       "  '170.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-14',\n",
       "  '2024-12'],\n",
       " ['NCT06143371',\n",
       "  'A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy|Plaque Psoriasis',\n",
       "  'BIOLOGICAL: CAN10|BIOLOGICAL: CAN10 - Placebo',\n",
       "  'Cantargia AB',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-08-21',\n",
       "  '2025-04-24'],\n",
       " ['NCT04862871',\n",
       "  'Enhancing Analgesia in Chronic Pain Through Exercise',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Pain|Chronic Widespread Pain|Fibromyalgia',\n",
       "  'BEHAVIORAL: Physical Activity - Pediatric Pain Rehabilitation Center',\n",
       "  \"Boston Children's Hospital\",\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2022-04-01',\n",
       "  '2022-11'],\n",
       " ['NCT02080871',\n",
       "  'A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.',\n",
       "  'VBXFLEX',\n",
       "  'COMPLETED',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'DEVICE: Stenting of the Common and/or External Iliac Arteries',\n",
       "  'W.L.Gore & Associates',\n",
       "  '',\n",
       "  '134.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2018-10'],\n",
       " ['NCT06132971',\n",
       "  'Multi-court Trial of NBP to Prevent Substance Abuse and Mental Health Disorders (MTC)',\n",
       "  'MTC',\n",
       "  'COMPLETED',\n",
       "  'Divorce|Drug Abuse|Mental Health Disorder',\n",
       "  'BEHAVIORAL: New Beginnings Program',\n",
       "  'Arizona State University',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '2415.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-07-30',\n",
       "  '2017-01-31'],\n",
       " ['NCT01044771',\n",
       "  'Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria',\n",
       "  'RALPIR',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Proteinuria',\n",
       "  'DRUG: change from tenofovir to raltegravir',\n",
       "  'Metropolis Medical',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-01',\n",
       "  '2011-06'],\n",
       " ['NCT05029271',\n",
       "  'InPen User Experience',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Type 1',\n",
       "  'DEVICE: InPen with Guardian 4 System',\n",
       "  'Medtronic Diabetes',\n",
       "  '',\n",
       "  '34.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2023-04-17',\n",
       "  '2023-12-08'],\n",
       " ['NCT03648671',\n",
       "  \"Pain in Parkinson's Disease With Motor Fluctuations.\",\n",
       "  'PAINinPD',\n",
       "  'UNKNOWN',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: safinamide metansolfonato (12 weeks)|DRUG: safinamide metansolfonato (12 weeks)|DRUG: rasagilina mesilato (12 weeks)|DRUG: rasagilina mesilato (12 weeks)',\n",
       "  'Universita di Verona',\n",
       "  'Azienda Ospedaliera Universitaria Integrata Verona',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-03-28',\n",
       "  '2019-11-30'],\n",
       " ['NCT02903771',\n",
       "  'Phase I Study of Cantrixil in Patients With Ovarian Cancer\",\" Fallopian Tube Cancer or Primary Peritoneal Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms',\n",
       "  'DRUG: Part A: Dose Escalation of Cantrixil|DRUG: Part B: Expansion Cohort of Cantrixil',\n",
       "  'Kazia Therapeutics Limited',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-11',\n",
       "  '2020-03-24'],\n",
       " ['NCT05524571',\n",
       "  'Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Thyroid Eye Disease',\n",
       "  'DRUG: Batoclimab|DRUG: Placebo',\n",
       "  'Immunovant Sciences GmbH',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-05',\n",
       "  '2025-01'],\n",
       " ['NCT02179671',\n",
       "  'Immune-Modulated Study of Selected Small Molecules (Gefitinib\", AZD9291,\" or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)',\n",
       "  'DRUG: Gefitinib|DRUG: AZD9291|DRUG: Selumetinib+Docetaxel|DRUG: Tremelimumab',\n",
       "  'AstraZeneca',\n",
       "  'Quintiles\",\" Inc.',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07-25',\n",
       "  '2016-06-11'],\n",
       " ['NCT00788671',\n",
       "  'Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Atypical Endometrial Hyperplasia|Stage I Uterine Corpus Cancer AJCC v7|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7',\n",
       "  'OTHER: Laboratory Biomarker Analysis|DEVICE: Levonorgestrel-Releasing Intrauterine System|OTHER: Quality-of-Life Assessment',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '69.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-11-03',\n",
       "  '2024-11-30'],\n",
       " ['NCT05003271',\n",
       "  'Pulmonary Rehabilitation Post-COVID-19',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'OTHER: Exercise program (virtual/remote)',\n",
       "  'University of Manitoba',\n",
       "  'Health Sciences Centre Foundation\", Manitoba|Health Sciences Centre, Winnipeg,\" Manitoba',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-04-04',\n",
       "  '2023-10-01'],\n",
       " ['NCT02047071',\n",
       "  'Effect of CPAP Treatment in Women With Moderate-to-severe OSA.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea',\n",
       "  'DEVICE: Continuous positive airways pressure',\n",
       "  'Francisco Campos-Rodriguez',\n",
       "  'Fondo de Investigacion Sanitaria|Sociedad Española de Neumología y Cirugía Torácica',\n",
       "  '307.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02',\n",
       "  '2015-07'],\n",
       " ['NCT04416971',\n",
       "  'Clinical Values of Mature Fistulas in Hemodialysis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hemodialysis Access Failure|Hemodialysis Complication',\n",
       "  'PROCEDURE: AVF puncture',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-20',\n",
       "  '2021-11-20'],\n",
       " ['NCT06000371',\n",
       "  'Cutoff Value of Ankle Brachial Pressure Index for Vacuum Assisted Closure Application in Diabetic Foot Ulcers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetic Foot',\n",
       "  'DEVICE: Vacuum assisted Closure application',\n",
       "  'Mansoura University',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-04-25',\n",
       "  '2021-10-02'],\n",
       " ['NCT00851071',\n",
       "  'Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anxiety',\n",
       "  'BEHAVIORAL: Cognitive Behavioral Therapy',\n",
       "  'The Cleveland Clinic',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-02',\n",
       "  '2017-12-20'],\n",
       " ['NCT02921971',\n",
       "  'Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Systemic Sclerosis',\n",
       "  'DRUG: SAR156597|DRUG: Placebo',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-12-21',\n",
       "  '2019-04-01'],\n",
       " ['NCT00256971',\n",
       "  'Balance in Patients After Surgery for Torn Meniscus',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Torn Menisci',\n",
       "  'PROCEDURE: meniscectomy',\n",
       "  'Hadassah Medical Organization',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-11',\n",
       "  '2008-01'],\n",
       " ['NCT00165971',\n",
       "  'Recovery From General Anesthesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia\", General|Recovery Period,\" Anesthesia',\n",
       "  'PROCEDURE: BIS monitoring',\n",
       "  'Emory University',\n",
       "  'CogState Ltd.',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '2003-12',\n",
       "  '2007-02'],\n",
       " ['NCT05698771',\n",
       "  'NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy',\n",
       "  'NAD-brain',\n",
       "  'RECRUITING',\n",
       "  'Healthy',\n",
       "  'DIETARY_SUPPLEMENT: nicotinamide riboside|DIETARY_SUPPLEMENT: nicotinamide mononucleotide',\n",
       "  'Haukeland University Hospital',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-29',\n",
       "  '2023-03-17'],\n",
       " ['NCT01159171',\n",
       "  'A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer',\n",
       "  'DRUG: bevacizumab [Avastin]|DRUG: capecitabine [Xeloda]|DRUG: oxaliplatin',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2010-07'],\n",
       " ['NCT01464671',\n",
       "  'Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention',\n",
       "  'STATUS PCI',\n",
       "  'TERMINATED',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Bivalirudin|DRUG: Heparin',\n",
       "  'Stony Brook University',\n",
       "  '',\n",
       "  '260.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2014-09'],\n",
       " ['NCT04251871',\n",
       "  'Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pneumonia Caused by Human Coronavirus (Disorder)',\n",
       "  'DRUG: Conventional medicines (Oxygen therapy\", alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|DRUG: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation,\" and lopinavir/ritonavir)',\n",
       "  'Beijing 302 Hospital',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01-22',\n",
       "  '2021-01-22'],\n",
       " ['NCT00067171',\n",
       "  'Telephone Enhancement Procedure for Continuing Care - 1',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Substance-Related Disorders',\n",
       "  'BEHAVIORAL: Behavior Therapy',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '339.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: ',\n",
       "  '2003-01',\n",
       "  '2004-01'],\n",
       " ['NCT04565171',\n",
       "  'Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Renal Impairment',\n",
       "  'DRUG: Yimitasvir Phosphate Capsule',\n",
       "  'Sunshine Lake Pharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '16.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04-15',\n",
       "  '2022-05-07'],\n",
       " ['NCT03167671',\n",
       "  'The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain',\n",
       "  'AposBack',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Low Back Pain',\n",
       "  'DEVICE: AposTherapy|OTHER: Traditional Physical Therapy',\n",
       "  'Montefiore Medical Center',\n",
       "  'Apos Medical and Sports Technology Ltd.',\n",
       "  '143.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-08-15',\n",
       "  '2024-01-28'],\n",
       " ['NCT03795571',\n",
       "  'Lenalidomide\", Rituximab, Gemcitabine,\" Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL',\n",
       "  'R2-GOD',\n",
       "  'UNKNOWN',\n",
       "  'Diffuse Large B-cell Lymphoma Recurrent|Diffuse Large B Cell Lymphoma Refractory',\n",
       "  'DRUG: Rituximab|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Dexamethasone|DRUG: Lenalidomide Oral Capsule',\n",
       "  'The First Affiliated Hospital with Nanjing Medical University',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-01',\n",
       "  '2019-12-31'],\n",
       " ['NCT00939471',\n",
       "  'Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis',\n",
       "  'INTACT',\n",
       "  'COMPLETED',\n",
       "  'Chronic Sinusitis',\n",
       "  'DEVICE: Relieva™ Balloon Sinuplasty™ System',\n",
       "  'Acclarent',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-04-01',\n",
       "  '2010-05-01'],\n",
       " ['NCT01957371',\n",
       "  'Mindful Yoga Therapy for Veterans With PTSD and Pain',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'PTSD|Chronic Pain',\n",
       "  'BEHAVIORAL: Mindful Yoga Therapy',\n",
       "  'VA Connecticut Healthcare System',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-09',\n",
       "  '2015-11'],\n",
       " ['NCT03223571',\n",
       "  'Brain Plasticity Mapping Post-stroke',\n",
       "  'MAPPY',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'OTHER: Motor rehabilitation training',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-07-27',\n",
       "  '2017-07-27'],\n",
       " ['NCT00645671',\n",
       "  'Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ocular Inflammation',\n",
       "  'DRUG: 0.5% Loteprednol Etabonate Ophthalmic Ointment|DRUG: Vehicle of Loteprednol Etabonate Ophthalmic Ointment',\n",
       "  'Bausch & Lomb Incorporated',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-03',\n",
       "  '2009-03'],\n",
       " ['NCT04909671',\n",
       "  'Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.',\n",
       "  'Timely',\n",
       "  'RECRUITING',\n",
       "  'Lynch Syndrome',\n",
       "  'DEVICE: Gi Genius\",\" Medtronic|OTHER: White light standart colonoscopy',\n",
       "  'Hospital Clinic of Barcelona',\n",
       "  'European Society of Gastrointestinal Endoscopy',\n",
       "  '404.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-09-13',\n",
       "  '2023-12-01'],\n",
       " ['NCT06091371',\n",
       "  'Arthrorisis of the Subtalar Joint With a Polymeric Endorthesis for Flexible Flatfoot Treatment During the Growth Age Prospective Evaluation',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Subtalar Arthrorisis|Flat Feet|Growth Age',\n",
       "  '',\n",
       "  'Istituto Ortopedico Rizzoli',\n",
       "  '',\n",
       "  '55.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-07-01',\n",
       "  '2028-01'],\n",
       " ['NCT00752271',\n",
       "  'AMS Study: Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Osteoarthritis',\n",
       "  '',\n",
       "  'National Institute on Aging (NIA)',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-05',\n",
       "  '2010-05'],\n",
       " ['NCT04094571',\n",
       "  'Muscle Delay Characterization',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Neurological Disorders',\n",
       "  'DEVICE: Functional Electrical Stimulation (FES) Control Protocol|DEVICE: Functional Electrical Stimulation (FES) Angle Protocol',\n",
       "  'University of Florida',\n",
       "  'National Science Foundation',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-10-01',\n",
       "  '2021-09-03'],\n",
       " ['NCT05797571',\n",
       "  \"SOSteniamoci: Stakeholders' Survey\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Informal Caregivers',\n",
       "  '',\n",
       "  'Istituto Auxologico Italiano',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01-15',\n",
       "  '2022-12-15'],\n",
       " ['NCT02499471',\n",
       "  'Brown Adipose Tissue Activity and Thyroid Hormone',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypothyroidism|Hyperthyroidism|Obesity',\n",
       "  'OTHER: Levothyroxine therapy (137.75 ± 23.75 μg/day)',\n",
       "  'Maastricht University Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-03',\n",
       "  '2014-07'],\n",
       " ['NCT04318171',\n",
       "  'The Evaluation of Tomographic 3D Ultrasound for the Assessment of Vascular Pathology',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Carotid Artery Plaque',\n",
       "  'DEVICE: 3D Imaging.',\n",
       "  'Imperial College London',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-07-01',\n",
       "  '2023-01-01'],\n",
       " ['NCT01231971',\n",
       "  \"Alzheimer's Disease Neuroimaging Initiative 2\",\n",
       "  'ADNI2',\n",
       "  'COMPLETED',\n",
       "  \"Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)|Significant Memory Concern (SMC)|Early Mild Cognitive Impairment (EMCI)|Late Mild Cognitive Impairment (LMCI)\",\n",
       "  'DRUG: Florbetapir|DRUG: Flortaucipir',\n",
       "  'University of Southern California',\n",
       "  \"Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute\",\n",
       "  '1182.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-02-14',\n",
       "  '2017-11-29'],\n",
       " ['NCT04695171',\n",
       "  'LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Hiatal Hernia Large|Gastro Esophageal Reflux|Hiatal Hernia|Hiatal Hernia\", Paraesophageal|Reflux,\" Gastroesophageal|Reflux Acid',\n",
       "  'DEVICE: LINX Reflux Management System|PROCEDURE: Fundoplication',\n",
       "  'Foregut Research Foundation',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-01-14',\n",
       "  '2028-01'],\n",
       " ['NCT03958071',\n",
       "  'A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Pulmonary Fibrosis',\n",
       "  'DRUG: Nintedanib|DRUG: Pirfenidone|OTHER: Untreated Cohort',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '13264.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2019-05-31'],\n",
       " ['NCT03711071',\n",
       "  'Ideas\", Concerns,\" Expectations. Implementing Patient-centered Communication',\n",
       "  'ICE',\n",
       "  'UNKNOWN',\n",
       "  'Communication|Back Pain',\n",
       "  '\"\"OTHER: Workshop \"\"\"\"ICE training\"\"\"\"\"\"',\n",
       "  'University of Erlangen-Nürnberg Medical School',\n",
       "  'German Federal Ministry of Education and Research|University of Erlangen-Nürnberg',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2017-10-01',\n",
       "  '2019-12'],\n",
       " ['NCT03516071',\n",
       "  'A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatocellular Carcinoma (HCC)',\n",
       "  'DRUG: Brivanib 800 mg\", QD|DRUG: Brivanib 400 mg,\" BID',\n",
       "  'Zai Lab (Shanghai) Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-05-17',\n",
       "  '2019-07-19'],\n",
       " ['NCT01953471',\n",
       "  'Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergic Rhinitis Due to Grass Pollen',\n",
       "  'OTHER: Allergic rhinitis',\n",
       "  'Hopital Foch',\n",
       "  '',\n",
       "  '959.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2011-12'],\n",
       " ['NCT03921671',\n",
       "  'Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)',\n",
       "  'RELEVENT',\n",
       "  'UNKNOWN',\n",
       "  'Thymic Carcinoma|Thymoma',\n",
       "  'COMBINATION_PRODUCT: Ramucirumab',\n",
       "  'Marina Garassino',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-01',\n",
       "  '2022-07-16'],\n",
       " ['NCT02134171',\n",
       "  'Early Predictive Factors of Cardiac and Cerebral Involvement in TMA',\n",
       "  'MATRISK',\n",
       "  'COMPLETED',\n",
       "  'Thrombotic Microangiopathies|Thrombotic Thrombocytopenic Purpura',\n",
       "  'OTHER: Biological and imaging investigations',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '119.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-06-10',\n",
       "  '2017-07-30'],\n",
       " ['NCT04855071',\n",
       "  'Radiofrequency and Pelvic Organ Prolapse',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pelvic Organ Prolapse',\n",
       "  'DEVICE: Non-ablative radiofrequency application|OTHER: Usual intervention',\n",
       "  \"Fundació d'investigació Sanitària de les Illes Balears\",\n",
       "  'University of the Balearic Islands',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-04-23',\n",
       "  '2022-10-23'],\n",
       " ['NCT01741571',\n",
       "  'Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lung Cancer',\n",
       "  'DEVICE: EBUS guided FNA with and without suction',\n",
       "  'American University of Beirut Medical Center',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-12',\n",
       "  '2017-01'],\n",
       " ['NCT00484471',\n",
       "  'ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness',\n",
       "  'ABLE',\n",
       "  'COMPLETED',\n",
       "  'Bipolar Disorder',\n",
       "  'DRUG: aripiprazole|DRUG: valproate|DRUG: placebo',\n",
       "  'Korea Otsuka International Asia Arab',\n",
       "  '',\n",
       "  '127.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-10',\n",
       "  '2012-11'],\n",
       " ['NCT02301871',\n",
       "  'The Effect of Soft Tissue Mobilization in Myofascial Neck Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Neck Pain',\n",
       "  \"DEVICE: Dr. Gene's Health and Wellness|PROCEDURE: Muscle Energy Technique|PROCEDURE: Static stretching and Cervical non thrust manipulation\",\n",
       "  'Maharishi Markendeswar University (Deemed to be University)',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2014-05'],\n",
       " ['NCT03906071',\n",
       "  'Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer',\n",
       "  'SAPPHIRE',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Metastatic Non-Squamous Non-Small Cell Lung Cancer',\n",
       "  'BIOLOGICAL: Nivolumab|DRUG: Sitravatinib|DRUG: Docetaxel',\n",
       "  'Mirati Therapeutics Inc.',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '532.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-15',\n",
       "  '2024-04-30'],\n",
       " ['NCT03679871',\n",
       "  'Spiritual Assessment in Chronic Pain Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Pain|Spirituality',\n",
       "  'OTHER: Questionnaire validation',\n",
       "  'University of Zurich',\n",
       "  'Swiss National Science Foundation',\n",
       "  '225.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2018-10-22',\n",
       "  '2019-11-13'],\n",
       " ['NCT03272971',\n",
       "  'Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lung Cancer|Lung Cancer Metastatic|Lung Cancer\",\" Non-small Cell',\n",
       "  'DEVICE: Radio-frequency Ablation',\n",
       "  'Broncus Medical Inc',\n",
       "  'Uptake Medical Technology\",\" Inc.',\n",
       "  '3.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2017-12-05',\n",
       "  '2019-01-30'],\n",
       " ['NCT01998971',\n",
       "  'A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: Daratumumab|DRUG: Velcade|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Melphalan|DRUG: Prednisone|DRUG: Thalidomide|DRUG: Diphenhydramine|DRUG: Acetaminophen|DRUG: Carfilzomib|DRUG: Lenalidomide|DRUG: Montelukast',\n",
       "  'Janssen Research & Development\",\" LLC',\n",
       "  '',\n",
       "  '242.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02-18',\n",
       "  '2023-12-29'],\n",
       " ['NCT03146871',\n",
       "  'Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome\", Chronic Myelomonocytic Leukemia,\" or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Adult Acute Myeloid Leukemia',\n",
       "  'DRUG: Azacitidine|DRUG: Decitabine|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein',\n",
       "  'University of Southern California',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '7.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-20',\n",
       "  '2019-03-27'],\n",
       " ['NCT01153971',\n",
       "  'A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  \"Non-Hodgkin's Lymphoma\",\n",
       "  'DRUG: rituximab',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '47.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-07-20',\n",
       "  '2010-09-24'],\n",
       " ['NCT05319171',\n",
       "  'Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.',\n",
       "  'PANTHEON',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Aortic Regurgitation',\n",
       "  'DEVICE: TAVR',\n",
       "  'IRCCS Policlinico S. Donato',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05',\n",
       "  '2022-11'],\n",
       " ['NCT05538871',\n",
       "  'Body Structure and Capacity Evaluation of Adults With Scoliosis',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Scoliosis',\n",
       "  'DIAGNOSTIC_TEST: Survey + Physical exam',\n",
       "  'University of Alberta',\n",
       "  '',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-06',\n",
       "  '2024-05-06'],\n",
       " ['NCT00046371',\n",
       "  'Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Neoplasms',\n",
       "  'DRUG: THERATOPE® vaccine',\n",
       "  'Oncothyreon Canada Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2002-08',\n",
       "  '2005-08'],\n",
       " ['NCT01515371',\n",
       "  'Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Habitual Snoring',\n",
       "  'DRUG: IncobotulinumtoxinA|DRUG: Placebo Comparator',\n",
       "  'Merz Pharmaceuticals GmbH',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2012-11'],\n",
       " ['NCT06149871',\n",
       "  'Effectiveness of Individual Physical Activity Programs to Prevent Sarcopenia and Frailty Among Older Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sarcopenia|Frailty',\n",
       "  'BEHAVIORAL: Physical activity',\n",
       "  'Ministry of Health\",\" Thailand',\n",
       "  'Chulalongkorn University',\n",
       "  '360.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2021-03-01',\n",
       "  '2022-08-31'],\n",
       " ['NCT03363971',\n",
       "  'Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Soft Tissue Injuries',\n",
       "  'DRUG: Zhi Kang Capsule|DRUG: Simulant agent for Zhi Kang Capsule',\n",
       "  \"Peking University People's Hospital\",\n",
       "  '',\n",
       "  '2200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-13',\n",
       "  '2018-03-13'],\n",
       " ['NCT05989971',\n",
       "  'The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Respiratory Failure With Hypercapnia',\n",
       "  'OTHER: continuous renal replacement therapy',\n",
       "  'Southeast University\",\" China',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-04-24',\n",
       "  '2023-12'],\n",
       " ['NCT02712671',\n",
       "  'Testing for Tuberculosis in the United Kingdom HIV Infected Population',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'HIV|Latent Tuberculosis',\n",
       "  'RADIATION: Chest radiograph|PROCEDURE: Blood interferon gamma release assay|PROCEDURE: Tuberculin skin testing (TST)|PROCEDURE: Sputum induction for mycobacterial microscopy and culture|OTHER: Mycobacterium tuberculosis polymerase chain reaction testing|PROCEDURE: Spirometry',\n",
       "  'University College\",\" London',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-06',\n",
       "  '2024-09'],\n",
       " ['NCT04089371',\n",
       "  'A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Arthroplasty|Hemiarthroplasty|Shoulder Pain',\n",
       "  'DEVICE: ReUnion Total Shoulder Arthroplasty (TSA)|DEVICE: ReUnion Reverse Shoulder Arthroplasty (RSA)',\n",
       "  'Stryker Trauma GmbH',\n",
       "  '',\n",
       "  '14.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-10-01',\n",
       "  '2022-07-08'],\n",
       " ['NCT02911571',\n",
       "  'PRospective Multiple Myeloma Impact Study',\n",
       "  'PROMMIS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DEVICE: MMprofiler SKY92 gene signature',\n",
       "  'SkylineDx',\n",
       "  'Medex15',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2018-02-27',\n",
       "  '2026-09-01'],\n",
       " ['NCT01623271',\n",
       "  'Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Complex Regional Pain Syndrome I (CRPS I)',\n",
       "  'DRUG: Gabapentin',\n",
       "  'Massachusetts General Hospital',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2014-06'],\n",
       " ['NCT02268071',\n",
       "  'Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension',\n",
       "  'DRUG: Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence',\n",
       "  'Central Hospital\", Nancy,\" France',\n",
       "  '',\n",
       "  '403.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-03-10',\n",
       "  '2020-10-21'],\n",
       " ['NCT05772871',\n",
       "  'The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Nephrotic Syndrome in Children',\n",
       "  'DRUG: Huaiqihuang granule|DRUG: Prednisone|DRUG: Levamisole placebo|DRUG: Levamisole|DRUG: Huaiqihuang Granule placebo',\n",
       "  'Jianhua Zhou',\n",
       "  'LinkDoc Technology (Beijing) Co. Ltd.',\n",
       "  '402.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-26',\n",
       "  '2025-10-30'],\n",
       " ['NCT02492971',\n",
       "  'Function-oriented Assistive Technology Indexing System Development and Promotion',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Disability',\n",
       "  '',\n",
       "  'Chang Gung Memorial Hospital',\n",
       "  '',\n",
       "  '175.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-09',\n",
       "  '2017-11'],\n",
       " ['NCT03505671',\n",
       "  'Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Grade 1 Peripheral Motor Neuropathy\", CTCAE|Grade 1 Peripheral Sensory Neuropathy, CTCAE|Grade 2 Peripheral Motor Neuropathy, CTCAE|Grade 2 Peripheral Sensory Neuropathy,\" CTCAE|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8',\n",
       "  'PROCEDURE: Acupuncture Therapy|OTHER: Best Practice|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-08-03',\n",
       "  '2021-02-21'],\n",
       " ['NCT04309071',\n",
       "  'Saliva Insulin Responses to a Standardized Meal Tolerance Test in Humans',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Diet Modification|Insulin Resistance|Hyperinsulinemia',\n",
       "  'OTHER: Dietary intervention',\n",
       "  'University of British Columbia',\n",
       "  'Mitacs|Core-Health Technologies Inc.',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-01-04',\n",
       "  '2022-09'],\n",
       " ['NCT04614571',\n",
       "  'T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Celiac Disease',\n",
       "  'DIETARY_SUPPLEMENT: Gluten Powder',\n",
       "  'Regeneron Pharmaceuticals',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-11-02',\n",
       "  '2024-09-30'],\n",
       " ['NCT00407771',\n",
       "  'The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Tirofiban',\n",
       "  'Jordan Hospital',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-11',\n",
       "  '2008-12'],\n",
       " ['NCT01724671',\n",
       "  'Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'MRSA Infection|Bacteremia|ABSSSI|Pneumonia',\n",
       "  '',\n",
       "  'CPL Associates',\n",
       "  'Forest Laboratories',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-12',\n",
       "  '2013-12'],\n",
       " ['NCT05150171',\n",
       "  'Happy Hands E-self-management Pilot Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hand Osteoarthritis',\n",
       "  'OTHER: e-self-management intervention',\n",
       "  'Diakonhjemmet Hospital',\n",
       "  'The Norwegian Rheumatism Association',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-11-23',\n",
       "  '2022-12-31'],\n",
       " ['NCT06106971',\n",
       "  'Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Gastric Varices Bleeding|Liver Decompensation',\n",
       "  'DRUG: Sodium tetradecyl sulfate|DRUG: Cyanoacrylate',\n",
       "  'Kaohsiung Veterans General Hospital.',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-06-28',\n",
       "  '2025-06'],\n",
       " ['NCT00115271',\n",
       "  'Antenatal Micronutrient Supplementation and Birth Weight',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Birth Weight|Infant Mortality|Pregnancy|Nutritional Status',\n",
       "  'DRUG: Nutritional supplements',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  'United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Johns Hopkins University',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '1999-01',\n",
       "  '2001-05'],\n",
       " ['NCT04661371',\n",
       "  'Necessity of Preoperative Empirical Antibiotic Use in Acute Cholecystitis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cholecystitis\",\" Acute',\n",
       "  'PROCEDURE: Laparoscopic cholecystectomy',\n",
       "  \"Seoul St. Mary's Hospital\",\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-03-02',\n",
       "  '2021-12-30'],\n",
       " ['NCT04921371',\n",
       "  'Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gingivitis|Plaque',\n",
       "  'OTHER: Colgate® Cavity Protection Toothpaste|OTHER: Listerine® Cool Mint®|OTHER: Concept Curve Winter Series Toothbrush|OTHER: 5% Hydroalcohol Mouthrinse|OTHER: Mouthrinse Prototype 1|OTHER: Mouthrinse Prototype 2',\n",
       "  'Johnson & Johnson Consumer Inc. (J&JCI)',\n",
       "  '',\n",
       "  '157.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-10-08',\n",
       "  '2019-12-19'],\n",
       " ['NCT01105871',\n",
       "  'Subjective Analgesic Effects of Naloxone and Virtual Reality',\n",
       "  'Narcan',\n",
       "  'UNKNOWN',\n",
       "  'Pain',\n",
       "  'DRUG: naloxone|DRUG: Placebo',\n",
       "  'University of Washington',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2010-08',\n",
       "  '2014-06'],\n",
       " ['NCT05482971',\n",
       "  'A Single-arm\", Multicenter Study to Assess the Efficacy, Safety,\" and Tolerability of P1101 in Adults With ET',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Essential Thrombocythemia',\n",
       "  'DRUG: Ropeginterferon alfa-2b-njft (P1101)',\n",
       "  'PharmaEssentia',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-09-29',\n",
       "  '2026-12-31'],\n",
       " ['NCT05752071',\n",
       "  'Gastrointestinal Stimulation as a Treatment of Postoperative Ileus Following Extensive Surgery',\n",
       "  'STIMULATE',\n",
       "  'RECRUITING',\n",
       "  'Postoperative Ileus|Bowel Paralysis',\n",
       "  'DEVICE: Gastric electric pacemaker',\n",
       "  'University of Aarhus',\n",
       "  'Danish Cancer Society',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-01',\n",
       "  '2025-09'],\n",
       " ['NCT02607371',\n",
       "  'Anticoagulation Preference by AF Patients Study',\n",
       "  'PRiSMA-AF',\n",
       "  'COMPLETED',\n",
       "  'Atrial Fibrillation',\n",
       "  'OTHER: VKAs|OTHER: NOACs including Rivaroxaban (Xarelto\",\" BAY59-7939)|OTHER: Edoxaban|OTHER: Apixaban|OTHER: Dabigatran-etexilate',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '198.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08-27',\n",
       "  '2016-10-15'],\n",
       " ['NCT03461471',\n",
       "  'Exercise in All ChemoTherapy',\n",
       "  'EnACT',\n",
       "  'COMPLETED',\n",
       "  'Chemotherapy|Exercise',\n",
       "  'BEHAVIORAL: Exercise Intervention',\n",
       "  'Milton S. Hershey Medical Center',\n",
       "  '',\n",
       "  '168.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-04-01',\n",
       "  '2019-03-30'],\n",
       " ['NCT01789671',\n",
       "  'Peer Counseling in Family-Based Treatment for Childhood Obesity',\n",
       "  'EPICH',\n",
       "  'COMPLETED',\n",
       "  'Childhood Obesity',\n",
       "  'BEHAVIORAL: Family-based behavioral intervention',\n",
       "  \"Seattle Children's Hospital\",\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-09',\n",
       "  '2014-06'],\n",
       " ['NCT06212271',\n",
       "  'A Mechanistic Clinical Trial of Colchicine in Patients Undergoing Femoral Endarterectomy',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Peripheral Artery Disease',\n",
       "  'DRUG: Colchicine|DRUG: Placebo',\n",
       "  'University of Pennsylvania',\n",
       "  'Doris Duke Charitable Foundation',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2024-02',\n",
       "  '2026-01'],\n",
       " ['NCT00324571',\n",
       "  'Dialysis Clinical Outcomes Revisited (DCOR) Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Kidney Disease',\n",
       "  'DRUG: Sevelamer hydrochloride|DRUG: Calcium-based phosphate binder',\n",
       "  'Genzyme\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '2000.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-03',\n",
       "  '2006-02'],\n",
       " ['NCT03360071',\n",
       "  'A Novel Biologic Therapy for Perennial Allergic Rhinitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergic Rhinitis',\n",
       "  'DRUG: Allergen Immunotherapy Extract|DRUG: Allergen Immunotherapy Control',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-12-19',\n",
       "  '2018-11-01'],\n",
       " ['NCT05758571',\n",
       "  'Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Interstitial Pneumonia|Neoplasms Malignant',\n",
       "  'DRUG: EGCG',\n",
       "  'Shandong Cancer Hospital and Institute',\n",
       "  '',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-05',\n",
       "  '2025-12-31'],\n",
       " ['NCT01589471',\n",
       "  'The Value of Botox-A for Management of Low Anterior Resection Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Anterior Resection Syndrome|Rectal Cancer',\n",
       "  'DRUG: intra-rectal Botulinum toxin A injection',\n",
       "  \"Centre hospitalier de l'Université de Montréal (CHUM)\",\n",
       "  'Allergan',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-05',\n",
       "  '2015-11'],\n",
       " ['NCT06062771',\n",
       "  'Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cataract',\n",
       "  'DEVICE: FIDIAL PLUS|DEVICE: IAL®-F',\n",
       "  'Fidia Farmaceutici s.p.a.',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-07-23',\n",
       "  '2023-01-01'],\n",
       " ['NCT04283071',\n",
       "  'Kinematic Assessment In Multiple Sclerosis',\n",
       "  'KAIMS',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis',\n",
       "  'DEVICE: Boxed infrared gross kinematic assessment tool',\n",
       "  'The Leeds Teaching Hospitals NHS Trust',\n",
       "  'University of Leeds',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-07',\n",
       "  '2021-10-30'],\n",
       " ['NCT00323271',\n",
       "  'Cognitive-behavior Therapy for MS-Related Chronic Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis',\n",
       "  'BEHAVIORAL: Cognitive-behavior therapy|OTHER: Interventional',\n",
       "  'US Department of Veterans Affairs',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-07',\n",
       "  '2011-03'],\n",
       " ['NCT03356171',\n",
       "  'Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer',\n",
       "  'APACCHE',\n",
       "  'UNKNOWN',\n",
       "  'Physical Activity|Cancer|Hematologic Diseases',\n",
       "  'PROCEDURE: Cardiac Coherence|PROCEDURE: Adapted Physical Activity',\n",
       "  'Centre Hospitalier Universitaire de la Réunion',\n",
       "  '',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-01',\n",
       "  '2019-06'],\n",
       " ['NCT01022671',\n",
       "  'Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Belotecan',\n",
       "  'Chong Kun Dang Pharmaceutical',\n",
       "  'Asan Medical Center|Samsung Medical Center|Seoul National University Hospital|Ulsan University Hospital',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-09',\n",
       "  '2010-03'],\n",
       " ['NCT01265771',\n",
       "  'Optimizing Diagnostics Of Arrhythmia Events In Children Using Intelligent Telemetric Solutions',\n",
       "  'TELEMARC2',\n",
       "  'UNKNOWN',\n",
       "  'Arrhythmia|Children',\n",
       "  'DEVICE: Prolonged telemetric Full Disclosure ECG recording.|DEVICE: Repeated 24 hours ECG Holter monitoring',\n",
       "  'National Institute of Cardiology\", Warsaw,\" Poland',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-02',\n",
       "  '2013-01'],\n",
       " ['NCT00006071',\n",
       "  'Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypercholesterolemia|Hypertension',\n",
       "  '',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2000-07',\n",
       "  '2001-03'],\n",
       " ['NCT02270671',\n",
       "  'Attention Bias Modification Training for Young People',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anxiety|Depression',\n",
       "  'BEHAVIORAL: ABMT|OTHER: Placebo',\n",
       "  'University College Dublin',\n",
       "  'Tel Aviv University',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-10',\n",
       "  '2015-05'],\n",
       " ['NCT02277171',\n",
       "  'Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Urinary Tract Infection|Bacteriuria',\n",
       "  'DEVICE: Nitric Oxide impregnated catheter',\n",
       "  'Enox Israel Ltd',\n",
       "  'Rabin Medical Center',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-12',\n",
       "  '2015-09'],\n",
       " ['NCT03482271',\n",
       "  'Connected Yorkshire: A Data-linkage Study of Pre-hospital\",\" Emergency Department and Out of Hours Service Data',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Emergency and Urgent Care Pathways',\n",
       "  'OTHER: No intervention - data collection only',\n",
       "  'University of Sheffield',\n",
       "  'Northern Health Science Alliance (NHSA)',\n",
       "  '7500000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-01',\n",
       "  ''],\n",
       " ['NCT05117671',\n",
       "  'Is the EBJIS Definition of Prosthetic Joint Infection Meaningful in Our Clinical Practice?',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Periprosthetic Joint Infection (PJI)',\n",
       "  'OTHER: data collection to classify infection status',\n",
       "  'University Hospital\", Basel,\" Switzerland',\n",
       "  '',\n",
       "  '1200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-16',\n",
       "  '2022-04'],\n",
       " ['NCT04288271',\n",
       "  'Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Medication Adherence|Kidney Transplantation',\n",
       "  'BEHAVIORAL: Adherence Intervention|OTHER: Healthy living education intervention',\n",
       "  'McGill University Health Centre/Research Institute of the McGill University Health Centre',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '96.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-02-04',\n",
       "  '2023-06'],\n",
       " ['NCT01222871',\n",
       "  'Treatment of Early Nasal Polyposis With Topical Triamcinolone',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Nasal Polyps',\n",
       "  'DRUG: Triamcinolone|DRUG: Saline soaked sponge',\n",
       "  'Steward St. Elizabeth\\'s Medical Center of Boston\",\" Inc.',\n",
       "  '',\n",
       "  '1.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-07',\n",
       "  '2012-08'],\n",
       " ['NCT02746471',\n",
       "  'Reveal LINQ Registry',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Arrhythmias\",\" Cardiac',\n",
       "  'DEVICE: Reveal LINQ',\n",
       "  'Medtronic Cardiac Rhythm and Heart Failure',\n",
       "  '',\n",
       "  '1604.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-04',\n",
       "  '2021-06-04'],\n",
       " ['NCT02923271',\n",
       "  'Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Teen Drivers|Motor Vehicle Accidents',\n",
       "  'DEVICE: CellControl',\n",
       "  \"Children's Hospital of Philadelphia\",\n",
       "  'University of Pennsylvania',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-12-07',\n",
       "  '2017-11-16'],\n",
       " ['NCT06027671',\n",
       "  'Structured Peer-delivered ART and Reentry Community Strategy',\n",
       "  'SPARCS',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Retention in Care',\n",
       "  'BEHAVIORAL: Group SPARCS Intervention|BEHAVIORAL: ART-SPARCS Intervention',\n",
       "  'Johns Hopkins University',\n",
       "  'Aurum Institute|Seoul National University|National Institute of Mental Health (NIMH)',\n",
       "  '640.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-04-01',\n",
       "  '2028-10-01'],\n",
       " ['NCT04511871',\n",
       "  'A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Solid Tumor|Gastric Cancer|Breast Cancer|Ovarian Cancer|Sarcoma',\n",
       "  'BIOLOGICAL: CCT303-406',\n",
       "  'Shanghai PerHum Therapeutics Co.\",\" Ltd.',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-07-09',\n",
       "  '2025-03-29'],\n",
       " ['NCT00505271',\n",
       "  'Safety and Efficacy Study Using Rexin-G for Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'GENETIC: Rexin-G',\n",
       "  'Epeius Biotechnologies',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2011-06'],\n",
       " ['NCT04966871',\n",
       "  'Safety\",\" Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Malaria',\n",
       "  'BIOLOGICAL: PfSPZ Vaccine|BIOLOGICAL: PfSPZ Challenge (7G8) for CHMI|OTHER: Normal Saline',\n",
       "  'Sanaria Inc.',\n",
       "  'Fred Hutchinson Cancer Center',\n",
       "  '54.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-09-27',\n",
       "  '2022-06-21'],\n",
       " ['NCT05605171',\n",
       "  'Posterior Urethrovesical Anastomotic Reconstruction in Comparison to Conventional Urethrovesical Anastomosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'PROCEDURE: Posterior reconstruction urethrovesical anastomosis.|PROCEDURE: Conventional vesicourethral anastomosis.',\n",
       "  \"St. Joseph's Healthcare Hamilton\",\n",
       "  '',\n",
       "  '163.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-03-19',\n",
       "  '2019-03-23'],\n",
       " ['NCT06235671',\n",
       "  'Effects of Chiropractic on Chronic Cancer-related Fatigue',\n",
       "  'CAN',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer|Fatigue',\n",
       "  'PROCEDURE: Chiropractic care',\n",
       "  'Life University',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-03-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT01770171',\n",
       "  'Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer',\n",
       "  'MITOBEVAEND2',\n",
       "  'UNKNOWN',\n",
       "  'Stage III-IV or Recurrent Endometrial Cancer',\n",
       "  'DRUG: Bevacizumab|DRUG: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles',\n",
       "  'Catholic University of the Sacred Heart',\n",
       "  '',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-04',\n",
       "  '2017-12'],\n",
       " ['NCT04541771',\n",
       "  'The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants',\n",
       "  'NEC',\n",
       "  'UNKNOWN',\n",
       "  'Necrotizing Enterocolitis|Sepsis',\n",
       "  'DRUG: Lactobacillus Reuteri DSM 17938|DRUG: Placebo',\n",
       "  'Children\\'s Hospital and Institute of Child Health\",\" Multan',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2020-10',\n",
       "  '2021-01'],\n",
       " ['NCT03061071',\n",
       "  'The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sleep Apnea Syndromes',\n",
       "  'DEVICE: NightBalance Sleep Position Trainer (SPT)|DEVICE: Automated Adjusting Positive Airway Pressure (APAP)',\n",
       "  'NightBalance',\n",
       "  '',\n",
       "  '117.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-01',\n",
       "  '2018-07-12'],\n",
       " ['NCT02665871',\n",
       "  'Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Influenza',\n",
       "  'BIOLOGICAL: one dose of Influenza Vaccine|BIOLOGICAL: one dose of Influenza Vaccine|BIOLOGICAL: placebo|BIOLOGICAL: placebo',\n",
       "  'Beijing Chaoyang District Centre for Disease Control and Prevention',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-03',\n",
       "  '2016-09'],\n",
       " ['NCT00748371',\n",
       "  'Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Platelet Aggregation',\n",
       "  'DRUG: aspirin|DRUG: aspirin|DRUG: placebo',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '51.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2004-06',\n",
       "  '2011-02'],\n",
       " ['NCT02412371',\n",
       "  'A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Non-small Cell Lung Cancer Stage III',\n",
       "  'DRUG: Paclitaxel|DRUG: Placebo for Veliparib|DRUG: Carboplatin|DRUG: Veliparib|RADIATION: Radiotherapy',\n",
       "  'AbbVie',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04-30',\n",
       "  '2019-08-05'],\n",
       " ['NCT04133571',\n",
       "  'Bladder Irrigation 0.05% Lidocaine Decreases Postoperative CRBD',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Bladder Discomfort',\n",
       "  'DRUG: 0.05% Lidocaine',\n",
       "  'Kaohsiung Medical University Chung-Ho Memorial Hospital',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2019-05-17',\n",
       "  '2020-12-31'],\n",
       " ['NCT03011671',\n",
       "  'Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Malignant Glioma of Brain',\n",
       "  'DRUG: Acetazolamide|DRUG: Temozolomide',\n",
       "  'University of Chicago',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-10-03',\n",
       "  '2026-10'],\n",
       " ['NCT04271371',\n",
       "  'Preventing Relapse to Smoking Among Prisoners After Release',\n",
       "  'PROSPER',\n",
       "  'RECRUITING',\n",
       "  'Smoking|Smoking Reduction|Electronic Cigarette Use',\n",
       "  'OTHER: Not yet developed',\n",
       "  'University of Nottingham',\n",
       "  \"Her Majesty's Prison and Probation Service (HMPPS)|Public Health England|Cancer Research UK|Plymouth University Peninsula Schools of Medicine & Dentistry (PUPSMD)\",\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-08-08',\n",
       "  '2024-05-30'],\n",
       " ['NCT00181571',\n",
       "  'A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'ADHD',\n",
       "  'DRUG: methylphenidate HCl (Concerta)|DRUG: Placebo',\n",
       "  'Massachusetts General Hospital',\n",
       "  'McNeil Consumer & Specialty Pharmaceuticals\", a Division of McNeil-PPC,\" Inc.',\n",
       "  '297.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2003-06',\n",
       "  '2007-08'],\n",
       " ['NCT03116971',\n",
       "  'Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Small Cell Lung Cancer',\n",
       "  'DRUG: M3814|DRUG: Cisplatin|DRUG: Etoposide',\n",
       "  'EMD Serono Research & Development Institute\",\" Inc.',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '2.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-05-25',\n",
       "  '2018-03-01'],\n",
       " ['NCT01926171',\n",
       "  'Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Non-small-cell Lung Cancer',\n",
       "  'DRUG: Icotinib plus WBRT',\n",
       "  'Betta Pharmaceuticals Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-06',\n",
       "  '2016-12'],\n",
       " ['NCT03990571',\n",
       "  'Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Adenoid Cystic Carcinoma|Progressive Disease|Recurrent Adenoid Cystic Carcinoma',\n",
       "  'DRUG: Avelumab|DRUG: Axitinib',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-22',\n",
       "  '2023-03-20'],\n",
       " ['NCT00696371',\n",
       "  'PET Imaging of Peripheral Benzodiazepine Receptors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  '',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-06-06',\n",
       "  '2014-08-19'],\n",
       " ['NCT02351271',\n",
       "  'Cataract Surgery: Femto LDV Z8 Versus Conventional',\n",
       "  'COMFORT',\n",
       "  'COMPLETED',\n",
       "  'Cataract',\n",
       "  'DEVICE: Femto LDV Z8|DEVICE: Manual capsulorhexis&lens fragmentation',\n",
       "  'Ziemer Ophthalmic Systems AG',\n",
       "  '',\n",
       "  '130.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-02',\n",
       "  '2017-02-28'],\n",
       " ['NCT02208271',\n",
       "  'A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Arthritis\",\" Failure of Total Hip',\n",
       "  '',\n",
       "  'OrthoCarolina Research Institute\",\" Inc.',\n",
       "  'Charlotte Orthopedic Hospital',\n",
       "  '174.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-08-04',\n",
       "  '2023-12-31'],\n",
       " ['NCT02144571',\n",
       "  'Sistas Inspiring Sistas Through Activity and Support',\n",
       "  'SISTAS',\n",
       "  'COMPLETED',\n",
       "  'Prevention Harmful Effects',\n",
       "  'BEHAVIORAL: Lifestyle',\n",
       "  'University of South Carolina',\n",
       "  '',\n",
       "  '350.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-11',\n",
       "  '2015-06'],\n",
       " ['NCT02694471',\n",
       "  'Effect of 14 Day Bed Rest on Health Outcomes in Young and Older Participants',\n",
       "  'BEDREST',\n",
       "  'COMPLETED',\n",
       "  'Muscular Atrophy',\n",
       "  'BEHAVIORAL: physical inactivity or bed rest with supervised recovery',\n",
       "  'University of Primorska',\n",
       "  'University of Trieste|University of Udine|University of Padova|Università degli Studi di Ferrara|University of Nottingham|DLR German Aerospace Center|Izola General Hospital|National Institute of Public Health\",\" Slovenia',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-08',\n",
       "  '2015-01'],\n",
       " ['NCT04458571',\n",
       "  'Effect of CRRT Duration on Solute Removal',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'AKI|Sepsis',\n",
       "  '',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '',\n",
       "  '112.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-01',\n",
       "  '2022-12-21'],\n",
       " ['NCT01712971',\n",
       "  'Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Surgery|Pancreatic Tumour|Peri-ampullary Tumour|Blood Loss',\n",
       "  '',\n",
       "  'Baki Topal',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-11',\n",
       "  '2014-06'],\n",
       " ['NCT01777971',\n",
       "  'The Effect of a Large-volume Paracentesis on Fatigue\", Sleep,\" and Quality of Life in Cirrhosis',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Cirrhosis|Hepatic Encephalopathy|Ascites|Fatigue',\n",
       "  '',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-07',\n",
       "  '2014-10'],\n",
       " ['NCT01507571',\n",
       "  'Implementation and Evaluation of Dignity Therapy in Denmark',\n",
       "  'DignityDK',\n",
       "  'COMPLETED',\n",
       "  'Cancer',\n",
       "  'OTHER: Dignity Therapy',\n",
       "  'Bispebjerg Hospital',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2005-09',\n",
       "  '2007-09'],\n",
       " ['NCT04346771',\n",
       "  'The Effect of Emotional Working Memory Training on Reducing Depressive Symptoms',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Depressive Symptoms',\n",
       "  'BEHAVIORAL: Working memory training|BEHAVIORAL: Positive ABMT',\n",
       "  'Hunan Normal University',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-12-18',\n",
       "  '2021-01-10'],\n",
       " ['NCT03968471',\n",
       "  'Chemotherapy-induced Necrosis in Ewing Sarcoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ewing Sarcoma of Bone',\n",
       "  'BEHAVIORAL: Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma',\n",
       "  'Istituto Ortopedico Rizzoli',\n",
       "  '',\n",
       "  '474.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-13',\n",
       "  '2020-01-15'],\n",
       " ['NCT00895271',\n",
       "  'Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Primary Immunodeficiency|DOCK8|Virus Susceptibility',\n",
       "  '',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-06-10',\n",
       "  ''],\n",
       " ['NCT01355471',\n",
       "  'Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rosacea',\n",
       "  'DRUG: CD07805/47 Gel|DRUG: Placebo',\n",
       "  'Galderma R&D',\n",
       "  '',\n",
       "  '293.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-05',\n",
       "  '2012-01'],\n",
       " ['NCT02603471',\n",
       "  'Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use',\n",
       "  'ALCTXT',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Alcohol Dependence',\n",
       "  'OTHER: Informational group|BEHAVIORAL: Text Messaging CBT (TXT-CBT)',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2016-12'],\n",
       " ['NCT01771471',\n",
       "  'A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'BIOLOGICAL: NuQu|OTHER: Placebo',\n",
       "  'ISTO Technologies\",\" Inc.',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2020-09'],\n",
       " ['NCT03566771',\n",
       "  'Treatment Results and Health Care Consumption From a Web-based Support System in Behavioural Childhood Obesity Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Childhood Obesity',\n",
       "  'BEHAVIORAL: Usual care|BEHAVIORAL: CLOSS',\n",
       "  'Karolinska Institutet',\n",
       "  '',\n",
       "  '82.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-04-11',\n",
       "  '2019-11-26'],\n",
       " ['NCT02776371',\n",
       "  'Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Helicobacter Pylori Eradication Rate',\n",
       "  'DRUG: Modified non-clarithromycin triple therapy|DRUG: Sequential therapy',\n",
       "  'Shandong University',\n",
       "  '',\n",
       "  '301.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-09',\n",
       "  '2018-02'],\n",
       " ['NCT02287571',\n",
       "  'Skin Traction Versus Position Splint in Patients With Hip Fracture',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hip Fractures|Complication of Traction Procedure|Pain|Splints',\n",
       "  'DEVICE: Derotation splint|DEVICE: elastic bandage',\n",
       "  'Saglik Bilimleri Universitesi Gulhane Tip Fakultesi',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2013-03',\n",
       "  '2014-07'],\n",
       " ['NCT04268771',\n",
       "  'A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products',\n",
       "  'RI-01-007',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'BIOLOGICAL: Experimental: Arm A: DRL_RI|BIOLOGICAL: Arm B: Rituxan®/Mabthera®',\n",
       "  \"Dr. Reddy's Laboratories Limited\",\n",
       "  'PPD',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-08',\n",
       "  '2022-04-20'],\n",
       " ['NCT02015871',\n",
       "  'An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer',\n",
       "  'PandaExtension',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Degarelix',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '206.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2017-08-01'],\n",
       " ['NCT03746171',\n",
       "  'Blue Light Imaging (BLI) for Optical Diagnosis of Colorectal Polyps',\n",
       "  'BIRD',\n",
       "  'COMPLETED',\n",
       "  'Colonic Polyp',\n",
       "  'DIAGNOSTIC_TEST: Colonic polyp characterization by BLI',\n",
       "  'Valduce Hospital',\n",
       "  '',\n",
       "  '324.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-01-01',\n",
       "  '2019-10-30'],\n",
       " ['NCT01828671',\n",
       "  'A Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals',\n",
       "  'SOYT-2013',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'OTHER: Oral Glucose Solution 296 mls|OTHER: Corn Tortilla|OTHER: Low Soy Flour Corn Tortilla|OTHER: Moderate Soy Flour Corn Tortilla|OTHER: High Soy Flour Corn Tortilla',\n",
       "  'University of Manitoba',\n",
       "  'Manitoba Pulse Growers',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2013-12',\n",
       "  '2014-05'],\n",
       " ['NCT04558671',\n",
       "  'Preschool Bronchial Remodeling and Risk of Exacerbation',\n",
       "  'RESPIRE',\n",
       "  'COMPLETED',\n",
       "  'Preschool Severe Asthma',\n",
       "  'OTHER: asthma exacerbations',\n",
       "  'University Hospital\",\" Bordeaux',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-16',\n",
       "  '2020-09-24'],\n",
       " ['NCT02962271',\n",
       "  'Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Enthesopathy',\n",
       "  'DEVICE: Musculoskeletal Ultrasound',\n",
       "  'Chinese PLA General Hospital',\n",
       "  '',\n",
       "  '187.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-01',\n",
       "  '2016-12'],\n",
       " ['NCT01432171',\n",
       "  'Lacosamide in Preventing Seizures in Participants With Malignant Glioma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Malignant Glioma',\n",
       "  'DRUG: Lacosamide|OTHER: Placebo',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '37.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-07-25',\n",
       "  '2017-06-20'],\n",
       " ['NCT02213471',\n",
       "  'Patient Preference for Biopsy Notification',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Elevated Risk for Melanoma',\n",
       "  '',\n",
       "  'Maria Wei',\n",
       "  '',\n",
       "  '301.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-07',\n",
       "  '2013-07'],\n",
       " ['NCT00718471',\n",
       "  'STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)',\n",
       "  'ATOLL',\n",
       "  'COMPLETED',\n",
       "  'Primary PCI - STEMI',\n",
       "  'DRUG: Enoxaparin|DRUG: UFH (unfractionated heparin)',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '910.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2010-08'],\n",
       " ['NCT02291471',\n",
       "  'Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatic Diseases',\n",
       "  'DRUG: T0001，10mg|DRUG: T0001，20mg|DRUG: T0001，35mg|DRUG: T0001，50mg|DRUG: T0001，65mg|DRUG: T0001，75mg',\n",
       "  'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-10',\n",
       "  '2015-02'],\n",
       " ['NCT01636271',\n",
       "  'SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coronary Heart Disease',\n",
       "  'DRUG: darapladib|DRUG: placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '28855.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-10',\n",
       "  '2014-04'],\n",
       " ['NCT02697071',\n",
       "  'Ketamine for Acute Migraine in the Emergency Department',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Headache',\n",
       "  'DRUG: Ketamine|DRUG: Normal Saline',\n",
       "  'Carilion Clinic',\n",
       "  'Virginia Polytechnic Institute and State University',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-02',\n",
       "  '2017-03'],\n",
       " ['NCT02564471',\n",
       "  'Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.',\n",
       "  'MALRAB',\n",
       "  'COMPLETED',\n",
       "  'Rabies',\n",
       "  'DRUG: Chloroquine|DRUG: Atovaquone and Proguanil|DRUG: Doxycycline|BIOLOGICAL: Rabies Vaccine',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  'Walter Reed Army Institute of Research (WRAIR)|Kansas State University',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2016-11-11',\n",
       "  '2019-02'],\n",
       " ['NCT02862171',\n",
       "  'To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy\",\" HIV-negative Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Prevention',\n",
       "  'DRUG: Dapivirine Vaginal Ring-004',\n",
       "  'International Partnership for Microbicides\",\" Inc.',\n",
       "  '',\n",
       "  '941.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2016-07-12',\n",
       "  '2019-01-11'],\n",
       " ['NCT01151371',\n",
       "  'Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myopia',\n",
       "  'DEVICE: narafilcon B contact lens|DEVICE: nelfilcon A contact lens|DEVICE: lotrafilcon B contact lens',\n",
       "  'Johnson & Johnson Vision Care\",\" Inc.',\n",
       "  'Visioncare Research Ltd.',\n",
       "  '452.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2010-02-01',\n",
       "  '2010-04-01'],\n",
       " ['NCT03594071',\n",
       "  'S&P of Q-Fix™ All-Suture Anchor System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bankart Lesion|Acetabular Labrum Tear|SLAP Lesion|Acromioclavicular Sprain|Capsular Shift/Capsulolabral Reconstruction|Deltoid Repair|Rotator Cuff Repair|Bicep Tendinitis|Extra-capsular Repair|Medial Collateral Ligament|Lateal Collateral Ligament|Posterior Oblique Ligament|IBT|Vastus Medialis|Obliquus Advancement|Joint Capsule Closure',\n",
       "  'DEVICE: The Q-Fix™ All-Suture Anchor',\n",
       "  'Smith & Nephew\",\" Inc.',\n",
       "  '',\n",
       "  '294.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-08-31',\n",
       "  '2019-12-11'],\n",
       " ['NCT04220671',\n",
       "  'Measles Vaccination at Health System Contacts',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Measles Vaccine|Hospital Admission|Mortality|Non-specific (Heterologous) Effects of Vaccines',\n",
       "  'BIOLOGICAL: measles vaccine|OTHER: Saline',\n",
       "  'Bandim Health Project',\n",
       "  '',\n",
       "  '5400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-01-08',\n",
       "  '2025-08'],\n",
       " ['NCT05169671',\n",
       "  'Safety\", Tolerability,\" and Pharmacokinetics Study of ATH-1020',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy Volunteers',\n",
       "  'DRUG: ATH-1020|DRUG: Placebo',\n",
       "  'Athira Pharma',\n",
       "  'Biotrial Inc.|Alturas Analytics\",\" Inc.',\n",
       "  '68.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-03-30',\n",
       "  '2022-12-12'],\n",
       " ['NCT01891071',\n",
       "  'Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Multiple Sclerosis',\n",
       "  'PROCEDURE: Lung volume recruitment',\n",
       "  'Ottawa Hospital Research Institute',\n",
       "  'The Ottawa Hospital',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-07',\n",
       "  '2017-04'],\n",
       " ['NCT03909971',\n",
       "  'A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Lorlatinib',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '109.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-04-28',\n",
       "  '2024-12-31'],\n",
       " ['NCT06156371',\n",
       "  'The Effect of Lymphatic Drainage Massage on Interdialytic Weight Gain and Fatigue',\n",
       "  'MLD',\n",
       "  'RECRUITING',\n",
       "  'Interdialytic Weight Gain|Fatigue',\n",
       "  'OTHER: lymphatic drainage massage|OTHER: classic massage',\n",
       "  'Mersin University',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12-11',\n",
       "  '2024-06-30'],\n",
       " ['NCT06151171',\n",
       "  'Pharmacokinetics of Different CoQ10 Formulations',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coenzyme Q10 Pharmacokinetics',\n",
       "  'DIETARY_SUPPLEMENT: CoQ10',\n",
       "  'Factors Group of Nutritional Companies Inc.',\n",
       "  'Isura',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-03-01',\n",
       "  '2022-10-31'],\n",
       " ['NCT04626271',\n",
       "  'Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Albuminuria',\n",
       "  'DEVICE: ACR | U.S. Urine Analysis Test System|DEVICE: URiSCAN Optima Urine Analyzer',\n",
       "  'Healthy.io Ltd.',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2020-08-31',\n",
       "  '2020-10-25'],\n",
       " ['NCT00095771',\n",
       "  'Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain and Central Nervous System Tumors',\n",
       "  'DRUG: arsenic trioxide|RADIATION: radiation therapy',\n",
       "  'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2004-11',\n",
       "  '2011-01'],\n",
       " ['NCT04627571',\n",
       "  'Corneal Nerves After Treatment With Cenegermin',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Neurotrophic Keratitis',\n",
       "  'DRUG: Cenegermin Ophthalmic Solution [Oxervate]',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-23',\n",
       "  '2024-12'],\n",
       " ['NCT05359471',\n",
       "  'Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD',\n",
       "  'Theratech',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Visceral Steatosis|Hiv|NAFLD',\n",
       "  'DEVICE: Bone densitometry|OTHER: Questionnaires|DEVICE: Review of medical chart',\n",
       "  'McGill University Health Centre/Research Institute of the McGill University Health Centre',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2021-04-09',\n",
       "  '2022-06-01'],\n",
       " ['NCT02459171',\n",
       "  'Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Influenza',\n",
       "  'OTHER: Questionnaire|OTHER: Blood sample|OTHER: Nasal wash|OTHER: Throat swab',\n",
       "  \"St. Jude Children's Research Hospital\",\n",
       "  'Department of Health and Human Services|Human Link',\n",
       "  '2400.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08-05',\n",
       "  '2024-03'],\n",
       " ['NCT00758771',\n",
       "  'Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents',\n",
       "  'GIST',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  '',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'Genentech\",\" Inc.',\n",
       "  '38.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2012-12'],\n",
       " ['NCT00620971',\n",
       "  'Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'DRUG: Vinorelbine|DRUG: Cisplatin|DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Bevacizumab',\n",
       "  'Hellenic Oncology Research Group',\n",
       "  'University Hospital of Crete',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2010-04'],\n",
       " ['NCT01209871',\n",
       "  'Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Lymphoplasmacytic Lymphoma',\n",
       "  'BIOLOGICAL: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|OTHER: Laboratory Biomarker Analysis',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-02-26',\n",
       "  '2024-02-20'],\n",
       " ['NCT04219371',\n",
       "  'Reference Range Study for the Quantra QStat System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coagulation Disorder',\n",
       "  'DIAGNOSTIC_TEST: Quantra System',\n",
       "  'HemoSonics LLC',\n",
       "  '',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-07',\n",
       "  '2020-06-30'],\n",
       " ['NCT02676271',\n",
       "  \"The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Legg-Calvé-Perthes Disease',\n",
       "  'PROCEDURE: Proximal varus derotational osteotomy',\n",
       "  'Assaf-Harofeh Medical Center',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2015-10'],\n",
       " ['NCT02079571',\n",
       "  'Investigation of Pulse Waves\", Channel Entries,\" and Food Attributes in Healthy Subjects With Different Constitutions',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy Subjects With Different Constitutions',\n",
       "  'DIETARY_SUPPLEMENT: Coconut water|DIETARY_SUPPLEMENT: ginger tea',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2013-05',\n",
       "  ''],\n",
       " ['NCT06034171',\n",
       "  'Clinical Study of Implants With Modified Surface Treatment',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Dental Implant|Hydroxyapatite',\n",
       "  'DEVICE: dental implant',\n",
       "  'SmileDent Kft.',\n",
       "  'S.G.S International Kft.',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-06-13',\n",
       "  '2023-12-31'],\n",
       " ['NCT05802771',\n",
       "  'Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice',\n",
       "  'LANTERN',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'PROCEDURE: surgical resection',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  'Technische Universität Dresden|University of Debrecen|Hospital de la Santa creu i Sant Pau - Barcelona|Koc University Hospital|Accademia del Paziente Esperto EUPATI\", Rome,\" Italy',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-06-01',\n",
       "  '2026-06-01'],\n",
       " ['NCT01595971',\n",
       "  'Distance Education Versus Usual Care Qualification in Asthma Care',\n",
       "  'RESPIRANET',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'BEHAVIORAL: Continuing education|OTHER: usual care',\n",
       "  'Hospital de Clinicas de Porto Alegre',\n",
       "  'Federal University of Rio Grande do Sul',\n",
       "  '467.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2010-08-12',\n",
       "  '2011-12-16'],\n",
       " ['NCT01476371',\n",
       "  'Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Disorders',\n",
       "  'BEHAVIORAL: Mindfulness-based group treatment',\n",
       "  'Lund University',\n",
       "  '',\n",
       "  '215.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2014-04'],\n",
       " ['NCT04172571',\n",
       "  'A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'BIOLOGICAL: AK105|DRUG: Anlotinib Hydrochloride',\n",
       "  'Akeso',\n",
       "  'Akeso Tiancheng\",\" Inc',\n",
       "  '31.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-22',\n",
       "  '2022-11-01'],\n",
       " ['NCT03188471',\n",
       "  'Preventive Application of GnRH Antagonist on Early OHSS',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ovarian Hyperstimulation Syndrome|GnRH Antagonist|Aspirin|Vascular Endothelial Growth Factor|Pigment Epithelium Derived Factor',\n",
       "  'DRUG: GnRH antagonist|DRUG: aspirin',\n",
       "  'First Affiliated Hospital\",\" Sun Yat-Sen University',\n",
       "  '',\n",
       "  '175.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-01',\n",
       "  '2018-03'],\n",
       " ['NCT01217671',\n",
       "  'International Study Evaluating the Safety and Efficacy of Inhaled\", Human,\" Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Emphysema',\n",
       "  'BIOLOGICAL: Kamada AAT for inhalation|OTHER: Placebo',\n",
       "  'Kamada\",\" Ltd.',\n",
       "  '',\n",
       "  '168.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-12',\n",
       "  '2015-06'],\n",
       " ['NCT01137071',\n",
       "  'Consolidation Therapy With Hu3S193 for Women With Ovarian\",\" Primary Peritoneal or Fallopian Tube Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer',\n",
       "  'BIOLOGICAL: Monoclonal antibody Hu3S193',\n",
       "  'Recepta Biopharma',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2015-06'],\n",
       " ['NCT02164071',\n",
       "  'Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies',\n",
       "  'GAH',\n",
       "  'COMPLETED',\n",
       "  'Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leuklemia\", Lymphocytic,\" Chronic',\n",
       "  'OTHER: Geriatric Assessment of Health Status Scale administration',\n",
       "  'Celgene',\n",
       "  '',\n",
       "  '363.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-04-11',\n",
       "  '2015-07-04'],\n",
       " ['NCT05897671',\n",
       "  'Foveal Sparing ILM Peeling With ILM Flap Transposition',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Full Thickness Macular Hole',\n",
       "  'OTHER: retrospective data analysis',\n",
       "  'Vienna Institute for Research in Ocular Surgery',\n",
       "  '',\n",
       "  '42.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-06-01',\n",
       "  '2023-06-01'],\n",
       " ['NCT02642471',\n",
       "  'Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cervical Cancer|Surgery|Quality of Life',\n",
       "  'PROCEDURE: no systematic pelvic lymphadenectomy',\n",
       "  'Sun Yat-sen University',\n",
       "  '',\n",
       "  '1080.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2022-12'],\n",
       " ['NCT04806971',\n",
       "  'Vitamin D Receptor\",\" Interleukin-1A and Interleukin-1B Gene Polymorphisms in Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis|Polymorphism\",\" Restriction Fragment Length',\n",
       "  '',\n",
       "  'Marmara University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-29',\n",
       "  '2019-09-27'],\n",
       " ['NCT02273271',\n",
       "  'Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo',\n",
       "  'EVIDENCE',\n",
       "  'UNKNOWN',\n",
       "  'Non-small Cell Lung Carcinoma',\n",
       "  'OTHER: 18F-FLT-PET/CT and DWI-MRI',\n",
       "  'European Organisation for Research and Treatment of Cancer - EORTC',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-10',\n",
       "  '2017-02'],\n",
       " ['NCT03295071',\n",
       "  'REALITY LHON Registry',\n",
       "  'REALITY',\n",
       "  'COMPLETED',\n",
       "  'Leber Hereditary Optic Neuropathy',\n",
       "  'OTHER: Patient-reported outcomes (PROs)',\n",
       "  'GenSight Biologics',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-03',\n",
       "  '2020-07-01'],\n",
       " ['NCT02859571',\n",
       "  'Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Intemittant\", Continue,\" Oxytocin',\n",
       "  'DRUG: Oxytocin',\n",
       "  'Zeynep Kamil Maternity and Pediatric Research and Training Hospital',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2017-01'],\n",
       " ['NCT05151471',\n",
       "  'Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'ALS',\n",
       "  'DRUG: MT-1186|DRUG: Placebo',\n",
       "  'Mitsubishi Tanabe Pharma America Inc.',\n",
       "  '',\n",
       "  '202.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-01-11',\n",
       "  '2023-09-29'],\n",
       " ['NCT01218971',\n",
       "  'ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Dependence',\n",
       "  'DRUG: Medisorb naltrexone 190 mg|DRUG: Medisorb naltrexone 380 mg',\n",
       "  'Alkermes\",\" Inc.',\n",
       "  '',\n",
       "  '332.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2002-08',\n",
       "  '2004-09'],\n",
       " ['NCT00900471',\n",
       "  'Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Unspecified Adult Solid Tumor\", Protocol Specific|Unspecified Childhood Solid Tumor,\" Protocol Specific',\n",
       "  'OTHER: biologic sample preservation procedure|OTHER: medical chart review',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '20000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-05',\n",
       "  '2025-05'],\n",
       " ['NCT00461071',\n",
       "  'Randomised Controlled Study on the Use of Psychoeducation for Bulimia Nervosa in Young Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bulimia Nervosa',\n",
       "  'BEHAVIORAL: Guided Self-help for Bulimia nervosa',\n",
       "  'Medical University of Vienna',\n",
       "  'National Bank of Austria',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2007-04',\n",
       "  '2010-04'],\n",
       " ['NCT01051271',\n",
       "  'Prophylaxis Against Metoclopramide-Induced Akathisia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Akathisia',\n",
       "  'DRUG: midazolam',\n",
       "  'Pamukkale University',\n",
       "  '',\n",
       "  '225.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2009-07',\n",
       "  '2009-11'],\n",
       " ['NCT00554671',\n",
       "  'Pharmacist-led Group Medical Visits to Help With Diabetes Management',\n",
       "  'MEDIC-1',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus|Cardiovascular Diseases',\n",
       "  'OTHER: Algorithm driven medication titration|BEHAVIORAL: Monitoring|BEHAVIORAL: Group support|BEHAVIORAL: Self efficacy',\n",
       "  'VA Office of Research and Development',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-05',\n",
       "  '2012-06'],\n",
       " ['NCT01920971',\n",
       "  'Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Low Back Pain',\n",
       "  'RADIATION: infrared therapy',\n",
       "  'Taipei Medical University',\n",
       "  'National Science Council\",\" Taiwan',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-08',\n",
       "  '2014-07'],\n",
       " ['NCT01304771',\n",
       "  'Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Influenza',\n",
       "  'BIOLOGICAL: Synbiotic AKSB',\n",
       "  'Mayo Clinic',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: ',\n",
       "  '2010-12',\n",
       "  '2011-04'],\n",
       " ['NCT03314571',\n",
       "  'Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.',\n",
       "  'AOMHE',\n",
       "  'UNKNOWN',\n",
       "  'Epidural Analgesia|Hospital Follow-up',\n",
       "  'OTHER: analgesia for labor',\n",
       "  'University Hospital\",\" Clermont-Ferrand',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-11',\n",
       "  '2020-12-31'],\n",
       " ['NCT04927871',\n",
       "  'Hybridized Three Steps Intervention to Prevent Diabetes in Venezuela',\n",
       "  'HITS',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Overweight|PreDiabetes|Diabetes Mellitus\", Type 2|Risk Factor,\" Cardiovascular',\n",
       "  'BEHAVIORAL: Total Diet Replacement (TDR)|BEHAVIORAL: Medical Nutritional Therapy (MNT)|BEHAVIORAL: Diabetes Prevention Program 4 months|BEHAVIORAL: Diabetes Prevention Program',\n",
       "  'Foundation for Public Health and Epidemiological Research of Venezuela',\n",
       "  '',\n",
       "  '156.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2020-11-16',\n",
       "  '2022-01-15'],\n",
       " ['NCT00602771',\n",
       "  'Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed\",\" Previously Untreated Acute Myeloid Leukemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia',\n",
       "  'DRUG: tipifarnib|DRUG: etoposide',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2011-10'],\n",
       " ['NCT02928471',\n",
       "  'Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss',\n",
       "  'IM-LOSEIT-I',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Obesity',\n",
       "  'DIETARY_SUPPLEMENT: Intensive dietary intervention',\n",
       "  'Henrik Gudbergsen',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-11',\n",
       "  '2019-03'],\n",
       " ['NCT00861471',\n",
       "  'Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostate Cancer|Prostatic Neoplasms',\n",
       "  'DRUG: Docetaxel|DRUG: Imatinib Mesylate',\n",
       "  'NYU Langone Health',\n",
       "  'Novartis',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2010-05'],\n",
       " ['NCT00561171',\n",
       "  'Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension|Type II Diabetes Mellitus',\n",
       "  'DRUG: SPP635',\n",
       "  'Speedel Pharma Ltd.',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-11',\n",
       "  '2008-09'],\n",
       " ['NCT02606071',\n",
       "  'Italian Registry On Multipoint Left Ventricular Pacing',\n",
       "  'IRON-MPP',\n",
       "  'UNKNOWN',\n",
       "  'Heart Failure|Ventricular Fibrillation|Ventricular Tachycardia',\n",
       "  'DEVICE: CRT-D',\n",
       "  'University of Rome Tor Vergata',\n",
       "  '',\n",
       "  '436.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-08',\n",
       "  '2018-09'],\n",
       " ['NCT05662371',\n",
       "  'Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on Robot-assisted Colorectal Surgery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Opioid Use\", Unspecified|Pain,\" Postoperative',\n",
       "  'DEVICE: Nociception Level monitor (NOL)|DEVICE: Standard care',\n",
       "  'University of Southern Denmark',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2023-08-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT02758171',\n",
       "  'Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Empagliflozin|DRUG: Linagliptin',\n",
       "  'Boehringer Ingelheim',\n",
       "  'Eli Lilly and Company',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05-17',\n",
       "  '2016-08-03'],\n",
       " ['NCT05685771',\n",
       "  'Sleep Modulation as Antidepressant Randomized Trial',\n",
       "  'SMART',\n",
       "  'RECRUITING',\n",
       "  'Depression|Healthy',\n",
       "  'DEVICE: Phase-targeted auditory stimulation',\n",
       "  'Giulia Da Poian',\n",
       "  'ETH Zurich|University of Zurich|Psychiatric University Hospital\",\" Zurich',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2023-02-20',\n",
       "  '2024-06-30'],\n",
       " ['NCT00597571',\n",
       "  '[Trial of device that is not approved or cleared by the U.S. FDA]',\n",
       "  '',\n",
       "  'WITHHELD',\n",
       "  '',\n",
       "  '',\n",
       "  '[Redacted]',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT04366271',\n",
       "  'Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19',\n",
       "  'MESCEL-COVID19',\n",
       "  'WITHDRAWN',\n",
       "  'COVID',\n",
       "  'BIOLOGICAL: Mesenchymal cells|DRUG: Standard of care',\n",
       "  'Hospital Infantil Universitario Niño Jesús\", Madrid,\" Spain',\n",
       "  'Apices Soluciones S.L.',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-05-07',\n",
       "  '2021-05-31'],\n",
       " ['NCT05642871',\n",
       "  'DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 Gene',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Malignant Tumor of the Ovary|XRCC2 Gene Mutation',\n",
       "  'RADIATION: DKI and APT',\n",
       "  'Qianqian Qu',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-01-31',\n",
       "  '2025-08-31'],\n",
       " ['NCT00541671',\n",
       "  'Prevention of Narcotic-Induced Nausea',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Nausea',\n",
       "  'DRUG: Saline|DRUG: Phenergan',\n",
       "  'Christiana Care Health Services',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2007-02',\n",
       "  '2009-11'],\n",
       " ['NCT00464971',\n",
       "  'Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Menopause|Postmenopausal Vaginal Atrophy',\n",
       "  'DRUG: estradiol\",\" 25 mcg',\n",
       "  'Novo Nordisk A/S',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '1995-01-31',\n",
       "  '1996-11-30'],\n",
       " ['NCT01732471',\n",
       "  'Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Phenylketonuria',\n",
       "  'DRUG: Kuvan®',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2013-10'],\n",
       " ['NCT02440971',\n",
       "  'Adaptive Servo Ventilation (ASV) in Heart Failure',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Acute Decompensated Heart Failure|Sleep Disordered Breathing',\n",
       "  'DEVICE: S9-Autoset CS-A',\n",
       "  'St Vincent\\'s University Hospital\",\" Ireland',\n",
       "  'ResMed',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-05',\n",
       "  '2019-09'],\n",
       " ['NCT06125171',\n",
       "  'Tucidinostat Plus Apatinib for Advanced Osteosarcoma',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Osteosarcoma',\n",
       "  'DRUG: Tucidinostat\",\" Apatinib',\n",
       "  'Wuhan Union Hospital\",\" China',\n",
       "  '',\n",
       "  '46.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01',\n",
       "  '2025-12'],\n",
       " ['NCT01074671',\n",
       "  'CG Future® Annuloplasty Ring/Band Clinical Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mitral Valve Insufficiency',\n",
       "  'DEVICE: CG Future Annuloplasty Ring/Band',\n",
       "  'Medtronic Bakken Research Center',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2011-09'],\n",
       " ['NCT03214471',\n",
       "  'Evaluation of a Lifestyle Intervention After Bariatric Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity',\n",
       "  'BEHAVIORAL: Lifestyle intervention',\n",
       "  'University College\",\" London',\n",
       "  '',\n",
       "  '153.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-02-20',\n",
       "  '2020-12-21'],\n",
       " ['NCT02659371',\n",
       "  'Weight Loss Prior Mamma Reduction - A Pilot Study',\n",
       "  'MAMMARED',\n",
       "  'COMPLETED',\n",
       "  'Weight Loss|Hypertrophy',\n",
       "  'DIETARY_SUPPLEMENT: Low energy diet',\n",
       "  'Copenhagen University Hospital at Herlev',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2016-05'],\n",
       " ['NCT03565471',\n",
       "  'Atrial Septal Defect - Exercise Capacity and Pulmonary Hypertension',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Atrial Septal Defect|Pulmonary Hypertension',\n",
       "  'DIAGNOSTIC_TEST: Echocardiography|DIAGNOSTIC_TEST: Right side catheterization|DIAGNOSTIC_TEST: Exercise test|DIAGNOSTIC_TEST: Holter monitor',\n",
       "  'University of Aarhus',\n",
       "  'Aarhus University Hospital',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-08-01',\n",
       "  '2019-11-01'],\n",
       " ['NCT05021471',\n",
       "  'Stretching With And Without Pressure Biofeeback In Patients With Postural Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Postural; Defect',\n",
       "  'OTHER: biofeedback|OTHER: hamstrings stretching',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-08-05',\n",
       "  '2022-02-28'],\n",
       " ['NCT02357771',\n",
       "  'Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Malocclusion',\n",
       "  'DRUG: Probiotic (L. brevis CD2 lozenges)|DRUG: Placebo',\n",
       "  'Next Gen Pharma India Pvt. Ltd.',\n",
       "  'Peoples University\", Bhanpur,\" Bhopal',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2015-09'],\n",
       " ['NCT01567371',\n",
       "  'LiDCO Monitor Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cardiac Surgery',\n",
       "  'DEVICE: LiDCO rapid monitor',\n",
       "  \"Nationwide Children's Hospital\",\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-03',\n",
       "  '2015-03'],\n",
       " ['NCT04272671',\n",
       "  'De-prescribing Program to Evaluate Falls in Older Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid-Related Disorders|Benzodiazepine-Related Disorders|Falls Injury',\n",
       "  'OTHER: Educational Intervention',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'Centers for Disease Control and Prevention',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2020-02-26',\n",
       "  '2021-10-01'],\n",
       " ['NCT04297371',\n",
       "  'Early Detection of Cardiac Impairment and Prediction of RV Hypertrophy in Patients With CTD',\n",
       "  'EARLY-MYO-CTD',\n",
       "  'COMPLETED',\n",
       "  'Connective Tissue Diseases|Right Ventricular Hypertrophy',\n",
       "  'DIAGNOSTIC_TEST: CMR examination',\n",
       "  'RenJi Hospital',\n",
       "  '',\n",
       "  '136.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-07',\n",
       "  '2016-11'],\n",
       " ['NCT02014571',\n",
       "  'Study to Assess the Safety\", Pharmacokinetics,\" and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C\",\" Chronic',\n",
       "  'DRUG: GSK2878175|DRUG: Placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  'PPD',\n",
       "  '37.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-12-26',\n",
       "  '2015-01-15'],\n",
       " ['NCT00999271',\n",
       "  'Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Subjects',\n",
       "  'OTHER: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)',\n",
       "  'Hvidovre University Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-08',\n",
       "  '2009-09'],\n",
       " ['NCT02429271',\n",
       "  'A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration\",\" in Patients With STEMI Treated With Thrombolysis - The \\'MIRTOS\\' Study',\n",
       "  'MIRTOS',\n",
       "  'COMPLETED',\n",
       "  'Myocardial Infarction|ST Segment Elevation Myocardial Infarction (STEMI)',\n",
       "  'DRUG: Ticagrelor|DRUG: Clopidogrel|PROCEDURE: Percutaneous Coronary Intervention (PCI)|PROCEDURE: Coronary Angiography',\n",
       "  'Hellenic Cardiovascular Research Society',\n",
       "  '',\n",
       "  '336.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-08',\n",
       "  '2019-02'],\n",
       " ['NCT01307371',\n",
       "  'Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Left Ventricular Function Systolic Dysfunction|Left Ventricular Function Diastolic Dysfunction|Death|Myocardial Reperfusion Injury',\n",
       "  '',\n",
       "  'Xijing Hospital',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-03',\n",
       "  '2011-12'],\n",
       " ['NCT03144271',\n",
       "  'Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Diabetes Mellitus\",\" Type 2|Healthy',\n",
       "  'DRUG: semaglutide|DRUG: Placebo',\n",
       "  'Novo Nordisk A/S',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-06-11',\n",
       "  '2007-10-08'],\n",
       " ['NCT03891771',\n",
       "  'Seniors Guardian: A Monitoring Platform for the Elderly',\n",
       "  'SEMONE',\n",
       "  'COMPLETED',\n",
       "  'Quality of Life',\n",
       "  'DEVICE: Telemonitoring sensors',\n",
       "  'Universidad de Valparaiso',\n",
       "  'Servicio de Vivienda y Urbanismo\", Chile|Ilustre Municipalidad de San Antonio, Chile|Corporación Municipal de Valparaíso,\" Chile',\n",
       "  '69.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-04-30',\n",
       "  '2021-06-06'],\n",
       " ['NCT04786171',\n",
       "  '4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Copd|Emphysema|Hyperinflation',\n",
       "  'DIAGNOSTIC_TEST: 4D X-ray Velocimetry',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  'American Thoracic Society',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-01-07',\n",
       "  '2024-11-01'],\n",
       " ['NCT04392271',\n",
       "  'A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: LY3372689|DIAGNOSTIC_TEST: [18F]LSN3316612',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2020-08-06',\n",
       "  '2020-10-14'],\n",
       " ['NCT02421471',\n",
       "  'PMS to Evaluate the Safety and Efficacy of Picato® Gel',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Actinic Keratosis',\n",
       "  'DRUG: Ingenol mebutate 0.015 percent or 0.05 percent gel',\n",
       "  'LEO Pharma',\n",
       "  '',\n",
       "  '1324.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-09',\n",
       "  '2018-01-19'],\n",
       " ['NCT04944771',\n",
       "  'Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Solid and Hematological Malignancies',\n",
       "  'DRUG: Capivasertib|DRUG: Rabeprazole',\n",
       "  'AstraZeneca',\n",
       "  'Parexel',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-07-26',\n",
       "  '2022-05-04'],\n",
       " ['NCT03688971',\n",
       "  'Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Seborrheic Dermatitis',\n",
       "  'DRUG: Omiganan|DRUG: Ketoconazole|DRUG: Placebo',\n",
       "  'Maruho Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-10-22',\n",
       "  '2019-12'],\n",
       " ['NCT01066871',\n",
       "  'Sprifermin (AS902330) in Cartilage Injury Repair (CIR)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Isolated Cartilage Injury of the Knee',\n",
       "  'DRUG: Sprifermin (AS902330) 10 mcg|DRUG: Sprifermin (AS902330) 30 mcg|DRUG: Sprifermin (AS902330) 100 mcg|OTHER: Placebo',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '',\n",
       "  '74.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-03',\n",
       "  '2013-04'],\n",
       " ['NCT00419471',\n",
       "  'Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depressive Disorder|Coronary Disease',\n",
       "  'DRUG: Escitalopram|DRUG: Placebo',\n",
       "  'Chonnam National University Hospital',\n",
       "  'H. Lundbeck A/S',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-05',\n",
       "  '2013-03'],\n",
       " ['NCT00558571',\n",
       "  '4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: BI 10773 low dose|DRUG: placebo to BI 10773|DRUG: BI 10773 medium dose|DRUG: BI 10773 high dose',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '78.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  ''],\n",
       " ['NCT04778371',\n",
       "  'The Effects of Almond Consumption on Functional Performance and Activity in Overweight Active Older Adults',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Overweight',\n",
       "  'OTHER: Almonds|OTHER: Placebo',\n",
       "  'Florida State University',\n",
       "  'Almond Board of California',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2021-03-02',\n",
       "  '2024-06-30'],\n",
       " ['NCT03358771',\n",
       "  'COPD Discharge Bundle Delivered Alone or Enhanced Through a Care Coordinator',\n",
       "  'PRIHS',\n",
       "  'COMPLETED',\n",
       "  'Pulmonary Disease\",\" Chronic Obstructive',\n",
       "  'OTHER: COPD discharge care bundle|OTHER: COPD discharge care bundle & coordinator',\n",
       "  'University of Alberta',\n",
       "  'University of Calgary|Alberta Health services|Alberta Innovates Health Solutions',\n",
       "  '3710.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2017-03-01',\n",
       "  '2019-12-30'],\n",
       " ['NCT03176771',\n",
       "  'Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Tardive Dyskinesia',\n",
       "  'DRUG: MT-5199|DRUG: Placebo',\n",
       "  'Mitsubishi Tanabe Pharma Corporation',\n",
       "  '',\n",
       "  '256.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-06-21',\n",
       "  '2020-09-29'],\n",
       " ['NCT00812071',\n",
       "  'Phase 1B Study of RiVax\",\" a Vaccine to Prevent the Toxic Effects of Ricin',\n",
       "  'FDA-OPD',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'BIOLOGICAL: RiVax',\n",
       "  'University of Texas Southwestern Medical Center',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2008-03',\n",
       "  '2012-05'],\n",
       " ['NCT05343871',\n",
       "  'Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: Sinovac|BIOLOGICAL: AZD1222|BIOLOGICAL: BNT162b2',\n",
       "  'Albert B. Sabin Vaccine Institute',\n",
       "  'Aga Khan University|Oswaldo Cruz Foundation|Stanford University',\n",
       "  '2354.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-07-05',\n",
       "  '2024-01-11'],\n",
       " ['NCT04281771',\n",
       "  'Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI',\n",
       "  'APPOSE',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  \"Transcatheter Aortic Valve Replacement|Hemodynamic Monitoring|Aortic Valve Insufficiency|Aortic Valve Stenosis|Heyde's Syndrome|Acquired Von Willebrand Disease\",\n",
       "  'PROCEDURE: cardiac MRI',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '92.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-09-17',\n",
       "  '2026-10-28'],\n",
       " ['NCT06129071',\n",
       "  'Analgesic Effect of Ultrasound Guided Maxillary Nerve Block in Trigeminal Neuralgia',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Trigeminal Neuralgia',\n",
       "  'PROCEDURE: US guided block of maxillary nerve',\n",
       "  'Varazdin General Hospital',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-01',\n",
       "  '2025-03-01'],\n",
       " ['NCT02472171',\n",
       "  'Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: High saturated fat meal\", placebo powder and sunflower oil|DIETARY_SUPPLEMENT: High saturated fat meal, blueberry powder and sunflower oil|DIETARY_SUPPLEMENT: High saturated fat meal,\" placebo powder and DHA',\n",
       "  'USDA\",\" Western Human Nutrition Research Center',\n",
       "  'University of California\",\" Davis',\n",
       "  '62.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-06',\n",
       "  '2017-11'],\n",
       " ['NCT03634371',\n",
       "  'Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'DRUG: Drug Levothyroxine 150 mcg|DRUG: Drug Eutirox 150 mcg',\n",
       "  'Tecnoquimicas',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-10',\n",
       "  '2018-10-06'],\n",
       " ['NCT05295771',\n",
       "  'Evaluation of Geistlich Fibro-Gide ® and Autogenous Connective Tissue Graft Prior to Orthodontic Maxillary Expansion.',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Thin Gingiva|Transverse Maxillary Deficiency|Cross Bite',\n",
       "  'PROCEDURE: Gingival Phenotype Modification',\n",
       "  'University of Alberta',\n",
       "  'Geistlich Pharma AG',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-04-01',\n",
       "  '2024-01-23'],\n",
       " ['NCT01985971',\n",
       "  'F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain Metastases From Breast Cancer',\n",
       "  'RADIATION: PET/CT Imaging',\n",
       "  'Abramson Cancer Center at Penn Medicine',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-03',\n",
       "  '2016-08-19'],\n",
       " ['NCT02175771',\n",
       "  'Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Persistent Asthma',\n",
       "  'DRUG: Fp MDPI|DRUG: FS MDPI|DRUG: FLOVENT HFA|DRUG: ADVAIR DISKUS|DRUG: albuterol/salbutamol HFA',\n",
       "  'Teva Branded Pharmaceutical Products R&D\",\" Inc.',\n",
       "  '',\n",
       "  '758.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2015-07'],\n",
       " ['NCT02000271',\n",
       "  'Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery?',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vaginal Packing Following Pelvic Reconstructive Surgery',\n",
       "  'PROCEDURE: Vaginal packing|PROCEDURE: No vaginal packing',\n",
       "  'TriHealth Inc.',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2014-06'],\n",
       " ['NCT00552071',\n",
       "  'Ultrasound Guided Octreotide LAR Injection in Acromegaly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acromegaly',\n",
       "  'DRUG: Octreotide LAR 30 MG Injection',\n",
       "  'Cedars-Sinai Medical Center',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2014-03'],\n",
       " ['NCT00321971',\n",
       "  'Prevention of Depression in Spouses of People With Cognitive Impairment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depression',\n",
       "  'BEHAVIORAL: PST-MCI/AD Caregiving|BEHAVIORAL: NT-MCI/AD Caregiving',\n",
       "  'University of Pittsburgh',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2007-02',\n",
       "  '2011-12'],\n",
       " ['NCT01003171',\n",
       "  'Pharmacokinetics of MCS in Healthy Volunteers',\n",
       "  'MCS-2-US-pk',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'DRUG: MCS-2 soft-gel capsule',\n",
       "  'Health Ever Bio-Tech Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-08',\n",
       "  '2012-12'],\n",
       " ['NCT05388071',\n",
       "  'Feasibility of Telemedicine Under Ambulance Station Conditions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Telemedicine|Disaster Medicine|Emergency Medicine',\n",
       "  'OTHER: Usage of telemedicine and tele-consultation for treatment',\n",
       "  'RWTH Aachen University',\n",
       "  '',\n",
       "  '404.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-07-01',\n",
       "  '2023-06-06'],\n",
       " ['NCT05401071',\n",
       "  'Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)',\n",
       "  'ORIENT',\n",
       "  'RECRUITING',\n",
       "  'Tuberculosis\",\" Pulmonary',\n",
       "  'OTHER: Short Regimen with Rifapentine 10mg/kg|COMBINATION_PRODUCT: Standardized Regimen|OTHER: Short Regimen with Rifapentine 15mg/kg|OTHER: Short Regimen with Rifapentine 20mg/kg',\n",
       "  'Huashan Hospital',\n",
       "  '',\n",
       "  '2442.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-13',\n",
       "  '2027-11-01'],\n",
       " ['NCT03852771',\n",
       "  'REST Study (CompRESsion Therapy for RLS)',\n",
       "  'REST',\n",
       "  'TERMINATED',\n",
       "  'Restless Legs Syndrome',\n",
       "  'DEVICE: Cirvo(TM) therapy',\n",
       "  'Radial Medical\",\" Inc.',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-03-12',\n",
       "  '2020-01-31'],\n",
       " ['NCT01722071',\n",
       "  'Deciphering the Role of Oxytocin in Motivation: an fMRI Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Focus of Study: Neural Correlates of Oxytocin Administration',\n",
       "  'DRUG: Placebo|DRUG: Oxytocin',\n",
       "  'Tiffany Love',\n",
       "  'University of Michigan',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-10',\n",
       "  '2015-10'],\n",
       " ['NCT05290571',\n",
       "  'Modified Otago Exercise Program on Balance Performance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Aging|Fall',\n",
       "  'OTHER: Modified Otago Exercise Program with music|OTHER: Modified Otago Exercise Program',\n",
       "  'Tung Wah College',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-10-27',\n",
       "  '2021-12-01'],\n",
       " ['NCT00007371',\n",
       "  'Hepatitis C in Clinically Discordant Hemophilic Siblings',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Blood Disease|Hemophilia A|Hepatitis\", Viral,\" Human',\n",
       "  '',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '1999-09',\n",
       "  '2004-08'],\n",
       " ['NCT01468571',\n",
       "  'Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pulmonary Hypertension',\n",
       "  'DRUG: Spironolactone|DRUG: Placebo',\n",
       "  'Baylor College of Medicine',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2015-12'],\n",
       " ['NCT01584271',\n",
       "  'Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Otitis Externa',\n",
       "  'DEVICE: Natural Ear Comfort(TM)\",\" a botanical ear drops product',\n",
       "  'Assuta Hospital Systems',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2013-12'],\n",
       " ['NCT01692171',\n",
       "  'Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Heparin\",\" Low-Molecular-Weight',\n",
       "  'Azidus Brasil',\n",
       "  'Blau Farmaceutica S.A.',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-02-28',\n",
       "  '2013-10-31'],\n",
       " ['NCT01751971',\n",
       "  'Estimating Apnea Phenotypes From Polysomnography: Oxygen',\n",
       "  'PSGtraits-O2',\n",
       "  'COMPLETED',\n",
       "  'Sleep Apnea',\n",
       "  'DRUG: Inspired oxygen (40%)|OTHER: Sham',\n",
       "  \"Brigham and Women's Hospital\",\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)|American Heart Association',\n",
       "  '47.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2016-07'],\n",
       " ['NCT02479971',\n",
       "  'Effect of Peritoneal Lavage With Clindamycin-gentamicin on Laparoscopic Sleeve Gastrectomy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain',\n",
       "  'DRUG: Clindamycin-gentamicin irrigation|DRUG: Normal saline irrigation',\n",
       "  'Hospital General Universitario Elche',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2014-01',\n",
       "  '2015-06'],\n",
       " ['NCT00808171',\n",
       "  'Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Leukemia|Non Hodgkin Lymphoma',\n",
       "  'DRUG: Livopan|DRUG: Livopan|DRUG: EMLA',\n",
       "  'Federal University of Minas Gerais',\n",
       "  '',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2009-02',\n",
       "  '2011-08'],\n",
       " ['NCT02113371',\n",
       "  'Evaluation of COMmunity of Practice And Safety Support (COMPASS) for Home Care Workers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Wounds and Injuries|Health Promotion',\n",
       "  'BEHAVIORAL: Intervention',\n",
       "  'Oregon Health and Science University',\n",
       "  'National Institute for Occupational Safety and Health (NIOSH/CDC)',\n",
       "  '210.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2011-10',\n",
       "  '2016-09'],\n",
       " ['NCT04016571',\n",
       "  'Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis',\n",
       "  'PRIVATE',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  '',\n",
       "  'Belfast Health and Social Care Trust',\n",
       "  'Queen\\'s University\",\" Belfast',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12-01',\n",
       "  '2019-03-01'],\n",
       " ['NCT02340871',\n",
       "  'Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases',\n",
       "  'NGS',\n",
       "  'UNKNOWN',\n",
       "  'Neurological Diseases',\n",
       "  'GENETIC: Genetic testing',\n",
       "  'Rabin Medical Center',\n",
       "  'Charite University\", Berlin,\" Germany|National Institute on Aging (NIA)',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2018-07'],\n",
       " ['NCT03770871',\n",
       "  'Indirect Pulp Treatment in Primary Molars',\n",
       "  'RCT',\n",
       "  'COMPLETED',\n",
       "  'Dental Caries',\n",
       "  'DRUG: Indirect pulp treatment using Dycal (TM)|DRUG: Indirect pulp treatment using Vitrebond (TM )',\n",
       "  'Cairo University',\n",
       "  '',\n",
       "  '88.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2018-07'],\n",
       " ['NCT04470271',\n",
       "  'Re-linkage to Care of Patients With Hepatitis C',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Viral Hepatitis C',\n",
       "  'OTHER: Patients with hepatitis C lost follow up',\n",
       "  'Austral University\",\" Argentina',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-01',\n",
       "  '2021-03-31'],\n",
       " ['NCT00290771',\n",
       "  'Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Recurrent Glioblastoma Multiforme (GBM)',\n",
       "  'DRUG: Imatinib tablets|DRUG: Hydroxyurea capsules',\n",
       "  'Novartis',\n",
       "  '',\n",
       "  '231.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-02',\n",
       "  '2008-08'],\n",
       " ['NCT00737971',\n",
       "  'Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema',\n",
       "  'ATEMD',\n",
       "  'COMPLETED',\n",
       "  'Diabetic Macular Edema',\n",
       "  'DRUG: Bevacizumab intravitreal|DRUG: Triamcinolone|DRUG: Triamcinolone + Bevacizumab',\n",
       "  'Rubens Belfort Jr.',\n",
       "  '',\n",
       "  '142.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2013-12'],\n",
       " ['NCT02444871',\n",
       "  'IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  '',\n",
       "  'Goethe University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01',\n",
       "  '2013-07'],\n",
       " ['NCT05876871',\n",
       "  'Stress Radiography for Pelvic Ring Injuries',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Pelvic Fracture',\n",
       "  'DIAGNOSTIC_TEST: Pelvic Binder Radiography',\n",
       "  'University of Southern California',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-02-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT04848571',\n",
       "  'Effects of Chinese Medicine on Early Pregnant Women',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pregnant Women',\n",
       "  'COMBINATION_PRODUCT: Fetal Protection Pill',\n",
       "  'Shanghai Meiji Health Science and Technology Co.\",\" Ltd.',\n",
       "  'Shanghai Institute of Palnned parenthood research',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2021-06-21',\n",
       "  '2022-06-20'],\n",
       " ['NCT00470171',\n",
       "  'Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis',\n",
       "  'URSONASH',\n",
       "  'COMPLETED',\n",
       "  'Serum Levels of ALAT Transaminases|Serum Markers for Fibrosis and Hepatic Inflammation',\n",
       "  'DRUG: Ursodesoxycholic acid',\n",
       "  'Axcan Pharma',\n",
       "  '',\n",
       "  '98.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2008-11'],\n",
       " ['NCT05375071',\n",
       "  'BFR After Biceps Tendon Repair and MPFLR',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Patellofemoral Joint Dislocation|Bicep Tendon Rupture',\n",
       "  'OTHER: Blood Flow Restriction (BFR) Therapy|OTHER: Physical Therapy',\n",
       "  'Mayo Clinic',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12',\n",
       "  '2024-01'],\n",
       " ['NCT01979471',\n",
       "  'The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH',\n",
       "  'RxEACH',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Chronic Kidney Disease|Established Atherosclerotic Vascular Disease|Framingham Risk Score More Than 20 Percent',\n",
       "  'OTHER: Advanced Care',\n",
       "  'University of Alberta',\n",
       "  'Alberta Health & Wellness|Alberta Health services|Merck Frosst Canada Ltd.',\n",
       "  '723.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2015-12'],\n",
       " ['NCT05507671',\n",
       "  'The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines',\n",
       "  'SARS-CoV-2',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: BCG (Bacillus Calmette-Guérin) vaccine|OTHER: Placebo',\n",
       "  'Oswaldo Cruz Foundation',\n",
       "  'University of Sao Paulo|Federal University of Juiz de Fora',\n",
       "  '556.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-05-27',\n",
       "  '2023-12-31'],\n",
       " ['NCT00428571',\n",
       "  'Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Type 2 Diabetes',\n",
       "  'PROCEDURE: laparoscopic gastric bypass surgery|PROCEDURE: laparoscopic adjustable gastric banding|PROCEDURE: Intensive Medical Management',\n",
       "  'Hamilton Health Sciences Corporation',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-05',\n",
       "  '2015-04'],\n",
       " ['NCT04324671',\n",
       "  'Upper Airway Obstruction in Non-obese Patients With Snoring and Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Snoring',\n",
       "  'DEVICE: nasofibroscopy',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-07-01',\n",
       "  '2021-12-01'],\n",
       " ['NCT03735771',\n",
       "  'Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 2.5ml of Bupivacaine 0.25% Plus Fentanyl 8 mcg/ml',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Labor Pain',\n",
       "  'DRUG: Bupivacaine',\n",
       "  'Samuel Lunenfeld Research Institute\",\" Mount Sinai Hospital',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-12-03',\n",
       "  '2019-11-01'],\n",
       " ['NCT06056271',\n",
       "  'Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation',\n",
       "  'COMPANION AI',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Atrial Fibrillation',\n",
       "  'DEVICE: AF Ablation',\n",
       "  'Volta Medical',\n",
       "  'Heart Rhythm Clinical and Research Solutions\",\" LLC',\n",
       "  '400.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10',\n",
       "  '2027-12'],\n",
       " ['NCT00971971',\n",
       "  'Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Kidney Injury|Acute Renal Failure',\n",
       "  'PROCEDURE: Dialysis|PROCEDURE: Standard SLED',\n",
       "  'Sao Jose do Rio Preto Medical School',\n",
       "  'Fundação de Amparo à Pesquisa do Estado de São Paulo',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2009-09'],\n",
       " ['NCT05278871',\n",
       "  'Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphedema of Upper Arm|Breast Cancer',\n",
       "  'DEVICE: Constructive Shearwave Interference (CSI)',\n",
       "  'Microelastic Ultrasound Systems Inc',\n",
       "  'Duke Health',\n",
       "  '21.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2022-05-26',\n",
       "  '2023-08-31'],\n",
       " ['NCT03513471',\n",
       "  'Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation',\n",
       "  'EarlyAna',\n",
       "  'WITHDRAWN',\n",
       "  'Asthma',\n",
       "  'BIOLOGICAL: Anakinra|OTHER: Anakinra Matching Placebo|DRUG: Dermatophagoides Farinae',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-09',\n",
       "  '2021-12'],\n",
       " ['NCT00705471',\n",
       "  \"Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Crohn Disease',\n",
       "  'BIOLOGICAL: Infliximab',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  'Centocor\",\" Inc.',\n",
       "  '42.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-04',\n",
       "  '2007-09'],\n",
       " ['NCT04354571',\n",
       "  'Erector Spinae Plane Block in Pediatric Hip Surgery',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Analgesia',\n",
       "  'PROCEDURE: Erector spinae plane block|PROCEDURE: caudal block',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-08-11',\n",
       "  '2020-09'],\n",
       " ['NCT04683471',\n",
       "  'Pilot Trial of a System for Motor Function Recovery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Spinal Cord Diseases',\n",
       "  'DEVICE: Stimulator|DEVICE: Sham',\n",
       "  'Niche Biomedical\",\" Inc. dba ANEUVO',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-11-30',\n",
       "  '2022-03-22'],\n",
       " ['NCT04544371',\n",
       "  'Ultrasound Assessment of Gastric Residual Volume in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aspiration Pneumonia',\n",
       "  'DEVICE: gastric ultrasound|PROCEDURE: nasogastric tube insertion',\n",
       "  'Fayoum University Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-10-15',\n",
       "  '2020-12-30'],\n",
       " ['NCT04145271',\n",
       "  'Pre-Hospital Zone 1 Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Injured Patients With Exsanguinating Sub-diaphragmatic Haemorrhage',\n",
       "  'P-PRO',\n",
       "  'COMPLETED',\n",
       "  'Emergencies|Trauma Injury|Trauma\",\" Multiple',\n",
       "  'DEVICE: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)',\n",
       "  'Barts & The London NHS Trust',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-27',\n",
       "  '2022-03-31'],\n",
       " ['NCT05824871',\n",
       "  'Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients',\n",
       "  'WISH',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Rifampicin-resistant Tuberculosis',\n",
       "  'DRUG: Sudapyridine|DRUG: Bedaquiline',\n",
       "  'Shanghai Jiatan Pharmatech Co.\",\" Ltd',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-09-02',\n",
       "  '2025-03-22'],\n",
       " ['NCT04119271',\n",
       "  'Durham Healthy Breathing in Healthy Homes Project',\n",
       "  'DHBHH',\n",
       "  'COMPLETED',\n",
       "  'Poor Asthma Control',\n",
       "  'OTHER: Breathe Easy at Home Kit Products',\n",
       "  'Duke University',\n",
       "  'Reinvestment Partners',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-05-18',\n",
       "  '2023-05-11'],\n",
       " ['NCT00757471',\n",
       "  'Brillant Blue Versus Indocyanine Green for Macular Hole Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Macular Holes',\n",
       "  'PROCEDURE: Brillant Blue|PROCEDURE: Indocyanine Green',\n",
       "  'The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2015-08'],\n",
       " ['NCT05147571',\n",
       "  'RNS System NAUTILUS Study',\n",
       "  'NAUTILUS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Epilepsy|Idiopathic Generalized Epilepsy|Generalized Tonic Clonic Seizure',\n",
       "  'DEVICE: Responsive stimulation|DEVICE: Sham stimulation',\n",
       "  'NeuroPace',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-09',\n",
       "  '2026-12'],\n",
       " ['NCT00005871',\n",
       "  'Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pancreatic Cancer',\n",
       "  'DRUG: fluorouracil|DRUG: rubitecan',\n",
       "  'Astex Pharmaceuticals\",\" Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1998-11',\n",
       "  ''],\n",
       " ['NCT04076371',\n",
       "  'The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia',\n",
       "  'DRUG: olanzapine-sertraline combination|DRUG: only olanzapine|DRUG: risperidone-sertraline combination|DRUG: only risperidone|DRUG: paliperidone-sertraline combination|DRUG: only paliperidone|DRUG: ziprasidone-sertraline combination|DRUG: only ziprasidone',\n",
       "  'Beijing HuiLongGuan Hospital',\n",
       "  '',\n",
       "  '1640.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2018-12'],\n",
       " ['NCT03950271',\n",
       "  'SHR-1210 Combined With Trastuzumab \",\" Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastric Cancer',\n",
       "  'DRUG: SHR-1210 Combined With Trastuzumab \",\" Oxaliplatin and Capecitabine',\n",
       "  'Henan Cancer Hospital',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01-21',\n",
       "  '2022-06-01'],\n",
       " ['NCT05624671',\n",
       "  'Is Elective Caesarean Sections for Predicting Post-spinal Hypotension Role of Overactive Bladder?',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  '18-45 Range of Age|Cesarean Section|Primigravid',\n",
       "  'OTHER: bupivacaine\",\"fentanyl',\n",
       "  'Ataturk University',\n",
       "  '',\n",
       "  '143.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2019-08-01',\n",
       "  '2021-12-30'],\n",
       " ['NCT04502771',\n",
       "  'Therapeutic Drug Monitoring of Antifungals in Intensive Care Units',\n",
       "  'Fungi-up',\n",
       "  'COMPLETED',\n",
       "  'Intensive Care Unit Patients',\n",
       "  'DRUG: Antifungal treatment',\n",
       "  'Hospices Civils de Lyon',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-01',\n",
       "  '2019-12-31'],\n",
       " ['NCT01394471',\n",
       "  'Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia',\n",
       "  'OTS-12WK',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizoaffective Disorder',\n",
       "  'DRUG: Intranasal Oxytocin Spray',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2015-01'],\n",
       " ['NCT03789071',\n",
       "  'Ultrasound to Predict Difficult Airway',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Difficult Intubation',\n",
       "  'DIAGNOSTIC_TEST: External ultrasound evaluation of the airway',\n",
       "  'Augusta University',\n",
       "  '',\n",
       "  '420.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2023-03-01'],\n",
       " ['NCT00145171',\n",
       "  'A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: apomorphine HCl injection',\n",
       "  'Mylan Bertek Pharmaceuticals',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-02',\n",
       "  '2002-08'],\n",
       " ['NCT01688271',\n",
       "  'Simulation-Based Training for Ultrasound-Guided Perineural Catheter Insertion',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain Management|Simulation|Training|Ultrasonography',\n",
       "  '',\n",
       "  'VA Palo Alto Health Care System',\n",
       "  'Stanford University',\n",
       "  '32.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-08',\n",
       "  '2014-07'],\n",
       " ['NCT01711671',\n",
       "  'A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: DKN-01 300 mg|DRUG: DKN-01 600 mg|DRUG: Standard of Care',\n",
       "  'Leap Therapeutics\",\" Inc.',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2015-07'],\n",
       " ['NCT04342871',\n",
       "  'An Evaluation of the Fathers and Mothers With Cancer Communication Tool',\n",
       "  'Fam-CT',\n",
       "  'COMPLETED',\n",
       "  'Neoplasms|Cancer|Parenting|Communication|Parents|Parent-Child Relations',\n",
       "  'BEHAVIORAL: Fam-CT',\n",
       "  'UNC Lineberger Comprehensive Cancer Center',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2020-10-05',\n",
       "  '2021-07-27'],\n",
       " ['NCT01034371',\n",
       "  'Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Artery Disease',\n",
       "  'PROCEDURE: Minimally invasive direct coronary artery bypass|PROCEDURE: PCI-Drug eluting stents|PROCEDURE: Off-pump coronary artery bypass',\n",
       "  'China National Center for Cardiovascular Diseases',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-12',\n",
       "  ''],\n",
       " ['NCT02390271',\n",
       "  'How Reducing Anxiety in Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia',\n",
       "  'OTHER: emotion focused therapy training',\n",
       "  'Institut de Recherche Biomedicale des Armees',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-06',\n",
       "  '2011-06'],\n",
       " ['NCT04727671',\n",
       "  'Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'In Vitro Fertilization|Intracytoplasmic Sperm Injection|Infertility|Polycystic Ovary Syndrome',\n",
       "  'DRUG: Triptorelin acetate|DRUG: Cetrorelix|DRUG: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|DRUG: Human Chorionic Gonadotropin (hCG)',\n",
       "  'Damascus University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-12-22',\n",
       "  '2021-12-30'],\n",
       " ['NCT01111071',\n",
       "  'Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Coronary Syndrome',\n",
       "  '',\n",
       "  'University College\",\" London',\n",
       "  'Barts & The London NHS Trust|Queen Mary University of London|University of Bristol|Yale University',\n",
       "  '316648.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-04',\n",
       "  '2014-12'],\n",
       " ['NCT01140971',\n",
       "  'Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pregnancy\",\" Prolonged|Pre Eclampsia|Oligohydramnios',\n",
       "  'DRUG: Misoprostol|DEVICE: Foley',\n",
       "  'Municipal Hospital Vila Nova Cachoeirinha',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2009-01'],\n",
       " ['NCT05934071',\n",
       "  'Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Heart Failure|Ventricular Remodeling|Ventricular Dysfunction',\n",
       "  'DRUG: SGLT2 inhibitor',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-10-10',\n",
       "  '2024-12-31'],\n",
       " ['NCT02299271',\n",
       "  'Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Osteoarthritis of the Hip',\n",
       "  'DRUG: Ropivacaine|DRUG: Saline',\n",
       "  'The Christ Hospital',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-06',\n",
       "  '2016-12'],\n",
       " ['NCT02425371',\n",
       "  'Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)',\n",
       "  'OPTIMIZE-HFPEF',\n",
       "  'UNKNOWN',\n",
       "  'Heart Failure\",\" Diastolic',\n",
       "  'OTHER: Screening and treatment of comorbidities|OTHER: Placebo Comparator',\n",
       "  'Göteborg University',\n",
       "  'Umeå University|Karolinska Institutet|Uppsala University|Vastra Gotaland Region',\n",
       "  '410.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-09',\n",
       "  '2019-07'],\n",
       " ['NCT01403571',\n",
       "  'Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes',\n",
       "  'LOSS',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus|Overweight|Obesity',\n",
       "  'DIETARY_SUPPLEMENT: Salba (Salvia hispanica L.)|DIETARY_SUPPLEMENT: Oat-based Control',\n",
       "  'Unity Health Toronto',\n",
       "  'Canadian Diabetes Association',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-10',\n",
       "  '2015-08'],\n",
       " ['NCT00945971',\n",
       "  'Exercise Effects in Children With Attention Deficit Hyperactivity Disorder',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Attention Deficit/Hyperactivity Disorder',\n",
       "  'OTHER: Physical activity',\n",
       "  'Meir Medical Center',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-10-01',\n",
       "  '2020-12-01'],\n",
       " ['NCT02177071',\n",
       "  \"A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy\",\n",
       "  'SPARE',\n",
       "  'COMPLETED',\n",
       "  \"Crohn's Disease\",\n",
       "  'DRUG: INFLIXIMAB|DRUG: AZATHIOPRINE|DRUG: MERCAPTOPURINE|DRUG: Methotrexate',\n",
       "  \"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives\",\n",
       "  'Saint-Louis Hospital\", Paris,\" France',\n",
       "  '211.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-10-09',\n",
       "  '2021-10'],\n",
       " ['NCT04704271',\n",
       "  'Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II',\n",
       "  'THC-Gender-II',\n",
       "  'RECRUITING',\n",
       "  'Cannabis',\n",
       "  'DRUG: Inhaled THC|DRUG: Placebo',\n",
       "  'Yale University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-10-09',\n",
       "  '2024-12-01'],\n",
       " ['NCT02879071',\n",
       "  'Long Term Follow-up After Embolization of Brain Arteriovenous Malformations',\n",
       "  'MAV-endovasc',\n",
       "  'RECRUITING',\n",
       "  'Arteriovenous Malformations',\n",
       "  '',\n",
       "  'Fondation Ophtalmologique Adolphe de Rothschild',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'NETWORK',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-11-26',\n",
       "  '2033-11-25'],\n",
       " ['NCT01491971',\n",
       "  'Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer',\n",
       "  'IM1',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Degarelix',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2012-11'],\n",
       " ['NCT04130971',\n",
       "  'Predicting Colorectal Cancer - Tissue Samples to Evaluate Tumour Characteristics and Treatment Response',\n",
       "  'Predict',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Neoplasms',\n",
       "  'OTHER: No intervention\",\" just observation',\n",
       "  'Sahlgrenska University Hospital\",\" Sweden',\n",
       "  'Göteborg University',\n",
       "  '800.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2027-12-31'],\n",
       " ['NCT03843671',\n",
       "  'Hyperbaric Radiation Sensitization of Head and Neck Cancers',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Squamous Cell Carcinoma of the Head and Neck',\n",
       "  'DRUG: Hyperbaric oxygen|DEVICE: Hyperbaric chamber',\n",
       "  'National Baromedical Services',\n",
       "  'Mayo Clinic|Dartmouth-Hitchcock Medical Center|CISSS de Chaudière-Appalaches|Memorial Hermann Hospital|David Grant U.S. Air Force Medical Center|59th Medical Wing|Prisma Health Richland Hospital|William Jennings Bryan Dorn VA Medical Center',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-07-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT04125771',\n",
       "  'Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain',\n",
       "  'DIAGNOSTIC_TEST: Diclofenac + HBB with hysteroscopy|DIAGNOSTIC_TEST: Diclofenav + placebo',\n",
       "  'Aljazeera Hospital',\n",
       "  'Cairo University',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2020-02-16',\n",
       "  '2020-10-01'],\n",
       " ['NCT00766571',\n",
       "  'Clinical and Genetic Studies of VACTERL Association',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Congenital Abnormalities|Birth Defects|Congenital Defects',\n",
       "  '',\n",
       "  'National Human Genome Research Institute (NHGRI)',\n",
       "  '',\n",
       "  '304.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-09-29',\n",
       "  '2017-06-29'],\n",
       " ['NCT03881371',\n",
       "  'A Study to Evaluate the Efficacy and Safety of Safinamide\", as add-on Therapy,\" in Idiopathic Chinese Parkinson\\'s Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: Safinamide|OTHER: Placebo',\n",
       "  'Zambon SpA',\n",
       "  '',\n",
       "  '307.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-01',\n",
       "  '2021-08-20'],\n",
       " ['NCT02360371',\n",
       "  'A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid Sensitivity|Individual Difference|Abuse Opioids',\n",
       "  'DRUG: Within-subject test of blinded study medication',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-04',\n",
       "  '2021-05'],\n",
       " ['NCT04175171',\n",
       "  'Clinical Trial of Comparative Study of GB221 Pharmacokinetics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Breast Cancer',\n",
       "  'DRUG: Coprelotamab Injection|DRUG: Trastuzumab Injection',\n",
       "  'Genor Biopharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-11-07',\n",
       "  '2012-03-08'],\n",
       " ['NCT05936671',\n",
       "  'EEG and ANI Guided Anesthesia and Quality of Recovery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Laparoscopic Gynecological Surgery',\n",
       "  'PROCEDURE: EEG-and-ANI-guided anesthesia|PROCEDURE: standard anesthesia|DRUG: Sevoflurane and remifentanil|DEVICE: EEG and ANI',\n",
       "  'Gangnam Severance Hospital',\n",
       "  '',\n",
       "  '126.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-13',\n",
       "  '2025-06-25'],\n",
       " ['NCT03391271',\n",
       "  'PBMT for the Prevention of CIPN',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'OTHER: photobiomodulation therapy (PBMT)|OTHER: sham laser sessions',\n",
       "  'Hasselt University',\n",
       "  'Jessa Hospital',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-11-13',\n",
       "  '2021-06-22'],\n",
       " ['NCT04080271',\n",
       "  'Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.',\n",
       "  'PET/CT',\n",
       "  'COMPLETED',\n",
       "  'Bone Metastases',\n",
       "  'DEVICE: 18F-FDG PET/CT',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-01',\n",
       "  '2021-12-01'],\n",
       " ['NCT01480271',\n",
       "  'An Investigation of the Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rhinitis\", Allergic,\" Seasonal',\n",
       "  'DRUG: 2 ng GSK2445053|DRUG: 20ng GSK2445053|DRUG: 100ng GSK2445053|DRUG: 200ng GSK2445053|DRUG: 400ng GSK2445053|DRUG: 1000ng GSK2445053|DRUG: 2000ng GSK2445053|DRUG: 4000ng GSK2445053|DRUG: Placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '61.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-05-30',\n",
       "  '2011-09-30'],\n",
       " ['NCT00639171',\n",
       "  'Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Tumors',\n",
       "  '',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-11',\n",
       "  '2015-08'],\n",
       " ['NCT00826371',\n",
       "  'Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients',\n",
       "  'EXTEND II',\n",
       "  'COMPLETED',\n",
       "  'Age Related Macular Degeneration',\n",
       "  'DRUG: ranibizumab 0.5 mg',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  ''],\n",
       " ['NCT02938871',\n",
       "  'Effect of Synbiotic on Postoperative Complications After Liver Transplantation',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Liver Disease',\n",
       "  'DIETARY_SUPPLEMENT: Synbiotic|DIETARY_SUPPLEMENT: Control',\n",
       "  'Hospital de Clinicas de Porto Alegre',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-03',\n",
       "  '2018-01'],\n",
       " ['NCT04596371',\n",
       "  'A Single-center Prospective Cohort Study for Pure Pulmonary Ground Glass Nodules in Women Preparing for Pregnancy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Cancer',\n",
       "  'OTHER: pure pulmonary ground glass nodules in women preparing for pregnancy',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-11-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT03322371',\n",
       "  'Validation of Frontal EEG to Formal Polysomnography in the ICU',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Sleep Deprivation|Sleep',\n",
       "  'DEVICE: 2-lead limited electroencephalography recording',\n",
       "  'University of Utah',\n",
       "  'Epitel\",\" Inc.',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2017-11-06',\n",
       "  '2020-01-01'],\n",
       " ['NCT03332771',\n",
       "  'Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy',\n",
       "  'SOTA-GLIM',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: Sotagliflozin (SAR439954)|DRUG: Glimepiride|DRUG: Metformin|DRUG: Placebo|DRUG: Placebo',\n",
       "  'Lexicon Pharmaceuticals',\n",
       "  'Sanofi',\n",
       "  '954.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-12-01',\n",
       "  '2019-09-06'],\n",
       " ['NCT04605471',\n",
       "  'A Study to Learn More About the Safety of Ultravist in Children and in the Elderly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypersensitivity',\n",
       "  'DRUG: Iopromide(Ultravist\",\" BAY86-4877)',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '132850.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-31',\n",
       "  '2021-03-31'],\n",
       " ['NCT04403971',\n",
       "  '0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hospital-acquired Pneumonia',\n",
       "  'DRUG: 0.12% Chlorhexidine Oral Liquid Product|DRUG: Listerine Oral Liquid Product|OTHER: Normal Saline Product',\n",
       "  'National Cheng-Kung University Hospital',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-05-25',\n",
       "  '2020-12-31'],\n",
       " ['NCT05559671',\n",
       "  'Safety of the Herpes Zoster Subunit Vaccine in Lupus',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Systemic Lupus Erythematosus',\n",
       "  'BIOLOGICAL: Herpes Zoster Subunit (HZ/su) Vaccine|BIOLOGICAL: Placebo',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '224.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-12-21',\n",
       "  '2027-01'],\n",
       " ['NCT01608971',\n",
       "  'Protamine in Cardiac Surgery and Haemostasis',\n",
       "  'PROTT',\n",
       "  'COMPLETED',\n",
       "  'Bleeding|Hemorrhage',\n",
       "  '',\n",
       "  'Heart and Diabetes Center North-Rhine Westfalia',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-01',\n",
       "  '2012-03'],\n",
       " ['NCT05533671',\n",
       "  'Conservative Versus Operative - First Time Patella Dislocations',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Patella Dislocation',\n",
       "  'PROCEDURE: medial patellofemoral reconstruction|PROCEDURE: Non-operative group',\n",
       "  'Columbia University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12',\n",
       "  '2032-09'],\n",
       " ['NCT03279471',\n",
       "  'Specifying and Treating Anxiety in Autism Research',\n",
       "  'STAAR',\n",
       "  'COMPLETED',\n",
       "  'Autism Spectrum Disorder|Anxiety',\n",
       "  'DRUG: Sertraline|BEHAVIORAL: CBT/BIACA|DRUG: Placebo',\n",
       "  'University of California\",\" Davis',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-01',\n",
       "  '2023-02-22'],\n",
       " ['NCT00316771',\n",
       "  'A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'DRUG: P38 Inhibitor (4) 150mg|DRUG: P38 Inhibitor (4) 25mg|DRUG: P38 Inhibitor (4) 300mg|DRUG: P38 Inhibitor (4) 50mg|DRUG: P38 Inhibitor (4) 75mg|DRUG: Placebo',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '374.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-11',\n",
       "  '2008-03'],\n",
       " ['NCT00795171',\n",
       "  'Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hormone Refractory Prostate Cancer',\n",
       "  'DRUG: Docetaxel * Sunitinib|DRUG: Docetaxel|DRUG: Docetaxel',\n",
       "  'Medical University of Vienna',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2008-11',\n",
       "  '2011-07'],\n",
       " ['NCT01459471',\n",
       "  'Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Complication of Surgical Procedure|Leak; Blood',\n",
       "  'PROCEDURE: Bariatric surgery',\n",
       "  'University of Rome Tor Vergata',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-04',\n",
       "  '2010-09'],\n",
       " ['NCT00671671',\n",
       "  'Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis\",\" Chronic|Hepatitis C Virus',\n",
       "  'DRUG: Small Molecule Agent (PF-868554)|DRUG: Small Molecule Agent (PF-868554)',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-04',\n",
       "  '2008-12'],\n",
       " ['NCT00601471',\n",
       "  'Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation\", Ankle Range of Motion,\" and Functional Outcome Scores in Individuals With Chronic Ankle Instability',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ankle Sprain|Ankle Injuries|Sprain',\n",
       "  'OTHER: proximal tibiofibular manipulation|OTHER: distal tibiofibular manipulation|OTHER: no intervention',\n",
       "  'University of Virginia',\n",
       "  'American Physical Therapy Association',\n",
       "  '61.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-04',\n",
       "  '2010-01'],\n",
       " ['NCT03750071',\n",
       "  'VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Recurrent Glioblastoma',\n",
       "  'BIOLOGICAL: VXM01|BIOLOGICAL: Avelumab',\n",
       "  'Vaximm GmbH',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany|Pfizer',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-21',\n",
       "  '2022-12-31'],\n",
       " ['NCT03064971',\n",
       "  'Enhancing Quitline Services for African American Smokers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Tobacco Use Cessation',\n",
       "  'BEHAVIORAL: Standard Care|BEHAVIORAL: smoking cessation DVD|BEHAVIORAL: PTF DVD',\n",
       "  'Case Comprehensive Cancer Center',\n",
       "  'American Cancer Society\",\" Inc.|Consumer Wellness Solutions|North Carolina Tobacco Quitline',\n",
       "  '1050.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2017-05-22',\n",
       "  '2020-06-24'],\n",
       " ['NCT00710671',\n",
       "  'Psychosocial Needs of YMSM',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV+ YMSM',\n",
       "  '',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)',\n",
       "  '254.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-06'],\n",
       " ['NCT05258071',\n",
       "  \"A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: Pirepemat|DRUG: Placebo',\n",
       "  'Integrative Research Laboratories AB',\n",
       "  '',\n",
       "  '165.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-06-15',\n",
       "  '2024-04'],\n",
       " ['NCT02205671',\n",
       "  'Building Better Caregivers: Development and Evaluation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Providing Care for People With Memory Problems',\n",
       "  'BEHAVIORAL: Building Better Caregivers Small-group Workshop',\n",
       "  'Stanford University',\n",
       "  '',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-08',\n",
       "  '2017-03'],\n",
       " ['NCT00487071',\n",
       "  'Anal Fistula Plug for High-type Anal Fistulae',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'High-type Anal Fistulae',\n",
       "  'DEVICE: Anal fistula plug',\n",
       "  'Chinese University of Hong Kong',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-08',\n",
       "  '2014-02'],\n",
       " ['NCT00744471',\n",
       "  'Tanezumab in Osteoarthritis Of The Hip',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Arthritis|Osteoarthritis|Osteoarthritis\",\" Hip',\n",
       "  'BIOLOGICAL: tanezumab|BIOLOGICAL: tanezumab|BIOLOGICAL: tanezumab|BIOLOGICAL: Placebo',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '627.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-11-17',\n",
       "  '2010-08-13'],\n",
       " ['NCT04388371',\n",
       "  'Glutamine PET Imaging in LAM',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphangioleiomyomatosis (LAM)',\n",
       "  'DRUG: Glutamine',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  'The LAM Foundation',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-10-18',\n",
       "  '2021-08-10'],\n",
       " ['NCT02546271',\n",
       "  'A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men',\n",
       "  'GPS',\n",
       "  'COMPLETED',\n",
       "  'Risk Behavior',\n",
       "  'BEHAVIORAL: GPS',\n",
       "  'Toronto Metropolitan University',\n",
       "  '',\n",
       "  '82.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2009-03',\n",
       "  '2013-11'],\n",
       " ['NCT05995171',\n",
       "  'Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence',\n",
       "  'TransEAsome',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Esophageal Atresia',\n",
       "  'OTHER: Questionnaire',\n",
       "  'University Hospital\",\" Lille',\n",
       "  'Institut National de la Santé Et de la Recherche Médicale\",\" France',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-12-05',\n",
       "  '2026-12-05'],\n",
       " ['NCT04904471',\n",
       "  'A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: Recombinant COVID-19 vaccine (Sf9 cells)|OTHER: Placebo control',\n",
       "  'WestVac Biopharma Co.\",\" Ltd.',\n",
       "  'West China Hospital',\n",
       "  '40000.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-06-15',\n",
       "  '2023-12-31'],\n",
       " ['NCT00113971',\n",
       "  'Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lupus Erythematosus\",\" Systemic',\n",
       "  'DRUG: epratuzumab',\n",
       "  'UCB Pharma',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-04',\n",
       "  '2007-06'],\n",
       " ['NCT03263871',\n",
       "  'PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Environmental Enteric Dysfunction',\n",
       "  'DIETARY_SUPPLEMENT: PTM202|DIETARY_SUPPLEMENT: micro-nutrient sprinkles',\n",
       "  'University of Virginia',\n",
       "  'International Centre for Diarrhoeal Disease Research\",\" Bangladesh|Virginia Commonwealth University',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-14',\n",
       "  '2019-02-15'],\n",
       " ['NCT01989871',\n",
       "  'Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm Infants',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Body Weight Changes|Feeding and Eating Disorders of Childhood|Breast Feeding|Evoked Response Audiometry',\n",
       "  'BEHAVIORAL: Adjusted individual feeding',\n",
       "  'Sheba Medical Center',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-12',\n",
       "  '2015-12'],\n",
       " ['NCT05173571',\n",
       "  'Homecare Integral Support Program for IPF Patients',\n",
       "  'PSPi-IPF',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Pulmonary Fibrosis',\n",
       "  'COMBINATION_PRODUCT: Comprehensive patient support program (educational\", physiotherapy, nutritional,\" emotional)',\n",
       "  \"Institut d'Investigació Biomèdica de Bellvitge\",\n",
       "  '',\n",
       "  '95.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-07-01',\n",
       "  '2021-12-12'],\n",
       " ['NCT04700371',\n",
       "  'Vessel Deformations and Restenosis After Stenting of the Popliteal Artery',\n",
       "  'FIRESTEP',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Peripheral Arterial Disease|Popliteal Artery Stenosis',\n",
       "  'DEVICE: Interwoven stent|DEVICE: Laser-cut stent',\n",
       "  'Kantonsspital Aarau',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-01',\n",
       "  '2024-08-01'],\n",
       " ['NCT04858971',\n",
       "  'Survey of Diet and Health Beliefs',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dietary Guidelines',\n",
       "  'OTHER: Perception of information source',\n",
       "  'USDA Grand Forks Human Nutrition Research Center',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-06-21',\n",
       "  '2021-09-24'],\n",
       " ['NCT02747771',\n",
       "  'Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder)',\n",
       "  'NorTriP',\n",
       "  'UNKNOWN',\n",
       "  'Trichotillomania',\n",
       "  'BEHAVIORAL: Cognitive behavioral therapy',\n",
       "  'Oslo University Hospital',\n",
       "  'Sorlandet Hospital HF|St. Olavs Hospital|Texas A&M University|University of Michigan',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01',\n",
       "  '2019-12'],\n",
       " ['NCT00849771',\n",
       "  'Operative Versus Nonoperative Treatment for Scapula Fractures',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Scapula Fracture|Clavicle Fracture',\n",
       "  '',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-01'],\n",
       " ['NCT05057871',\n",
       "  'Efficacy of Pulse Electromagnetic Field Therapy (PEMF) in Patients With Subacromial Impingement Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Shoulder Pain|Musculoskeletal Diseases|Subacromial Impingement Syndrome|Shoulder Injuries and Disorders',\n",
       "  'DEVICE: Pulse electromagnetic field therapy|DEVICE: Sham pulse electromagnetic field therapy',\n",
       "  'Afyonkarahisar Health Sciences University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-01-01',\n",
       "  '2022-06-01'],\n",
       " ['NCT01550471',\n",
       "  'Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma|Allergic Rhinitis',\n",
       "  'DRUG: Alvesco/Omnaris\", QVAR/Beconase, Placebo/Placebo|DRUG: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|DRUG: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|DRUG: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|DRUG: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|DRUG: Placebo/Placebo, QVAR/Beconase,\" Alvesco/Omnaris',\n",
       "  'West Penn Allegheny Health System',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2015-08'],\n",
       " ['NCT03675971',\n",
       "  'COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement',\n",
       "  'COPE',\n",
       "  'UNKNOWN',\n",
       "  'Arthroplasty\", Replacement,\" Knee',\n",
       "  'DRUG: Cannabinol|DRUG: Placebo oral capsule',\n",
       "  'Unity Health Toronto',\n",
       "  '',\n",
       "  '220.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-05-01',\n",
       "  '2022-05'],\n",
       " ['NCT05970471',\n",
       "  'Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital',\n",
       "  'IMPLICATION',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Preference\",\" Patient|Pharmacist-Patient Relations|Caregiver|Cancer',\n",
       "  '',\n",
       "  'Centre Hospitalier Universitaire de Besancon',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-09-01',\n",
       "  '2024-02-29'],\n",
       " ['NCT00467571',\n",
       "  'Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Idiopathic Thrombocytopenic Purpura|Helicobacter Pylori Infection',\n",
       "  'DRUG: lansoprazole\", clarithromycin,\" amoxycillin',\n",
       "  'Mahidol University',\n",
       "  'Ramathibodi Hospital',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-03',\n",
       "  '2008-12'],\n",
       " ['NCT02106871',\n",
       "  'Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer',\n",
       "  'PCC',\n",
       "  'WITHDRAWN',\n",
       "  'Pancreatic Cancer|Cholangiocarcinoma',\n",
       "  'DRUG: Sildenafil',\n",
       "  'The University of Texas Medical Branch\",\" Galveston',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2014-04',\n",
       "  '2017-06'],\n",
       " ['NCT04305171',\n",
       "  'Effect of Non-surgical Periodontal Treatment on Cardiovascular Risk Markers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coronary Heart Disease|Periodontitis',\n",
       "  'PROCEDURE: non-surgical periodontal treatment',\n",
       "  'Mahidol University',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-04-06',\n",
       "  '2020-02-20'],\n",
       " ['NCT03205371',\n",
       "  'Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Meningitis\",\" Meningococcal',\n",
       "  'BIOLOGICAL: MenACYW conjugate vaccine|BIOLOGICAL: MMR|BIOLOGICAL: Varicella|BIOLOGICAL: DTaP-IPV-HB-Hib|BIOLOGICAL: PCV13',\n",
       "  'Sanofi Pasteur\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '1183.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-11-07',\n",
       "  '2018-07-19'],\n",
       " ['NCT05670171',\n",
       "  'Debulking Atherectomy Versus Stent Angioplasty for Limb Ischaemia of Diabetic Lower Limb Atherosclerosis-occlusive Disease.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'PROCEDURE: Debulking Atherectomy|PROCEDURE: Stent Angioplasty',\n",
       "  'Xuanwu Hospital\",\" Beijing',\n",
       "  'The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Second Hospital of Hebei Medical University|Shanxi Bethune Hospital|First Affiliated Hospital Xi\\'an Jiaotong University|The Affiliated Hospital of Qingdao University|Shanghai Pudong Hospital|Tianjin Medical University General Hospital|China-Japan Union Hospital\",\" Jilin University|Fudan University',\n",
       "  '244.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01',\n",
       "  '2025-12'],\n",
       " ['NCT00515671',\n",
       "  'Illness Management and Recovery for Veterans With Severe Mental Illness',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizo-affective Disorder',\n",
       "  'BEHAVIORAL: Illness Management and Recovery|BEHAVIORAL: Problem Solving',\n",
       "  'VA Office of Research and Development',\n",
       "  'Indiana University|Dartmouth College',\n",
       "  '118.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2013-09'],\n",
       " ['NCT02387671',\n",
       "  'Weight Management Among Breast Cancer Survivors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Body Weight',\n",
       "  'BEHAVIORAL: Device: FitBit Flex wrist band|BEHAVIORAL: Device: FitBit Aria weight scale|BEHAVIORAL: Diet Intake Messages|BEHAVIORAL: Behavioral Counseling',\n",
       "  'Boston Medical Center',\n",
       "  'Boston University',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2015-02',\n",
       "  '2015-07'],\n",
       " ['NCT02725671',\n",
       "  'Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Coronary Heart Disease|Coronary Artery Disease|Ischemic Heart Disease',\n",
       "  'DEVICE: Explorer',\n",
       "  'Johns Hopkins University',\n",
       "  'Enverdis Corp.',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-04',\n",
       "  '2020-06-26'],\n",
       " ['NCT01338571',\n",
       "  'Horton & Maizy Pilot Study for Resistant to Starch',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'pH|Weight Gain',\n",
       "  '',\n",
       "  'Pennington Biomedical Research Center',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-02',\n",
       "  '2008-07'],\n",
       " ['NCT05104671',\n",
       "  'Thoracic Manipulation Versus Myofascial Release in Patients With Shoulder Impingement Syndrome',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Impingement Shoulder',\n",
       "  'OTHER: scapular stabilization exercises.|OTHER: Thoracic manipulation.|OTHER: Myofascial release.',\n",
       "  'manar sameh el taher',\n",
       "  'Cairo University',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-12-01',\n",
       "  '2022-09-01'],\n",
       " ['NCT05209971',\n",
       "  'Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Macular Edema',\n",
       "  '',\n",
       "  'Sohag University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01',\n",
       "  '2022-12'],\n",
       " ['NCT00869271',\n",
       "  'Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Unresectable Liver Metastasis of Colorectal Cancer',\n",
       "  'PROCEDURE: tac + folfox4|PROCEDURE: Folfox4',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-01',\n",
       "  '2007-12'],\n",
       " ['NCT05537571',\n",
       "  'Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Cardiovascular Diseases|Atherosclerosis|Lipoprotein(a)',\n",
       "  'DRUG: SLN360|DRUG: Placebo',\n",
       "  'Silence Therapeutics plc',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-03',\n",
       "  '2024-06'],\n",
       " ['NCT02021071',\n",
       "  'Virtual Path Planning for Image-guided Needle Interventions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastrointestinal Diseases|Bone Diseases|Muscular Diseases|Spinal Diseases|Vascular Diseases',\n",
       "  'RADIATION: XperGuide|RADIATION: XperGuide with virtual path planning',\n",
       "  'Philips Clinical & Medical Affairs Global',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-12',\n",
       "  '2014-06'],\n",
       " ['NCT04998071',\n",
       "  'Posterior Quadratus Lumborum Block Using 0.125% Versus 0.25% Bupivacaine for Analgesia in Children Undergoing LPEC',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Bupivacaine hydrochloride',\n",
       "  'Queen Sirikit National Institute of Child Health',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-08-15',\n",
       "  '2022-06-30'],\n",
       " ['NCT03477071',\n",
       "  'A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Unrecognized Condition',\n",
       "  'PROCEDURE: Angioplasty for Transplant Renal Artery Stenosis (TRAS)',\n",
       "  'Centre Hospitalier Universitaire de Nice',\n",
       "  'Institut National de la Santé Et de la Recherche Médicale\",\" France',\n",
       "  '1323.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-01-01',\n",
       "  '2017-12-01'],\n",
       " ['NCT01200771',\n",
       "  'Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP',\n",
       "  'FUO-TEP',\n",
       "  'COMPLETED',\n",
       "  'Fever',\n",
       "  'PROCEDURE: TEP',\n",
       "  'University Hospital\",\" Limoges',\n",
       "  '',\n",
       "  '116.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2008-05',\n",
       "  '2014-02'],\n",
       " ['NCT00661271',\n",
       "  'Mindfulness-based Stress Reduction for Urban Youth',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stress\",\" Psychological',\n",
       "  'BEHAVIORAL: Mindfulness-based stress reduction (MBSR)|BEHAVIORAL: Healthy topics',\n",
       "  'Johns Hopkins University',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '96.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2012-03'],\n",
       " ['NCT03595371',\n",
       "  \"Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Schnitzler Syndrome',\n",
       "  'DRUG: dapansutrile',\n",
       "  'Olatec Therapeutics LLC',\n",
       "  'Radboud University Medical Center',\n",
       "  '2.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-05-15',\n",
       "  '2018-05-29'],\n",
       " ['NCT02710071',\n",
       "  'Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide',\n",
       "  'nebhctz',\n",
       "  'COMPLETED',\n",
       "  'Hypertension',\n",
       "  'DRUG: Nebivolol|DRUG: Hydrochlorothiazide',\n",
       "  'University of California\",\" San Diego',\n",
       "  '',\n",
       "  '41.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2016-04'],\n",
       " ['NCT05716971',\n",
       "  'Redetachment Under Densiron for RD Multiple Breaks',\n",
       "  'Densiron',\n",
       "  'COMPLETED',\n",
       "  'Retinal Detachment Multiple Breaks',\n",
       "  'PROCEDURE: Densiron-68 (heavy silicone oil) tamponade for retinal detachment',\n",
       "  'Dar El Oyoun Hospital',\n",
       "  'Cairo University',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-10-01',\n",
       "  '2022-12-22'],\n",
       " ['NCT02411071',\n",
       "  'Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'HIV-infection',\n",
       "  '',\n",
       "  'University Hospital\",\" Essen',\n",
       "  'Janssen Medical Affairs',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-12',\n",
       "  '2016-12'],\n",
       " ['NCT04216771',\n",
       "  'Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'AML in Remission',\n",
       "  'DRUG: Idarubicin|DRUG: ID cytarabine',\n",
       "  'Fujian Medical University',\n",
       "  '',\n",
       "  '320.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2024-05'],\n",
       " ['NCT00060671',\n",
       "  \"Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lymphoma\", Follicular|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular|Lymphoma,\" Low-Grade',\n",
       "  'DRUG: rituximab|DRUG: Pixantrone (BBR 2778)',\n",
       "  'CTI BioPharma',\n",
       "  '',\n",
       "  '800.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-01',\n",
       "  '2006-01'],\n",
       " ['NCT04849871',\n",
       "  'Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma',\n",
       "  'BreaStBRT',\n",
       "  'RECRUITING',\n",
       "  'Breast Carcinoma|Breast Cancer|Stage 0 Breast Cancer|Stage I Breast Cancer',\n",
       "  'RADIATION: External Beam Accelerated Partial Breast Irradiation',\n",
       "  'Washington University School of Medicine',\n",
       "  'The Foundation for Barnes-Jewish Hospital',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-08-12',\n",
       "  '2029-06-30'],\n",
       " ['NCT02580071',\n",
       "  'Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Leukemia',\n",
       "  'DIETARY_SUPPLEMENT: Sheng-Yu-Tang',\n",
       "  'China Medical University Hospital',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2017-08'],\n",
       " ['NCT05077371',\n",
       "  'Peer Support Program in Cancer Patients Elkar Laguntza',\n",
       "  'ElkarLaguntz',\n",
       "  'RECRUITING',\n",
       "  'Neoplasms|Social Skills|Psychological Distress',\n",
       "  'BEHAVIORAL: Peer support program',\n",
       "  'Joana Perez Tejada',\n",
       "  'University of the Basque Country (UPV/EHU)',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-06-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT00511771',\n",
       "  'A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation',\n",
       "  '',\n",
       "  'NO_LONGER_AVAILABLE',\n",
       "  'Irritable Bowel Syndrome With Constipation|Chronic Idiopathic Constipation',\n",
       "  'DRUG: Tegaserod',\n",
       "  'Novartis',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'EXPANDED_ACCESS',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT03336671',\n",
       "  'Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Chronic Sinusitis|Adenoid Disease - Chronic',\n",
       "  'PROCEDURE: Endoscopic Sinus surgery|PROCEDURE: Adenoidectomy',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-07-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT02245971',\n",
       "  'A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Gastric Adenoma and Early Gastric Cancer',\n",
       "  'PROCEDURE: Partial precutting|PROCEDURE: Whole precutting',\n",
       "  'Yonsei University',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07-26',\n",
       "  '2014-08-12'],\n",
       " ['NCT01937871',\n",
       "  'A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostate Hyperplasia|Erectile Dysfunction',\n",
       "  'DRUG: 5 mg Tadalafil|DRUG: Placebo|DRUG: 0.2 mg Tamsulosin',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '909.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-09',\n",
       "  '2015-12'],\n",
       " ['NCT03317171',\n",
       "  'Safety and Efficacy of a Flavonoids- and omega3s-based Compound for the Treatment of Muscular Dystrophies',\n",
       "  'PRO1',\n",
       "  'COMPLETED',\n",
       "  'Muscular Dystrophies|Muscle Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: Flavonoids\", DHA,\" EPA|DIETARY_SUPPLEMENT: placebo compound',\n",
       "  'Fondazione IRCCS Ca\\' Granda\",\" Ospedale Maggiore Policlinico',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-02-28',\n",
       "  '2016-12-31'],\n",
       " ['NCT02602171',\n",
       "  'Virtual Acoustic Localization Experiment',\n",
       "  'VALEEvE',\n",
       "  'COMPLETED',\n",
       "  'Hearing Loss',\n",
       "  'OTHER: Oldenburger sentence test\",\" localization test',\n",
       "  'University of Zurich',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER',\n",
       "  '2015-04',\n",
       "  '2015-12'],\n",
       " ['NCT03245671',\n",
       "  'Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Lumbar Spinal Stenosis',\n",
       "  'DRUG: Kenalog Injectable Product|DRUG: Decadron Phosphate\",\" Injectable|PROCEDURE: Epidural Steroid Injection',\n",
       "  'Hospital for Special Surgery\",\" New York',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2017-12',\n",
       "  '2019-04'],\n",
       " ['NCT04588571',\n",
       "  'Efficacy and Safety Comparison of the Open Surgical and Endovascular Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee\", TASC II,\" Type D.',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Atherosclerosis|Ischemia Limb|Superficial Femoral Artery Occlusion|Popliteal Artery Occlusion',\n",
       "  'PROCEDURE: Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|PROCEDURE: Femoropopliteal proximal bypass',\n",
       "  'Meshalkin Research Institute of Pathology of Circulation',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-10-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT04285671',\n",
       "  'Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Metastatic Lung Non-Small Cell Carcinoma|Refractory Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8',\n",
       "  'BIOLOGICAL: Necitumumab|DRUG: Osimertinib|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Trastuzumab',\n",
       "  'Jonsson Comprehensive Cancer Center',\n",
       "  'Eli Lilly and Company|Genentech\",\" Inc.',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-01-29',\n",
       "  '2025-12-02'],\n",
       " ['NCT00347971',\n",
       "  \"Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphoma\",\" Non-Hodgkin',\n",
       "  'DRUG: recombinant human interleukin 21 and rituximab',\n",
       "  'ZymoGenetics',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-06',\n",
       "  '2008-04'],\n",
       " ['NCT04873271',\n",
       "  'Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study',\n",
       "  'TITAN 1',\n",
       "  'COMPLETED',\n",
       "  'Overactive Bladder',\n",
       "  'DEVICE: Medtronic Implantable Tibial Neuromodulation (TNM) System',\n",
       "  'MedtronicNeuro',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2021-05-11',\n",
       "  '2022-07-08'],\n",
       " ['NCT01610271',\n",
       "  'Air Barrier System for the Prevention of Surgical Site Infection',\n",
       "  'ABS',\n",
       "  'COMPLETED',\n",
       "  'Surgical Site Infection',\n",
       "  'DEVICE: Air Barrier System',\n",
       "  'Nimbic Systems\",\" LLC',\n",
       "  'National Institute of General Medical Sciences (NIGMS)|Baylor College of Medicine',\n",
       "  '300.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-01',\n",
       "  '2015-04'],\n",
       " ['NCT05719571',\n",
       "  'Measurement of Maximal Oxygen Uptake (VO2max) Using Mankato Submaximal Exercise Test in Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  '',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-18',\n",
       "  '2020-10-31'],\n",
       " ['NCT03938571',\n",
       "  'Standard Duodenal Switch vs. Single Anastomosis Duodeno-Ileostomy Duodenal Switch',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Obesity|Surgery|Metabolic Syndrome|Malnutrition',\n",
       "  'PROCEDURE: Duodenal Switch',\n",
       "  'Värmland County Council\",\" Sweden',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2029-01'],\n",
       " ['NCT02230371',\n",
       "  'Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myofascial Pain|Temporomandibular Disorders',\n",
       "  'DRUG: Granisetron|DRUG: Control (placebo)',\n",
       "  'Karolinska Institutet',\n",
       "  'Folktandvården Stockholms län AB',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-03',\n",
       "  '2014-12'],\n",
       " ['NCT01179971',\n",
       "  'n-3 and n-6 Fatty Acids in Rheumatoid Arthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'DIETARY_SUPPLEMENT: Fish oil\",\" gamma-linolenic acid',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  'University of Jena',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2010-01'],\n",
       " ['NCT00230971',\n",
       "  'Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Appendicitis|Cholecystitis|Diverticulitis|Intra-Abdominal Abscess|Intra-Abdominal Infection|Peritonitis',\n",
       "  'DRUG: tigecycline|DRUG: ceftriaxone plus metronidazole',\n",
       "  'Wyeth is now a wholly owned subsidiary of Pfizer',\n",
       "  '',\n",
       "  '473.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2008-09'],\n",
       " ['NCT01488071',\n",
       "  'A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication',\n",
       "  'REVIVE',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorder',\n",
       "  'DRUG: Vortioxetine (Lu AA21004)|DRUG: Agomelatine',\n",
       "  'H. Lundbeck A/S',\n",
       "  '',\n",
       "  '495.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  ''],\n",
       " ['NCT03383471',\n",
       "  'The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Osteoarthritis',\n",
       "  'BIOLOGICAL: Invossa K Inj.|DRUG: Placebo',\n",
       "  'Kolon Life Science',\n",
       "  '',\n",
       "  '146.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-02-12',\n",
       "  '2020-03-30'],\n",
       " ['NCT00527371',\n",
       "  'PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate',\n",
       "  'PVP',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostatic Hyperplasia',\n",
       "  'DEVICE: GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|PROCEDURE: Transurethral resection of the prostate',\n",
       "  \"St. Joseph's Healthcare Hamilton\",\n",
       "  'Ontario Ministry of Health and Long Term Care',\n",
       "  '164.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2013-10'],\n",
       " ['NCT04312971',\n",
       "  'Norepinephrine Infusion During Cardiopulmonary Bypass',\n",
       "  'Norcal',\n",
       "  'COMPLETED',\n",
       "  'Cardiac Surgery|Cardiopulmonary Bypass',\n",
       "  'DRUG: Placebo|DRUG: Norepinephrine|OTHER: Increase infusion rate|OTHER: Decrease infusion rate',\n",
       "  'Imam Abdulrahman Bin Faisal University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-05-06',\n",
       "  '2021-09-20'],\n",
       " ['NCT01324271',\n",
       "  'inVENT-In-Office Study',\n",
       "  'inVENT-IO',\n",
       "  'COMPLETED',\n",
       "  'Otitis Media',\n",
       "  'DEVICE: Acclarent Tympanostomy Tube Delivery system (TTDS)',\n",
       "  'Acclarent',\n",
       "  '',\n",
       "  '85.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-01',\n",
       "  '2012-05'],\n",
       " ['NCT05687071',\n",
       "  'A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hyper-low-density Lipoprotein (LDL) Cholesterolemia',\n",
       "  'DRUG: 180mg of ETC-1002(bempedoic acid)',\n",
       "  'Otsuka Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-02-27',\n",
       "  '2024-10-31'],\n",
       " ['NCT00271271',\n",
       "  'Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients',\n",
       "  'GON',\n",
       "  'COMPLETED',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'DRUG: oxaliplatine / gemcitabine / Vinorelbine',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-06',\n",
       "  '2006-10'],\n",
       " ['NCT03932071',\n",
       "  'Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Metastases|Tumor Necrosis',\n",
       "  'DRUG: Zoledronic Acid',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2017-01-01',\n",
       "  '2023-01-01'],\n",
       " ['NCT03785171',\n",
       "  'Predicative Value of Multimodal MRI in Moyamoya Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Moyamoya Disease|Magnetic Resonance Imaging',\n",
       "  'PROCEDURE: surgical revascularization',\n",
       "  'Chinese PLA General Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-07',\n",
       "  '2021-09'],\n",
       " ['NCT00878371',\n",
       "  'Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dissecting Aneurysm of the Thoracic Aorta',\n",
       "  'DRUG: morphine',\n",
       "  'Nova Scotia Health Authority',\n",
       "  'Dalhousie University',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-05',\n",
       "  '2013-02'],\n",
       " ['NCT02600871',\n",
       "  'Skin and Soft Tissue Infection (SSTI) Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Skin Diseases\",\" Infectious|Soft Tissue Infections',\n",
       "  'DRUG: Provodine|PROCEDURE: Incision and Drainage',\n",
       "  'The University of Texas Health Science Center at San Antonio',\n",
       "  '',\n",
       "  '101.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2017-05-30'],\n",
       " ['NCT01779271',\n",
       "  'Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Upper Respiratory Infection|Fever',\n",
       "  'DRUG: Pelubiprofen|DRUG: Loxoprofen',\n",
       "  'Daewon Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '183.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  ''],\n",
       " ['NCT01489371',\n",
       "  'EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer\", Fallopian Tube Cancer,\" or Primary Peritoneal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma',\n",
       "  'OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|DRUG: Pegylated Liposomal Doxorubicin Hydrochloride',\n",
       "  'Gynecologic Oncology Group',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '16.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-07-09',\n",
       "  '2018-01-27'],\n",
       " ['NCT02508571',\n",
       "  'Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Premature Birth of Newborn|Intervention Studies',\n",
       "  'OTHER: Direct swallowing training (DST)|OTHER: Oral sensorimotor stimulation (OSMS)|OTHER: Sham intervention',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '189.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-07',\n",
       "  '2026-06'],\n",
       " ['NCT06171971',\n",
       "  'Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers',\n",
       "  'CS-PEDIA',\n",
       "  'RECRUITING',\n",
       "  'Pediatric Solid Tumors',\n",
       "  '',\n",
       "  'University Hospital\", Strasbourg,\" France',\n",
       "  '',\n",
       "  '230.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-06-20',\n",
       "  '2023-12'],\n",
       " ['NCT05723471',\n",
       "  'Impact of a Collaborative Program of Physical Activity of Newly-diagnosed Cancer Patients',\n",
       "  'PROGRESS',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer',\n",
       "  'OTHER: Adaptative Physical Activity',\n",
       "  'University Hospital\",\" Toulouse',\n",
       "  '',\n",
       "  '350.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12-01',\n",
       "  '2027-12-31'],\n",
       " ['NCT03826771',\n",
       "  'Post-Stroke Optimization of Walking Using Explosive Resistance',\n",
       "  'POWER-D',\n",
       "  'RECRUITING',\n",
       "  'Stroke|Depression',\n",
       "  'BEHAVIORAL: Power training|BEHAVIORAL: Stretching',\n",
       "  'Medical University of South Carolina',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-02-06',\n",
       "  '2024-08'],\n",
       " ['NCT01559571',\n",
       "  'Registry for Severe ROP and Treatment on Visual Outcomes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Retinopathy of Prematurity',\n",
       "  '',\n",
       "  'Pediatrix',\n",
       "  '',\n",
       "  '324.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-05',\n",
       "  '2020-05-15'],\n",
       " ['NCT03323671',\n",
       "  'Preemptive Analgesia for Primary Dysmenorrhoea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Dysmenorrhea',\n",
       "  'DRUG: preemptive mefenamic acid|DRUG: mefenamic acid',\n",
       "  'Hanan Nabil',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-08-01',\n",
       "  '2017-12-01'],\n",
       " ['NCT02108171',\n",
       "  'Intranasal Dexmedetomidine Premedication',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benign Neoplasm of Vocal Fold - Glottis',\n",
       "  'DRUG: Dexmedetomidine|DRUG: placebo',\n",
       "  \"Guangzhou First People's Hospital\",\n",
       "  '',\n",
       "  '81.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-03',\n",
       "  '2014-07'],\n",
       " ['NCT01715571',\n",
       "  'Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate ED',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Organic Erectile Dysfunction',\n",
       "  'DEVICE: Viberect',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '11.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-03-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT02855671',\n",
       "  'Infrared Imaging in Septic Illness',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  'DEVICE: Infrared thermal imaging',\n",
       "  'University Hospitals\",\" Leicester',\n",
       "  'Association of Anaesthetists of Great Britain and Ireland',\n",
       "  '112.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  '2019-02-01'],\n",
       " ['NCT03349671',\n",
       "  'Predictors of Intrauterine Growth Restriction',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pre-Eclampsia',\n",
       "  'PROCEDURE: ultrasound',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-10',\n",
       "  '2019-12'],\n",
       " ['NCT04192071',\n",
       "  'Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Cancer',\n",
       "  'OTHER: virtual technology - high interactive|OTHER: virtual technology - low interactive|OTHER: non-colorectal cancer related module',\n",
       "  'University of Florida',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING',\n",
       "  '2020-01-06',\n",
       "  '2024-01-31'],\n",
       " ['NCT03202771',\n",
       "  'Randomized Controlled Trial of Home Versus Office Biofeedback for Constipation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Constipation|Dyssynergia',\n",
       "  'DEVICE: Home Biofeedback Therapy|OTHER: Office Biofeedback Therapy',\n",
       "  'Augusta University',\n",
       "  'National Institutes of Health (NIH)',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-02',\n",
       "  '2011-07'],\n",
       " ['NCT04419571',\n",
       "  'Outcomes in Emergency Laparotomies During COVID-19 Pandemic',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19|Emergency General Surgery',\n",
       "  'PROCEDURE: Emergency Laparotomy',\n",
       "  'Barking\",\" Havering and Redbridge University Hospitals NHS Trust',\n",
       "  '',\n",
       "  '94.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-03-23',\n",
       "  '2020-06-16'],\n",
       " ['NCT05199571',\n",
       "  'Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Relapsing Multiple Sclerosis',\n",
       "  'BIOLOGICAL: Ofatumumab',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '99.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-07-22',\n",
       "  '2025-03-21'],\n",
       " ['NCT02295371',\n",
       "  'Medication Incidents in Primary Care Medicine',\n",
       "  'MIPC',\n",
       "  'COMPLETED',\n",
       "  'Medication Incidents',\n",
       "  '',\n",
       "  'University of Zurich',\n",
       "  'University of Lausanne',\n",
       "  '213.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-01',\n",
       "  '2016-01'],\n",
       " ['NCT02671071',\n",
       "  'Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cervix Cancer',\n",
       "  'BEHAVIORAL: Quality of Life Questionnaire (QLQ)',\n",
       "  'Latin American Cooperative Oncology Group',\n",
       "  'EVA - Grupo Brasileiro de Tumores Ginecológicos|Roche Pharma AG',\n",
       "  '638.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-04',\n",
       "  '2021-12'],\n",
       " ['NCT02763371',\n",
       "  'Cognition Intervention Study Dortmund- Glycemic Index (CogniDo GI)',\n",
       "  'CogniDo-GI',\n",
       "  'UNKNOWN',\n",
       "  'Cognitive Function',\n",
       "  'OTHER: Dietary: high GI lunch|OTHER: Dietary: low GI lunch',\n",
       "  'Research Institute of Child Nutrition\",\" Dortmund',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2016-04',\n",
       "  '2016-12'],\n",
       " ['NCT01576471',\n",
       "  'Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo',\n",
       "  'TRUST-I',\n",
       "  'COMPLETED',\n",
       "  \"Crohn's Disease\",\n",
       "  'BIOLOGICAL: Trichuris suis ova (TSO)|BIOLOGICAL: Placebo',\n",
       "  'Coronado Biosciences\",\" Inc.',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-07',\n",
       "  '2014-10'],\n",
       " ['NCT05960071',\n",
       "  'Effects of Alveolar Recruitment Strategies on Arterial Oxygenation and Postoperative Inflammatory Response During Laparoscopic Bariatric Surgery: A Randomised Control Trial.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bariatric Surgery Candidate',\n",
       "  'PROCEDURE: protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|PROCEDURE: protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2022-11-05',\n",
       "  '2023-06-05'],\n",
       " ['NCT05134571',\n",
       "  'China Post-marketing Surveillance (PMS) Study of Aldurazyme®',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mucopolysaccharidosis I',\n",
       "  'DRUG: Laronidase',\n",
       "  'Genzyme\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-10-28',\n",
       "  '2023-07-26'],\n",
       " ['NCT02122471',\n",
       "  '12-Week Study of Plecanatide for CIC (The National CIC3 Study)',\n",
       "  'CIC',\n",
       "  'COMPLETED',\n",
       "  'Chronic Idiopathic Constipation',\n",
       "  'DRUG: Plecanatide|DRUG: Placebo',\n",
       "  'Bausch Health Americas\",\" Inc.',\n",
       "  '',\n",
       "  '1410.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-04',\n",
       "  '2015-07'],\n",
       " ['NCT00001271',\n",
       "  'A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'B Cell Lymphoma',\n",
       "  'DRUG: IgG-RFB4-SMPT-dgA',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1991-07',\n",
       "  '2001-04'],\n",
       " ['NCT01761071',\n",
       "  'Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myopes Who Have Undergone PRK.',\n",
       "  'DRUG: topical ketorolac 0.5% (Acular®\", Allergan Inc, Irvine, CA)|DRUG: topical diclofenac 0.1% (Voltaren®, Novartis, Bern,\" Switzerland)',\n",
       "  'Yonsei University',\n",
       "  '',\n",
       "  '94.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2012-01',\n",
       "  '2012-12'],\n",
       " ['NCT05216471',\n",
       "  'Identify Coronavirus Disease by Chest X-ray',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronavirus Disease 2019',\n",
       "  'RADIATION: chest X-ray',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-05-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT03592771',\n",
       "  'THRIVE Breast Cancer App Study',\n",
       "  'THRIVE',\n",
       "  'COMPLETED',\n",
       "  'Breast Neoplasm Female',\n",
       "  'BEHAVIORAL: THRIVE App|BEHAVIORAL: Tailored Feedback Messages',\n",
       "  'Emory University',\n",
       "  'National Cancer Institute (NCI)|West Cancer Center|Vector Oncology',\n",
       "  '304.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-11-15',\n",
       "  '2022-06-30'],\n",
       " ['NCT00405171',\n",
       "  'Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Hypercholesterolemia|Antiretroviral Therapy',\n",
       "  'DRUG: Nevirapine',\n",
       "  'University Hospital\",\" Caen',\n",
       "  'Boehringer Ingelheim',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2003-06',\n",
       "  '2006-02'],\n",
       " ['NCT03331471',\n",
       "  'Alveolar Recruitment Maneuver During Pneumoperitoneum',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Oxygen Deficiency',\n",
       "  'PROCEDURE: alveolar recruitment maneuver|PROCEDURE: conventional ventilation',\n",
       "  'Gachon University Gil Medical Center',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-09-18',\n",
       "  '2019-11-30'],\n",
       " ['NCT01896271',\n",
       "  'High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Clear Cell Renal Cell Carcinoma',\n",
       "  'DRUG: IL-2|RADIATION: Stereotactic Ablative Body Radiation Therapy',\n",
       "  'University of Texas Southwestern Medical Center',\n",
       "  'Prometheus Laboratories',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-10-02',\n",
       "  '2021-04-20'],\n",
       " ['NCT05091671',\n",
       "  'Free From Pain Exercise Programme Study',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Musculoskeletal Pain|Fear of Falling',\n",
       "  'OTHER: Free From Pain Exercise Programme Variation 1|OTHER: Free From Pain Exercise Programme Variation 2',\n",
       "  'Talita Cumi Ltd.',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-02-28',\n",
       "  '2023-12-31'],\n",
       " ['NCT04182971',\n",
       "  'Effect of Added Fruit Pomace Fiber\", Juice,\" and Whole Fruit on Postprandial Glycemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Glycemic Index',\n",
       "  'OTHER: Fruit|OTHER: Fruit juice|OTHER: Fruit juice plus fiber',\n",
       "  'PepsiCo Global R&D',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-08-28',\n",
       "  '2019-09-03'],\n",
       " ['NCT04732871',\n",
       "  'Immunogenicity\", Safety,\" Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Respiratory Syncytial Virus Infections',\n",
       "  'BIOLOGICAL: RSVPreF3 OA investigational vaccine',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '1720.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-02-15',\n",
       "  '2026-05-25'],\n",
       " ['NCT05109871',\n",
       "  'Reliability and Validity of Inline Dynamometry Study for Measuring Knee Extensor Torque',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anterior Cruciate Ligament Injuries|Anterior Cruciate Ligament Rupture|Anterior Cruciate Ligament Tear',\n",
       "  'OTHER: KForce Link',\n",
       "  'Liverpool University Hospitals NHS Foundation Trust',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2021-09-20',\n",
       "  '2022-08-02'],\n",
       " ['NCT05653271',\n",
       "  'ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'B-cell Lymphoma|Non Hodgkin Lymphoma|DLBCL|Primary Mediastinal Large B Cell Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma',\n",
       "  'DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: ACE1831|DRUG: Obinutuzumab',\n",
       "  'Acepodia Biotech\",\" Inc.',\n",
       "  '',\n",
       "  '42.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-21',\n",
       "  '2027-09'],\n",
       " ['NCT01850771',\n",
       "  'Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Radiculopathy|Herniated Disc|Disc Degeneration',\n",
       "  'PROCEDURE: Regenexx PL-Disc|PROCEDURE: Steroid Epidural',\n",
       "  'Regenexx\",\" LLC',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2016-05'],\n",
       " ['NCT01685671',\n",
       "  'Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anemia',\n",
       "  'DRUG: NESP 60μg|DRUG: CKD-11101 60μg',\n",
       "  'Chong Kun Dang Pharmaceutical',\n",
       "  'Seoul National University Hospital',\n",
       "  '34.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-10-26',\n",
       "  '2013-01-15'],\n",
       " ['NCT00002671',\n",
       "  'Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Cancer',\n",
       "  'DRUG: aminocamptothecin',\n",
       "  'NYU Langone Health',\n",
       "  'National Cancer Institute (NCI)|Eastern Cooperative Oncology Group',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1995-12',\n",
       "  ''],\n",
       " ['NCT04267471',\n",
       "  'Tai Chi for Patients With Essential Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hypertension',\n",
       "  'BEHAVIORAL: Tai Chi|BEHAVIORAL: Walking',\n",
       "  'Chengdu University of Traditional Chinese Medicine',\n",
       "  '',\n",
       "  '234.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06',\n",
       "  '2022-12'],\n",
       " ['NCT01325571',\n",
       "  'A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myasthenia Gravis',\n",
       "  'DRUG: Tacrolimus capsule|DRUG: Placebo',\n",
       "  'Astellas Pharma Inc',\n",
       "  'Astellas Pharma China\",\" Inc.',\n",
       "  '83.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-03',\n",
       "  '2014-05'],\n",
       " ['NCT03722771',\n",
       "  'Influence of Lavender Oil on Vital Signs in Oral Surgery Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dental Anxiety|Sedative; Anxiety Disorder',\n",
       "  'BEHAVIORAL: Inhalation|OTHER: Anxiety Questionnaires 1|OTHER: Anxiety Questionnaires 2|DIAGNOSTIC_TEST: Vital Signs 1|DIAGNOSTIC_TEST: Vital Signs 2|DIAGNOSTIC_TEST: Vital Signs 3|DIAGNOSTIC_TEST: Vital Signs 4',\n",
       "  'Nazife Begüm KARAN',\n",
       "  '',\n",
       "  '126.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-09-01',\n",
       "  '2018-11-02'],\n",
       " ['NCT02034071',\n",
       "  'Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prader-Willi Syndrome',\n",
       "  'DRUG: DCCR|DRUG: Placebo',\n",
       "  'Essentialis\",\" Inc.',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-04',\n",
       "  '2015-05'],\n",
       " ['NCT04002271',\n",
       "  'Total Knee Replacement TIVA With Robotic Arm Assisted',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Propofol|DRUG: Sevoflurane|PROCEDURE: Spinal anaesthesia',\n",
       "  'The University of Hong Kong',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-07-22',\n",
       "  '2024-05-31'],\n",
       " ['NCT02569671',\n",
       "  'Bone Level Tapered Multi-Center Study',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Tooth Loss',\n",
       "  'DEVICE: Straumann Bone Level Tapered Implant - Immediate Placement|DEVICE: Straumann Bone Level Tapered Implant - Delayed Placement',\n",
       "  'Institut Straumann AG',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-03',\n",
       "  '2024-03'],\n",
       " ['NCT04669171',\n",
       "  'A Novel Vaccine (EO2463) as Monotherapy and in Combination\",\" for Treatment of Patients With Indolent Non-Hodgkin Lymphoma',\n",
       "  'SIDNEY',\n",
       "  'RECRUITING',\n",
       "  'Follicular Lymphoma|Marginal Zone Lymphoma',\n",
       "  'BIOLOGICAL: EO2463|DRUG: lenalidomide|BIOLOGICAL: rituximab',\n",
       "  'Enterome',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-07-05',\n",
       "  '2029-09-30'],\n",
       " ['NCT01096771',\n",
       "  'The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Respiratory Distress Syndrome',\n",
       "  'DRUG: ClinOleic 20%|DRUG: Intralipid 20%',\n",
       "  'Methodist Research Institute\",\" Indianapolis',\n",
       "  '',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-06',\n",
       "  '2012-11'],\n",
       " ['NCT05840471',\n",
       "  'Tranexamic Acid as an Intervention in Abruptio Placenta',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vaginal Bleeding|Prolonged Pregnancy',\n",
       "  'DRUG: Tranexamic acid injection|OTHER: Glucose water 5%',\n",
       "  'Hawler Medical University',\n",
       "  '',\n",
       "  '116.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-10',\n",
       "  '2024-02-10'],\n",
       " ['NCT06162871',\n",
       "  'Social Participation and Healthy Aging',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy Aging',\n",
       "  'BEHAVIORAL: Presentations and interactive debate sessions\",\" with intergenerational exchange',\n",
       "  'University of Cagliari',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2023-09-01',\n",
       "  '2025-06-01'],\n",
       " ['NCT04270071',\n",
       "  'Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Heart Disease|Stable Angina',\n",
       "  'DRUG: Yangxin Shengmai|DRUG: Yangxin Shengmai placebo|DRUG: nitroglycerin tablets',\n",
       "  \"Guang'anmen Hospital of China Academy of Chinese Medical Sciences\",\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-12',\n",
       "  '2021-12'],\n",
       " ['NCT00546871',\n",
       "  'Comparison of Intravenous and Subcutaneous Administration of IGIV\",\" 10% in Primary Immunodeficiency (PID) Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Immunodeficiency Diseases (PID)',\n",
       "  'DRUG: Immune Globulin Intravenous (Human)\",\" 10%',\n",
       "  'Baxalta now part of Shire',\n",
       "  '',\n",
       "  '49.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-10-03',\n",
       "  '2009-09-01'],\n",
       " ['NCT01328171',\n",
       "  'FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)',\n",
       "  'VOLFI',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: FOLFOXIRI + Panitumumab|DRUG: FOLFOXIRI',\n",
       "  'AIO-Studien-gGmbH',\n",
       "  'Amgen|ClinAssess GmbH',\n",
       "  '93.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2022-01'],\n",
       " ['NCT05546671',\n",
       "  'Impact of Hand Grip Strength on Length of Hospital Stay After Cardiac Surgery Among Elderly Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Sarcopenia|Frailty',\n",
       "  'DIAGNOSTIC_TEST: Hand grip strength measurement',\n",
       "  'Kartal Kosuyolu High Speciality Training and Research Hospital',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-11-01',\n",
       "  '2023-11-30'],\n",
       " ['NCT02866071',\n",
       "  'Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Acute Traumatic Pain',\n",
       "  'DRUG: Ketamine Hydrochloride|DRUG: Placebo-Comparator',\n",
       "  'Jason McMullan',\n",
       "  '',\n",
       "  '224.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-03',\n",
       "  '2022-12-31'],\n",
       " ['NCT04925271',\n",
       "  'Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Polyp of Colon|Fistula',\n",
       "  'DEVICE: X-Tack|DEVICE: Overstitch',\n",
       "  'Thomas Jefferson University',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2021-07-01',\n",
       "  '2022-07-30'],\n",
       " ['NCT00966771',\n",
       "  'The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception',\n",
       "  'IUD EC',\n",
       "  'COMPLETED',\n",
       "  'Pregnancy',\n",
       "  'DRUG: Copper T380 IUD|DRUG: Oral levonorgestrel',\n",
       "  'University of Utah',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Society of Family Planning',\n",
       "  '548.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-10',\n",
       "  '2011-08'],\n",
       " ['NCT06221371',\n",
       "  'Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion',\n",
       "  'TNK-PLUS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Ischemic Stroke\",\" Acute|Thrombolysis|Endovascular Treatment',\n",
       "  'DRUG: rhTNK-tPA|DEVICE: direct EVT',\n",
       "  'Beijing Tiantan Hospital',\n",
       "  \"Linyi People's Hospital\",\n",
       "  '390.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-12-16',\n",
       "  '2025-05'],\n",
       " ['NCT04064671',\n",
       "  'ZEPHYR: A Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Erectile Dysfunction|Gender Dysphoria',\n",
       "  'OTHER: Implantation of the Zephyr ZSI 475 FTM erectile implant',\n",
       "  'University Hospital\",\" Ghent',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-09-19',\n",
       "  '2029-12'],\n",
       " ['NCT02927171',\n",
       "  'Shifting Rehabilitation Paradigms in Skilled Nursing Facilities',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Deconditioning',\n",
       "  'OTHER: IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents',\n",
       "  'VA Office of Research and Development',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '104.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2016-02-28',\n",
       "  '2019-01-01'],\n",
       " ['NCT02437071',\n",
       "  'Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: Pembrolizumab|RADIATION: Radiotherapy|PROCEDURE: Radiofrequency ablation',\n",
       "  'Memorial Sloan Kettering Cancer Center',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2024-04'],\n",
       " ['NCT05906771',\n",
       "  'Study of the Effect of the Combined Extract of Lemon Verbena and Hibiscus on Health Indicators',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Diet\",\" Mediterranean|Antioxidant Effect|Body Weight|Cardiovascular Diseases|Densitometry|Body Composition',\n",
       "  'DIETARY_SUPPLEMENT: Metabolaid(R)|DIETARY_SUPPLEMENT: Nutraceutical placebo',\n",
       "  'University of Alicante',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-01',\n",
       "  '2024-06-30'],\n",
       " ['NCT03638271',\n",
       "  'Cardiac Magnetic Resonance in Non Ischemic Cardiomyopathy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy',\n",
       "  'DIAGNOSTIC_TEST: Cardiac magnetic resonance imaging',\n",
       "  'Reham Sameeh',\n",
       "  'Assiut University',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-10-01',\n",
       "  '2021-10-01'],\n",
       " ['NCT06195371',\n",
       "  'Impact of CASP3 Gene in Chemoresistance',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  '',\n",
       "  'Gehad Salah El-Din shaker',\n",
       "  'Assiut University',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2024-05-01',\n",
       "  '2026-12'],\n",
       " ['NCT01810471',\n",
       "  'External Ankle Supports - 3D Motion Analysis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Ankle Instability',\n",
       "  'DEVICE: Applying ankle support device (white non-elastic tape\", kinesiotape (TM),\" soft brace (Malleotrain TM)',\n",
       "  'University Hospital Heidelberg',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-02',\n",
       "  '2010-12'],\n",
       " ['NCT01433471',\n",
       "  'Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova',\n",
       "  'MUCUS',\n",
       "  'COMPLETED',\n",
       "  'Ulcerative Colitis',\n",
       "  'DRUG: Trichuris suis ova',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-08',\n",
       "  '2015-05'],\n",
       " ['NCT01642771',\n",
       "  'Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: 5-Fu/epirubicin/CTX following Docetaxel|DRUG: Docetaxel/capecitabine followed by XEC',\n",
       "  'China Breast Cancer Clinical Study Group',\n",
       "  '',\n",
       "  '636.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-06',\n",
       "  '2020-05'],\n",
       " ['NCT02377271',\n",
       "  'ENDOTHELION Study Group: Effect of Bosentan in NAION Patients',\n",
       "  'ENDOTHELION',\n",
       "  'RECRUITING',\n",
       "  'Ischemic Optic Neuropathy',\n",
       "  'DRUG: bosentan|DRUG: placebo',\n",
       "  'University Hospital\",\" Grenoble',\n",
       "  '',\n",
       "  '86.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-08',\n",
       "  '2025-12'],\n",
       " ['NCT05566171',\n",
       "  'The Effect of Probiotic Supported Yogurt Consumption on Gastrointestinal Symptoms',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Gastrointestinal Dysfunction',\n",
       "  'DIETARY_SUPPLEMENT: Activia Probiotic Yogurt',\n",
       "  'Eastern Mediterranean University',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2023-03-30'],\n",
       " ['NCT00229671',\n",
       "  'Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pediatric ALL',\n",
       "  'OTHER: Survey 1|OTHER: Survey 2',\n",
       "  'Weill Medical College of Cornell University',\n",
       "  \"Brigham and Women's Hospital|Boston Children's Hospital|The Commonwealth Fund\",\n",
       "  '6341.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2001-09',\n",
       "  '2005-07'],\n",
       " ['NCT00349271',\n",
       "  'Cell Therapy in Chagas Cardiomyopathy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Chagas Cardiomyopathy',\n",
       "  'PROCEDURE: Stem cell|DRUG: Filgrastime (G-CSF)|DRUG: Standart therapy',\n",
       "  'Ministry of Health\",\" Brazil',\n",
       "  'Financiadora de Estudos e Projetos',\n",
       "  '182.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2011-12'],\n",
       " ['NCT02156271',\n",
       "  'Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Insomnia',\n",
       "  'DRUG: ramelteon|DRUG: placebo',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  ''],\n",
       " ['NCT00429871',\n",
       "  'Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Epirubicin|DRUG: Docetaxel',\n",
       "  'Hellenic Oncology Research Group',\n",
       "  'University Hospital of Crete',\n",
       "  '272.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2002-05',\n",
       "  '2007-11'],\n",
       " ['NCT05859971',\n",
       "  'ICG and SLN Mapping',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: SLN mapping using technetium-99m +/- isosulfan blue dye|DEVICE: SLN mapping with ICG fluorescence using the Asimov Platform',\n",
       "  'University of Wisconsin\",\" Madison',\n",
       "  'OnLume Inc.|National Cancer Institute (NCI)',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-04-13',\n",
       "  '2024-03'],\n",
       " ['NCT01013571',\n",
       "  'Self Titration With Apidra to Reach Target Study (START)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: insulin glargine|DRUG: Apidra (insulin glulisine)',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '493.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-10',\n",
       "  '2012-01'],\n",
       " ['NCT01677871',\n",
       "  'Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Liver Disease With Tuberclosis',\n",
       "  'DRUG: 2HRZE/4HR|DRUG: 2HRLE/4HR|DRUG: 9HLE|DRUG: 9RLE',\n",
       "  'Institute of Liver and Biliary Sciences\",\" India',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-09',\n",
       "  '2014-09'],\n",
       " ['NCT00740571',\n",
       "  'Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer',\n",
       "  'Off-label',\n",
       "  'UNKNOWN',\n",
       "  'Cancer|Neuralgia',\n",
       "  'DRUG: amitriptyline|DRUG: pregabalin',\n",
       "  'Radboud University Medical Center',\n",
       "  'Erasmus Medical Center|University of Amsterdam',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-09',\n",
       "  '2010-12'],\n",
       " ['NCT04492371',\n",
       "  'COVID-19 Infection and Multiple Myeloma',\n",
       "  'EMN-COVID',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma|Covid19|Corona Virus Infection',\n",
       "  '',\n",
       "  'Stichting European Myeloma Network',\n",
       "  'Fondazione EMN Italy Onlus',\n",
       "  '1054.0',\n",
       "  'NETWORK',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-07-01',\n",
       "  '2024-12'],\n",
       " ['NCT02790671',\n",
       "  'A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pharmacokinetics',\n",
       "  'DRUG: DS-8500a|DRUG: Itraconazole',\n",
       "  'Daiichi Sankyo',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05',\n",
       "  '2016-06'],\n",
       " ['NCT03744871',\n",
       "  'Air Pollution: Strategies for Personalized Intervention to Reduce Exposure',\n",
       "  'ASPIRE',\n",
       "  'COMPLETED',\n",
       "  'Air Pollution',\n",
       "  'OTHER: N95 Respirator',\n",
       "  'University Hospitals Cleveland Medical Center',\n",
       "  'University of Michigan|Peking University',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2019-03-22',\n",
       "  '2023-07-31'],\n",
       " ['NCT00562471',\n",
       "  'Safety and Efficacy Study of a Hydrogel\", Applied Following Removal of Myomas During Gynecologic Surgery,\" Administered for the Prevention/Reduction of Postoperative Adhesion Formation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myoma',\n",
       "  'OTHER: Adhibit Adhesion Prevention Gel|OTHER: Standard of Care Comparator',\n",
       "  'Angiotech Pharmaceuticals',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2003-07',\n",
       "  '2005-01'],\n",
       " ['NCT01251471',\n",
       "  'Neural\", Genetic,\" and Peripheral Correlates of SSRI Pharmaco-Response',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depression',\n",
       "  'DRUG: Escitalopram',\n",
       "  'Medical University of Vienna',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2011-08',\n",
       "  '2015-03'],\n",
       " ['NCT00935571',\n",
       "  'Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Cancer|Neoplasms\",\" Lung',\n",
       "  'DRUG: propofol\", remifentanil,\" sevoflurane',\n",
       "  'Asan Medical Center',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2009-09'],\n",
       " ['NCT04493671',\n",
       "  'Evaluate Safety\", Tolerability,\" PK of TBAJ-876 in Healthy Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pulmonary Disease|Tuberculosis\",\" Pulmonary|Tuberculosis|Multi Drug Resistant Tuberculosis|Drug Sensitive Tuberculosis|Drug-resistant Tuberculosis|Mycobacterium Tuberculosis Infection',\n",
       "  'DRUG: TBAJ-876 10mg|DRUG: TBAJ-876 25mg|DRUG: TBAJ-876 50mg|DRUG: TBAJ-876 100mg|DRUG: TBAJ-876 200mg|DRUG: TBAJ-876 400mg|DRUG: TBAJ-876 Dose XXXmg for Food cohort|DRUG: TBAJ-876 XXXmg for Part 2|DRUG: Matching Placebo for TBAJ-876 tablet',\n",
       "  'Global Alliance for TB Drug Development',\n",
       "  '',\n",
       "  '107.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06-08',\n",
       "  '2022-11-15'],\n",
       " ['NCT03488771',\n",
       "  'Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Kidney Transplant Infection|Kidney Transplant Rejection',\n",
       "  '',\n",
       "  'Clinical Hospital Merkur',\n",
       "  'Clinical Hospital Centre Zagreb',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-03-05',\n",
       "  '2018-12-01'],\n",
       " ['NCT05068271',\n",
       "  'Multi-Domain Exercise and Memory in Adults Relative to ApoE Genotype: A fMRI Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Exercise Training|Executive Function|Aging',\n",
       "  'BEHAVIORAL: Multi-Domain Exercise Program|BEHAVIORAL: Control Group',\n",
       "  'National Taiwan Normal University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2022-04-12',\n",
       "  '2025-09'],\n",
       " ['NCT04442971',\n",
       "  'Effectiveness of Music Therapy on Level of Consciousness',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Neurologic Disorder|Traumatic Brain Injury|Disorder of Consciousness',\n",
       "  'BEHAVIORAL: Music Stimulation|BEHAVIORAL: Alternative Stimulation|BEHAVIORAL: No Auditory Stimulation',\n",
       "  'BDH-Klinik Hessisch Oldendorf',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06-15',\n",
       "  '2024-12-15'],\n",
       " ['NCT03665571',\n",
       "  'Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pancreatic Neoplasms',\n",
       "  'DIAGNOSTIC_TEST: Receptor specific activation method',\n",
       "  'Asan Medical Center',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  '2019-10'],\n",
       " ['NCT00001571',\n",
       "  \"A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Lymphoma\", AIDS-Related|Lymphoma,\" Non-Hodgkin',\n",
       "  '',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '1997-02',\n",
       "  '2000-12'],\n",
       " ['NCT05128071',\n",
       "  'PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Methamphetamine-dependence|Postpartum Abstinence',\n",
       "  'DRUG: Progesterone|DRUG: Placebo',\n",
       "  'University of Utah',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-02-04',\n",
       "  '2025-04'],\n",
       " ['NCT00927771',\n",
       "  'Azelaic Acid Versus Hydroquinone in Melasma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Melanosis',\n",
       "  'DRUG: azelaic acid gel|DRUG: hydroquinone cream',\n",
       "  'Callender Center for Clinical Research',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2010-12'],\n",
       " ['NCT02646371',\n",
       "  'Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Shigellosis',\n",
       "  'BIOLOGICAL: Flexyn2a|BIOLOGICAL: Placebo',\n",
       "  'LimmaTech Biologics AG',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  '67.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-12',\n",
       "  '2017-07'],\n",
       " ['NCT00670371',\n",
       "  'Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Functional Psychoses|Informal Caregivers',\n",
       "  '',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-11'],\n",
       " ['NCT00268671',\n",
       "  'Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Head and Neck Neoplasms',\n",
       "  'DRUG: Docetaxel',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-08',\n",
       "  '2006-04'],\n",
       " ['NCT00570271',\n",
       "  'Placebo Effects on Blood Pressure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Blood Pressure',\n",
       "  'OTHER: Placebo with BP dec (written form)|OTHER: Placebo with BP dec (doctor)|OTHER: Placebo with BP inc (written)|OTHER: Placebo with BP inc (doctor)|OTHER: Placebo info given (written)|OTHER: Placebo info given (doc)',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2007-04',\n",
       "  '2008-02'],\n",
       " ['NCT02286271',\n",
       "  'Preliminary Testing of a Novel Device to Detect Epileptic Seizures',\n",
       "  'PTEpD',\n",
       "  'COMPLETED',\n",
       "  'Epilepsy',\n",
       "  '',\n",
       "  'University of Edinburgh',\n",
       "  'NHS Lothian',\n",
       "  '117.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-01-20',\n",
       "  '2016-12-31'],\n",
       " ['NCT02901171',\n",
       "  'The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking',\n",
       "  'BEHAVIORAL: ACT group treatment combined with smartphone application|BEHAVIORAL: ACT group treatment|BEHAVIORAL: Group based Behavioural Support Programme',\n",
       "  'University College Dublin',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-09',\n",
       "  '2018-07'],\n",
       " ['NCT01352871',\n",
       "  'The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Innate Immune Response',\n",
       "  'BEHAVIORAL: Concentration / meditation|DRUG: lipopolysaccharide',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '1.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-03',\n",
       "  '2011-05'],\n",
       " ['NCT04007471',\n",
       "  'Adolescent Dysmenorrhea : Prevalence\", Severity,\" Experience and Management in the Use of Medication in High School Girls in Ille-et-Vilaine',\n",
       "  'DAPsvs',\n",
       "  'COMPLETED',\n",
       "  'Adolescent Dysmenorrhea',\n",
       "  'OTHER: Anonymous survey',\n",
       "  'Rennes University Hospital',\n",
       "  '',\n",
       "  '979.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-04-24',\n",
       "  '2019-05-17'],\n",
       " ['NCT03525171',\n",
       "  'Evalutation of Insulin Sensitivity Through Hyperinsulinemic Clamp in Children With GH Deficiency',\n",
       "  'clamp-GHD',\n",
       "  'COMPLETED',\n",
       "  'Growth Hormone Deficiency',\n",
       "  'DIAGNOSTIC_TEST: euglycemic hyperinsulinemic clamp',\n",
       "  'University of Palermo',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-01-01',\n",
       "  '2015-12-30'],\n",
       " ['NCT02741271',\n",
       "  'Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: MF MDI 100 mcg BID (Open Label)|DRUG: MF/F MDI 100/10 mcg BID|DRUG: MF MDI 100 mcg BID|DRUG: Albuterol/Salbutamol PRN|DRUG: Prednisone/Prednisolone',\n",
       "  'Organon and Co',\n",
       "  '',\n",
       "  '181.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-05-11',\n",
       "  '2017-12-04'],\n",
       " ['NCT03341871',\n",
       "  'Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C Virus (HCV)',\n",
       "  '',\n",
       "  'AbbVie',\n",
       "  '',\n",
       "  '1095.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-12-27',\n",
       "  '2020-09-15'],\n",
       " ['NCT03070171',\n",
       "  'Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: dabigatran etexilate',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-03-21',\n",
       "  '2017-06-20'],\n",
       " ['NCT02850471',\n",
       "  'Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Reperfusion Injury',\n",
       "  'DEVICE: electroacupuncture',\n",
       "  'Shengjing Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-03',\n",
       "  '2016-08'],\n",
       " ['NCT03636971',\n",
       "  'Gait Analysis Following Knee Viscosupplementation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gait|Knee Osteoarthritis|Injection',\n",
       "  'DRUG: hyaluronic acid with mannitol|DRUG: hyaluronic acid with sorbitol|DRUG: Placebos',\n",
       "  'Brigitte Jolles\",\" MD',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SCREENING',\n",
       "  '2013-05-01',\n",
       "  '2017-01-01'],\n",
       " ['NCT04916171',\n",
       "  'Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome\",\" or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Endometriosis|Polycystic Ovary Syndrome|Adenomyosis',\n",
       "  'OTHER: incidence',\n",
       "  'Kanuni Sultan Suleyman Training and Research Hospital',\n",
       "  'Engin Oral|Berna Dilbaz|Gürkan Bozdag|Cem Atabekoğlu|Nuray Bozkurt|Gokce Anik Ilhan|Ali Kolusari|Cihan Kaya|Banu Yılmaz|Engin Yildirim|Ahmet Başar Tekin|Servet Ozden hacivelioglu',\n",
       "  '2450.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-06-01',\n",
       "  '2023-01-20'],\n",
       " ['NCT00048971',\n",
       "  'Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer|Diarrhea|Neutropenia',\n",
       "  'GENETIC: mutation analysis|GENETIC: polymorphic microsatellite marker analysis',\n",
       "  'Alliance for Clinical Trials in Oncology',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '308.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2002-04',\n",
       "  '2006-11'],\n",
       " ['NCT05038371',\n",
       "  'Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Wet Macular Degeneration',\n",
       "  '',\n",
       "  'Johns Hopkins University',\n",
       "  'Olix Pharmaceuticals\",\" Inc.',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-09-01',\n",
       "  '2022-09-22'],\n",
       " ['NCT01611571',\n",
       "  'Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis',\n",
       "  'RPM',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'DRUG: Risedronate|DRUG: Teriparatide|DRUG: Placebo Teriparatide|DRUG: placebo Risedronate',\n",
       "  'Columbia University',\n",
       "  'Alliance for Better Bone Health',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2003-12',\n",
       "  '2011-11'],\n",
       " ['NCT04844671',\n",
       "  \"Patients' Expectations About Effects of Robotic Surgery for Cancer\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  \"Cancer|Robotic Surgery|Patients' Expectations\",\n",
       "  'DEVICE: da Vinci Surgical Systems',\n",
       "  \"First Affiliated Hospital Xi'an Jiaotong University\",\n",
       "  '',\n",
       "  '3000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-20',\n",
       "  '2022-06-30'],\n",
       " ['NCT02681471',\n",
       "  'Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Hyponatremia',\n",
       "  'OTHER: 5% Mannitol|OTHER: 0\",\"9% Sodium chloride|DEVICE: monopolar resectoscope|DEVICE: bipolar resectoscope TURis',\n",
       "  'Istanbul University',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-12',\n",
       "  '2015-04'],\n",
       " ['NCT00003471',\n",
       "  'Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Low-Grade Astrocytoma\",\" Nos',\n",
       "  'DRUG: Antineoplaston therapy (Atengenal + Astugenal)',\n",
       "  'Burzynski Research Institute',\n",
       "  '',\n",
       "  '7.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '1996-03',\n",
       "  '2003-07'],\n",
       " ['NCT04632771',\n",
       "  'Nutritional Status and Bouillon Use in Northern Ghana',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Iron Deficiency|Vitamin A Deficiency|Vitamin B 12 Deficiency|Folate Deficiency|Zinc Deficiency|Dietary Habits|Anemia',\n",
       "  'OTHER: N/A (observational study)',\n",
       "  'University of California\",\" Davis',\n",
       "  'University of Ghana|Newcastle University|Penn State University|Helen Keller International',\n",
       "  '995.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-19',\n",
       "  '2022-02-28'],\n",
       " ['NCT02834871',\n",
       "  'Integration of the Cervical Proprioceptive Signals in Patients With Cervical Dystonia',\n",
       "  'STAC2',\n",
       "  'COMPLETED',\n",
       "  'Cervical Dystonia',\n",
       "  'DEVICE: Electromyogram',\n",
       "  'Fondation Ophtalmologique Adolphe de Rothschild',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-03',\n",
       "  '2015-07'],\n",
       " ['NCT00202371',\n",
       "  'Transfusion Effects in Myelodysplastic Patients: Limiting Exposure',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Myelodysplastic Syndromes',\n",
       "  'PROCEDURE: Red Blood Cell transfusion',\n",
       "  'Sanquin Research & Blood Bank Divisions',\n",
       "  'Ministry of Health\", Welfare and Sports,\" The Netherlands',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT',\n",
       "  '2002-07',\n",
       "  '2005-07'],\n",
       " ['NCT03129971',\n",
       "  'Platelet-rich Plasma Combined With Conventional Surgery in the Treatment of Atrophic Nonunion of Femoral Shaft Fractures',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Nonunion of Fracture',\n",
       "  'PROCEDURE: conventional surgery|PROCEDURE: autologous platelet-rich plasma',\n",
       "  'Qinghai University',\n",
       "  '',\n",
       "  '92.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-08',\n",
       "  '2018-12'],\n",
       " ['NCT03683771',\n",
       "  'Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Infertility',\n",
       "  'DIAGNOSTIC_TEST: Transvaginal US with Doppler study',\n",
       "  'Aljazeera Hospital',\n",
       "  'Kasr El Aini Hospital|National Research Centre\",\" Egypt',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-28',\n",
       "  '2019-02-20'],\n",
       " ['NCT01142271',\n",
       "  'Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastrectomy',\n",
       "  'PROCEDURE: Billroth-I|PROCEDURE: Roux en Y',\n",
       "  'Ajou University School of Medicine',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-06',\n",
       "  '2012-05'],\n",
       " ['NCT02743871',\n",
       "  'Study Of PF-06817024 In Healthy Subjects\",\" In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy|Chronic Rhinosinusitis With Nasal Polyps|Atopic Dermatitis',\n",
       "  'BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-04-27',\n",
       "  '2021-03-09'],\n",
       " ['NCT03880071',\n",
       "  'DIalectical Behavior Therapy and Acceptance Commitment Therapy Short Program for BOrderLine persOnality Disorder',\n",
       "  'DIABOLO',\n",
       "  'WITHDRAWN',\n",
       "  'Female|Borderline Personality Disorder',\n",
       "  'BEHAVIORAL: DBT+ACT|BEHAVIORAL: DBT',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '\"\"INSERM 1061\",\" \"\"\"\" Neuropsychiatry: epidemiological and clinical research\"\"\"\"\",\" Montpellier\"\"',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2019-11-30',\n",
       "  '2020-03-09'],\n",
       " ['NCT05792371',\n",
       "  'The Role of Type H Vessel Formation in Induced Membrane of Patients With Critical Size Bone Defect',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Bone Injury',\n",
       "  'PROCEDURE: induced membrane technique|PROCEDURE: Bone graft (Stage II of IMT)',\n",
       "  'Chang Gung Memorial Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2023-04-01',\n",
       "  '2026-01-02'],\n",
       " ['NCT00388271',\n",
       "  'Use of Alfuzosin in Stone Treatment With ESWL',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Urinary Calculi',\n",
       "  'DRUG: Alfuzosin (Xatral)|DRUG: standard treatment',\n",
       "  'Singapore General Hospital',\n",
       "  'Sanofi',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-10',\n",
       "  '2007-12'],\n",
       " ['NCT05330871',\n",
       "  'Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: 1 Nebulized inhalation for booster groups|BIOLOGICAL: 2 Nebulized inhalation for booster groups|BIOLOGICAL: 3 Nebulized inhalation for booster groups|BIOLOGICAL: 4 Nebulized inhalation for booster groups|BIOLOGICAL: 5 Intramuscular injection for booster groups|BIOLOGICAL: 6 Intramuscular injection for booster groups|BIOLOGICAL: 7 Intramuscular injection for booster groups|BIOLOGICAL: 8 Intramuscular injection for booster groups|BIOLOGICAL: 9 Intramuscular injection for booster groups|BIOLOGICAL: 10 Intramuscular injection for booster groups|BIOLOGICAL: 11 Nebulized inhalation for booster groups|BIOLOGICAL: 12 Nebulized inhalation for booster groups|BIOLOGICAL: 13 Nebulized inhalation for booster groups|BIOLOGICAL: 14 Nebulized inhalation for booster groups|BIOLOGICAL: 15 Intramuscular injection for booster groups|BIOLOGICAL: 16 Intramuscular injection for booster groups|BIOLOGICAL: 17 Intramuscular injection for booster groups|BIOLOGICAL: 18 Intramuscular injection for booster groups|BIOLOGICAL: 19 Intramuscular injection for booster groups|BIOLOGICAL: 20 Intramuscular injection for booster groups|BIOLOGICAL: 21 Nebulized inhalation for primary groups|BIOLOGICAL: 22 Nebulized inhalation for primary groups|BIOLOGICAL: 23 Nebulized inhalation for primary groups|BIOLOGICAL: 24 Nebulized inhalation for primary groups',\n",
       "  'Seventh Medical Center of PLA General Hospital',\n",
       "  '',\n",
       "  '410.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-04-17',\n",
       "  '2023-05-30'],\n",
       " ['NCT02654171',\n",
       "  'Viral Inhibition in Children for Treatment of RSV',\n",
       "  'VICTOR',\n",
       "  'COMPLETED',\n",
       "  'RESPIRATORY SYNCYTIAL VIRUS INFECTIONS',\n",
       "  'DRUG: AK0529|DRUG: Placebo',\n",
       "  'Shanghai Ark Biopharmaceutical Co.\",\" Ltd.',\n",
       "  'Ark Biosciences Pty Ltd.',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-05-27',\n",
       "  '2019-04-09'],\n",
       " ['NCT04121871',\n",
       "  'Molecular Characterization of Candida Auris',\n",
       "  'OC',\n",
       "  'COMPLETED',\n",
       "  'Oral Fungal Infection',\n",
       "  'OTHER: No intervention',\n",
       "  'Islamia University of Bahawalpur',\n",
       "  '',\n",
       "  '384.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-15',\n",
       "  '2020-02-29'],\n",
       " ['NCT04023071',\n",
       "  'FT516 in Subjects With Advanced Hematologic Malignancies',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Myelogenous Leukemia|B-cell Lymphoma',\n",
       "  'DRUG: FT516|DRUG: Rituximab|DRUG: Obinutuzumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|DRUG: Bendamustine',\n",
       "  'Fate Therapeutics',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-10-04',\n",
       "  '2023-10-23'],\n",
       " ['NCT05304871',\n",
       "  'Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Vascular Access Ports',\n",
       "  'DRUG: Cefazolin|OTHER: saline',\n",
       "  'Dartmouth-Hitchcock Medical Center',\n",
       "  '',\n",
       "  '2550.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2024-01',\n",
       "  '2027-12'],\n",
       " ['NCT05676671',\n",
       "  'Microbiological Evaluation and Clinical 24-month Follow-up of Adhesive Systems on Carious Dentin',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dental Caries',\n",
       "  'PROCEDURE: Applications of self-etching adhesives and dental restorations',\n",
       "  'University of Sao Paulo',\n",
       "  '',\n",
       "  '104.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2020-02'],\n",
       " ['NCT05766371',\n",
       "  'Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Castrate Resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Prostate Cancer|Prostate Carcinoma',\n",
       "  'DRUG: Pembrolizumab|DRUG: 177Lu-PSMA-617',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'Merck Sharp & Dohme LLC|Prostate Cancer Foundation',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-15',\n",
       "  '2031-05-31'],\n",
       " ['NCT01018771',\n",
       "  'Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion',\n",
       "  'APPRAISET2',\n",
       "  'COMPLETED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'PROCEDURE: Actifuse ABX|PROCEDURE: INFUSE\",\" plus Mastergraft granules',\n",
       "  'Baxter Healthcare Corporation',\n",
       "  'Apatech\",\" Inc.',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2012-12'],\n",
       " ['NCT00001071',\n",
       "  'A Study of Stem Cells and Filgrastim',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Filgrastim',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  '1998-10'],\n",
       " ['NCT02193971',\n",
       "  'Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Coronary Syndrome',\n",
       "  'DEVICE: BS-DES (Biostable polymer drug-eluting stent)|DEVICE: BD-DES (Biodegradable polymer drug-eluting stent)|DRUG: Prasugrel 5mg',\n",
       "  'Seoul National University Hospital',\n",
       "  'Boston Scientific Korea Co. Ltd|Dio|Terumo Corporation|Abbott',\n",
       "  '3384.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2022-06'],\n",
       " ['NCT03600571',\n",
       "  'Injection Site Diversity Influences HA Distribution and Clinical Results in CP and KOA',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis\",\" Knee|Hyaluronan',\n",
       "  'PROCEDURE: medial midpatellar (MMP) portal|PROCEDURE: anteromedial (AM) portal',\n",
       "  'Nanfang Hospital\",\" Southern Medical University',\n",
       "  '',\n",
       "  '164.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-08-30',\n",
       "  '2018-05-01'],\n",
       " ['NCT00978471',\n",
       "  'Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma',\n",
       "  'OSII-TTP',\n",
       "  'COMPLETED',\n",
       "  'Osteosarcoma',\n",
       "  'DRUG: Thiotepa',\n",
       "  'Centre Leon Berard',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2018-10-29'],\n",
       " ['NCT00150371',\n",
       "  'Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration',\n",
       "  'CANACTFAST',\n",
       "  'COMPLETED',\n",
       "  'Hypercholesterolemia',\n",
       "  'DRUG: atorvastatin',\n",
       "  \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\",\n",
       "  '',\n",
       "  '1100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-06',\n",
       "  '2005-05'],\n",
       " ['NCT02919371',\n",
       "  'Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Renal Cell Carcinoma',\n",
       "  'DRUG: Sunitinib|DRUG: Bevacizumab',\n",
       "  'King Faisal Specialist Hospital & Research Center',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-12',\n",
       "  '2021-12'],\n",
       " ['NCT05666271',\n",
       "  'Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: Radiofrequency ablation',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-08-29',\n",
       "  '2024-08-30'],\n",
       " ['NCT00666471',\n",
       "  'Minimally Invasive Control of Epistaxis (MICE)',\n",
       "  'MICE',\n",
       "  'TERMINATED',\n",
       "  'Epistaxis',\n",
       "  'PROCEDURE: MICE|PROCEDURE: SPA ligation',\n",
       "  'University of Calgary',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-06',\n",
       "  '2009-06'],\n",
       " ['NCT03258671',\n",
       "  'IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: EGFR-TK Inhibitor|RADIATION: Intensity Modulated Radiation Therapy',\n",
       "  'LuBing',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-10-01',\n",
       "  '2020-12-30'],\n",
       " ['NCT05540171',\n",
       "  'An Educational Intervention Program to Improve the Oral Health of HIV-Positive Children in Kano\",\" Nigeria.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'HIV|Dental Caries|Quality of Life|Oral Disease|Oral Infection|Oral Manifestations',\n",
       "  'OTHER: Oral health education and instructions/training for self-oral care',\n",
       "  'Aminu Kano Teaching Hospital',\n",
       "  'NIH Office of AIDS Research (OAR)|Fogarty International Center of the National Institute of Health',\n",
       "  '172.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-12-22',\n",
       "  '2023-08-10'],\n",
       " ['NCT01152671',\n",
       "  'A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Volunteer',\n",
       "  'DRUG: Placebo|DRUG: RO5024048',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: ',\n",
       "  '2010-06',\n",
       "  '2010-08'],\n",
       " ['NCT01855971',\n",
       "  '\"\"\"\"\"\"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome\"\"\"\" (TESFX)\"\"',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Fragile X Syndrome',\n",
       "  'DIETARY_SUPPLEMENT: EGCG|DIETARY_SUPPLEMENT: Placebo|OTHER: Cognitive training',\n",
       "  'Parc de Salut Mar',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-06-11',\n",
       "  '2015-10-31'],\n",
       " ['NCT03321071',\n",
       "  'Healthy Summer Learners',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Overweight and Obesity|Academic Acheivement',\n",
       "  'BEHAVIORAL: Healthy Summer Learners|BEHAVIORAL: 21st Century Summer Learning Center',\n",
       "  'University of South Carolina',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2018-05-01',\n",
       "  '2021-05-01'],\n",
       " ['NCT03185871',\n",
       "  'Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Breast Carcinoma',\n",
       "  'DRUG: Celecoxib',\n",
       "  'University of Wisconsin\",\" Madison',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2017-09-20',\n",
       "  '2018-10-10'],\n",
       " ['NCT02100371',\n",
       "  'Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Basal Cell Nevus Syndrome',\n",
       "  'DRUG: BMS-833923',\n",
       "  'University Health Network\",\" Toronto',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02',\n",
       "  '2017-05'],\n",
       " ['NCT01644071',\n",
       "  'Serotonergic System and Violent Video Games',\n",
       "  'Serogen',\n",
       "  'COMPLETED',\n",
       "  'Healthy Volunteers',\n",
       "  'DRUG: cipralex',\n",
       "  'RWTH Aachen University',\n",
       "  '',\n",
       "  '47.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-02',\n",
       "  '2014-06'],\n",
       " ['NCT03227471',\n",
       "  'A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  'DRUG: IVA|DRUG: TEZ/IVA|DRUG: VX-445|DRUG: Matched Placebo|DRUG: TEZ|DRUG: VX-561|DRUG: VX-445',\n",
       "  'Vertex Pharmaceuticals Incorporated',\n",
       "  '',\n",
       "  '225.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-01-23',\n",
       "  '2018-03-27'],\n",
       " ['NCT03712371',\n",
       "  'Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Chitosan',\n",
       "  'Medical University of South Carolina',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-16',\n",
       "  '2021-09-07'],\n",
       " ['NCT03653871',\n",
       "  'Caregiver Study Dr. Phillips',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alzheimer Disease|Dementia',\n",
       "  'BEHAVIORAL: Performing Arts Instruction',\n",
       "  'AdventHealth',\n",
       "  'Dr. Phillips Center for the Performing Arts',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-09-11',\n",
       "  '2019-12-31'],\n",
       " ['NCT00656071',\n",
       "  'Retrospective Postoperative ARDS Study at Vanderbilt University',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'ARDS',\n",
       "  '',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2008-08'],\n",
       " ['NCT03107871',\n",
       "  'Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants',\n",
       "  'ValEAR',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Cmv Congenital|CMV|Congenital Cmv|SNHL|Sensorineural Hearing Loss',\n",
       "  'DRUG: Valganciclovir|DRUG: Simple Syrup',\n",
       "  'Albert Park',\n",
       "  'National Institute on Deafness and Other Communication Disorders (NIDCD)|Genentech\",\" Inc.',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-31',\n",
       "  '2024-07'],\n",
       " ['NCT01234571',\n",
       "  'Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pulmonary Hypertension|End-Stage Renal Disease|Hemo-dialysis Therapy',\n",
       "  '',\n",
       "  'Rambam Health Care Campus',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-11',\n",
       "  ''],\n",
       " ['NCT02967471',\n",
       "  'Discovery of New Early Detection Biomarkers From Peripheral Blood of Acute Respiratory Distress Syndrome(ARDS)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Respiratory Distress Syndrome',\n",
       "  '',\n",
       "  'The Third Affiliated Hospital of Southern Medical University',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-10',\n",
       "  '2018-12'],\n",
       " ['NCT00503971',\n",
       "  'Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Non-small Cell Lung Cancer',\n",
       "  'DRUG: Vorinostat plus Erlotinib',\n",
       "  'Spanish Lung Cancer Group',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2011-12'],\n",
       " ['NCT04484571',\n",
       "  'Multimodal Instrumented Assessment of Post-stroke Elbow',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Spasticity\",\" Muscle|Stroke|Upper Limb',\n",
       "  'DEVICE: Neuroexsos elbow module',\n",
       "  'Azienda USL Toscana Nord Ovest',\n",
       "  \"Scuola Superiore Sant'Anna Pisa\",\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-07-06',\n",
       "  '2024-07-30'],\n",
       " ['NCT06066671',\n",
       "  'The Effect of an Experimental Gel Based on Copaiba Oil Resin in Reducing Post-bleaching Tooth Sensitivity',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Tooth Bleaching Pain',\n",
       "  'OTHER: GCO (Experimental copaiba oil resin gel)',\n",
       "  'Universidade Federal do Para',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-10',\n",
       "  '2024-05-25'],\n",
       " ['NCT04533971',\n",
       "  'The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis (ICD10-G35)|Surface Electromyography|Whole-body Cryotherapy',\n",
       "  'OTHER: Whole body cryotherapy',\n",
       "  'Pomeranian Medical University Szczecin',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-04-01',\n",
       "  '2019-12-20'],\n",
       " ['NCT04608071',\n",
       "  'A Modified Method for Blind Bedside Placement of Post-pyloric Feeding Tube.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Nutritional Support\", Catheterization, Post-pyloric Feeding Tube,\" Dysphagia',\n",
       "  'PROCEDURE: A modified method for blind bedside placement of post-pyloric feeding tube.',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '99.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-01',\n",
       "  '2019-10-30'],\n",
       " ['NCT04050371',\n",
       "  'Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy',\n",
       "  'I-BrEATHe',\n",
       "  'COMPLETED',\n",
       "  'HIV Prevention|Transgender Health',\n",
       "  'DRUG: 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'San Francisco AIDS Foundation|California HIV/AIDS Research Program',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2017-08-03',\n",
       "  '2018-05-23'],\n",
       " ['NCT01276171',\n",
       "  'Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia',\n",
       "  'PROCEDURE: Ultrasound|PROCEDURE: Doppler|PROCEDURE: Palpation',\n",
       "  'University of Iowa',\n",
       "  '',\n",
       "  '749.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2015-04'],\n",
       " ['NCT03929471',\n",
       "  'Target Weight Correction and Vascular Stiffness in Hemodialysis Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Fluid Overload|Vascular Stiffness',\n",
       "  'OTHER: Target weight correction protocol',\n",
       "  'University of Alberta',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2019-09-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT00630071',\n",
       "  'Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Appendicitis',\n",
       "  '',\n",
       "  'Ruhr University of Bochum',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-02',\n",
       "  '2008-08'],\n",
       " ['NCT03668171',\n",
       "  'Mesenchymal Stem Cell Transplantation for Acute-on-chronic Liver Failure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute-On-Chronic Liver Failure',\n",
       "  'PROCEDURE: mesenchymal stem cell transplantation or placebo infusion via peripheral vein',\n",
       "  'Xijing Hospital of Digestive Diseases',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-12-10',\n",
       "  '2020-12-31'],\n",
       " ['NCT02067871',\n",
       "  'Treatment of Knee Osteoarthritis: Neuromuscular Electrical Stimulation and Low-level Laser.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Knee Osteoarthritis',\n",
       "  'OTHER: Laser Therapy|OTHER: Electrical Stimulation',\n",
       "  'Marco Aurélio Vaz\",\" PhD',\n",
       "  'Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul\",\" Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2012-12'],\n",
       " ['NCT00497471',\n",
       "  'RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Malaria|Anemia',\n",
       "  'DRUG: Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|DRUG: iron (2 mg/kg/daily)',\n",
       "  'Hospital Clinic of Barcelona',\n",
       "  'Agencia Española de Cooperación Internacional|World Health Organization',\n",
       "  '832.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '1995-02',\n",
       "  '1999-07'],\n",
       " ['NCT02235571',\n",
       "  'iChoose Decision Kidney Aid for End-Stage Renal Disease Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'End-Stage Kidney Disease|Kidney Failure\",\" Chronic|Kidney Transplantation',\n",
       "  'BEHAVIORAL: iChoose Kidney Decision Aid',\n",
       "  'Emory University',\n",
       "  'Columbia University|Northwestern University|Satellite Healthcare|Norman S. Coplon Extramural Grant Program',\n",
       "  '470.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-09',\n",
       "  '2017-09'],\n",
       " ['NCT05112471',\n",
       "  'Efficacy of GBT vs SRP+US\",\" in the Treatment of Severe Generalized Periodontitis.',\n",
       "  'ERISRP',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis\",\" Aggressive|Periodontal Diseases|Periodontitis',\n",
       "  'DEVICE: Airflow\",\" Perioflow and Erythritol powder and ultrasonic debridement|DEVICE: Ultrasonic debridement and curettes',\n",
       "  'Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2016-11-22',\n",
       "  '2020-04-04'],\n",
       " ['NCT00019071',\n",
       "  'Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain and Central Nervous System Tumors',\n",
       "  'DRUG: chemotherapy|DRUG: cladribine|RADIATION: radiation therapy',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1995-03',\n",
       "  ''],\n",
       " ['NCT05170971',\n",
       "  'Fecal Microbiota Transplantation for Liver Failure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Liver Failure',\n",
       "  'OTHER: fecal microbiota transplantation',\n",
       "  'Ningbo Medical Center Lihuili Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-05-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT00771771',\n",
       "  'Early Supported Discharge After Stroke in Bergen',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'OTHER: Early supported discharge with day unit rehabilitation|OTHER: Early supported discharge with home rehabilitation',\n",
       "  'Haukeland University Hospital',\n",
       "  'University of Bergen|Municipality of Bergen\",\" Norway|Kavli Research Centre for Ageing and Dementia',\n",
       "  '306.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2013-12'],\n",
       " ['NCT01333371',\n",
       "  'Assessing Volar Locking Plates in Patients Under 65 With a Distal Radius Fracture',\n",
       "  'DRF',\n",
       "  'UNKNOWN',\n",
       "  'Distal Radius Fracture',\n",
       "  'PROCEDURE: Surgical Repair of Distal Radius Fracture',\n",
       "  'Hand and Upper Limb Clinic\",\" Canada',\n",
       "  'Canadian Orthopaedic Foundation',\n",
       "  '64.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2014-03'],\n",
       " ['NCT01878071',\n",
       "  'The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Peri-implant Inflammation|Peri-implantitis',\n",
       "  '',\n",
       "  'University of Iowa',\n",
       "  'Osseointegration Foundation|University of Iowa Institute of Clinical and Translational Science',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-06',\n",
       "  ''],\n",
       " ['NCT02687971',\n",
       "  'Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cutaneous Leishmaniasis',\n",
       "  'DRUG: Miltefosine',\n",
       "  'Drugs for Neglected Diseases',\n",
       "  '',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-12',\n",
       "  '2019-09-10'],\n",
       " ['NCT00956371',\n",
       "  'ONO-7746 Study in Healthy Adult Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Adult Subjects',\n",
       "  'DRUG: ONO-7746|DRUG: ONO-7746',\n",
       "  'Ono Pharmaceutical Co. Ltd',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  ''],\n",
       " ['NCT01322971',\n",
       "  'Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Vaginosis\",\" Bacterial|Infertility|Miscarriage',\n",
       "  'DRUG: Metronidazole|DRUG: Placebo',\n",
       "  'Stanford University',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-02',\n",
       "  '2012-06'],\n",
       " ['NCT03803371',\n",
       "  'Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Ultracet Tablets|DRUG: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2019-03-26',\n",
       "  '2019-06-28'],\n",
       " ['NCT01408771',\n",
       "  '\"\"\"\"\"\"Swallow my Urine Back\"\"\"\" : Inhibition of Detrusor Overactivity by Swallowing Maneuver\"\"',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Overactive Detrusor',\n",
       "  '',\n",
       "  'Assaf-Harofeh Medical Center',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2011-07'],\n",
       " ['NCT01767571',\n",
       "  'Bioequivalence Study of Cephalexin Suspension 250',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infections\",\" Respiratory Tract',\n",
       "  'DRUG: Cephalexin 125 mg/5ml|DRUG: Cephalexin 250mg/5ml',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2011-01-30',\n",
       "  '2011-02-08'],\n",
       " ['NCT00925171',\n",
       "  'Maintenance Schedules Following Pulmonary Rehabilitation',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Obstructive Pulmonary Disease|Pulmonary Rehabilitation',\n",
       "  'BEHAVIORAL: Pulmonary Intervention',\n",
       "  'University of East Anglia',\n",
       "  '',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2009-06',\n",
       "  '2012-06'],\n",
       " ['NCT02153671',\n",
       "  'Immunogenicity of H5N1 Vaccine Following H5N2',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Influenza Vaccine',\n",
       "  'BIOLOGICAL: A(H5N1) inactivated influenza vaccine (IIV)|BIOLOGICAL: A(H5N2) live attenuated influenza vaccine (LAIV)',\n",
       "  'PATH',\n",
       "  'Institute of Experimental Medicine\", Russia|Research Institute of Influenza,\" Russia',\n",
       "  '43.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-05',\n",
       "  '2014-09'],\n",
       " ['NCT05603871',\n",
       "  'Ligamentoplasty of Ligamentum Tere Developmental Dysplasia of the Hip',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Orthopedic Disorder',\n",
       "  'PROCEDURE: ligamentoplasty of ligamentum teres',\n",
       "  'Al-Azhar University',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-11-29',\n",
       "  '2023-11-29'],\n",
       " ['NCT04364971',\n",
       "  'Comparison of Multiradius and Singleradius Total Knee Arthroplasty',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gonarthrosis; Primary|Gonarthrosis|Gonarthrosis; Primary\",\" Bilateral|Knee Osteoarthritis|Knee Arthritis',\n",
       "  'PROCEDURE: singleradius and multiradius total knee arthroplasty',\n",
       "  'Bezmialem Vakif University',\n",
       "  '',\n",
       "  '494.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-25',\n",
       "  '2023-07-25'],\n",
       " ['NCT00555971',\n",
       "  'Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aspirin Sensitivity',\n",
       "  'DRUG: Omalizumab|DRUG: placebo',\n",
       "  'David Lang',\n",
       "  'Genentech\",\" Inc.',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-05',\n",
       "  '2016-02'],\n",
       " ['NCT03926871',\n",
       "  'Ergonomics Training Program to Industrial Workers',\n",
       "  'Ergonomics',\n",
       "  'COMPLETED',\n",
       "  'Occupational Exposure',\n",
       "  'OTHER: Ergonomic Training',\n",
       "  'Rosimeire Simprini Padula',\n",
       "  '',\n",
       "  '133.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2014-08-20',\n",
       "  '2015-02-20'],\n",
       " ['NCT00005571',\n",
       "  'Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dermatomyositis',\n",
       "  'DRUG: h5G1.1-mAb',\n",
       "  'National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)',\n",
       "  '',\n",
       "  '17.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2000-04',\n",
       "  '2001-12'],\n",
       " ['NCT01026571',\n",
       "  'Identification of Genetic Causes of Bicuspid Aortic Valve Disease',\n",
       "  'BAV Genetics',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Bicuspid Aortic Valve',\n",
       "  '',\n",
       "  'Boston University',\n",
       "  'Massachusetts General Hospital|Brigham and Women\\'s Hospital|National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '4000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-12',\n",
       "  '2030-12'],\n",
       " ['NCT00578071',\n",
       "  'Phase I/II Study of Panitumumab\",\" Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer',\n",
       "  'POXX',\n",
       "  'COMPLETED',\n",
       "  'Cancer of the Esophagus',\n",
       "  'DRUG: Panitumumab|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: Radiation Therapy (RT)',\n",
       "  'Brian Czito',\n",
       "  'Amgen',\n",
       "  '29.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2012-06'],\n",
       " ['NCT01087671',\n",
       "  'Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ocular Hypertension|Open-Angle Glaucoma',\n",
       "  'DRUG: tafluprost',\n",
       "  'Santen Oy',\n",
       "  '',\n",
       "  '185.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-04',\n",
       "  '2010-10'],\n",
       " ['NCT06075771',\n",
       "  'Dopaminergic Therapy for Anhedonia - 2',\n",
       "  'DTA-2',\n",
       "  'RECRUITING',\n",
       "  'Anhedonia|Depression',\n",
       "  'DRUG: Carbidopa Levodopa|DRUG: Placebo',\n",
       "  'Emory University',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-21',\n",
       "  '2027-01'],\n",
       " ['NCT06165471',\n",
       "  'The Effectiveness of a Mobile Application for Teaching Clinical Nursing Skill at a Higher Education Institution in Chenzhou\",\" China',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Nursing Education',\n",
       "  'BEHAVIORAL: Online and offline blended teaching|BEHAVIORAL: Traditional teaching',\n",
       "  'Universiti Sains Malaysia',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2023-12-15',\n",
       "  '2024-09-20'],\n",
       " ['NCT03072771',\n",
       "  'Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diffuse Large B Cell Lymphoma',\n",
       "  'DRUG: Blinatumomab|PROCEDURE: Autologous stem cell transplant|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan|PROCEDURE: Peripheral blood draws',\n",
       "  'Washington University School of Medicine',\n",
       "  'Amgen',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-08-01',\n",
       "  '2023-10-30'],\n",
       " ['NCT03239171',\n",
       "  'Bioinformation Therapy for Lung Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Small-cell Lung Cancer',\n",
       "  'DEVICE: Cancer ablation|DRUG: Life information rehabilitation therapy',\n",
       "  'Fuda Cancer Hospital\",\" Guangzhou',\n",
       "  'Shengxin Biotechnology Institute\",\" Beijing',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-09-02',\n",
       "  '2018-09-02'],\n",
       " ['NCT05333471',\n",
       "  'Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Granulomatous Disease-associated Colitis',\n",
       "  'DRUG: MTP 101-LF',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-08',\n",
       "  '2026-03-01'],\n",
       " ['NCT03023371',\n",
       "  'National Registry of IgG4-RD in China',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'IgG4-Related Disease',\n",
       "  '',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  '',\n",
       "  '900.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12',\n",
       "  '2026-12'],\n",
       " ['NCT02096471',\n",
       "  'MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1',\n",
       "  'MEK Inhibitor',\n",
       "  'COMPLETED',\n",
       "  'Neurofibromatosis Type 1 and Growing or Symptomatic\",\" Inoperable PN',\n",
       "  'DRUG: PD-0325901',\n",
       "  'University of Alabama at Birmingham',\n",
       "  '',\n",
       "  '19.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-06',\n",
       "  '2018-08-01'],\n",
       " ['NCT02495571',\n",
       "  'Assessment of Voluntary and Reflex Cough in Patients With ALS',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'ALS|Cough',\n",
       "  'OTHER: Cough Assessment in ALS Patients',\n",
       "  'IRCCS San Camillo\", Venezia,\" Italy',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-10',\n",
       "  '2016-06'],\n",
       " ['NCT05042271',\n",
       "  'PK of Meropenem in Patients on Plasma Exchange',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Autoimmune Diseases',\n",
       "  'DRUG: meropenem',\n",
       "  'Prince of Songkla University',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT05300971',\n",
       "  'Passive Heat Therapy for Lowering Systolic Blood Pressure and Improving Vascular Function in Mid-life and Older Adults',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Aging',\n",
       "  'OTHER: Heat therapy|OTHER: Thermoneutral water immersion',\n",
       "  'University of Colorado\",\" Boulder',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2027-01-01'],\n",
       " ['NCT00908271',\n",
       "  'Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: Dapagliflozin',\n",
       "  'AstraZeneca',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '7.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2009-07',\n",
       "  '2009-08'],\n",
       " ['NCT00797771',\n",
       "  'User Satisfaction Using the ADI Insulin Pump',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes',\n",
       "  '\"\"DEVICE: \"\"\"\"Adi\"\"\"\" Insulin pump\"\"',\n",
       "  'NiliMedix',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2010-01'],\n",
       " ['NCT02707471',\n",
       "  'Improving Well-Being for Breast Cancer Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Self-management Intervention (SM-AET)|General Health Education',\n",
       "  'BEHAVIORAL: SM-AET|BEHAVIORAL: general health education',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '312.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-03-14',\n",
       "  '2023-11-09'],\n",
       " ['NCT03867071',\n",
       "  'Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients',\n",
       "  'EPREX',\n",
       "  'COMPLETED',\n",
       "  'Trauma',\n",
       "  'OTHER: recombinant erythropoietin injection|OTHER: placebo injection',\n",
       "  'Centre Hospitalier Universitaire de Nīmes',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: OTHER',\n",
       "  '2005-10',\n",
       "  '2012-07'],\n",
       " ['NCT05263271',\n",
       "  'Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Acute Myelogenous Leukemia|Myelodysplastic Syndromes',\n",
       "  'DRUG: Gentulizumab',\n",
       "  'Changchun GeneScience Pharmaceutical Co.\",\" Ltd.',\n",
       "  'Ruijin Hospital|Shanghai Tong Ren Hospital|First Affiliated Hospital of Zhejiang University',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04-01',\n",
       "  '2024-07-30'],\n",
       " ['NCT06019871',\n",
       "  'The Danish Symptomburden Study Among Patients With Advanced Kidney Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Kidney Diseases',\n",
       "  'PROCEDURE: Dialysis',\n",
       "  'University of Aarhus',\n",
       "  '',\n",
       "  '341.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-03-15',\n",
       "  '2025-09-15'],\n",
       " ['NCT06009471',\n",
       "  \"A Multicenter Clinical Study of rTMS for Parkinson's Disease\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  \"Parkinson's Disease\",\n",
       "  'OTHER: Routine treatment in Neurology|DEVICE: Routine treatment in Neurology and rTMS',\n",
       "  'Affiliated Hospital of Nantong University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-01',\n",
       "  '2025-08'],\n",
       " ['NCT02485171',\n",
       "  'SAFEWALKER Contribution to the Rehabilitation of Older People After a Post-fall Syndrome',\n",
       "  'SAFEER',\n",
       "  'COMPLETED',\n",
       "  'Post-fall Syndrome',\n",
       "  'DEVICE: SAFEWALKER',\n",
       "  'University Hospital\",\" Toulouse',\n",
       "  'Safe Step and Walk Movement (SSWM)\", Toulouse,\" France',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-06-10',\n",
       "  '2017-02-01'],\n",
       " ['NCT04273971',\n",
       "  'Acute Effect of Plyometric Exercises on Musculotendinous Properties',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'OTHER: Plyometric exercises',\n",
       "  'Universidade Federal de Santa Maria',\n",
       "  'Conselho Nacional de Desenvolvimento Científico e Tecnológico|Federal University of Rio Grande do Sul',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-20',\n",
       "  '2022-03-30'],\n",
       " ['NCT00442871',\n",
       "  'Study Of SB-497115 in Healthy Subjects and Subjects With Mild\",\" Moderate or Severe Renal Impairment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Purpura\", Thrombocytopaenic,\" Idiopathic',\n",
       "  'DRUG: eltrombopag',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-09-28',\n",
       "  '2008-01-03'],\n",
       " ['NCT03022071',\n",
       "  'Mechanisms of Change in Psychotherapy',\n",
       "  'MOP',\n",
       "  'UNKNOWN',\n",
       "  'Depression',\n",
       "  'OTHER: Cognitive behavior therapy',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-02-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT03794271',\n",
       "  'Effect of Pupilometer Guided Analgesia on Postoperative Pain',\n",
       "  'PUPIL_pain',\n",
       "  'COMPLETED',\n",
       "  'Cholecystectomy\", Laparoscopic|Anesthesia, General|Reflex,\" Pupillary',\n",
       "  'PROCEDURE: Pupilometer guided anesthesia|PROCEDURE: SPI guided anesthesia',\n",
       "  'Daegu Catholic University Medical Center',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2019-01-03',\n",
       "  '2019-05-10'],\n",
       " ['NCT02625571',\n",
       "  'Tx for Child Sexual Behavior Problems',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sexual Behavior',\n",
       "  'BEHAVIORAL: Phase-based treatment of sexual behavior problems of children',\n",
       "  'Milton S. Hershey Medical Center',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2017-06-30'],\n",
       " ['NCT03942471',\n",
       "  'Mindfulness for Adolescents With Type 1 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 1 Diabetes Mellitus',\n",
       "  'BEHAVIORAL: Mindfulness Based Stress Reduction',\n",
       "  'Duquesne University',\n",
       "  '',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-10-14',\n",
       "  '2019-01-05'],\n",
       " ['NCT05511571',\n",
       "  'Effect of Progressive Relaxation Exercises and TENS on Women Delivering Via Cesarean',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cesarean Section|Acute Pain',\n",
       "  'DEVICE: Transcutaneous electrical neural stimulation (TENS)|OTHER: Progressive relaxation exercises (PRE)|OTHER: Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)',\n",
       "  'Derya Öztürk Özen',\n",
       "  'Hacettepe University|Saglik Bilimleri Universitesi',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-08-20',\n",
       "  '2019-04-15'],\n",
       " ['NCT01471171',\n",
       "  'Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Obstructive Pulmonary Disease (COPD)',\n",
       "  'DRUG: Aclidinium Bromide|DRUG: Placebo',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '112.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-11',\n",
       "  '2012-06'],\n",
       " ['NCT02971371',\n",
       "  'The Role of MNS in Improving Motor Performance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'DEVICE: Lokomat',\n",
       "  '\"\"IRCCS Centro Neurolesi \"\"\"\"Bonino-Pulejo\"\"\"\"\"\"',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2016-02'],\n",
       " ['NCT03919071',\n",
       "  'Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Anaplastic Astrocytoma|Anaplastic Astrocytoma\",\" Not Otherwise Specified|Anaplastic Ganglioglioma|Anaplastic Pleomorphic Xanthoastrocytoma|Glioblastoma|Malignant Glioma|WHO Grade 3 Glioma',\n",
       "  'PROCEDURE: Biospecimen Collection|DRUG: Dabrafenib Mesylate|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|RADIATION: Radiation Therapy|DRUG: Trametinib Dimethyl Sulfoxide',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-20',\n",
       "  '2027-09-30'],\n",
       " ['NCT01267071',\n",
       "  'A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastroparesis',\n",
       "  'DRUG: A|DRUG: B',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-06-14',\n",
       "  '2010-09-01'],\n",
       " ['NCT00929071',\n",
       "  'Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®',\n",
       "  'AD-1016',\n",
       "  'COMPLETED',\n",
       "  'Aging|Pain',\n",
       "  'DEVICE: Evolence|DEVICE: Lidocaine|DRUG: topical anesthetic',\n",
       "  'Weinkle\", Susan H.,\" M.D.',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDIV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  '2009-02'],\n",
       " ['NCT03811171',\n",
       "  'Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Renal Calculi|Urinary Calculi',\n",
       "  'DEVICE: Break Wave extracorporeal lithotripsy',\n",
       "  'SonoMotion',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-08-20',\n",
       "  '2023-12-30'],\n",
       " ['NCT03133871',\n",
       "  'Evaluation of Scanoskin for the Assessment of Vitiligo',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vitiligo',\n",
       "  '',\n",
       "  'Chelsea and Westminster NHS Foundation Trust',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-03-01',\n",
       "  '2018-11-20'],\n",
       " ['NCT05941871',\n",
       "  'Chronotype-adapted Diet and Weight Loss',\n",
       "  'CHRONODIET',\n",
       "  'RECRUITING',\n",
       "  'Overweight and Obesity',\n",
       "  'OTHER: Dietary intervention - intervention group|OTHER: Dietary intervention - control group',\n",
       "  'Azienda Ospedaliero-Universitaria Careggi',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-03-06',\n",
       "  '2025-03-06'],\n",
       " ['NCT03561571',\n",
       "  'Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetes',\n",
       "  'COMPLETE',\n",
       "  'COMPLETED',\n",
       "  'Type2 Diabetes',\n",
       "  'OTHER: butter based breakfast|OTHER: Chocolate spread based breakfast',\n",
       "  'Hospices Civils de Lyon',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-10-15',\n",
       "  '2019-05-14'],\n",
       " ['NCT03454971',\n",
       "  'Health Course of Patients Undergoing Per os Anti-cancer Therapy.',\n",
       "  'MinOS',\n",
       "  'COMPLETED',\n",
       "  'Cancer',\n",
       "  'OTHER: MinOS protocol',\n",
       "  'Groupe Hospitalier Mutualiste de Grenoble',\n",
       "  \"Fondation de l'Avenir\",\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2018-04-25',\n",
       "  '2020-05-12'],\n",
       " ['NCT05835271',\n",
       "  'Powered Assist Hip Exoskeleton to Improve Ambulation in Severe Lung Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Lung Disease Chronic',\n",
       "  'DEVICE: exoskeleton assist',\n",
       "  'West Park Healthcare Centre',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-08-01',\n",
       "  '2024-03-30'],\n",
       " ['NCT06088771',\n",
       "  'Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Non-Small Cell Lung Cancer',\n",
       "  'BIOLOGICAL: Dupilumab|BIOLOGICAL: Cemiplimab',\n",
       "  'Icahn School of Medicine at Mount Sinai',\n",
       "  '',\n",
       "  '21.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01',\n",
       "  '2032-03'],\n",
       " ['NCT05212571',\n",
       "  'Long-term Pain Modulation by Intravenous Esketamine in CRPS',\n",
       "  'KetCRPS-2',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Complex Regional Pain Syndromes|CRPS (Complex Regional Pain Syndromes)',\n",
       "  'DRUG: S-ketamine infusion inpatient setting|DRUG: S-ketamine infusion outpatient setting',\n",
       "  'Erasmus Medical Center',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-04-19',\n",
       "  '2027-10-01'],\n",
       " ['NCT02902471',\n",
       "  'Forced Oscillations for Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation',\n",
       "  'OSCILLOMOELL',\n",
       "  'COMPLETED',\n",
       "  'Bronchiolitis Obliterans|Bone Marrow Transplantation',\n",
       "  'OTHER: Forced oscillations measure',\n",
       "  'Hopital Foch',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-06',\n",
       "  '2015-09'],\n",
       " ['NCT00402571',\n",
       "  'Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Related Disorders',\n",
       "  'DRUG: acetaminophen',\n",
       "  'Denver Health and Hospital Authority',\n",
       "  'McNeil Consumer & Specialty Pharmaceuticals\", a Division of McNeil-PPC,\" Inc.',\n",
       "  '420.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: ',\n",
       "  '2002-01',\n",
       "  '2004-07'],\n",
       " ['NCT04522271',\n",
       "  \"Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)\",\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Crohn Disease|Ulcerative Colitis|Inflammatory Bowel Diseases',\n",
       "  'OTHER: Resistant Starch|OTHER: Placebo',\n",
       "  \"Children's Hospital of Eastern Ontario\",\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2020-08-25',\n",
       "  '2024-05-01'],\n",
       " ['NCT05382871',\n",
       "  'Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above',\n",
       "  'COVID-19',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|BIOLOGICAL: WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|BIOLOGICAL: COVID-19 Vaccine (Vero Cell)\",\" Inactivated',\n",
       "  'China National Biotec Group Company Limited',\n",
       "  'Beijing Institute of Biological Products Co Ltd.|Wuhan Institute of Biological Products Co.\",\" Ltd|The University of Hong Kong',\n",
       "  '1804.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-05-27',\n",
       "  '2024-03-31'],\n",
       " ['NCT01319071',\n",
       "  'Genetic Polymorphism and Israeli Top-level Athletes',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Top-level Athletes',\n",
       "  'OTHER: Blood sample',\n",
       "  'Hillel Yaffe Medical Center',\n",
       "  'Wingate Institute',\n",
       "  '200.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2012-12'],\n",
       " ['NCT03579771',\n",
       "  'Gemcitabine\", Cisplatin,\" and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Resectable Cholangiocarcinoma|Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|Stage II Intrahepatic Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8',\n",
       "  'DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Nab-paclitaxel',\n",
       "  'Emory University',\n",
       "  'Celgene|National Institutes of Health (NIH)|National Cancer Institute (NCI)',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-09-26',\n",
       "  '2023-09-16'],\n",
       " ['NCT01156571',\n",
       "  'A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)',\n",
       "  'CHAMPION',\n",
       "  'COMPLETED',\n",
       "  'Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome',\n",
       "  'DRUG: cangrelor P2Y12 (platelet) inhibitor|DRUG: Clopidogrel - 300 or 600 mg (study arm)|DRUG: Clopidogrel 600 mg post cangrelor',\n",
       "  'The Medicines Company',\n",
       "  '',\n",
       "  '11145.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-09',\n",
       "  '2012-12'],\n",
       " ['NCT04345471',\n",
       "  'A Study of MD-120 in Patients With Depression',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorder',\n",
       "  'DRUG: Desvenlafaxine 100 mg|DRUG: Desvenlafaxine 50 mg|DRUG: Placebo',\n",
       "  'Mochida Pharmaceutical Company\",\" Ltd.',\n",
       "  'Pfizer',\n",
       "  '615.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-05-18',\n",
       "  '2022-09-14'],\n",
       " ['NCT05395871',\n",
       "  'Behavioural Science Messages in Breast Cancer Screening',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'BEHAVIORAL: Behavioural Message|BEHAVIORAL: Behavioural Message + Video|OTHER: Usual Care Message',\n",
       "  'Imperial College London',\n",
       "  'NHS England (NHSE/I) London',\n",
       "  '34047.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: SCREENING',\n",
       "  '2022-07-15',\n",
       "  '2023-01-15'],\n",
       " ['NCT04968171',\n",
       "  'Diabetes Type 1 and Fitness.',\n",
       "  'Diab1Fit',\n",
       "  'RECRUITING',\n",
       "  'Diabetes Mellitus',\n",
       "  '',\n",
       "  'Poznan University of Medical Sciences',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT02218671',\n",
       "  'Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: WE 941 OD tablets',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2000-03',\n",
       "  ''],\n",
       " ['NCT06222671',\n",
       "  'A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Axial Spondyloarthritis',\n",
       "  'DRUG: 608|DRUG: 608|DRUG: Placebo',\n",
       "  'Sunshine Guojian Pharmaceutical (Shanghai) Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-31',\n",
       "  '2025-11-30'],\n",
       " ['NCT02265471',\n",
       "  'Knowledge and Perception of Resistance to Antimicrobials Among Healthcare Workers in France',\n",
       "  'PerceptR',\n",
       "  'COMPLETED',\n",
       "  'Knowledge\",\" Perception and Behaviour of Resistance to Antimicrobial Among HCW',\n",
       "  '',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '10000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-06',\n",
       "  '2016-02'],\n",
       " ['NCT05628571',\n",
       "  'Evaluation of the Antibacterial Effect of a Toothpaste Containing Zinc Lactate',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Oral Bacterial Infection',\n",
       "  'COMBINATION_PRODUCT: Zinc toothpaste|COMBINATION_PRODUCT: Fluoride Toothpaste',\n",
       "  'Hospital Israelita Albert Einstein',\n",
       "  'Colgate Palmolive|Associação Latinoamericana para Promoção de Saúde Bucal e Pesquisa Odontológica (LAOHA)',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2023-02-01',\n",
       "  '2023-06-30'],\n",
       " ['NCT01848171',\n",
       "  'Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hypothyroidism|Thyroid Diseases|Endocrine System Diseases',\n",
       "  'DRUG: L-thyroxine',\n",
       "  'Shandong Provincial Hospital',\n",
       "  '',\n",
       "  '700.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2023-07'],\n",
       " ['NCT03048071',\n",
       "  'Morbimortality of Contegra Duct Replacements Versus Homografts in Pulmonary Position',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Congenital Heart Disease',\n",
       "  'OTHER: Data collection within medical files',\n",
       "  'Pierre Wauthy',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-02-14',\n",
       "  '2017-06-01'],\n",
       " ['NCT00002271',\n",
       "  'An Ascending\",\" Single Oral Dose Pharmacokinetic Study of 3\\'-Deoxy-3\\'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Alovudine',\n",
       "  'Lederle Laboratories',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT02992171',\n",
       "  'Primary Palliative Care for Patients With Advanced Hematologic Malignancies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Advanced Cancer',\n",
       "  'BEHAVIORAL: care management by oncology nurses',\n",
       "  'University of Pittsburgh',\n",
       "  'American Cancer Society\",\" Inc.',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-05-02',\n",
       "  '2020-03-19'],\n",
       " ['NCT04488471',\n",
       "  'Impact of Isolation in Patients With IBD During the COVID-19 Crisis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Inflammatory Bowel Diseases',\n",
       "  '',\n",
       "  'Sheffield Teaching Hospitals NHS Foundation Trust',\n",
       "  '',\n",
       "  '232.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-30',\n",
       "  '2022-06-30'],\n",
       " ['NCT05233371',\n",
       "  'Study of Parental Stress and Care Consumption Until 24 Months Corrected Age of Infants at a High Risk of Developmental Delay\",\" After Discharge From Neonatal Intensive Care',\n",
       "  'DeStreSs',\n",
       "  'RECRUITING',\n",
       "  'Cerebral Palsy',\n",
       "  'OTHER: Parenting Stress Index (PSI)|OTHER: Collection of health care consumption|OTHER: Assessment of parent satisfaction',\n",
       "  'Centre Hospitalier Universitaire Dijon',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-04-22',\n",
       "  '2026-04'],\n",
       " ['NCT05347771',\n",
       "  'Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents',\n",
       "  'PANDA',\n",
       "  'RECRUITING',\n",
       "  'Asthma',\n",
       "  'DRUG: Dupilumab|DRUG: Placebo',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Childhood Asthma in Urban Settings (CAUSE)|Regeneron Pharmaceuticals|Rho Federal Systems Division\",\" Inc.',\n",
       "  '240.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-05-04',\n",
       "  '2025-12-15'],\n",
       " ['NCT00337571',\n",
       "  'Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Behavioral Symptoms|Autistic Disorder',\n",
       "  'DRUG: Aripiprazole|DRUG: Placebo',\n",
       "  'Otsuka Pharmaceutical Development & Commercialization\",\" Inc.',\n",
       "  'Otsuka America Pharmaceutical',\n",
       "  '218.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-06',\n",
       "  '2008-06'],\n",
       " ['NCT04019171',\n",
       "  'EXercise Training for Reducing Anxiety in First-Time Inmates',\n",
       "  'EXTRA',\n",
       "  'COMPLETED',\n",
       "  'Anxiety State',\n",
       "  'BEHAVIORAL: exercise training',\n",
       "  'Université de Reims Champagne-Ardenne',\n",
       "  '',\n",
       "  '43.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-03-01',\n",
       "  '2018-09-03'],\n",
       " ['NCT00926471',\n",
       "  'Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Autistic Disorder|Child Development Disorders\",\" Pervasive',\n",
       "  'BEHAVIORAL: Cognitive Behavioral Therapy (CBT) Program',\n",
       "  'Virginia Polytechnic Institute and State University',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-09',\n",
       "  '2013-01'],\n",
       " ['NCT03907371',\n",
       "  'The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Radiation Injuries|Cognitive Impairment',\n",
       "  'DRUG: Donepezil Hydrochloride|OTHER: Placebo',\n",
       "  'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University',\n",
       "  '',\n",
       "  '238.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-05-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT06131671',\n",
       "  'Whole-body Electrostimulation on Functional Mobility and Quality of Life in the Elderly',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Aged',\n",
       "  'OTHER: Whole-body electrical stimulation',\n",
       "  'Federal University of Health Science of Porto Alegre',\n",
       "  'Leonhardt Ventures LLC',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01-22',\n",
       "  '2024-04-15'],\n",
       " ['NCT05393271',\n",
       "  'First-Time-in-Human (FTIH) Study to Evaluate the Safety\",\" Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: VH4011499|DRUG: Placebo|DRUG: Midazolam',\n",
       "  'ViiV Healthcare',\n",
       "  '',\n",
       "  '73.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-05-27',\n",
       "  '2023-04-24'],\n",
       " ['NCT04670471',\n",
       "  'Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia',\n",
       "  'DRUG: Remimazolam|DRUG: Remifentanil',\n",
       "  'Paion UK Ltd.',\n",
       "  'University Medical Center Groningen|QPS Holdings LLC',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2021-04-13',\n",
       "  '2022-01-28'],\n",
       " ['NCT02005471',\n",
       "  'A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)',\n",
       "  'MURANO',\n",
       "  'COMPLETED',\n",
       "  'Chronic Lymphocytic Leukemia',\n",
       "  'DRUG: Bendamustine|DRUG: Venetoclax|DRUG: Rituximab',\n",
       "  'Hoffmann-La Roche',\n",
       "  'AbbVie',\n",
       "  '389.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-03-17',\n",
       "  '2022-08-03'],\n",
       " ['NCT05740371',\n",
       "  'Safety of Argatroban Infusion in Conduction Disturbances',\n",
       "  'SAICoDis',\n",
       "  'COMPLETED',\n",
       "  'Stable Coronary Artery Disease (CAD)|Unstable Angina (Troponin Negative)',\n",
       "  'DRUG: Argatroban',\n",
       "  'Mitsubishi Tanabe Pharma GmbH',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-18',\n",
       "  '2021-05-06'],\n",
       " ['NCT01099371',\n",
       "  'Resistance Training in Knee Osteoarthritis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Knee Osteoarthritis',\n",
       "  'OTHER: exercise',\n",
       "  'Federal University of São Paulo',\n",
       "  'Fundação de Amparo à Pesquisa do Estado de São Paulo',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-02',\n",
       "  '2011-02'],\n",
       " ['NCT00058071',\n",
       "  'Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gestational Trophoblastic Tumor|Neurotoxicity|Peripheral Neuropathy|Unspecified Adult Solid Tumor\",\" Protocol Specific',\n",
       "  'DRUG: amifostine trihydrate',\n",
       "  'Gynecologic Oncology Group',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '100.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2003-03',\n",
       "  ''],\n",
       " ['NCT05484271',\n",
       "  'Relationship Between the Arthroscopic Anatomy of the Middle Glenohumeral Ligament and the Rotator Cuff Tear Position',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Rotator Cuff Tears',\n",
       "  'PROCEDURE: Rotator cuff repair',\n",
       "  'RenJi Hospital',\n",
       "  '',\n",
       "  '125.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-08-05',\n",
       "  '2022-08-28'],\n",
       " ['NCT01078571',\n",
       "  'Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis',\n",
       "  'DALI',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'BIOLOGICAL: adalimumab (HUMIRA®)',\n",
       "  'Abbott',\n",
       "  '',\n",
       "  '705.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2006-05',\n",
       "  '2010-05'],\n",
       " ['NCT05919771',\n",
       "  \"Effects of Rock Climbing on Parkinson's Disease\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Parkinson Disease',\n",
       "  'OTHER: rock climbing',\n",
       "  'Marymount University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-07-12',\n",
       "  '2024-05-31'],\n",
       " ['NCT01892371',\n",
       "  'Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'FLT3 Gene Mutation Negative|FLT3 Internal Tandem Duplication Positive|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome',\n",
       "  'DRUG: Azacitidine|DRUG: Cytarabine|OTHER: Pharmacodynamic Study|DRUG: Quizartinib',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-11-12',\n",
       "  '2023-02-07'],\n",
       " ['NCT03521271',\n",
       "  'Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Duchenne Muscular Dystrophy',\n",
       "  '',\n",
       "  'Hacettepe University',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-04-05',\n",
       "  '2018-01-26'],\n",
       " ['NCT06123871',\n",
       "  'Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Diabetic Nephropathy',\n",
       "  'OTHER: Grouping based on previous laboratory results\",\" no intervention.',\n",
       "  'Yipeng Liu',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-01',\n",
       "  '2024-01-31'],\n",
       " ['NCT03569371',\n",
       "  'A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hidradenitis Suppurativa',\n",
       "  'DRUG: INCB054707',\n",
       "  'Incyte Corporation',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-07-17',\n",
       "  '2019-04-22'],\n",
       " ['NCT00678171',\n",
       "  'A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'DEVICE: TLIF with a PEEK Spacer System and XIA Spinal System',\n",
       "  'Olympus Biotech Corporation',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-02',\n",
       "  '2010-03'],\n",
       " ['NCT02942771',\n",
       "  'A MAD Study of TT301/MW189 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Adult Volunteers',\n",
       "  'DRUG: 0.075mg/kg TT301/MW189|DRUG: 0.15mg/kg TT301MW189|DRUG: 0.25mg/kg TT301/MW189|DRUG: 0.30mg/kg TT301/MW189|DRUG: Placebo',\n",
       "  'Linda Van Eldik',\n",
       "  \"Duke Clinical Research Institute|Alzheimer's Association\",\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-20',\n",
       "  '2018-06-04'],\n",
       " ['NCT03824171',\n",
       "  'Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'DRUG: Raloxifene 60mg/Cholecalciferol 800IU|DRUG: AD-102',\n",
       "  'Addpharma Inc.',\n",
       "  '',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-02-28',\n",
       "  '2019-04-08'],\n",
       " ['NCT04908371',\n",
       "  'Selective Trunk Block vs Hybrid Interscalene Supraclavicular BPB for Anaesthesia of the Entire Upper Extremity',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Musculoskeletal Diseases or Conditions',\n",
       "  'PROCEDURE: Selective Trunk Block|PROCEDURE: Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)',\n",
       "  'Chinese University of Hong Kong',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12',\n",
       "  '2024-01'],\n",
       " ['NCT05609071',\n",
       "  'Technology of Intracranial Pressure Estimation by Single-Channel EEG in Brain Disease',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Intracranial Pressure Increase|Brain Diseases',\n",
       "  '',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-03-22',\n",
       "  '2024-12-31'],\n",
       " ['NCT00502671',\n",
       "  'A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer',\n",
       "  'DRUG: capecitabine [Xeloda]',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '228.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2012-03'],\n",
       " ['NCT05372471',\n",
       "  'Efficacy of the Digital Platform for Diabetes Care Compared to Usual Care in Patients Diagnosed With Type 2 Diabetes.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Treated With Insulin',\n",
       "  'OTHER: mHealth|OTHER: Usual Care',\n",
       "  'Hospital Universitario San Ignacio',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2020-10-01',\n",
       "  '2021-08-31'],\n",
       " ['NCT02009371',\n",
       "  'A Clinical Study of Light Therapy on Depressive Episodes of Bipolar Disorder',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depressive Episodes of Bipolar Disorder',\n",
       "  'DEVICE: Bright Light therapy|DEVICE: dim Red Light therapy',\n",
       "  'Peking University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2015-07'],\n",
       " ['NCT02559271',\n",
       "  'Pediatric Refraction With SVOne Autorefractor',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ocular Refraction',\n",
       "  '',\n",
       "  'Smart Vision Labs',\n",
       "  'State University of New York College of Optometry',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08',\n",
       "  '2015-12'],\n",
       " ['NCT00606671',\n",
       "  'Metabolic Disturbances in Polycystic Ovary Syndrome (PCOS)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Polycystic Ovary Syndrome',\n",
       "  '',\n",
       "  'Hvidovre University Hospital',\n",
       "  'Diabetesforeningen|Danish Hospital foundation for medical research. region Copenhagen\",\" The Faroe Islands and Greenland.|Aage Bangs Fond',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-02',\n",
       "  '2006-05'],\n",
       " ['NCT02772471',\n",
       "  'Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain Injuries|Intracranial Hypertension',\n",
       "  'DEVICE: HS-1000',\n",
       "  'HeadSense Medical',\n",
       "  'Oslo University Hospital',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-03',\n",
       "  '2014-12'],\n",
       " ['NCT05939271',\n",
       "  'Lower Extremity Amputations in Persons With Diabetes Mellitus in the Netherlands',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Lower Extremity Amputations|Diabetes Mellitus',\n",
       "  'PROCEDURE: lower extremity amputation',\n",
       "  'University Medical Center Groningen',\n",
       "  'Isala|Innofeet|Vektis health care information center|National Institute for Public Health and the Environment (RIVM)',\n",
       "  '2808.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-09-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT03326271',\n",
       "  'Postoperative Periprosthetic Fractures in Hip Fracture Patients: Exeter vs Anatomic SP2 Lubinus Stem',\n",
       "  'PPFEvL',\n",
       "  'COMPLETED',\n",
       "  'Femoral Neck Fractures|Periprosthetic Fractures',\n",
       "  'PROCEDURE: Exeter stem|PROCEDURE: Lubinus SP2 stem',\n",
       "  'Sundsvall Hospital',\n",
       "  'Sunderby Hospital|Karolinska Institutet',\n",
       "  '2527.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-05-04',\n",
       "  '2017-10-11'],\n",
       " ['NCT04571671',\n",
       "  'Do müllerian Anomalies Affect Embryo Implantation?',\n",
       "  'AM',\n",
       "  'COMPLETED',\n",
       "  'Uterine Diseases',\n",
       "  'OTHER: Collect retrospectively data',\n",
       "  'IVI Vigo',\n",
       "  'Instituto Valenciano de Infertilidad\",\" IVI VALENCIA',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-01-20',\n",
       "  '2019-07-25'],\n",
       " ['NCT05441371',\n",
       "  'Antibacterial Effect of Paradontax Toothpaste',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Plaque Induced Gingivitis|Plaque\",\" Dental',\n",
       "  'OTHER: Toothpaste; Paradontax',\n",
       "  'University of Oslo',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-04-21',\n",
       "  '2022-07-12'],\n",
       " ['NCT00263471',\n",
       "  'Myopia Progression and the Effect of 7-Methylxanthine',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Myopia',\n",
       "  'DRUG: 7-methylxanthine',\n",
       "  'Trier Research Laboratories',\n",
       "  'Generalkonsul Einar Høyvalds Fond|Jørgen Bagenkop Nielsens Myopi-Fond|Chr. Andersen og hustru Ingeborg Andersen\", f. Schmidts legat (fond) oprettet af deres datter,\" frk. Lilli Ellen Andersen.',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '2003-10',\n",
       "  '2006-03'],\n",
       " ['NCT05089071',\n",
       "  'Effect of Two Colonoscopy AI Systems for Colon Polyp Detection',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Adenoma|Colonoscopy|Sessile Serrated Adenoma',\n",
       "  'DEVICE: Assist by artificial intelligence system for colon polyp detection',\n",
       "  'Seoul National University Hospital',\n",
       "  'Seoul National University',\n",
       "  '3046.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-11-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT02563171',\n",
       "  'Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Periodontitis',\n",
       "  'OTHER: non surgical periodontal treatment|OTHER: Gingival crevicular fluid collection',\n",
       "  'Umut BALLI',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2015-05'],\n",
       " ['NCT01836471',\n",
       "  'A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: QAW039|DRUG: Placebo QAW039|DRUG: Fluticasone 250 mcg|DRUG: Fluticasone 100 mcg',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '345.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2016-02'],\n",
       " ['NCT03798171',\n",
       "  'Reduction of Exit Site Infection in Peritoneal Dialysis Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Peritoneal Dialysis Catheter Infection',\n",
       "  '',\n",
       "  'Tel-Aviv Sourasky Medical Center',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-05-15',\n",
       "  '2021-05-15'],\n",
       " ['NCT04851171',\n",
       "  'Semi-rigid Ureteroscopy Versus Flexible Ureteroscopy For the Treatment of Proximal Ureteric Stone',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ureteric Stone|Stone Ureter',\n",
       "  'PROCEDURE: Flexible Ureteroscopy|PROCEDURE: Semi-rigid Ureteroscopy',\n",
       "  'Hamad Medical Corporation',\n",
       "  '',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-11-26',\n",
       "  '2023-01'],\n",
       " ['NCT04595071',\n",
       "  'Functional Outcomes of Voice Recognition Prosthesis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prosthesis|Amputation|Prosthesis User',\n",
       "  'DEVICE: Voice Activated Prosthetic Interface (VAPI) Controller',\n",
       "  'Liberating Technologies\",\" Inc.',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "  '4.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2019-11-13',\n",
       "  '2020-06-30'],\n",
       " ['NCT03837171',\n",
       "  'TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock',\n",
       "  'TRANSPORT',\n",
       "  'UNKNOWN',\n",
       "  'Septic Shock|Anemia|Cancer',\n",
       "  'BIOLOGICAL: Liberal Red blood cell transfusion|BIOLOGICAL: Restrictive Red blood cell transfusion',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '260.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-03-24',\n",
       "  '2022-02-20'],\n",
       " ['NCT04467671',\n",
       "  'Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts',\n",
       "  'TEVG-2',\n",
       "  'RECRUITING',\n",
       "  'HLH - Hypoplastic Left Heart Syndrome|DORV|DILV - Double Inlet Left Ventricle|Mitral Atresia|Tricuspid Atresia|Unbalanced AV Canal|Single-ventricle|Heart Defects\",\" Congenital|Cardiovascular Abnormalities|Cardiovascular Diseases|Heart Diseases',\n",
       "  'COMBINATION_PRODUCT: Tissue Engineered Vascular Grafts',\n",
       "  \"Nationwide Children's Hospital\",\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)|Gunze Limited|National Institutes of Health (NIH)',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-07-15',\n",
       "  '2027-08'],\n",
       " ['NCT05287971',\n",
       "  'Standard of Care Lifestyle Support for Stage III NSCLC Patients',\n",
       "  'PERCUSSION',\n",
       "  'WITHDRAWN',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'BEHAVIORAL: Lifestyle advice',\n",
       "  'Maastricht Radiation Oncology',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-08-01',\n",
       "  '2025-05-01'],\n",
       " ['NCT00776971',\n",
       "  'Effect of Carbonated Soft Drinks on Appetite-Regulation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Diet',\n",
       "  'OTHER: Sugar-sweetened soft drink|OTHER: Aspartame-sweetened soft drink|OTHER: Semi-skimmed milk|OTHER: Water',\n",
       "  'Aarhus University Hospital',\n",
       "  'LG Life Sciences',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2007-11',\n",
       "  '2008-09'],\n",
       " ['NCT05026671',\n",
       "  'The Effect of The Use of a Videolaryngoscope and/or Stylet on Intubation Time in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Intubation Time',\n",
       "  'PROCEDURE: Endotracheal Tube Alone|PROCEDURE: Endotracheal Tube+ Stylet|PROCEDURE: Endotracheal Tube + Video-laryngoscope|PROCEDURE: Endotracheal tube + stylet with Video-laryngoscope',\n",
       "  'Karaman Training and Research Hospital',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-09-01',\n",
       "  '2022-04-30'],\n",
       " ['NCT05935371',\n",
       "  'Consequences of Obstetric Anal Sphincter Injuries on Maternal Psychology and Relationship Experience',\n",
       "  'COMPaRE',\n",
       "  'RECRUITING',\n",
       "  'Obstetric Complication|Obstetric Trauma|Perineal Tear|Incontinence|Mental Health Impairment|Relation\", Family|Relation,\" Mother-Child',\n",
       "  '',\n",
       "  'London North West Healthcare NHS Trust',\n",
       "  'Imperial College Healthcare NHS Trust',\n",
       "  '87.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10-26',\n",
       "  '2025-10'],\n",
       " ['NCT00059371',\n",
       "  'Male Circumcision and HIV Rates in Kenya',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'PROCEDURE: male circumcision',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '2887.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2002-02',\n",
       "  '2006-12'],\n",
       " ['NCT01629771',\n",
       "  'Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphatic Filariasis',\n",
       "  '',\n",
       "  'Northwestern University',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-05',\n",
       "  '2012-06'],\n",
       " ['NCT01072071',\n",
       "  'The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Intra-Abdominal Hypertension',\n",
       "  'DRUG: furosemide',\n",
       "  'Ziekenhuis Netwerk Antwerpen (ZNA)',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2012-03'],\n",
       " ['NCT02032771',\n",
       "  'Impact of M22 Synergistic Sequential Treatment (SST)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Improvement of Wrinkles/Elastosis and/or Pigmentation',\n",
       "  'DEVICE: M22 IPL and ResurFX',\n",
       "  'Lumenis Be Ltd.',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2016-02'],\n",
       " ['NCT05765071',\n",
       "  'Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Chronic Exertional Compartment Syndrome',\n",
       "  'BIOLOGICAL: Botulinum toxin A|BIOLOGICAL: Normal saline',\n",
       "  'University of Calgary',\n",
       "  'Canadian Academy of Sport and Exercise Medicine (CASEM)|Kinesis Medical Centre Inc.',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-06-01',\n",
       "  '2024-06'],\n",
       " ['NCT03761771',\n",
       "  'Artificial Intelligence Identifying Polyps in Real-world Colonoscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sensitivity of the ADS in Identifying Polyps in Real-world Colonoscopy|Mean Number of Polyps Per Colonoscopy for Colonoscopists and Colonoscopists + ADS',\n",
       "  'DEVICE: colonoscopy withdrawal with the ADS monitoring',\n",
       "  'Zhaoshen Li',\n",
       "  '',\n",
       "  '209.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-11-01',\n",
       "  '2018-12-10'],\n",
       " ['NCT03297671',\n",
       "  'The Prevention of Rh Disease of Newborns in Pakistan',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rhesus Disease|Anti-D (Rh) Antibodies Affecting Care of Mother',\n",
       "  'DRUG: RhIg prophylaxis|DEVICE: ELDONCARD|DIAGNOSTIC_TEST: ELDONCARD Test',\n",
       "  'Aga Khan University',\n",
       "  'The Hospital for Sick Children|Grand Challenges Canada',\n",
       "  '1654.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-06-27',\n",
       "  '2020-02-28'],\n",
       " ['NCT00865371',\n",
       "  'A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Abrika Bupropion 150 mg Extended-Released Tablet|DRUG: Wellbutrin SR® 150 mg Extended-Release Tablet\",\" single dose',\n",
       "  'Actavis Inc.',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2004-09',\n",
       "  '2004-09'],\n",
       " ['NCT00420771',\n",
       "  'Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benzodiazepine Dependence|Opioid Dependence',\n",
       "  'DRUG: Gabapentin|DRUG: Placebo',\n",
       "  'New York State Psychiatric Institute',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '19.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-01',\n",
       "  '2011-01'],\n",
       " ['NCT03175471',\n",
       "  'MRI Based Biomarkers in Pediatric Autoimmune Liver Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Autoimmune Liver Disease|Primary Sclerosing Cholangitis|Autoimmune Hepatitis',\n",
       "  '',\n",
       "  'Children\\'s Hospital Medical Center\",\" Cincinnati',\n",
       "  '',\n",
       "  '115.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-17',\n",
       "  '2027-01-30'],\n",
       " ['NCT02420171',\n",
       "  'Adding Insulin to IVF Culture Media Significantly Improve Outcome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infertility',\n",
       "  'OTHER: Adding insulin to In Vitro culture media',\n",
       "  'Ibn Sina Hospital',\n",
       "  'Banon IVF Center Assiut\",\" Egypt',\n",
       "  '360.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-01',\n",
       "  '2015-12'],\n",
       " ['NCT02768571',\n",
       "  'Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'DRUG: Cerebrolysin|DRUG: Placebo',\n",
       "  'Samsung Medical Center',\n",
       "  'Ever Neuro Pharma GmbH',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-03-14',\n",
       "  '2019-02-14'],\n",
       " ['NCT00563771',\n",
       "  'Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hyperuricemia',\n",
       "  'DRUG: Rasburicase',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '38.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-03',\n",
       "  '2004-01'],\n",
       " ['NCT02226471',\n",
       "  'Serum CTRP3 and RBP4 Levels in Obesity and Hypertension',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Hypertension',\n",
       "  '',\n",
       "  'Third Military Medical University',\n",
       "  '',\n",
       "  '2000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-03',\n",
       "  '2014-02'],\n",
       " ['NCT04965571',\n",
       "  \"Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Wilson Disease|Generalized Epilepsy',\n",
       "  'GENETIC: genetic test',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-09-01',\n",
       "  '2019-03-01'],\n",
       " ['NCT00346671',\n",
       "  'Effects of Reiki on Stress',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stress',\n",
       "  'OTHER: Rest|OTHER: Sham|OTHER: Reiki',\n",
       "  'The Cleveland Clinic',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '257.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2010-06'],\n",
       " ['NCT04647071',\n",
       "  'Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Immunity',\n",
       "  'DIETARY_SUPPLEMENT: Garlic and onion concentrate|DIETARY_SUPPLEMENT: Control',\n",
       "  'DOMCA S.A.',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-11-16',\n",
       "  '2022-01-31'],\n",
       " ['NCT01861171',\n",
       "  'Effect of Green Tea in Obese Pre-hypertensive Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obese|Hypertension',\n",
       "  'DIETARY_SUPPLEMENT: Green Tea',\n",
       "  'Rio de Janeiro State University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2010-07',\n",
       "  '2012-09'],\n",
       " ['NCT04301271',\n",
       "  'Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression',\n",
       "  'SIMCODE',\n",
       "  'RECRUITING',\n",
       "  'Depressive Disorder\",\" Major|Obesity',\n",
       "  'DRUG: Simvastatin 40mg|DRUG: Placebo oral tablet',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  'NeuroCure Clinical Research Center\", Charite,\" Berlin|University Medical Center Goettingen',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-08-13',\n",
       "  '2025-02'],\n",
       " ['NCT05268471',\n",
       "  'Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Obstructive Sleep Apnea of Adult',\n",
       "  'DEVICE: Positional device (PD)|DEVICE: Continuos Positive Airway Pressure (CPAP)',\n",
       "  'Hospital Universitario Ramon y Cajal',\n",
       "  'Philips Healthcare',\n",
       "  '154.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-10-01',\n",
       "  '2024-12-01'],\n",
       " ['NCT05399771',\n",
       "  'Radiofrequency Hyperthermia Safety Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Pain|Soft Tissue Injuries|Wound Heal|Blood Flow',\n",
       "  'DEVICE: Laser Doppler|DEVICE: Radiofrequency Heating System|DEVICE: Thermal Imaging|OTHER: Healthcare Questionnaire & Measurement',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'Thermofield',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-06-27',\n",
       "  '2024-04'],\n",
       " ['NCT05308771',\n",
       "  '\"\"To Investigate the Use of a New Syringe \"\"\"\"Visual Pressure Control (VPC)\"\"\"\" for Epidural Anesthesia in Children Surgery\"\"',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Abdominal Hernia|Abdominal Wall Defect|Abdominal Neoplasm|Urogenital Disease|Urologic Neoplasms|Thoracic Diseases|Lung Diseases',\n",
       "  'DEVICE: VPC syringe',\n",
       "  'Centre Hospitalier Universitaire de Tivoli',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-03-25',\n",
       "  '2022-09'],\n",
       " ['NCT05403671',\n",
       "  'Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer Survivor',\n",
       "  'OTHER: Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer',\n",
       "  'Turku University Hospital',\n",
       "  'Lounais-Suomen Syöpäyhdistys',\n",
       "  '50.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-09-01',\n",
       "  '2024-05-31'],\n",
       " ['NCT01147471',\n",
       "  'Flail Chest - Rib Fixation Study',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Flail Chest',\n",
       "  'DEVICE: operative rib fixation|PROCEDURE: operative rib fixation surgery',\n",
       "  'Virginia Commonwealth University',\n",
       "  'Synthes Inc.',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ',\n",
       "  '2010-09',\n",
       "  '2014-08'],\n",
       " ['NCT04046471',\n",
       "  'Weight Loss Physical Disabilities',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Physical Disability',\n",
       "  'DIETARY_SUPPLEMENT: enhanced Stop Light Diet|BEHAVIORAL: Group Remote|BEHAVIORAL: Individual In-Person',\n",
       "  'University of Kansas Medical Center',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-02-01',\n",
       "  '2024-06-20'],\n",
       " ['NCT03709771',\n",
       "  'Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Renal Cell Carcinoma|Hypertension|Melanoma|Cancer',\n",
       "  'DIAGNOSTIC_TEST: Ambulatory Blood Pressure Measurement',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-09',\n",
       "  '2020-10-01'],\n",
       " ['NCT00995371',\n",
       "  'Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lumbar Spinal Stenosis',\n",
       "  'DEVICE: MILD® (Minimally Invasive Lumbar Decompression)|DRUG: Epidural Steroid Injection',\n",
       "  'Coastal Orthopedics & Sports Medicine',\n",
       "  'Vertos Medical\",\" Inc.',\n",
       "  '38.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2013-05'],\n",
       " ['NCT01075971',\n",
       "  'Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid Dependency',\n",
       "  'DRUG: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|DRUG: Buprenorphine hydrochloride fast dissolving tablet (FDT)',\n",
       "  'Indivior Inc.',\n",
       "  'Reckitt Benckiser LLC',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-09',\n",
       "  '2005-11'],\n",
       " ['NCT01790971',\n",
       "  'Spinal Morphine for Patients With Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Obstructive Sleep Apnea',\n",
       "  'DRUG: Intrathecal Morphine|DRUG: No Intrathecal Morphine',\n",
       "  'University Health Network\",\" Toronto',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2020-08'],\n",
       " ['NCT01242371',\n",
       "  'Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizoaffective Disorder',\n",
       "  'DIETARY_SUPPLEMENT: Probiotic Supplement|DIETARY_SUPPLEMENT: Identical-appearing Placebo',\n",
       "  'Sheppard Pratt Health System',\n",
       "  'Stanley Medical Research Institute',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-08',\n",
       "  '2012-08'],\n",
       " ['NCT03618771',\n",
       "  'A Functional Comparison of Two TKR Designs',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Knee Osteoarthritis',\n",
       "  'DEVICE: Total knee arthroplasty',\n",
       "  'Manchester University NHS Foundation Trust',\n",
       "  'Medacta International SA',\n",
       "  '170.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-02-06',\n",
       "  '2024-08-01'],\n",
       " ['NCT04791371',\n",
       "  'Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes',\n",
       "  'REACH',\n",
       "  'RECRUITING',\n",
       "  'Type 2 Diabetes|Overweight and Obesity',\n",
       "  'BEHAVIORAL: Cardiovascular exercise',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  'University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-06-17',\n",
       "  '2027-12-01'],\n",
       " ['NCT00017771',\n",
       "  'Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Peripheral Nervous System Disease',\n",
       "  '',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2001-06',\n",
       "  '2004-07'],\n",
       " ['NCT00659971',\n",
       "  'Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Oral Candidiasis',\n",
       "  'DRUG: PAC113',\n",
       "  'Pacgen Biopharmaceuticals Corporation',\n",
       "  'Quintiles\",\" Inc.',\n",
       "  '223.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2008-06'],\n",
       " ['NCT05328271',\n",
       "  'A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion',\n",
       "  'BBA',\n",
       "  'COMPLETED',\n",
       "  'Absorption; Chemicals',\n",
       "  'DIETARY_SUPPLEMENT: Beta-Aminoisobutyric Acid',\n",
       "  'Lindenwood University',\n",
       "  'NNB Nutrition',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: OTHER',\n",
       "  '2020-11-20',\n",
       "  '2022-02-01'],\n",
       " ['NCT02595671',\n",
       "  'B-slim\",\" a Multi-source Digital Super Coach for Sustainable Weight Loss',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity',\n",
       "  'OTHER: Digital Super Coach|OTHER: Conventional face to face PA & dietitian|OTHER: Digital Super Coach + minimal coaching|OTHER: Waiting Group',\n",
       "  'Universitaire Ziekenhuizen KU Leuven',\n",
       "  'KU Leuven|iMinds|Brand New Health|Yorbody|Delhaize',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2016-04'],\n",
       " ['NCT05688371',\n",
       "  'Dexmedetomidine Plus Low Dose Morphine Versus Standard Dose of Morphine in PCA in Children .',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'PCA|Children|Dexmedetomidine|Morphine',\n",
       "  'DRUG: standard dose morphine|DRUG: low dose morphine plus dexmedetomidine',\n",
       "  'Beni-Suef University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2023-02-01',\n",
       "  '2024-03'],\n",
       " ['NCT05737771',\n",
       "  'To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'FDC|Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: DWC202213|DRUG: DWJ1563|DRUG: DWP16001',\n",
       "  'Daewoong Pharmaceutical Co. LTD.',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-25',\n",
       "  '2023-06-30'],\n",
       " ['NCT00132171',\n",
       "  'Helicobacter Pylori Eradication With a New Sequential Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Helicobacter Pylori Infection|Non Ulcer Dyspepsia|Duodenal Ulcer|Gastric Ulcer|Chronic Active Gastritis|Gastritis',\n",
       "  'DRUG: Sequential therapy',\n",
       "  'IRCCS Azienda Ospedaliero-Universitaria di Bologna',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-01',\n",
       "  '2001-12'],\n",
       " ['NCT05499871',\n",
       "  'Effect of a Gait Retraining Intervention and a Minimalist Footwear Transition on Foot-ankle Strength\",\" Running Economy and Injury in Endurance Runners.',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Running|Wounds and Injuries|Oxygen Consumption',\n",
       "  'BEHAVIORAL: Gait retraining intervention|DEVICE: Transition to minimalist footwear.',\n",
       "  'University of Liege',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-06-01',\n",
       "  '2024-09-30'],\n",
       " ['NCT01521871',\n",
       "  'Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors',\n",
       "  'TG-CYANO',\n",
       "  'COMPLETED',\n",
       "  'Skin Closure of Surgical Incisions by Tissue Glue vs Suture',\n",
       "  'PROCEDURE: Skin wound closure by tissue glue|PROCEDURE: Skin wound closure by conventional suture + dressing',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2013-02'],\n",
       " ['NCT04049071',\n",
       "  'TARGET GCAT Registry',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Giant Cell Arteritis',\n",
       "  '',\n",
       "  'University of Leeds',\n",
       "  'University of Oxford|Hoffmann-La Roche',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-13',\n",
       "  '2020-06-30'],\n",
       " ['NCT02841371',\n",
       "  'Early Screening and Diagnosis of CKD',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Kidney; Disease (Functional)|Chronic Kidney Disease',\n",
       "  'RADIATION: 99mTc-DTPA',\n",
       "  'Nanjing First Hospital\",\" Nanjing Medical University',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-08-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT05889871',\n",
       "  'A Randomized\", Controlled,\" Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'HR+/HER2-breast Cancer',\n",
       "  'DRUG: Standard endocrine therapy plus Apatinib',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '916.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-06-01',\n",
       "  '2026-06-01'],\n",
       " ['NCT02234271',\n",
       "  'Plan A Birth Control: Randomized Controlled Trial of a Mobile Health Application for Contraception Information',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mobile Applications|Contraception|Contraception Behavior',\n",
       "  'OTHER: Mobile Health Application|OTHER: Health Educator Counseling',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2012-09',\n",
       "  '2013-08'],\n",
       " ['NCT06067971',\n",
       "  'Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery\",\" by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)',\n",
       "  'ENDORA2',\n",
       "  'RECRUITING',\n",
       "  'Myoma;Uterus|Adenomyoma of Uterus',\n",
       "  'DEVICE: Laparoscopic surgery with augmented reality device',\n",
       "  'University Hospital\",\" Clermont-Ferrand',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-03-29',\n",
       "  '2024-03-29'],\n",
       " ['NCT03730571',\n",
       "  'The AbsorbaSeal Vascular Closure Device Trial',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'DEVICE: AbsorbaSeal 6Fr Vascular Closure Device',\n",
       "  'ID3 Medical',\n",
       "  'CyndRx\",\" LLC',\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2017-08-16',\n",
       "  '2019-04-11'],\n",
       " ['NCT06160271',\n",
       "  'Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis',\n",
       "  'HEFITEP',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Non-alcoholic Steatohepatitis',\n",
       "  'DRUG: PET scan of 68Ga-FAPI',\n",
       "  'Central Hospital\", Nancy,\" France',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2024-09-01',\n",
       "  '2027-06-01'],\n",
       " ['NCT05281471',\n",
       "  'Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime\",\" GOG-3076)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Platinum-resistant Ovarian Cancer|Platinum-refractory Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|High-grade Serous Ovarian Cancer|Endometrioid Ovarian Cancer|Ovarian Clear Cell Carcinoma',\n",
       "  'BIOLOGICAL: olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin|DRUG: Non-platinum chemotherapy: Physician\\'s Choice of gemcitabine\", taxane (paclitaxel,\" docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|DRUG: Bevacizumab (or biosimilar)',\n",
       "  'Genelux Corporation',\n",
       "  'GOG Foundation',\n",
       "  '186.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-31',\n",
       "  '2026-10'],\n",
       " ['NCT02002871',\n",
       "  'Blue Light for Treating Eczema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Eczema',\n",
       "  'DEVICE: PSO-CT02 device',\n",
       "  'Philips Electronics Nederland BV',\n",
       "  '',\n",
       "  '21.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-10',\n",
       "  '2014-03'],\n",
       " ['NCT05817071',\n",
       "  'Results of Arthroscopic Massive Rotator Cuff Tears Repair With or Without Using Long Head of Biceps Tendon',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Rotator Cuff Tears',\n",
       "  'PROCEDURE: Arthroscopic massive rotator cuff repair|PROCEDURE: Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon',\n",
       "  'Ain Shams University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-15',\n",
       "  '2024-01-14'],\n",
       " ['NCT02669771',\n",
       "  'Long-Term Specified Drug Use-Results Survey for Xtandi Capsule',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Castration-resistant Prostate Cancer',\n",
       "  'DRUG: enzalutamide',\n",
       "  'Astellas Pharma Inc',\n",
       "  'Pfizer',\n",
       "  '1018.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-11-30',\n",
       "  '2018-11-30'],\n",
       " ['NCT05463471',\n",
       "  'Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Shock',\n",
       "  'DRUG: Compound sodium acetate ringer injection|DRUG: Albumin',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  '',\n",
       "  '500.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2027-12-12'],\n",
       " ['NCT02173171',\n",
       "  'Registry Study for Talimogene Laherparepvec',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial',\n",
       "  'OTHER: Information collection',\n",
       "  'Amgen',\n",
       "  '',\n",
       "  '185.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-04-27',\n",
       "  '2021-09-23'],\n",
       " ['NCT05677971',\n",
       "  'Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Alpha1-Antitrypsin Deficiency',\n",
       "  'DRUG: Fazirsiran Injection|OTHER: Placebo',\n",
       "  'Takeda',\n",
       "  'Takeda Development Center Americas\",\" Inc.',\n",
       "  '160.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-03-06',\n",
       "  '2029-03-31'],\n",
       " ['NCT04752371',\n",
       "  \"A Study to Evaluate Camoteskimab in Participants With Still's Disease\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  \"Adult Onset Still's Disease\",\n",
       "  'DRUG: Camoteskimab (CERC-007\", AVTX-007,\" AEVI-007)',\n",
       "  'Apollo Therapeutics Ltd',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-03-25',\n",
       "  '2022-05-24'],\n",
       " ['NCT01241071',\n",
       "  'Effects of Myofascial Release on Pain\",\" Disability and Electromyography of Erector Spinae in Chronic Low Back Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Back Pain|Disability|Motor Activity|Range of Motion',\n",
       "  'OTHER: myofascial treatment|OTHER: Placebo',\n",
       "  'Cardenal Herrera University',\n",
       "  'Hospital Arnau de Vilanova',\n",
       "  '54.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-01',\n",
       "  '2013-03'],\n",
       " ['NCT02065271',\n",
       "  'Herbal Preparation and Glucose Homeostasis',\n",
       "  'Herbie',\n",
       "  'COMPLETED',\n",
       "  'Glucose Tolerance|Lipid Homeostasis|Vascular Function|Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: herbal supplement|OTHER: placebo supplement',\n",
       "  'Wageningen University',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-09',\n",
       "  '2014-02'],\n",
       " ['NCT03991871',\n",
       "  'HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study',\n",
       "  'HARTEC',\n",
       "  'UNKNOWN',\n",
       "  'Cardiac Rehabilitation|Angiogenesis|Refractory Angina',\n",
       "  'DEVICE: External Counter Pulsation (ECP) therapy',\n",
       "  'National Cardiovascular Center Harapan Kita Hospital Indonesia',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-01',\n",
       "  '2020-08-01'],\n",
       " ['NCT00102271',\n",
       "  'Nitrite Infusion Studies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Oxypurinol|DRUG: Sodium Nitrite',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2005-01-19',\n",
       "  '2011-04-12'],\n",
       " ['NCT01871571',\n",
       "  'Bevacizumab\", Fluorouracil, Leucovorin Calcium,\" and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer',\n",
       "  'BIOLOGICAL: bevacizumab|DRUG: oxaliplatin|DRUG: leucovorin calcium|DRUG: fluorouracil|OTHER: laboratory biomarker analysis',\n",
       "  'University of Southern California',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '17.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-08-02',\n",
       "  '2023-06-24'],\n",
       " ['NCT01573871',\n",
       "  'Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infant|Gastrointestinal Intolerance',\n",
       "  'OTHER: Experimental Hydrolyzed infant formula',\n",
       "  'Abbott Nutrition',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-02',\n",
       "  '2012-09'],\n",
       " ['NCT01082471',\n",
       "  'An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Morphine 6-glucuronide|DRUG: Morphine',\n",
       "  'Paion UK Ltd.',\n",
       "  'Chiltern International Ltd.|HFL Ltd.',\n",
       "  '517.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-11',\n",
       "  '2006-12'],\n",
       " ['NCT04913571',\n",
       "  'Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study',\n",
       "  'TEMPLATE',\n",
       "  'UNKNOWN',\n",
       "  'Triple Negative Breast Cancer',\n",
       "  'DRUG: Eribulin|DRUG: Tislelizumab',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '265.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-05-27',\n",
       "  '2023-06-01'],\n",
       " ['NCT03025971',\n",
       "  'Safety & Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aortic Valve Disease',\n",
       "  'DEVICE: J-Valve Transcatheter Aortic valve replacement',\n",
       "  'JC Medical\",\" Inc.',\n",
       "  '',\n",
       "  '107.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-03',\n",
       "  '2020-04'],\n",
       " ['NCT00799071',\n",
       "  'Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)',\n",
       "  'iPOD',\n",
       "  'COMPLETED',\n",
       "  'Chronic Granulomatous Disease',\n",
       "  'DRUG: posaconazole (PSZ)',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2009-02',\n",
       "  '2010-08'],\n",
       " ['NCT00584571',\n",
       "  'SAT vs Escitalopram for Rectal Hypersensitivity',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rectal Hypersensitivity|Irritable Bowel Syndrome-Constipation',\n",
       "  'PROCEDURE: Sensory Adaptation Training|DRUG: Escitalopram Therapy',\n",
       "  'Augusta University',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '55.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2019-12-31'],\n",
       " ['NCT00390871',\n",
       "  'Acute Neurological ICU Sedation Trial (ANIST)',\n",
       "  'ANIST',\n",
       "  'COMPLETED',\n",
       "  'Sedation',\n",
       "  'DRUG: Fentanyl/Dexmedetomidine|DRUG: Fentanyl/Propofol|DRUG: Fentanyl',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2007-12'],\n",
       " ['NCT04706871',\n",
       "  'Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Functional Dyspepsia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Functional Dyspepsia',\n",
       "  'DEVICE: taVNS|DEVICE: tnVNS',\n",
       "  'Beijing Tongren Hospital',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-07-01',\n",
       "  '2020-01-01'],\n",
       " ['NCT05200871',\n",
       "  'Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)',\n",
       "  'HONUS',\n",
       "  'COMPLETED',\n",
       "  'Focal Segmental Glomerulosclerosis|Immunoglobulin A Nephropathy',\n",
       "  '',\n",
       "  'Travere Therapeutics\",\" Inc.',\n",
       "  '',\n",
       "  '290.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-02-05',\n",
       "  '2023-10-31'],\n",
       " ['NCT04160871',\n",
       "  '\"\"\"\"\"\"Family Connections\"\"\"\": a Program for Relatives of People With Borderline Personality Disorder\"\"',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Relatives',\n",
       "  'BEHAVIORAL: Family Connections|BEHAVIORAL: Treatment As Usual',\n",
       "  'Universitat Jaume I',\n",
       "  'University of Valencia',\n",
       "  '124.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-11-15',\n",
       "  '2020-09'],\n",
       " ['NCT01924871',\n",
       "  'Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Deep Extubation',\n",
       "  'DRUG: Desflurane with remifentanil|DRUG: Desflurane',\n",
       "  'Chung-Ang University Hosptial\",\" Chung-Ang University College of Medicine',\n",
       "  '',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2014-03'],\n",
       " ['NCT04532671',\n",
       "  'Evaluation of Clinical Performance of 3D Printed Polyether Ether Ketone (PEEK) Inlays',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Occlusal Caries',\n",
       "  'OTHER: Poly ether ether ketone (PEEK)|OTHER: CADCAM Poly ether ether ketone (PEEK)|OTHER: indirect resin composite',\n",
       "  'Cairo University',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-10-01',\n",
       "  '2022-10-01'],\n",
       " ['NCT01424371',\n",
       "  'Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Influenza',\n",
       "  '',\n",
       "  'Fraser Health',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-11',\n",
       "  '2013-06'],\n",
       " ['NCT02829671',\n",
       "  'Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas',\n",
       "  'SOLSTIS',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorders',\n",
       "  'OTHER: Clinical and biological assessment',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2016-10-11',\n",
       "  '2020-06-24'],\n",
       " ['NCT01824771',\n",
       "  'Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Kidney Injury\",\" Acute',\n",
       "  'OTHER: Plasma lactate were measured',\n",
       "  'First Affiliated Hospital\",\" Sun Yat-Sen University',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-03-03',\n",
       "  '2015-03-20'],\n",
       " ['NCT06035471',\n",
       "  'Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Pathological Response Rate\",\" Circulating Tumour DNA',\n",
       "  'DIAGNOSTIC_TEST: MeD-seq',\n",
       "  'Erasmus Medical Center',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10-01',\n",
       "  '2027-06-01'],\n",
       " ['NCT02317471',\n",
       "  'Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastric Carcinoma',\n",
       "  'BIOLOGICAL: autologous gp96 vaccination|DRUG: Oxaliplatin+S-1',\n",
       "  'Chinese PLA General Hospital',\n",
       "  'Cure&Sure Biotech Co.\",\" LTD',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-11',\n",
       "  '2017-12'],\n",
       " ['NCT01244971',\n",
       "  'Exercise and Acarbose in Type 2 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus Type 2',\n",
       "  'DRUG: Acarbose|BEHAVIORAL: Exercise|OTHER: Exercise + Acarbose',\n",
       "  'Karolinska Institutet',\n",
       "  'The Swedish Research Council|Bayer',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-01',\n",
       "  ''],\n",
       " ['NCT01634971',\n",
       "  'External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)',\n",
       "  'EDIDPD',\n",
       "  'UNKNOWN',\n",
       "  'Postoperative Fistula|Complications of Surgical and Medical Care: General Terms',\n",
       "  'PROCEDURE: Internal Drainage of Pancreatic Duct after pancreatomy',\n",
       "  'Tianjin Medical University Cancer Institute and Hospital',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-05',\n",
       "  '2016-12'],\n",
       " ['NCT04654871',\n",
       "  'Effects of Glucosamine and Chondroitin Sulfate Supplementation in Addition to Resistance Exercise Training and Manual Therapy in Patients With Knee Osteoarthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Osteoarthritis\",\" Knee',\n",
       "  'DIETARY_SUPPLEMENT: Chondroitin Sulfate|PROCEDURE: Resistance exercise training|PROCEDURE: Manual therapy / Joint Mobilization|PROCEDURE: THE therapy',\n",
       "  'Foundation University Islamabad',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01-01',\n",
       "  '2020-11-01'],\n",
       " ['NCT03547271',\n",
       "  'Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Meningococcal Infections',\n",
       "  'BIOLOGICAL: MenACYW conjugate vaccine|BIOLOGICAL: Meningococcal group A\", C, W-135,\" and Y conjugate vaccine|BIOLOGICAL: DTaP-IPV-HB-Hib vaccine|BIOLOGICAL: Pneumococcal vaccine (13-valent)|BIOLOGICAL: Pneumococcal vaccine (10-valent)|BIOLOGICAL: MMR vaccine',\n",
       "  'Sanofi Pasteur\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '1660.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2018-12-14',\n",
       "  '2023-05-17'],\n",
       " ['NCT03089671',\n",
       "  'Ureteric Visualization: Vitamin B Vs 5% Dextrose in Water',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pelvic Floor Disorders|Ureter; Kink',\n",
       "  'OTHER: Vitamin B (riboflavin\",\" vitamin B2)|OTHER: 5% Dextrose in Water (D5W)',\n",
       "  'Mount Sinai Hospital\",\" Canada',\n",
       "  \"Sunnybrook Health Sciences Centre|Women's College Hospital\",\n",
       "  '238.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2017-12-07',\n",
       "  '2021-07-21'],\n",
       " ['NCT04289571',\n",
       "  'Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cone-Rod Degeneration|Rod-Cone Degeneration',\n",
       "  'DIAGNOSTIC_TEST: VR Motility Tool',\n",
       "  'National Eye Institute (NEI)',\n",
       "  '',\n",
       "  '165.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-07-25',\n",
       "  '2030-12-31'],\n",
       " ['NCT01473771',\n",
       "  'Caring Letters for Military Suicide Prevention',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Suicide|Suicide\",\" Attempted',\n",
       "  'BEHAVIORAL: Caring Letter (email)',\n",
       "  'National Center for Telehealth and Technology',\n",
       "  'United States Department of Defense|U.S. Army Medical Research and Development Command',\n",
       "  '1319.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2011-11',\n",
       "  '2018-08'],\n",
       " ['NCT03961971',\n",
       "  'Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Glioblastoma Multiforme',\n",
       "  'DRUG: MBG453',\n",
       "  'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-18',\n",
       "  '2025-09'],\n",
       " ['NCT02232971',\n",
       "  'Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes',\n",
       "  'GluST1',\n",
       "  'UNKNOWN',\n",
       "  'Diabetes Mellitus\",\" Type 1',\n",
       "  'DRUG: Glucagon|OTHER: Isotonic saline solution',\n",
       "  'Hvidovre University Hospital',\n",
       "  'The Novo Nordic Foundation|University of Copenhagen',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2014-09',\n",
       "  '2015-07'],\n",
       " ['NCT03829371',\n",
       "  'STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: Velcade|DRUG: Melphalan|DRUG: Prednisone|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Daratumumab',\n",
       "  'University of Turin\",\" Italy',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-03',\n",
       "  '2030-01-03'],\n",
       " ['NCT05810571',\n",
       "  'Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Renal Cell Carcinoma',\n",
       "  'PROCEDURE: preoperative remifentanil consumption|PROCEDURE: postopeartive controlled anlagesia with morphine',\n",
       "  'Kocaeli University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-03-01',\n",
       "  '2024-04-03'],\n",
       " ['NCT04613271',\n",
       "  'Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia',\n",
       "  'FVR',\n",
       "  'COMPLETED',\n",
       "  'Infectious Disease|SARS-CoV Infection|Covid19',\n",
       "  'DRUG: Favipiravir|DRUG: Azithromycin',\n",
       "  'Ina-Respond',\n",
       "  'Center for Research and Development of Health Resources and Services\", National Institute of Health Research and Development (NIHRD),\" Indonesia',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-10-15',\n",
       "  '2021-11-08'],\n",
       " ['NCT06142071',\n",
       "  'Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting',\n",
       "  'SALUTE',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer',\n",
       "  'BEHAVIORAL: Telephone questionnaire',\n",
       "  'Swansea Bay University Health Board',\n",
       "  'Swansea University',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-12',\n",
       "  '2024-08'],\n",
       " ['NCT03211871',\n",
       "  'Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pain\",\" Postoperative',\n",
       "  'DRUG: Dexmedetomidine|DRUG: Normal Saline Flush\",\" 0.9% Injectable Solution_#1',\n",
       "  'Bogomolets National Medical University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05-01',\n",
       "  '2017-10-01'],\n",
       " ['NCT04146571',\n",
       "  'Expanded Access to Ensartinib for Participants With ALK+ NSCLC',\n",
       "  '',\n",
       "  'AVAILABLE',\n",
       "  'Non-Small Cell Lung Cancer|ALK Gene Rearrangement Positive',\n",
       "  'DRUG: Ensartinib',\n",
       "  'Xcovery Holdings\",\" Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'EXPANDED_ACCESS',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT00227071',\n",
       "  'Aquatic Verses Land Exercise to Decrease Fall Risk',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'BEHAVIORAL: exercise',\n",
       "  'University of Saskatchewan',\n",
       "  'Saskatchewan Health Research Foundation',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE|Primary Purpose: TREATMENT',\n",
       "  '1999-09',\n",
       "  '2002-06'],\n",
       " ['NCT04341571',\n",
       "  'Effect of Probiotics Versus Metformin on Glycemic Control\",\" Insulin Sensitivity and Insulin Secretion in Prediabetes.',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'PreDiabetes|Impaired Glucose Tolerance|Hyperglycemia|Resistance\",\" Insulin',\n",
       "  'DIETARY_SUPPLEMENT: Probiotics|DRUG: Metformin',\n",
       "  'University of Guadalajara',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-10-24',\n",
       "  '2024-12'],\n",
       " ['NCT01755871',\n",
       "  'Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis',\n",
       "  'BiobankII',\n",
       "  'TERMINATED',\n",
       "  'Relapsing Remitting Multiple Sclerosis',\n",
       "  'DRUG: Fingolimod',\n",
       "  'Heinrich-Heine University\",\" Duesseldorf',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2016-02'],\n",
       " ['NCT00721071',\n",
       "  'Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  'DRUG: Hypertonic Saline',\n",
       "  'The Hospital for Sick Children',\n",
       "  '',\n",
       "  '95.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2006-12',\n",
       "  '2008-05'],\n",
       " ['NCT05402371',\n",
       "  'A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis',\n",
       "  'ASCEND',\n",
       "  'RECRUITING',\n",
       "  'Nonalcoholic Steatohepatitis (NASH)|Fibrosis\",\" Liver|NAFLD',\n",
       "  'DRUG: Rencofilstat|DRUG: Placebo',\n",
       "  'Hepion Pharmaceuticals\",\" Inc.',\n",
       "  '',\n",
       "  '336.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-10-15',\n",
       "  '2025-09'],\n",
       " ...]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clinicaltrial_2023rdd2 =clinicaltrial_2023rdd1.map(lambda line: line.strip(',\\\"').split('\\t')) \\\n",
    "    .filter(lambda line: len(line) > 1)\n",
    "header = clinicaltrial_2023rdd2.first()\n",
    "clinicaltrial_2023rdd3 = clinicaltrial_2023rdd2.filter(lambda k:k!=header)\n",
    "\n",
    "clinicaltrial_2023rdd3.collect()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "8c2d5aaa-d08c-4d62-88fc-32145dea8782",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[['Id',\n",
       "  'Study Title',\n",
       "  'Acronym',\n",
       "  'Status',\n",
       "  'Conditions',\n",
       "  'Interventions',\n",
       "  'Sponsor',\n",
       "  'Collaborators',\n",
       "  'Enrollment',\n",
       "  'Funder Type',\n",
       "  'Type',\n",
       "  'Study Design',\n",
       "  'Start',\n",
       "  'Completion'],\n",
       " ['NCT03630471',\n",
       "  'Effectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India',\n",
       "  'PRIDE',\n",
       "  'COMPLETED',\n",
       "  'Mental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)',\n",
       "  \"BEHAVIORAL: PRIDE 'Step 1' problem-solving intervention|BEHAVIORAL: Enhanced usual care\",\n",
       "  'Sangath',\n",
       "  'Harvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine',\n",
       "  '250.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-20',\n",
       "  '2019-02-28'],\n",
       " ['NCT05992571',\n",
       "  'Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cerebrovascular Function|Cognition',\n",
       "  'OTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB',\n",
       "  'McMaster University',\n",
       "  'Alzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2023-10-25',\n",
       "  '2024-08'],\n",
       " ['NCT00237471',\n",
       "  'Impact of Tight Glycaemic Control in Acute Myocardial Infarction',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Myocardial Infarct|Hyperglycemia',\n",
       "  'DRUG: Insulin (tight blood glucose control)',\n",
       "  'Melbourne Health',\n",
       "  'National Health and Medical Research Council\",\" Australia|Bristol-Myers Squibb',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2006-05'],\n",
       " ['NCT03820271',\n",
       "  'New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation',\n",
       "  'SUPERMELD',\n",
       "  'RECRUITING',\n",
       "  'Decompensated Cirrhosis|Liver Transplantation',\n",
       "  'OTHER: SuperMELD',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '500.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-10-01',\n",
       "  '2023-10-01'],\n",
       " ['NCT06229171',\n",
       "  'InTake Care: Development and Validation of an Innovative\",\" Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention',\n",
       "  'InTakeCare',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Hypertension|Treatment Adherence and Compliance|Digital Health',\n",
       "  'OTHER: adherence support system based on a vocal assistant',\n",
       "  'Istituto Auxologico Italiano',\n",
       "  'Istituti Clinici Scientifici Maugeri SpA|Politecnico di Milano',\n",
       "  '206.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2024-10-01',\n",
       "  '2026-04-01'],\n",
       " ['NCT02945371',\n",
       "  'Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life',\n",
       "  'REV',\n",
       "  'COMPLETED',\n",
       "  'Smoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced',\n",
       "  'BEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training',\n",
       "  'University of Oregon',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2014-09',\n",
       "  '2016-05'],\n",
       " ['NCT01055171',\n",
       "  'Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Dependence|PTSD',\n",
       "  'DRUG: Propranolol|DRUG: Placebo',\n",
       "  'Medical University of South Carolina',\n",
       "  'National Institute on Alcohol Abuse and Alcoholism (NIAAA)',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-01',\n",
       "  '2012-08'],\n",
       " ['NCT01125371',\n",
       "  'Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection',\n",
       "  'BEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Alcohol Abuse and Alcoholism (NIAAA)',\n",
       "  '439.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-10',\n",
       "  '2016-06-07'],\n",
       " ['NCT02554071',\n",
       "  'Manitoba Pharmacist Initiated Smoking Cessation Pilot Project',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking Cessation',\n",
       "  'OTHER: Pharmacist - Smoking Cessation Support',\n",
       "  'University of Manitoba',\n",
       "  'Govenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada',\n",
       "  '119.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2014-01',\n",
       "  '2014-11'],\n",
       " ['NCT01772771',\n",
       "  'Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma',\n",
       "  'PROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '12000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-03-01',\n",
       "  '2033-03-01'],\n",
       " ['NCT02633371',\n",
       "  'A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hyperhidrosis',\n",
       "  'DRUG: Oxybutynin 3% gel',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  'Society for Pediatric Dermatology',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-02',\n",
       "  '2017-05'],\n",
       " ['NCT03400371',\n",
       "  'Biology of Juvenile Myoclonic Epilepsy',\n",
       "  'BIOJUME',\n",
       "  'RECRUITING',\n",
       "  'Juvenile Myoclonic Epilepsy',\n",
       "  'OTHER: Blood draw|OTHER: Existing samples',\n",
       "  \"King's College London\",\n",
       "  'King\\'s College Hospital NHS Trust|Charles University\",\" Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-07-13',\n",
       "  '2026-06-30'],\n",
       " ['NCT00120471',\n",
       "  'Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)',\n",
       "  '122.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2006-11',\n",
       "  '2011-12'],\n",
       " ['NCT04784871',\n",
       "  'Promoting Wellbeing: The Five Ways to All Intervention',\n",
       "  '5WaysA',\n",
       "  'COMPLETED',\n",
       "  'Wellbeing|Health Attitude|Quality of Life',\n",
       "  'BEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control',\n",
       "  'University of Oslo',\n",
       "  'Norwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation',\n",
       "  '970.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-03-04',\n",
       "  '2023-02-24'],\n",
       " ['NCT02383771',\n",
       "  'Reversal of the Anti-platelet Effects of Ticagrelor',\n",
       "  'REVERSAL',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor',\n",
       "  'The First Affiliated Hospital with Nanjing Medical University',\n",
       "  'National Natural Science Foundation of China',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-03',\n",
       "  '2016-12'],\n",
       " ['NCT03269071',\n",
       "  'Neural Stem Cell Transplantation in Multiple Sclerosis Patients',\n",
       "  'STEMS',\n",
       "  'COMPLETED',\n",
       "  'Progressive Multiple Sclerosis',\n",
       "  'DRUG: human fetal-derived Neural Stem Cells (hNSCs)',\n",
       "  'IRCCS San Raffaele',\n",
       "  'Fondazione Italiana Sclerosi Multipla',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-05-17',\n",
       "  '2021-07-31'],\n",
       " ['NCT01659671',\n",
       "  'RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea',\n",
       "  'SKUP3',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea Syndrome',\n",
       "  'PROCEDURE: Uvulopalatopharyngoplasty',\n",
       "  'Karolinska University Hospital',\n",
       "  'Karolinska Institutet',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-06',\n",
       "  '2014-05'],\n",
       " ['NCT04765371',\n",
       "  'Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy\",\" With CoViD-19',\n",
       "  'COPreDex',\n",
       "  'COMPLETED',\n",
       "  'Coronavirus Infection',\n",
       "  'DRUG: DEXAMETHASONE|DRUG: PREDNISOLONE',\n",
       "  'Hôpital NOVO',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-03-03',\n",
       "  '2022-05-13'],\n",
       " ['NCT02830971',\n",
       "  'Developing a Standardized Learning Curve',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Registered Nurses|Nursing Personnel|Motor Skills',\n",
       "  'PROCEDURE: Doing Different ICU techniques and skills',\n",
       "  'Baqiyatallah Medical Sciences University',\n",
       "  'Shahid Beheshti University|Tehran University of Medical Sciences',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2016-07',\n",
       "  '2021-04-12'],\n",
       " ['NCT00416871',\n",
       "  'Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Kidney Cancer',\n",
       "  'BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa',\n",
       "  'Centre Leon Berard',\n",
       "  '',\n",
       "  '220.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  '2006-02'],\n",
       " ['NCT05900271',\n",
       "  'Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS',\n",
       "  'DDOT',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Treatment Resistant Depression',\n",
       "  'DEVICE: rTMS|DEVICE: iTBS',\n",
       "  'Amsterdam UMC\",\" location VUmc',\n",
       "  'Radboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-15',\n",
       "  '2027-12'],\n",
       " ['NCT02469571',\n",
       "  'Modulation of Gut Microbiota in Early Sepsis: A Pilot Study',\n",
       "  'MGM-sepsis',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  'DIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo',\n",
       "  'Medical University of Graz',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-09-01',\n",
       "  '2018-03-01'],\n",
       " ['NCT05807971',\n",
       "  'Assessment of Safety\", Tolerability, Pharmacokinetics,\" and Pharmacodynamics of ATH-063 in Healthy Subjects',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases',\n",
       "  'DRUG: ATH-063|DRUG: Placebo',\n",
       "  'Athos Therapeutics Inc',\n",
       "  'Syneos Health|Athos Therapeutics Australia Pty Ltd',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-06',\n",
       "  '2024-02-08'],\n",
       " ['NCT02083471',\n",
       "  \"Cow's Milk and Hen's Egg Hyposensitization in Adults\",\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  \"Egg Allergy|Cow's Milk Allergy\",\n",
       "  \"DIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow's milk\",\n",
       "  'Turku University Hospital',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2017-05'],\n",
       " ['NCT01062971',\n",
       "  'Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Open Angle Glaucoma|Ocular Hypertension',\n",
       "  'DRUG: dorzolamide-timolol-brimonidine',\n",
       "  'Laboratorios Sophia S.A de C.V.',\n",
       "  '',\n",
       "  '124.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-02',\n",
       "  '2008-06'],\n",
       " ['NCT03928171',\n",
       "  'The Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery',\n",
       "  'PERFUSION',\n",
       "  'COMPLETED',\n",
       "  'Laparoscopic Surgery|Pneumoperitoneum',\n",
       "  'OTHER: Intra-abdominal pressure during laparoscopy',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-06-13',\n",
       "  '2018-12-24'],\n",
       " ['NCT00897871',\n",
       "  'Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Unspecified Childhood Solid Tumor\",\" Protocol Specific',\n",
       "  'DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study',\n",
       "  \"Children's Cancer and Leukaemia Group\",\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-02',\n",
       "  ''],\n",
       " ['NCT00848471',\n",
       "  'Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)',\n",
       "  'Protocol Quark',\n",
       "  'UNKNOWN',\n",
       "  'Healthy|Obesity',\n",
       "  'DEVICE: Quark RMR|DEVICE: Deltatrac II',\n",
       "  'Hospices Civils de Lyon',\n",
       "  'Centre de Recherche en Nutrition Humaine Rhone-Alpe',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2009-01',\n",
       "  '2009-12'],\n",
       " ['NCT06135571',\n",
       "  'Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Cancer|Lymph Node Metastasis',\n",
       "  'PROCEDURE: Laparoscopic colorectal surgery',\n",
       "  'Cancer Institute and Hospital\",\" Chinese Academy of Medical Sciences',\n",
       "  'Peking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital',\n",
       "  '3000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-09-01',\n",
       "  '2026-09-01'],\n",
       " ['NCT01189071',\n",
       "  'Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Overactive Bladder|Renal Colic|Pain\",\" Postoperative',\n",
       "  'DRUG: Darifenacin',\n",
       "  'University of Missouri-Columbia',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2011-07'],\n",
       " ['NCT00728871',\n",
       "  'The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cervical Cancer|Cervical Intraepithelial Neoplasia',\n",
       "  'PROCEDURE: peripheral blood isolation',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2005-12',\n",
       "  '2011-12'],\n",
       " ['NCT05592171',\n",
       "  'Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC',\n",
       "  'SEASON-HCC',\n",
       "  'RECRUITING',\n",
       "  'HCC',\n",
       "  'PROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE',\n",
       "  'University of Pisa',\n",
       "  'Azienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero\",\" Universitaria Pisana',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-10-17',\n",
       "  '2025-10-17'],\n",
       " ['NCT00520871',\n",
       "  'The Water-Blueberry Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cardiovascular Disease',\n",
       "  'DRUG: Blueberry juice',\n",
       "  'University of Oslo',\n",
       "  'Ullevaal University Hospital',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION',\n",
       "  '2003-03',\n",
       "  '2004-04'],\n",
       " ['NCT05913271',\n",
       "  'Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Heart Failure|Levosimendan|Efficacy|Safety',\n",
       "  '',\n",
       "  'Yi Han',\n",
       "  'Qianfoshan Hospital',\n",
       "  '352.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-05-30',\n",
       "  '2025-05-30'],\n",
       " ['NCT04006171',\n",
       "  'Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women',\n",
       "  'CNP',\n",
       "  'COMPLETED',\n",
       "  'Polycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism',\n",
       "  'DIAGNOSTIC_TEST: C type natriuretic peptide',\n",
       "  'Near East University\",\" Turkey',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-07-15',\n",
       "  '2020-09-01'],\n",
       " ['NCT04370171',\n",
       "  'Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic',\n",
       "  'TeleCoviDiab',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Covid-19',\n",
       "  'OTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation',\n",
       "  'University Hospital\", Strasbourg,\" France',\n",
       "  '',\n",
       "  '610.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-05-04',\n",
       "  '2020-05-29'],\n",
       " ['NCT04340271',\n",
       "  'The Clinical Utility of Extracorporeal Shock Wave Therapy on Burns',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Burn Scar',\n",
       "  'OTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy',\n",
       "  'Hangang Sacred Heart Hospital',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-15',\n",
       "  '2020-05-31'],\n",
       " ['NCT03075371',\n",
       "  'Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anorexia Nervosa|Healthy',\n",
       "  'OTHER: Glucose|OTHER: Placebo',\n",
       "  'University of Heidelberg Medical Center',\n",
       "  'German Research Foundation',\n",
       "  '85.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2014-09',\n",
       "  '2019-02'],\n",
       " ['NCT05966571',\n",
       "  'Ovarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Polycystic Ovary Syndrome',\n",
       "  'PROCEDURE: Ovary Biopsie',\n",
       "  'Albanian University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-07-01',\n",
       "  '2024-12-01'],\n",
       " ['NCT03313271',\n",
       "  'China Lymphoma Patient Registry Study',\n",
       "  'CLAP',\n",
       "  'RECRUITING',\n",
       "  'Lymphoma',\n",
       "  '',\n",
       "  'Jun Zhu',\n",
       "  'Peking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-05-17',\n",
       "  '2027-08-30'],\n",
       " ['NCT03490071',\n",
       "  'Long-term Follow up of Patients With Longstanding Hip and Groin Pain',\n",
       "  'Lund LHGP',\n",
       "  'RECRUITING',\n",
       "  'Hip Pain Chronic',\n",
       "  '',\n",
       "  'Lund University',\n",
       "  '',\n",
       "  '81.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT05801471',\n",
       "  'Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Glaucoma',\n",
       "  '',\n",
       "  'Centervue SpA',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-06',\n",
       "  '2025-11-06'],\n",
       " ['NCT00266071',\n",
       "  'Study of the Cutaneous Microcirculation in Elderly People',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Elderly People',\n",
       "  'BEHAVIORAL: Cutaneous response',\n",
       "  'University Hospital\",\" Angers',\n",
       "  '',\n",
       "  '',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-12',\n",
       "  ''],\n",
       " ['NCT04405271',\n",
       "  'TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthcare Workers|COVID-19|SARS-CoV 2',\n",
       "  'DRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo',\n",
       "  'Hospital Italiano de Buenos Aires',\n",
       "  'Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)',\n",
       "  '1378.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-07-31',\n",
       "  '2020-11-15'],\n",
       " ['NCT02121171',\n",
       "  'Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Congenital Glaucoma',\n",
       "  'DEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy',\n",
       "  'National Centre of Ophthalmology named after academician Zarifa Aliyeva',\n",
       "  'Aeon Astron Europe B.V.',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-09',\n",
       "  '2015-09'],\n",
       " ['NCT01068171',\n",
       "  'Developing a Diabetic Foot Ulcer Protocol',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Diabetic Foot Ulcers',\n",
       "  'OTHER: type of footwear|OTHER: collagen dressing with and without silver',\n",
       "  'The University of Texas Health Science Center\",\" Houston',\n",
       "  'Harris County Hospital District|Baylor College of Medicine',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-05',\n",
       "  '2012-06'],\n",
       " ['NCT04875871',\n",
       "  'Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors',\n",
       "  'PARTICLE-PATHY',\n",
       "  'RECRUITING',\n",
       "  'Cancer',\n",
       "  'RADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling',\n",
       "  'EBG MedAustron GmbH',\n",
       "  'CW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring',\n",
       "  '22.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-11-11',\n",
       "  '2024-12'],\n",
       " ['NCT00553371',\n",
       "  'Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Testicular Germ Cell Tumor',\n",
       "  'OTHER: biomarker analysis|PROCEDURE: computed tomography',\n",
       "  'Royal Marsden NHS Foundation Trust',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2006-04',\n",
       "  ''],\n",
       " ['NCT04674371',\n",
       "  'German Point Prevalence Study on CVC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Data Collection',\n",
       "  'OTHER: central venous catheter insertion',\n",
       "  'Wolfram Schummer\", MD,\" PhD',\n",
       "  '',\n",
       "  '537.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-17',\n",
       "  '2022-05-20'],\n",
       " ['NCT02321371',\n",
       "  'Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute-On-Chronic Liver Failure',\n",
       "  'DRUG: Lactulose + Rifaximin|DRUG: Lactulose',\n",
       "  'Institute of Liver and Biliary Sciences\",\" India',\n",
       "  '',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-10-19',\n",
       "  '2016-01-31'],\n",
       " ['NCT02344771',\n",
       "  'Perioperative Endothelial Dysfunction',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myocardial Injury',\n",
       "  'PROCEDURE: Elective colon cancer surgery',\n",
       "  'Zealand University Hospital',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2015-06'],\n",
       " ['NCT03354871',\n",
       "  'Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables',\n",
       "  'IoT4Resident',\n",
       "  'UNKNOWN',\n",
       "  'Fatigue',\n",
       "  '',\n",
       "  'Hillel Yaffe Medical Center',\n",
       "  'International Business Machines (IBM)',\n",
       "  '6.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-11',\n",
       "  '2018-02-28'],\n",
       " ['NCT02804971',\n",
       "  'Cardiovascular Comorbidities and Bronchiectasis',\n",
       "  'BRONCOCA',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Bronchiectasis',\n",
       "  '',\n",
       "  'Centre Hospitalier Intercommunal Creteil',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-10-25',\n",
       "  '2023-12'],\n",
       " ['NCT04591171',\n",
       "  'Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension|Chronic Kidney Diseases',\n",
       "  'PROCEDURE: n-of-1 trial guided clinical decision making',\n",
       "  'The University of Texas Health Science Center\",\" Houston',\n",
       "  \"Children's Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\",\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-01-25',\n",
       "  '2022-02-18'],\n",
       " ['NCT04814771',\n",
       "  'Mass Balance Study of TS-142 in Healthy Adult Subjects.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Male Subjects',\n",
       "  'DRUG: [14C] TS-142',\n",
       "  'Taisho Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2021-04-19',\n",
       "  '2021-05-19'],\n",
       " ['NCT00991471',\n",
       "  'The Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times',\n",
       "  'MDRNSTAT',\n",
       "  'COMPLETED',\n",
       "  'Emergencies',\n",
       "  'BEHAVIORAL: Interaction with MDRN STAT|BEHAVIORAL: No MDRNSTAT',\n",
       "  'Sunnybrook Health Sciences Centre',\n",
       "  '',\n",
       "  '6300.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2009-09',\n",
       "  '2010-02'],\n",
       " ['NCT05702671',\n",
       "  'Kenota 1 CWS Method Comparison Validation Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergy|Immunoglobulin E-Mediated Allergic Disorder',\n",
       "  'DIAGNOSTIC_TEST: Total Immunoglobulin E\",\" Obtained From Fingerstick Sample',\n",
       "  'Kenota Inc.',\n",
       "  '',\n",
       "  '411.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-01-27',\n",
       "  '2023-04-07'],\n",
       " ['NCT02069171',\n",
       "  'Cross-sectional and Questionnaire Study for Leg Lymphedema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gynecologic Cancer',\n",
       "  '',\n",
       "  'National Cancer Center\",\" Korea',\n",
       "  '',\n",
       "  '333.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-06',\n",
       "  '2012-11'],\n",
       " ['NCT00474071',\n",
       "  'Optimum Dose of Remifentanil for Intubation in Small Children',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Endotracheal Intubation',\n",
       "  'DRUG: Remifentanil',\n",
       "  'University of British Columbia',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-03',\n",
       "  '2008-04'],\n",
       " ['NCT02022371',\n",
       "  'Prostate Cancer Genomic Heterogeneity',\n",
       "  'PROGENY',\n",
       "  'COMPLETED',\n",
       "  'PROSTATE CANCER',\n",
       "  'PROCEDURE: Targeted biopsies of the prostate',\n",
       "  'University College London Hospitals',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-09',\n",
       "  '2016-06'],\n",
       " ['NCT04585971',\n",
       "  'A Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of Brain Magnetic Resonance Imaging\",\" and Carotid Doppler Ultrasound',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cerebral Blood Flow',\n",
       "  'DIAGNOSTIC_TEST: Signal intensity gradient',\n",
       "  'Chonbuk National University Hospital',\n",
       "  'Medi Image\",\" Inc',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-03',\n",
       "  '2021-01-31'],\n",
       " ['NCT05473871',\n",
       "  'Enhancing Capacity in Churches to Implement PA Programs',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cardiovascular Diseases',\n",
       "  'BEHAVIORAL: Faith in Action|BEHAVIORAL: Faith in Action+|BEHAVIORAL: Faith in Action++',\n",
       "  'San Diego State University',\n",
       "  'Washington University School of Medicine|University of California\", Berkeley|University of California,\" San Diego',\n",
       "  '812.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-11-15',\n",
       "  '2026-10-31'],\n",
       " ['NCT01523171',\n",
       "  'Phase II\", Open Label,\" Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib',\n",
       "  'JAKARTA2',\n",
       "  'COMPLETED',\n",
       "  'Hematopoietic Neoplasm',\n",
       "  'DRUG: SAR302503',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-04',\n",
       "  '2014-04'],\n",
       " ['NCT00000571',\n",
       "  'Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lung Diseases|Lung Diseases\",\" Obstructive|Chronic Obstructive Pulmonary Disease',\n",
       "  'DEVICE: ventilators\",\" negative pressure',\n",
       "  'McGill University',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1986-02',\n",
       "  ''],\n",
       " ['NCT01053871',\n",
       "  'Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastritis|Functional Dyspepsia',\n",
       "  'DRUG: propofol|DRUG: midazolam with fentanyl',\n",
       "  'Shandong University',\n",
       "  '',\n",
       "  '104.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: ',\n",
       "  '2010-01',\n",
       "  '2010-05'],\n",
       " ['NCT02370771',\n",
       "  'Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis',\n",
       "  'PASEO',\n",
       "  'COMPLETED',\n",
       "  'Erosive Hand Osteoarthritis',\n",
       "  'PROCEDURE: Biological sampling|DEVICE: Radiographic evaluation',\n",
       "  'University Hospital\",\" Rouen',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-06-09',\n",
       "  '2019-11-17'],\n",
       " ['NCT05974371',\n",
       "  'Episodic Memory Integration and Interference',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Episodic Memory',\n",
       "  'OTHER: emotional context similarity',\n",
       "  'Boston College',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2024-08',\n",
       "  '2027-08'],\n",
       " ['NCT03713671',\n",
       "  'Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Hyperparathyroidism',\n",
       "  'DIAGNOSTIC_TEST: gait analysis',\n",
       "  'Recep Tayyip Erdogan University Training and Research Hospital',\n",
       "  'Hacettepe University|Ankara Education and Research Hospital',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING',\n",
       "  '2021-10-17',\n",
       "  '2023-08-27'],\n",
       " ['NCT02645071',\n",
       "  'Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Activity',\n",
       "  'BEHAVIORAL: Physical Activity',\n",
       "  'The University of Hong Kong',\n",
       "  'Hong Kong Jockey Club Charities Trust',\n",
       "  '141.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2015-07',\n",
       "  '2017-07'],\n",
       " ['NCT04004871',\n",
       "  'Induction Chemotherapy With Nab-paclitaxel\",\" Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Nasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer',\n",
       "  'DRUG: Nab-paclitaxel\",\" Cisplatin and Fluorouracil|RADIATION: concurrent chemoradiotherapy',\n",
       "  'Guangxi Medical University',\n",
       "  'Second Affiliated Hospital of Guangxi Medical University|Guilin Medical University\",\" China|Liuzhou Workers Hospital|Wuzhou Red Cross Hospital',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-05',\n",
       "  '2022-06-30'],\n",
       " ['NCT05953571',\n",
       "  'Laparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Uretro-pelvic Junction Obstruction|Poorly Function Kidney',\n",
       "  'PROCEDURE: Dismembered Pyeloplasty',\n",
       "  'Al-Azhar University',\n",
       "  'University Hospital Fattouma Bourguiba',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01-08',\n",
       "  '2023-06-30'],\n",
       " ['NCT02570971',\n",
       "  'Mannitol Versus Supportive Care in Ciguatera Fish Poisoning',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ciguatoxin',\n",
       "  'DRUG: Mannitol',\n",
       "  'University of South Florida',\n",
       "  'Florida Poison Control Center',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-10',\n",
       "  ''],\n",
       " ['NCT03987971',\n",
       "  'Acupuncture on GB26 to Treat Chronic Low Back Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Low-back Pain',\n",
       "  'OTHER: acupuncture',\n",
       "  'Wenzhou Medical University',\n",
       "  \"Qingtian People's hospital\",\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2021-07'],\n",
       " ['NCT01425671',\n",
       "  'Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder',\n",
       "  '',\n",
       "  'University of Maryland\",\" Baltimore',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '800.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-11-30',\n",
       "  '2024-06'],\n",
       " ['NCT04962971',\n",
       "  'Comparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Recurrent Cystitis',\n",
       "  'DIETARY_SUPPLEMENT: X|DIETARY_SUPPLEMENT: Y|DIETARY_SUPPLEMENT: Z',\n",
       "  'CEN Biotech',\n",
       "  'Nexira|CEN Nutriment',\n",
       "  '216.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-01',\n",
       "  '2022-02-01'],\n",
       " ['NCT02827071',\n",
       "  'Ocular Imaging Study Using Advanced OCT',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Retinal Vascular Disorder|Macular Degeneration',\n",
       "  '',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  ''],\n",
       " ['NCT04236271',\n",
       "  'TELEsurveillance of Patients in PostopErative Bridge surgeryAge CoronairE',\n",
       "  'TELE-PEACE',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Bypass',\n",
       "  'DEVICE: connected objects',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  'GFI',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-03-13',\n",
       "  '2022-12-31'],\n",
       " ['NCT01780571',\n",
       "  'CPAP/PSV Preoxygenation in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Anaesthesia',\n",
       "  'PROCEDURE: CPAP 5 cm H2O + PSV 5 cm H2O',\n",
       "  'Karolinska Institutet',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2009-05',\n",
       "  '2012-12'],\n",
       " ['NCT05078671',\n",
       "  'Pharmacokinetic Boosting of Olaparib to Improve Exposure\",\" Tolerance and Cost-effectiveness',\n",
       "  'PROACTIVE',\n",
       "  'RECRUITING',\n",
       "  'Cancer',\n",
       "  'DRUG: Olaparib|DRUG: Cobicistat',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-12-15',\n",
       "  '2025-12-31'],\n",
       " ['NCT02529371',\n",
       "  'Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Urinary Incontinence',\n",
       "  'DEVICE: UriCap-RM',\n",
       "  'G.R. Dome Medical Ltd.',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-09',\n",
       "  '2015-10'],\n",
       " ['NCT02309671',\n",
       "  'A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infertility',\n",
       "  'DRUG: FE 999049|DRUG: follitropin beta',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '159.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-12',\n",
       "  '2016-09'],\n",
       " ['NCT03876171',\n",
       "  'Culturally Modified Family Based Therapy for Haitian Youth in South Florida',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Problem Behavior',\n",
       "  'BEHAVIORAL: Haitian youth and family intervention study: family functioning|BEHAVIORAL: Haitian youth intervention study: youth psychoeducational|BEHAVIORAL: Haitian family intervention study: family psychoeducational|BEHAVIORAL: Diversion Programs',\n",
       "  'University of Miami',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2019-04-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT05031871',\n",
       "  'Pharmacokinetics of HR17031 Injection in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection',\n",
       "  'Jiangsu HengRui Medicine Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-09-02',\n",
       "  '2021-11-19'],\n",
       " ['NCT04769271',\n",
       "  'Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis',\n",
       "  'PROCEDURE: Scaling and Root Planing|DRUG: Scaling and Root Planing with tea tree oil',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-11-10',\n",
       "  '2020-08-25'],\n",
       " ['NCT06044571',\n",
       "  'Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Obesity|Multiple Chronic Conditions',\n",
       "  'OTHER: Prescriptive|BEHAVIORAL: Behavioral',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute on Aging (NIA)',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2024-03-01',\n",
       "  '2027-09-01'],\n",
       " ['NCT01889771',\n",
       "  'A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking Cessation',\n",
       "  'DRUG: Nicotine Patch',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '',\n",
       "  '1495.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2010-03',\n",
       "  '2012-03'],\n",
       " ['NCT03077971',\n",
       "  'Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Carer Stress Syndrome',\n",
       "  'BEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support',\n",
       "  'University of Nottingham',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2016-12-01',\n",
       "  '2018-06'],\n",
       " ['NCT02912871',\n",
       "  \"Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  \"Parkinson's Disease\",\n",
       "  'OTHER: MRIgHIFU unilateral subthalamotomy',\n",
       "  'Fundación de investigación HM',\n",
       "  'Insightech',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-04',\n",
       "  '2017-01'],\n",
       " ['NCT03548571',\n",
       "  'Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy',\n",
       "  'DEN-STEM',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Glioblastoma',\n",
       "  'BIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-04-26',\n",
       "  '2025-05-01'],\n",
       " ['NCT01449071',\n",
       "  'Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Systemic Lupus Erythematosus',\n",
       "  'BIOLOGICAL: Placebo|BIOLOGICAL: Epratuzumab 400 mg|BIOLOGICAL: Epratuzumab 1200 mg|BIOLOGICAL: Epratuzumab 100 mg|BIOLOGICAL: Epratuzumab 600 mg',\n",
       "  'UCB Pharma',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-10',\n",
       "  '2013-03'],\n",
       " ['NCT03530371',\n",
       "  'Intranasal Dexmedetomidine for Sedated Hearing Testing',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Auditory Brainstem Response',\n",
       "  'DRUG: Dexmedetomidine Hydrochloride',\n",
       "  'Fondation Lenval',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-05-02',\n",
       "  '2021-12-31'],\n",
       " ['NCT05921071',\n",
       "  'Do Patients Who Received Tranexamic Acid in Vaginal Hysterectomy Loose Les Blood\",\" Comparing to Patients Who Did Not?',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Vaginal Hysterectomy',\n",
       "  'DRUG: Tranexamic acid|DRUG: Placebo',\n",
       "  'Wolfson Medical Center',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-01-22',\n",
       "  '2025-01-01'],\n",
       " ['NCT04974671',\n",
       "  'Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Oligoprogressive|Progression',\n",
       "  'RADIATION: Stereotactic Body Radiation Therapy',\n",
       "  'Yale University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-08',\n",
       "  '2027-04-01'],\n",
       " ['NCT00080171',\n",
       "  'Osteoarthritis Initiative (OAI): A Knee Health Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Knee Osteoarthritis',\n",
       "  '',\n",
       "  'National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)',\n",
       "  'GlaxoSmithKline|Merck Sharp & Dohme LLC|Novartis|Pfizer',\n",
       "  '4796.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-02',\n",
       "  '2015-10'],\n",
       " ['NCT00368771',\n",
       "  'A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Irritable Bowel Syndrome',\n",
       "  'BEHAVIORAL: IBS Stress Management|BEHAVIORAL: IBS Symptom Management|BEHAVIORAL: IBS Educational Training',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  'National Institute of Nursing Research (NINR)',\n",
       "  '163.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2002-07',\n",
       "  '2010-05'],\n",
       " ['NCT04979871',\n",
       "  'SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19',\n",
       "  'DER-CoV2-001',\n",
       "  'COMPLETED',\n",
       "  'Vaccine Reaction',\n",
       "  'PROCEDURE: Venous bleeding',\n",
       "  'University of Zurich',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-07-22',\n",
       "  '2021-12-31'],\n",
       " ['NCT04097171',\n",
       "  'The Effect of Diet Composition on Performance\", Expenditure, Blood Lipids,\" and Appetite Hormones in Highly Trained Cyclists',\n",
       "  'DCAP',\n",
       "  'COMPLETED',\n",
       "  'Endurance Cycling Performance',\n",
       "  'OTHER: Diet',\n",
       "  'Texas Christian University',\n",
       "  '',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-11-11',\n",
       "  '2020-03-30'],\n",
       " ['NCT06199271',\n",
       "  'Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Head and Neck Squamous Cell Carcinoma',\n",
       "  'DRUG: Adebrelimab and dalpiciclib',\n",
       "  'Zhongzheng Xiang',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01-31',\n",
       "  '2026-12-31'],\n",
       " ['NCT04032171',\n",
       "  'Study of Evobrutinib in Participants With RMS',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Relapsing-remitting Multiple Sclerosis',\n",
       "  'DRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo',\n",
       "  'EMD Serono Research & Development Institute\",\" Inc.',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '1.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-09-10',\n",
       "  '2020-05-20'],\n",
       " ['NCT05674071',\n",
       "  'Applying an Osteopathic Intervention to Improve Mental Health Symptoms: a Mixed-methods Feasibility Study Protocol.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Health Issue',\n",
       "  'BEHAVIORAL: Articulation/HVT|BEHAVIORAL: Soft-tissue massage|BEHAVIORAL: Craniosacral techniques|BEHAVIORAL: Combination of the three interventions: HVT\",\" soft-tissue and craniosacral techniques',\n",
       "  'Swansea University',\n",
       "  'Osteopathic Foundation|University College of Osteopathy',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-20',\n",
       "  '2023-08-01'],\n",
       " ['NCT00858871',\n",
       "  'First Line Hepato Cellular Carcinoma (HCC)',\n",
       "  'BRISK FL',\n",
       "  'COMPLETED',\n",
       "  'Hepato Cellular Carcinoma (HCC)',\n",
       "  'DRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '',\n",
       "  '1714.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-05',\n",
       "  '2013-09'],\n",
       " ['NCT01776671',\n",
       "  'Once Daily Gabapentin in the Treatment of Post Amputation Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pain|Quality of Life',\n",
       "  'DRUG: Gralise',\n",
       "  'Chicago Anesthesia Pain Specialists',\n",
       "  '',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-02',\n",
       "  '2018-12'],\n",
       " ['NCT01363271',\n",
       "  'Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Complicated Skin and Structure Infection|Nosocomial Pneumonia',\n",
       "  'DRUG: Linezolid|DRUG: Vancomycin|DRUG: Linezolid|DRUG: Vancomycin',\n",
       "  'Pfizer',\n",
       "  'University of Maryland|Lodise & Lodise\",\" LLC',\n",
       "  '7260.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-05',\n",
       "  '2012-05'],\n",
       " ['NCT01282671',\n",
       "  'Effects of Deep Breathing Exercises Two Months After Cardiac Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'CABG|Valve Surgery',\n",
       "  'OTHER: Breathing exercises',\n",
       "  'Uppsala University',\n",
       "  'The Swedish Research Council|Örebro County Council',\n",
       "  '357.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2012-08'],\n",
       " ['NCT05683171',\n",
       "  'A Phase 1/2\",\" Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Lymphoma',\n",
       "  'DRUG: Rituximab|DRUG: Lenalidomide|DRUG: Valemetostat',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'Daiichi Sankyo',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-05-19',\n",
       "  '2027-09-30'],\n",
       " ['NCT05334771',\n",
       "  'Early Detection of Endolymphatic Hydrops in Hypothyroid Patients',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Hypothyroidism',\n",
       "  'DEVICE: Dual band pure tune audiometer',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-09',\n",
       "  '2025-04'],\n",
       " ['NCT04718571',\n",
       "  'An Ecological Analysis of Nontuberculous Mycobacteria in the Geneva Area (2015-2020)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ecology of Nontubercuous Mycobacteria|Geneva Area',\n",
       "  '',\n",
       "  'University Hospital\",\" Geneva',\n",
       "  '',\n",
       "  '231.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-01',\n",
       "  '2020-12-01'],\n",
       " ['NCT05072171',\n",
       "  'Evidence of Myogenic Growth Factors in 3D Dynamic Inguinal Hernia Scaffold ProFlor',\n",
       "  'HERNIA',\n",
       "  'UNKNOWN',\n",
       "  'Inguinal Hernia',\n",
       "  'PROCEDURE: Inguinal hernia repair with dynamic prosthesis',\n",
       "  'University of Palermo',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01-01',\n",
       "  '2021-12-31'],\n",
       " ['NCT05638971',\n",
       "  'Optical Detection Infiltration/Extravasation in Neonates (ODINE)',\n",
       "  'ODINE',\n",
       "  'COMPLETED',\n",
       "  'Extravasation Injury|Infant\", Premature,\" Diseases',\n",
       "  'DEVICE: ivWatch',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-08-01',\n",
       "  '2022-07-12'],\n",
       " ['NCT05138471',\n",
       "  'Addition of Transcranial Direct Current Stimulation and Transcutaneous Electrical Nerve Stimulation to an Education and Exercise Program in Subjects With Chronic Pain Due to Knee Osteoarthritis',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Osteo Arthritis Knee|Chronic Pain',\n",
       "  'DEVICE: transcranial direct current stimulation (tDCS)|DEVICE: TENS|BEHAVIORAL: Exercise and General Education',\n",
       "  'Universidad de Murcia',\n",
       "  '',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2021-11-17',\n",
       "  '2024-03-01'],\n",
       " ['NCT00961571',\n",
       "  'Sunitinib and Capecitabine for First Line Colon Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: sunitinib and capecitabine',\n",
       "  'Georgetown University',\n",
       "  'Pfizer',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2011-03'],\n",
       " ['NCT03635671',\n",
       "  'Diabetic Retinopathy and Subclinical Signs of Disease Transition',\n",
       "  'DIRECTION',\n",
       "  'TERMINATED',\n",
       "  'Diabetic Retinopathy',\n",
       "  'DIAGNOSTIC_TEST: Optical Coherence Tomography Angiography',\n",
       "  'University of British Columbia',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-01',\n",
       "  '2019-07-15'],\n",
       " ['NCT01143571',\n",
       "  'Evaluation of Skin\", Colonic,\" and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'BMI|General Demographics Characteristics',\n",
       "  '',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-11-20',\n",
       "  ''],\n",
       " ['NCT02240771',\n",
       "  'Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: Transarterial chemotherapy|DRUG: Oral chemotherapy',\n",
       "  'All India Institute of Medical Sciences\",\" New Delhi',\n",
       "  'Indian Council of Medical Research',\n",
       "  '124.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2015-03'],\n",
       " ['NCT03365271',\n",
       "  'The Post-operative Effect of Applying Drainage on Total Knee Arthroplasty',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Knee Osteoarthritis',\n",
       "  'PROCEDURE: drainage|PROCEDURE: non-drainage',\n",
       "  \"Peking University People's Hospital\",\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-02',\n",
       "  '2019-02'],\n",
       " ['NCT06183671',\n",
       "  'A Study to Evaluate Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics of JX09 in Healthy Subjects.',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Resistant Hypertension',\n",
       "  'DRUG: JX09 or placebo SAD|DRUG: JX09 or placebo MAD|DRUG: JX09',\n",
       "  'Ji Xing Pharmaceuticals Australia Pty Ltd',\n",
       "  'Novotech (Australia) Pty Limited',\n",
       "  '92.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT02781571',\n",
       "  'Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C Virus Infection',\n",
       "  'DRUG: SOF/VEL',\n",
       "  'Gilead Sciences',\n",
       "  '',\n",
       "  '79.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-07-27',\n",
       "  '2017-07-28'],\n",
       " ['NCT03956771',\n",
       "  'Neurofeedback for Treatment-resistant Obsessive-compulsive Disorder (OCD)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Obsessive-Compulsive Disorder|OCD',\n",
       "  'BEHAVIORAL: Real neurofeedback|BEHAVIORAL: Sham neurofeedback',\n",
       "  'Pedro Morgado',\n",
       "  'Hospital de Braga|Clinical Academic Center (2CA)',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-04-05',\n",
       "  '2021-08-31'],\n",
       " ['NCT03737071',\n",
       "  'The Effects of Low Carbohydrate Diet on Liver Fat Content and Mitochondrial Fluxes',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Fatty Liver',\n",
       "  'BEHAVIORAL: Low Carbohydrate Diet',\n",
       "  'Helsinki University Central Hospital',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-11-15',\n",
       "  '2022-11'],\n",
       " ['NCT05661071',\n",
       "  'Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor Functions',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Duchenne Muscular Dystrophy',\n",
       "  \"OTHER: Modified Mini Mental Test:|OTHER: The Controlled Oral Word Association Test|OTHER: The Central Nervous System Vital Signs|OTHER: Conners' Parent Rating Scale-48 (Parent Report)|OTHER: Child Behavior Checklist 6-18 ages (Parent Report)|OTHER: Strengths and Difficulties Questionnaire (Self-Reported)|OTHER: Brooke Lower Extremity Functional Classification|OTHER: Motor Function Measurement-32 Items|OTHER: Four Square Step Test|OTHER: Six Minutes Walk Test|OTHER: Timed Performance Test\",\n",
       "  'Hacettepe University',\n",
       "  '',\n",
       "  '74.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-11',\n",
       "  '2023-03-01'],\n",
       " ['NCT03439371',\n",
       "  'Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia',\n",
       "  'MTSA',\n",
       "  'RECRUITING',\n",
       "  'Acute Myeloid Leukemia',\n",
       "  'OTHER: HLA-mismatched micro-transplantation after induction chemotherapy',\n",
       "  'Centre Hospitalier Universitaire de Saint Etienne',\n",
       "  'Institut de Cancérologie de la Loire',\n",
       "  '21.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-08',\n",
       "  '2025-12-31'],\n",
       " ['NCT03257371',\n",
       "  'A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Post-traumatic Osteoarthritis',\n",
       "  '',\n",
       "  'James Stannard',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12-30',\n",
       "  '2019-07'],\n",
       " ['NCT06103071',\n",
       "  'Role of Membrane Sweeping on Initiation of Labor and Vaginal Birth in Previous Cesarean Section',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Vaginal Birth After Cesarean Section',\n",
       "  'PROCEDURE: Sweeping of membranes',\n",
       "  'HITEC-Institute of Medical Sciences',\n",
       "  '',\n",
       "  '384.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2023-01-15',\n",
       "  '2024-08-01'],\n",
       " ['NCT05924971',\n",
       "  'Aspirin for Postpartum Patients With Preeclampsia',\n",
       "  'ASAPP',\n",
       "  'RECRUITING',\n",
       "  'Preeclampsia Postpartum',\n",
       "  'DRUG: Aspirin 81Mg Ec Tab',\n",
       "  'MemorialCare Health System',\n",
       "  'University of California\",\" Irvine',\n",
       "  '86.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-26',\n",
       "  '2024-09'],\n",
       " ['NCT04242771',\n",
       "  'Mindfulness Meditation for Insomnia',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Insomnia',\n",
       "  'BEHAVIORAL: Mindfulness',\n",
       "  'Beth Israel Deaconess Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2022-12-02',\n",
       "  '2023-12-01'],\n",
       " ['NCT05121571',\n",
       "  'The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: HAIC|DRUG: Sorafenib',\n",
       "  'Sun Yat-sen University',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-04-21',\n",
       "  '2021-05-01'],\n",
       " ['NCT01740271',\n",
       "  'A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Neoplasms',\n",
       "  'DRUG: Epirubicin',\n",
       "  'AHS Cancer Control Alberta',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-12',\n",
       "  '2025-06'],\n",
       " ['NCT00912171',\n",
       "  'Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children',\n",
       "  'SB-OSAS',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea Syndrome',\n",
       "  'DRUG: budesonide (Aircort 50 nasal spray)|DRUG: montelukast (Singulair)',\n",
       "  'University of Bologna',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  '2010-06'],\n",
       " ['NCT01640171',\n",
       "  'Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Age-related Macular Degeneration|Central Retinal Vein Occlusion|Diabetic Macular Edema',\n",
       "  'PROCEDURE: Xylocaine 2% Injectable Anesthetic|DRUG: Proparacaine Hydrochloride 0.5% Drop|DRUG: Tetravisc 0.5% Gel|DRUG: Acuvail|DRUG: Intra-vitreal Anti-VEGF Drug',\n",
       "  'Retina Vitreous Associates of Florida',\n",
       "  '',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-07',\n",
       "  '2013-10'],\n",
       " ['NCT00507871',\n",
       "  'Transmission and the Respiratory Tract in Cryptosporidiosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cryptosporidiosis',\n",
       "  '',\n",
       "  'Tufts University',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '480.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2009-01'],\n",
       " ['NCT03128671',\n",
       "  'Family Automated Voice Reorientation Study',\n",
       "  'FAVoR',\n",
       "  'COMPLETED',\n",
       "  'Delirium|Cognitive Impairment|Health\",\" Subjective|Sleep',\n",
       "  'BEHAVIORAL: FAVoR Intervention',\n",
       "  'University of Miami',\n",
       "  'University of South Florida|National Institute of Nursing Research (NINR)',\n",
       "  '178.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-05-19',\n",
       "  '2021-05-17'],\n",
       " ['NCT00672971',\n",
       "  'Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Head Lice',\n",
       "  'OTHER: 4% dimethicone foam|OTHER: 1% permethrin',\n",
       "  'Oystershell NV',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2007-11'],\n",
       " ['NCT04852471',\n",
       "  'Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gynecologic Cancer',\n",
       "  'BEHAVIORAL: Standard Post-Operative Counseling + FACT-G|BEHAVIORAL: PROM symptom tracker',\n",
       "  'University of Michigan Rogel Cancer Center',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-01-05',\n",
       "  '2023-05-02'],\n",
       " ['NCT02960971',\n",
       "  'Neuropathic Pain After Lung Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Neuropathic Pain\", Postoperative|Chronic Pain,\" Postoperative|Chronic Chemotherapy-induced Neuropathic Pain|Chronic Chemotherapy-induced Pain|Chronic Chemotherapy-induced Peripheral Neuropathy',\n",
       "  'PROCEDURE: Thoracic surgery for lung cancer',\n",
       "  'Danish Pain Research Center',\n",
       "  'DOLORisk Consortium|Aarhus University Hospital',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-02',\n",
       "  '2021-06-16'],\n",
       " ['NCT02352571',\n",
       "  'Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Neoplasm Metastasis|Gastric Cancer|Colorectal Cancer',\n",
       "  'BIOLOGICAL: GC1118',\n",
       "  'Green Cross Corporation',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2017-06'],\n",
       " ['NCT00611871',\n",
       "  'The Use of Propranolol to Block Memory Reconsolidation in PTSD',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Posttraumatic Stress Disorders',\n",
       "  'DRUG: Propranolol|DRUG: Placebo',\n",
       "  'Wayne State University',\n",
       "  'John D. Dingell VA Medical Center|New York University',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2015-09'],\n",
       " ['NCT04676971',\n",
       "  'Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'DRUG: hzVSF-v13|DRUG: Placebo (Normal saline solution)',\n",
       "  'ImmuneMed\",\" Inc.',\n",
       "  '',\n",
       "  '115.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-12-11',\n",
       "  '2021-10-28'],\n",
       " ['NCT01191671',\n",
       "  'Language and Deglutition in Children',\n",
       "  'LDC',\n",
       "  'COMPLETED',\n",
       "  'Child|Development',\n",
       "  '',\n",
       "  'Fortaleza University',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-05',\n",
       "  '2009-12'],\n",
       " ['NCT01909271',\n",
       "  'Tailored Approaches to Stroke Health Education',\n",
       "  'TASHE',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'BEHAVIORAL: Stroke Education Film Viewing|OTHER: Stroke Education Pamphlet Exposure',\n",
       "  'Columbia University',\n",
       "  'National Institute of Neurological Disorders and Stroke (NINDS)',\n",
       "  '290.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2014-04-16',\n",
       "  '2019-12'],\n",
       " ['NCT03673371',\n",
       "  \"Women's-Specific Footwear With Prosthetic Feet\",\n",
       "  'WSF',\n",
       "  'COMPLETED',\n",
       "  'Lower Limb Amputation Below Knee (Injury)|Lower Limb Amputation Above Knee (Injury)',\n",
       "  'OTHER: Questionnaire',\n",
       "  'Minneapolis Veterans Affairs Medical Center',\n",
       "  'United States Department of Defense',\n",
       "  '100.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-03-04',\n",
       "  '2023-01-06'],\n",
       " ['NCT05503771',\n",
       "  'Improving Pediatrician Counseling About Infant Safe Sleep Using the Electronic Medical Record',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Sudden Infant Death|Sudden Unexplained Infant Death',\n",
       "  'BEHAVIORAL: ISA-MI|OTHER: Standard of Care (SOC)',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Minority Health and Health Disparities (NIMHD)',\n",
       "  '470.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-10-10',\n",
       "  '2026-02-28'],\n",
       " ['NCT05898971',\n",
       "  'Robotic Hand on Hand Functions in Strokes',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'CVA (Cerebrovascular Accident)',\n",
       "  'OTHER: Robotic|OTHER: Mirror|OTHER: Traditional Physical Therapy',\n",
       "  'Cairo University',\n",
       "  'Batterjee Medical College',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-12',\n",
       "  '2023-10-11'],\n",
       " ['NCT04429971',\n",
       "  'Pre-Exposure Prophylaxis in the Emergency Department',\n",
       "  'PrEPPED',\n",
       "  'COMPLETED',\n",
       "  'HIV/AIDS|PrEP',\n",
       "  'OTHER: PrEP screening program|OTHER: PrEP starter pack',\n",
       "  'Icahn School of Medicine at Mount Sinai',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2020-03-18',\n",
       "  '2023-07-31'],\n",
       " ['NCT02626871',\n",
       "  'Atrial Fibrillation\", Stroke,\" and Bleeding in Patients Undergoing Aortic Biovalve Implantation',\n",
       "  'CAREAVR',\n",
       "  'COMPLETED',\n",
       "  'Atrial Fibrillation|Stroke|Transient Ischemic Attack|Bleeding|Aortic Stenosis',\n",
       "  '',\n",
       "  'University of Turku',\n",
       "  'Helsinki University Central Hospital|Oulu University Hospital|Kuopio University Hospital',\n",
       "  '850.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2002-01',\n",
       "  '2015-12'],\n",
       " ['NCT00932971',\n",
       "  'HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis',\n",
       "  'HIDIT-II',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis D',\n",
       "  'DRUG: PEG-IFN alfa-2a\", Tenofovir|DRUG: PEG-IFN alfa-2a,\" placebo',\n",
       "  'HepNet Study House\",\" German Liverfoundation',\n",
       "  'Hannover Medical School|Hoffmann-La Roche|Gilead Sciences',\n",
       "  '70.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2017-08-02'],\n",
       " ['NCT02528071',\n",
       "  'Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis',\n",
       "  'SLA',\n",
       "  'TERMINATED',\n",
       "  'ALS (Amyotrophic Lateral Sclerosis)',\n",
       "  'OTHER: Diaphragmatic endurance test',\n",
       "  'Centre Hospitalier Universitaire de Saint Etienne',\n",
       "  '',\n",
       "  '136.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-09-29',\n",
       "  '2020-10-28'],\n",
       " ['NCT04840771',\n",
       "  'Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pituitary Adenoma',\n",
       "  'PROCEDURE: Endoscopic Endonasal Pituitary Surgery',\n",
       "  'Federico II University',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-01',\n",
       "  '2020-07-31'],\n",
       " ['NCT06155071',\n",
       "  'Effects of 8 Week Plyometric Training on Physical Fitness and Technical Skills of Domestic Cricket Players',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Fitness|Technical Skills',\n",
       "  'OTHER: Plyometric Training|OTHER: Conventional Exercises',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-08-14',\n",
       "  '2024-01-10'],\n",
       " ['NCT03170271',\n",
       "  'A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.',\n",
       "  'ANDHI',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: Benralizumab (Medi-563)|DRUG: Placebo',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '660.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-07-07',\n",
       "  '2020-10-21'],\n",
       " ['NCT01982071',\n",
       "  'A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Candidemia|Candidiasis',\n",
       "  'DRUG: Micafungin',\n",
       "  'Astellas Pharma China\",\" Inc.',\n",
       "  '',\n",
       "  '59.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-09-26',\n",
       "  '2015-08-28'],\n",
       " ['NCT03016871',\n",
       "  'Nivolumab\", Ifosfamide, Carboplatin,\" and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma',\n",
       "  'DRUG: Carboplatin|DRUG: Etoposide|DRUG: Ifosfamide|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab',\n",
       "  'City of Hope Medical Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-24',\n",
       "  '2026-01-30'],\n",
       " ['NCT05313971',\n",
       "  'Impact of Self-awareness in Medical Students',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Burnout\", Student|Stress,\" Psychological|Compassion|Self-Perception',\n",
       "  'OTHER: Self knowledge course',\n",
       "  'University of Coimbra',\n",
       "  '',\n",
       "  '46.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-10-01',\n",
       "  '2020-12-31'],\n",
       " ['NCT02732171',\n",
       "  'PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  'OTHER: Research Blood Collection',\n",
       "  'Abramson Cancer Center at Penn Medicine',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2016-04',\n",
       "  '2026-04'],\n",
       " ['NCT00510471',\n",
       "  'Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  \"Non-Hodgkin's Lymphoma\",\n",
       "  'DRUG: autologous immunoglobulin idiotype-KLH conjugate vaccine',\n",
       "  'Genitope Corporation',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2007-05',\n",
       "  ''],\n",
       " ['NCT04856371',\n",
       "  'Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+\",\" HER2- Advanced Breast Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Advanced Breast Cancer',\n",
       "  'DRUG: CYH33|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib',\n",
       "  'Haihe Biopharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '228.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04',\n",
       "  '2022-12'],\n",
       " ['NCT00769171',\n",
       "  'Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)',\n",
       "  'DRAGON',\n",
       "  'COMPLETED',\n",
       "  'Infection\",\" Intra-abdominal',\n",
       "  'DRUG: Avelox (Moxifloxacin\",\" BAY12-8039)|DRUG: Ceftriaxone + Metronidazole',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '364.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2007-01'],\n",
       " ['NCT03522571',\n",
       "  'Experimental Gingivitis in Patients With Altered Passive Eruption',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Altered Passive Eruption of Teeth',\n",
       "  'BEHAVIORAL: Experimental gingivitis',\n",
       "  'Rustam Aghazada',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2017-02-21',\n",
       "  '2017-07-19'],\n",
       " ['NCT00116571',\n",
       "  'Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostatic Hyperplasia',\n",
       "  'DRUG: Lemuteporfin for injection|DEVICE: Transurethral drug delivery system|DEVICE: Transurethral light delivery system',\n",
       "  'QLT Inc.',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2006-12'],\n",
       " ['NCT00782171',\n",
       "  'Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Partial Edentulism',\n",
       "  'DEVICE: SLActive dental implant',\n",
       "  'Institut Straumann AG',\n",
       "  '',\n",
       "  '266.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-07',\n",
       "  '2010-02'],\n",
       " ['NCT05982171',\n",
       "  'Transcutaneous Spinal Cord Stimulation to Promote Walking Recovery After Spinal Cord Injury',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Spinal Cord Injuries',\n",
       "  'DEVICE: Exo + TSCS|DEVICE: Exo + Sham',\n",
       "  'Craig Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-15',\n",
       "  '2024-09-15'],\n",
       " ['NCT00376571',\n",
       "  'Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?',\n",
       "  'BIFI',\n",
       "  'COMPLETED',\n",
       "  'Coronary Artery Disease',\n",
       "  'PROCEDURE: Percutaneous coronary intervention',\n",
       "  'Aarhus University Hospital Skejby',\n",
       "  'Johnson & Johnson',\n",
       "  '413.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-10',\n",
       "  '2011-03'],\n",
       " ['NCT00410371',\n",
       "  'Study to Compare Two Formulations of Lamotrigine in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Disorders',\n",
       "  'DRUG: Lamotrigine|DRUG: GI267119',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '96.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-12-28',\n",
       "  '2007-01-25'],\n",
       " ['NCT03066271',\n",
       "  'Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer',\n",
       "  'PRIME',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Non-Small Cell Lung Cancer Stage|Chemoradiation',\n",
       "  'OTHER: Exercise +|OTHER: Control +',\n",
       "  'Rigshospitalet\",\" Denmark',\n",
       "  'University of Copenhagen',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-04-03',\n",
       "  '2023-12-31'],\n",
       " ['NCT02125071',\n",
       "  'Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation',\n",
       "  'LT',\n",
       "  'COMPLETED',\n",
       "  'Liver Cirrhosis|Chronic Hepatitis B',\n",
       "  'OTHER: Blood Sample Collection',\n",
       "  'Dong-Gu Kim',\n",
       "  'Green Cross Corporation',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-11',\n",
       "  '2015-09'],\n",
       " ['NCT02869971',\n",
       "  'Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia',\n",
       "  'PARTEM',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostatic Hyperplasia',\n",
       "  'DEVICE: Embosphere® (Prostatic Arteries Embolization)|DRUG: Drug therapy',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  'Ministry of Health\",\" France',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2022-03-25'],\n",
       " ['NCT01801371',\n",
       "  '68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma',\n",
       "  'GRGDG',\n",
       "  'UNKNOWN',\n",
       "  'Glioma',\n",
       "  'DRUG: 68Ga-BNOTA-PRGD2',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  'Beijing Tiantan Hospital',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-10',\n",
       "  '2017-12'],\n",
       " ['NCT05800171',\n",
       "  'Efficacy of Single Use Disposable Elevator Cap (DEC) Duodenoscopy',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cholangitis',\n",
       "  '',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-04-24',\n",
       "  '2025-02-21'],\n",
       " ['NCT04293471',\n",
       "  'Prediction of Outcome by Echocardiography in Left Bundle Branch Block',\n",
       "  'EchoLBBB',\n",
       "  'RECRUITING',\n",
       "  'Left Bundle-Branch Block',\n",
       "  '',\n",
       "  'University Hospital of North Norway',\n",
       "  'Oslo University Hospital|University of Bergen|Norwegian University of Science and Technology|University of Tromso|KU Leuven',\n",
       "  '2000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-15',\n",
       "  '2036-12-31'],\n",
       " ['NCT05973071',\n",
       "  'Clinical Use of a Contraceptive Decision Aid and Patient Outcomes',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Contraceptive Usage',\n",
       "  'BEHAVIORAL: Tuune Supplemented Contraceptive Visit|BEHAVIORAL: Traditional Contraceptive Visit',\n",
       "  'Texas Christian University',\n",
       "  'Oklahoma State University',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2024-01-01',\n",
       "  '2025-12-30'],\n",
       " ['NCT03118271',\n",
       "  'Comparison of the Effect of Lumbar Traction\", Spinal Manipulation,\" and Surgery in the Treatment of Lumbar Disc Herniation',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lumbar Disc Herniation|Lumbar Traction|Spinal Manipulation|Lumbar Surgery',\n",
       "  'DEVICE: lumbar traction|PROCEDURE: spinal manipulation|PROCEDURE: surgery',\n",
       "  'Shin Kong Wu Ho-Su Memorial Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-01',\n",
       "  '2019-12'],\n",
       " ['NCT00708071',\n",
       "  'Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin\", Vapor Heated,\" Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Facial Rhytidectomy (Face-lift)',\n",
       "  'BIOLOGICAL: Fibrin Sealant with 4 IU/ml Thrombin\", Vapor-Heated,\" Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)',\n",
       "  'Baxter Healthcare Corporation',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-06',\n",
       "  '2008-09'],\n",
       " ['NCT01875471',\n",
       "  'Clinical Evaluation of Two Daily Disposable Contact Lenses',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Refractive Error',\n",
       "  'DEVICE: delefilcon A|DEVICE: narafilcon A',\n",
       "  'Johnson & Johnson Vision Care\",\" Inc.',\n",
       "  '',\n",
       "  '279.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER',\n",
       "  '2013-06',\n",
       "  '2013-08'],\n",
       " ['NCT01637571',\n",
       "  'Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain',\n",
       "  'Dexilant',\n",
       "  'WITHDRAWN',\n",
       "  'Chest Pain|Gastrointestinal Reflux Disease',\n",
       "  'DRUG: Dexilant|DRUG: Dexilant Placebo',\n",
       "  'University of Iowa',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT01216371',\n",
       "  'Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)',\n",
       "  'SMAT',\n",
       "  'UNKNOWN',\n",
       "  'Renal Cell Carcinoma|Pulmonary Metastases',\n",
       "  'DRUG: Sunitinib|DRUG: Placebo',\n",
       "  'Association of Urologic Oncology (AUO)',\n",
       "  'University Hospital\",\" Essen',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-10',\n",
       "  '2015-10'],\n",
       " ['NCT00021671',\n",
       "  'Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Erythromycin|DRUG: Nevirapine|DRUG: Ampicillin sodium|DRUG: Metronidazole',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)',\n",
       "  '3720.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '',\n",
       "  '2004-11'],\n",
       " ['NCT05610371',\n",
       "  'Intrauterine Anesthesia in Operative\", Awake,\" Office Hysteroscopy. A Randomized Double-blind Placebo-controlled Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia\",\" Local|Office Hysteroscopy',\n",
       "  'DRUG: Lidocaine|DRUG: Saline',\n",
       "  'Assuta Ashdod Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-01',\n",
       "  '2022-05-01'],\n",
       " ['NCT00172471',\n",
       "  'The Relationship Between Sleep Disorders and Cytokine Levels Among Hemodialysis and Peritoneal Dialysis Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Renal Failure|Sleep Disorder|Hemodialysis|Peritoneal Dialysis',\n",
       "  '',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT03237871',\n",
       "  'The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Feasibility',\n",
       "  'BEHAVIORAL: Text-message survey and informational text messages',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '17.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2017-07-07',\n",
       "  '2017-09-19'],\n",
       " ['NCT04039971',\n",
       "  'Tendon-Bone Versus All-Soft-Tissue for ACL Reconstruction: A Patient-Blinded Randomized Clinical Trial',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Anterior Cruciate Ligament Injuries|Anterior Cruciate Ligament Rupture|Anterior Cruciate Ligament Tear',\n",
       "  'PROCEDURE: ACL Reconstruction',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  \"Children's Hospital Colorado\",\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2020-08-01',\n",
       "  '2029-08-31'],\n",
       " ['NCT01558271',\n",
       "  'A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: LY2189265|DRUG: Placebo|DRUG: Liraglutide',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '492.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2014-05'],\n",
       " ['NCT04597671',\n",
       "  'Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)',\n",
       "  'NVALT28',\n",
       "  'RECRUITING',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Durvalumab|RADIATION: low-dose PCI',\n",
       "  'Association NVALT Studies',\n",
       "  '',\n",
       "  '170.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-12-06',\n",
       "  '2032-12'],\n",
       " ['NCT03994471',\n",
       "  'Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.',\n",
       "  'ELIXIR',\n",
       "  'RECRUITING',\n",
       "  'End Stage Renal Disease',\n",
       "  'DRUG: XyloCore Low Strenght\", XyloCore Medium Strenght, XyloCore High Strenght|DRUG: 1.36%,1.50%,2.27%,2.50%,3.86%,\" 2.25% Glucose PD Solution',\n",
       "  'Iperboreal Pharma Srl',\n",
       "  '',\n",
       "  '170.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-14',\n",
       "  '2024-12'],\n",
       " ['NCT06143371',\n",
       "  'A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy|Plaque Psoriasis',\n",
       "  'BIOLOGICAL: CAN10|BIOLOGICAL: CAN10 - Placebo',\n",
       "  'Cantargia AB',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-08-21',\n",
       "  '2025-04-24'],\n",
       " ['NCT04862871',\n",
       "  'Enhancing Analgesia in Chronic Pain Through Exercise',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Pain|Chronic Widespread Pain|Fibromyalgia',\n",
       "  'BEHAVIORAL: Physical Activity - Pediatric Pain Rehabilitation Center',\n",
       "  \"Boston Children's Hospital\",\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2022-04-01',\n",
       "  '2022-11'],\n",
       " ['NCT02080871',\n",
       "  'A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.',\n",
       "  'VBXFLEX',\n",
       "  'COMPLETED',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'DEVICE: Stenting of the Common and/or External Iliac Arteries',\n",
       "  'W.L.Gore & Associates',\n",
       "  '',\n",
       "  '134.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2018-10'],\n",
       " ['NCT06132971',\n",
       "  'Multi-court Trial of NBP to Prevent Substance Abuse and Mental Health Disorders (MTC)',\n",
       "  'MTC',\n",
       "  'COMPLETED',\n",
       "  'Divorce|Drug Abuse|Mental Health Disorder',\n",
       "  'BEHAVIORAL: New Beginnings Program',\n",
       "  'Arizona State University',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '2415.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-07-30',\n",
       "  '2017-01-31'],\n",
       " ['NCT01044771',\n",
       "  'Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria',\n",
       "  'RALPIR',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Proteinuria',\n",
       "  'DRUG: change from tenofovir to raltegravir',\n",
       "  'Metropolis Medical',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-01',\n",
       "  '2011-06'],\n",
       " ['NCT05029271',\n",
       "  'InPen User Experience',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Type 1',\n",
       "  'DEVICE: InPen with Guardian 4 System',\n",
       "  'Medtronic Diabetes',\n",
       "  '',\n",
       "  '34.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2023-04-17',\n",
       "  '2023-12-08'],\n",
       " ['NCT03648671',\n",
       "  \"Pain in Parkinson's Disease With Motor Fluctuations.\",\n",
       "  'PAINinPD',\n",
       "  'UNKNOWN',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: safinamide metansolfonato (12 weeks)|DRUG: safinamide metansolfonato (12 weeks)|DRUG: rasagilina mesilato (12 weeks)|DRUG: rasagilina mesilato (12 weeks)',\n",
       "  'Universita di Verona',\n",
       "  'Azienda Ospedaliera Universitaria Integrata Verona',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-03-28',\n",
       "  '2019-11-30'],\n",
       " ['NCT02903771',\n",
       "  'Phase I Study of Cantrixil in Patients With Ovarian Cancer\",\" Fallopian Tube Cancer or Primary Peritoneal Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms',\n",
       "  'DRUG: Part A: Dose Escalation of Cantrixil|DRUG: Part B: Expansion Cohort of Cantrixil',\n",
       "  'Kazia Therapeutics Limited',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-11',\n",
       "  '2020-03-24'],\n",
       " ['NCT05524571',\n",
       "  'Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Thyroid Eye Disease',\n",
       "  'DRUG: Batoclimab|DRUG: Placebo',\n",
       "  'Immunovant Sciences GmbH',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-05',\n",
       "  '2025-01'],\n",
       " ['NCT02179671',\n",
       "  'Immune-Modulated Study of Selected Small Molecules (Gefitinib\", AZD9291,\" or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)',\n",
       "  'DRUG: Gefitinib|DRUG: AZD9291|DRUG: Selumetinib+Docetaxel|DRUG: Tremelimumab',\n",
       "  'AstraZeneca',\n",
       "  'Quintiles\",\" Inc.',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07-25',\n",
       "  '2016-06-11'],\n",
       " ['NCT00788671',\n",
       "  'Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Atypical Endometrial Hyperplasia|Stage I Uterine Corpus Cancer AJCC v7|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7',\n",
       "  'OTHER: Laboratory Biomarker Analysis|DEVICE: Levonorgestrel-Releasing Intrauterine System|OTHER: Quality-of-Life Assessment',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '69.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-11-03',\n",
       "  '2024-11-30'],\n",
       " ['NCT05003271',\n",
       "  'Pulmonary Rehabilitation Post-COVID-19',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'OTHER: Exercise program (virtual/remote)',\n",
       "  'University of Manitoba',\n",
       "  'Health Sciences Centre Foundation\", Manitoba|Health Sciences Centre, Winnipeg,\" Manitoba',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-04-04',\n",
       "  '2023-10-01'],\n",
       " ['NCT02047071',\n",
       "  'Effect of CPAP Treatment in Women With Moderate-to-severe OSA.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obstructive Sleep Apnea',\n",
       "  'DEVICE: Continuous positive airways pressure',\n",
       "  'Francisco Campos-Rodriguez',\n",
       "  'Fondo de Investigacion Sanitaria|Sociedad Española de Neumología y Cirugía Torácica',\n",
       "  '307.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02',\n",
       "  '2015-07'],\n",
       " ['NCT04416971',\n",
       "  'Clinical Values of Mature Fistulas in Hemodialysis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hemodialysis Access Failure|Hemodialysis Complication',\n",
       "  'PROCEDURE: AVF puncture',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-20',\n",
       "  '2021-11-20'],\n",
       " ['NCT06000371',\n",
       "  'Cutoff Value of Ankle Brachial Pressure Index for Vacuum Assisted Closure Application in Diabetic Foot Ulcers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetic Foot',\n",
       "  'DEVICE: Vacuum assisted Closure application',\n",
       "  'Mansoura University',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-04-25',\n",
       "  '2021-10-02'],\n",
       " ['NCT00851071',\n",
       "  'Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anxiety',\n",
       "  'BEHAVIORAL: Cognitive Behavioral Therapy',\n",
       "  'The Cleveland Clinic',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-02',\n",
       "  '2017-12-20'],\n",
       " ['NCT02921971',\n",
       "  'Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Systemic Sclerosis',\n",
       "  'DRUG: SAR156597|DRUG: Placebo',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-12-21',\n",
       "  '2019-04-01'],\n",
       " ['NCT00256971',\n",
       "  'Balance in Patients After Surgery for Torn Meniscus',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Torn Menisci',\n",
       "  'PROCEDURE: meniscectomy',\n",
       "  'Hadassah Medical Organization',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-11',\n",
       "  '2008-01'],\n",
       " ['NCT00165971',\n",
       "  'Recovery From General Anesthesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia\", General|Recovery Period,\" Anesthesia',\n",
       "  'PROCEDURE: BIS monitoring',\n",
       "  'Emory University',\n",
       "  'CogState Ltd.',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '2003-12',\n",
       "  '2007-02'],\n",
       " ['NCT05698771',\n",
       "  'NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy',\n",
       "  'NAD-brain',\n",
       "  'RECRUITING',\n",
       "  'Healthy',\n",
       "  'DIETARY_SUPPLEMENT: nicotinamide riboside|DIETARY_SUPPLEMENT: nicotinamide mononucleotide',\n",
       "  'Haukeland University Hospital',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-29',\n",
       "  '2023-03-17'],\n",
       " ['NCT01159171',\n",
       "  'A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer',\n",
       "  'DRUG: bevacizumab [Avastin]|DRUG: capecitabine [Xeloda]|DRUG: oxaliplatin',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2010-07'],\n",
       " ['NCT01464671',\n",
       "  'Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention',\n",
       "  'STATUS PCI',\n",
       "  'TERMINATED',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Bivalirudin|DRUG: Heparin',\n",
       "  'Stony Brook University',\n",
       "  '',\n",
       "  '260.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2014-09'],\n",
       " ['NCT04251871',\n",
       "  'Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pneumonia Caused by Human Coronavirus (Disorder)',\n",
       "  'DRUG: Conventional medicines (Oxygen therapy\", alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|DRUG: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation,\" and lopinavir/ritonavir)',\n",
       "  'Beijing 302 Hospital',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01-22',\n",
       "  '2021-01-22'],\n",
       " ['NCT00067171',\n",
       "  'Telephone Enhancement Procedure for Continuing Care - 1',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Substance-Related Disorders',\n",
       "  'BEHAVIORAL: Behavior Therapy',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '339.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: ',\n",
       "  '2003-01',\n",
       "  '2004-01'],\n",
       " ['NCT04565171',\n",
       "  'Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Renal Impairment',\n",
       "  'DRUG: Yimitasvir Phosphate Capsule',\n",
       "  'Sunshine Lake Pharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '16.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04-15',\n",
       "  '2022-05-07'],\n",
       " ['NCT03167671',\n",
       "  'The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain',\n",
       "  'AposBack',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Low Back Pain',\n",
       "  'DEVICE: AposTherapy|OTHER: Traditional Physical Therapy',\n",
       "  'Montefiore Medical Center',\n",
       "  'Apos Medical and Sports Technology Ltd.',\n",
       "  '143.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-08-15',\n",
       "  '2024-01-28'],\n",
       " ['NCT03795571',\n",
       "  'Lenalidomide\", Rituximab, Gemcitabine,\" Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL',\n",
       "  'R2-GOD',\n",
       "  'UNKNOWN',\n",
       "  'Diffuse Large B-cell Lymphoma Recurrent|Diffuse Large B Cell Lymphoma Refractory',\n",
       "  'DRUG: Rituximab|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Dexamethasone|DRUG: Lenalidomide Oral Capsule',\n",
       "  'The First Affiliated Hospital with Nanjing Medical University',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-01',\n",
       "  '2019-12-31'],\n",
       " ['NCT00939471',\n",
       "  'Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis',\n",
       "  'INTACT',\n",
       "  'COMPLETED',\n",
       "  'Chronic Sinusitis',\n",
       "  'DEVICE: Relieva™ Balloon Sinuplasty™ System',\n",
       "  'Acclarent',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-04-01',\n",
       "  '2010-05-01'],\n",
       " ['NCT01957371',\n",
       "  'Mindful Yoga Therapy for Veterans With PTSD and Pain',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'PTSD|Chronic Pain',\n",
       "  'BEHAVIORAL: Mindful Yoga Therapy',\n",
       "  'VA Connecticut Healthcare System',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-09',\n",
       "  '2015-11'],\n",
       " ['NCT03223571',\n",
       "  'Brain Plasticity Mapping Post-stroke',\n",
       "  'MAPPY',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'OTHER: Motor rehabilitation training',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-07-27',\n",
       "  '2017-07-27'],\n",
       " ['NCT00645671',\n",
       "  'Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ocular Inflammation',\n",
       "  'DRUG: 0.5% Loteprednol Etabonate Ophthalmic Ointment|DRUG: Vehicle of Loteprednol Etabonate Ophthalmic Ointment',\n",
       "  'Bausch & Lomb Incorporated',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-03',\n",
       "  '2009-03'],\n",
       " ['NCT04909671',\n",
       "  'Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.',\n",
       "  'Timely',\n",
       "  'RECRUITING',\n",
       "  'Lynch Syndrome',\n",
       "  'DEVICE: Gi Genius\",\" Medtronic|OTHER: White light standart colonoscopy',\n",
       "  'Hospital Clinic of Barcelona',\n",
       "  'European Society of Gastrointestinal Endoscopy',\n",
       "  '404.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-09-13',\n",
       "  '2023-12-01'],\n",
       " ['NCT06091371',\n",
       "  'Arthrorisis of the Subtalar Joint With a Polymeric Endorthesis for Flexible Flatfoot Treatment During the Growth Age Prospective Evaluation',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Subtalar Arthrorisis|Flat Feet|Growth Age',\n",
       "  '',\n",
       "  'Istituto Ortopedico Rizzoli',\n",
       "  '',\n",
       "  '55.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-07-01',\n",
       "  '2028-01'],\n",
       " ['NCT00752271',\n",
       "  'AMS Study: Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Osteoarthritis',\n",
       "  '',\n",
       "  'National Institute on Aging (NIA)',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-05',\n",
       "  '2010-05'],\n",
       " ['NCT04094571',\n",
       "  'Muscle Delay Characterization',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Neurological Disorders',\n",
       "  'DEVICE: Functional Electrical Stimulation (FES) Control Protocol|DEVICE: Functional Electrical Stimulation (FES) Angle Protocol',\n",
       "  'University of Florida',\n",
       "  'National Science Foundation',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-10-01',\n",
       "  '2021-09-03'],\n",
       " ['NCT05797571',\n",
       "  \"SOSteniamoci: Stakeholders' Survey\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Informal Caregivers',\n",
       "  '',\n",
       "  'Istituto Auxologico Italiano',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01-15',\n",
       "  '2022-12-15'],\n",
       " ['NCT02499471',\n",
       "  'Brown Adipose Tissue Activity and Thyroid Hormone',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypothyroidism|Hyperthyroidism|Obesity',\n",
       "  'OTHER: Levothyroxine therapy (137.75 ± 23.75 μg/day)',\n",
       "  'Maastricht University Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-03',\n",
       "  '2014-07'],\n",
       " ['NCT04318171',\n",
       "  'The Evaluation of Tomographic 3D Ultrasound for the Assessment of Vascular Pathology',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Carotid Artery Plaque',\n",
       "  'DEVICE: 3D Imaging.',\n",
       "  'Imperial College London',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-07-01',\n",
       "  '2023-01-01'],\n",
       " ['NCT01231971',\n",
       "  \"Alzheimer's Disease Neuroimaging Initiative 2\",\n",
       "  'ADNI2',\n",
       "  'COMPLETED',\n",
       "  \"Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)|Significant Memory Concern (SMC)|Early Mild Cognitive Impairment (EMCI)|Late Mild Cognitive Impairment (LMCI)\",\n",
       "  'DRUG: Florbetapir|DRUG: Flortaucipir',\n",
       "  'University of Southern California',\n",
       "  \"Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute\",\n",
       "  '1182.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-02-14',\n",
       "  '2017-11-29'],\n",
       " ['NCT04695171',\n",
       "  'LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Hiatal Hernia Large|Gastro Esophageal Reflux|Hiatal Hernia|Hiatal Hernia\", Paraesophageal|Reflux,\" Gastroesophageal|Reflux Acid',\n",
       "  'DEVICE: LINX Reflux Management System|PROCEDURE: Fundoplication',\n",
       "  'Foregut Research Foundation',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-01-14',\n",
       "  '2028-01'],\n",
       " ['NCT03958071',\n",
       "  'A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Pulmonary Fibrosis',\n",
       "  'DRUG: Nintedanib|DRUG: Pirfenidone|OTHER: Untreated Cohort',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '13264.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2019-05-31'],\n",
       " ['NCT03711071',\n",
       "  'Ideas\", Concerns,\" Expectations. Implementing Patient-centered Communication',\n",
       "  'ICE',\n",
       "  'UNKNOWN',\n",
       "  'Communication|Back Pain',\n",
       "  '\"\"OTHER: Workshop \"\"\"\"ICE training\"\"\"\"\"\"',\n",
       "  'University of Erlangen-Nürnberg Medical School',\n",
       "  'German Federal Ministry of Education and Research|University of Erlangen-Nürnberg',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2017-10-01',\n",
       "  '2019-12'],\n",
       " ['NCT03516071',\n",
       "  'A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatocellular Carcinoma (HCC)',\n",
       "  'DRUG: Brivanib 800 mg\", QD|DRUG: Brivanib 400 mg,\" BID',\n",
       "  'Zai Lab (Shanghai) Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-05-17',\n",
       "  '2019-07-19'],\n",
       " ['NCT01953471',\n",
       "  'Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergic Rhinitis Due to Grass Pollen',\n",
       "  'OTHER: Allergic rhinitis',\n",
       "  'Hopital Foch',\n",
       "  '',\n",
       "  '959.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2011-12'],\n",
       " ['NCT03921671',\n",
       "  'Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)',\n",
       "  'RELEVENT',\n",
       "  'UNKNOWN',\n",
       "  'Thymic Carcinoma|Thymoma',\n",
       "  'COMBINATION_PRODUCT: Ramucirumab',\n",
       "  'Marina Garassino',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-01',\n",
       "  '2022-07-16'],\n",
       " ['NCT02134171',\n",
       "  'Early Predictive Factors of Cardiac and Cerebral Involvement in TMA',\n",
       "  'MATRISK',\n",
       "  'COMPLETED',\n",
       "  'Thrombotic Microangiopathies|Thrombotic Thrombocytopenic Purpura',\n",
       "  'OTHER: Biological and imaging investigations',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '119.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-06-10',\n",
       "  '2017-07-30'],\n",
       " ['NCT04855071',\n",
       "  'Radiofrequency and Pelvic Organ Prolapse',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pelvic Organ Prolapse',\n",
       "  'DEVICE: Non-ablative radiofrequency application|OTHER: Usual intervention',\n",
       "  \"Fundació d'investigació Sanitària de les Illes Balears\",\n",
       "  'University of the Balearic Islands',\n",
       "  '40.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-04-23',\n",
       "  '2022-10-23'],\n",
       " ['NCT01741571',\n",
       "  'Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lung Cancer',\n",
       "  'DEVICE: EBUS guided FNA with and without suction',\n",
       "  'American University of Beirut Medical Center',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-12',\n",
       "  '2017-01'],\n",
       " ['NCT00484471',\n",
       "  'ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness',\n",
       "  'ABLE',\n",
       "  'COMPLETED',\n",
       "  'Bipolar Disorder',\n",
       "  'DRUG: aripiprazole|DRUG: valproate|DRUG: placebo',\n",
       "  'Korea Otsuka International Asia Arab',\n",
       "  '',\n",
       "  '127.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-10',\n",
       "  '2012-11'],\n",
       " ['NCT02301871',\n",
       "  'The Effect of Soft Tissue Mobilization in Myofascial Neck Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Neck Pain',\n",
       "  \"DEVICE: Dr. Gene's Health and Wellness|PROCEDURE: Muscle Energy Technique|PROCEDURE: Static stretching and Cervical non thrust manipulation\",\n",
       "  'Maharishi Markendeswar University (Deemed to be University)',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2014-05'],\n",
       " ['NCT03906071',\n",
       "  'Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer',\n",
       "  'SAPPHIRE',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Metastatic Non-Squamous Non-Small Cell Lung Cancer',\n",
       "  'BIOLOGICAL: Nivolumab|DRUG: Sitravatinib|DRUG: Docetaxel',\n",
       "  'Mirati Therapeutics Inc.',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '532.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-15',\n",
       "  '2024-04-30'],\n",
       " ['NCT03679871',\n",
       "  'Spiritual Assessment in Chronic Pain Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Pain|Spirituality',\n",
       "  'OTHER: Questionnaire validation',\n",
       "  'University of Zurich',\n",
       "  'Swiss National Science Foundation',\n",
       "  '225.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2018-10-22',\n",
       "  '2019-11-13'],\n",
       " ['NCT03272971',\n",
       "  'Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lung Cancer|Lung Cancer Metastatic|Lung Cancer\",\" Non-small Cell',\n",
       "  'DEVICE: Radio-frequency Ablation',\n",
       "  'Broncus Medical Inc',\n",
       "  'Uptake Medical Technology\",\" Inc.',\n",
       "  '3.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2017-12-05',\n",
       "  '2019-01-30'],\n",
       " ['NCT01998971',\n",
       "  'A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: Daratumumab|DRUG: Velcade|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Melphalan|DRUG: Prednisone|DRUG: Thalidomide|DRUG: Diphenhydramine|DRUG: Acetaminophen|DRUG: Carfilzomib|DRUG: Lenalidomide|DRUG: Montelukast',\n",
       "  'Janssen Research & Development\",\" LLC',\n",
       "  '',\n",
       "  '242.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02-18',\n",
       "  '2023-12-29'],\n",
       " ['NCT03146871',\n",
       "  'Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome\", Chronic Myelomonocytic Leukemia,\" or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Adult Acute Myeloid Leukemia',\n",
       "  'DRUG: Azacitidine|DRUG: Decitabine|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein',\n",
       "  'University of Southern California',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '7.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-20',\n",
       "  '2019-03-27'],\n",
       " ['NCT01153971',\n",
       "  'A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  \"Non-Hodgkin's Lymphoma\",\n",
       "  'DRUG: rituximab',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '47.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-07-20',\n",
       "  '2010-09-24'],\n",
       " ['NCT05319171',\n",
       "  'Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.',\n",
       "  'PANTHEON',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Aortic Regurgitation',\n",
       "  'DEVICE: TAVR',\n",
       "  'IRCCS Policlinico S. Donato',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05',\n",
       "  '2022-11'],\n",
       " ['NCT05538871',\n",
       "  'Body Structure and Capacity Evaluation of Adults With Scoliosis',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Scoliosis',\n",
       "  'DIAGNOSTIC_TEST: Survey + Physical exam',\n",
       "  'University of Alberta',\n",
       "  '',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-06',\n",
       "  '2024-05-06'],\n",
       " ['NCT00046371',\n",
       "  'Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Neoplasms',\n",
       "  'DRUG: THERATOPE® vaccine',\n",
       "  'Oncothyreon Canada Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2002-08',\n",
       "  '2005-08'],\n",
       " ['NCT01515371',\n",
       "  'Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Habitual Snoring',\n",
       "  'DRUG: IncobotulinumtoxinA|DRUG: Placebo Comparator',\n",
       "  'Merz Pharmaceuticals GmbH',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2012-11'],\n",
       " ['NCT06149871',\n",
       "  'Effectiveness of Individual Physical Activity Programs to Prevent Sarcopenia and Frailty Among Older Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sarcopenia|Frailty',\n",
       "  'BEHAVIORAL: Physical activity',\n",
       "  'Ministry of Health\",\" Thailand',\n",
       "  'Chulalongkorn University',\n",
       "  '360.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2021-03-01',\n",
       "  '2022-08-31'],\n",
       " ['NCT03363971',\n",
       "  'Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Soft Tissue Injuries',\n",
       "  'DRUG: Zhi Kang Capsule|DRUG: Simulant agent for Zhi Kang Capsule',\n",
       "  \"Peking University People's Hospital\",\n",
       "  '',\n",
       "  '2200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-13',\n",
       "  '2018-03-13'],\n",
       " ['NCT05989971',\n",
       "  'The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Respiratory Failure With Hypercapnia',\n",
       "  'OTHER: continuous renal replacement therapy',\n",
       "  'Southeast University\",\" China',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-04-24',\n",
       "  '2023-12'],\n",
       " ['NCT02712671',\n",
       "  'Testing for Tuberculosis in the United Kingdom HIV Infected Population',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'HIV|Latent Tuberculosis',\n",
       "  'RADIATION: Chest radiograph|PROCEDURE: Blood interferon gamma release assay|PROCEDURE: Tuberculin skin testing (TST)|PROCEDURE: Sputum induction for mycobacterial microscopy and culture|OTHER: Mycobacterium tuberculosis polymerase chain reaction testing|PROCEDURE: Spirometry',\n",
       "  'University College\",\" London',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-06',\n",
       "  '2024-09'],\n",
       " ['NCT04089371',\n",
       "  'A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Arthroplasty|Hemiarthroplasty|Shoulder Pain',\n",
       "  'DEVICE: ReUnion Total Shoulder Arthroplasty (TSA)|DEVICE: ReUnion Reverse Shoulder Arthroplasty (RSA)',\n",
       "  'Stryker Trauma GmbH',\n",
       "  '',\n",
       "  '14.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-10-01',\n",
       "  '2022-07-08'],\n",
       " ['NCT02911571',\n",
       "  'PRospective Multiple Myeloma Impact Study',\n",
       "  'PROMMIS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DEVICE: MMprofiler SKY92 gene signature',\n",
       "  'SkylineDx',\n",
       "  'Medex15',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2018-02-27',\n",
       "  '2026-09-01'],\n",
       " ['NCT01623271',\n",
       "  'Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Complex Regional Pain Syndrome I (CRPS I)',\n",
       "  'DRUG: Gabapentin',\n",
       "  'Massachusetts General Hospital',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2014-06'],\n",
       " ['NCT02268071',\n",
       "  'Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension',\n",
       "  'DRUG: Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence',\n",
       "  'Central Hospital\", Nancy,\" France',\n",
       "  '',\n",
       "  '403.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-03-10',\n",
       "  '2020-10-21'],\n",
       " ['NCT05772871',\n",
       "  'The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Nephrotic Syndrome in Children',\n",
       "  'DRUG: Huaiqihuang granule|DRUG: Prednisone|DRUG: Levamisole placebo|DRUG: Levamisole|DRUG: Huaiqihuang Granule placebo',\n",
       "  'Jianhua Zhou',\n",
       "  'LinkDoc Technology (Beijing) Co. Ltd.',\n",
       "  '402.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-26',\n",
       "  '2025-10-30'],\n",
       " ['NCT02492971',\n",
       "  'Function-oriented Assistive Technology Indexing System Development and Promotion',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Disability',\n",
       "  '',\n",
       "  'Chang Gung Memorial Hospital',\n",
       "  '',\n",
       "  '175.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-09',\n",
       "  '2017-11'],\n",
       " ['NCT03505671',\n",
       "  'Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Grade 1 Peripheral Motor Neuropathy\", CTCAE|Grade 1 Peripheral Sensory Neuropathy, CTCAE|Grade 2 Peripheral Motor Neuropathy, CTCAE|Grade 2 Peripheral Sensory Neuropathy,\" CTCAE|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8',\n",
       "  'PROCEDURE: Acupuncture Therapy|OTHER: Best Practice|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-08-03',\n",
       "  '2021-02-21'],\n",
       " ['NCT04309071',\n",
       "  'Saliva Insulin Responses to a Standardized Meal Tolerance Test in Humans',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Diet Modification|Insulin Resistance|Hyperinsulinemia',\n",
       "  'OTHER: Dietary intervention',\n",
       "  'University of British Columbia',\n",
       "  'Mitacs|Core-Health Technologies Inc.',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-01-04',\n",
       "  '2022-09'],\n",
       " ['NCT04614571',\n",
       "  'T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Celiac Disease',\n",
       "  'DIETARY_SUPPLEMENT: Gluten Powder',\n",
       "  'Regeneron Pharmaceuticals',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2020-11-02',\n",
       "  '2024-09-30'],\n",
       " ['NCT00407771',\n",
       "  'The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Artery Disease',\n",
       "  'DRUG: Tirofiban',\n",
       "  'Jordan Hospital',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-11',\n",
       "  '2008-12'],\n",
       " ['NCT01724671',\n",
       "  'Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'MRSA Infection|Bacteremia|ABSSSI|Pneumonia',\n",
       "  '',\n",
       "  'CPL Associates',\n",
       "  'Forest Laboratories',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-12',\n",
       "  '2013-12'],\n",
       " ['NCT05150171',\n",
       "  'Happy Hands E-self-management Pilot Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hand Osteoarthritis',\n",
       "  'OTHER: e-self-management intervention',\n",
       "  'Diakonhjemmet Hospital',\n",
       "  'The Norwegian Rheumatism Association',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-11-23',\n",
       "  '2022-12-31'],\n",
       " ['NCT06106971',\n",
       "  'Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Gastric Varices Bleeding|Liver Decompensation',\n",
       "  'DRUG: Sodium tetradecyl sulfate|DRUG: Cyanoacrylate',\n",
       "  'Kaohsiung Veterans General Hospital.',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-06-28',\n",
       "  '2025-06'],\n",
       " ['NCT00115271',\n",
       "  'Antenatal Micronutrient Supplementation and Birth Weight',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Birth Weight|Infant Mortality|Pregnancy|Nutritional Status',\n",
       "  'DRUG: Nutritional supplements',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  'United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Johns Hopkins University',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '1999-01',\n",
       "  '2001-05'],\n",
       " ['NCT04661371',\n",
       "  'Necessity of Preoperative Empirical Antibiotic Use in Acute Cholecystitis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cholecystitis\",\" Acute',\n",
       "  'PROCEDURE: Laparoscopic cholecystectomy',\n",
       "  \"Seoul St. Mary's Hospital\",\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-03-02',\n",
       "  '2021-12-30'],\n",
       " ['NCT04921371',\n",
       "  'Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gingivitis|Plaque',\n",
       "  'OTHER: Colgate® Cavity Protection Toothpaste|OTHER: Listerine® Cool Mint®|OTHER: Concept Curve Winter Series Toothbrush|OTHER: 5% Hydroalcohol Mouthrinse|OTHER: Mouthrinse Prototype 1|OTHER: Mouthrinse Prototype 2',\n",
       "  'Johnson & Johnson Consumer Inc. (J&JCI)',\n",
       "  '',\n",
       "  '157.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-10-08',\n",
       "  '2019-12-19'],\n",
       " ['NCT01105871',\n",
       "  'Subjective Analgesic Effects of Naloxone and Virtual Reality',\n",
       "  'Narcan',\n",
       "  'UNKNOWN',\n",
       "  'Pain',\n",
       "  'DRUG: naloxone|DRUG: Placebo',\n",
       "  'University of Washington',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2010-08',\n",
       "  '2014-06'],\n",
       " ['NCT05482971',\n",
       "  'A Single-arm\", Multicenter Study to Assess the Efficacy, Safety,\" and Tolerability of P1101 in Adults With ET',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Essential Thrombocythemia',\n",
       "  'DRUG: Ropeginterferon alfa-2b-njft (P1101)',\n",
       "  'PharmaEssentia',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-09-29',\n",
       "  '2026-12-31'],\n",
       " ['NCT05752071',\n",
       "  'Gastrointestinal Stimulation as a Treatment of Postoperative Ileus Following Extensive Surgery',\n",
       "  'STIMULATE',\n",
       "  'RECRUITING',\n",
       "  'Postoperative Ileus|Bowel Paralysis',\n",
       "  'DEVICE: Gastric electric pacemaker',\n",
       "  'University of Aarhus',\n",
       "  'Danish Cancer Society',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-04-01',\n",
       "  '2025-09'],\n",
       " ['NCT02607371',\n",
       "  'Anticoagulation Preference by AF Patients Study',\n",
       "  'PRiSMA-AF',\n",
       "  'COMPLETED',\n",
       "  'Atrial Fibrillation',\n",
       "  'OTHER: VKAs|OTHER: NOACs including Rivaroxaban (Xarelto\",\" BAY59-7939)|OTHER: Edoxaban|OTHER: Apixaban|OTHER: Dabigatran-etexilate',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '198.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08-27',\n",
       "  '2016-10-15'],\n",
       " ['NCT03461471',\n",
       "  'Exercise in All ChemoTherapy',\n",
       "  'EnACT',\n",
       "  'COMPLETED',\n",
       "  'Chemotherapy|Exercise',\n",
       "  'BEHAVIORAL: Exercise Intervention',\n",
       "  'Milton S. Hershey Medical Center',\n",
       "  '',\n",
       "  '168.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-04-01',\n",
       "  '2019-03-30'],\n",
       " ['NCT01789671',\n",
       "  'Peer Counseling in Family-Based Treatment for Childhood Obesity',\n",
       "  'EPICH',\n",
       "  'COMPLETED',\n",
       "  'Childhood Obesity',\n",
       "  'BEHAVIORAL: Family-based behavioral intervention',\n",
       "  \"Seattle Children's Hospital\",\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-09',\n",
       "  '2014-06'],\n",
       " ['NCT06212271',\n",
       "  'A Mechanistic Clinical Trial of Colchicine in Patients Undergoing Femoral Endarterectomy',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Peripheral Artery Disease',\n",
       "  'DRUG: Colchicine|DRUG: Placebo',\n",
       "  'University of Pennsylvania',\n",
       "  'Doris Duke Charitable Foundation',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2024-02',\n",
       "  '2026-01'],\n",
       " ['NCT00324571',\n",
       "  'Dialysis Clinical Outcomes Revisited (DCOR) Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Kidney Disease',\n",
       "  'DRUG: Sevelamer hydrochloride|DRUG: Calcium-based phosphate binder',\n",
       "  'Genzyme\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '2000.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-03',\n",
       "  '2006-02'],\n",
       " ['NCT03360071',\n",
       "  'A Novel Biologic Therapy for Perennial Allergic Rhinitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Allergic Rhinitis',\n",
       "  'DRUG: Allergen Immunotherapy Extract|DRUG: Allergen Immunotherapy Control',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-12-19',\n",
       "  '2018-11-01'],\n",
       " ['NCT05758571',\n",
       "  'Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Interstitial Pneumonia|Neoplasms Malignant',\n",
       "  'DRUG: EGCG',\n",
       "  'Shandong Cancer Hospital and Institute',\n",
       "  '',\n",
       "  '78.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-05',\n",
       "  '2025-12-31'],\n",
       " ['NCT01589471',\n",
       "  'The Value of Botox-A for Management of Low Anterior Resection Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Anterior Resection Syndrome|Rectal Cancer',\n",
       "  'DRUG: intra-rectal Botulinum toxin A injection',\n",
       "  \"Centre hospitalier de l'Université de Montréal (CHUM)\",\n",
       "  'Allergan',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-05',\n",
       "  '2015-11'],\n",
       " ['NCT06062771',\n",
       "  'Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cataract',\n",
       "  'DEVICE: FIDIAL PLUS|DEVICE: IAL®-F',\n",
       "  'Fidia Farmaceutici s.p.a.',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-07-23',\n",
       "  '2023-01-01'],\n",
       " ['NCT04283071',\n",
       "  'Kinematic Assessment In Multiple Sclerosis',\n",
       "  'KAIMS',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis',\n",
       "  'DEVICE: Boxed infrared gross kinematic assessment tool',\n",
       "  'The Leeds Teaching Hospitals NHS Trust',\n",
       "  'University of Leeds',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-07',\n",
       "  '2021-10-30'],\n",
       " ['NCT00323271',\n",
       "  'Cognitive-behavior Therapy for MS-Related Chronic Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis',\n",
       "  'BEHAVIORAL: Cognitive-behavior therapy|OTHER: Interventional',\n",
       "  'US Department of Veterans Affairs',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-07',\n",
       "  '2011-03'],\n",
       " ['NCT03356171',\n",
       "  'Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer',\n",
       "  'APACCHE',\n",
       "  'UNKNOWN',\n",
       "  'Physical Activity|Cancer|Hematologic Diseases',\n",
       "  'PROCEDURE: Cardiac Coherence|PROCEDURE: Adapted Physical Activity',\n",
       "  'Centre Hospitalier Universitaire de la Réunion',\n",
       "  '',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-01',\n",
       "  '2019-06'],\n",
       " ['NCT01022671',\n",
       "  'Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Belotecan',\n",
       "  'Chong Kun Dang Pharmaceutical',\n",
       "  'Asan Medical Center|Samsung Medical Center|Seoul National University Hospital|Ulsan University Hospital',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-09',\n",
       "  '2010-03'],\n",
       " ['NCT01265771',\n",
       "  'Optimizing Diagnostics Of Arrhythmia Events In Children Using Intelligent Telemetric Solutions',\n",
       "  'TELEMARC2',\n",
       "  'UNKNOWN',\n",
       "  'Arrhythmia|Children',\n",
       "  'DEVICE: Prolonged telemetric Full Disclosure ECG recording.|DEVICE: Repeated 24 hours ECG Holter monitoring',\n",
       "  'National Institute of Cardiology\", Warsaw,\" Poland',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-02',\n",
       "  '2013-01'],\n",
       " ['NCT00006071',\n",
       "  'Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypercholesterolemia|Hypertension',\n",
       "  '',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2000-07',\n",
       "  '2001-03'],\n",
       " ['NCT02270671',\n",
       "  'Attention Bias Modification Training for Young People',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anxiety|Depression',\n",
       "  'BEHAVIORAL: ABMT|OTHER: Placebo',\n",
       "  'University College Dublin',\n",
       "  'Tel Aviv University',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-10',\n",
       "  '2015-05'],\n",
       " ['NCT02277171',\n",
       "  'Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Urinary Tract Infection|Bacteriuria',\n",
       "  'DEVICE: Nitric Oxide impregnated catheter',\n",
       "  'Enox Israel Ltd',\n",
       "  'Rabin Medical Center',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-12',\n",
       "  '2015-09'],\n",
       " ['NCT03482271',\n",
       "  'Connected Yorkshire: A Data-linkage Study of Pre-hospital\",\" Emergency Department and Out of Hours Service Data',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Emergency and Urgent Care Pathways',\n",
       "  'OTHER: No intervention - data collection only',\n",
       "  'University of Sheffield',\n",
       "  'Northern Health Science Alliance (NHSA)',\n",
       "  '7500000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-01',\n",
       "  ''],\n",
       " ['NCT05117671',\n",
       "  'Is the EBJIS Definition of Prosthetic Joint Infection Meaningful in Our Clinical Practice?',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Periprosthetic Joint Infection (PJI)',\n",
       "  'OTHER: data collection to classify infection status',\n",
       "  'University Hospital\", Basel,\" Switzerland',\n",
       "  '',\n",
       "  '1200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-16',\n",
       "  '2022-04'],\n",
       " ['NCT04288271',\n",
       "  'Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Medication Adherence|Kidney Transplantation',\n",
       "  'BEHAVIORAL: Adherence Intervention|OTHER: Healthy living education intervention',\n",
       "  'McGill University Health Centre/Research Institute of the McGill University Health Centre',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '96.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-02-04',\n",
       "  '2023-06'],\n",
       " ['NCT01222871',\n",
       "  'Treatment of Early Nasal Polyposis With Topical Triamcinolone',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Nasal Polyps',\n",
       "  'DRUG: Triamcinolone|DRUG: Saline soaked sponge',\n",
       "  'Steward St. Elizabeth\\'s Medical Center of Boston\",\" Inc.',\n",
       "  '',\n",
       "  '1.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-07',\n",
       "  '2012-08'],\n",
       " ['NCT02746471',\n",
       "  'Reveal LINQ Registry',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Arrhythmias\",\" Cardiac',\n",
       "  'DEVICE: Reveal LINQ',\n",
       "  'Medtronic Cardiac Rhythm and Heart Failure',\n",
       "  '',\n",
       "  '1604.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-04',\n",
       "  '2021-06-04'],\n",
       " ['NCT02923271',\n",
       "  'Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Teen Drivers|Motor Vehicle Accidents',\n",
       "  'DEVICE: CellControl',\n",
       "  \"Children's Hospital of Philadelphia\",\n",
       "  'University of Pennsylvania',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-12-07',\n",
       "  '2017-11-16'],\n",
       " ['NCT06027671',\n",
       "  'Structured Peer-delivered ART and Reentry Community Strategy',\n",
       "  'SPARCS',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Retention in Care',\n",
       "  'BEHAVIORAL: Group SPARCS Intervention|BEHAVIORAL: ART-SPARCS Intervention',\n",
       "  'Johns Hopkins University',\n",
       "  'Aurum Institute|Seoul National University|National Institute of Mental Health (NIMH)',\n",
       "  '640.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-04-01',\n",
       "  '2028-10-01'],\n",
       " ['NCT04511871',\n",
       "  'A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Solid Tumor|Gastric Cancer|Breast Cancer|Ovarian Cancer|Sarcoma',\n",
       "  'BIOLOGICAL: CCT303-406',\n",
       "  'Shanghai PerHum Therapeutics Co.\",\" Ltd.',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-07-09',\n",
       "  '2025-03-29'],\n",
       " ['NCT00505271',\n",
       "  'Safety and Efficacy Study Using Rexin-G for Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'GENETIC: Rexin-G',\n",
       "  'Epeius Biotechnologies',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2011-06'],\n",
       " ['NCT04966871',\n",
       "  'Safety\",\" Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Malaria',\n",
       "  'BIOLOGICAL: PfSPZ Vaccine|BIOLOGICAL: PfSPZ Challenge (7G8) for CHMI|OTHER: Normal Saline',\n",
       "  'Sanaria Inc.',\n",
       "  'Fred Hutchinson Cancer Center',\n",
       "  '54.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-09-27',\n",
       "  '2022-06-21'],\n",
       " ['NCT05605171',\n",
       "  'Posterior Urethrovesical Anastomotic Reconstruction in Comparison to Conventional Urethrovesical Anastomosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'PROCEDURE: Posterior reconstruction urethrovesical anastomosis.|PROCEDURE: Conventional vesicourethral anastomosis.',\n",
       "  \"St. Joseph's Healthcare Hamilton\",\n",
       "  '',\n",
       "  '163.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-03-19',\n",
       "  '2019-03-23'],\n",
       " ['NCT06235671',\n",
       "  'Effects of Chiropractic on Chronic Cancer-related Fatigue',\n",
       "  'CAN',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer|Fatigue',\n",
       "  'PROCEDURE: Chiropractic care',\n",
       "  'Life University',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-03-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT01770171',\n",
       "  'Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer',\n",
       "  'MITOBEVAEND2',\n",
       "  'UNKNOWN',\n",
       "  'Stage III-IV or Recurrent Endometrial Cancer',\n",
       "  'DRUG: Bevacizumab|DRUG: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles',\n",
       "  'Catholic University of the Sacred Heart',\n",
       "  '',\n",
       "  '108.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-04',\n",
       "  '2017-12'],\n",
       " ['NCT04541771',\n",
       "  'The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants',\n",
       "  'NEC',\n",
       "  'UNKNOWN',\n",
       "  'Necrotizing Enterocolitis|Sepsis',\n",
       "  'DRUG: Lactobacillus Reuteri DSM 17938|DRUG: Placebo',\n",
       "  'Children\\'s Hospital and Institute of Child Health\",\" Multan',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2020-10',\n",
       "  '2021-01'],\n",
       " ['NCT03061071',\n",
       "  'The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sleep Apnea Syndromes',\n",
       "  'DEVICE: NightBalance Sleep Position Trainer (SPT)|DEVICE: Automated Adjusting Positive Airway Pressure (APAP)',\n",
       "  'NightBalance',\n",
       "  '',\n",
       "  '117.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-01',\n",
       "  '2018-07-12'],\n",
       " ['NCT02665871',\n",
       "  'Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Influenza',\n",
       "  'BIOLOGICAL: one dose of Influenza Vaccine|BIOLOGICAL: one dose of Influenza Vaccine|BIOLOGICAL: placebo|BIOLOGICAL: placebo',\n",
       "  'Beijing Chaoyang District Centre for Disease Control and Prevention',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-03',\n",
       "  '2016-09'],\n",
       " ['NCT00748371',\n",
       "  'Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Platelet Aggregation',\n",
       "  'DRUG: aspirin|DRUG: aspirin|DRUG: placebo',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '51.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2004-06',\n",
       "  '2011-02'],\n",
       " ['NCT02412371',\n",
       "  'A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Non-small Cell Lung Cancer Stage III',\n",
       "  'DRUG: Paclitaxel|DRUG: Placebo for Veliparib|DRUG: Carboplatin|DRUG: Veliparib|RADIATION: Radiotherapy',\n",
       "  'AbbVie',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04-30',\n",
       "  '2019-08-05'],\n",
       " ['NCT04133571',\n",
       "  'Bladder Irrigation 0.05% Lidocaine Decreases Postoperative CRBD',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Bladder Discomfort',\n",
       "  'DRUG: 0.05% Lidocaine',\n",
       "  'Kaohsiung Medical University Chung-Ho Memorial Hospital',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2019-05-17',\n",
       "  '2020-12-31'],\n",
       " ['NCT03011671',\n",
       "  'Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Malignant Glioma of Brain',\n",
       "  'DRUG: Acetazolamide|DRUG: Temozolomide',\n",
       "  'University of Chicago',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-10-03',\n",
       "  '2026-10'],\n",
       " ['NCT04271371',\n",
       "  'Preventing Relapse to Smoking Among Prisoners After Release',\n",
       "  'PROSPER',\n",
       "  'RECRUITING',\n",
       "  'Smoking|Smoking Reduction|Electronic Cigarette Use',\n",
       "  'OTHER: Not yet developed',\n",
       "  'University of Nottingham',\n",
       "  \"Her Majesty's Prison and Probation Service (HMPPS)|Public Health England|Cancer Research UK|Plymouth University Peninsula Schools of Medicine & Dentistry (PUPSMD)\",\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-08-08',\n",
       "  '2024-05-30'],\n",
       " ['NCT00181571',\n",
       "  'A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'ADHD',\n",
       "  'DRUG: methylphenidate HCl (Concerta)|DRUG: Placebo',\n",
       "  'Massachusetts General Hospital',\n",
       "  'McNeil Consumer & Specialty Pharmaceuticals\", a Division of McNeil-PPC,\" Inc.',\n",
       "  '297.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2003-06',\n",
       "  '2007-08'],\n",
       " ['NCT03116971',\n",
       "  'Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Small Cell Lung Cancer',\n",
       "  'DRUG: M3814|DRUG: Cisplatin|DRUG: Etoposide',\n",
       "  'EMD Serono Research & Development Institute\",\" Inc.',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '2.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-05-25',\n",
       "  '2018-03-01'],\n",
       " ['NCT01926171',\n",
       "  'Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Non-small-cell Lung Cancer',\n",
       "  'DRUG: Icotinib plus WBRT',\n",
       "  'Betta Pharmaceuticals Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-06',\n",
       "  '2016-12'],\n",
       " ['NCT03990571',\n",
       "  'Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Adenoid Cystic Carcinoma|Progressive Disease|Recurrent Adenoid Cystic Carcinoma',\n",
       "  'DRUG: Avelumab|DRUG: Axitinib',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-22',\n",
       "  '2023-03-20'],\n",
       " ['NCT00696371',\n",
       "  'PET Imaging of Peripheral Benzodiazepine Receptors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  '',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-06-06',\n",
       "  '2014-08-19'],\n",
       " ['NCT02351271',\n",
       "  'Cataract Surgery: Femto LDV Z8 Versus Conventional',\n",
       "  'COMFORT',\n",
       "  'COMPLETED',\n",
       "  'Cataract',\n",
       "  'DEVICE: Femto LDV Z8|DEVICE: Manual capsulorhexis&lens fragmentation',\n",
       "  'Ziemer Ophthalmic Systems AG',\n",
       "  '',\n",
       "  '130.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-02',\n",
       "  '2017-02-28'],\n",
       " ['NCT02208271',\n",
       "  'A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Arthritis\",\" Failure of Total Hip',\n",
       "  '',\n",
       "  'OrthoCarolina Research Institute\",\" Inc.',\n",
       "  'Charlotte Orthopedic Hospital',\n",
       "  '174.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-08-04',\n",
       "  '2023-12-31'],\n",
       " ['NCT02144571',\n",
       "  'Sistas Inspiring Sistas Through Activity and Support',\n",
       "  'SISTAS',\n",
       "  'COMPLETED',\n",
       "  'Prevention Harmful Effects',\n",
       "  'BEHAVIORAL: Lifestyle',\n",
       "  'University of South Carolina',\n",
       "  '',\n",
       "  '350.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-11',\n",
       "  '2015-06'],\n",
       " ['NCT02694471',\n",
       "  'Effect of 14 Day Bed Rest on Health Outcomes in Young and Older Participants',\n",
       "  'BEDREST',\n",
       "  'COMPLETED',\n",
       "  'Muscular Atrophy',\n",
       "  'BEHAVIORAL: physical inactivity or bed rest with supervised recovery',\n",
       "  'University of Primorska',\n",
       "  'University of Trieste|University of Udine|University of Padova|Università degli Studi di Ferrara|University of Nottingham|DLR German Aerospace Center|Izola General Hospital|National Institute of Public Health\",\" Slovenia',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-08',\n",
       "  '2015-01'],\n",
       " ['NCT04458571',\n",
       "  'Effect of CRRT Duration on Solute Removal',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'AKI|Sepsis',\n",
       "  '',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '',\n",
       "  '112.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-01',\n",
       "  '2022-12-21'],\n",
       " ['NCT01712971',\n",
       "  'Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Surgery|Pancreatic Tumour|Peri-ampullary Tumour|Blood Loss',\n",
       "  '',\n",
       "  'Baki Topal',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-11',\n",
       "  '2014-06'],\n",
       " ['NCT01777971',\n",
       "  'The Effect of a Large-volume Paracentesis on Fatigue\", Sleep,\" and Quality of Life in Cirrhosis',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Cirrhosis|Hepatic Encephalopathy|Ascites|Fatigue',\n",
       "  '',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-07',\n",
       "  '2014-10'],\n",
       " ['NCT01507571',\n",
       "  'Implementation and Evaluation of Dignity Therapy in Denmark',\n",
       "  'DignityDK',\n",
       "  'COMPLETED',\n",
       "  'Cancer',\n",
       "  'OTHER: Dignity Therapy',\n",
       "  'Bispebjerg Hospital',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2005-09',\n",
       "  '2007-09'],\n",
       " ['NCT04346771',\n",
       "  'The Effect of Emotional Working Memory Training on Reducing Depressive Symptoms',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Depressive Symptoms',\n",
       "  'BEHAVIORAL: Working memory training|BEHAVIORAL: Positive ABMT',\n",
       "  'Hunan Normal University',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-12-18',\n",
       "  '2021-01-10'],\n",
       " ['NCT03968471',\n",
       "  'Chemotherapy-induced Necrosis in Ewing Sarcoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ewing Sarcoma of Bone',\n",
       "  'BEHAVIORAL: Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma',\n",
       "  'Istituto Ortopedico Rizzoli',\n",
       "  '',\n",
       "  '474.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-13',\n",
       "  '2020-01-15'],\n",
       " ['NCT00895271',\n",
       "  'Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Primary Immunodeficiency|DOCK8|Virus Susceptibility',\n",
       "  '',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-06-10',\n",
       "  ''],\n",
       " ['NCT01355471',\n",
       "  'Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rosacea',\n",
       "  'DRUG: CD07805/47 Gel|DRUG: Placebo',\n",
       "  'Galderma R&D',\n",
       "  '',\n",
       "  '293.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-05',\n",
       "  '2012-01'],\n",
       " ['NCT02603471',\n",
       "  'Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use',\n",
       "  'ALCTXT',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Alcohol Dependence',\n",
       "  'OTHER: Informational group|BEHAVIORAL: Text Messaging CBT (TXT-CBT)',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2016-12'],\n",
       " ['NCT01771471',\n",
       "  'A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'BIOLOGICAL: NuQu|OTHER: Placebo',\n",
       "  'ISTO Technologies\",\" Inc.',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2020-09'],\n",
       " ['NCT03566771',\n",
       "  'Treatment Results and Health Care Consumption From a Web-based Support System in Behavioural Childhood Obesity Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Childhood Obesity',\n",
       "  'BEHAVIORAL: Usual care|BEHAVIORAL: CLOSS',\n",
       "  'Karolinska Institutet',\n",
       "  '',\n",
       "  '82.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-04-11',\n",
       "  '2019-11-26'],\n",
       " ['NCT02776371',\n",
       "  'Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Helicobacter Pylori Eradication Rate',\n",
       "  'DRUG: Modified non-clarithromycin triple therapy|DRUG: Sequential therapy',\n",
       "  'Shandong University',\n",
       "  '',\n",
       "  '301.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-09',\n",
       "  '2018-02'],\n",
       " ['NCT02287571',\n",
       "  'Skin Traction Versus Position Splint in Patients With Hip Fracture',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hip Fractures|Complication of Traction Procedure|Pain|Splints',\n",
       "  'DEVICE: Derotation splint|DEVICE: elastic bandage',\n",
       "  'Saglik Bilimleri Universitesi Gulhane Tip Fakultesi',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2013-03',\n",
       "  '2014-07'],\n",
       " ['NCT04268771',\n",
       "  'A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products',\n",
       "  'RI-01-007',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'BIOLOGICAL: Experimental: Arm A: DRL_RI|BIOLOGICAL: Arm B: Rituxan®/Mabthera®',\n",
       "  \"Dr. Reddy's Laboratories Limited\",\n",
       "  'PPD',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-08',\n",
       "  '2022-04-20'],\n",
       " ['NCT02015871',\n",
       "  'An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer',\n",
       "  'PandaExtension',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Degarelix',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '206.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2017-08-01'],\n",
       " ['NCT03746171',\n",
       "  'Blue Light Imaging (BLI) for Optical Diagnosis of Colorectal Polyps',\n",
       "  'BIRD',\n",
       "  'COMPLETED',\n",
       "  'Colonic Polyp',\n",
       "  'DIAGNOSTIC_TEST: Colonic polyp characterization by BLI',\n",
       "  'Valduce Hospital',\n",
       "  '',\n",
       "  '324.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-01-01',\n",
       "  '2019-10-30'],\n",
       " ['NCT01828671',\n",
       "  'A Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals',\n",
       "  'SOYT-2013',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'OTHER: Oral Glucose Solution 296 mls|OTHER: Corn Tortilla|OTHER: Low Soy Flour Corn Tortilla|OTHER: Moderate Soy Flour Corn Tortilla|OTHER: High Soy Flour Corn Tortilla',\n",
       "  'University of Manitoba',\n",
       "  'Manitoba Pulse Growers',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2013-12',\n",
       "  '2014-05'],\n",
       " ['NCT04558671',\n",
       "  'Preschool Bronchial Remodeling and Risk of Exacerbation',\n",
       "  'RESPIRE',\n",
       "  'COMPLETED',\n",
       "  'Preschool Severe Asthma',\n",
       "  'OTHER: asthma exacerbations',\n",
       "  'University Hospital\",\" Bordeaux',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-16',\n",
       "  '2020-09-24'],\n",
       " ['NCT02962271',\n",
       "  'Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Enthesopathy',\n",
       "  'DEVICE: Musculoskeletal Ultrasound',\n",
       "  'Chinese PLA General Hospital',\n",
       "  '',\n",
       "  '187.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-01',\n",
       "  '2016-12'],\n",
       " ['NCT01432171',\n",
       "  'Lacosamide in Preventing Seizures in Participants With Malignant Glioma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Malignant Glioma',\n",
       "  'DRUG: Lacosamide|OTHER: Placebo',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '37.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-07-25',\n",
       "  '2017-06-20'],\n",
       " ['NCT02213471',\n",
       "  'Patient Preference for Biopsy Notification',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Elevated Risk for Melanoma',\n",
       "  '',\n",
       "  'Maria Wei',\n",
       "  '',\n",
       "  '301.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-07',\n",
       "  '2013-07'],\n",
       " ['NCT00718471',\n",
       "  'STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)',\n",
       "  'ATOLL',\n",
       "  'COMPLETED',\n",
       "  'Primary PCI - STEMI',\n",
       "  'DRUG: Enoxaparin|DRUG: UFH (unfractionated heparin)',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '910.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2010-08'],\n",
       " ['NCT02291471',\n",
       "  'Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatic Diseases',\n",
       "  'DRUG: T0001，10mg|DRUG: T0001，20mg|DRUG: T0001，35mg|DRUG: T0001，50mg|DRUG: T0001，65mg|DRUG: T0001，75mg',\n",
       "  'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-10',\n",
       "  '2015-02'],\n",
       " ['NCT01636271',\n",
       "  'SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coronary Heart Disease',\n",
       "  'DRUG: darapladib|DRUG: placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '28855.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-10',\n",
       "  '2014-04'],\n",
       " ['NCT02697071',\n",
       "  'Ketamine for Acute Migraine in the Emergency Department',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Headache',\n",
       "  'DRUG: Ketamine|DRUG: Normal Saline',\n",
       "  'Carilion Clinic',\n",
       "  'Virginia Polytechnic Institute and State University',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-02',\n",
       "  '2017-03'],\n",
       " ['NCT02564471',\n",
       "  'Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.',\n",
       "  'MALRAB',\n",
       "  'COMPLETED',\n",
       "  'Rabies',\n",
       "  'DRUG: Chloroquine|DRUG: Atovaquone and Proguanil|DRUG: Doxycycline|BIOLOGICAL: Rabies Vaccine',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  'Walter Reed Army Institute of Research (WRAIR)|Kansas State University',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2016-11-11',\n",
       "  '2019-02'],\n",
       " ['NCT02862171',\n",
       "  'To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy\",\" HIV-negative Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Prevention',\n",
       "  'DRUG: Dapivirine Vaginal Ring-004',\n",
       "  'International Partnership for Microbicides\",\" Inc.',\n",
       "  '',\n",
       "  '941.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2016-07-12',\n",
       "  '2019-01-11'],\n",
       " ['NCT01151371',\n",
       "  'Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myopia',\n",
       "  'DEVICE: narafilcon B contact lens|DEVICE: nelfilcon A contact lens|DEVICE: lotrafilcon B contact lens',\n",
       "  'Johnson & Johnson Vision Care\",\" Inc.',\n",
       "  'Visioncare Research Ltd.',\n",
       "  '452.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2010-02-01',\n",
       "  '2010-04-01'],\n",
       " ['NCT03594071',\n",
       "  'S&P of Q-Fix™ All-Suture Anchor System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bankart Lesion|Acetabular Labrum Tear|SLAP Lesion|Acromioclavicular Sprain|Capsular Shift/Capsulolabral Reconstruction|Deltoid Repair|Rotator Cuff Repair|Bicep Tendinitis|Extra-capsular Repair|Medial Collateral Ligament|Lateal Collateral Ligament|Posterior Oblique Ligament|IBT|Vastus Medialis|Obliquus Advancement|Joint Capsule Closure',\n",
       "  'DEVICE: The Q-Fix™ All-Suture Anchor',\n",
       "  'Smith & Nephew\",\" Inc.',\n",
       "  '',\n",
       "  '294.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-08-31',\n",
       "  '2019-12-11'],\n",
       " ['NCT04220671',\n",
       "  'Measles Vaccination at Health System Contacts',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Measles Vaccine|Hospital Admission|Mortality|Non-specific (Heterologous) Effects of Vaccines',\n",
       "  'BIOLOGICAL: measles vaccine|OTHER: Saline',\n",
       "  'Bandim Health Project',\n",
       "  '',\n",
       "  '5400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-01-08',\n",
       "  '2025-08'],\n",
       " ['NCT05169671',\n",
       "  'Safety\", Tolerability,\" and Pharmacokinetics Study of ATH-1020',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy Volunteers',\n",
       "  'DRUG: ATH-1020|DRUG: Placebo',\n",
       "  'Athira Pharma',\n",
       "  'Biotrial Inc.|Alturas Analytics\",\" Inc.',\n",
       "  '68.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-03-30',\n",
       "  '2022-12-12'],\n",
       " ['NCT01891071',\n",
       "  'Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Multiple Sclerosis',\n",
       "  'PROCEDURE: Lung volume recruitment',\n",
       "  'Ottawa Hospital Research Institute',\n",
       "  'The Ottawa Hospital',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-07',\n",
       "  '2017-04'],\n",
       " ['NCT03909971',\n",
       "  'A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: Lorlatinib',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '109.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-04-28',\n",
       "  '2024-12-31'],\n",
       " ['NCT06156371',\n",
       "  'The Effect of Lymphatic Drainage Massage on Interdialytic Weight Gain and Fatigue',\n",
       "  'MLD',\n",
       "  'RECRUITING',\n",
       "  'Interdialytic Weight Gain|Fatigue',\n",
       "  'OTHER: lymphatic drainage massage|OTHER: classic massage',\n",
       "  'Mersin University',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12-11',\n",
       "  '2024-06-30'],\n",
       " ['NCT06151171',\n",
       "  'Pharmacokinetics of Different CoQ10 Formulations',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coenzyme Q10 Pharmacokinetics',\n",
       "  'DIETARY_SUPPLEMENT: CoQ10',\n",
       "  'Factors Group of Nutritional Companies Inc.',\n",
       "  'Isura',\n",
       "  '15.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-03-01',\n",
       "  '2022-10-31'],\n",
       " ['NCT04626271',\n",
       "  'Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Albuminuria',\n",
       "  'DEVICE: ACR | U.S. Urine Analysis Test System|DEVICE: URiSCAN Optima Urine Analyzer',\n",
       "  'Healthy.io Ltd.',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2020-08-31',\n",
       "  '2020-10-25'],\n",
       " ['NCT00095771',\n",
       "  'Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain and Central Nervous System Tumors',\n",
       "  'DRUG: arsenic trioxide|RADIATION: radiation therapy',\n",
       "  'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '36.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2004-11',\n",
       "  '2011-01'],\n",
       " ['NCT04627571',\n",
       "  'Corneal Nerves After Treatment With Cenegermin',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Neurotrophic Keratitis',\n",
       "  'DRUG: Cenegermin Ophthalmic Solution [Oxervate]',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-05-23',\n",
       "  '2024-12'],\n",
       " ['NCT05359471',\n",
       "  'Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD',\n",
       "  'Theratech',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Visceral Steatosis|Hiv|NAFLD',\n",
       "  'DEVICE: Bone densitometry|OTHER: Questionnaires|DEVICE: Review of medical chart',\n",
       "  'McGill University Health Centre/Research Institute of the McGill University Health Centre',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2021-04-09',\n",
       "  '2022-06-01'],\n",
       " ['NCT02459171',\n",
       "  'Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Influenza',\n",
       "  'OTHER: Questionnaire|OTHER: Blood sample|OTHER: Nasal wash|OTHER: Throat swab',\n",
       "  \"St. Jude Children's Research Hospital\",\n",
       "  'Department of Health and Human Services|Human Link',\n",
       "  '2400.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08-05',\n",
       "  '2024-03'],\n",
       " ['NCT00758771',\n",
       "  'Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents',\n",
       "  'GIST',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  '',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'Genentech\",\" Inc.',\n",
       "  '38.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2012-12'],\n",
       " ['NCT00620971',\n",
       "  'Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'DRUG: Vinorelbine|DRUG: Cisplatin|DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Gemcitabine|DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Bevacizumab',\n",
       "  'Hellenic Oncology Research Group',\n",
       "  'University Hospital of Crete',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2010-04'],\n",
       " ['NCT01209871',\n",
       "  'Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Lymphoplasmacytic Lymphoma',\n",
       "  'BIOLOGICAL: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|OTHER: Laboratory Biomarker Analysis',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-02-26',\n",
       "  '2024-02-20'],\n",
       " ['NCT04219371',\n",
       "  'Reference Range Study for the Quantra QStat System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coagulation Disorder',\n",
       "  'DIAGNOSTIC_TEST: Quantra System',\n",
       "  'HemoSonics LLC',\n",
       "  '',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-07',\n",
       "  '2020-06-30'],\n",
       " ['NCT02676271',\n",
       "  \"The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Legg-Calvé-Perthes Disease',\n",
       "  'PROCEDURE: Proximal varus derotational osteotomy',\n",
       "  'Assaf-Harofeh Medical Center',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2015-10'],\n",
       " ['NCT02079571',\n",
       "  'Investigation of Pulse Waves\", Channel Entries,\" and Food Attributes in Healthy Subjects With Different Constitutions',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy Subjects With Different Constitutions',\n",
       "  'DIETARY_SUPPLEMENT: Coconut water|DIETARY_SUPPLEMENT: ginger tea',\n",
       "  'National Taiwan University Hospital',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2013-05',\n",
       "  ''],\n",
       " ['NCT06034171',\n",
       "  'Clinical Study of Implants With Modified Surface Treatment',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Dental Implant|Hydroxyapatite',\n",
       "  'DEVICE: dental implant',\n",
       "  'SmileDent Kft.',\n",
       "  'S.G.S International Kft.',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-06-13',\n",
       "  '2023-12-31'],\n",
       " ['NCT05802771',\n",
       "  'Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice',\n",
       "  'LANTERN',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'PROCEDURE: surgical resection',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  'Technische Universität Dresden|University of Debrecen|Hospital de la Santa creu i Sant Pau - Barcelona|Koc University Hospital|Accademia del Paziente Esperto EUPATI\", Rome,\" Italy',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-06-01',\n",
       "  '2026-06-01'],\n",
       " ['NCT01595971',\n",
       "  'Distance Education Versus Usual Care Qualification in Asthma Care',\n",
       "  'RESPIRANET',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'BEHAVIORAL: Continuing education|OTHER: usual care',\n",
       "  'Hospital de Clinicas de Porto Alegre',\n",
       "  'Federal University of Rio Grande do Sul',\n",
       "  '467.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2010-08-12',\n",
       "  '2011-12-16'],\n",
       " ['NCT01476371',\n",
       "  'Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mental Disorders',\n",
       "  'BEHAVIORAL: Mindfulness-based group treatment',\n",
       "  'Lund University',\n",
       "  '',\n",
       "  '215.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2014-04'],\n",
       " ['NCT04172571',\n",
       "  'A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'BIOLOGICAL: AK105|DRUG: Anlotinib Hydrochloride',\n",
       "  'Akeso',\n",
       "  'Akeso Tiancheng\",\" Inc',\n",
       "  '31.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-22',\n",
       "  '2022-11-01'],\n",
       " ['NCT03188471',\n",
       "  'Preventive Application of GnRH Antagonist on Early OHSS',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ovarian Hyperstimulation Syndrome|GnRH Antagonist|Aspirin|Vascular Endothelial Growth Factor|Pigment Epithelium Derived Factor',\n",
       "  'DRUG: GnRH antagonist|DRUG: aspirin',\n",
       "  'First Affiliated Hospital\",\" Sun Yat-Sen University',\n",
       "  '',\n",
       "  '175.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-01',\n",
       "  '2018-03'],\n",
       " ['NCT01217671',\n",
       "  'International Study Evaluating the Safety and Efficacy of Inhaled\", Human,\" Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Emphysema',\n",
       "  'BIOLOGICAL: Kamada AAT for inhalation|OTHER: Placebo',\n",
       "  'Kamada\",\" Ltd.',\n",
       "  '',\n",
       "  '168.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-12',\n",
       "  '2015-06'],\n",
       " ['NCT01137071',\n",
       "  'Consolidation Therapy With Hu3S193 for Women With Ovarian\",\" Primary Peritoneal or Fallopian Tube Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer',\n",
       "  'BIOLOGICAL: Monoclonal antibody Hu3S193',\n",
       "  'Recepta Biopharma',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2015-06'],\n",
       " ['NCT02164071',\n",
       "  'Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies',\n",
       "  'GAH',\n",
       "  'COMPLETED',\n",
       "  'Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leuklemia\", Lymphocytic,\" Chronic',\n",
       "  'OTHER: Geriatric Assessment of Health Status Scale administration',\n",
       "  'Celgene',\n",
       "  '',\n",
       "  '363.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-04-11',\n",
       "  '2015-07-04'],\n",
       " ['NCT05897671',\n",
       "  'Foveal Sparing ILM Peeling With ILM Flap Transposition',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Full Thickness Macular Hole',\n",
       "  'OTHER: retrospective data analysis',\n",
       "  'Vienna Institute for Research in Ocular Surgery',\n",
       "  '',\n",
       "  '42.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-06-01',\n",
       "  '2023-06-01'],\n",
       " ['NCT02642471',\n",
       "  'Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cervical Cancer|Surgery|Quality of Life',\n",
       "  'PROCEDURE: no systematic pelvic lymphadenectomy',\n",
       "  'Sun Yat-sen University',\n",
       "  '',\n",
       "  '1080.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2022-12'],\n",
       " ['NCT04806971',\n",
       "  'Vitamin D Receptor\",\" Interleukin-1A and Interleukin-1B Gene Polymorphisms in Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis|Polymorphism\",\" Restriction Fragment Length',\n",
       "  '',\n",
       "  'Marmara University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-29',\n",
       "  '2019-09-27'],\n",
       " ['NCT02273271',\n",
       "  'Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo',\n",
       "  'EVIDENCE',\n",
       "  'UNKNOWN',\n",
       "  'Non-small Cell Lung Carcinoma',\n",
       "  'OTHER: 18F-FLT-PET/CT and DWI-MRI',\n",
       "  'European Organisation for Research and Treatment of Cancer - EORTC',\n",
       "  '',\n",
       "  '31.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-10',\n",
       "  '2017-02'],\n",
       " ['NCT03295071',\n",
       "  'REALITY LHON Registry',\n",
       "  'REALITY',\n",
       "  'COMPLETED',\n",
       "  'Leber Hereditary Optic Neuropathy',\n",
       "  'OTHER: Patient-reported outcomes (PROs)',\n",
       "  'GenSight Biologics',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-03',\n",
       "  '2020-07-01'],\n",
       " ['NCT02859571',\n",
       "  'Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Intemittant\", Continue,\" Oxytocin',\n",
       "  'DRUG: Oxytocin',\n",
       "  'Zeynep Kamil Maternity and Pediatric Research and Training Hospital',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2017-01'],\n",
       " ['NCT05151471',\n",
       "  'Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'ALS',\n",
       "  'DRUG: MT-1186|DRUG: Placebo',\n",
       "  'Mitsubishi Tanabe Pharma America Inc.',\n",
       "  '',\n",
       "  '202.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-01-11',\n",
       "  '2023-09-29'],\n",
       " ['NCT01218971',\n",
       "  'ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Dependence',\n",
       "  'DRUG: Medisorb naltrexone 190 mg|DRUG: Medisorb naltrexone 380 mg',\n",
       "  'Alkermes\",\" Inc.',\n",
       "  '',\n",
       "  '332.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2002-08',\n",
       "  '2004-09'],\n",
       " ['NCT00900471',\n",
       "  'Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Unspecified Adult Solid Tumor\", Protocol Specific|Unspecified Childhood Solid Tumor,\" Protocol Specific',\n",
       "  'OTHER: biologic sample preservation procedure|OTHER: medical chart review',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '20000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-05',\n",
       "  '2025-05'],\n",
       " ['NCT00461071',\n",
       "  'Randomised Controlled Study on the Use of Psychoeducation for Bulimia Nervosa in Young Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bulimia Nervosa',\n",
       "  'BEHAVIORAL: Guided Self-help for Bulimia nervosa',\n",
       "  'Medical University of Vienna',\n",
       "  'National Bank of Austria',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2007-04',\n",
       "  '2010-04'],\n",
       " ['NCT01051271',\n",
       "  'Prophylaxis Against Metoclopramide-Induced Akathisia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Akathisia',\n",
       "  'DRUG: midazolam',\n",
       "  'Pamukkale University',\n",
       "  '',\n",
       "  '225.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2009-07',\n",
       "  '2009-11'],\n",
       " ['NCT00554671',\n",
       "  'Pharmacist-led Group Medical Visits to Help With Diabetes Management',\n",
       "  'MEDIC-1',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus|Cardiovascular Diseases',\n",
       "  'OTHER: Algorithm driven medication titration|BEHAVIORAL: Monitoring|BEHAVIORAL: Group support|BEHAVIORAL: Self efficacy',\n",
       "  'VA Office of Research and Development',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-05',\n",
       "  '2012-06'],\n",
       " ['NCT01920971',\n",
       "  'Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Low Back Pain',\n",
       "  'RADIATION: infrared therapy',\n",
       "  'Taipei Medical University',\n",
       "  'National Science Council\",\" Taiwan',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-08',\n",
       "  '2014-07'],\n",
       " ['NCT01304771',\n",
       "  'Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Influenza',\n",
       "  'BIOLOGICAL: Synbiotic AKSB',\n",
       "  'Mayo Clinic',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: ',\n",
       "  '2010-12',\n",
       "  '2011-04'],\n",
       " ['NCT03314571',\n",
       "  'Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.',\n",
       "  'AOMHE',\n",
       "  'UNKNOWN',\n",
       "  'Epidural Analgesia|Hospital Follow-up',\n",
       "  'OTHER: analgesia for labor',\n",
       "  'University Hospital\",\" Clermont-Ferrand',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-11',\n",
       "  '2020-12-31'],\n",
       " ['NCT04927871',\n",
       "  'Hybridized Three Steps Intervention to Prevent Diabetes in Venezuela',\n",
       "  'HITS',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Overweight|PreDiabetes|Diabetes Mellitus\", Type 2|Risk Factor,\" Cardiovascular',\n",
       "  'BEHAVIORAL: Total Diet Replacement (TDR)|BEHAVIORAL: Medical Nutritional Therapy (MNT)|BEHAVIORAL: Diabetes Prevention Program 4 months|BEHAVIORAL: Diabetes Prevention Program',\n",
       "  'Foundation for Public Health and Epidemiological Research of Venezuela',\n",
       "  '',\n",
       "  '156.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2020-11-16',\n",
       "  '2022-01-15'],\n",
       " ['NCT00602771',\n",
       "  'Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed\",\" Previously Untreated Acute Myeloid Leukemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia',\n",
       "  'DRUG: tipifarnib|DRUG: etoposide',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2011-10'],\n",
       " ['NCT02928471',\n",
       "  'Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss',\n",
       "  'IM-LOSEIT-I',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Obesity',\n",
       "  'DIETARY_SUPPLEMENT: Intensive dietary intervention',\n",
       "  'Henrik Gudbergsen',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-11',\n",
       "  '2019-03'],\n",
       " ['NCT00861471',\n",
       "  'Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostate Cancer|Prostatic Neoplasms',\n",
       "  'DRUG: Docetaxel|DRUG: Imatinib Mesylate',\n",
       "  'NYU Langone Health',\n",
       "  'Novartis',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2010-05'],\n",
       " ['NCT00561171',\n",
       "  'Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypertension|Type II Diabetes Mellitus',\n",
       "  'DRUG: SPP635',\n",
       "  'Speedel Pharma Ltd.',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-11',\n",
       "  '2008-09'],\n",
       " ['NCT02606071',\n",
       "  'Italian Registry On Multipoint Left Ventricular Pacing',\n",
       "  'IRON-MPP',\n",
       "  'UNKNOWN',\n",
       "  'Heart Failure|Ventricular Fibrillation|Ventricular Tachycardia',\n",
       "  'DEVICE: CRT-D',\n",
       "  'University of Rome Tor Vergata',\n",
       "  '',\n",
       "  '436.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-08',\n",
       "  '2018-09'],\n",
       " ['NCT05662371',\n",
       "  'Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on Robot-assisted Colorectal Surgery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Opioid Use\", Unspecified|Pain,\" Postoperative',\n",
       "  'DEVICE: Nociception Level monitor (NOL)|DEVICE: Standard care',\n",
       "  'University of Southern Denmark',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2023-08-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT02758171',\n",
       "  'Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Empagliflozin|DRUG: Linagliptin',\n",
       "  'Boehringer Ingelheim',\n",
       "  'Eli Lilly and Company',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05-17',\n",
       "  '2016-08-03'],\n",
       " ['NCT05685771',\n",
       "  'Sleep Modulation as Antidepressant Randomized Trial',\n",
       "  'SMART',\n",
       "  'RECRUITING',\n",
       "  'Depression|Healthy',\n",
       "  'DEVICE: Phase-targeted auditory stimulation',\n",
       "  'Giulia Da Poian',\n",
       "  'ETH Zurich|University of Zurich|Psychiatric University Hospital\",\" Zurich',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: OTHER',\n",
       "  '2023-02-20',\n",
       "  '2024-06-30'],\n",
       " ['NCT00597571',\n",
       "  '[Trial of device that is not approved or cleared by the U.S. FDA]',\n",
       "  '',\n",
       "  'WITHHELD',\n",
       "  '',\n",
       "  '',\n",
       "  '[Redacted]',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT04366271',\n",
       "  'Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19',\n",
       "  'MESCEL-COVID19',\n",
       "  'WITHDRAWN',\n",
       "  'COVID',\n",
       "  'BIOLOGICAL: Mesenchymal cells|DRUG: Standard of care',\n",
       "  'Hospital Infantil Universitario Niño Jesús\", Madrid,\" Spain',\n",
       "  'Apices Soluciones S.L.',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-05-07',\n",
       "  '2021-05-31'],\n",
       " ['NCT05642871',\n",
       "  'DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 Gene',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Malignant Tumor of the Ovary|XRCC2 Gene Mutation',\n",
       "  'RADIATION: DKI and APT',\n",
       "  'Qianqian Qu',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-01-31',\n",
       "  '2025-08-31'],\n",
       " ['NCT00541671',\n",
       "  'Prevention of Narcotic-Induced Nausea',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Nausea',\n",
       "  'DRUG: Saline|DRUG: Phenergan',\n",
       "  'Christiana Care Health Services',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: PREVENTION',\n",
       "  '2007-02',\n",
       "  '2009-11'],\n",
       " ['NCT00464971',\n",
       "  'Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Menopause|Postmenopausal Vaginal Atrophy',\n",
       "  'DRUG: estradiol\",\" 25 mcg',\n",
       "  'Novo Nordisk A/S',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '1995-01-31',\n",
       "  '1996-11-30'],\n",
       " ['NCT01732471',\n",
       "  'Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Phenylketonuria',\n",
       "  'DRUG: Kuvan®',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2013-10'],\n",
       " ['NCT02440971',\n",
       "  'Adaptive Servo Ventilation (ASV) in Heart Failure',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Acute Decompensated Heart Failure|Sleep Disordered Breathing',\n",
       "  'DEVICE: S9-Autoset CS-A',\n",
       "  'St Vincent\\'s University Hospital\",\" Ireland',\n",
       "  'ResMed',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-05',\n",
       "  '2019-09'],\n",
       " ['NCT06125171',\n",
       "  'Tucidinostat Plus Apatinib for Advanced Osteosarcoma',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Osteosarcoma',\n",
       "  'DRUG: Tucidinostat\",\" Apatinib',\n",
       "  'Wuhan Union Hospital\",\" China',\n",
       "  '',\n",
       "  '46.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01',\n",
       "  '2025-12'],\n",
       " ['NCT01074671',\n",
       "  'CG Future® Annuloplasty Ring/Band Clinical Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mitral Valve Insufficiency',\n",
       "  'DEVICE: CG Future Annuloplasty Ring/Band',\n",
       "  'Medtronic Bakken Research Center',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2011-09'],\n",
       " ['NCT03214471',\n",
       "  'Evaluation of a Lifestyle Intervention After Bariatric Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity',\n",
       "  'BEHAVIORAL: Lifestyle intervention',\n",
       "  'University College\",\" London',\n",
       "  '',\n",
       "  '153.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-02-20',\n",
       "  '2020-12-21'],\n",
       " ['NCT02659371',\n",
       "  'Weight Loss Prior Mamma Reduction - A Pilot Study',\n",
       "  'MAMMARED',\n",
       "  'COMPLETED',\n",
       "  'Weight Loss|Hypertrophy',\n",
       "  'DIETARY_SUPPLEMENT: Low energy diet',\n",
       "  'Copenhagen University Hospital at Herlev',\n",
       "  '',\n",
       "  '6.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2016-05'],\n",
       " ['NCT03565471',\n",
       "  'Atrial Septal Defect - Exercise Capacity and Pulmonary Hypertension',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Atrial Septal Defect|Pulmonary Hypertension',\n",
       "  'DIAGNOSTIC_TEST: Echocardiography|DIAGNOSTIC_TEST: Right side catheterization|DIAGNOSTIC_TEST: Exercise test|DIAGNOSTIC_TEST: Holter monitor',\n",
       "  'University of Aarhus',\n",
       "  'Aarhus University Hospital',\n",
       "  '57.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-08-01',\n",
       "  '2019-11-01'],\n",
       " ['NCT05021471',\n",
       "  'Stretching With And Without Pressure Biofeeback In Patients With Postural Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Postural; Defect',\n",
       "  'OTHER: biofeedback|OTHER: hamstrings stretching',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-08-05',\n",
       "  '2022-02-28'],\n",
       " ['NCT02357771',\n",
       "  'Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Malocclusion',\n",
       "  'DRUG: Probiotic (L. brevis CD2 lozenges)|DRUG: Placebo',\n",
       "  'Next Gen Pharma India Pvt. Ltd.',\n",
       "  'Peoples University\", Bhanpur,\" Bhopal',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2015-09'],\n",
       " ['NCT01567371',\n",
       "  'LiDCO Monitor Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cardiac Surgery',\n",
       "  'DEVICE: LiDCO rapid monitor',\n",
       "  \"Nationwide Children's Hospital\",\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2012-03',\n",
       "  '2015-03'],\n",
       " ['NCT04272671',\n",
       "  'De-prescribing Program to Evaluate Falls in Older Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid-Related Disorders|Benzodiazepine-Related Disorders|Falls Injury',\n",
       "  'OTHER: Educational Intervention',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'Centers for Disease Control and Prevention',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2020-02-26',\n",
       "  '2021-10-01'],\n",
       " ['NCT04297371',\n",
       "  'Early Detection of Cardiac Impairment and Prediction of RV Hypertrophy in Patients With CTD',\n",
       "  'EARLY-MYO-CTD',\n",
       "  'COMPLETED',\n",
       "  'Connective Tissue Diseases|Right Ventricular Hypertrophy',\n",
       "  'DIAGNOSTIC_TEST: CMR examination',\n",
       "  'RenJi Hospital',\n",
       "  '',\n",
       "  '136.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-07',\n",
       "  '2016-11'],\n",
       " ['NCT02014571',\n",
       "  'Study to Assess the Safety\", Pharmacokinetics,\" and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C\",\" Chronic',\n",
       "  'DRUG: GSK2878175|DRUG: Placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  'PPD',\n",
       "  '37.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-12-26',\n",
       "  '2015-01-15'],\n",
       " ['NCT00999271',\n",
       "  'Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Subjects',\n",
       "  'OTHER: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)',\n",
       "  'Hvidovre University Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-08',\n",
       "  '2009-09'],\n",
       " ['NCT02429271',\n",
       "  'A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration\",\" in Patients With STEMI Treated With Thrombolysis - The \\'MIRTOS\\' Study',\n",
       "  'MIRTOS',\n",
       "  'COMPLETED',\n",
       "  'Myocardial Infarction|ST Segment Elevation Myocardial Infarction (STEMI)',\n",
       "  'DRUG: Ticagrelor|DRUG: Clopidogrel|PROCEDURE: Percutaneous Coronary Intervention (PCI)|PROCEDURE: Coronary Angiography',\n",
       "  'Hellenic Cardiovascular Research Society',\n",
       "  '',\n",
       "  '336.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-08',\n",
       "  '2019-02'],\n",
       " ['NCT01307371',\n",
       "  'Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Left Ventricular Function Systolic Dysfunction|Left Ventricular Function Diastolic Dysfunction|Death|Myocardial Reperfusion Injury',\n",
       "  '',\n",
       "  'Xijing Hospital',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-03',\n",
       "  '2011-12'],\n",
       " ['NCT03144271',\n",
       "  'Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Diabetes Mellitus\",\" Type 2|Healthy',\n",
       "  'DRUG: semaglutide|DRUG: Placebo',\n",
       "  'Novo Nordisk A/S',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-06-11',\n",
       "  '2007-10-08'],\n",
       " ['NCT03891771',\n",
       "  'Seniors Guardian: A Monitoring Platform for the Elderly',\n",
       "  'SEMONE',\n",
       "  'COMPLETED',\n",
       "  'Quality of Life',\n",
       "  'DEVICE: Telemonitoring sensors',\n",
       "  'Universidad de Valparaiso',\n",
       "  'Servicio de Vivienda y Urbanismo\", Chile|Ilustre Municipalidad de San Antonio, Chile|Corporación Municipal de Valparaíso,\" Chile',\n",
       "  '69.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-04-30',\n",
       "  '2021-06-06'],\n",
       " ['NCT04786171',\n",
       "  '4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Copd|Emphysema|Hyperinflation',\n",
       "  'DIAGNOSTIC_TEST: 4D X-ray Velocimetry',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  'American Thoracic Society',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-01-07',\n",
       "  '2024-11-01'],\n",
       " ['NCT04392271',\n",
       "  'A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: LY3372689|DIAGNOSTIC_TEST: [18F]LSN3316612',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2020-08-06',\n",
       "  '2020-10-14'],\n",
       " ['NCT02421471',\n",
       "  'PMS to Evaluate the Safety and Efficacy of Picato® Gel',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Actinic Keratosis',\n",
       "  'DRUG: Ingenol mebutate 0.015 percent or 0.05 percent gel',\n",
       "  'LEO Pharma',\n",
       "  '',\n",
       "  '1324.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-09',\n",
       "  '2018-01-19'],\n",
       " ['NCT04944771',\n",
       "  'Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Solid and Hematological Malignancies',\n",
       "  'DRUG: Capivasertib|DRUG: Rabeprazole',\n",
       "  'AstraZeneca',\n",
       "  'Parexel',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-07-26',\n",
       "  '2022-05-04'],\n",
       " ['NCT03688971',\n",
       "  'Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Seborrheic Dermatitis',\n",
       "  'DRUG: Omiganan|DRUG: Ketoconazole|DRUG: Placebo',\n",
       "  'Maruho Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-10-22',\n",
       "  '2019-12'],\n",
       " ['NCT01066871',\n",
       "  'Sprifermin (AS902330) in Cartilage Injury Repair (CIR)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Isolated Cartilage Injury of the Knee',\n",
       "  'DRUG: Sprifermin (AS902330) 10 mcg|DRUG: Sprifermin (AS902330) 30 mcg|DRUG: Sprifermin (AS902330) 100 mcg|OTHER: Placebo',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany',\n",
       "  '',\n",
       "  '74.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-03',\n",
       "  '2013-04'],\n",
       " ['NCT00419471',\n",
       "  'Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depressive Disorder|Coronary Disease',\n",
       "  'DRUG: Escitalopram|DRUG: Placebo',\n",
       "  'Chonnam National University Hospital',\n",
       "  'H. Lundbeck A/S',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-05',\n",
       "  '2013-03'],\n",
       " ['NCT00558571',\n",
       "  '4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: BI 10773 low dose|DRUG: placebo to BI 10773|DRUG: BI 10773 medium dose|DRUG: BI 10773 high dose',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '78.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  ''],\n",
       " ['NCT04778371',\n",
       "  'The Effects of Almond Consumption on Functional Performance and Activity in Overweight Active Older Adults',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Overweight',\n",
       "  'OTHER: Almonds|OTHER: Placebo',\n",
       "  'Florida State University',\n",
       "  'Almond Board of California',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2021-03-02',\n",
       "  '2024-06-30'],\n",
       " ['NCT03358771',\n",
       "  'COPD Discharge Bundle Delivered Alone or Enhanced Through a Care Coordinator',\n",
       "  'PRIHS',\n",
       "  'COMPLETED',\n",
       "  'Pulmonary Disease\",\" Chronic Obstructive',\n",
       "  'OTHER: COPD discharge care bundle|OTHER: COPD discharge care bundle & coordinator',\n",
       "  'University of Alberta',\n",
       "  'University of Calgary|Alberta Health services|Alberta Innovates Health Solutions',\n",
       "  '3710.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2017-03-01',\n",
       "  '2019-12-30'],\n",
       " ['NCT03176771',\n",
       "  'Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Tardive Dyskinesia',\n",
       "  'DRUG: MT-5199|DRUG: Placebo',\n",
       "  'Mitsubishi Tanabe Pharma Corporation',\n",
       "  '',\n",
       "  '256.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-06-21',\n",
       "  '2020-09-29'],\n",
       " ['NCT00812071',\n",
       "  'Phase 1B Study of RiVax\",\" a Vaccine to Prevent the Toxic Effects of Ricin',\n",
       "  'FDA-OPD',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'BIOLOGICAL: RiVax',\n",
       "  'University of Texas Southwestern Medical Center',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2008-03',\n",
       "  '2012-05'],\n",
       " ['NCT05343871',\n",
       "  'Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: Sinovac|BIOLOGICAL: AZD1222|BIOLOGICAL: BNT162b2',\n",
       "  'Albert B. Sabin Vaccine Institute',\n",
       "  'Aga Khan University|Oswaldo Cruz Foundation|Stanford University',\n",
       "  '2354.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-07-05',\n",
       "  '2024-01-11'],\n",
       " ['NCT04281771',\n",
       "  'Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI',\n",
       "  'APPOSE',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  \"Transcatheter Aortic Valve Replacement|Hemodynamic Monitoring|Aortic Valve Insufficiency|Aortic Valve Stenosis|Heyde's Syndrome|Acquired Von Willebrand Disease\",\n",
       "  'PROCEDURE: cardiac MRI',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '92.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-09-17',\n",
       "  '2026-10-28'],\n",
       " ['NCT06129071',\n",
       "  'Analgesic Effect of Ultrasound Guided Maxillary Nerve Block in Trigeminal Neuralgia',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Trigeminal Neuralgia',\n",
       "  'PROCEDURE: US guided block of maxillary nerve',\n",
       "  'Varazdin General Hospital',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-01',\n",
       "  '2025-03-01'],\n",
       " ['NCT02472171',\n",
       "  'Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: High saturated fat meal\", placebo powder and sunflower oil|DIETARY_SUPPLEMENT: High saturated fat meal, blueberry powder and sunflower oil|DIETARY_SUPPLEMENT: High saturated fat meal,\" placebo powder and DHA',\n",
       "  'USDA\",\" Western Human Nutrition Research Center',\n",
       "  'University of California\",\" Davis',\n",
       "  '62.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-06',\n",
       "  '2017-11'],\n",
       " ['NCT03634371',\n",
       "  'Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'DRUG: Drug Levothyroxine 150 mcg|DRUG: Drug Eutirox 150 mcg',\n",
       "  'Tecnoquimicas',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-10',\n",
       "  '2018-10-06'],\n",
       " ['NCT05295771',\n",
       "  'Evaluation of Geistlich Fibro-Gide ® and Autogenous Connective Tissue Graft Prior to Orthodontic Maxillary Expansion.',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Thin Gingiva|Transverse Maxillary Deficiency|Cross Bite',\n",
       "  'PROCEDURE: Gingival Phenotype Modification',\n",
       "  'University of Alberta',\n",
       "  'Geistlich Pharma AG',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-04-01',\n",
       "  '2024-01-23'],\n",
       " ['NCT01985971',\n",
       "  'F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain Metastases From Breast Cancer',\n",
       "  'RADIATION: PET/CT Imaging',\n",
       "  'Abramson Cancer Center at Penn Medicine',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-03',\n",
       "  '2016-08-19'],\n",
       " ['NCT02175771',\n",
       "  'Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Persistent Asthma',\n",
       "  'DRUG: Fp MDPI|DRUG: FS MDPI|DRUG: FLOVENT HFA|DRUG: ADVAIR DISKUS|DRUG: albuterol/salbutamol HFA',\n",
       "  'Teva Branded Pharmaceutical Products R&D\",\" Inc.',\n",
       "  '',\n",
       "  '758.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2015-07'],\n",
       " ['NCT02000271',\n",
       "  'Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery?',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vaginal Packing Following Pelvic Reconstructive Surgery',\n",
       "  'PROCEDURE: Vaginal packing|PROCEDURE: No vaginal packing',\n",
       "  'TriHealth Inc.',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2014-06'],\n",
       " ['NCT00552071',\n",
       "  'Ultrasound Guided Octreotide LAR Injection in Acromegaly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acromegaly',\n",
       "  'DRUG: Octreotide LAR 30 MG Injection',\n",
       "  'Cedars-Sinai Medical Center',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2014-03'],\n",
       " ['NCT00321971',\n",
       "  'Prevention of Depression in Spouses of People With Cognitive Impairment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depression',\n",
       "  'BEHAVIORAL: PST-MCI/AD Caregiving|BEHAVIORAL: NT-MCI/AD Caregiving',\n",
       "  'University of Pittsburgh',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2007-02',\n",
       "  '2011-12'],\n",
       " ['NCT01003171',\n",
       "  'Pharmacokinetics of MCS in Healthy Volunteers',\n",
       "  'MCS-2-US-pk',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'DRUG: MCS-2 soft-gel capsule',\n",
       "  'Health Ever Bio-Tech Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-08',\n",
       "  '2012-12'],\n",
       " ['NCT05388071',\n",
       "  'Feasibility of Telemedicine Under Ambulance Station Conditions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Telemedicine|Disaster Medicine|Emergency Medicine',\n",
       "  'OTHER: Usage of telemedicine and tele-consultation for treatment',\n",
       "  'RWTH Aachen University',\n",
       "  '',\n",
       "  '404.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-07-01',\n",
       "  '2023-06-06'],\n",
       " ['NCT05401071',\n",
       "  'Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)',\n",
       "  'ORIENT',\n",
       "  'RECRUITING',\n",
       "  'Tuberculosis\",\" Pulmonary',\n",
       "  'OTHER: Short Regimen with Rifapentine 10mg/kg|COMBINATION_PRODUCT: Standardized Regimen|OTHER: Short Regimen with Rifapentine 15mg/kg|OTHER: Short Regimen with Rifapentine 20mg/kg',\n",
       "  'Huashan Hospital',\n",
       "  '',\n",
       "  '2442.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-13',\n",
       "  '2027-11-01'],\n",
       " ['NCT03852771',\n",
       "  'REST Study (CompRESsion Therapy for RLS)',\n",
       "  'REST',\n",
       "  'TERMINATED',\n",
       "  'Restless Legs Syndrome',\n",
       "  'DEVICE: Cirvo(TM) therapy',\n",
       "  'Radial Medical\",\" Inc.',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-03-12',\n",
       "  '2020-01-31'],\n",
       " ['NCT01722071',\n",
       "  'Deciphering the Role of Oxytocin in Motivation: an fMRI Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Focus of Study: Neural Correlates of Oxytocin Administration',\n",
       "  'DRUG: Placebo|DRUG: Oxytocin',\n",
       "  'Tiffany Love',\n",
       "  'University of Michigan',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-10',\n",
       "  '2015-10'],\n",
       " ['NCT05290571',\n",
       "  'Modified Otago Exercise Program on Balance Performance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Aging|Fall',\n",
       "  'OTHER: Modified Otago Exercise Program with music|OTHER: Modified Otago Exercise Program',\n",
       "  'Tung Wah College',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-10-27',\n",
       "  '2021-12-01'],\n",
       " ['NCT00007371',\n",
       "  'Hepatitis C in Clinically Discordant Hemophilic Siblings',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Blood Disease|Hemophilia A|Hepatitis\", Viral,\" Human',\n",
       "  '',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '1999-09',\n",
       "  '2004-08'],\n",
       " ['NCT01468571',\n",
       "  'Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pulmonary Hypertension',\n",
       "  'DRUG: Spironolactone|DRUG: Placebo',\n",
       "  'Baylor College of Medicine',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2015-12'],\n",
       " ['NCT01584271',\n",
       "  'Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Otitis Externa',\n",
       "  'DEVICE: Natural Ear Comfort(TM)\",\" a botanical ear drops product',\n",
       "  'Assuta Hospital Systems',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2013-12'],\n",
       " ['NCT01692171',\n",
       "  'Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Heparin\",\" Low-Molecular-Weight',\n",
       "  'Azidus Brasil',\n",
       "  'Blau Farmaceutica S.A.',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-02-28',\n",
       "  '2013-10-31'],\n",
       " ['NCT01751971',\n",
       "  'Estimating Apnea Phenotypes From Polysomnography: Oxygen',\n",
       "  'PSGtraits-O2',\n",
       "  'COMPLETED',\n",
       "  'Sleep Apnea',\n",
       "  'DRUG: Inspired oxygen (40%)|OTHER: Sham',\n",
       "  \"Brigham and Women's Hospital\",\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)|American Heart Association',\n",
       "  '47.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-11',\n",
       "  '2016-07'],\n",
       " ['NCT02479971',\n",
       "  'Effect of Peritoneal Lavage With Clindamycin-gentamicin on Laparoscopic Sleeve Gastrectomy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain',\n",
       "  'DRUG: Clindamycin-gentamicin irrigation|DRUG: Normal saline irrigation',\n",
       "  'Hospital General Universitario Elche',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2014-01',\n",
       "  '2015-06'],\n",
       " ['NCT00808171',\n",
       "  'Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Leukemia|Non Hodgkin Lymphoma',\n",
       "  'DRUG: Livopan|DRUG: Livopan|DRUG: EMLA',\n",
       "  'Federal University of Minas Gerais',\n",
       "  '',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2009-02',\n",
       "  '2011-08'],\n",
       " ['NCT02113371',\n",
       "  'Evaluation of COMmunity of Practice And Safety Support (COMPASS) for Home Care Workers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Wounds and Injuries|Health Promotion',\n",
       "  'BEHAVIORAL: Intervention',\n",
       "  'Oregon Health and Science University',\n",
       "  'National Institute for Occupational Safety and Health (NIOSH/CDC)',\n",
       "  '210.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2011-10',\n",
       "  '2016-09'],\n",
       " ['NCT04016571',\n",
       "  'Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis',\n",
       "  'PRIVATE',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  '',\n",
       "  'Belfast Health and Social Care Trust',\n",
       "  'Queen\\'s University\",\" Belfast',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12-01',\n",
       "  '2019-03-01'],\n",
       " ['NCT02340871',\n",
       "  'Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases',\n",
       "  'NGS',\n",
       "  'UNKNOWN',\n",
       "  'Neurological Diseases',\n",
       "  'GENETIC: Genetic testing',\n",
       "  'Rabin Medical Center',\n",
       "  'Charite University\", Berlin,\" Germany|National Institute on Aging (NIA)',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-03',\n",
       "  '2018-07'],\n",
       " ['NCT03770871',\n",
       "  'Indirect Pulp Treatment in Primary Molars',\n",
       "  'RCT',\n",
       "  'COMPLETED',\n",
       "  'Dental Caries',\n",
       "  'DRUG: Indirect pulp treatment using Dycal (TM)|DRUG: Indirect pulp treatment using Vitrebond (TM )',\n",
       "  'Cairo University',\n",
       "  '',\n",
       "  '88.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2018-07'],\n",
       " ['NCT04470271',\n",
       "  'Re-linkage to Care of Patients With Hepatitis C',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Viral Hepatitis C',\n",
       "  'OTHER: Patients with hepatitis C lost follow up',\n",
       "  'Austral University\",\" Argentina',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-09-01',\n",
       "  '2021-03-31'],\n",
       " ['NCT00290771',\n",
       "  'Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Recurrent Glioblastoma Multiforme (GBM)',\n",
       "  'DRUG: Imatinib tablets|DRUG: Hydroxyurea capsules',\n",
       "  'Novartis',\n",
       "  '',\n",
       "  '231.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-02',\n",
       "  '2008-08'],\n",
       " ['NCT00737971',\n",
       "  'Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema',\n",
       "  'ATEMD',\n",
       "  'COMPLETED',\n",
       "  'Diabetic Macular Edema',\n",
       "  'DRUG: Bevacizumab intravitreal|DRUG: Triamcinolone|DRUG: Triamcinolone + Bevacizumab',\n",
       "  'Rubens Belfort Jr.',\n",
       "  '',\n",
       "  '142.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2013-12'],\n",
       " ['NCT02444871',\n",
       "  'IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  '',\n",
       "  'Goethe University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01',\n",
       "  '2013-07'],\n",
       " ['NCT05876871',\n",
       "  'Stress Radiography for Pelvic Ring Injuries',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Pelvic Fracture',\n",
       "  'DIAGNOSTIC_TEST: Pelvic Binder Radiography',\n",
       "  'University of Southern California',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-02-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT04848571',\n",
       "  'Effects of Chinese Medicine on Early Pregnant Women',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pregnant Women',\n",
       "  'COMBINATION_PRODUCT: Fetal Protection Pill',\n",
       "  'Shanghai Meiji Health Science and Technology Co.\",\" Ltd.',\n",
       "  'Shanghai Institute of Palnned parenthood research',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2021-06-21',\n",
       "  '2022-06-20'],\n",
       " ['NCT00470171',\n",
       "  'Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis',\n",
       "  'URSONASH',\n",
       "  'COMPLETED',\n",
       "  'Serum Levels of ALAT Transaminases|Serum Markers for Fibrosis and Hepatic Inflammation',\n",
       "  'DRUG: Ursodesoxycholic acid',\n",
       "  'Axcan Pharma',\n",
       "  '',\n",
       "  '98.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2008-11'],\n",
       " ['NCT05375071',\n",
       "  'BFR After Biceps Tendon Repair and MPFLR',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Patellofemoral Joint Dislocation|Bicep Tendon Rupture',\n",
       "  'OTHER: Blood Flow Restriction (BFR) Therapy|OTHER: Physical Therapy',\n",
       "  'Mayo Clinic',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12',\n",
       "  '2024-01'],\n",
       " ['NCT01979471',\n",
       "  'The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH',\n",
       "  'RxEACH',\n",
       "  'COMPLETED',\n",
       "  'Diabetes|Chronic Kidney Disease|Established Atherosclerotic Vascular Disease|Framingham Risk Score More Than 20 Percent',\n",
       "  'OTHER: Advanced Care',\n",
       "  'University of Alberta',\n",
       "  'Alberta Health & Wellness|Alberta Health services|Merck Frosst Canada Ltd.',\n",
       "  '723.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2015-12'],\n",
       " ['NCT05507671',\n",
       "  'The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines',\n",
       "  'SARS-CoV-2',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: BCG (Bacillus Calmette-Guérin) vaccine|OTHER: Placebo',\n",
       "  'Oswaldo Cruz Foundation',\n",
       "  'University of Sao Paulo|Federal University of Juiz de Fora',\n",
       "  '556.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-05-27',\n",
       "  '2023-12-31'],\n",
       " ['NCT00428571',\n",
       "  'Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Type 2 Diabetes',\n",
       "  'PROCEDURE: laparoscopic gastric bypass surgery|PROCEDURE: laparoscopic adjustable gastric banding|PROCEDURE: Intensive Medical Management',\n",
       "  'Hamilton Health Sciences Corporation',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-05',\n",
       "  '2015-04'],\n",
       " ['NCT04324671',\n",
       "  'Upper Airway Obstruction in Non-obese Patients With Snoring and Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Snoring',\n",
       "  'DEVICE: nasofibroscopy',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-07-01',\n",
       "  '2021-12-01'],\n",
       " ['NCT03735771',\n",
       "  'Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 2.5ml of Bupivacaine 0.25% Plus Fentanyl 8 mcg/ml',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Labor Pain',\n",
       "  'DRUG: Bupivacaine',\n",
       "  'Samuel Lunenfeld Research Institute\",\" Mount Sinai Hospital',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-12-03',\n",
       "  '2019-11-01'],\n",
       " ['NCT06056271',\n",
       "  'Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation',\n",
       "  'COMPANION AI',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Atrial Fibrillation',\n",
       "  'DEVICE: AF Ablation',\n",
       "  'Volta Medical',\n",
       "  'Heart Rhythm Clinical and Research Solutions\",\" LLC',\n",
       "  '400.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10',\n",
       "  '2027-12'],\n",
       " ['NCT00971971',\n",
       "  'Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Kidney Injury|Acute Renal Failure',\n",
       "  'PROCEDURE: Dialysis|PROCEDURE: Standard SLED',\n",
       "  'Sao Jose do Rio Preto Medical School',\n",
       "  'Fundação de Amparo à Pesquisa do Estado de São Paulo',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2009-09'],\n",
       " ['NCT05278871',\n",
       "  'Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphedema of Upper Arm|Breast Cancer',\n",
       "  'DEVICE: Constructive Shearwave Interference (CSI)',\n",
       "  'Microelastic Ultrasound Systems Inc',\n",
       "  'Duke Health',\n",
       "  '21.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2022-05-26',\n",
       "  '2023-08-31'],\n",
       " ['NCT03513471',\n",
       "  'Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation',\n",
       "  'EarlyAna',\n",
       "  'WITHDRAWN',\n",
       "  'Asthma',\n",
       "  'BIOLOGICAL: Anakinra|OTHER: Anakinra Matching Placebo|DRUG: Dermatophagoides Farinae',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-09',\n",
       "  '2021-12'],\n",
       " ['NCT00705471',\n",
       "  \"Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Crohn Disease',\n",
       "  'BIOLOGICAL: Infliximab',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  'Centocor\",\" Inc.',\n",
       "  '42.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-04',\n",
       "  '2007-09'],\n",
       " ['NCT04354571',\n",
       "  'Erector Spinae Plane Block in Pediatric Hip Surgery',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Analgesia',\n",
       "  'PROCEDURE: Erector spinae plane block|PROCEDURE: caudal block',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-08-11',\n",
       "  '2020-09'],\n",
       " ['NCT04683471',\n",
       "  'Pilot Trial of a System for Motor Function Recovery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Spinal Cord Diseases',\n",
       "  'DEVICE: Stimulator|DEVICE: Sham',\n",
       "  'Niche Biomedical\",\" Inc. dba ANEUVO',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-11-30',\n",
       "  '2022-03-22'],\n",
       " ['NCT04544371',\n",
       "  'Ultrasound Assessment of Gastric Residual Volume in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aspiration Pneumonia',\n",
       "  'DEVICE: gastric ultrasound|PROCEDURE: nasogastric tube insertion',\n",
       "  'Fayoum University Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-10-15',\n",
       "  '2020-12-30'],\n",
       " ['NCT04145271',\n",
       "  'Pre-Hospital Zone 1 Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Injured Patients With Exsanguinating Sub-diaphragmatic Haemorrhage',\n",
       "  'P-PRO',\n",
       "  'COMPLETED',\n",
       "  'Emergencies|Trauma Injury|Trauma\",\" Multiple',\n",
       "  'DEVICE: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)',\n",
       "  'Barts & The London NHS Trust',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-27',\n",
       "  '2022-03-31'],\n",
       " ['NCT05824871',\n",
       "  'Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients',\n",
       "  'WISH',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Rifampicin-resistant Tuberculosis',\n",
       "  'DRUG: Sudapyridine|DRUG: Bedaquiline',\n",
       "  'Shanghai Jiatan Pharmatech Co.\",\" Ltd',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-09-02',\n",
       "  '2025-03-22'],\n",
       " ['NCT04119271',\n",
       "  'Durham Healthy Breathing in Healthy Homes Project',\n",
       "  'DHBHH',\n",
       "  'COMPLETED',\n",
       "  'Poor Asthma Control',\n",
       "  'OTHER: Breathe Easy at Home Kit Products',\n",
       "  'Duke University',\n",
       "  'Reinvestment Partners',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-05-18',\n",
       "  '2023-05-11'],\n",
       " ['NCT00757471',\n",
       "  'Brillant Blue Versus Indocyanine Green for Macular Hole Surgery',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Macular Holes',\n",
       "  'PROCEDURE: Brillant Blue|PROCEDURE: Indocyanine Green',\n",
       "  'The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-08',\n",
       "  '2015-08'],\n",
       " ['NCT05147571',\n",
       "  'RNS System NAUTILUS Study',\n",
       "  'NAUTILUS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Epilepsy|Idiopathic Generalized Epilepsy|Generalized Tonic Clonic Seizure',\n",
       "  'DEVICE: Responsive stimulation|DEVICE: Sham stimulation',\n",
       "  'NeuroPace',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-09',\n",
       "  '2026-12'],\n",
       " ['NCT00005871',\n",
       "  'Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pancreatic Cancer',\n",
       "  'DRUG: fluorouracil|DRUG: rubitecan',\n",
       "  'Astex Pharmaceuticals\",\" Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1998-11',\n",
       "  ''],\n",
       " ['NCT04076371',\n",
       "  'The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia',\n",
       "  'DRUG: olanzapine-sertraline combination|DRUG: only olanzapine|DRUG: risperidone-sertraline combination|DRUG: only risperidone|DRUG: paliperidone-sertraline combination|DRUG: only paliperidone|DRUG: ziprasidone-sertraline combination|DRUG: only ziprasidone',\n",
       "  'Beijing HuiLongGuan Hospital',\n",
       "  '',\n",
       "  '1640.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2018-12'],\n",
       " ['NCT03950271',\n",
       "  'SHR-1210 Combined With Trastuzumab \",\" Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastric Cancer',\n",
       "  'DRUG: SHR-1210 Combined With Trastuzumab \",\" Oxaliplatin and Capecitabine',\n",
       "  'Henan Cancer Hospital',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01-21',\n",
       "  '2022-06-01'],\n",
       " ['NCT05624671',\n",
       "  'Is Elective Caesarean Sections for Predicting Post-spinal Hypotension Role of Overactive Bladder?',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  '18-45 Range of Age|Cesarean Section|Primigravid',\n",
       "  'OTHER: bupivacaine\",\"fentanyl',\n",
       "  'Ataturk University',\n",
       "  '',\n",
       "  '143.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING',\n",
       "  '2019-08-01',\n",
       "  '2021-12-30'],\n",
       " ['NCT04502771',\n",
       "  'Therapeutic Drug Monitoring of Antifungals in Intensive Care Units',\n",
       "  'Fungi-up',\n",
       "  'COMPLETED',\n",
       "  'Intensive Care Unit Patients',\n",
       "  'DRUG: Antifungal treatment',\n",
       "  'Hospices Civils de Lyon',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-01-01',\n",
       "  '2019-12-31'],\n",
       " ['NCT01394471',\n",
       "  'Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia',\n",
       "  'OTS-12WK',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizoaffective Disorder',\n",
       "  'DRUG: Intranasal Oxytocin Spray',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-07',\n",
       "  '2015-01'],\n",
       " ['NCT03789071',\n",
       "  'Ultrasound to Predict Difficult Airway',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Difficult Intubation',\n",
       "  'DIAGNOSTIC_TEST: External ultrasound evaluation of the airway',\n",
       "  'Augusta University',\n",
       "  '',\n",
       "  '420.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2023-03-01'],\n",
       " ['NCT00145171',\n",
       "  'A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: apomorphine HCl injection',\n",
       "  'Mylan Bertek Pharmaceuticals',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-02',\n",
       "  '2002-08'],\n",
       " ['NCT01688271',\n",
       "  'Simulation-Based Training for Ultrasound-Guided Perineural Catheter Insertion',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain Management|Simulation|Training|Ultrasonography',\n",
       "  '',\n",
       "  'VA Palo Alto Health Care System',\n",
       "  'Stanford University',\n",
       "  '32.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-08',\n",
       "  '2014-07'],\n",
       " ['NCT01711671',\n",
       "  'A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: DKN-01 300 mg|DRUG: DKN-01 600 mg|DRUG: Standard of Care',\n",
       "  'Leap Therapeutics\",\" Inc.',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2015-07'],\n",
       " ['NCT04342871',\n",
       "  'An Evaluation of the Fathers and Mothers With Cancer Communication Tool',\n",
       "  'Fam-CT',\n",
       "  'COMPLETED',\n",
       "  'Neoplasms|Cancer|Parenting|Communication|Parents|Parent-Child Relations',\n",
       "  'BEHAVIORAL: Fam-CT',\n",
       "  'UNC Lineberger Comprehensive Cancer Center',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2020-10-05',\n",
       "  '2021-07-27'],\n",
       " ['NCT01034371',\n",
       "  'Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Artery Disease',\n",
       "  'PROCEDURE: Minimally invasive direct coronary artery bypass|PROCEDURE: PCI-Drug eluting stents|PROCEDURE: Off-pump coronary artery bypass',\n",
       "  'China National Center for Cardiovascular Diseases',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-12',\n",
       "  ''],\n",
       " ['NCT02390271',\n",
       "  'How Reducing Anxiety in Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia',\n",
       "  'OTHER: emotion focused therapy training',\n",
       "  'Institut de Recherche Biomedicale des Armees',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-06',\n",
       "  '2011-06'],\n",
       " ['NCT04727671',\n",
       "  'Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'In Vitro Fertilization|Intracytoplasmic Sperm Injection|Infertility|Polycystic Ovary Syndrome',\n",
       "  'DRUG: Triptorelin acetate|DRUG: Cetrorelix|DRUG: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|DRUG: Human Chorionic Gonadotropin (hCG)',\n",
       "  'Damascus University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-12-22',\n",
       "  '2021-12-30'],\n",
       " ['NCT01111071',\n",
       "  'Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Coronary Syndrome',\n",
       "  '',\n",
       "  'University College\",\" London',\n",
       "  'Barts & The London NHS Trust|Queen Mary University of London|University of Bristol|Yale University',\n",
       "  '316648.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-04',\n",
       "  '2014-12'],\n",
       " ['NCT01140971',\n",
       "  'Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pregnancy\",\" Prolonged|Pre Eclampsia|Oligohydramnios',\n",
       "  'DRUG: Misoprostol|DEVICE: Foley',\n",
       "  'Municipal Hospital Vila Nova Cachoeirinha',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2009-01'],\n",
       " ['NCT05934071',\n",
       "  'Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Heart Failure|Ventricular Remodeling|Ventricular Dysfunction',\n",
       "  'DRUG: SGLT2 inhibitor',\n",
       "  'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-10-10',\n",
       "  '2024-12-31'],\n",
       " ['NCT02299271',\n",
       "  'Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Osteoarthritis of the Hip',\n",
       "  'DRUG: Ropivacaine|DRUG: Saline',\n",
       "  'The Christ Hospital',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-06',\n",
       "  '2016-12'],\n",
       " ['NCT02425371',\n",
       "  'Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)',\n",
       "  'OPTIMIZE-HFPEF',\n",
       "  'UNKNOWN',\n",
       "  'Heart Failure\",\" Diastolic',\n",
       "  'OTHER: Screening and treatment of comorbidities|OTHER: Placebo Comparator',\n",
       "  'Göteborg University',\n",
       "  'Umeå University|Karolinska Institutet|Uppsala University|Vastra Gotaland Region',\n",
       "  '410.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-09',\n",
       "  '2019-07'],\n",
       " ['NCT01403571',\n",
       "  'Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes',\n",
       "  'LOSS',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus|Overweight|Obesity',\n",
       "  'DIETARY_SUPPLEMENT: Salba (Salvia hispanica L.)|DIETARY_SUPPLEMENT: Oat-based Control',\n",
       "  'Unity Health Toronto',\n",
       "  'Canadian Diabetes Association',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-10',\n",
       "  '2015-08'],\n",
       " ['NCT00945971',\n",
       "  'Exercise Effects in Children With Attention Deficit Hyperactivity Disorder',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Attention Deficit/Hyperactivity Disorder',\n",
       "  'OTHER: Physical activity',\n",
       "  'Meir Medical Center',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-10-01',\n",
       "  '2020-12-01'],\n",
       " ['NCT02177071',\n",
       "  \"A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy\",\n",
       "  'SPARE',\n",
       "  'COMPLETED',\n",
       "  \"Crohn's Disease\",\n",
       "  'DRUG: INFLIXIMAB|DRUG: AZATHIOPRINE|DRUG: MERCAPTOPURINE|DRUG: Methotrexate',\n",
       "  \"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives\",\n",
       "  'Saint-Louis Hospital\", Paris,\" France',\n",
       "  '211.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-10-09',\n",
       "  '2021-10'],\n",
       " ['NCT04704271',\n",
       "  'Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II',\n",
       "  'THC-Gender-II',\n",
       "  'RECRUITING',\n",
       "  'Cannabis',\n",
       "  'DRUG: Inhaled THC|DRUG: Placebo',\n",
       "  'Yale University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-10-09',\n",
       "  '2024-12-01'],\n",
       " ['NCT02879071',\n",
       "  'Long Term Follow-up After Embolization of Brain Arteriovenous Malformations',\n",
       "  'MAV-endovasc',\n",
       "  'RECRUITING',\n",
       "  'Arteriovenous Malformations',\n",
       "  '',\n",
       "  'Fondation Ophtalmologique Adolphe de Rothschild',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'NETWORK',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-11-26',\n",
       "  '2033-11-25'],\n",
       " ['NCT01491971',\n",
       "  'Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer',\n",
       "  'IM1',\n",
       "  'COMPLETED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Degarelix',\n",
       "  'Ferring Pharmaceuticals',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2012-11'],\n",
       " ['NCT04130971',\n",
       "  'Predicting Colorectal Cancer - Tissue Samples to Evaluate Tumour Characteristics and Treatment Response',\n",
       "  'Predict',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Neoplasms',\n",
       "  'OTHER: No intervention\",\" just observation',\n",
       "  'Sahlgrenska University Hospital\",\" Sweden',\n",
       "  'Göteborg University',\n",
       "  '800.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-02-01',\n",
       "  '2027-12-31'],\n",
       " ['NCT03843671',\n",
       "  'Hyperbaric Radiation Sensitization of Head and Neck Cancers',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Squamous Cell Carcinoma of the Head and Neck',\n",
       "  'DRUG: Hyperbaric oxygen|DEVICE: Hyperbaric chamber',\n",
       "  'National Baromedical Services',\n",
       "  'Mayo Clinic|Dartmouth-Hitchcock Medical Center|CISSS de Chaudière-Appalaches|Memorial Hermann Hospital|David Grant U.S. Air Force Medical Center|59th Medical Wing|Prisma Health Richland Hospital|William Jennings Bryan Dorn VA Medical Center',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-07-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT04125771',\n",
       "  'Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pain',\n",
       "  'DIAGNOSTIC_TEST: Diclofenac + HBB with hysteroscopy|DIAGNOSTIC_TEST: Diclofenav + placebo',\n",
       "  'Aljazeera Hospital',\n",
       "  'Cairo University',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2020-02-16',\n",
       "  '2020-10-01'],\n",
       " ['NCT00766571',\n",
       "  'Clinical and Genetic Studies of VACTERL Association',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Congenital Abnormalities|Birth Defects|Congenital Defects',\n",
       "  '',\n",
       "  'National Human Genome Research Institute (NHGRI)',\n",
       "  '',\n",
       "  '304.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-09-29',\n",
       "  '2017-06-29'],\n",
       " ['NCT03881371',\n",
       "  'A Study to Evaluate the Efficacy and Safety of Safinamide\", as add-on Therapy,\" in Idiopathic Chinese Parkinson\\'s Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: Safinamide|OTHER: Placebo',\n",
       "  'Zambon SpA',\n",
       "  '',\n",
       "  '307.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-08-01',\n",
       "  '2021-08-20'],\n",
       " ['NCT02360371',\n",
       "  'A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid Sensitivity|Individual Difference|Abuse Opioids',\n",
       "  'DRUG: Within-subject test of blinded study medication',\n",
       "  'Johns Hopkins University',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-04',\n",
       "  '2021-05'],\n",
       " ['NCT04175171',\n",
       "  'Clinical Trial of Comparative Study of GB221 Pharmacokinetics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Breast Cancer',\n",
       "  'DRUG: Coprelotamab Injection|DRUG: Trastuzumab Injection',\n",
       "  'Genor Biopharma Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-11-07',\n",
       "  '2012-03-08'],\n",
       " ['NCT05936671',\n",
       "  'EEG and ANI Guided Anesthesia and Quality of Recovery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Laparoscopic Gynecological Surgery',\n",
       "  'PROCEDURE: EEG-and-ANI-guided anesthesia|PROCEDURE: standard anesthesia|DRUG: Sevoflurane and remifentanil|DEVICE: EEG and ANI',\n",
       "  'Gangnam Severance Hospital',\n",
       "  '',\n",
       "  '126.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-13',\n",
       "  '2025-06-25'],\n",
       " ['NCT03391271',\n",
       "  'PBMT for the Prevention of CIPN',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'OTHER: photobiomodulation therapy (PBMT)|OTHER: sham laser sessions',\n",
       "  'Hasselt University',\n",
       "  'Jessa Hospital',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-11-13',\n",
       "  '2021-06-22'],\n",
       " ['NCT04080271',\n",
       "  'Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.',\n",
       "  'PET/CT',\n",
       "  'COMPLETED',\n",
       "  'Bone Metastases',\n",
       "  'DEVICE: 18F-FDG PET/CT',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-01',\n",
       "  '2021-12-01'],\n",
       " ['NCT01480271',\n",
       "  'An Investigation of the Safety\", Tolerability,\" Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rhinitis\", Allergic,\" Seasonal',\n",
       "  'DRUG: 2 ng GSK2445053|DRUG: 20ng GSK2445053|DRUG: 100ng GSK2445053|DRUG: 200ng GSK2445053|DRUG: 400ng GSK2445053|DRUG: 1000ng GSK2445053|DRUG: 2000ng GSK2445053|DRUG: 4000ng GSK2445053|DRUG: Placebo',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '61.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-05-30',\n",
       "  '2011-09-30'],\n",
       " ['NCT00639171',\n",
       "  'Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Tumors',\n",
       "  '',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2005-11',\n",
       "  '2015-08'],\n",
       " ['NCT00826371',\n",
       "  'Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients',\n",
       "  'EXTEND II',\n",
       "  'COMPLETED',\n",
       "  'Age Related Macular Degeneration',\n",
       "  'DRUG: ranibizumab 0.5 mg',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  ''],\n",
       " ['NCT02938871',\n",
       "  'Effect of Synbiotic on Postoperative Complications After Liver Transplantation',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Liver Disease',\n",
       "  'DIETARY_SUPPLEMENT: Synbiotic|DIETARY_SUPPLEMENT: Control',\n",
       "  'Hospital de Clinicas de Porto Alegre',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-03',\n",
       "  '2018-01'],\n",
       " ['NCT04596371',\n",
       "  'A Single-center Prospective Cohort Study for Pure Pulmonary Ground Glass Nodules in Women Preparing for Pregnancy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Cancer',\n",
       "  'OTHER: pure pulmonary ground glass nodules in women preparing for pregnancy',\n",
       "  'Shanghai Zhongshan Hospital',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-11-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT03322371',\n",
       "  'Validation of Frontal EEG to Formal Polysomnography in the ICU',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Sleep Deprivation|Sleep',\n",
       "  'DEVICE: 2-lead limited electroencephalography recording',\n",
       "  'University of Utah',\n",
       "  'Epitel\",\" Inc.',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2017-11-06',\n",
       "  '2020-01-01'],\n",
       " ['NCT03332771',\n",
       "  'Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy',\n",
       "  'SOTA-GLIM',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: Sotagliflozin (SAR439954)|DRUG: Glimepiride|DRUG: Metformin|DRUG: Placebo|DRUG: Placebo',\n",
       "  'Lexicon Pharmaceuticals',\n",
       "  'Sanofi',\n",
       "  '954.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-12-01',\n",
       "  '2019-09-06'],\n",
       " ['NCT04605471',\n",
       "  'A Study to Learn More About the Safety of Ultravist in Children and in the Elderly',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hypersensitivity',\n",
       "  'DRUG: Iopromide(Ultravist\",\" BAY86-4877)',\n",
       "  'Bayer',\n",
       "  '',\n",
       "  '132850.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-31',\n",
       "  '2021-03-31'],\n",
       " ['NCT04403971',\n",
       "  '0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hospital-acquired Pneumonia',\n",
       "  'DRUG: 0.12% Chlorhexidine Oral Liquid Product|DRUG: Listerine Oral Liquid Product|OTHER: Normal Saline Product',\n",
       "  'National Cheng-Kung University Hospital',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-05-25',\n",
       "  '2020-12-31'],\n",
       " ['NCT05559671',\n",
       "  'Safety of the Herpes Zoster Subunit Vaccine in Lupus',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Systemic Lupus Erythematosus',\n",
       "  'BIOLOGICAL: Herpes Zoster Subunit (HZ/su) Vaccine|BIOLOGICAL: Placebo',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '224.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-12-21',\n",
       "  '2027-01'],\n",
       " ['NCT01608971',\n",
       "  'Protamine in Cardiac Surgery and Haemostasis',\n",
       "  'PROTT',\n",
       "  'COMPLETED',\n",
       "  'Bleeding|Hemorrhage',\n",
       "  '',\n",
       "  'Heart and Diabetes Center North-Rhine Westfalia',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-01',\n",
       "  '2012-03'],\n",
       " ['NCT05533671',\n",
       "  'Conservative Versus Operative - First Time Patella Dislocations',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Patella Dislocation',\n",
       "  'PROCEDURE: medial patellofemoral reconstruction|PROCEDURE: Non-operative group',\n",
       "  'Columbia University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12',\n",
       "  '2032-09'],\n",
       " ['NCT03279471',\n",
       "  'Specifying and Treating Anxiety in Autism Research',\n",
       "  'STAAR',\n",
       "  'COMPLETED',\n",
       "  'Autism Spectrum Disorder|Anxiety',\n",
       "  'DRUG: Sertraline|BEHAVIORAL: CBT/BIACA|DRUG: Placebo',\n",
       "  'University of California\",\" Davis',\n",
       "  '',\n",
       "  '68.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-01',\n",
       "  '2023-02-22'],\n",
       " ['NCT00316771',\n",
       "  'A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'DRUG: P38 Inhibitor (4) 150mg|DRUG: P38 Inhibitor (4) 25mg|DRUG: P38 Inhibitor (4) 300mg|DRUG: P38 Inhibitor (4) 50mg|DRUG: P38 Inhibitor (4) 75mg|DRUG: Placebo',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '374.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-11',\n",
       "  '2008-03'],\n",
       " ['NCT00795171',\n",
       "  'Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hormone Refractory Prostate Cancer',\n",
       "  'DRUG: Docetaxel * Sunitinib|DRUG: Docetaxel|DRUG: Docetaxel',\n",
       "  'Medical University of Vienna',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2008-11',\n",
       "  '2011-07'],\n",
       " ['NCT01459471',\n",
       "  'Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Complication of Surgical Procedure|Leak; Blood',\n",
       "  'PROCEDURE: Bariatric surgery',\n",
       "  'University of Rome Tor Vergata',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-04',\n",
       "  '2010-09'],\n",
       " ['NCT00671671',\n",
       "  'Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis\",\" Chronic|Hepatitis C Virus',\n",
       "  'DRUG: Small Molecule Agent (PF-868554)|DRUG: Small Molecule Agent (PF-868554)',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-04',\n",
       "  '2008-12'],\n",
       " ['NCT00601471',\n",
       "  'Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation\", Ankle Range of Motion,\" and Functional Outcome Scores in Individuals With Chronic Ankle Instability',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ankle Sprain|Ankle Injuries|Sprain',\n",
       "  'OTHER: proximal tibiofibular manipulation|OTHER: distal tibiofibular manipulation|OTHER: no intervention',\n",
       "  'University of Virginia',\n",
       "  'American Physical Therapy Association',\n",
       "  '61.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-04',\n",
       "  '2010-01'],\n",
       " ['NCT03750071',\n",
       "  'VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Recurrent Glioblastoma',\n",
       "  'BIOLOGICAL: VXM01|BIOLOGICAL: Avelumab',\n",
       "  'Vaximm GmbH',\n",
       "  'Merck KGaA\", Darmstadt,\" Germany|Pfizer',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-11-21',\n",
       "  '2022-12-31'],\n",
       " ['NCT03064971',\n",
       "  'Enhancing Quitline Services for African American Smokers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Tobacco Use Cessation',\n",
       "  'BEHAVIORAL: Standard Care|BEHAVIORAL: smoking cessation DVD|BEHAVIORAL: PTF DVD',\n",
       "  'Case Comprehensive Cancer Center',\n",
       "  'American Cancer Society\",\" Inc.|Consumer Wellness Solutions|North Carolina Tobacco Quitline',\n",
       "  '1050.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2017-05-22',\n",
       "  '2020-06-24'],\n",
       " ['NCT00710671',\n",
       "  'Psychosocial Needs of YMSM',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV+ YMSM',\n",
       "  '',\n",
       "  'University of North Carolina\",\" Chapel Hill',\n",
       "  'National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)',\n",
       "  '254.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-06'],\n",
       " ['NCT05258071',\n",
       "  \"A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Parkinson Disease',\n",
       "  'DRUG: Pirepemat|DRUG: Placebo',\n",
       "  'Integrative Research Laboratories AB',\n",
       "  '',\n",
       "  '165.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-06-15',\n",
       "  '2024-04'],\n",
       " ['NCT02205671',\n",
       "  'Building Better Caregivers: Development and Evaluation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Providing Care for People With Memory Problems',\n",
       "  'BEHAVIORAL: Building Better Caregivers Small-group Workshop',\n",
       "  'Stanford University',\n",
       "  '',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-08',\n",
       "  '2017-03'],\n",
       " ['NCT00487071',\n",
       "  'Anal Fistula Plug for High-type Anal Fistulae',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'High-type Anal Fistulae',\n",
       "  'DEVICE: Anal fistula plug',\n",
       "  'Chinese University of Hong Kong',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-08',\n",
       "  '2014-02'],\n",
       " ['NCT00744471',\n",
       "  'Tanezumab in Osteoarthritis Of The Hip',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Arthritis|Osteoarthritis|Osteoarthritis\",\" Hip',\n",
       "  'BIOLOGICAL: tanezumab|BIOLOGICAL: tanezumab|BIOLOGICAL: tanezumab|BIOLOGICAL: Placebo',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '627.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-11-17',\n",
       "  '2010-08-13'],\n",
       " ['NCT04388371',\n",
       "  'Glutamine PET Imaging in LAM',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphangioleiomyomatosis (LAM)',\n",
       "  'DRUG: Glutamine',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  'The LAM Foundation',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2019-10-18',\n",
       "  '2021-08-10'],\n",
       " ['NCT02546271',\n",
       "  'A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men',\n",
       "  'GPS',\n",
       "  'COMPLETED',\n",
       "  'Risk Behavior',\n",
       "  'BEHAVIORAL: GPS',\n",
       "  'Toronto Metropolitan University',\n",
       "  '',\n",
       "  '82.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2009-03',\n",
       "  '2013-11'],\n",
       " ['NCT05995171',\n",
       "  'Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence',\n",
       "  'TransEAsome',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Esophageal Atresia',\n",
       "  'OTHER: Questionnaire',\n",
       "  'University Hospital\",\" Lille',\n",
       "  'Institut National de la Santé Et de la Recherche Médicale\",\" France',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-12-05',\n",
       "  '2026-12-05'],\n",
       " ['NCT04904471',\n",
       "  'A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: Recombinant COVID-19 vaccine (Sf9 cells)|OTHER: Placebo control',\n",
       "  'WestVac Biopharma Co.\",\" Ltd.',\n",
       "  'West China Hospital',\n",
       "  '40000.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2021-06-15',\n",
       "  '2023-12-31'],\n",
       " ['NCT00113971',\n",
       "  'Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lupus Erythematosus\",\" Systemic',\n",
       "  'DRUG: epratuzumab',\n",
       "  'UCB Pharma',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-04',\n",
       "  '2007-06'],\n",
       " ['NCT03263871',\n",
       "  'PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Environmental Enteric Dysfunction',\n",
       "  'DIETARY_SUPPLEMENT: PTM202|DIETARY_SUPPLEMENT: micro-nutrient sprinkles',\n",
       "  'University of Virginia',\n",
       "  'International Centre for Diarrhoeal Disease Research\",\" Bangladesh|Virginia Commonwealth University',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-14',\n",
       "  '2019-02-15'],\n",
       " ['NCT01989871',\n",
       "  'Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm Infants',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Body Weight Changes|Feeding and Eating Disorders of Childhood|Breast Feeding|Evoked Response Audiometry',\n",
       "  'BEHAVIORAL: Adjusted individual feeding',\n",
       "  'Sheba Medical Center',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-12',\n",
       "  '2015-12'],\n",
       " ['NCT05173571',\n",
       "  'Homecare Integral Support Program for IPF Patients',\n",
       "  'PSPi-IPF',\n",
       "  'COMPLETED',\n",
       "  'Idiopathic Pulmonary Fibrosis',\n",
       "  'COMBINATION_PRODUCT: Comprehensive patient support program (educational\", physiotherapy, nutritional,\" emotional)',\n",
       "  \"Institut d'Investigació Biomèdica de Bellvitge\",\n",
       "  '',\n",
       "  '95.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-07-01',\n",
       "  '2021-12-12'],\n",
       " ['NCT04700371',\n",
       "  'Vessel Deformations and Restenosis After Stenting of the Popliteal Artery',\n",
       "  'FIRESTEP',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Peripheral Arterial Disease|Popliteal Artery Stenosis',\n",
       "  'DEVICE: Interwoven stent|DEVICE: Laser-cut stent',\n",
       "  'Kantonsspital Aarau',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-01',\n",
       "  '2024-08-01'],\n",
       " ['NCT04858971',\n",
       "  'Survey of Diet and Health Beliefs',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dietary Guidelines',\n",
       "  'OTHER: Perception of information source',\n",
       "  'USDA Grand Forks Human Nutrition Research Center',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'FED',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-06-21',\n",
       "  '2021-09-24'],\n",
       " ['NCT02747771',\n",
       "  'Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder)',\n",
       "  'NorTriP',\n",
       "  'UNKNOWN',\n",
       "  'Trichotillomania',\n",
       "  'BEHAVIORAL: Cognitive behavioral therapy',\n",
       "  'Oslo University Hospital',\n",
       "  'Sorlandet Hospital HF|St. Olavs Hospital|Texas A&M University|University of Michigan',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-01',\n",
       "  '2019-12'],\n",
       " ['NCT00849771',\n",
       "  'Operative Versus Nonoperative Treatment for Scapula Fractures',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Scapula Fracture|Clavicle Fracture',\n",
       "  '',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-01'],\n",
       " ['NCT05057871',\n",
       "  'Efficacy of Pulse Electromagnetic Field Therapy (PEMF) in Patients With Subacromial Impingement Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Shoulder Pain|Musculoskeletal Diseases|Subacromial Impingement Syndrome|Shoulder Injuries and Disorders',\n",
       "  'DEVICE: Pulse electromagnetic field therapy|DEVICE: Sham pulse electromagnetic field therapy',\n",
       "  'Afyonkarahisar Health Sciences University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-01-01',\n",
       "  '2022-06-01'],\n",
       " ['NCT01550471',\n",
       "  'Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma|Allergic Rhinitis',\n",
       "  'DRUG: Alvesco/Omnaris\", QVAR/Beconase, Placebo/Placebo|DRUG: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|DRUG: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|DRUG: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|DRUG: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|DRUG: Placebo/Placebo, QVAR/Beconase,\" Alvesco/Omnaris',\n",
       "  'West Penn Allegheny Health System',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2015-08'],\n",
       " ['NCT03675971',\n",
       "  'COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement',\n",
       "  'COPE',\n",
       "  'UNKNOWN',\n",
       "  'Arthroplasty\", Replacement,\" Knee',\n",
       "  'DRUG: Cannabinol|DRUG: Placebo oral capsule',\n",
       "  'Unity Health Toronto',\n",
       "  '',\n",
       "  '220.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-05-01',\n",
       "  '2022-05'],\n",
       " ['NCT05970471',\n",
       "  'Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital',\n",
       "  'IMPLICATION',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Preference\",\" Patient|Pharmacist-Patient Relations|Caregiver|Cancer',\n",
       "  '',\n",
       "  'Centre Hospitalier Universitaire de Besancon',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-09-01',\n",
       "  '2024-02-29'],\n",
       " ['NCT00467571',\n",
       "  'Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Idiopathic Thrombocytopenic Purpura|Helicobacter Pylori Infection',\n",
       "  'DRUG: lansoprazole\", clarithromycin,\" amoxycillin',\n",
       "  'Mahidol University',\n",
       "  'Ramathibodi Hospital',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-03',\n",
       "  '2008-12'],\n",
       " ['NCT02106871',\n",
       "  'Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer',\n",
       "  'PCC',\n",
       "  'WITHDRAWN',\n",
       "  'Pancreatic Cancer|Cholangiocarcinoma',\n",
       "  'DRUG: Sildenafil',\n",
       "  'The University of Texas Medical Branch\",\" Galveston',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2014-04',\n",
       "  '2017-06'],\n",
       " ['NCT04305171',\n",
       "  'Effect of Non-surgical Periodontal Treatment on Cardiovascular Risk Markers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Coronary Heart Disease|Periodontitis',\n",
       "  'PROCEDURE: non-surgical periodontal treatment',\n",
       "  'Mahidol University',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-04-06',\n",
       "  '2020-02-20'],\n",
       " ['NCT03205371',\n",
       "  'Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Meningitis\",\" Meningococcal',\n",
       "  'BIOLOGICAL: MenACYW conjugate vaccine|BIOLOGICAL: MMR|BIOLOGICAL: Varicella|BIOLOGICAL: DTaP-IPV-HB-Hib|BIOLOGICAL: PCV13',\n",
       "  'Sanofi Pasteur\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '1183.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2016-11-07',\n",
       "  '2018-07-19'],\n",
       " ['NCT05670171',\n",
       "  'Debulking Atherectomy Versus Stent Angioplasty for Limb Ischaemia of Diabetic Lower Limb Atherosclerosis-occlusive Disease.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'PROCEDURE: Debulking Atherectomy|PROCEDURE: Stent Angioplasty',\n",
       "  'Xuanwu Hospital\",\" Beijing',\n",
       "  'The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The Second Hospital of Hebei Medical University|Shanxi Bethune Hospital|First Affiliated Hospital Xi\\'an Jiaotong University|The Affiliated Hospital of Qingdao University|Shanghai Pudong Hospital|Tianjin Medical University General Hospital|China-Japan Union Hospital\",\" Jilin University|Fudan University',\n",
       "  '244.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01',\n",
       "  '2025-12'],\n",
       " ['NCT00515671',\n",
       "  'Illness Management and Recovery for Veterans With Severe Mental Illness',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizo-affective Disorder',\n",
       "  'BEHAVIORAL: Illness Management and Recovery|BEHAVIORAL: Problem Solving',\n",
       "  'VA Office of Research and Development',\n",
       "  'Indiana University|Dartmouth College',\n",
       "  '118.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2013-09'],\n",
       " ['NCT02387671',\n",
       "  'Weight Management Among Breast Cancer Survivors',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Body Weight',\n",
       "  'BEHAVIORAL: Device: FitBit Flex wrist band|BEHAVIORAL: Device: FitBit Aria weight scale|BEHAVIORAL: Diet Intake Messages|BEHAVIORAL: Behavioral Counseling',\n",
       "  'Boston Medical Center',\n",
       "  'Boston University',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2015-02',\n",
       "  '2015-07'],\n",
       " ['NCT02725671',\n",
       "  'Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Coronary Heart Disease|Coronary Artery Disease|Ischemic Heart Disease',\n",
       "  'DEVICE: Explorer',\n",
       "  'Johns Hopkins University',\n",
       "  'Enverdis Corp.',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-04',\n",
       "  '2020-06-26'],\n",
       " ['NCT01338571',\n",
       "  'Horton & Maizy Pilot Study for Resistant to Starch',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'pH|Weight Gain',\n",
       "  '',\n",
       "  'Pennington Biomedical Research Center',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-02',\n",
       "  '2008-07'],\n",
       " ['NCT05104671',\n",
       "  'Thoracic Manipulation Versus Myofascial Release in Patients With Shoulder Impingement Syndrome',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Impingement Shoulder',\n",
       "  'OTHER: scapular stabilization exercises.|OTHER: Thoracic manipulation.|OTHER: Myofascial release.',\n",
       "  'manar sameh el taher',\n",
       "  'Cairo University',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-12-01',\n",
       "  '2022-09-01'],\n",
       " ['NCT05209971',\n",
       "  'Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Macular Edema',\n",
       "  '',\n",
       "  'Sohag University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-01',\n",
       "  '2022-12'],\n",
       " ['NCT00869271',\n",
       "  'Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Unresectable Liver Metastasis of Colorectal Cancer',\n",
       "  'PROCEDURE: tac + folfox4|PROCEDURE: Folfox4',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-01',\n",
       "  '2007-12'],\n",
       " ['NCT05537571',\n",
       "  'Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Cardiovascular Diseases|Atherosclerosis|Lipoprotein(a)',\n",
       "  'DRUG: SLN360|DRUG: Placebo',\n",
       "  'Silence Therapeutics plc',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-03',\n",
       "  '2024-06'],\n",
       " ['NCT02021071',\n",
       "  'Virtual Path Planning for Image-guided Needle Interventions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastrointestinal Diseases|Bone Diseases|Muscular Diseases|Spinal Diseases|Vascular Diseases',\n",
       "  'RADIATION: XperGuide|RADIATION: XperGuide with virtual path planning',\n",
       "  'Philips Clinical & Medical Affairs Global',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-12',\n",
       "  '2014-06'],\n",
       " ['NCT04998071',\n",
       "  'Posterior Quadratus Lumborum Block Using 0.125% Versus 0.25% Bupivacaine for Analgesia in Children Undergoing LPEC',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Bupivacaine hydrochloride',\n",
       "  'Queen Sirikit National Institute of Child Health',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-08-15',\n",
       "  '2022-06-30'],\n",
       " ['NCT03477071',\n",
       "  'A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Unrecognized Condition',\n",
       "  'PROCEDURE: Angioplasty for Transplant Renal Artery Stenosis (TRAS)',\n",
       "  'Centre Hospitalier Universitaire de Nice',\n",
       "  'Institut National de la Santé Et de la Recherche Médicale\",\" France',\n",
       "  '1323.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-01-01',\n",
       "  '2017-12-01'],\n",
       " ['NCT01200771',\n",
       "  'Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP',\n",
       "  'FUO-TEP',\n",
       "  'COMPLETED',\n",
       "  'Fever',\n",
       "  'PROCEDURE: TEP',\n",
       "  'University Hospital\",\" Limoges',\n",
       "  '',\n",
       "  '116.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2008-05',\n",
       "  '2014-02'],\n",
       " ['NCT00661271',\n",
       "  'Mindfulness-based Stress Reduction for Urban Youth',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stress\",\" Psychological',\n",
       "  'BEHAVIORAL: Mindfulness-based stress reduction (MBSR)|BEHAVIORAL: Healthy topics',\n",
       "  'Johns Hopkins University',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '96.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-09',\n",
       "  '2012-03'],\n",
       " ['NCT03595371',\n",
       "  \"Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Schnitzler Syndrome',\n",
       "  'DRUG: dapansutrile',\n",
       "  'Olatec Therapeutics LLC',\n",
       "  'Radboud University Medical Center',\n",
       "  '2.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-05-15',\n",
       "  '2018-05-29'],\n",
       " ['NCT02710071',\n",
       "  'Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide',\n",
       "  'nebhctz',\n",
       "  'COMPLETED',\n",
       "  'Hypertension',\n",
       "  'DRUG: Nebivolol|DRUG: Hydrochlorothiazide',\n",
       "  'University of California\",\" San Diego',\n",
       "  '',\n",
       "  '41.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-01',\n",
       "  '2016-04'],\n",
       " ['NCT05716971',\n",
       "  'Redetachment Under Densiron for RD Multiple Breaks',\n",
       "  'Densiron',\n",
       "  'COMPLETED',\n",
       "  'Retinal Detachment Multiple Breaks',\n",
       "  'PROCEDURE: Densiron-68 (heavy silicone oil) tamponade for retinal detachment',\n",
       "  'Dar El Oyoun Hospital',\n",
       "  'Cairo University',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-10-01',\n",
       "  '2022-12-22'],\n",
       " ['NCT02411071',\n",
       "  'Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'HIV-infection',\n",
       "  '',\n",
       "  'University Hospital\",\" Essen',\n",
       "  'Janssen Medical Affairs',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-12',\n",
       "  '2016-12'],\n",
       " ['NCT04216771',\n",
       "  'Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'AML in Remission',\n",
       "  'DRUG: Idarubicin|DRUG: ID cytarabine',\n",
       "  'Fujian Medical University',\n",
       "  '',\n",
       "  '320.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2024-05'],\n",
       " ['NCT00060671',\n",
       "  \"Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Lymphoma\", Follicular|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular|Lymphoma,\" Low-Grade',\n",
       "  'DRUG: rituximab|DRUG: Pixantrone (BBR 2778)',\n",
       "  'CTI BioPharma',\n",
       "  '',\n",
       "  '800.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-01',\n",
       "  '2006-01'],\n",
       " ['NCT04849871',\n",
       "  'Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma',\n",
       "  'BreaStBRT',\n",
       "  'RECRUITING',\n",
       "  'Breast Carcinoma|Breast Cancer|Stage 0 Breast Cancer|Stage I Breast Cancer',\n",
       "  'RADIATION: External Beam Accelerated Partial Breast Irradiation',\n",
       "  'Washington University School of Medicine',\n",
       "  'The Foundation for Barnes-Jewish Hospital',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-08-12',\n",
       "  '2029-06-30'],\n",
       " ['NCT02580071',\n",
       "  'Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Leukemia',\n",
       "  'DIETARY_SUPPLEMENT: Sheng-Yu-Tang',\n",
       "  'China Medical University Hospital',\n",
       "  '',\n",
       "  '18.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2017-08'],\n",
       " ['NCT05077371',\n",
       "  'Peer Support Program in Cancer Patients Elkar Laguntza',\n",
       "  'ElkarLaguntz',\n",
       "  'RECRUITING',\n",
       "  'Neoplasms|Social Skills|Psychological Distress',\n",
       "  'BEHAVIORAL: Peer support program',\n",
       "  'Joana Perez Tejada',\n",
       "  'University of the Basque Country (UPV/EHU)',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2019-06-01',\n",
       "  '2024-12-31'],\n",
       " ['NCT00511771',\n",
       "  'A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation',\n",
       "  '',\n",
       "  'NO_LONGER_AVAILABLE',\n",
       "  'Irritable Bowel Syndrome With Constipation|Chronic Idiopathic Constipation',\n",
       "  'DRUG: Tegaserod',\n",
       "  'Novartis',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'EXPANDED_ACCESS',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT03336671',\n",
       "  'Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Chronic Sinusitis|Adenoid Disease - Chronic',\n",
       "  'PROCEDURE: Endoscopic Sinus surgery|PROCEDURE: Adenoidectomy',\n",
       "  'State University of New York - Upstate Medical University',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-07-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT02245971',\n",
       "  'A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Gastric Adenoma and Early Gastric Cancer',\n",
       "  'PROCEDURE: Partial precutting|PROCEDURE: Whole precutting',\n",
       "  'Yonsei University',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07-26',\n",
       "  '2014-08-12'],\n",
       " ['NCT01937871',\n",
       "  'A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostate Hyperplasia|Erectile Dysfunction',\n",
       "  'DRUG: 5 mg Tadalafil|DRUG: Placebo|DRUG: 0.2 mg Tamsulosin',\n",
       "  'Eli Lilly and Company',\n",
       "  '',\n",
       "  '909.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-09',\n",
       "  '2015-12'],\n",
       " ['NCT03317171',\n",
       "  'Safety and Efficacy of a Flavonoids- and omega3s-based Compound for the Treatment of Muscular Dystrophies',\n",
       "  'PRO1',\n",
       "  'COMPLETED',\n",
       "  'Muscular Dystrophies|Muscle Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: Flavonoids\", DHA,\" EPA|DIETARY_SUPPLEMENT: placebo compound',\n",
       "  'Fondazione IRCCS Ca\\' Granda\",\" Ospedale Maggiore Policlinico',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-02-28',\n",
       "  '2016-12-31'],\n",
       " ['NCT02602171',\n",
       "  'Virtual Acoustic Localization Experiment',\n",
       "  'VALEEvE',\n",
       "  'COMPLETED',\n",
       "  'Hearing Loss',\n",
       "  'OTHER: Oldenburger sentence test\",\" localization test',\n",
       "  'University of Zurich',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER',\n",
       "  '2015-04',\n",
       "  '2015-12'],\n",
       " ['NCT03245671',\n",
       "  'Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Lumbar Spinal Stenosis',\n",
       "  'DRUG: Kenalog Injectable Product|DRUG: Decadron Phosphate\",\" Injectable|PROCEDURE: Epidural Steroid Injection',\n",
       "  'Hospital for Special Surgery\",\" New York',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT',\n",
       "  '2017-12',\n",
       "  '2019-04'],\n",
       " ['NCT04588571',\n",
       "  'Efficacy and Safety Comparison of the Open Surgical and Endovascular Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee\", TASC II,\" Type D.',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Atherosclerosis|Ischemia Limb|Superficial Femoral Artery Occlusion|Popliteal Artery Occlusion',\n",
       "  'PROCEDURE: Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|PROCEDURE: Femoropopliteal proximal bypass',\n",
       "  'Meshalkin Research Institute of Pathology of Circulation',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-10-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT04285671',\n",
       "  'Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Metastatic Lung Non-Small Cell Carcinoma|Refractory Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8',\n",
       "  'BIOLOGICAL: Necitumumab|DRUG: Osimertinib|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Trastuzumab',\n",
       "  'Jonsson Comprehensive Cancer Center',\n",
       "  'Eli Lilly and Company|Genentech\",\" Inc.',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-01-29',\n",
       "  '2025-12-02'],\n",
       " ['NCT00347971',\n",
       "  \"Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphoma\",\" Non-Hodgkin',\n",
       "  'DRUG: recombinant human interleukin 21 and rituximab',\n",
       "  'ZymoGenetics',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-06',\n",
       "  '2008-04'],\n",
       " ['NCT04873271',\n",
       "  'Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study',\n",
       "  'TITAN 1',\n",
       "  'COMPLETED',\n",
       "  'Overactive Bladder',\n",
       "  'DEVICE: Medtronic Implantable Tibial Neuromodulation (TNM) System',\n",
       "  'MedtronicNeuro',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2021-05-11',\n",
       "  '2022-07-08'],\n",
       " ['NCT01610271',\n",
       "  'Air Barrier System for the Prevention of Surgical Site Infection',\n",
       "  'ABS',\n",
       "  'COMPLETED',\n",
       "  'Surgical Site Infection',\n",
       "  'DEVICE: Air Barrier System',\n",
       "  'Nimbic Systems\",\" LLC',\n",
       "  'National Institute of General Medical Sciences (NIGMS)|Baylor College of Medicine',\n",
       "  '300.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2012-01',\n",
       "  '2015-04'],\n",
       " ['NCT05719571',\n",
       "  'Measurement of Maximal Oxygen Uptake (VO2max) Using Mankato Submaximal Exercise Test in Young Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  '',\n",
       "  'Riphah International University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-08-18',\n",
       "  '2020-10-31'],\n",
       " ['NCT03938571',\n",
       "  'Standard Duodenal Switch vs. Single Anastomosis Duodeno-Ileostomy Duodenal Switch',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Obesity|Surgery|Metabolic Syndrome|Malnutrition',\n",
       "  'PROCEDURE: Duodenal Switch',\n",
       "  'Värmland County Council\",\" Sweden',\n",
       "  '',\n",
       "  '56.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-08',\n",
       "  '2029-01'],\n",
       " ['NCT02230371',\n",
       "  'Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myofascial Pain|Temporomandibular Disorders',\n",
       "  'DRUG: Granisetron|DRUG: Control (placebo)',\n",
       "  'Karolinska Institutet',\n",
       "  'Folktandvården Stockholms län AB',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-03',\n",
       "  '2014-12'],\n",
       " ['NCT01179971',\n",
       "  'n-3 and n-6 Fatty Acids in Rheumatoid Arthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'DIETARY_SUPPLEMENT: Fish oil\",\" gamma-linolenic acid',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  'University of Jena',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2010-01'],\n",
       " ['NCT00230971',\n",
       "  'Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Appendicitis|Cholecystitis|Diverticulitis|Intra-Abdominal Abscess|Intra-Abdominal Infection|Peritonitis',\n",
       "  'DRUG: tigecycline|DRUG: ceftriaxone plus metronidazole',\n",
       "  'Wyeth is now a wholly owned subsidiary of Pfizer',\n",
       "  '',\n",
       "  '473.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-10',\n",
       "  '2008-09'],\n",
       " ['NCT01488071',\n",
       "  'A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication',\n",
       "  'REVIVE',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorder',\n",
       "  'DRUG: Vortioxetine (Lu AA21004)|DRUG: Agomelatine',\n",
       "  'H. Lundbeck A/S',\n",
       "  '',\n",
       "  '495.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  ''],\n",
       " ['NCT03383471',\n",
       "  'The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Osteoarthritis',\n",
       "  'BIOLOGICAL: Invossa K Inj.|DRUG: Placebo',\n",
       "  'Kolon Life Science',\n",
       "  '',\n",
       "  '146.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-02-12',\n",
       "  '2020-03-30'],\n",
       " ['NCT00527371',\n",
       "  'PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate',\n",
       "  'PVP',\n",
       "  'COMPLETED',\n",
       "  'Benign Prostatic Hyperplasia',\n",
       "  'DEVICE: GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|PROCEDURE: Transurethral resection of the prostate',\n",
       "  \"St. Joseph's Healthcare Hamilton\",\n",
       "  'Ontario Ministry of Health and Long Term Care',\n",
       "  '164.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2013-10'],\n",
       " ['NCT04312971',\n",
       "  'Norepinephrine Infusion During Cardiopulmonary Bypass',\n",
       "  'Norcal',\n",
       "  'COMPLETED',\n",
       "  'Cardiac Surgery|Cardiopulmonary Bypass',\n",
       "  'DRUG: Placebo|DRUG: Norepinephrine|OTHER: Increase infusion rate|OTHER: Decrease infusion rate',\n",
       "  'Imam Abdulrahman Bin Faisal University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-05-06',\n",
       "  '2021-09-20'],\n",
       " ['NCT01324271',\n",
       "  'inVENT-In-Office Study',\n",
       "  'inVENT-IO',\n",
       "  'COMPLETED',\n",
       "  'Otitis Media',\n",
       "  'DEVICE: Acclarent Tympanostomy Tube Delivery system (TTDS)',\n",
       "  'Acclarent',\n",
       "  '',\n",
       "  '85.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-01',\n",
       "  '2012-05'],\n",
       " ['NCT05687071',\n",
       "  'A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hyper-low-density Lipoprotein (LDL) Cholesterolemia',\n",
       "  'DRUG: 180mg of ETC-1002(bempedoic acid)',\n",
       "  'Otsuka Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-02-27',\n",
       "  '2024-10-31'],\n",
       " ['NCT00271271',\n",
       "  'Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients',\n",
       "  'GON',\n",
       "  'COMPLETED',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'DRUG: oxaliplatine / gemcitabine / Vinorelbine',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-06',\n",
       "  '2006-10'],\n",
       " ['NCT03932071',\n",
       "  'Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Metastases|Tumor Necrosis',\n",
       "  'DRUG: Zoledronic Acid',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2017-01-01',\n",
       "  '2023-01-01'],\n",
       " ['NCT03785171',\n",
       "  'Predicative Value of Multimodal MRI in Moyamoya Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Moyamoya Disease|Magnetic Resonance Imaging',\n",
       "  'PROCEDURE: surgical revascularization',\n",
       "  'Chinese PLA General Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-07',\n",
       "  '2021-09'],\n",
       " ['NCT00878371',\n",
       "  'Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dissecting Aneurysm of the Thoracic Aorta',\n",
       "  'DRUG: morphine',\n",
       "  'Nova Scotia Health Authority',\n",
       "  'Dalhousie University',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-05',\n",
       "  '2013-02'],\n",
       " ['NCT02600871',\n",
       "  'Skin and Soft Tissue Infection (SSTI) Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Skin Diseases\",\" Infectious|Soft Tissue Infections',\n",
       "  'DRUG: Provodine|PROCEDURE: Incision and Drainage',\n",
       "  'The University of Texas Health Science Center at San Antonio',\n",
       "  '',\n",
       "  '101.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2017-05-30'],\n",
       " ['NCT01779271',\n",
       "  'Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Upper Respiratory Infection|Fever',\n",
       "  'DRUG: Pelubiprofen|DRUG: Loxoprofen',\n",
       "  'Daewon Pharmaceutical Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '183.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  ''],\n",
       " ['NCT01489371',\n",
       "  'EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer\", Fallopian Tube Cancer,\" or Primary Peritoneal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma',\n",
       "  'OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|DRUG: Pegylated Liposomal Doxorubicin Hydrochloride',\n",
       "  'Gynecologic Oncology Group',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '16.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-07-09',\n",
       "  '2018-01-27'],\n",
       " ['NCT02508571',\n",
       "  'Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Premature Birth of Newborn|Intervention Studies',\n",
       "  'OTHER: Direct swallowing training (DST)|OTHER: Oral sensorimotor stimulation (OSMS)|OTHER: Sham intervention',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '189.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-07',\n",
       "  '2026-06'],\n",
       " ['NCT06171971',\n",
       "  'Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers',\n",
       "  'CS-PEDIA',\n",
       "  'RECRUITING',\n",
       "  'Pediatric Solid Tumors',\n",
       "  '',\n",
       "  'University Hospital\", Strasbourg,\" France',\n",
       "  '',\n",
       "  '230.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-06-20',\n",
       "  '2023-12'],\n",
       " ['NCT05723471',\n",
       "  'Impact of a Collaborative Program of Physical Activity of Newly-diagnosed Cancer Patients',\n",
       "  'PROGRESS',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer',\n",
       "  'OTHER: Adaptative Physical Activity',\n",
       "  'University Hospital\",\" Toulouse',\n",
       "  '',\n",
       "  '350.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-12-01',\n",
       "  '2027-12-31'],\n",
       " ['NCT03826771',\n",
       "  'Post-Stroke Optimization of Walking Using Explosive Resistance',\n",
       "  'POWER-D',\n",
       "  'RECRUITING',\n",
       "  'Stroke|Depression',\n",
       "  'BEHAVIORAL: Power training|BEHAVIORAL: Stretching',\n",
       "  'Medical University of South Carolina',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-02-06',\n",
       "  '2024-08'],\n",
       " ['NCT01559571',\n",
       "  'Registry for Severe ROP and Treatment on Visual Outcomes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Retinopathy of Prematurity',\n",
       "  '',\n",
       "  'Pediatrix',\n",
       "  '',\n",
       "  '324.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-05',\n",
       "  '2020-05-15'],\n",
       " ['NCT03323671',\n",
       "  'Preemptive Analgesia for Primary Dysmenorrhoea',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Dysmenorrhea',\n",
       "  'DRUG: preemptive mefenamic acid|DRUG: mefenamic acid',\n",
       "  'Hanan Nabil',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-08-01',\n",
       "  '2017-12-01'],\n",
       " ['NCT02108171',\n",
       "  'Intranasal Dexmedetomidine Premedication',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benign Neoplasm of Vocal Fold - Glottis',\n",
       "  'DRUG: Dexmedetomidine|DRUG: placebo',\n",
       "  \"Guangzhou First People's Hospital\",\n",
       "  '',\n",
       "  '81.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-03',\n",
       "  '2014-07'],\n",
       " ['NCT01715571',\n",
       "  'Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate ED',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Organic Erectile Dysfunction',\n",
       "  'DEVICE: Viberect',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '11.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-03-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT02855671',\n",
       "  'Infrared Imaging in Septic Illness',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sepsis',\n",
       "  'DEVICE: Infrared thermal imaging',\n",
       "  'University Hospitals\",\" Leicester',\n",
       "  'Association of Anaesthetists of Great Britain and Ireland',\n",
       "  '112.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  '2019-02-01'],\n",
       " ['NCT03349671',\n",
       "  'Predictors of Intrauterine Growth Restriction',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pre-Eclampsia',\n",
       "  'PROCEDURE: ultrasound',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '300.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-10',\n",
       "  '2019-12'],\n",
       " ['NCT04192071',\n",
       "  'Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Colorectal Cancer',\n",
       "  'OTHER: virtual technology - high interactive|OTHER: virtual technology - low interactive|OTHER: non-colorectal cancer related module',\n",
       "  'University of Florida',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING',\n",
       "  '2020-01-06',\n",
       "  '2024-01-31'],\n",
       " ['NCT03202771',\n",
       "  'Randomized Controlled Trial of Home Versus Office Biofeedback for Constipation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Constipation|Dyssynergia',\n",
       "  'DEVICE: Home Biofeedback Therapy|OTHER: Office Biofeedback Therapy',\n",
       "  'Augusta University',\n",
       "  'National Institutes of Health (NIH)',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-02',\n",
       "  '2011-07'],\n",
       " ['NCT04419571',\n",
       "  'Outcomes in Emergency Laparotomies During COVID-19 Pandemic',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'COVID-19|Emergency General Surgery',\n",
       "  'PROCEDURE: Emergency Laparotomy',\n",
       "  'Barking\",\" Havering and Redbridge University Hospitals NHS Trust',\n",
       "  '',\n",
       "  '94.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-03-23',\n",
       "  '2020-06-16'],\n",
       " ['NCT05199571',\n",
       "  'Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Relapsing Multiple Sclerosis',\n",
       "  'BIOLOGICAL: Ofatumumab',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '99.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-07-22',\n",
       "  '2025-03-21'],\n",
       " ['NCT02295371',\n",
       "  'Medication Incidents in Primary Care Medicine',\n",
       "  'MIPC',\n",
       "  'COMPLETED',\n",
       "  'Medication Incidents',\n",
       "  '',\n",
       "  'University of Zurich',\n",
       "  'University of Lausanne',\n",
       "  '213.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-01',\n",
       "  '2016-01'],\n",
       " ['NCT02671071',\n",
       "  'Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cervix Cancer',\n",
       "  'BEHAVIORAL: Quality of Life Questionnaire (QLQ)',\n",
       "  'Latin American Cooperative Oncology Group',\n",
       "  'EVA - Grupo Brasileiro de Tumores Ginecológicos|Roche Pharma AG',\n",
       "  '638.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-04',\n",
       "  '2021-12'],\n",
       " ['NCT02763371',\n",
       "  'Cognition Intervention Study Dortmund- Glycemic Index (CogniDo GI)',\n",
       "  'CogniDo-GI',\n",
       "  'UNKNOWN',\n",
       "  'Cognitive Function',\n",
       "  'OTHER: Dietary: high GI lunch|OTHER: Dietary: low GI lunch',\n",
       "  'Research Institute of Child Nutrition\",\" Dortmund',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2016-04',\n",
       "  '2016-12'],\n",
       " ['NCT01576471',\n",
       "  'Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo',\n",
       "  'TRUST-I',\n",
       "  'COMPLETED',\n",
       "  \"Crohn's Disease\",\n",
       "  'BIOLOGICAL: Trichuris suis ova (TSO)|BIOLOGICAL: Placebo',\n",
       "  'Coronado Biosciences\",\" Inc.',\n",
       "  '',\n",
       "  '250.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-07',\n",
       "  '2014-10'],\n",
       " ['NCT05960071',\n",
       "  'Effects of Alveolar Recruitment Strategies on Arterial Oxygenation and Postoperative Inflammatory Response During Laparoscopic Bariatric Surgery: A Randomised Control Trial.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Bariatric Surgery Candidate',\n",
       "  'PROCEDURE: protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|PROCEDURE: protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP',\n",
       "  'Alexandria University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2022-11-05',\n",
       "  '2023-06-05'],\n",
       " ['NCT05134571',\n",
       "  'China Post-marketing Surveillance (PMS) Study of Aldurazyme®',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mucopolysaccharidosis I',\n",
       "  'DRUG: Laronidase',\n",
       "  'Genzyme\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-10-28',\n",
       "  '2023-07-26'],\n",
       " ['NCT02122471',\n",
       "  '12-Week Study of Plecanatide for CIC (The National CIC3 Study)',\n",
       "  'CIC',\n",
       "  'COMPLETED',\n",
       "  'Chronic Idiopathic Constipation',\n",
       "  'DRUG: Plecanatide|DRUG: Placebo',\n",
       "  'Bausch Health Americas\",\" Inc.',\n",
       "  '',\n",
       "  '1410.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-04',\n",
       "  '2015-07'],\n",
       " ['NCT00001271',\n",
       "  'A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'B Cell Lymphoma',\n",
       "  'DRUG: IgG-RFB4-SMPT-dgA',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1991-07',\n",
       "  '2001-04'],\n",
       " ['NCT01761071',\n",
       "  'Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myopes Who Have Undergone PRK.',\n",
       "  'DRUG: topical ketorolac 0.5% (Acular®\", Allergan Inc, Irvine, CA)|DRUG: topical diclofenac 0.1% (Voltaren®, Novartis, Bern,\" Switzerland)',\n",
       "  'Yonsei University',\n",
       "  '',\n",
       "  '94.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2012-01',\n",
       "  '2012-12'],\n",
       " ['NCT05216471',\n",
       "  'Identify Coronavirus Disease by Chest X-ray',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronavirus Disease 2019',\n",
       "  'RADIATION: chest X-ray',\n",
       "  'Assiut University',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-05-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT03592771',\n",
       "  'THRIVE Breast Cancer App Study',\n",
       "  'THRIVE',\n",
       "  'COMPLETED',\n",
       "  'Breast Neoplasm Female',\n",
       "  'BEHAVIORAL: THRIVE App|BEHAVIORAL: Tailored Feedback Messages',\n",
       "  'Emory University',\n",
       "  'National Cancer Institute (NCI)|West Cancer Center|Vector Oncology',\n",
       "  '304.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-11-15',\n",
       "  '2022-06-30'],\n",
       " ['NCT00405171',\n",
       "  'Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Hypercholesterolemia|Antiretroviral Therapy',\n",
       "  'DRUG: Nevirapine',\n",
       "  'University Hospital\",\" Caen',\n",
       "  'Boehringer Ingelheim',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2003-06',\n",
       "  '2006-02'],\n",
       " ['NCT03331471',\n",
       "  'Alveolar Recruitment Maneuver During Pneumoperitoneum',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Oxygen Deficiency',\n",
       "  'PROCEDURE: alveolar recruitment maneuver|PROCEDURE: conventional ventilation',\n",
       "  'Gachon University Gil Medical Center',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2017-09-18',\n",
       "  '2019-11-30'],\n",
       " ['NCT01896271',\n",
       "  'High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Clear Cell Renal Cell Carcinoma',\n",
       "  'DRUG: IL-2|RADIATION: Stereotactic Ablative Body Radiation Therapy',\n",
       "  'University of Texas Southwestern Medical Center',\n",
       "  'Prometheus Laboratories',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-10-02',\n",
       "  '2021-04-20'],\n",
       " ['NCT05091671',\n",
       "  'Free From Pain Exercise Programme Study',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Musculoskeletal Pain|Fear of Falling',\n",
       "  'OTHER: Free From Pain Exercise Programme Variation 1|OTHER: Free From Pain Exercise Programme Variation 2',\n",
       "  'Talita Cumi Ltd.',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-02-28',\n",
       "  '2023-12-31'],\n",
       " ['NCT04182971',\n",
       "  'Effect of Added Fruit Pomace Fiber\", Juice,\" and Whole Fruit on Postprandial Glycemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Glycemic Index',\n",
       "  'OTHER: Fruit|OTHER: Fruit juice|OTHER: Fruit juice plus fiber',\n",
       "  'PepsiCo Global R&D',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-08-28',\n",
       "  '2019-09-03'],\n",
       " ['NCT04732871',\n",
       "  'Immunogenicity\", Safety,\" Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Respiratory Syncytial Virus Infections',\n",
       "  'BIOLOGICAL: RSVPreF3 OA investigational vaccine',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '1720.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2021-02-15',\n",
       "  '2026-05-25'],\n",
       " ['NCT05109871',\n",
       "  'Reliability and Validity of Inline Dynamometry Study for Measuring Knee Extensor Torque',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anterior Cruciate Ligament Injuries|Anterior Cruciate Ligament Rupture|Anterior Cruciate Ligament Tear',\n",
       "  'OTHER: KForce Link',\n",
       "  'Liverpool University Hospitals NHS Foundation Trust',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2021-09-20',\n",
       "  '2022-08-02'],\n",
       " ['NCT05653271',\n",
       "  'ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'B-cell Lymphoma|Non Hodgkin Lymphoma|DLBCL|Primary Mediastinal Large B Cell Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma',\n",
       "  'DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: ACE1831|DRUG: Obinutuzumab',\n",
       "  'Acepodia Biotech\",\" Inc.',\n",
       "  '',\n",
       "  '42.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-21',\n",
       "  '2027-09'],\n",
       " ['NCT01850771',\n",
       "  'Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Radiculopathy|Herniated Disc|Disc Degeneration',\n",
       "  'PROCEDURE: Regenexx PL-Disc|PROCEDURE: Steroid Epidural',\n",
       "  'Regenexx\",\" LLC',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2016-05'],\n",
       " ['NCT01685671',\n",
       "  'Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anemia',\n",
       "  'DRUG: NESP 60μg|DRUG: CKD-11101 60μg',\n",
       "  'Chong Kun Dang Pharmaceutical',\n",
       "  'Seoul National University Hospital',\n",
       "  '34.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-10-26',\n",
       "  '2013-01-15'],\n",
       " ['NCT00002671',\n",
       "  'Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ovarian Cancer',\n",
       "  'DRUG: aminocamptothecin',\n",
       "  'NYU Langone Health',\n",
       "  'National Cancer Institute (NCI)|Eastern Cooperative Oncology Group',\n",
       "  '',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1995-12',\n",
       "  ''],\n",
       " ['NCT04267471',\n",
       "  'Tai Chi for Patients With Essential Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Hypertension',\n",
       "  'BEHAVIORAL: Tai Chi|BEHAVIORAL: Walking',\n",
       "  'Chengdu University of Traditional Chinese Medicine',\n",
       "  '',\n",
       "  '234.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06',\n",
       "  '2022-12'],\n",
       " ['NCT01325571',\n",
       "  'A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myasthenia Gravis',\n",
       "  'DRUG: Tacrolimus capsule|DRUG: Placebo',\n",
       "  'Astellas Pharma Inc',\n",
       "  'Astellas Pharma China\",\" Inc.',\n",
       "  '83.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-03',\n",
       "  '2014-05'],\n",
       " ['NCT03722771',\n",
       "  'Influence of Lavender Oil on Vital Signs in Oral Surgery Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dental Anxiety|Sedative; Anxiety Disorder',\n",
       "  'BEHAVIORAL: Inhalation|OTHER: Anxiety Questionnaires 1|OTHER: Anxiety Questionnaires 2|DIAGNOSTIC_TEST: Vital Signs 1|DIAGNOSTIC_TEST: Vital Signs 2|DIAGNOSTIC_TEST: Vital Signs 3|DIAGNOSTIC_TEST: Vital Signs 4',\n",
       "  'Nazife Begüm KARAN',\n",
       "  '',\n",
       "  '126.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-09-01',\n",
       "  '2018-11-02'],\n",
       " ['NCT02034071',\n",
       "  'Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prader-Willi Syndrome',\n",
       "  'DRUG: DCCR|DRUG: Placebo',\n",
       "  'Essentialis\",\" Inc.',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-04',\n",
       "  '2015-05'],\n",
       " ['NCT04002271',\n",
       "  'Total Knee Replacement TIVA With Robotic Arm Assisted',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Propofol|DRUG: Sevoflurane|PROCEDURE: Spinal anaesthesia',\n",
       "  'The University of Hong Kong',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-07-22',\n",
       "  '2024-05-31'],\n",
       " ['NCT02569671',\n",
       "  'Bone Level Tapered Multi-Center Study',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Tooth Loss',\n",
       "  'DEVICE: Straumann Bone Level Tapered Implant - Immediate Placement|DEVICE: Straumann Bone Level Tapered Implant - Delayed Placement',\n",
       "  'Institut Straumann AG',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-03',\n",
       "  '2024-03'],\n",
       " ['NCT04669171',\n",
       "  'A Novel Vaccine (EO2463) as Monotherapy and in Combination\",\" for Treatment of Patients With Indolent Non-Hodgkin Lymphoma',\n",
       "  'SIDNEY',\n",
       "  'RECRUITING',\n",
       "  'Follicular Lymphoma|Marginal Zone Lymphoma',\n",
       "  'BIOLOGICAL: EO2463|DRUG: lenalidomide|BIOLOGICAL: rituximab',\n",
       "  'Enterome',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-07-05',\n",
       "  '2029-09-30'],\n",
       " ['NCT01096771',\n",
       "  'The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Respiratory Distress Syndrome',\n",
       "  'DRUG: ClinOleic 20%|DRUG: Intralipid 20%',\n",
       "  'Methodist Research Institute\",\" Indianapolis',\n",
       "  '',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-06',\n",
       "  '2012-11'],\n",
       " ['NCT05840471',\n",
       "  'Tranexamic Acid as an Intervention in Abruptio Placenta',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vaginal Bleeding|Prolonged Pregnancy',\n",
       "  'DRUG: Tranexamic acid injection|OTHER: Glucose water 5%',\n",
       "  'Hawler Medical University',\n",
       "  '',\n",
       "  '116.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-01-10',\n",
       "  '2024-02-10'],\n",
       " ['NCT06162871',\n",
       "  'Social Participation and Healthy Aging',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Healthy Aging',\n",
       "  'BEHAVIORAL: Presentations and interactive debate sessions\",\" with intergenerational exchange',\n",
       "  'University of Cagliari',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2023-09-01',\n",
       "  '2025-06-01'],\n",
       " ['NCT04270071',\n",
       "  'Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Coronary Heart Disease|Stable Angina',\n",
       "  'DRUG: Yangxin Shengmai|DRUG: Yangxin Shengmai placebo|DRUG: nitroglycerin tablets',\n",
       "  \"Guang'anmen Hospital of China Academy of Chinese Medical Sciences\",\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-12',\n",
       "  '2021-12'],\n",
       " ['NCT00546871',\n",
       "  'Comparison of Intravenous and Subcutaneous Administration of IGIV\",\" 10% in Primary Immunodeficiency (PID) Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Primary Immunodeficiency Diseases (PID)',\n",
       "  'DRUG: Immune Globulin Intravenous (Human)\",\" 10%',\n",
       "  'Baxalta now part of Shire',\n",
       "  '',\n",
       "  '49.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-10-03',\n",
       "  '2009-09-01'],\n",
       " ['NCT01328171',\n",
       "  'FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)',\n",
       "  'VOLFI',\n",
       "  'COMPLETED',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: FOLFOXIRI + Panitumumab|DRUG: FOLFOXIRI',\n",
       "  'AIO-Studien-gGmbH',\n",
       "  'Amgen|ClinAssess GmbH',\n",
       "  '93.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2022-01'],\n",
       " ['NCT05546671',\n",
       "  'Impact of Hand Grip Strength on Length of Hospital Stay After Cardiac Surgery Among Elderly Patients',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Sarcopenia|Frailty',\n",
       "  'DIAGNOSTIC_TEST: Hand grip strength measurement',\n",
       "  'Kartal Kosuyolu High Speciality Training and Research Hospital',\n",
       "  '',\n",
       "  '240.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-11-01',\n",
       "  '2023-11-30'],\n",
       " ['NCT02866071',\n",
       "  'Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Acute Traumatic Pain',\n",
       "  'DRUG: Ketamine Hydrochloride|DRUG: Placebo-Comparator',\n",
       "  'Jason McMullan',\n",
       "  '',\n",
       "  '224.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-10-03',\n",
       "  '2022-12-31'],\n",
       " ['NCT04925271',\n",
       "  'Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Polyp of Colon|Fistula',\n",
       "  'DEVICE: X-Tack|DEVICE: Overstitch',\n",
       "  'Thomas Jefferson University',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2021-07-01',\n",
       "  '2022-07-30'],\n",
       " ['NCT00966771',\n",
       "  'The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception',\n",
       "  'IUD EC',\n",
       "  'COMPLETED',\n",
       "  'Pregnancy',\n",
       "  'DRUG: Copper T380 IUD|DRUG: Oral levonorgestrel',\n",
       "  'University of Utah',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Society of Family Planning',\n",
       "  '548.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-10',\n",
       "  '2011-08'],\n",
       " ['NCT06221371',\n",
       "  'Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion',\n",
       "  'TNK-PLUS',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Ischemic Stroke\",\" Acute|Thrombolysis|Endovascular Treatment',\n",
       "  'DRUG: rhTNK-tPA|DEVICE: direct EVT',\n",
       "  'Beijing Tiantan Hospital',\n",
       "  \"Linyi People's Hospital\",\n",
       "  '390.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-12-16',\n",
       "  '2025-05'],\n",
       " ['NCT04064671',\n",
       "  'ZEPHYR: A Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Erectile Dysfunction|Gender Dysphoria',\n",
       "  'OTHER: Implantation of the Zephyr ZSI 475 FTM erectile implant',\n",
       "  'University Hospital\",\" Ghent',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-09-19',\n",
       "  '2029-12'],\n",
       " ['NCT02927171',\n",
       "  'Shifting Rehabilitation Paradigms in Skilled Nursing Facilities',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Physical Deconditioning',\n",
       "  'OTHER: IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents',\n",
       "  'VA Office of Research and Development',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  '104.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2016-02-28',\n",
       "  '2019-01-01'],\n",
       " ['NCT02437071',\n",
       "  'Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Metastatic Colorectal Cancer',\n",
       "  'DRUG: Pembrolizumab|RADIATION: Radiotherapy|PROCEDURE: Radiofrequency ablation',\n",
       "  'Memorial Sloan Kettering Cancer Center',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '34.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-04',\n",
       "  '2024-04'],\n",
       " ['NCT05906771',\n",
       "  'Study of the Effect of the Combined Extract of Lemon Verbena and Hibiscus on Health Indicators',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Diet\",\" Mediterranean|Antioxidant Effect|Body Weight|Cardiovascular Diseases|Densitometry|Body Composition',\n",
       "  'DIETARY_SUPPLEMENT: Metabolaid(R)|DIETARY_SUPPLEMENT: Nutraceutical placebo',\n",
       "  'University of Alicante',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-01',\n",
       "  '2024-06-30'],\n",
       " ['NCT03638271',\n",
       "  'Cardiac Magnetic Resonance in Non Ischemic Cardiomyopathy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Cardiac Magnetic Resonance Imaging in Non Ischemic Cardiomyopathy',\n",
       "  'DIAGNOSTIC_TEST: Cardiac magnetic resonance imaging',\n",
       "  'Reham Sameeh',\n",
       "  'Assiut University',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-10-01',\n",
       "  '2021-10-01'],\n",
       " ['NCT06195371',\n",
       "  'Impact of CASP3 Gene in Chemoresistance',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  '',\n",
       "  'Gehad Salah El-Din shaker',\n",
       "  'Assiut University',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2024-05-01',\n",
       "  '2026-12'],\n",
       " ['NCT01810471',\n",
       "  'External Ankle Supports - 3D Motion Analysis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Ankle Instability',\n",
       "  'DEVICE: Applying ankle support device (white non-elastic tape\", kinesiotape (TM),\" soft brace (Malleotrain TM)',\n",
       "  'University Hospital Heidelberg',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2010-02',\n",
       "  '2010-12'],\n",
       " ['NCT01433471',\n",
       "  'Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova',\n",
       "  'MUCUS',\n",
       "  'COMPLETED',\n",
       "  'Ulcerative Colitis',\n",
       "  'DRUG: Trichuris suis ova',\n",
       "  'NYU Langone Health',\n",
       "  '',\n",
       "  '4.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-08',\n",
       "  '2015-05'],\n",
       " ['NCT01642771',\n",
       "  'Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: 5-Fu/epirubicin/CTX following Docetaxel|DRUG: Docetaxel/capecitabine followed by XEC',\n",
       "  'China Breast Cancer Clinical Study Group',\n",
       "  '',\n",
       "  '636.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-06',\n",
       "  '2020-05'],\n",
       " ['NCT02377271',\n",
       "  'ENDOTHELION Study Group: Effect of Bosentan in NAION Patients',\n",
       "  'ENDOTHELION',\n",
       "  'RECRUITING',\n",
       "  'Ischemic Optic Neuropathy',\n",
       "  'DRUG: bosentan|DRUG: placebo',\n",
       "  'University Hospital\",\" Grenoble',\n",
       "  '',\n",
       "  '86.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2015-08',\n",
       "  '2025-12'],\n",
       " ['NCT05566171',\n",
       "  'The Effect of Probiotic Supported Yogurt Consumption on Gastrointestinal Symptoms',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Gastrointestinal Dysfunction',\n",
       "  'DIETARY_SUPPLEMENT: Activia Probiotic Yogurt',\n",
       "  'Eastern Mediterranean University',\n",
       "  '',\n",
       "  '102.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2023-03-30'],\n",
       " ['NCT00229671',\n",
       "  'Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pediatric ALL',\n",
       "  'OTHER: Survey 1|OTHER: Survey 2',\n",
       "  'Weill Medical College of Cornell University',\n",
       "  \"Brigham and Women's Hospital|Boston Children's Hospital|The Commonwealth Fund\",\n",
       "  '6341.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2001-09',\n",
       "  '2005-07'],\n",
       " ['NCT00349271',\n",
       "  'Cell Therapy in Chagas Cardiomyopathy',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Chagas Cardiomyopathy',\n",
       "  'PROCEDURE: Stem cell|DRUG: Filgrastime (G-CSF)|DRUG: Standart therapy',\n",
       "  'Ministry of Health\",\" Brazil',\n",
       "  'Financiadora de Estudos e Projetos',\n",
       "  '182.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2011-12'],\n",
       " ['NCT02156271',\n",
       "  'Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Insomnia',\n",
       "  'DRUG: ramelteon|DRUG: placebo',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  ''],\n",
       " ['NCT00429871',\n",
       "  'Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Epirubicin|DRUG: Docetaxel',\n",
       "  'Hellenic Oncology Research Group',\n",
       "  'University Hospital of Crete',\n",
       "  '272.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2002-05',\n",
       "  '2007-11'],\n",
       " ['NCT05859971',\n",
       "  'ICG and SLN Mapping',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Breast Cancer',\n",
       "  'DRUG: SLN mapping using technetium-99m +/- isosulfan blue dye|DEVICE: SLN mapping with ICG fluorescence using the Asimov Platform',\n",
       "  'University of Wisconsin\",\" Madison',\n",
       "  'OnLume Inc.|National Cancer Institute (NCI)',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-04-13',\n",
       "  '2024-03'],\n",
       " ['NCT01013571',\n",
       "  'Self Titration With Apidra to Reach Target Study (START)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: insulin glargine|DRUG: Apidra (insulin glulisine)',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '493.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-10',\n",
       "  '2012-01'],\n",
       " ['NCT01677871',\n",
       "  'Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Liver Disease With Tuberclosis',\n",
       "  'DRUG: 2HRZE/4HR|DRUG: 2HRLE/4HR|DRUG: 9HLE|DRUG: 9RLE',\n",
       "  'Institute of Liver and Biliary Sciences\",\" India',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-09',\n",
       "  '2014-09'],\n",
       " ['NCT00740571',\n",
       "  'Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer',\n",
       "  'Off-label',\n",
       "  'UNKNOWN',\n",
       "  'Cancer|Neuralgia',\n",
       "  'DRUG: amitriptyline|DRUG: pregabalin',\n",
       "  'Radboud University Medical Center',\n",
       "  'Erasmus Medical Center|University of Amsterdam',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-09',\n",
       "  '2010-12'],\n",
       " ['NCT04492371',\n",
       "  'COVID-19 Infection and Multiple Myeloma',\n",
       "  'EMN-COVID',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Multiple Myeloma|Covid19|Corona Virus Infection',\n",
       "  '',\n",
       "  'Stichting European Myeloma Network',\n",
       "  'Fondazione EMN Italy Onlus',\n",
       "  '1054.0',\n",
       "  'NETWORK',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-07-01',\n",
       "  '2024-12'],\n",
       " ['NCT02790671',\n",
       "  'A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pharmacokinetics',\n",
       "  'DRUG: DS-8500a|DRUG: Itraconazole',\n",
       "  'Daiichi Sankyo',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05',\n",
       "  '2016-06'],\n",
       " ['NCT03744871',\n",
       "  'Air Pollution: Strategies for Personalized Intervention to Reduce Exposure',\n",
       "  'ASPIRE',\n",
       "  'COMPLETED',\n",
       "  'Air Pollution',\n",
       "  'OTHER: N95 Respirator',\n",
       "  'University Hospitals Cleveland Medical Center',\n",
       "  'University of Michigan|Peking University',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2019-03-22',\n",
       "  '2023-07-31'],\n",
       " ['NCT00562471',\n",
       "  'Safety and Efficacy Study of a Hydrogel\", Applied Following Removal of Myomas During Gynecologic Surgery,\" Administered for the Prevention/Reduction of Postoperative Adhesion Formation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Myoma',\n",
       "  'OTHER: Adhibit Adhesion Prevention Gel|OTHER: Standard of Care Comparator',\n",
       "  'Angiotech Pharmaceuticals',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION',\n",
       "  '2003-07',\n",
       "  '2005-01'],\n",
       " ['NCT01251471',\n",
       "  'Neural\", Genetic,\" and Peripheral Correlates of SSRI Pharmaco-Response',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depression',\n",
       "  'DRUG: Escitalopram',\n",
       "  'Medical University of Vienna',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2011-08',\n",
       "  '2015-03'],\n",
       " ['NCT00935571',\n",
       "  'Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Lung Cancer|Neoplasms\",\" Lung',\n",
       "  'DRUG: propofol\", remifentanil,\" sevoflurane',\n",
       "  'Asan Medical Center',\n",
       "  '',\n",
       "  '400.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2009-09'],\n",
       " ['NCT04493671',\n",
       "  'Evaluate Safety\", Tolerability,\" PK of TBAJ-876 in Healthy Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pulmonary Disease|Tuberculosis\",\" Pulmonary|Tuberculosis|Multi Drug Resistant Tuberculosis|Drug Sensitive Tuberculosis|Drug-resistant Tuberculosis|Mycobacterium Tuberculosis Infection',\n",
       "  'DRUG: TBAJ-876 10mg|DRUG: TBAJ-876 25mg|DRUG: TBAJ-876 50mg|DRUG: TBAJ-876 100mg|DRUG: TBAJ-876 200mg|DRUG: TBAJ-876 400mg|DRUG: TBAJ-876 Dose XXXmg for Food cohort|DRUG: TBAJ-876 XXXmg for Part 2|DRUG: Matching Placebo for TBAJ-876 tablet',\n",
       "  'Global Alliance for TB Drug Development',\n",
       "  '',\n",
       "  '107.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06-08',\n",
       "  '2022-11-15'],\n",
       " ['NCT03488771',\n",
       "  'Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Kidney Transplant Infection|Kidney Transplant Rejection',\n",
       "  '',\n",
       "  'Clinical Hospital Merkur',\n",
       "  'Clinical Hospital Centre Zagreb',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-03-05',\n",
       "  '2018-12-01'],\n",
       " ['NCT05068271',\n",
       "  'Multi-Domain Exercise and Memory in Adults Relative to ApoE Genotype: A fMRI Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Exercise Training|Executive Function|Aging',\n",
       "  'BEHAVIORAL: Multi-Domain Exercise Program|BEHAVIORAL: Control Group',\n",
       "  'National Taiwan Normal University',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2022-04-12',\n",
       "  '2025-09'],\n",
       " ['NCT04442971',\n",
       "  'Effectiveness of Music Therapy on Level of Consciousness',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Neurologic Disorder|Traumatic Brain Injury|Disorder of Consciousness',\n",
       "  'BEHAVIORAL: Music Stimulation|BEHAVIORAL: Alternative Stimulation|BEHAVIORAL: No Auditory Stimulation',\n",
       "  'BDH-Klinik Hessisch Oldendorf',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-06-15',\n",
       "  '2024-12-15'],\n",
       " ['NCT03665571',\n",
       "  'Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pancreatic Neoplasms',\n",
       "  'DIAGNOSTIC_TEST: Receptor specific activation method',\n",
       "  'Asan Medical Center',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-07',\n",
       "  '2019-10'],\n",
       " ['NCT00001571',\n",
       "  \"A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Lymphoma\", AIDS-Related|Lymphoma,\" Non-Hodgkin',\n",
       "  '',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '1997-02',\n",
       "  '2000-12'],\n",
       " ['NCT05128071',\n",
       "  'PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Methamphetamine-dependence|Postpartum Abstinence',\n",
       "  'DRUG: Progesterone|DRUG: Placebo',\n",
       "  'University of Utah',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-02-04',\n",
       "  '2025-04'],\n",
       " ['NCT00927771',\n",
       "  'Azelaic Acid Versus Hydroquinone in Melasma',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Melanosis',\n",
       "  'DRUG: azelaic acid gel|DRUG: hydroquinone cream',\n",
       "  'Callender Center for Clinical Research',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-06',\n",
       "  '2010-12'],\n",
       " ['NCT02646371',\n",
       "  'Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Shigellosis',\n",
       "  'BIOLOGICAL: Flexyn2a|BIOLOGICAL: Placebo',\n",
       "  'LimmaTech Biologics AG',\n",
       "  'Johns Hopkins Bloomberg School of Public Health',\n",
       "  '67.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-12',\n",
       "  '2017-07'],\n",
       " ['NCT00670371',\n",
       "  'Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Functional Psychoses|Informal Caregivers',\n",
       "  '',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-03',\n",
       "  '2009-11'],\n",
       " ['NCT00268671',\n",
       "  'Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Head and Neck Neoplasms',\n",
       "  'DRUG: Docetaxel',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '45.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-08',\n",
       "  '2006-04'],\n",
       " ['NCT00570271',\n",
       "  'Placebo Effects on Blood Pressure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Blood Pressure',\n",
       "  'OTHER: Placebo with BP dec (written form)|OTHER: Placebo with BP dec (doctor)|OTHER: Placebo with BP inc (written)|OTHER: Placebo with BP inc (doctor)|OTHER: Placebo info given (written)|OTHER: Placebo info given (doc)',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2007-04',\n",
       "  '2008-02'],\n",
       " ['NCT02286271',\n",
       "  'Preliminary Testing of a Novel Device to Detect Epileptic Seizures',\n",
       "  'PTEpD',\n",
       "  'COMPLETED',\n",
       "  'Epilepsy',\n",
       "  '',\n",
       "  'University of Edinburgh',\n",
       "  'NHS Lothian',\n",
       "  '117.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-01-20',\n",
       "  '2016-12-31'],\n",
       " ['NCT02901171',\n",
       "  'The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Smoking',\n",
       "  'BEHAVIORAL: ACT group treatment combined with smartphone application|BEHAVIORAL: ACT group treatment|BEHAVIORAL: Group based Behavioural Support Programme',\n",
       "  'University College Dublin',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-09',\n",
       "  '2018-07'],\n",
       " ['NCT01352871',\n",
       "  'The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Innate Immune Response',\n",
       "  'BEHAVIORAL: Concentration / meditation|DRUG: lipopolysaccharide',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '1.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-03',\n",
       "  '2011-05'],\n",
       " ['NCT04007471',\n",
       "  'Adolescent Dysmenorrhea : Prevalence\", Severity,\" Experience and Management in the Use of Medication in High School Girls in Ille-et-Vilaine',\n",
       "  'DAPsvs',\n",
       "  'COMPLETED',\n",
       "  'Adolescent Dysmenorrhea',\n",
       "  'OTHER: Anonymous survey',\n",
       "  'Rennes University Hospital',\n",
       "  '',\n",
       "  '979.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-04-24',\n",
       "  '2019-05-17'],\n",
       " ['NCT03525171',\n",
       "  'Evalutation of Insulin Sensitivity Through Hyperinsulinemic Clamp in Children With GH Deficiency',\n",
       "  'clamp-GHD',\n",
       "  'COMPLETED',\n",
       "  'Growth Hormone Deficiency',\n",
       "  'DIAGNOSTIC_TEST: euglycemic hyperinsulinemic clamp',\n",
       "  'University of Palermo',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-01-01',\n",
       "  '2015-12-30'],\n",
       " ['NCT02741271',\n",
       "  'Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: MF MDI 100 mcg BID (Open Label)|DRUG: MF/F MDI 100/10 mcg BID|DRUG: MF MDI 100 mcg BID|DRUG: Albuterol/Salbutamol PRN|DRUG: Prednisone/Prednisolone',\n",
       "  'Organon and Co',\n",
       "  '',\n",
       "  '181.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-05-11',\n",
       "  '2017-12-04'],\n",
       " ['NCT03341871',\n",
       "  'Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hepatitis C Virus (HCV)',\n",
       "  '',\n",
       "  'AbbVie',\n",
       "  '',\n",
       "  '1095.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-12-27',\n",
       "  '2020-09-15'],\n",
       " ['NCT03070171',\n",
       "  'Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: dabigatran etexilate',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-03-21',\n",
       "  '2017-06-20'],\n",
       " ['NCT02850471',\n",
       "  'Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Reperfusion Injury',\n",
       "  'DEVICE: electroacupuncture',\n",
       "  'Shengjing Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2015-03',\n",
       "  '2016-08'],\n",
       " ['NCT03636971',\n",
       "  'Gait Analysis Following Knee Viscosupplementation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gait|Knee Osteoarthritis|Injection',\n",
       "  'DRUG: hyaluronic acid with mannitol|DRUG: hyaluronic acid with sorbitol|DRUG: Placebos',\n",
       "  'Brigitte Jolles\",\" MD',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: SCREENING',\n",
       "  '2013-05-01',\n",
       "  '2017-01-01'],\n",
       " ['NCT04916171',\n",
       "  'Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome\",\" or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Endometriosis|Polycystic Ovary Syndrome|Adenomyosis',\n",
       "  'OTHER: incidence',\n",
       "  'Kanuni Sultan Suleyman Training and Research Hospital',\n",
       "  'Engin Oral|Berna Dilbaz|Gürkan Bozdag|Cem Atabekoğlu|Nuray Bozkurt|Gokce Anik Ilhan|Ali Kolusari|Cihan Kaya|Banu Yılmaz|Engin Yildirim|Ahmet Başar Tekin|Servet Ozden hacivelioglu',\n",
       "  '2450.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-06-01',\n",
       "  '2023-01-20'],\n",
       " ['NCT00048971',\n",
       "  'Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer|Diarrhea|Neutropenia',\n",
       "  'GENETIC: mutation analysis|GENETIC: polymorphic microsatellite marker analysis',\n",
       "  'Alliance for Clinical Trials in Oncology',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '308.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2002-04',\n",
       "  '2006-11'],\n",
       " ['NCT05038371',\n",
       "  'Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Wet Macular Degeneration',\n",
       "  '',\n",
       "  'Johns Hopkins University',\n",
       "  'Olix Pharmaceuticals\",\" Inc.',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-09-01',\n",
       "  '2022-09-22'],\n",
       " ['NCT01611571',\n",
       "  'Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis',\n",
       "  'RPM',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'DRUG: Risedronate|DRUG: Teriparatide|DRUG: Placebo Teriparatide|DRUG: placebo Risedronate',\n",
       "  'Columbia University',\n",
       "  'Alliance for Better Bone Health',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2003-12',\n",
       "  '2011-11'],\n",
       " ['NCT04844671',\n",
       "  \"Patients' Expectations About Effects of Robotic Surgery for Cancer\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  \"Cancer|Robotic Surgery|Patients' Expectations\",\n",
       "  'DEVICE: da Vinci Surgical Systems',\n",
       "  \"First Affiliated Hospital Xi'an Jiaotong University\",\n",
       "  '',\n",
       "  '3000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2021-04-20',\n",
       "  '2022-06-30'],\n",
       " ['NCT02681471',\n",
       "  'Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Acute Hyponatremia',\n",
       "  'OTHER: 5% Mannitol|OTHER: 0\",\"9% Sodium chloride|DEVICE: monopolar resectoscope|DEVICE: bipolar resectoscope TURis',\n",
       "  'Istanbul University',\n",
       "  '',\n",
       "  '53.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2013-12',\n",
       "  '2015-04'],\n",
       " ['NCT00003471',\n",
       "  'Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Low-Grade Astrocytoma\",\" Nos',\n",
       "  'DRUG: Antineoplaston therapy (Atengenal + Astugenal)',\n",
       "  'Burzynski Research Institute',\n",
       "  '',\n",
       "  '7.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '1996-03',\n",
       "  '2003-07'],\n",
       " ['NCT04632771',\n",
       "  'Nutritional Status and Bouillon Use in Northern Ghana',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Iron Deficiency|Vitamin A Deficiency|Vitamin B 12 Deficiency|Folate Deficiency|Zinc Deficiency|Dietary Habits|Anemia',\n",
       "  'OTHER: N/A (observational study)',\n",
       "  'University of California\",\" Davis',\n",
       "  'University of Ghana|Newcastle University|Penn State University|Helen Keller International',\n",
       "  '995.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-10-19',\n",
       "  '2022-02-28'],\n",
       " ['NCT02834871',\n",
       "  'Integration of the Cervical Proprioceptive Signals in Patients With Cervical Dystonia',\n",
       "  'STAC2',\n",
       "  'COMPLETED',\n",
       "  'Cervical Dystonia',\n",
       "  'DEVICE: Electromyogram',\n",
       "  'Fondation Ophtalmologique Adolphe de Rothschild',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-03',\n",
       "  '2015-07'],\n",
       " ['NCT00202371',\n",
       "  'Transfusion Effects in Myelodysplastic Patients: Limiting Exposure',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Myelodysplastic Syndromes',\n",
       "  'PROCEDURE: Red Blood Cell transfusion',\n",
       "  'Sanquin Research & Blood Bank Divisions',\n",
       "  'Ministry of Health\", Welfare and Sports,\" The Netherlands',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT',\n",
       "  '2002-07',\n",
       "  '2005-07'],\n",
       " ['NCT03129971',\n",
       "  'Platelet-rich Plasma Combined With Conventional Surgery in the Treatment of Atrophic Nonunion of Femoral Shaft Fractures',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Nonunion of Fracture',\n",
       "  'PROCEDURE: conventional surgery|PROCEDURE: autologous platelet-rich plasma',\n",
       "  'Qinghai University',\n",
       "  '',\n",
       "  '92.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-08',\n",
       "  '2018-12'],\n",
       " ['NCT03683771',\n",
       "  'Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Infertility',\n",
       "  'DIAGNOSTIC_TEST: Transvaginal US with Doppler study',\n",
       "  'Aljazeera Hospital',\n",
       "  'Kasr El Aini Hospital|National Research Centre\",\" Egypt',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-09-28',\n",
       "  '2019-02-20'],\n",
       " ['NCT01142271',\n",
       "  'Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastrectomy',\n",
       "  'PROCEDURE: Billroth-I|PROCEDURE: Roux en Y',\n",
       "  'Ajou University School of Medicine',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-06',\n",
       "  '2012-05'],\n",
       " ['NCT02743871',\n",
       "  'Study Of PF-06817024 In Healthy Subjects\",\" In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy|Chronic Rhinosinusitis With Nasal Polyps|Atopic Dermatitis',\n",
       "  'BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024|BIOLOGICAL: PF-06817024|OTHER: Placebo for PF-06817024',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-04-27',\n",
       "  '2021-03-09'],\n",
       " ['NCT03880071',\n",
       "  'DIalectical Behavior Therapy and Acceptance Commitment Therapy Short Program for BOrderLine persOnality Disorder',\n",
       "  'DIABOLO',\n",
       "  'WITHDRAWN',\n",
       "  'Female|Borderline Personality Disorder',\n",
       "  'BEHAVIORAL: DBT+ACT|BEHAVIORAL: DBT',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '\"\"INSERM 1061\",\" \"\"\"\" Neuropsychiatry: epidemiological and clinical research\"\"\"\"\",\" Montpellier\"\"',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2019-11-30',\n",
       "  '2020-03-09'],\n",
       " ['NCT05792371',\n",
       "  'The Role of Type H Vessel Formation in Induced Membrane of Patients With Critical Size Bone Defect',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Bone Injury',\n",
       "  'PROCEDURE: induced membrane technique|PROCEDURE: Bone graft (Stage II of IMT)',\n",
       "  'Chang Gung Memorial Hospital',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2023-04-01',\n",
       "  '2026-01-02'],\n",
       " ['NCT00388271',\n",
       "  'Use of Alfuzosin in Stone Treatment With ESWL',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Urinary Calculi',\n",
       "  'DRUG: Alfuzosin (Xatral)|DRUG: standard treatment',\n",
       "  'Singapore General Hospital',\n",
       "  'Sanofi',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-10',\n",
       "  '2007-12'],\n",
       " ['NCT05330871',\n",
       "  'Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: 1 Nebulized inhalation for booster groups|BIOLOGICAL: 2 Nebulized inhalation for booster groups|BIOLOGICAL: 3 Nebulized inhalation for booster groups|BIOLOGICAL: 4 Nebulized inhalation for booster groups|BIOLOGICAL: 5 Intramuscular injection for booster groups|BIOLOGICAL: 6 Intramuscular injection for booster groups|BIOLOGICAL: 7 Intramuscular injection for booster groups|BIOLOGICAL: 8 Intramuscular injection for booster groups|BIOLOGICAL: 9 Intramuscular injection for booster groups|BIOLOGICAL: 10 Intramuscular injection for booster groups|BIOLOGICAL: 11 Nebulized inhalation for booster groups|BIOLOGICAL: 12 Nebulized inhalation for booster groups|BIOLOGICAL: 13 Nebulized inhalation for booster groups|BIOLOGICAL: 14 Nebulized inhalation for booster groups|BIOLOGICAL: 15 Intramuscular injection for booster groups|BIOLOGICAL: 16 Intramuscular injection for booster groups|BIOLOGICAL: 17 Intramuscular injection for booster groups|BIOLOGICAL: 18 Intramuscular injection for booster groups|BIOLOGICAL: 19 Intramuscular injection for booster groups|BIOLOGICAL: 20 Intramuscular injection for booster groups|BIOLOGICAL: 21 Nebulized inhalation for primary groups|BIOLOGICAL: 22 Nebulized inhalation for primary groups|BIOLOGICAL: 23 Nebulized inhalation for primary groups|BIOLOGICAL: 24 Nebulized inhalation for primary groups',\n",
       "  'Seventh Medical Center of PLA General Hospital',\n",
       "  '',\n",
       "  '410.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-04-17',\n",
       "  '2023-05-30'],\n",
       " ['NCT02654171',\n",
       "  'Viral Inhibition in Children for Treatment of RSV',\n",
       "  'VICTOR',\n",
       "  'COMPLETED',\n",
       "  'RESPIRATORY SYNCYTIAL VIRUS INFECTIONS',\n",
       "  'DRUG: AK0529|DRUG: Placebo',\n",
       "  'Shanghai Ark Biopharmaceutical Co.\",\" Ltd.',\n",
       "  'Ark Biosciences Pty Ltd.',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-05-27',\n",
       "  '2019-04-09'],\n",
       " ['NCT04121871',\n",
       "  'Molecular Characterization of Candida Auris',\n",
       "  'OC',\n",
       "  'COMPLETED',\n",
       "  'Oral Fungal Infection',\n",
       "  'OTHER: No intervention',\n",
       "  'Islamia University of Bahawalpur',\n",
       "  '',\n",
       "  '384.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-11-15',\n",
       "  '2020-02-29'],\n",
       " ['NCT04023071',\n",
       "  'FT516 in Subjects With Advanced Hematologic Malignancies',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Acute Myelogenous Leukemia|B-cell Lymphoma',\n",
       "  'DRUG: FT516|DRUG: Rituximab|DRUG: Obinutuzumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|DRUG: Bendamustine',\n",
       "  'Fate Therapeutics',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-10-04',\n",
       "  '2023-10-23'],\n",
       " ['NCT05304871',\n",
       "  'Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Vascular Access Ports',\n",
       "  'DRUG: Cefazolin|OTHER: saline',\n",
       "  'Dartmouth-Hitchcock Medical Center',\n",
       "  '',\n",
       "  '2550.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2024-01',\n",
       "  '2027-12'],\n",
       " ['NCT05676671',\n",
       "  'Microbiological Evaluation and Clinical 24-month Follow-up of Adhesive Systems on Carious Dentin',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dental Caries',\n",
       "  'PROCEDURE: Applications of self-etching adhesives and dental restorations',\n",
       "  'University of Sao Paulo',\n",
       "  '',\n",
       "  '104.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2020-02'],\n",
       " ['NCT05766371',\n",
       "  'Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Castrate Resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Prostate Cancer|Prostate Carcinoma',\n",
       "  'DRUG: Pembrolizumab|DRUG: 177Lu-PSMA-617',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'Merck Sharp & Dohme LLC|Prostate Cancer Foundation',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-12-15',\n",
       "  '2031-05-31'],\n",
       " ['NCT01018771',\n",
       "  'Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion',\n",
       "  'APPRAISET2',\n",
       "  'COMPLETED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'PROCEDURE: Actifuse ABX|PROCEDURE: INFUSE\",\" plus Mastergraft granules',\n",
       "  'Baxter Healthcare Corporation',\n",
       "  'Apatech\",\" Inc.',\n",
       "  '100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2012-12'],\n",
       " ['NCT00001071',\n",
       "  'A Study of Stem Cells and Filgrastim',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Filgrastim',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  '1998-10'],\n",
       " ['NCT02193971',\n",
       "  'Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Coronary Syndrome',\n",
       "  'DEVICE: BS-DES (Biostable polymer drug-eluting stent)|DEVICE: BD-DES (Biodegradable polymer drug-eluting stent)|DRUG: Prasugrel 5mg',\n",
       "  'Seoul National University Hospital',\n",
       "  'Boston Scientific Korea Co. Ltd|Dio|Terumo Corporation|Abbott',\n",
       "  '3384.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2022-06'],\n",
       " ['NCT03600571',\n",
       "  'Injection Site Diversity Influences HA Distribution and Clinical Results in CP and KOA',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis\",\" Knee|Hyaluronan',\n",
       "  'PROCEDURE: medial midpatellar (MMP) portal|PROCEDURE: anteromedial (AM) portal',\n",
       "  'Nanfang Hospital\",\" Southern Medical University',\n",
       "  '',\n",
       "  '164.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-08-30',\n",
       "  '2018-05-01'],\n",
       " ['NCT00978471',\n",
       "  'Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma',\n",
       "  'OSII-TTP',\n",
       "  'COMPLETED',\n",
       "  'Osteosarcoma',\n",
       "  'DRUG: Thiotepa',\n",
       "  'Centre Leon Berard',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-07',\n",
       "  '2018-10-29'],\n",
       " ['NCT00150371',\n",
       "  'Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration',\n",
       "  'CANACTFAST',\n",
       "  'COMPLETED',\n",
       "  'Hypercholesterolemia',\n",
       "  'DRUG: atorvastatin',\n",
       "  \"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\",\n",
       "  '',\n",
       "  '1100.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-06',\n",
       "  '2005-05'],\n",
       " ['NCT02919371',\n",
       "  'Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Renal Cell Carcinoma',\n",
       "  'DRUG: Sunitinib|DRUG: Bevacizumab',\n",
       "  'King Faisal Specialist Hospital & Research Center',\n",
       "  '',\n",
       "  '77.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-12',\n",
       "  '2021-12'],\n",
       " ['NCT05666271',\n",
       "  'Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Hepatocellular Carcinoma',\n",
       "  'PROCEDURE: Radiofrequency ablation',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-08-29',\n",
       "  '2024-08-30'],\n",
       " ['NCT00666471',\n",
       "  'Minimally Invasive Control of Epistaxis (MICE)',\n",
       "  'MICE',\n",
       "  'TERMINATED',\n",
       "  'Epistaxis',\n",
       "  'PROCEDURE: MICE|PROCEDURE: SPA ligation',\n",
       "  'University of Calgary',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-06',\n",
       "  '2009-06'],\n",
       " ['NCT03258671',\n",
       "  'IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Carcinoma\",\" Non-Small-Cell Lung',\n",
       "  'DRUG: EGFR-TK Inhibitor|RADIATION: Intensity Modulated Radiation Therapy',\n",
       "  'LuBing',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-10-01',\n",
       "  '2020-12-30'],\n",
       " ['NCT05540171',\n",
       "  'An Educational Intervention Program to Improve the Oral Health of HIV-Positive Children in Kano\",\" Nigeria.',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'HIV|Dental Caries|Quality of Life|Oral Disease|Oral Infection|Oral Manifestations',\n",
       "  'OTHER: Oral health education and instructions/training for self-oral care',\n",
       "  'Aminu Kano Teaching Hospital',\n",
       "  'NIH Office of AIDS Research (OAR)|Fogarty International Center of the National Institute of Health',\n",
       "  '172.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-12-22',\n",
       "  '2023-08-10'],\n",
       " ['NCT01152671',\n",
       "  'A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Volunteer',\n",
       "  'DRUG: Placebo|DRUG: RO5024048',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '97.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: ',\n",
       "  '2010-06',\n",
       "  '2010-08'],\n",
       " ['NCT01855971',\n",
       "  '\"\"\"\"\"\"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome\"\"\"\" (TESFX)\"\"',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Fragile X Syndrome',\n",
       "  'DIETARY_SUPPLEMENT: EGCG|DIETARY_SUPPLEMENT: Placebo|OTHER: Cognitive training',\n",
       "  'Parc de Salut Mar',\n",
       "  '',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-06-11',\n",
       "  '2015-10-31'],\n",
       " ['NCT03321071',\n",
       "  'Healthy Summer Learners',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Overweight and Obesity|Academic Acheivement',\n",
       "  'BEHAVIORAL: Healthy Summer Learners|BEHAVIORAL: 21st Century Summer Learning Center',\n",
       "  'University of South Carolina',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2018-05-01',\n",
       "  '2021-05-01'],\n",
       " ['NCT03185871',\n",
       "  'Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Breast Carcinoma',\n",
       "  'DRUG: Celecoxib',\n",
       "  'University of Wisconsin\",\" Madison',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2017-09-20',\n",
       "  '2018-10-10'],\n",
       " ['NCT02100371',\n",
       "  'Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Basal Cell Nevus Syndrome',\n",
       "  'DRUG: BMS-833923',\n",
       "  'University Health Network\",\" Toronto',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-02',\n",
       "  '2017-05'],\n",
       " ['NCT01644071',\n",
       "  'Serotonergic System and Violent Video Games',\n",
       "  'Serogen',\n",
       "  'COMPLETED',\n",
       "  'Healthy Volunteers',\n",
       "  'DRUG: cipralex',\n",
       "  'RWTH Aachen University',\n",
       "  '',\n",
       "  '47.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2012-02',\n",
       "  '2014-06'],\n",
       " ['NCT03227471',\n",
       "  'A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  'DRUG: IVA|DRUG: TEZ/IVA|DRUG: VX-445|DRUG: Matched Placebo|DRUG: TEZ|DRUG: VX-561|DRUG: VX-445',\n",
       "  'Vertex Pharmaceuticals Incorporated',\n",
       "  '',\n",
       "  '225.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-01-23',\n",
       "  '2018-03-27'],\n",
       " ['NCT03712371',\n",
       "  'Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Prostate Cancer',\n",
       "  'DRUG: Chitosan',\n",
       "  'Medical University of South Carolina',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-16',\n",
       "  '2021-09-07'],\n",
       " ['NCT03653871',\n",
       "  'Caregiver Study Dr. Phillips',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alzheimer Disease|Dementia',\n",
       "  'BEHAVIORAL: Performing Arts Instruction',\n",
       "  'AdventHealth',\n",
       "  'Dr. Phillips Center for the Performing Arts',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-09-11',\n",
       "  '2019-12-31'],\n",
       " ['NCT00656071',\n",
       "  'Retrospective Postoperative ARDS Study at Vanderbilt University',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'ARDS',\n",
       "  '',\n",
       "  'Vanderbilt University',\n",
       "  '',\n",
       "  '89.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2007-10',\n",
       "  '2008-08'],\n",
       " ['NCT03107871',\n",
       "  'Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants',\n",
       "  'ValEAR',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Cmv Congenital|CMV|Congenital Cmv|SNHL|Sensorineural Hearing Loss',\n",
       "  'DRUG: Valganciclovir|DRUG: Simple Syrup',\n",
       "  'Albert Park',\n",
       "  'National Institute on Deafness and Other Communication Disorders (NIDCD)|Genentech\",\" Inc.',\n",
       "  '52.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-08-31',\n",
       "  '2024-07'],\n",
       " ['NCT01234571',\n",
       "  'Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pulmonary Hypertension|End-Stage Renal Disease|Hemo-dialysis Therapy',\n",
       "  '',\n",
       "  'Rambam Health Care Campus',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-11',\n",
       "  ''],\n",
       " ['NCT02967471',\n",
       "  'Discovery of New Early Detection Biomarkers From Peripheral Blood of Acute Respiratory Distress Syndrome(ARDS)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute Respiratory Distress Syndrome',\n",
       "  '',\n",
       "  'The Third Affiliated Hospital of Southern Medical University',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-10',\n",
       "  '2018-12'],\n",
       " ['NCT00503971',\n",
       "  'Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Non-small Cell Lung Cancer',\n",
       "  'DRUG: Vorinostat plus Erlotinib',\n",
       "  'Spanish Lung Cancer Group',\n",
       "  'Merck Sharp & Dohme LLC',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2011-12'],\n",
       " ['NCT04484571',\n",
       "  'Multimodal Instrumented Assessment of Post-stroke Elbow',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Spasticity\",\" Muscle|Stroke|Upper Limb',\n",
       "  'DEVICE: Neuroexsos elbow module',\n",
       "  'Azienda USL Toscana Nord Ovest',\n",
       "  \"Scuola Superiore Sant'Anna Pisa\",\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-07-06',\n",
       "  '2024-07-30'],\n",
       " ['NCT06066671',\n",
       "  'The Effect of an Experimental Gel Based on Copaiba Oil Resin in Reducing Post-bleaching Tooth Sensitivity',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Tooth Bleaching Pain',\n",
       "  'OTHER: GCO (Experimental copaiba oil resin gel)',\n",
       "  'Universidade Federal do Para',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-10',\n",
       "  '2024-05-25'],\n",
       " ['NCT04533971',\n",
       "  'The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Multiple Sclerosis (ICD10-G35)|Surface Electromyography|Whole-body Cryotherapy',\n",
       "  'OTHER: Whole body cryotherapy',\n",
       "  'Pomeranian Medical University Szczecin',\n",
       "  '',\n",
       "  '114.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-04-01',\n",
       "  '2019-12-20'],\n",
       " ['NCT04608071',\n",
       "  'A Modified Method for Blind Bedside Placement of Post-pyloric Feeding Tube.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Nutritional Support\", Catheterization, Post-pyloric Feeding Tube,\" Dysphagia',\n",
       "  'PROCEDURE: A modified method for blind bedside placement of post-pyloric feeding tube.',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '99.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-01',\n",
       "  '2019-10-30'],\n",
       " ['NCT04050371',\n",
       "  'Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy',\n",
       "  'I-BrEATHe',\n",
       "  'COMPLETED',\n",
       "  'HIV Prevention|Transgender Health',\n",
       "  'DRUG: 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate',\n",
       "  'University of California\",\" San Francisco',\n",
       "  'San Francisco AIDS Foundation|California HIV/AIDS Research Program',\n",
       "  '48.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2017-08-03',\n",
       "  '2018-05-23'],\n",
       " ['NCT01276171',\n",
       "  'Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia',\n",
       "  'PROCEDURE: Ultrasound|PROCEDURE: Doppler|PROCEDURE: Palpation',\n",
       "  'University of Iowa',\n",
       "  '',\n",
       "  '749.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2015-04'],\n",
       " ['NCT03929471',\n",
       "  'Target Weight Correction and Vascular Stiffness in Hemodialysis Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Fluid Overload|Vascular Stiffness',\n",
       "  'OTHER: Target weight correction protocol',\n",
       "  'University of Alberta',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2019-09-01',\n",
       "  '2020-07-01'],\n",
       " ['NCT00630071',\n",
       "  'Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Appendicitis',\n",
       "  '',\n",
       "  'Ruhr University of Bochum',\n",
       "  '',\n",
       "  '103.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2008-02',\n",
       "  '2008-08'],\n",
       " ['NCT03668171',\n",
       "  'Mesenchymal Stem Cell Transplantation for Acute-on-chronic Liver Failure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Acute-On-Chronic Liver Failure',\n",
       "  'PROCEDURE: mesenchymal stem cell transplantation or placebo infusion via peripheral vein',\n",
       "  'Xijing Hospital of Digestive Diseases',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-12-10',\n",
       "  '2020-12-31'],\n",
       " ['NCT02067871',\n",
       "  'Treatment of Knee Osteoarthritis: Neuromuscular Electrical Stimulation and Low-level Laser.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Knee Osteoarthritis',\n",
       "  'OTHER: Laser Therapy|OTHER: Electrical Stimulation',\n",
       "  'Marco Aurélio Vaz\",\" PhD',\n",
       "  'Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul\",\" Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico',\n",
       "  '44.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-03',\n",
       "  '2012-12'],\n",
       " ['NCT00497471',\n",
       "  'RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Malaria|Anemia',\n",
       "  'DRUG: Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|DRUG: iron (2 mg/kg/daily)',\n",
       "  'Hospital Clinic of Barcelona',\n",
       "  'Agencia Española de Cooperación Internacional|World Health Organization',\n",
       "  '832.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '1995-02',\n",
       "  '1999-07'],\n",
       " ['NCT02235571',\n",
       "  'iChoose Decision Kidney Aid for End-Stage Renal Disease Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'End-Stage Kidney Disease|Kidney Failure\",\" Chronic|Kidney Transplantation',\n",
       "  'BEHAVIORAL: iChoose Kidney Decision Aid',\n",
       "  'Emory University',\n",
       "  'Columbia University|Northwestern University|Satellite Healthcare|Norman S. Coplon Extramural Grant Program',\n",
       "  '470.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-09',\n",
       "  '2017-09'],\n",
       " ['NCT05112471',\n",
       "  'Efficacy of GBT vs SRP+US\",\" in the Treatment of Severe Generalized Periodontitis.',\n",
       "  'ERISRP',\n",
       "  'COMPLETED',\n",
       "  'Periodontitis\",\" Aggressive|Periodontal Diseases|Periodontitis',\n",
       "  'DEVICE: Airflow\",\" Perioflow and Erythritol powder and ultrasonic debridement|DEVICE: Ultrasonic debridement and curettes',\n",
       "  'Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2016-11-22',\n",
       "  '2020-04-04'],\n",
       " ['NCT00019071',\n",
       "  'Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain and Central Nervous System Tumors',\n",
       "  'DRUG: chemotherapy|DRUG: cladribine|RADIATION: radiation therapy',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '1995-03',\n",
       "  ''],\n",
       " ['NCT05170971',\n",
       "  'Fecal Microbiota Transplantation for Liver Failure',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Liver Failure',\n",
       "  'OTHER: fecal microbiota transplantation',\n",
       "  'Ningbo Medical Center Lihuili Hospital',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-05-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT00771771',\n",
       "  'Early Supported Discharge After Stroke in Bergen',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'OTHER: Early supported discharge with day unit rehabilitation|OTHER: Early supported discharge with home rehabilitation',\n",
       "  'Haukeland University Hospital',\n",
       "  'University of Bergen|Municipality of Bergen\",\" Norway|Kavli Research Centre for Ageing and Dementia',\n",
       "  '306.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2013-12'],\n",
       " ['NCT01333371',\n",
       "  'Assessing Volar Locking Plates in Patients Under 65 With a Distal Radius Fracture',\n",
       "  'DRF',\n",
       "  'UNKNOWN',\n",
       "  'Distal Radius Fracture',\n",
       "  'PROCEDURE: Surgical Repair of Distal Radius Fracture',\n",
       "  'Hand and Upper Limb Clinic\",\" Canada',\n",
       "  'Canadian Orthopaedic Foundation',\n",
       "  '64.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-04',\n",
       "  '2014-03'],\n",
       " ['NCT01878071',\n",
       "  'The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Peri-implant Inflammation|Peri-implantitis',\n",
       "  '',\n",
       "  'University of Iowa',\n",
       "  'Osseointegration Foundation|University of Iowa Institute of Clinical and Translational Science',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-06',\n",
       "  ''],\n",
       " ['NCT02687971',\n",
       "  'Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cutaneous Leishmaniasis',\n",
       "  'DRUG: Miltefosine',\n",
       "  'Drugs for Neglected Diseases',\n",
       "  '',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-12',\n",
       "  '2019-09-10'],\n",
       " ['NCT00956371',\n",
       "  'ONO-7746 Study in Healthy Adult Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Adult Subjects',\n",
       "  'DRUG: ONO-7746|DRUG: ONO-7746',\n",
       "  'Ono Pharmaceutical Co. Ltd',\n",
       "  '',\n",
       "  '48.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  ''],\n",
       " ['NCT01322971',\n",
       "  'Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Vaginosis\",\" Bacterial|Infertility|Miscarriage',\n",
       "  'DRUG: Metronidazole|DRUG: Placebo',\n",
       "  'Stanford University',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-02',\n",
       "  '2012-06'],\n",
       " ['NCT03803371',\n",
       "  'Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Ultracet Tablets|DRUG: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)',\n",
       "  'Pfizer',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2019-03-26',\n",
       "  '2019-06-28'],\n",
       " ['NCT01408771',\n",
       "  '\"\"\"\"\"\"Swallow my Urine Back\"\"\"\" : Inhibition of Detrusor Overactivity by Swallowing Maneuver\"\"',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Overactive Detrusor',\n",
       "  '',\n",
       "  'Assaf-Harofeh Medical Center',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2011-07'],\n",
       " ['NCT01767571',\n",
       "  'Bioequivalence Study of Cephalexin Suspension 250',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infections\",\" Respiratory Tract',\n",
       "  'DRUG: Cephalexin 125 mg/5ml|DRUG: Cephalexin 250mg/5ml',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2011-01-30',\n",
       "  '2011-02-08'],\n",
       " ['NCT00925171',\n",
       "  'Maintenance Schedules Following Pulmonary Rehabilitation',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Chronic Obstructive Pulmonary Disease|Pulmonary Rehabilitation',\n",
       "  'BEHAVIORAL: Pulmonary Intervention',\n",
       "  'University of East Anglia',\n",
       "  '',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2009-06',\n",
       "  '2012-06'],\n",
       " ['NCT02153671',\n",
       "  'Immunogenicity of H5N1 Vaccine Following H5N2',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Influenza Vaccine',\n",
       "  'BIOLOGICAL: A(H5N1) inactivated influenza vaccine (IIV)|BIOLOGICAL: A(H5N2) live attenuated influenza vaccine (LAIV)',\n",
       "  'PATH',\n",
       "  'Institute of Experimental Medicine\", Russia|Research Institute of Influenza,\" Russia',\n",
       "  '43.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2014-05',\n",
       "  '2014-09'],\n",
       " ['NCT05603871',\n",
       "  'Ligamentoplasty of Ligamentum Tere Developmental Dysplasia of the Hip',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Orthopedic Disorder',\n",
       "  'PROCEDURE: ligamentoplasty of ligamentum teres',\n",
       "  'Al-Azhar University',\n",
       "  '',\n",
       "  '3.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-11-29',\n",
       "  '2023-11-29'],\n",
       " ['NCT04364971',\n",
       "  'Comparison of Multiradius and Singleradius Total Knee Arthroplasty',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gonarthrosis; Primary|Gonarthrosis|Gonarthrosis; Primary\",\" Bilateral|Knee Osteoarthritis|Knee Arthritis',\n",
       "  'PROCEDURE: singleradius and multiradius total knee arthroplasty',\n",
       "  'Bezmialem Vakif University',\n",
       "  '',\n",
       "  '494.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-04-25',\n",
       "  '2023-07-25'],\n",
       " ['NCT00555971',\n",
       "  'Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aspirin Sensitivity',\n",
       "  'DRUG: Omalizumab|DRUG: placebo',\n",
       "  'David Lang',\n",
       "  'Genentech\",\" Inc.',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-05',\n",
       "  '2016-02'],\n",
       " ['NCT03926871',\n",
       "  'Ergonomics Training Program to Industrial Workers',\n",
       "  'Ergonomics',\n",
       "  'COMPLETED',\n",
       "  'Occupational Exposure',\n",
       "  'OTHER: Ergonomic Training',\n",
       "  'Rosimeire Simprini Padula',\n",
       "  '',\n",
       "  '133.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2014-08-20',\n",
       "  '2015-02-20'],\n",
       " ['NCT00005571',\n",
       "  'Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Dermatomyositis',\n",
       "  'DRUG: h5G1.1-mAb',\n",
       "  'National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)',\n",
       "  '',\n",
       "  '17.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2000-04',\n",
       "  '2001-12'],\n",
       " ['NCT01026571',\n",
       "  'Identification of Genetic Causes of Bicuspid Aortic Valve Disease',\n",
       "  'BAV Genetics',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Bicuspid Aortic Valve',\n",
       "  '',\n",
       "  'Boston University',\n",
       "  'Massachusetts General Hospital|Brigham and Women\\'s Hospital|National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '4000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-12',\n",
       "  '2030-12'],\n",
       " ['NCT00578071',\n",
       "  'Phase I/II Study of Panitumumab\",\" Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer',\n",
       "  'POXX',\n",
       "  'COMPLETED',\n",
       "  'Cancer of the Esophagus',\n",
       "  'DRUG: Panitumumab|DRUG: Capecitabine|DRUG: Oxaliplatin|RADIATION: Radiation Therapy (RT)',\n",
       "  'Brian Czito',\n",
       "  'Amgen',\n",
       "  '29.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2012-06'],\n",
       " ['NCT01087671',\n",
       "  'Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Ocular Hypertension|Open-Angle Glaucoma',\n",
       "  'DRUG: tafluprost',\n",
       "  'Santen Oy',\n",
       "  '',\n",
       "  '185.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-04',\n",
       "  '2010-10'],\n",
       " ['NCT06075771',\n",
       "  'Dopaminergic Therapy for Anhedonia - 2',\n",
       "  'DTA-2',\n",
       "  'RECRUITING',\n",
       "  'Anhedonia|Depression',\n",
       "  'DRUG: Carbidopa Levodopa|DRUG: Placebo',\n",
       "  'Emory University',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-11-21',\n",
       "  '2027-01'],\n",
       " ['NCT06165471',\n",
       "  'The Effectiveness of a Mobile Application for Teaching Clinical Nursing Skill at a Higher Education Institution in Chenzhou\",\" China',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Nursing Education',\n",
       "  'BEHAVIORAL: Online and offline blended teaching|BEHAVIORAL: Traditional teaching',\n",
       "  'Universiti Sains Malaysia',\n",
       "  '',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2023-12-15',\n",
       "  '2024-09-20'],\n",
       " ['NCT03072771',\n",
       "  'Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diffuse Large B Cell Lymphoma',\n",
       "  'DRUG: Blinatumomab|PROCEDURE: Autologous stem cell transplant|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan|PROCEDURE: Peripheral blood draws',\n",
       "  'Washington University School of Medicine',\n",
       "  'Amgen',\n",
       "  '14.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-08-01',\n",
       "  '2023-10-30'],\n",
       " ['NCT03239171',\n",
       "  'Bioinformation Therapy for Lung Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Small-cell Lung Cancer',\n",
       "  'DEVICE: Cancer ablation|DRUG: Life information rehabilitation therapy',\n",
       "  'Fuda Cancer Hospital\",\" Guangzhou',\n",
       "  'Shengxin Biotechnology Institute\",\" Beijing',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-09-02',\n",
       "  '2018-09-02'],\n",
       " ['NCT05333471',\n",
       "  'Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Granulomatous Disease-associated Colitis',\n",
       "  'DRUG: MTP 101-LF',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-08',\n",
       "  '2026-03-01'],\n",
       " ['NCT03023371',\n",
       "  'National Registry of IgG4-RD in China',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'IgG4-Related Disease',\n",
       "  '',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  '',\n",
       "  '900.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-12',\n",
       "  '2026-12'],\n",
       " ['NCT02096471',\n",
       "  'MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1',\n",
       "  'MEK Inhibitor',\n",
       "  'COMPLETED',\n",
       "  'Neurofibromatosis Type 1 and Growing or Symptomatic\",\" Inoperable PN',\n",
       "  'DRUG: PD-0325901',\n",
       "  'University of Alabama at Birmingham',\n",
       "  '',\n",
       "  '19.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-06',\n",
       "  '2018-08-01'],\n",
       " ['NCT02495571',\n",
       "  'Assessment of Voluntary and Reflex Cough in Patients With ALS',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'ALS|Cough',\n",
       "  'OTHER: Cough Assessment in ALS Patients',\n",
       "  'IRCCS San Camillo\", Venezia,\" Italy',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2015-10',\n",
       "  '2016-06'],\n",
       " ['NCT05042271',\n",
       "  'PK of Meropenem in Patients on Plasma Exchange',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Autoimmune Diseases',\n",
       "  'DRUG: meropenem',\n",
       "  'Prince of Songkla University',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT05300971',\n",
       "  'Passive Heat Therapy for Lowering Systolic Blood Pressure and Improving Vascular Function in Mid-life and Older Adults',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Aging',\n",
       "  'OTHER: Heat therapy|OTHER: Thermoneutral water immersion',\n",
       "  'University of Colorado\",\" Boulder',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2027-01-01'],\n",
       " ['NCT00908271',\n",
       "  'Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Mellitus',\n",
       "  'DRUG: Dapagliflozin',\n",
       "  'AstraZeneca',\n",
       "  'Bristol-Myers Squibb',\n",
       "  '7.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2009-07',\n",
       "  '2009-08'],\n",
       " ['NCT00797771',\n",
       "  'User Satisfaction Using the ADI Insulin Pump',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes',\n",
       "  '\"\"DEVICE: \"\"\"\"Adi\"\"\"\" Insulin pump\"\"',\n",
       "  'NiliMedix',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2008-12',\n",
       "  '2010-01'],\n",
       " ['NCT02707471',\n",
       "  'Improving Well-Being for Breast Cancer Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Self-management Intervention (SM-AET)|General Health Education',\n",
       "  'BEHAVIORAL: SM-AET|BEHAVIORAL: general health education',\n",
       "  'Duke University',\n",
       "  '',\n",
       "  '312.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-03-14',\n",
       "  '2023-11-09'],\n",
       " ['NCT03867071',\n",
       "  'Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients',\n",
       "  'EPREX',\n",
       "  'COMPLETED',\n",
       "  'Trauma',\n",
       "  'OTHER: recombinant erythropoietin injection|OTHER: placebo injection',\n",
       "  'Centre Hospitalier Universitaire de Nīmes',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: OTHER',\n",
       "  '2005-10',\n",
       "  '2012-07'],\n",
       " ['NCT05263271',\n",
       "  'Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Acute Myelogenous Leukemia|Myelodysplastic Syndromes',\n",
       "  'DRUG: Gentulizumab',\n",
       "  'Changchun GeneScience Pharmaceutical Co.\",\" Ltd.',\n",
       "  'Ruijin Hospital|Shanghai Tong Ren Hospital|First Affiliated Hospital of Zhejiang University',\n",
       "  '58.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-04-01',\n",
       "  '2024-07-30'],\n",
       " ['NCT06019871',\n",
       "  'The Danish Symptomburden Study Among Patients With Advanced Kidney Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Kidney Diseases',\n",
       "  'PROCEDURE: Dialysis',\n",
       "  'University of Aarhus',\n",
       "  '',\n",
       "  '341.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-03-15',\n",
       "  '2025-09-15'],\n",
       " ['NCT06009471',\n",
       "  \"A Multicenter Clinical Study of rTMS for Parkinson's Disease\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  \"Parkinson's Disease\",\n",
       "  'OTHER: Routine treatment in Neurology|DEVICE: Routine treatment in Neurology and rTMS',\n",
       "  'Affiliated Hospital of Nantong University',\n",
       "  '',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2023-07-01',\n",
       "  '2025-08'],\n",
       " ['NCT02485171',\n",
       "  'SAFEWALKER Contribution to the Rehabilitation of Older People After a Post-fall Syndrome',\n",
       "  'SAFEER',\n",
       "  'COMPLETED',\n",
       "  'Post-fall Syndrome',\n",
       "  'DEVICE: SAFEWALKER',\n",
       "  'University Hospital\",\" Toulouse',\n",
       "  'Safe Step and Walk Movement (SSWM)\", Toulouse,\" France',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-06-10',\n",
       "  '2017-02-01'],\n",
       " ['NCT04273971',\n",
       "  'Acute Effect of Plyometric Exercises on Musculotendinous Properties',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Healthy',\n",
       "  'OTHER: Plyometric exercises',\n",
       "  'Universidade Federal de Santa Maria',\n",
       "  'Conselho Nacional de Desenvolvimento Científico e Tecnológico|Federal University of Rio Grande do Sul',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-20',\n",
       "  '2022-03-30'],\n",
       " ['NCT00442871',\n",
       "  'Study Of SB-497115 in Healthy Subjects and Subjects With Mild\",\" Moderate or Severe Renal Impairment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Purpura\", Thrombocytopaenic,\" Idiopathic',\n",
       "  'DRUG: eltrombopag',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '29.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2006-09-28',\n",
       "  '2008-01-03'],\n",
       " ['NCT03022071',\n",
       "  'Mechanisms of Change in Psychotherapy',\n",
       "  'MOP',\n",
       "  'UNKNOWN',\n",
       "  'Depression',\n",
       "  'OTHER: Cognitive behavior therapy',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-02-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT03794271',\n",
       "  'Effect of Pupilometer Guided Analgesia on Postoperative Pain',\n",
       "  'PUPIL_pain',\n",
       "  'COMPLETED',\n",
       "  'Cholecystectomy\", Laparoscopic|Anesthesia, General|Reflex,\" Pupillary',\n",
       "  'PROCEDURE: Pupilometer guided anesthesia|PROCEDURE: SPI guided anesthesia',\n",
       "  'Daegu Catholic University Medical Center',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2019-01-03',\n",
       "  '2019-05-10'],\n",
       " ['NCT02625571',\n",
       "  'Tx for Child Sexual Behavior Problems',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sexual Behavior',\n",
       "  'BEHAVIORAL: Phase-based treatment of sexual behavior problems of children',\n",
       "  'Milton S. Hershey Medical Center',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-12',\n",
       "  '2017-06-30'],\n",
       " ['NCT03942471',\n",
       "  'Mindfulness for Adolescents With Type 1 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 1 Diabetes Mellitus',\n",
       "  'BEHAVIORAL: Mindfulness Based Stress Reduction',\n",
       "  'Duquesne University',\n",
       "  '',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2015-10-14',\n",
       "  '2019-01-05'],\n",
       " ['NCT05511571',\n",
       "  'Effect of Progressive Relaxation Exercises and TENS on Women Delivering Via Cesarean',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cesarean Section|Acute Pain',\n",
       "  'DEVICE: Transcutaneous electrical neural stimulation (TENS)|OTHER: Progressive relaxation exercises (PRE)|OTHER: Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)',\n",
       "  'Derya Öztürk Özen',\n",
       "  'Hacettepe University|Saglik Bilimleri Universitesi',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2018-08-20',\n",
       "  '2019-04-15'],\n",
       " ['NCT01471171',\n",
       "  'Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Chronic Obstructive Pulmonary Disease (COPD)',\n",
       "  'DRUG: Aclidinium Bromide|DRUG: Placebo',\n",
       "  'AstraZeneca',\n",
       "  '',\n",
       "  '112.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-11',\n",
       "  '2012-06'],\n",
       " ['NCT02971371',\n",
       "  'The Role of MNS in Improving Motor Performance',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'DEVICE: Lokomat',\n",
       "  '\"\"IRCCS Centro Neurolesi \"\"\"\"Bonino-Pulejo\"\"\"\"\"\"',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2016-02'],\n",
       " ['NCT03919071',\n",
       "  'Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Anaplastic Astrocytoma|Anaplastic Astrocytoma\",\" Not Otherwise Specified|Anaplastic Ganglioglioma|Anaplastic Pleomorphic Xanthoastrocytoma|Glioblastoma|Malignant Glioma|WHO Grade 3 Glioma',\n",
       "  'PROCEDURE: Biospecimen Collection|DRUG: Dabrafenib Mesylate|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|RADIATION: Radiation Therapy|DRUG: Trametinib Dimethyl Sulfoxide',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '',\n",
       "  '58.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-20',\n",
       "  '2027-09-30'],\n",
       " ['NCT01267071',\n",
       "  'A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gastroparesis',\n",
       "  'DRUG: A|DRUG: B',\n",
       "  'GlaxoSmithKline',\n",
       "  '',\n",
       "  '8.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2010-06-14',\n",
       "  '2010-09-01'],\n",
       " ['NCT00929071',\n",
       "  'Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®',\n",
       "  'AD-1016',\n",
       "  'COMPLETED',\n",
       "  'Aging|Pain',\n",
       "  'DEVICE: Evolence|DEVICE: Lidocaine|DRUG: topical anesthetic',\n",
       "  'Weinkle\", Susan H.,\" M.D.',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDIV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2009-01',\n",
       "  '2009-02'],\n",
       " ['NCT03811171',\n",
       "  'Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Renal Calculi|Urinary Calculi',\n",
       "  'DEVICE: Break Wave extracorporeal lithotripsy',\n",
       "  'SonoMotion',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-08-20',\n",
       "  '2023-12-30'],\n",
       " ['NCT03133871',\n",
       "  'Evaluation of Scanoskin for the Assessment of Vitiligo',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Vitiligo',\n",
       "  '',\n",
       "  'Chelsea and Westminster NHS Foundation Trust',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-03-01',\n",
       "  '2018-11-20'],\n",
       " ['NCT05941871',\n",
       "  'Chronotype-adapted Diet and Weight Loss',\n",
       "  'CHRONODIET',\n",
       "  'RECRUITING',\n",
       "  'Overweight and Obesity',\n",
       "  'OTHER: Dietary intervention - intervention group|OTHER: Dietary intervention - control group',\n",
       "  'Azienda Ospedaliero-Universitaria Careggi',\n",
       "  '',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-03-06',\n",
       "  '2025-03-06'],\n",
       " ['NCT03561571',\n",
       "  'Triglyceride Rich Lipoproteins and Platelet Activation in Type 2 Diabetes',\n",
       "  'COMPLETE',\n",
       "  'COMPLETED',\n",
       "  'Type2 Diabetes',\n",
       "  'OTHER: butter based breakfast|OTHER: Chocolate spread based breakfast',\n",
       "  'Hospices Civils de Lyon',\n",
       "  '',\n",
       "  '32.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2018-10-15',\n",
       "  '2019-05-14'],\n",
       " ['NCT03454971',\n",
       "  'Health Course of Patients Undergoing Per os Anti-cancer Therapy.',\n",
       "  'MinOS',\n",
       "  'COMPLETED',\n",
       "  'Cancer',\n",
       "  'OTHER: MinOS protocol',\n",
       "  'Groupe Hospitalier Mutualiste de Grenoble',\n",
       "  \"Fondation de l'Avenir\",\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2018-04-25',\n",
       "  '2020-05-12'],\n",
       " ['NCT05835271',\n",
       "  'Powered Assist Hip Exoskeleton to Improve Ambulation in Severe Lung Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Lung Disease Chronic',\n",
       "  'DEVICE: exoskeleton assist',\n",
       "  'West Park Healthcare Centre',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-08-01',\n",
       "  '2024-03-30'],\n",
       " ['NCT06088771',\n",
       "  'Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Non-Small Cell Lung Cancer',\n",
       "  'BIOLOGICAL: Dupilumab|BIOLOGICAL: Cemiplimab',\n",
       "  'Icahn School of Medicine at Mount Sinai',\n",
       "  '',\n",
       "  '21.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01',\n",
       "  '2032-03'],\n",
       " ['NCT05212571',\n",
       "  'Long-term Pain Modulation by Intravenous Esketamine in CRPS',\n",
       "  'KetCRPS-2',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Complex Regional Pain Syndromes|CRPS (Complex Regional Pain Syndromes)',\n",
       "  'DRUG: S-ketamine infusion inpatient setting|DRUG: S-ketamine infusion outpatient setting',\n",
       "  'Erasmus Medical Center',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-04-19',\n",
       "  '2027-10-01'],\n",
       " ['NCT02902471',\n",
       "  'Forced Oscillations for Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation',\n",
       "  'OSCILLOMOELL',\n",
       "  'COMPLETED',\n",
       "  'Bronchiolitis Obliterans|Bone Marrow Transplantation',\n",
       "  'OTHER: Forced oscillations measure',\n",
       "  'Hopital Foch',\n",
       "  '',\n",
       "  '110.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2011-06',\n",
       "  '2015-09'],\n",
       " ['NCT00402571',\n",
       "  'Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Alcohol Related Disorders',\n",
       "  'DRUG: acetaminophen',\n",
       "  'Denver Health and Hospital Authority',\n",
       "  'McNeil Consumer & Specialty Pharmaceuticals\", a Division of McNeil-PPC,\" Inc.',\n",
       "  '420.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: ',\n",
       "  '2002-01',\n",
       "  '2004-07'],\n",
       " ['NCT04522271',\n",
       "  \"Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)\",\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Crohn Disease|Ulcerative Colitis|Inflammatory Bowel Diseases',\n",
       "  'OTHER: Resistant Starch|OTHER: Placebo',\n",
       "  \"Children's Hospital of Eastern Ontario\",\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2020-08-25',\n",
       "  '2024-05-01'],\n",
       " ['NCT05382871',\n",
       "  'Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above',\n",
       "  'COVID-19',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'COVID-19',\n",
       "  'BIOLOGICAL: BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|BIOLOGICAL: WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|BIOLOGICAL: COVID-19 Vaccine (Vero Cell)\",\" Inactivated',\n",
       "  'China National Biotec Group Company Limited',\n",
       "  'Beijing Institute of Biological Products Co Ltd.|Wuhan Institute of Biological Products Co.\",\" Ltd|The University of Hong Kong',\n",
       "  '1804.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2022-05-27',\n",
       "  '2024-03-31'],\n",
       " ['NCT01319071',\n",
       "  'Genetic Polymorphism and Israeli Top-level Athletes',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Top-level Athletes',\n",
       "  'OTHER: Blood sample',\n",
       "  'Hillel Yaffe Medical Center',\n",
       "  'Wingate Institute',\n",
       "  '200.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-04',\n",
       "  '2012-12'],\n",
       " ['NCT03579771',\n",
       "  'Gemcitabine\", Cisplatin,\" and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Resectable Cholangiocarcinoma|Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|Stage II Intrahepatic Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8',\n",
       "  'DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Nab-paclitaxel',\n",
       "  'Emory University',\n",
       "  'Celgene|National Institutes of Health (NIH)|National Cancer Institute (NCI)',\n",
       "  '31.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-09-26',\n",
       "  '2023-09-16'],\n",
       " ['NCT01156571',\n",
       "  'A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)',\n",
       "  'CHAMPION',\n",
       "  'COMPLETED',\n",
       "  'Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome',\n",
       "  'DRUG: cangrelor P2Y12 (platelet) inhibitor|DRUG: Clopidogrel - 300 or 600 mg (study arm)|DRUG: Clopidogrel 600 mg post cangrelor',\n",
       "  'The Medicines Company',\n",
       "  '',\n",
       "  '11145.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-09',\n",
       "  '2012-12'],\n",
       " ['NCT04345471',\n",
       "  'A Study of MD-120 in Patients With Depression',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorder',\n",
       "  'DRUG: Desvenlafaxine 100 mg|DRUG: Desvenlafaxine 50 mg|DRUG: Placebo',\n",
       "  'Mochida Pharmaceutical Company\",\" Ltd.',\n",
       "  'Pfizer',\n",
       "  '615.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-05-18',\n",
       "  '2022-09-14'],\n",
       " ['NCT05395871',\n",
       "  'Behavioural Science Messages in Breast Cancer Screening',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Breast Cancer',\n",
       "  'BEHAVIORAL: Behavioural Message|BEHAVIORAL: Behavioural Message + Video|OTHER: Usual Care Message',\n",
       "  'Imperial College London',\n",
       "  'NHS England (NHSE/I) London',\n",
       "  '34047.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: SCREENING',\n",
       "  '2022-07-15',\n",
       "  '2023-01-15'],\n",
       " ['NCT04968171',\n",
       "  'Diabetes Type 1 and Fitness.',\n",
       "  'Diab1Fit',\n",
       "  'RECRUITING',\n",
       "  'Diabetes Mellitus',\n",
       "  '',\n",
       "  'Poznan University of Medical Sciences',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT02218671',\n",
       "  'Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: WE 941 OD tablets',\n",
       "  'Boehringer Ingelheim',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2000-03',\n",
       "  ''],\n",
       " ['NCT06222671',\n",
       "  'A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Axial Spondyloarthritis',\n",
       "  'DRUG: 608|DRUG: 608|DRUG: Placebo',\n",
       "  'Sunshine Guojian Pharmaceutical (Shanghai) Co.\",\" Ltd.',\n",
       "  '',\n",
       "  '180.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2024-01-31',\n",
       "  '2025-11-30'],\n",
       " ['NCT02265471',\n",
       "  'Knowledge and Perception of Resistance to Antimicrobials Among Healthcare Workers in France',\n",
       "  'PerceptR',\n",
       "  'COMPLETED',\n",
       "  'Knowledge\",\" Perception and Behaviour of Resistance to Antimicrobial Among HCW',\n",
       "  '',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '10000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-06',\n",
       "  '2016-02'],\n",
       " ['NCT05628571',\n",
       "  'Evaluation of the Antibacterial Effect of a Toothpaste Containing Zinc Lactate',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Oral Bacterial Infection',\n",
       "  'COMBINATION_PRODUCT: Zinc toothpaste|COMBINATION_PRODUCT: Fluoride Toothpaste',\n",
       "  'Hospital Israelita Albert Einstein',\n",
       "  'Colgate Palmolive|Associação Latinoamericana para Promoção de Saúde Bucal e Pesquisa Odontológica (LAOHA)',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2023-02-01',\n",
       "  '2023-06-30'],\n",
       " ['NCT01848171',\n",
       "  'Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Hypothyroidism|Thyroid Diseases|Endocrine System Diseases',\n",
       "  'DRUG: L-thyroxine',\n",
       "  'Shandong Provincial Hospital',\n",
       "  '',\n",
       "  '700.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2023-07'],\n",
       " ['NCT03048071',\n",
       "  'Morbimortality of Contegra Duct Replacements Versus Homografts in Pulmonary Position',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Congenital Heart Disease',\n",
       "  'OTHER: Data collection within medical files',\n",
       "  'Pierre Wauthy',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-02-14',\n",
       "  '2017-06-01'],\n",
       " ['NCT00002271',\n",
       "  'An Ascending\",\" Single Oral Dose Pharmacokinetic Study of 3\\'-Deoxy-3\\'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: Alovudine',\n",
       "  'Lederle Laboratories',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT02992171',\n",
       "  'Primary Palliative Care for Patients With Advanced Hematologic Malignancies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Advanced Cancer',\n",
       "  'BEHAVIORAL: care management by oncology nurses',\n",
       "  'University of Pittsburgh',\n",
       "  'American Cancer Society\",\" Inc.',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2017-05-02',\n",
       "  '2020-03-19'],\n",
       " ['NCT04488471',\n",
       "  'Impact of Isolation in Patients With IBD During the COVID-19 Crisis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Inflammatory Bowel Diseases',\n",
       "  '',\n",
       "  'Sheffield Teaching Hospitals NHS Foundation Trust',\n",
       "  '',\n",
       "  '232.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-30',\n",
       "  '2022-06-30'],\n",
       " ['NCT05233371',\n",
       "  'Study of Parental Stress and Care Consumption Until 24 Months Corrected Age of Infants at a High Risk of Developmental Delay\",\" After Discharge From Neonatal Intensive Care',\n",
       "  'DeStreSs',\n",
       "  'RECRUITING',\n",
       "  'Cerebral Palsy',\n",
       "  'OTHER: Parenting Stress Index (PSI)|OTHER: Collection of health care consumption|OTHER: Assessment of parent satisfaction',\n",
       "  'Centre Hospitalier Universitaire Dijon',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-04-22',\n",
       "  '2026-04'],\n",
       " ['NCT05347771',\n",
       "  'Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents',\n",
       "  'PANDA',\n",
       "  'RECRUITING',\n",
       "  'Asthma',\n",
       "  'DRUG: Dupilumab|DRUG: Placebo',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Childhood Asthma in Urban Settings (CAUSE)|Regeneron Pharmaceuticals|Rho Federal Systems Division\",\" Inc.',\n",
       "  '240.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-05-04',\n",
       "  '2025-12-15'],\n",
       " ['NCT00337571',\n",
       "  'Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Behavioral Symptoms|Autistic Disorder',\n",
       "  'DRUG: Aripiprazole|DRUG: Placebo',\n",
       "  'Otsuka Pharmaceutical Development & Commercialization\",\" Inc.',\n",
       "  'Otsuka America Pharmaceutical',\n",
       "  '218.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-06',\n",
       "  '2008-06'],\n",
       " ['NCT04019171',\n",
       "  'EXercise Training for Reducing Anxiety in First-Time Inmates',\n",
       "  'EXTRA',\n",
       "  'COMPLETED',\n",
       "  'Anxiety State',\n",
       "  'BEHAVIORAL: exercise training',\n",
       "  'Université de Reims Champagne-Ardenne',\n",
       "  '',\n",
       "  '43.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-03-01',\n",
       "  '2018-09-03'],\n",
       " ['NCT00926471',\n",
       "  'Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Autistic Disorder|Child Development Disorders\",\" Pervasive',\n",
       "  'BEHAVIORAL: Cognitive Behavioral Therapy (CBT) Program',\n",
       "  'Virginia Polytechnic Institute and State University',\n",
       "  'National Institute of Mental Health (NIMH)',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-09',\n",
       "  '2013-01'],\n",
       " ['NCT03907371',\n",
       "  'The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Radiation Injuries|Cognitive Impairment',\n",
       "  'DRUG: Donepezil Hydrochloride|OTHER: Placebo',\n",
       "  'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University',\n",
       "  '',\n",
       "  '238.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-05-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT06131671',\n",
       "  'Whole-body Electrostimulation on Functional Mobility and Quality of Life in the Elderly',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Aged',\n",
       "  'OTHER: Whole-body electrical stimulation',\n",
       "  'Federal University of Health Science of Porto Alegre',\n",
       "  'Leonhardt Ventures LLC',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2024-01-22',\n",
       "  '2024-04-15'],\n",
       " ['NCT05393271',\n",
       "  'First-Time-in-Human (FTIH) Study to Evaluate the Safety\",\" Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'DRUG: VH4011499|DRUG: Placebo|DRUG: Midazolam',\n",
       "  'ViiV Healthcare',\n",
       "  '',\n",
       "  '73.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-05-27',\n",
       "  '2023-04-24'],\n",
       " ['NCT04670471',\n",
       "  'Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Anesthesia',\n",
       "  'DRUG: Remimazolam|DRUG: Remifentanil',\n",
       "  'Paion UK Ltd.',\n",
       "  'University Medical Center Groningen|QPS Holdings LLC',\n",
       "  '28.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2021-04-13',\n",
       "  '2022-01-28'],\n",
       " ['NCT02005471',\n",
       "  'A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)',\n",
       "  'MURANO',\n",
       "  'COMPLETED',\n",
       "  'Chronic Lymphocytic Leukemia',\n",
       "  'DRUG: Bendamustine|DRUG: Venetoclax|DRUG: Rituximab',\n",
       "  'Hoffmann-La Roche',\n",
       "  'AbbVie',\n",
       "  '389.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-03-17',\n",
       "  '2022-08-03'],\n",
       " ['NCT05740371',\n",
       "  'Safety of Argatroban Infusion in Conduction Disturbances',\n",
       "  'SAICoDis',\n",
       "  'COMPLETED',\n",
       "  'Stable Coronary Artery Disease (CAD)|Unstable Angina (Troponin Negative)',\n",
       "  'DRUG: Argatroban',\n",
       "  'Mitsubishi Tanabe Pharma GmbH',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2017-04-18',\n",
       "  '2021-05-06'],\n",
       " ['NCT01099371',\n",
       "  'Resistance Training in Knee Osteoarthritis',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Knee Osteoarthritis',\n",
       "  'OTHER: exercise',\n",
       "  'Federal University of São Paulo',\n",
       "  'Fundação de Amparo à Pesquisa do Estado de São Paulo',\n",
       "  '70.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-02',\n",
       "  '2011-02'],\n",
       " ['NCT00058071',\n",
       "  'Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Gestational Trophoblastic Tumor|Neurotoxicity|Peripheral Neuropathy|Unspecified Adult Solid Tumor\",\" Protocol Specific',\n",
       "  'DRUG: amifostine trihydrate',\n",
       "  'Gynecologic Oncology Group',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '100.0',\n",
       "  'NETWORK',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2003-03',\n",
       "  ''],\n",
       " ['NCT05484271',\n",
       "  'Relationship Between the Arthroscopic Anatomy of the Middle Glenohumeral Ligament and the Rotator Cuff Tear Position',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Rotator Cuff Tears',\n",
       "  'PROCEDURE: Rotator cuff repair',\n",
       "  'RenJi Hospital',\n",
       "  '',\n",
       "  '125.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-08-05',\n",
       "  '2022-08-28'],\n",
       " ['NCT01078571',\n",
       "  'Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis',\n",
       "  'DALI',\n",
       "  'COMPLETED',\n",
       "  'Rheumatoid Arthritis',\n",
       "  'BIOLOGICAL: adalimumab (HUMIRA®)',\n",
       "  'Abbott',\n",
       "  '',\n",
       "  '705.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2006-05',\n",
       "  '2010-05'],\n",
       " ['NCT05919771',\n",
       "  \"Effects of Rock Climbing on Parkinson's Disease\",\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Parkinson Disease',\n",
       "  'OTHER: rock climbing',\n",
       "  'Marymount University',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-07-12',\n",
       "  '2024-05-31'],\n",
       " ['NCT01892371',\n",
       "  'Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'FLT3 Gene Mutation Negative|FLT3 Internal Tandem Duplication Positive|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome',\n",
       "  'DRUG: Azacitidine|DRUG: Cytarabine|OTHER: Pharmacodynamic Study|DRUG: Quizartinib',\n",
       "  'M.D. Anderson Cancer Center',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '200.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-11-12',\n",
       "  '2023-02-07'],\n",
       " ['NCT03521271',\n",
       "  'Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Duchenne Muscular Dystrophy',\n",
       "  '',\n",
       "  'Hacettepe University',\n",
       "  '',\n",
       "  '23.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-04-05',\n",
       "  '2018-01-26'],\n",
       " ['NCT06123871',\n",
       "  'Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Diabetic Nephropathy',\n",
       "  'OTHER: Grouping based on previous laboratory results\",\" no intervention.',\n",
       "  'Yipeng Liu',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-06-01',\n",
       "  '2024-01-31'],\n",
       " ['NCT03569371',\n",
       "  'A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hidradenitis Suppurativa',\n",
       "  'DRUG: INCB054707',\n",
       "  'Incyte Corporation',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2018-07-17',\n",
       "  '2019-04-22'],\n",
       " ['NCT00678171',\n",
       "  'A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Degenerative Disc Disease',\n",
       "  'DEVICE: TLIF with a PEEK Spacer System and XIA Spinal System',\n",
       "  'Olympus Biotech Corporation',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-02',\n",
       "  '2010-03'],\n",
       " ['NCT02942771',\n",
       "  'A MAD Study of TT301/MW189 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy Adult Volunteers',\n",
       "  'DRUG: 0.075mg/kg TT301/MW189|DRUG: 0.15mg/kg TT301MW189|DRUG: 0.25mg/kg TT301/MW189|DRUG: 0.30mg/kg TT301/MW189|DRUG: Placebo',\n",
       "  'Linda Van Eldik',\n",
       "  \"Duke Clinical Research Institute|Alzheimer's Association\",\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2017-03-20',\n",
       "  '2018-06-04'],\n",
       " ['NCT03824171',\n",
       "  'Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'DRUG: Raloxifene 60mg/Cholecalciferol 800IU|DRUG: AD-102',\n",
       "  'Addpharma Inc.',\n",
       "  '',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-02-28',\n",
       "  '2019-04-08'],\n",
       " ['NCT04908371',\n",
       "  'Selective Trunk Block vs Hybrid Interscalene Supraclavicular BPB for Anaesthesia of the Entire Upper Extremity',\n",
       "  '',\n",
       "  'WITHDRAWN',\n",
       "  'Musculoskeletal Diseases or Conditions',\n",
       "  'PROCEDURE: Selective Trunk Block|PROCEDURE: Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)',\n",
       "  'Chinese University of Hong Kong',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2022-12',\n",
       "  '2024-01'],\n",
       " ['NCT05609071',\n",
       "  'Technology of Intracranial Pressure Estimation by Single-Channel EEG in Brain Disease',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Intracranial Pressure Increase|Brain Diseases',\n",
       "  '',\n",
       "  'Seoul National University Hospital',\n",
       "  '',\n",
       "  '10.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-03-22',\n",
       "  '2024-12-31'],\n",
       " ['NCT00502671',\n",
       "  'A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Colorectal Cancer',\n",
       "  'DRUG: capecitabine [Xeloda]',\n",
       "  'Hoffmann-La Roche',\n",
       "  '',\n",
       "  '228.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2007-07',\n",
       "  '2012-03'],\n",
       " ['NCT05372471',\n",
       "  'Efficacy of the Digital Platform for Diabetes Care Compared to Usual Care in Patients Diagnosed With Type 2 Diabetes.',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Type 2 Diabetes Treated With Insulin',\n",
       "  'OTHER: mHealth|OTHER: Usual Care',\n",
       "  'Hospital Universitario San Ignacio',\n",
       "  '',\n",
       "  '84.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2020-10-01',\n",
       "  '2021-08-31'],\n",
       " ['NCT02009371',\n",
       "  'A Clinical Study of Light Therapy on Depressive Episodes of Bipolar Disorder',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Depressive Episodes of Bipolar Disorder',\n",
       "  'DEVICE: Bright Light therapy|DEVICE: dim Red Light therapy',\n",
       "  'Peking University',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2015-07'],\n",
       " ['NCT02559271',\n",
       "  'Pediatric Refraction With SVOne Autorefractor',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ocular Refraction',\n",
       "  '',\n",
       "  'Smart Vision Labs',\n",
       "  'State University of New York College of Optometry',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2015-08',\n",
       "  '2015-12'],\n",
       " ['NCT00606671',\n",
       "  'Metabolic Disturbances in Polycystic Ovary Syndrome (PCOS)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Polycystic Ovary Syndrome',\n",
       "  '',\n",
       "  'Hvidovre University Hospital',\n",
       "  'Diabetesforeningen|Danish Hospital foundation for medical research. region Copenhagen\",\" The Faroe Islands and Greenland.|Aage Bangs Fond',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2004-02',\n",
       "  '2006-05'],\n",
       " ['NCT02772471',\n",
       "  'Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Brain Injuries|Intracranial Hypertension',\n",
       "  'DEVICE: HS-1000',\n",
       "  'HeadSense Medical',\n",
       "  'Oslo University Hospital',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2014-03',\n",
       "  '2014-12'],\n",
       " ['NCT05939271',\n",
       "  'Lower Extremity Amputations in Persons With Diabetes Mellitus in the Netherlands',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Lower Extremity Amputations|Diabetes Mellitus',\n",
       "  'PROCEDURE: lower extremity amputation',\n",
       "  'University Medical Center Groningen',\n",
       "  'Isala|Innofeet|Vektis health care information center|National Institute for Public Health and the Environment (RIVM)',\n",
       "  '2808.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-09-01',\n",
       "  '2023-12-01'],\n",
       " ['NCT03326271',\n",
       "  'Postoperative Periprosthetic Fractures in Hip Fracture Patients: Exeter vs Anatomic SP2 Lubinus Stem',\n",
       "  'PPFEvL',\n",
       "  'COMPLETED',\n",
       "  'Femoral Neck Fractures|Periprosthetic Fractures',\n",
       "  'PROCEDURE: Exeter stem|PROCEDURE: Lubinus SP2 stem',\n",
       "  'Sundsvall Hospital',\n",
       "  'Sunderby Hospital|Karolinska Institutet',\n",
       "  '2527.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2016-05-04',\n",
       "  '2017-10-11'],\n",
       " ['NCT04571671',\n",
       "  'Do müllerian Anomalies Affect Embryo Implantation?',\n",
       "  'AM',\n",
       "  'COMPLETED',\n",
       "  'Uterine Diseases',\n",
       "  'OTHER: Collect retrospectively data',\n",
       "  'IVI Vigo',\n",
       "  'Instituto Valenciano de Infertilidad\",\" IVI VALENCIA',\n",
       "  '5000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-01-20',\n",
       "  '2019-07-25'],\n",
       " ['NCT05441371',\n",
       "  'Antibacterial Effect of Paradontax Toothpaste',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Plaque Induced Gingivitis|Plaque\",\" Dental',\n",
       "  'OTHER: Toothpaste; Paradontax',\n",
       "  'University of Oslo',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-04-21',\n",
       "  '2022-07-12'],\n",
       " ['NCT00263471',\n",
       "  'Myopia Progression and the Effect of 7-Methylxanthine',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Myopia',\n",
       "  'DRUG: 7-methylxanthine',\n",
       "  'Trier Research Laboratories',\n",
       "  'Generalkonsul Einar Høyvalds Fond|Jørgen Bagenkop Nielsens Myopi-Fond|Chr. Andersen og hustru Ingeborg Andersen\", f. Schmidts legat (fond) oprettet af deres datter,\" frk. Lilli Ellen Andersen.',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION',\n",
       "  '2003-10',\n",
       "  '2006-03'],\n",
       " ['NCT05089071',\n",
       "  'Effect of Two Colonoscopy AI Systems for Colon Polyp Detection',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Adenoma|Colonoscopy|Sessile Serrated Adenoma',\n",
       "  'DEVICE: Assist by artificial intelligence system for colon polyp detection',\n",
       "  'Seoul National University Hospital',\n",
       "  'Seoul National University',\n",
       "  '3046.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2021-11-01',\n",
       "  '2022-12-31'],\n",
       " ['NCT02563171',\n",
       "  'Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Periodontitis',\n",
       "  'OTHER: non surgical periodontal treatment|OTHER: Gingival crevicular fluid collection',\n",
       "  'Umut BALLI',\n",
       "  '',\n",
       "  '76.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2014-07',\n",
       "  '2015-05'],\n",
       " ['NCT01836471',\n",
       "  'A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Asthma',\n",
       "  'DRUG: QAW039|DRUG: Placebo QAW039|DRUG: Fluticasone 250 mcg|DRUG: Fluticasone 100 mcg',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '',\n",
       "  '345.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-05',\n",
       "  '2016-02'],\n",
       " ['NCT03798171',\n",
       "  'Reduction of Exit Site Infection in Peritoneal Dialysis Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Peritoneal Dialysis Catheter Infection',\n",
       "  '',\n",
       "  'Tel-Aviv Sourasky Medical Center',\n",
       "  '',\n",
       "  '80.0',\n",
       "  'OTHER_GOV',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-05-15',\n",
       "  '2021-05-15'],\n",
       " ['NCT04851171',\n",
       "  'Semi-rigid Ureteroscopy Versus Flexible Ureteroscopy For the Treatment of Proximal Ureteric Stone',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Ureteric Stone|Stone Ureter',\n",
       "  'PROCEDURE: Flexible Ureteroscopy|PROCEDURE: Semi-rigid Ureteroscopy',\n",
       "  'Hamad Medical Corporation',\n",
       "  '',\n",
       "  '140.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-11-26',\n",
       "  '2023-01'],\n",
       " ['NCT04595071',\n",
       "  'Functional Outcomes of Voice Recognition Prosthesis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Prosthesis|Amputation|Prosthesis User',\n",
       "  'DEVICE: Voice Activated Prosthetic Interface (VAPI) Controller',\n",
       "  'Liberating Technologies\",\" Inc.',\n",
       "  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "  '4.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY',\n",
       "  '2019-11-13',\n",
       "  '2020-06-30'],\n",
       " ['NCT03837171',\n",
       "  'TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock',\n",
       "  'TRANSPORT',\n",
       "  'UNKNOWN',\n",
       "  'Septic Shock|Anemia|Cancer',\n",
       "  'BIOLOGICAL: Liberal Red blood cell transfusion|BIOLOGICAL: Restrictive Red blood cell transfusion',\n",
       "  'Assistance Publique - Hôpitaux de Paris',\n",
       "  '',\n",
       "  '260.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-03-24',\n",
       "  '2022-02-20'],\n",
       " ['NCT04467671',\n",
       "  'Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts',\n",
       "  'TEVG-2',\n",
       "  'RECRUITING',\n",
       "  'HLH - Hypoplastic Left Heart Syndrome|DORV|DILV - Double Inlet Left Ventricle|Mitral Atresia|Tricuspid Atresia|Unbalanced AV Canal|Single-ventricle|Heart Defects\",\" Congenital|Cardiovascular Abnormalities|Cardiovascular Diseases|Heart Diseases',\n",
       "  'COMBINATION_PRODUCT: Tissue Engineered Vascular Grafts',\n",
       "  \"Nationwide Children's Hospital\",\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)|Gunze Limited|National Institutes of Health (NIH)',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-07-15',\n",
       "  '2027-08'],\n",
       " ['NCT05287971',\n",
       "  'Standard of Care Lifestyle Support for Stage III NSCLC Patients',\n",
       "  'PERCUSSION',\n",
       "  'WITHDRAWN',\n",
       "  'Non Small Cell Lung Cancer',\n",
       "  'BEHAVIORAL: Lifestyle advice',\n",
       "  'Maastricht Radiation Oncology',\n",
       "  '',\n",
       "  '0.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-08-01',\n",
       "  '2025-05-01'],\n",
       " ['NCT00776971',\n",
       "  'Effect of Carbonated Soft Drinks on Appetite-Regulation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Diet',\n",
       "  'OTHER: Sugar-sweetened soft drink|OTHER: Aspartame-sweetened soft drink|OTHER: Semi-skimmed milk|OTHER: Water',\n",
       "  'Aarhus University Hospital',\n",
       "  'LG Life Sciences',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2007-11',\n",
       "  '2008-09'],\n",
       " ['NCT05026671',\n",
       "  'The Effect of The Use of a Videolaryngoscope and/or Stylet on Intubation Time in Obese Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Intubation Time',\n",
       "  'PROCEDURE: Endotracheal Tube Alone|PROCEDURE: Endotracheal Tube+ Stylet|PROCEDURE: Endotracheal Tube + Video-laryngoscope|PROCEDURE: Endotracheal tube + stylet with Video-laryngoscope',\n",
       "  'Karaman Training and Research Hospital',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2021-09-01',\n",
       "  '2022-04-30'],\n",
       " ['NCT05935371',\n",
       "  'Consequences of Obstetric Anal Sphincter Injuries on Maternal Psychology and Relationship Experience',\n",
       "  'COMPaRE',\n",
       "  'RECRUITING',\n",
       "  'Obstetric Complication|Obstetric Trauma|Perineal Tear|Incontinence|Mental Health Impairment|Relation\", Family|Relation,\" Mother-Child',\n",
       "  '',\n",
       "  'London North West Healthcare NHS Trust',\n",
       "  'Imperial College Healthcare NHS Trust',\n",
       "  '87.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10-26',\n",
       "  '2025-10'],\n",
       " ['NCT00059371',\n",
       "  'Male Circumcision and HIV Rates in Kenya',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections',\n",
       "  'PROCEDURE: male circumcision',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '2887.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2002-02',\n",
       "  '2006-12'],\n",
       " ['NCT01629771',\n",
       "  'Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lymphatic Filariasis',\n",
       "  '',\n",
       "  'Northwestern University',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-05',\n",
       "  '2012-06'],\n",
       " ['NCT01072071',\n",
       "  'The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Intra-Abdominal Hypertension',\n",
       "  'DRUG: furosemide',\n",
       "  'Ziekenhuis Netwerk Antwerpen (ZNA)',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2010-02',\n",
       "  '2012-03'],\n",
       " ['NCT02032771',\n",
       "  'Impact of M22 Synergistic Sequential Treatment (SST)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Improvement of Wrinkles/Elastosis and/or Pigmentation',\n",
       "  'DEVICE: M22 IPL and ResurFX',\n",
       "  'Lumenis Be Ltd.',\n",
       "  '',\n",
       "  '33.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-01',\n",
       "  '2016-02'],\n",
       " ['NCT05765071',\n",
       "  'Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Chronic Exertional Compartment Syndrome',\n",
       "  'BIOLOGICAL: Botulinum toxin A|BIOLOGICAL: Normal saline',\n",
       "  'University of Calgary',\n",
       "  'Canadian Academy of Sport and Exercise Medicine (CASEM)|Kinesis Medical Centre Inc.',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-06-01',\n",
       "  '2024-06'],\n",
       " ['NCT03761771',\n",
       "  'Artificial Intelligence Identifying Polyps in Real-world Colonoscopy',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Sensitivity of the ADS in Identifying Polyps in Real-world Colonoscopy|Mean Number of Polyps Per Colonoscopy for Colonoscopists and Colonoscopists + ADS',\n",
       "  'DEVICE: colonoscopy withdrawal with the ADS monitoring',\n",
       "  'Zhaoshen Li',\n",
       "  '',\n",
       "  '209.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-11-01',\n",
       "  '2018-12-10'],\n",
       " ['NCT03297671',\n",
       "  'The Prevention of Rh Disease of Newborns in Pakistan',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rhesus Disease|Anti-D (Rh) Antibodies Affecting Care of Mother',\n",
       "  'DRUG: RhIg prophylaxis|DEVICE: ELDONCARD|DIAGNOSTIC_TEST: ELDONCARD Test',\n",
       "  'Aga Khan University',\n",
       "  'The Hospital for Sick Children|Grand Challenges Canada',\n",
       "  '1654.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2018-06-27',\n",
       "  '2020-02-28'],\n",
       " ['NCT00865371',\n",
       "  'A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Abrika Bupropion 150 mg Extended-Released Tablet|DRUG: Wellbutrin SR® 150 mg Extended-Release Tablet\",\" single dose',\n",
       "  'Actavis Inc.',\n",
       "  '',\n",
       "  '26.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ',\n",
       "  '2004-09',\n",
       "  '2004-09'],\n",
       " ['NCT00420771',\n",
       "  'Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Benzodiazepine Dependence|Opioid Dependence',\n",
       "  'DRUG: Gabapentin|DRUG: Placebo',\n",
       "  'New York State Psychiatric Institute',\n",
       "  'National Institute on Drug Abuse (NIDA)',\n",
       "  '19.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-01',\n",
       "  '2011-01'],\n",
       " ['NCT03175471',\n",
       "  'MRI Based Biomarkers in Pediatric Autoimmune Liver Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Autoimmune Liver Disease|Primary Sclerosing Cholangitis|Autoimmune Hepatitis',\n",
       "  '',\n",
       "  'Children\\'s Hospital Medical Center\",\" Cincinnati',\n",
       "  '',\n",
       "  '115.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2017-01-17',\n",
       "  '2027-01-30'],\n",
       " ['NCT02420171',\n",
       "  'Adding Insulin to IVF Culture Media Significantly Improve Outcome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infertility',\n",
       "  'OTHER: Adding insulin to In Vitro culture media',\n",
       "  'Ibn Sina Hospital',\n",
       "  'Banon IVF Center Assiut\",\" Egypt',\n",
       "  '360.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2015-01',\n",
       "  '2015-12'],\n",
       " ['NCT02768571',\n",
       "  'Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stroke',\n",
       "  'DRUG: Cerebrolysin|DRUG: Placebo',\n",
       "  'Samsung Medical Center',\n",
       "  'Ever Neuro Pharma GmbH',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2016-03-14',\n",
       "  '2019-02-14'],\n",
       " ['NCT00563771',\n",
       "  'Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Hyperuricemia',\n",
       "  'DRUG: Rasburicase',\n",
       "  'Sanofi',\n",
       "  '',\n",
       "  '38.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2003-03',\n",
       "  '2004-01'],\n",
       " ['NCT02226471',\n",
       "  'Serum CTRP3 and RBP4 Levels in Obesity and Hypertension',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity|Hypertension',\n",
       "  '',\n",
       "  'Third Military Medical University',\n",
       "  '',\n",
       "  '2000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2012-03',\n",
       "  '2014-02'],\n",
       " ['NCT04965571',\n",
       "  \"Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients\",\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Wilson Disease|Generalized Epilepsy',\n",
       "  'GENETIC: genetic test',\n",
       "  'Second Affiliated Hospital\", School of Medicine,\" Zhejiang University',\n",
       "  '',\n",
       "  '13.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-09-01',\n",
       "  '2019-03-01'],\n",
       " ['NCT00346671',\n",
       "  'Effects of Reiki on Stress',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Stress',\n",
       "  'OTHER: Rest|OTHER: Sham|OTHER: Reiki',\n",
       "  'The Cleveland Clinic',\n",
       "  'National Center for Complementary and Integrative Health (NCCIH)',\n",
       "  '257.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2006-01',\n",
       "  '2010-06'],\n",
       " ['NCT04647071',\n",
       "  'Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Immunity',\n",
       "  'DIETARY_SUPPLEMENT: Garlic and onion concentrate|DIETARY_SUPPLEMENT: Control',\n",
       "  'DOMCA S.A.',\n",
       "  '',\n",
       "  '66.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2020-11-16',\n",
       "  '2022-01-31'],\n",
       " ['NCT01861171',\n",
       "  'Effect of Green Tea in Obese Pre-hypertensive Women',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obese|Hypertension',\n",
       "  'DIETARY_SUPPLEMENT: Green Tea',\n",
       "  'Rio de Janeiro State University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2010-07',\n",
       "  '2012-09'],\n",
       " ['NCT04301271',\n",
       "  'Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression',\n",
       "  'SIMCODE',\n",
       "  'RECRUITING',\n",
       "  'Depressive Disorder\",\" Major|Obesity',\n",
       "  'DRUG: Simvastatin 40mg|DRUG: Placebo oral tablet',\n",
       "  'Charite University\", Berlin,\" Germany',\n",
       "  'NeuroCure Clinical Research Center\", Charite,\" Berlin|University Medical Center Goettingen',\n",
       "  '160.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-08-13',\n",
       "  '2025-02'],\n",
       " ['NCT05268471',\n",
       "  'Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Obstructive Sleep Apnea of Adult',\n",
       "  'DEVICE: Positional device (PD)|DEVICE: Continuos Positive Airway Pressure (CPAP)',\n",
       "  'Hospital Universitario Ramon y Cajal',\n",
       "  'Philips Healthcare',\n",
       "  '154.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-10-01',\n",
       "  '2024-12-01'],\n",
       " ['NCT05399771',\n",
       "  'Radiofrequency Hyperthermia Safety Study',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Chronic Pain|Soft Tissue Injuries|Wound Heal|Blood Flow',\n",
       "  'DEVICE: Laser Doppler|DEVICE: Radiofrequency Heating System|DEVICE: Thermal Imaging|OTHER: Healthcare Questionnaire & Measurement',\n",
       "  'Wake Forest University Health Sciences',\n",
       "  'Thermofield',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-06-27',\n",
       "  '2024-04'],\n",
       " ['NCT05308771',\n",
       "  '\"\"To Investigate the Use of a New Syringe \"\"\"\"Visual Pressure Control (VPC)\"\"\"\" for Epidural Anesthesia in Children Surgery\"\"',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Abdominal Hernia|Abdominal Wall Defect|Abdominal Neoplasm|Urogenital Disease|Urologic Neoplasms|Thoracic Diseases|Lung Diseases',\n",
       "  'DEVICE: VPC syringe',\n",
       "  'Centre Hospitalier Universitaire de Tivoli',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-03-25',\n",
       "  '2022-09'],\n",
       " ['NCT05403671',\n",
       "  'Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer Survivor',\n",
       "  'OTHER: Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer',\n",
       "  'Turku University Hospital',\n",
       "  'Lounais-Suomen Syöpäyhdistys',\n",
       "  '50.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2022-09-01',\n",
       "  '2024-05-31'],\n",
       " ['NCT01147471',\n",
       "  'Flail Chest - Rib Fixation Study',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Flail Chest',\n",
       "  'DEVICE: operative rib fixation|PROCEDURE: operative rib fixation surgery',\n",
       "  'Virginia Commonwealth University',\n",
       "  'Synthes Inc.',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ',\n",
       "  '2010-09',\n",
       "  '2014-08'],\n",
       " ['NCT04046471',\n",
       "  'Weight Loss Physical Disabilities',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Physical Disability',\n",
       "  'DIETARY_SUPPLEMENT: enhanced Stop Light Diet|BEHAVIORAL: Group Remote|BEHAVIORAL: Individual In-Person',\n",
       "  'University of Kansas Medical Center',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '128.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-02-01',\n",
       "  '2024-06-20'],\n",
       " ['NCT03709771',\n",
       "  'Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Renal Cell Carcinoma|Hypertension|Melanoma|Cancer',\n",
       "  'DIAGNOSTIC_TEST: Ambulatory Blood Pressure Measurement',\n",
       "  'Vanderbilt University Medical Center',\n",
       "  '',\n",
       "  '2.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2020-01-09',\n",
       "  '2020-10-01'],\n",
       " ['NCT00995371',\n",
       "  'Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Lumbar Spinal Stenosis',\n",
       "  'DEVICE: MILD® (Minimally Invasive Lumbar Decompression)|DRUG: Epidural Steroid Injection',\n",
       "  'Coastal Orthopedics & Sports Medicine',\n",
       "  'Vertos Medical\",\" Inc.',\n",
       "  '38.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2009-08',\n",
       "  '2013-05'],\n",
       " ['NCT01075971',\n",
       "  'Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Opioid Dependency',\n",
       "  'DRUG: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|DRUG: Buprenorphine hydrochloride fast dissolving tablet (FDT)',\n",
       "  'Indivior Inc.',\n",
       "  'Reckitt Benckiser LLC',\n",
       "  '52.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2005-09',\n",
       "  '2005-11'],\n",
       " ['NCT01790971',\n",
       "  'Spinal Morphine for Patients With Obstructive Sleep Apnea',\n",
       "  '',\n",
       "  'SUSPENDED',\n",
       "  'Obstructive Sleep Apnea',\n",
       "  'DRUG: Intrathecal Morphine|DRUG: No Intrathecal Morphine',\n",
       "  'University Health Network\",\" Toronto',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01',\n",
       "  '2020-08'],\n",
       " ['NCT01242371',\n",
       "  'Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Schizophrenia|Schizoaffective Disorder',\n",
       "  'DIETARY_SUPPLEMENT: Probiotic Supplement|DIETARY_SUPPLEMENT: Identical-appearing Placebo',\n",
       "  'Sheppard Pratt Health System',\n",
       "  'Stanley Medical Research Institute',\n",
       "  '65.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2010-08',\n",
       "  '2012-08'],\n",
       " ['NCT03618771',\n",
       "  'A Functional Comparison of Two TKR Designs',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Knee Osteoarthritis',\n",
       "  'DEVICE: Total knee arthroplasty',\n",
       "  'Manchester University NHS Foundation Trust',\n",
       "  'Medacta International SA',\n",
       "  '170.0',\n",
       "  'OTHER_GOV',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2019-02-06',\n",
       "  '2024-08-01'],\n",
       " ['NCT04791371',\n",
       "  'Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes',\n",
       "  'REACH',\n",
       "  'RECRUITING',\n",
       "  'Type 2 Diabetes|Overweight and Obesity',\n",
       "  'BEHAVIORAL: Cardiovascular exercise',\n",
       "  'University of Colorado\",\" Denver',\n",
       "  'University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '150.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-06-17',\n",
       "  '2027-12-01'],\n",
       " ['NCT00017771',\n",
       "  'Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'HIV Infections|Peripheral Nervous System Disease',\n",
       "  '',\n",
       "  'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  '',\n",
       "  '100.0',\n",
       "  'NIH',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2001-06',\n",
       "  '2004-07'],\n",
       " ['NCT00659971',\n",
       "  'Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Oral Candidiasis',\n",
       "  'DRUG: PAC113',\n",
       "  'Pacgen Biopharmaceuticals Corporation',\n",
       "  'Quintiles\",\" Inc.',\n",
       "  '223.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2008-01',\n",
       "  '2008-06'],\n",
       " ['NCT05328271',\n",
       "  'A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion',\n",
       "  'BBA',\n",
       "  'COMPLETED',\n",
       "  'Absorption; Chemicals',\n",
       "  'DIETARY_SUPPLEMENT: Beta-Aminoisobutyric Acid',\n",
       "  'Lindenwood University',\n",
       "  'NNB Nutrition',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: OTHER',\n",
       "  '2020-11-20',\n",
       "  '2022-02-01'],\n",
       " ['NCT02595671',\n",
       "  'B-slim\",\" a Multi-source Digital Super Coach for Sustainable Weight Loss',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Obesity',\n",
       "  'OTHER: Digital Super Coach|OTHER: Conventional face to face PA & dietitian|OTHER: Digital Super Coach + minimal coaching|OTHER: Waiting Group',\n",
       "  'Universitaire Ziekenhuizen KU Leuven',\n",
       "  'KU Leuven|iMinds|Brand New Health|Yorbody|Delhaize',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2015-10',\n",
       "  '2016-04'],\n",
       " ['NCT05688371',\n",
       "  'Dexmedetomidine Plus Low Dose Morphine Versus Standard Dose of Morphine in PCA in Children .',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'PCA|Children|Dexmedetomidine|Morphine',\n",
       "  'DRUG: standard dose morphine|DRUG: low dose morphine plus dexmedetomidine',\n",
       "  'Beni-Suef University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2023-02-01',\n",
       "  '2024-03'],\n",
       " ['NCT05737771',\n",
       "  'To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'FDC|Diabetes Mellitus\",\" Type 2',\n",
       "  'DRUG: DWC202213|DRUG: DWJ1563|DRUG: DWP16001',\n",
       "  'Daewoong Pharmaceutical Co. LTD.',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-01-25',\n",
       "  '2023-06-30'],\n",
       " ['NCT00132171',\n",
       "  'Helicobacter Pylori Eradication With a New Sequential Treatment',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Helicobacter Pylori Infection|Non Ulcer Dyspepsia|Duodenal Ulcer|Gastric Ulcer|Chronic Active Gastritis|Gastritis',\n",
       "  'DRUG: Sequential therapy',\n",
       "  'IRCCS Azienda Ospedaliero-Universitaria di Bologna',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2001-01',\n",
       "  '2001-12'],\n",
       " ['NCT05499871',\n",
       "  'Effect of a Gait Retraining Intervention and a Minimalist Footwear Transition on Foot-ankle Strength\",\" Running Economy and Injury in Endurance Runners.',\n",
       "  '',\n",
       "  'ENROLLING_BY_INVITATION',\n",
       "  'Running|Wounds and Injuries|Oxygen Consumption',\n",
       "  'BEHAVIORAL: Gait retraining intervention|DEVICE: Transition to minimalist footwear.',\n",
       "  'University of Liege',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2022-06-01',\n",
       "  '2024-09-30'],\n",
       " ['NCT01521871',\n",
       "  'Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors',\n",
       "  'TG-CYANO',\n",
       "  'COMPLETED',\n",
       "  'Skin Closure of Surgical Incisions by Tissue Glue vs Suture',\n",
       "  'PROCEDURE: Skin wound closure by tissue glue|PROCEDURE: Skin wound closure by conventional suture + dressing',\n",
       "  'Oslo University Hospital',\n",
       "  '',\n",
       "  '64.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-01',\n",
       "  '2013-02'],\n",
       " ['NCT04049071',\n",
       "  'TARGET GCAT Registry',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Giant Cell Arteritis',\n",
       "  '',\n",
       "  'University of Leeds',\n",
       "  'University of Oxford|Hoffmann-La Roche',\n",
       "  '80.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2019-05-13',\n",
       "  '2020-06-30'],\n",
       " ['NCT02841371',\n",
       "  'Early Screening and Diagnosis of CKD',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Kidney; Disease (Functional)|Chronic Kidney Disease',\n",
       "  'RADIATION: 99mTc-DTPA',\n",
       "  'Nanjing First Hospital\",\" Nanjing Medical University',\n",
       "  '',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2009-08-01',\n",
       "  '2025-12-31'],\n",
       " ['NCT05889871',\n",
       "  'A Randomized\", Controlled,\" Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'HR+/HER2-breast Cancer',\n",
       "  'DRUG: Standard endocrine therapy plus Apatinib',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '916.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2023-06-01',\n",
       "  '2026-06-01'],\n",
       " ['NCT02234271',\n",
       "  'Plan A Birth Control: Randomized Controlled Trial of a Mobile Health Application for Contraception Information',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Mobile Applications|Contraception|Contraception Behavior',\n",
       "  'OTHER: Mobile Health Application|OTHER: Health Educator Counseling',\n",
       "  'University of California\",\" Los Angeles',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ',\n",
       "  '2012-09',\n",
       "  '2013-08'],\n",
       " ['NCT06067971',\n",
       "  'Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery\",\" by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)',\n",
       "  'ENDORA2',\n",
       "  'RECRUITING',\n",
       "  'Myoma;Uterus|Adenomyoma of Uterus',\n",
       "  'DEVICE: Laparoscopic surgery with augmented reality device',\n",
       "  'University Hospital\",\" Clermont-Ferrand',\n",
       "  '',\n",
       "  '40.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE',\n",
       "  '2023-03-29',\n",
       "  '2024-03-29'],\n",
       " ['NCT03730571',\n",
       "  'The AbsorbaSeal Vascular Closure Device Trial',\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  'Peripheral Arterial Disease',\n",
       "  'DEVICE: AbsorbaSeal 6Fr Vascular Closure Device',\n",
       "  'ID3 Medical',\n",
       "  'CyndRx\",\" LLC',\n",
       "  '9.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH',\n",
       "  '2017-08-16',\n",
       "  '2019-04-11'],\n",
       " ['NCT06160271',\n",
       "  'Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis',\n",
       "  'HEFITEP',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Non-alcoholic Steatohepatitis',\n",
       "  'DRUG: PET scan of 68Ga-FAPI',\n",
       "  'Central Hospital\", Nancy,\" France',\n",
       "  '',\n",
       "  '72.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2024-09-01',\n",
       "  '2027-06-01'],\n",
       " ['NCT05281471',\n",
       "  'Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime\",\" GOG-3076)',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Platinum-resistant Ovarian Cancer|Platinum-refractory Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|High-grade Serous Ovarian Cancer|Endometrioid Ovarian Cancer|Ovarian Clear Cell Carcinoma',\n",
       "  'BIOLOGICAL: olvimulogene nanivacirepvec|DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin|DRUG: Non-platinum chemotherapy: Physician\\'s Choice of gemcitabine\", taxane (paclitaxel,\" docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|DRUG: Bevacizumab (or biosimilar)',\n",
       "  'Genelux Corporation',\n",
       "  'GOG Foundation',\n",
       "  '186.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-31',\n",
       "  '2026-10'],\n",
       " ['NCT02002871',\n",
       "  'Blue Light for Treating Eczema',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Eczema',\n",
       "  'DEVICE: PSO-CT02 device',\n",
       "  'Philips Electronics Nederland BV',\n",
       "  '',\n",
       "  '21.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-10',\n",
       "  '2014-03'],\n",
       " ['NCT05817071',\n",
       "  'Results of Arthroscopic Massive Rotator Cuff Tears Repair With or Without Using Long Head of Biceps Tendon',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Rotator Cuff Tears',\n",
       "  'PROCEDURE: Arthroscopic massive rotator cuff repair|PROCEDURE: Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon',\n",
       "  'Ain Shams University',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT',\n",
       "  '2022-12-15',\n",
       "  '2024-01-14'],\n",
       " ['NCT02669771',\n",
       "  'Long-Term Specified Drug Use-Results Survey for Xtandi Capsule',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Castration-resistant Prostate Cancer',\n",
       "  'DRUG: enzalutamide',\n",
       "  'Astellas Pharma Inc',\n",
       "  'Pfizer',\n",
       "  '1018.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2014-11-30',\n",
       "  '2018-11-30'],\n",
       " ['NCT05463471',\n",
       "  'Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Shock',\n",
       "  'DRUG: Compound sodium acetate ringer injection|DRUG: Albumin',\n",
       "  'Peking Union Medical College Hospital',\n",
       "  '',\n",
       "  '500.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2022-08-01',\n",
       "  '2027-12-12'],\n",
       " ['NCT02173171',\n",
       "  'Registry Study for Talimogene Laherparepvec',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial',\n",
       "  'OTHER: Information collection',\n",
       "  'Amgen',\n",
       "  '',\n",
       "  '185.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2010-04-27',\n",
       "  '2021-09-23'],\n",
       " ['NCT05677971',\n",
       "  'Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Alpha1-Antitrypsin Deficiency',\n",
       "  'DRUG: Fazirsiran Injection|OTHER: Placebo',\n",
       "  'Takeda',\n",
       "  'Takeda Development Center Americas\",\" Inc.',\n",
       "  '160.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2023-03-06',\n",
       "  '2029-03-31'],\n",
       " ['NCT04752371',\n",
       "  \"A Study to Evaluate Camoteskimab in Participants With Still's Disease\",\n",
       "  '',\n",
       "  'TERMINATED',\n",
       "  \"Adult Onset Still's Disease\",\n",
       "  'DRUG: Camoteskimab (CERC-007\", AVTX-007,\" AEVI-007)',\n",
       "  'Apollo Therapeutics Ltd',\n",
       "  '',\n",
       "  '5.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-03-25',\n",
       "  '2022-05-24'],\n",
       " ['NCT01241071',\n",
       "  'Effects of Myofascial Release on Pain\",\" Disability and Electromyography of Erector Spinae in Chronic Low Back Pain',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Low Back Pain|Disability|Motor Activity|Range of Motion',\n",
       "  'OTHER: myofascial treatment|OTHER: Placebo',\n",
       "  'Cardenal Herrera University',\n",
       "  'Hospital Arnau de Vilanova',\n",
       "  '54.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2011-01',\n",
       "  '2013-03'],\n",
       " ['NCT02065271',\n",
       "  'Herbal Preparation and Glucose Homeostasis',\n",
       "  'Herbie',\n",
       "  'COMPLETED',\n",
       "  'Glucose Tolerance|Lipid Homeostasis|Vascular Function|Inflammation',\n",
       "  'DIETARY_SUPPLEMENT: herbal supplement|OTHER: placebo supplement',\n",
       "  'Wageningen University',\n",
       "  '',\n",
       "  '22.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: PREVENTION',\n",
       "  '2013-09',\n",
       "  '2014-02'],\n",
       " ['NCT03991871',\n",
       "  'HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study',\n",
       "  'HARTEC',\n",
       "  'UNKNOWN',\n",
       "  'Cardiac Rehabilitation|Angiogenesis|Refractory Angina',\n",
       "  'DEVICE: External Counter Pulsation (ECP) therapy',\n",
       "  'National Cardiovascular Center Harapan Kita Hospital Indonesia',\n",
       "  '',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-07-01',\n",
       "  '2020-08-01'],\n",
       " ['NCT00102271',\n",
       "  'Nitrite Infusion Studies',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Healthy',\n",
       "  'DRUG: Oxypurinol|DRUG: Sodium Nitrite',\n",
       "  'National Heart\", Lung,\" and Blood Institute (NHLBI)',\n",
       "  '',\n",
       "  '36.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT',\n",
       "  '2005-01-19',\n",
       "  '2011-04-12'],\n",
       " ['NCT01871571',\n",
       "  'Bevacizumab\", Fluorouracil, Leucovorin Calcium,\" and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer',\n",
       "  'BIOLOGICAL: bevacizumab|DRUG: oxaliplatin|DRUG: leucovorin calcium|DRUG: fluorouracil|OTHER: laboratory biomarker analysis',\n",
       "  'University of Southern California',\n",
       "  'National Cancer Institute (NCI)',\n",
       "  '17.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-08-02',\n",
       "  '2023-06-24'],\n",
       " ['NCT01573871',\n",
       "  'Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Infant|Gastrointestinal Intolerance',\n",
       "  'OTHER: Experimental Hydrolyzed infant formula',\n",
       "  'Abbott Nutrition',\n",
       "  '',\n",
       "  '25.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2012-02',\n",
       "  '2012-09'],\n",
       " ['NCT01082471',\n",
       "  'An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Postoperative Pain',\n",
       "  'DRUG: Morphine 6-glucuronide|DRUG: Morphine',\n",
       "  'Paion UK Ltd.',\n",
       "  'Chiltern International Ltd.|HFL Ltd.',\n",
       "  '517.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-11',\n",
       "  '2006-12'],\n",
       " ['NCT04913571',\n",
       "  'Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study',\n",
       "  'TEMPLATE',\n",
       "  'UNKNOWN',\n",
       "  'Triple Negative Breast Cancer',\n",
       "  'DRUG: Eribulin|DRUG: Tislelizumab',\n",
       "  'Fudan University',\n",
       "  '',\n",
       "  '265.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2021-05-27',\n",
       "  '2023-06-01'],\n",
       " ['NCT03025971',\n",
       "  'Safety & Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Aortic Valve Disease',\n",
       "  'DEVICE: J-Valve Transcatheter Aortic valve replacement',\n",
       "  'JC Medical\",\" Inc.',\n",
       "  '',\n",
       "  '107.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-03',\n",
       "  '2020-04'],\n",
       " ['NCT00799071',\n",
       "  'Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)',\n",
       "  'iPOD',\n",
       "  'COMPLETED',\n",
       "  'Chronic Granulomatous Disease',\n",
       "  'DRUG: posaconazole (PSZ)',\n",
       "  'Radboud University Medical Center',\n",
       "  '',\n",
       "  '12.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2009-02',\n",
       "  '2010-08'],\n",
       " ['NCT00584571',\n",
       "  'SAT vs Escitalopram for Rectal Hypersensitivity',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Rectal Hypersensitivity|Irritable Bowel Syndrome-Constipation',\n",
       "  'PROCEDURE: Sensory Adaptation Training|DRUG: Escitalopram Therapy',\n",
       "  'Augusta University',\n",
       "  'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  '55.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2007-12',\n",
       "  '2019-12-31'],\n",
       " ['NCT00390871',\n",
       "  'Acute Neurological ICU Sedation Trial (ANIST)',\n",
       "  'ANIST',\n",
       "  'COMPLETED',\n",
       "  'Sedation',\n",
       "  'DRUG: Fentanyl/Dexmedetomidine|DRUG: Fentanyl/Propofol|DRUG: Fentanyl',\n",
       "  'Johns Hopkins University',\n",
       "  '',\n",
       "  '35.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2005-05',\n",
       "  '2007-12'],\n",
       " ['NCT04706871',\n",
       "  'Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Functional Dyspepsia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Functional Dyspepsia',\n",
       "  'DEVICE: taVNS|DEVICE: tnVNS',\n",
       "  'Beijing Tongren Hospital',\n",
       "  '',\n",
       "  '90.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2018-07-01',\n",
       "  '2020-01-01'],\n",
       " ['NCT05200871',\n",
       "  'Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)',\n",
       "  'HONUS',\n",
       "  'COMPLETED',\n",
       "  'Focal Segmental Glomerulosclerosis|Immunoglobulin A Nephropathy',\n",
       "  '',\n",
       "  'Travere Therapeutics\",\" Inc.',\n",
       "  '',\n",
       "  '290.0',\n",
       "  'INDUSTRY',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2022-02-05',\n",
       "  '2023-10-31'],\n",
       " ['NCT04160871',\n",
       "  '\"\"\"\"\"\"Family Connections\"\"\"\": a Program for Relatives of People With Borderline Personality Disorder\"\"',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Relatives',\n",
       "  'BEHAVIORAL: Family Connections|BEHAVIORAL: Treatment As Usual',\n",
       "  'Universitat Jaume I',\n",
       "  'University of Valencia',\n",
       "  '124.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-11-15',\n",
       "  '2020-09'],\n",
       " ['NCT01924871',\n",
       "  'Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Deep Extubation',\n",
       "  'DRUG: Desflurane with remifentanil|DRUG: Desflurane',\n",
       "  'Chung-Ang University Hosptial\",\" Chung-Ang University College of Medicine',\n",
       "  '',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2013-07',\n",
       "  '2014-03'],\n",
       " ['NCT04532671',\n",
       "  'Evaluation of Clinical Performance of 3D Printed Polyether Ether Ketone (PEEK) Inlays',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Occlusal Caries',\n",
       "  'OTHER: Poly ether ether ketone (PEEK)|OTHER: CADCAM Poly ether ether ketone (PEEK)|OTHER: indirect resin composite',\n",
       "  'Cairo University',\n",
       "  '',\n",
       "  '20.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-10-01',\n",
       "  '2022-10-01'],\n",
       " ['NCT01424371',\n",
       "  'Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Influenza',\n",
       "  '',\n",
       "  'Fraser Health',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '1000.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2011-11',\n",
       "  '2013-06'],\n",
       " ['NCT02829671',\n",
       "  'Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas',\n",
       "  'SOLSTIS',\n",
       "  'COMPLETED',\n",
       "  'Major Depressive Disorders',\n",
       "  'OTHER: Clinical and biological assessment',\n",
       "  'University Hospital\",\" Montpellier',\n",
       "  '',\n",
       "  '600.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER',\n",
       "  '2016-10-11',\n",
       "  '2020-06-24'],\n",
       " ['NCT01824771',\n",
       "  'Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Kidney Injury\",\" Acute',\n",
       "  'OTHER: Plasma lactate were measured',\n",
       "  'First Affiliated Hospital\",\" Sun Yat-Sen University',\n",
       "  '',\n",
       "  '15.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2013-03-03',\n",
       "  '2015-03-20'],\n",
       " ['NCT06035471',\n",
       "  'Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study',\n",
       "  '',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Pathological Response Rate\",\" Circulating Tumour DNA',\n",
       "  'DIAGNOSTIC_TEST: MeD-seq',\n",
       "  'Erasmus Medical Center',\n",
       "  '',\n",
       "  '75.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-10-01',\n",
       "  '2027-06-01'],\n",
       " ['NCT02317471',\n",
       "  'Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Gastric Carcinoma',\n",
       "  'BIOLOGICAL: autologous gp96 vaccination|DRUG: Oxaliplatin+S-1',\n",
       "  'Chinese PLA General Hospital',\n",
       "  'Cure&Sure Biotech Co.\",\" LTD',\n",
       "  '45.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2014-11',\n",
       "  '2017-12'],\n",
       " ['NCT01244971',\n",
       "  'Exercise and Acarbose in Type 2 Diabetes',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Diabetes Mellitus Type 2',\n",
       "  'DRUG: Acarbose|BEHAVIORAL: Exercise|OTHER: Exercise + Acarbose',\n",
       "  'Karolinska Institutet',\n",
       "  'The Swedish Research Council|Bayer',\n",
       "  '62.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2004-01',\n",
       "  ''],\n",
       " ['NCT01634971',\n",
       "  'External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)',\n",
       "  'EDIDPD',\n",
       "  'UNKNOWN',\n",
       "  'Postoperative Fistula|Complications of Surgical and Medical Care: General Terms',\n",
       "  'PROCEDURE: Internal Drainage of Pancreatic Duct after pancreatomy',\n",
       "  'Tianjin Medical University Cancer Institute and Hospital',\n",
       "  '',\n",
       "  '120.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2012-05',\n",
       "  '2016-12'],\n",
       " ['NCT04654871',\n",
       "  'Effects of Glucosamine and Chondroitin Sulfate Supplementation in Addition to Resistance Exercise Training and Manual Therapy in Patients With Knee Osteoarthritis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoarthritis|Osteoarthritis\",\" Knee',\n",
       "  'DIETARY_SUPPLEMENT: Chondroitin Sulfate|PROCEDURE: Resistance exercise training|PROCEDURE: Manual therapy / Joint Mobilization|PROCEDURE: THE therapy',\n",
       "  'Foundation University Islamabad',\n",
       "  '',\n",
       "  '24.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT',\n",
       "  '2020-01-01',\n",
       "  '2020-11-01'],\n",
       " ['NCT03547271',\n",
       "  'Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Meningococcal Infections',\n",
       "  'BIOLOGICAL: MenACYW conjugate vaccine|BIOLOGICAL: Meningococcal group A\", C, W-135,\" and Y conjugate vaccine|BIOLOGICAL: DTaP-IPV-HB-Hib vaccine|BIOLOGICAL: Pneumococcal vaccine (13-valent)|BIOLOGICAL: Pneumococcal vaccine (10-valent)|BIOLOGICAL: MMR vaccine',\n",
       "  'Sanofi Pasteur\",\" a Sanofi Company',\n",
       "  '',\n",
       "  '1660.0',\n",
       "  'INDUSTRY',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION',\n",
       "  '2018-12-14',\n",
       "  '2023-05-17'],\n",
       " ['NCT03089671',\n",
       "  'Ureteric Visualization: Vitamin B Vs 5% Dextrose in Water',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Pelvic Floor Disorders|Ureter; Kink',\n",
       "  'OTHER: Vitamin B (riboflavin\",\" vitamin B2)|OTHER: 5% Dextrose in Water (D5W)',\n",
       "  'Mount Sinai Hospital\",\" Canada',\n",
       "  \"Sunnybrook Health Sciences Centre|Women's College Hospital\",\n",
       "  '238.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2017-12-07',\n",
       "  '2021-07-21'],\n",
       " ['NCT04289571',\n",
       "  'Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Cone-Rod Degeneration|Rod-Cone Degeneration',\n",
       "  'DIAGNOSTIC_TEST: VR Motility Tool',\n",
       "  'National Eye Institute (NEI)',\n",
       "  '',\n",
       "  '165.0',\n",
       "  'NIH',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-07-25',\n",
       "  '2030-12-31'],\n",
       " ['NCT01473771',\n",
       "  'Caring Letters for Military Suicide Prevention',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Suicide|Suicide\",\" Attempted',\n",
       "  'BEHAVIORAL: Caring Letter (email)',\n",
       "  'National Center for Telehealth and Technology',\n",
       "  'United States Department of Defense|U.S. Army Medical Research and Development Command',\n",
       "  '1319.0',\n",
       "  'FED',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION',\n",
       "  '2011-11',\n",
       "  '2018-08'],\n",
       " ['NCT03961971',\n",
       "  'Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Glioblastoma Multiforme',\n",
       "  'DRUG: MBG453',\n",
       "  'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '16.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-02-18',\n",
       "  '2025-09'],\n",
       " ['NCT02232971',\n",
       "  'Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes',\n",
       "  'GluST1',\n",
       "  'UNKNOWN',\n",
       "  'Diabetes Mellitus\",\" Type 1',\n",
       "  'DRUG: Glucagon|OTHER: Isotonic saline solution',\n",
       "  'Hvidovre University Hospital',\n",
       "  'The Novo Nordic Foundation|University of Copenhagen',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE',\n",
       "  '2014-09',\n",
       "  '2015-07'],\n",
       " ['NCT03829371',\n",
       "  'STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA',\n",
       "  '',\n",
       "  'RECRUITING',\n",
       "  'Multiple Myeloma',\n",
       "  'DRUG: Velcade|DRUG: Melphalan|DRUG: Prednisone|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Daratumumab',\n",
       "  'University of Turin\",\" Italy',\n",
       "  '',\n",
       "  '450.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2019-01-03',\n",
       "  '2030-01-03'],\n",
       " ['NCT05810571',\n",
       "  'Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'Renal Cell Carcinoma',\n",
       "  'PROCEDURE: preoperative remifentanil consumption|PROCEDURE: postopeartive controlled anlagesia with morphine',\n",
       "  'Kocaeli University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC',\n",
       "  '2023-03-01',\n",
       "  '2024-04-03'],\n",
       " ['NCT04613271',\n",
       "  'Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia',\n",
       "  'FVR',\n",
       "  'COMPLETED',\n",
       "  'Infectious Disease|SARS-CoV Infection|Covid19',\n",
       "  'DRUG: Favipiravir|DRUG: Azithromycin',\n",
       "  'Ina-Respond',\n",
       "  'Center for Research and Development of Health Resources and Services\", National Institute of Health Research and Development (NIHRD),\" Indonesia',\n",
       "  '130.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2020-10-15',\n",
       "  '2021-11-08'],\n",
       " ['NCT06142071',\n",
       "  'Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting',\n",
       "  'SALUTE',\n",
       "  'NOT_YET_RECRUITING',\n",
       "  'Cancer',\n",
       "  'BEHAVIORAL: Telephone questionnaire',\n",
       "  'Swansea Bay University Health Board',\n",
       "  'Swansea University',\n",
       "  '50.0',\n",
       "  'OTHER',\n",
       "  'OBSERVATIONAL',\n",
       "  'Observational Model: |Time Perspective: p',\n",
       "  '2023-12',\n",
       "  '2024-08'],\n",
       " ['NCT03211871',\n",
       "  'Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy',\n",
       "  '',\n",
       "  'UNKNOWN',\n",
       "  'Pain\",\" Postoperative',\n",
       "  'DRUG: Dexmedetomidine|DRUG: Normal Saline Flush\",\" 0.9% Injectable Solution_#1',\n",
       "  'Bogomolets National Medical University',\n",
       "  '',\n",
       "  '60.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2016-05-01',\n",
       "  '2017-10-01'],\n",
       " ['NCT04146571',\n",
       "  'Expanded Access to Ensartinib for Participants With ALK+ NSCLC',\n",
       "  '',\n",
       "  'AVAILABLE',\n",
       "  'Non-Small Cell Lung Cancer|ALK Gene Rearrangement Positive',\n",
       "  'DRUG: Ensartinib',\n",
       "  'Xcovery Holdings\",\" Inc.',\n",
       "  '',\n",
       "  '',\n",
       "  'INDUSTRY',\n",
       "  'EXPANDED_ACCESS',\n",
       "  '',\n",
       "  '',\n",
       "  ''],\n",
       " ['NCT00227071',\n",
       "  'Aquatic Verses Land Exercise to Decrease Fall Risk',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Osteoporosis',\n",
       "  'BEHAVIORAL: exercise',\n",
       "  'University of Saskatchewan',\n",
       "  'Saskatchewan Health Research Foundation',\n",
       "  '73.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE|Primary Purpose: TREATMENT',\n",
       "  '1999-09',\n",
       "  '2002-06'],\n",
       " ['NCT04341571',\n",
       "  'Effect of Probiotics Versus Metformin on Glycemic Control\",\" Insulin Sensitivity and Insulin Secretion in Prediabetes.',\n",
       "  '',\n",
       "  'ACTIVE_NOT_RECRUITING',\n",
       "  'PreDiabetes|Impaired Glucose Tolerance|Hyperglycemia|Resistance\",\" Insulin',\n",
       "  'DIETARY_SUPPLEMENT: Probiotics|DRUG: Metformin',\n",
       "  'University of Guadalajara',\n",
       "  '',\n",
       "  '30.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT',\n",
       "  '2019-10-24',\n",
       "  '2024-12'],\n",
       " ['NCT01755871',\n",
       "  'Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis',\n",
       "  'BiobankII',\n",
       "  'TERMINATED',\n",
       "  'Relapsing Remitting Multiple Sclerosis',\n",
       "  'DRUG: Fingolimod',\n",
       "  'Heinrich-Heine University\",\" Duesseldorf',\n",
       "  'Novartis Pharmaceuticals',\n",
       "  '8.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT',\n",
       "  '2013-01',\n",
       "  '2016-02'],\n",
       " ['NCT00721071',\n",
       "  'Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis',\n",
       "  '',\n",
       "  'COMPLETED',\n",
       "  'Cystic Fibrosis',\n",
       "  'DRUG: Hypertonic Saline',\n",
       "  'The Hospital for Sick Children',\n",
       "  '',\n",
       "  '95.0',\n",
       "  'OTHER',\n",
       "  'INTERVENTIONAL',\n",
       "  'Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC',\n",
       "  '2006-12',\n",
       "  '2008-05'],\n",
       " ...]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking our cleaned dataset\n",
    "clinicaltrial_2023rdd2.collect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "d8306c8e-15e8-4e70-ab97-b89875c86485",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "#loading the pharma csv using the spark content\n",
    "pharma_rdd = sc.textFile(pharma)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "dfb4f745-311c-4fad-98eb-5d53f3176b2b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[['\"Company\"',\n",
       "  '\"Parent_Company\"',\n",
       "  '\"Penalty_Amount\"',\n",
       "  '\"Subtraction_From_Penalty\"',\n",
       "  '\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\"',\n",
       "  '\"Penalty_Year\"',\n",
       "  '\"Penalty_Date\"',\n",
       "  '\"Offense_Group\"',\n",
       "  '\"Primary_Offense\"',\n",
       "  '\"Secondary_Offense\"',\n",
       "  '\"Description\"',\n",
       "  '\"Level_of_Government\"',\n",
       "  '\"Action_Type\"',\n",
       "  '\"Agency\"',\n",
       "  '\"Civil/Criminal\"',\n",
       "  '\"Prosecution_Agreement\"',\n",
       "  '\"Court\"',\n",
       "  '\"Case_ID\"',\n",
       "  '\"Private_Litigation_Case_Title\"',\n",
       "  '\"Lawsuit_Resolution\"',\n",
       "  '\"Facility_State\"',\n",
       "  '\"City\"',\n",
       "  '\"Address\"',\n",
       "  '\"Zip\"',\n",
       "  '\"NAICS_Code\"',\n",
       "  '\"NAICS_Translation\"',\n",
       "  '\"HQ_Country_of_Parent\"',\n",
       "  '\"HQ_State_of_Parent\"',\n",
       "  '\"Ownership_Structure\"',\n",
       "  '\"Parent_Company_Stock_Ticker\"',\n",
       "  '\"Major_Industry_of_Parent\"',\n",
       "  '\"Specific_Industry_of_Parent\"',\n",
       "  '\"Info_Source\"',\n",
       "  '\"Notes\"'],\n",
       " ['\"Abbott Laboratories\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$5',\n",
       "  '475',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$5',\n",
       "  '475',\n",
       "  '000\"',\n",
       "  '\"2013\"',\n",
       "  '\"20131227\"',\n",
       "  '\"government-contracting-related offenses\"',\n",
       "  '\"False Claims Act and related\"',\n",
       "  '\"kickbacks and bribery\"',\n",
       "  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n",
       "  ' biliary and peripheral vascular products.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Justice Department Civil Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Inc.\"',\n",
       "  '\"AbbVie\"',\n",
       "  '\"$1',\n",
       "  '500',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$1',\n",
       "  '500',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"2012\"',\n",
       "  '\"20120507\"',\n",
       "  '\"healthcare-related offenses\"',\n",
       "  '\"off-label or unapproved promotion of medical products\"',\n",
       "  '\"\"',\n",
       "  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Food and Drug Administration referral to the Justice Department\"',\n",
       "  '\"civil and criminal\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABBV\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Inc.\"',\n",
       "  '\"AbbVie\"',\n",
       "  '\"$126',\n",
       "  '500',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$126',\n",
       "  '500',\n",
       "  '000\"',\n",
       "  '\"2010\"',\n",
       "  '\"20101207\"',\n",
       "  '\"government-contracting-related offenses\"',\n",
       "  '\"False Claims Act and related\"',\n",
       "  '\"\"',\n",
       "  '\"Abbott Laboratories Inc.',\n",
       "  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n",
       "  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Justice Department Civil Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABBV\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Puerto Rico',\n",
       "  ' Inc.\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$49',\n",
       "  '045\"',\n",
       "  '\"$0\"',\n",
       "  '\"$49',\n",
       "  '045\"',\n",
       "  '\"2009\"',\n",
       "  '\"20090305\"',\n",
       "  '\"employment-related offenses\"',\n",
       "  '\"wage and hour violation\"',\n",
       "  '\"Fair Labor Standards Act\"',\n",
       "  '\"\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Labor Department Wage and Hour Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"1527129\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"Puerto Rico\"',\n",
       "  '\"San Juan\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"423450\"',\n",
       "  '\"423450: Medical',\n",
       "  ' Dental',\n",
       "  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"March 7',\n",
       "  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n",
       "  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n",
       "  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n",
       "  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"'],\n",
       " ['\"Acclarent Inc.\"',\n",
       "  '\"Johnson & Johnson\"',\n",
       "  '\"$18',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$18',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"2016\"',\n",
       "  '\"20160722\"',\n",
       "  '\"government-contracting-related offenses\"',\n",
       "  '\"False Claims Act and related\"',\n",
       "  '\"\"',\n",
       "  '\"California-based medical device manufacturer Acclarent Inc.',\n",
       "  ' a subsidiary of Johnson & Johnson',\n",
       "  ' agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Justice Department Civil Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"New Jersey\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"JNJ\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\"',\n",
       "  '\"\"'],\n",
       " ['\"Advanced Medical Optics\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$16',\n",
       "  '800\"',\n",
       "  '\"$0\"',\n",
       "  '\"$16',\n",
       "  '800\"',\n",
       "  '\"2004\"',\n",
       "  '\"20040412\"',\n",
       "  '\"employment-related offenses\"',\n",
       "  '\"labor relations violation\"',\n",
       "  '\"\"',\n",
       "  '\"back pay award in unfair labor practices case\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"National Labor Relations Board\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"21-CA-36104-001\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"California\"',\n",
       "  '\"Irvine\"',\n",
       "  '\"\"',\n",
       "  '\"92606\"',\n",
       "  '\"333314\"',\n",
       "  '\"333314: Optical Instrument and Lens Manufacturing\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\"',\n",
       "  '\"\"'],\n",
       " ['\"Advanced Neuromodulation Systems',\n",
       "  ' Inc.\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$2',\n",
       "  '950',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$2',\n",
       "  '950',\n",
       "  '000\"',\n",
       "  '\"2007\"',\n",
       "  '\"20070702\"',\n",
       "  '\"healthcare-related offenses\"',\n",
       "  '\"HHS civil monetary penalties\"',\n",
       "  '\"kickbacks and bribery\"',\n",
       "  '\"The HHS Inspector General announced that Advanced Neuromodulation Systems',\n",
       "  ' Inc.',\n",
       "  '  a medical device manufacturer specializing in spinal cord stimulation used for pain management',\n",
       "  ' agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Health & Human Services Department Office of Inspector General\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\"',\n",
       "  '\"\"'],\n",
       " ['\"Advanced Sterilization Products\"',\n",
       "  '\"Johnson & Johnson\"',\n",
       "  '\"$136',\n",
       "  '800\"',\n",
       "  '\"$0\"',\n",
       "  '\"$136',\n",
       "  '800\"',\n",
       "  '\"2014\"',\n",
       "  '\"20140520\"',\n",
       "  '\"environment-related offenses\"',\n",
       "  '\"environmental violation\"',\n",
       "  '\"\"',\n",
       "  '\"The U.S. Environmental Protection Agency announced that an Irvine',\n",
       "  ' Calif. company',\n",
       "  ' Advanced Sterilization Products',\n",
       "  ' has agreed to pay a $136',\n",
       "  '800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Environmental Protection Agency\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"California\"',\n",
       "  '\"Irvine\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"New Jersey\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"JNJ\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\"',\n",
       "  '\"\"'],\n",
       " ['\"Advanced Sterilization Products',\n",
       "  ' a division of Ethicon Inc.\"',\n",
       "  '\"Johnson & Johnson\"',\n",
       "  '\"$1',\n",
       "  '200',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$1',\n",
       "  '200',\n",
       "  '000\"',\n",
       "  '\"2013\"',\n",
       "  '\"20131204\"',\n",
       "  '\"safety-related offenses\"',\n",
       "  '\"drug or medical equipment safety violation\"',\n",
       "  '\"\"',\n",
       "  '\"Settlement of a civil money penalty action against Advanced Sterilization Products',\n",
       "  ' a division of Ethicon Inc.',\n",
       "  ' a Johnson & Johnson company',\n",
       "  ' and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Food and Drug Administration\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"California\"',\n",
       "  '\"Irvine\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"New Jersey\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"JNJ\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\"',\n",
       "  '\"\"']]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pharma_rdd2 = sc.textFile(pharma)\\\n",
    "                          .map(lambda line: line.split(','))\\\n",
    "                          .filter(lambda line: len(line)>1)\n",
    "\n",
    "\n",
    "\n",
    "pharma_rdd2.take(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "e0e0af27-1932-4fe6-884f-48594fc95951",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[['\"Abbott Laboratories\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$5',\n",
       "  '475',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$5',\n",
       "  '475',\n",
       "  '000\"',\n",
       "  '\"2013\"',\n",
       "  '\"20131227\"',\n",
       "  '\"government-contracting-related offenses\"',\n",
       "  '\"False Claims Act and related\"',\n",
       "  '\"kickbacks and bribery\"',\n",
       "  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n",
       "  ' biliary and peripheral vascular products.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Justice Department Civil Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Inc.\"',\n",
       "  '\"AbbVie\"',\n",
       "  '\"$1',\n",
       "  '500',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$1',\n",
       "  '500',\n",
       "  '000',\n",
       "  '000\"',\n",
       "  '\"2012\"',\n",
       "  '\"20120507\"',\n",
       "  '\"healthcare-related offenses\"',\n",
       "  '\"off-label or unapproved promotion of medical products\"',\n",
       "  '\"\"',\n",
       "  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Food and Drug Administration referral to the Justice Department\"',\n",
       "  '\"civil and criminal\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABBV\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Inc.\"',\n",
       "  '\"AbbVie\"',\n",
       "  '\"$126',\n",
       "  '500',\n",
       "  '000\"',\n",
       "  '\"$0\"',\n",
       "  '\"$126',\n",
       "  '500',\n",
       "  '000\"',\n",
       "  '\"2010\"',\n",
       "  '\"20101207\"',\n",
       "  '\"government-contracting-related offenses\"',\n",
       "  '\"False Claims Act and related\"',\n",
       "  '\"\"',\n",
       "  '\"Abbott Laboratories Inc.',\n",
       "  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n",
       "  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Justice Department Civil Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABBV\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n",
       "  '\"\"'],\n",
       " ['\"Abbott Laboratories Puerto Rico',\n",
       "  ' Inc.\"',\n",
       "  '\"Abbott Laboratories\"',\n",
       "  '\"$49',\n",
       "  '045\"',\n",
       "  '\"$0\"',\n",
       "  '\"$49',\n",
       "  '045\"',\n",
       "  '\"2009\"',\n",
       "  '\"20090305\"',\n",
       "  '\"employment-related offenses\"',\n",
       "  '\"wage and hour violation\"',\n",
       "  '\"Fair Labor Standards Act\"',\n",
       "  '\"\"',\n",
       "  '\"federal\"',\n",
       "  '\"agency action\"',\n",
       "  '\"Labor Department Wage and Hour Division\"',\n",
       "  '\"civil\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"1527129\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"Puerto Rico\"',\n",
       "  '\"San Juan\"',\n",
       "  '\"\"',\n",
       "  '\"\"',\n",
       "  '\"423450\"',\n",
       "  '\"423450: Medical',\n",
       "  ' Dental',\n",
       "  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n",
       "  '\"USA\"',\n",
       "  '\"Illinois\"',\n",
       "  '\"publicly traded\"',\n",
       "  '\"ABT\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"pharmaceuticals\"',\n",
       "  '\"March 7',\n",
       "  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n",
       "  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n",
       "  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n",
       "  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"']]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#filtering out the header\n",
    "header = pharma_rdd2.first()\n",
    "pharma_rdd3 = pharma_rdd2.filter(lambda k:k !=header)\n",
    "\n",
    "pharma_rdd3.take(4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "95fecdeb-50e0-44cd-9765-17276e401d10",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Company', 'Parent_Company', 'Penalty_Amount', 'Subtraction_From_Penalty', 'Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting', 'Penalty_Year', 'Penalty_Date', 'Offense_Group', 'Primary_Offense', 'Secondary_Offense', 'Description', 'Level_of_Government', 'Action_Type', 'Agency', 'Civil/Criminal', 'Prosecution_Agreement', 'Court', 'Case_ID', 'Private_Litigation_Case_Title', 'Lawsuit_Resolution', 'Facility_State', 'City', 'Address', 'Zip', 'NAICS_Code', 'NAICS_Translation', 'HQ_Country_of_Parent', 'HQ_State_of_Parent', 'Ownership_Structure', 'Parent_Company_Stock_Ticker', 'Major_Industry_of_Parent', 'Specific_Industry_of_Parent', 'Info_Source', 'Notes'], ['Abbott Laboratories', 'Abbott Laboratories', '$5', '475', '000', '$0', '$5', '475', '000', '2013', '20131227', 'government-contracting-related offenses', 'False Claims Act and related', 'kickbacks and bribery', \"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid\", ' biliary and peripheral vascular products.', 'federal', 'agency action', 'Justice Department Civil Division', 'civil', '', '', '', '', '', '', '', '', '', '', '', 'USA', 'Illinois', 'publicly traded', 'ABT', 'pharmaceuticals', 'pharmaceuticals', 'https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians', ''], ['Abbott Laboratories Inc.', 'AbbVie', '$1', '500', '000', '000', '$0', '$1', '500', '000', '000', '2012', '20120507', 'healthcare-related offenses', 'off-label or unapproved promotion of medical products', '', \"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\", 'federal', 'agency action', 'Food and Drug Administration referral to the Justice Department', 'civil and criminal', '', '', '', '', '', '', '', '', '', '', '', 'USA', 'Illinois', 'publicly traded', 'ABBV', 'pharmaceuticals', 'pharmaceuticals', 'http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote', ''], ['Abbott Laboratories Inc.', 'AbbVie', '$126', '500', '000', '$0', '$126', '500', '000', '2010', '20101207', 'government-contracting-related offenses', 'False Claims Act and related', '', 'Abbott Laboratories Inc.', ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations', ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.', 'federal', 'agency action', 'Justice Department Civil Division', 'civil', '', '', '', '', '', '', '', '', '', '', '', 'USA', 'Illinois', 'publicly traded', 'ABBV', 'pharmaceuticals', 'pharmaceuticals', 'https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases', '']]\n"
     ]
    }
   ],
   "source": [
    "# Apply transformations to create pharma_rdd4\n",
    "pharma_rdd4 = pharma_rdd \\\n",
    "    .map(lambda x: x.replace('\"', '')) \\\n",
    "    .map(lambda line: line.split(','))\n",
    "\n",
    "# Print the first two lines of data\n",
    "print(pharma_rdd4.take(4))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "102184fc-ea1e-4a9f-b478-13345369e8c2",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "# 1) The number of studies in the dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "d1a231d9-f40d-462f-9a8b-588863b02e1e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The number of distinct studies in the dataset (excluding header) is: 483422\n"
     ]
    }
   ],
   "source": [
    "# Extract the header\n",
    "header = clinicaltrial_2023rdd1.first()\n",
    "\n",
    "# Filter out the header line from the RDD\n",
    "data_without_header = clinicaltrial_2023rdd1.filter(lambda line: line != header)\n",
    "\n",
    "# Split each line by tabs, extract study identifier, and get distinct studies\n",
    "distinct_studies = data_without_header.map(lambda line: line.strip(',\"').split('\\t')[0]).distinct()\n",
    "\n",
    "# Count the number of distinct studies\n",
    "num_distinct_studies = distinct_studies.count()\n",
    "\n",
    "# Print the result\n",
    "print(\"The number of distinct studies in the dataset (excluding header) is:\", num_distinct_studies)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "261d9aad-5a29-4d3d-b94d-8140c34eb7c0",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#2)Types of Studies and their Frequencies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0fc7d0a3-e25f-4527-a17a-990da59628ad",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('INTERVENTIONAL', 371382),\n",
       " ('OBSERVATIONAL', 110221),\n",
       " ('EXPANDED_ACCESS', 928),\n",
       " ('', 889)]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#  clinicaltrial_2023RDD is the initial RDD\n",
    "clinicaltrial_2023RDD_st = clinicaltrial_2023rdd1.map(lambda k: (k.split(\"\\t\")[10] if len(k.split(\"\\t\")) > 10 else None, 1))\n",
    "\n",
    "# Filter out records where the split didn't produce enough fields\n",
    "clinicaltrial_2023RDD_st_filtered = clinicaltrial_2023RDD_st.filter(lambda x: x[0] is not None)\n",
    "\n",
    "# Reduce by key, sort, and take the first 4 elements\n",
    "clinicaltrial_rdd_studies = clinicaltrial_2023RDD_st_filtered.reduceByKey(lambda a, b: a + b) \\\n",
    "    .sortBy(lambda k: k[1], ascending=False)\n",
    "\n",
    "# Take the first 4 elements for inspection\n",
    "clinicaltrial_rdd_studies.take(4)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "ce5c139c-924e-4a32-a8ab-5b9578f55d21",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#3)The top 5 conditions (from Conditions) with their frequencies."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "677adf4f-2595-44de-8937-1ef23d89a829",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('Healthy', 9731), ('Breast Cancer', 7502), ('Obesity', 6549), ('Stroke', 4071), ('Hypertension', 4020)]\n"
     ]
    }
   ],
   "source": [
    "from operator import add\n",
    "\n",
    "def get_top_5_conditions(clinicaltrial_data):\n",
    "    \"\"\"\n",
    "    This function takes clinical trial data as input and returns the top 5 conditions \n",
    "    based on frequency of occurrence.\n",
    "    \n",
    "    Parameters:\n",
    "    clinicaltrial_data (RDD): RDD containing clinical trial data.\n",
    "    \n",
    "    Returns:\n",
    "    list: Top 5 conditions with their respective frequencies.\n",
    "    \"\"\"\n",
    "    top_5_conditions = clinicaltrial_data \\\n",
    "        .map(lambda col: col[4]) \\\n",
    "        .filter(lambda x: x != '') \\\n",
    "        .flatMap(lambda x: x.split('|')) \\\n",
    "        .map(lambda x: (x, 1)) \\\n",
    "        .reduceByKey(add) \\\n",
    "        .sortBy(lambda x: x[1], ascending=False) \\\n",
    "        .take(5)\n",
    "    \n",
    "    return top_5_conditions\n",
    "\n",
    "# clinicaltrial_2023RDD2 is your RDD\n",
    "top_5_Conditions = get_top_5_conditions(clinicaltrial_2023rdd2)\n",
    "\n",
    "# Displaying the top 5 Conditions\n",
    "print(top_5_Conditions)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "cff696c3-0901-4dfb-9d9d-5e2188020e38",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('Sangath', 1),\n",
       " ('McMaster University', 1),\n",
       " ('Melbourne Health', 1),\n",
       " ('Assistance Publique - Hôpitaux de Paris', 1),\n",
       " ('Istituto Auxologico Italiano', 1)]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "header = clinicaltrial_2023rdd1.first()\n",
    "clinicaltrialsponsors_rdd = clinicaltrial_2023rdd1.filter(lambda k:k !=header)\\\n",
    ".map(lambda k: k.split(\"\\t\"))\\\n",
    ".map(lambda k: (k[6],1))\n",
    "clinicaltrialsponsors_rdd.take(5)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "a3ab78c2-5029-403f-9b4b-126db0875cff",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('Parent_Company', 1),\n",
       " ('Abbott Laboratories', 1),\n",
       " ('AbbVie', 1),\n",
       " ('AbbVie', 1)]"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#splitting by delimiter, replacing, selecting index, and mapping\n",
    "pcc_rdd = pharma_rdd.map(lambda k: k.split(\",\"))\\\n",
    ".map(lambda k: (k[1].replace('\"', '')))\\\n",
    ".map(lambda k: (k,1)) \n",
    "\n",
    "pcc_rdd.take(4)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "4c8187c7-2b35-4d88-a4a8-d73771479495",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#4)10 most common sponsors that are not pharmaceutical companies, al"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "d2a9f222-2efb-4431-8b8a-2dc7bcf93b5d",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('National Cancer Institute (NCI)', 3410),\n",
       " ('Assiut University', 3335),\n",
       " ('Cairo University', 3023),\n",
       " ('Assistance Publique - Hôpitaux de Paris', 2951),\n",
       " ('Mayo Clinic', 2766),\n",
       " ('M.D. Anderson Cancer Center', 2702),\n",
       " ('Novartis Pharmaceuticals', 2393),\n",
       " ('National Institute of Allergy and Infectious Diseases (NIAID)', 2340),\n",
       " ('Massachusetts General Hospital', 2263),\n",
       " ('National Taiwan University Hospital', 2181)]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#joining sponsors data with parent companies that are not pharmaceutical companies\n",
    "sponsors = clinicaltrialsponsors_rdd.leftOuterJoin(pcc_rdd)\\\n",
    ".filter(lambda k: k[1][1]==None)\\\n",
    ".map(lambda k: (k[0],1))\\\n",
    ".reduceByKey(lambda a,b: a+b)\\\n",
    ".sortBy(lambda k: k[1], False)\n",
    "\n",
    "sponsors.take(10)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "263d91d3-22a9-489c-8846-aed90b90d8a3",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#5)Plot number of completed studies for each month in 2023. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "5dde5e10-d363-4581-9088-6f8da50a0dca",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('01', 1494),\n",
       " ('02', 1272),\n",
       " ('03', 1552),\n",
       " ('04', 1324),\n",
       " ('05', 1415),\n",
       " ('06', 1619),\n",
       " ('07', 1360),\n",
       " ('08', 1230),\n",
       " ('09', 1152),\n",
       " ('10', 1058),\n",
       " ('11', 909),\n",
       " ('12', 1082)]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "year = '2023'\n",
    "Completed_Studies = clinicaltrial_2023rdd2 \\\n",
    "    .map(lambda col: (col[3], col[-1])) \\\n",
    "    .filter(lambda x: x[0] == 'COMPLETED') \\\n",
    "    .map(lambda x: x[1]) \\\n",
    "    .filter(lambda x: x.split('-')[0] == year) \\\n",
    "    .map(lambda x: (x.split('-')[1], 1)) \\\n",
    "    .reduceByKey(lambda x, y: x + y) \\\n",
    "    .sortByKey()\n",
    "\n",
    "Completed_Studies.collect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "9c56007d-809d-4af4-8993-ed7187d9f289",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Changed months after applying changer function:\n['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec']\n"
     ]
    }
   ],
   "source": [
    "def changer(month):\n",
    "    month_dict = {'01': 'Jan', '02': 'Feb', '03': 'Mar', '04': 'Apr', '05': 'May', '06': 'Jun', '07': 'Jul', '08': 'Aug', '09': 'Sep', '10': 'Oct', '11': 'Nov', '12': 'Dec'}\n",
    "    return month_dict.get(month, None)\n",
    "\n",
    "changed_months = Completed_Studies.map(lambda x: changer(x[0])).collect()\n",
    "\n",
    "print(\"Changed months after applying changer function:\")\n",
    "print(changed_months)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "fe31893f-ba67-4350-92da-da30ef137b32",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Completed_Studies_final:\n[('Apr', 1324), ('Aug', 1230), ('Dec', 1082), ('Feb', 1272), ('Jan', 1494), ('Jul', 1360), ('Jun', 1619), ('Mar', 1552), ('May', 1415), ('Nov', 909), ('Oct', 1058), ('Sep', 1152)]\n"
     ]
    }
   ],
   "source": [
    "# Apply changer function and filter out None values\n",
    "Completed_Studies_final = Completed_Studies.map(lambda x: (changer(x[0]), x[1])) \\\n",
    "    .filter(lambda x: x[0] is not None) \\\n",
    "    .sortBy(lambda x: x[0], ascending=True) \\\n",
    "    .map(lambda x: (x[0], x[1]))\n",
    "\n",
    "# Collect the sorted months along with the counts into a list\n",
    "result = Completed_Studies_final.collect()\n",
    "\n",
    "# Print the final result\n",
    "print(\"Completed_Studies_final:\")\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "364515ae-0312-4d9f-a06f-d0cc998d6379",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA90AAAJOCAYAAACqS2TfAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8pXeV/AAAACXBIWXMAAA9hAAAPYQGoP6dpAACWm0lEQVR4nOzdeVhVVf/+8fsgk6KAaDIUImo5T1EpDqWJIg5pWuaQ4pBaqTmUUzlbOWbOmT2pVPrUY5qlFYqzJpITOWSmZmoqaA4QqIiwf3/4Y389gQZ5jgi8X9d1rou91tr7fPbmIN6sPVgMwzAEAAAAAABsziG3CwAAAAAAIL8idAMAAAAAYCeEbgAAAAAA7ITQDQAAAACAnRC6AQAAAACwE0I3AAAAAAB2QugGAAAAAMBOCN0AAAAAANgJoRsAAAAAADshdAMAcAuLxaKxY8fmdhlWxo4dK4vFkttlZMumTZtksVi0adMms61bt24qU6ZMrtWE28v4bP3555+5XQoA5FuEbgCAzR07dkx9+vRR2bJl5erqKnd3d9WrV08zZ87U1atXc7s8uzhz5ozGjh2r2NjYXK1j1apVeuqpp1SqVCkVKVJEZcuWVfv27RUZGWmOuV9qze/KlCkji8WikJCQLPs/+ugjWSwWWSwW7dq1y661vPvuu1q5cqVd3wMAkDVCNwDApr799ltVq1ZN//vf/9SqVSvNnj1bEydOVOnSpTVkyBANGDAgt0u0izNnzmjcuHG5GmSnTZumZ555RhaLRSNGjND777+vdu3a6ciRI/r8889zrdaPPvpIhw8fvifvdb9xdXXVxo0bFRcXl6lvyZIlcnV1vSd1ELoBIPc45nYBAID84/jx4+rQoYMCAgK0YcMG+fr6mn19+/bV0aNH9e233+ZihfnXjRs3NGHCBDVp0kRr167N1H/u3LlcqOomJyenXHtve7px44bS09Pl7Ox82zH16tXTzp079cUXX1j9wemPP/7Q1q1b9eyzz2r58uX3olwAQC5hphsAYDNTpkxRUlKSPv74Y6vAnaF8+fJWwSMjKJYrV04uLi4qU6aM3nzzTaWkpFitV6ZMGbVs2VKbNm3SY489psKFC6tatWrmdcMrVqxQtWrV5OrqqqCgIO3du9dq/W7duqlo0aL67bffFBoaKjc3N/n5+Wn8+PEyDOMf9+v06dPq0aOHvL295eLioipVqmjhwoVm/6ZNm/T4449Lkrp3726eMrx48WJzTExMjJo1ayYPDw8VKVJETz31lH744YdM77Vt2zY9/vjjcnV1Vbly5fThhx/+Y32S9OeffyoxMVH16tXLsr9UqVLZqrVMmTLq1q1bpvUbNmyohg0bWrX98ccfatOmjdzc3FSqVCkNGjQo0/dOyvqa7vT0dM2YMUNVqlSRq6urvL291adPH126dMlq3K5duxQaGqqSJUuqcOHCCgwMVI8ePf7xeGR8ZtauXauaNWvK1dVVlStX1ooVKzKNvXz5sgYOHCh/f3+5uLiofPnymjx5stLT080xv//+uywWi6ZNm6YZM2aYn9mff/75jnW4urqqbdu2Wrp0qVX7f//7XxUvXlyhoaFZrrdhwwY1aNBAbm5u8vT0VOvWrXXo0CGrMRnXYx89elTdunWTp6enPDw81L17d125csUcZ7FYlJycrIiICPP7/ffv8eXLl++4DQDAv8dMNwDAZlatWqWyZcuqbt262Rr/0ksvKSIiQs8995xef/11xcTEaOLEiTp06JC++uorq7FHjx5Vp06d1KdPH7344ouaNm2aWrVqpfnz5+vNN9/Uq6++KkmaOHGi2rdvr8OHD8vB4f/+tpyWlqZmzZqpTp06mjJliiIjIzVmzBjduHFD48ePv22N8fHxqlOnjiwWi/r166cHHnhA33//vXr27KnExEQNHDhQlSpV0vjx4zV69Gj17t1bDRo0kCTzOGzYsEFhYWEKCgrSmDFj5ODgoEWLFunpp5/W1q1b9cQTT0iS9u/fr6ZNm+qBBx7Q2LFjdePGDY0ZM0be3t7/eCxLlSqlwoULa9WqVerfv7+8vLyyHPdPtWbX1atX1bhxY508eVKvvfaa/Pz89Omnn2rDhg3ZWr9Pnz5avHixunfvrtdee03Hjx/XnDlztHfvXv3www9ycnLSuXPnzOMxfPhweXp66vfff88yOGflyJEjeuGFF/Tyyy8rPDxcixYt0vPPP6/IyEg1adJEknTlyhU99dRTOn36tPr06aPSpUtr+/btGjFihM6ePasZM2ZYbXPRokW6du2aevfuLRcXl9se51t16tRJTZs21bFjx1SuXDlJ0tKlS/Xcc89leRbAunXrFBYWprJly2rs2LG6evWqZs+erXr16mnPnj2Z/oDRvn17BQYGauLEidqzZ4/+85//qFSpUpo8ebIk6dNPP9VLL72kJ554Qr1795Yks47sbgMAcBcMAABsICEhwZBktG7dOlvjY2NjDUnGSy+9ZNX+xhtvGJKMDRs2mG0BAQGGJGP79u1m25o1awxJRuHChY0TJ06Y7R9++KEhydi4caPZFh4ebkgy+vfvb7alp6cbLVq0MJydnY3z58+b7ZKMMWPGmMs9e/Y0fH19jT///NOqzg4dOhgeHh7GlStXDMMwjJ07dxqSjEWLFlmNS09PNx5++GEjNDTUSE9PN9uvXLliBAYGGk2aNDHb2rRpY7i6ulrtz88//2wUKlTIyM6v7NGjRxuSDDc3NyMsLMx45513jN27d2cad7taDePmsQ4PD8/U/tRTTxlPPfWUuTxjxgxDkvG///3PbEtOTjbKly+f5fEPCAgwl7du3WpIMpYsWWL1HpGRkVbtX331lSHJ2Llz5z/ue1b7IclYvny52ZaQkGD4+voatWrVMtsmTJhguLm5Gb/++qvV+sOHDzcKFSpknDx50jAMwzh+/LghyXB3dzfOnTuX7RpatGhh3Lhxw/Dx8TEmTJhgGMbN76kkY/PmzcaiRYsy7WPNmjWNUqVKGRcuXDDbfvrpJ8PBwcHo2rWr2TZmzBhDktGjRw+r93322WeNEiVKWLW5ubll+X3NyTYAAP8Op5cDAGwiMTFRklSsWLFsjf/uu+8kSYMHD7Zqf/311yUp07XflStXVnBwsLlcu3ZtSdLTTz+t0qVLZ2r/7bffMr1nv379zK8zZq6vX7+udevWZVmjYRhavny5WrVqJcMw9Oeff5qv0NBQJSQkaM+ePXfcz9jYWB05ckSdOnXShQsXzPWTk5PVuHFjbdmyRenp6UpLS9OaNWvUpk0bq/2pVKnSbU9B/rtx48Zp6dKlqlWrltasWaO33npLQUFBevTRRzOdmny3vvvuO/n6+uq5554z24oUKWLOpN7JsmXL5OHhoSZNmlgd06CgIBUtWlQbN26UJHl6ekqSVq9erdTU1BzX6Ofnp2effdZcdnd3V9euXbV3717zxmbLli1TgwYNVLx4cataQkJClJaWpi1btlhts127dnrggQdyVEehQoXUvn17/fe//5V08wZq/v7+5lkGtzp79qxiY2PVrVs3q1n06tWrq0mTJubPza1efvllq+UGDRrowoUL5s9kdthiGwCArHF6OQDAJtzd3SVJf/31V7bGnzhxQg4ODipfvrxVu4+Pjzw9PXXixAmr9luDqCR5eHhIkvz9/bNs//u1wQ4ODipbtqxV2yOPPCLp5vW6WTl//rwuX76sBQsWaMGCBVmO+acblB05ckSSFB4eftsxCQkJSklJ0dWrV/Xwww9n6q9QoUKWYSsrHTt2VMeOHZWYmKiYmBgtXrxYS5cuVatWrXTgwAGb3S37xIkTKl++fKbnh1eoUOEf1z1y5IgSEhLM68z/LuOYPvXUU2rXrp3GjRun999/Xw0bNlSbNm3UqVMnubi4/OP7ZFXfrd9zHx8fHTlyRPv27bttkP779zcwMPAf3zcrnTp10qxZs/TTTz9p6dKl6tChQ5bPXs/43Gd1HCtVqqQ1a9YoOTlZbm5uZvvffzaKFy8u6ebPQMbP5T+xxTYAAFkjdAMAbMLd3V1+fn46cOBAjtbLKnhkpVChQjlqN7Jxg7R/knEjrRdffPG2obl69erZ2sbUqVNVs2bNLMcULVo0yxuQ3Q13d3c1adJETZo0kZOTkyIiIhQTE6Onnnrqjuvd7vuRlpZ222OdU+np6SpVqpSWLFmSZX9GALZYLPryyy+1Y8cOrVq1SmvWrFGPHj303nvvaceOHSpatKhNamnSpImGDh2aZX9GSM9QuHDhf/U+tWvXVrly5TRw4EAdP35cnTp1+lfbyYotfgbs+XMEAAUdoRsAYDMtW7bUggULFB0dbXUqeFYCAgKUnp6uI0eOqFKlSmZ7fHy8Ll++rICAAJvWlp6ert9++80qRP3666+SlOnGVBkeeOABFStWTGlpaQoJCbnj9m8XVjNuWOXu7n7HbTzwwAMqXLiwOTN+q7t9xvVjjz2miIgInT179o61SjdnOC9fvpyp/cSJE1ZnCgQEBOjAgQMyDMNqe9mptVy5clq3bp3q1auXrRBbp04d1alTR++8846WLl2qzp076/PPP9dLL710x/WOHj2aqb6/f8/LlSunpKSkf/z+2kLHjh319ttvq1KlSrf9A0zG5z6r4/jLL7+oZMmSVrPc2ZXdP24BAGyPa7oBADYzdOhQubm56aWXXlJ8fHym/mPHjmnmzJmSpObNm0tSprtDT58+XZLUokULm9c3Z84c82vDMDRnzhw5OTmpcePGWY4vVKiQ2rVrp+XLl2c5g3/+/Hnz64wg9PfAGhQUpHLlymnatGlKSkq67TYKFSqk0NBQrVy5UidPnjT7Dx06pDVr1vzjvl25ckXR0dFZ9n3//feS/u+U5dvVKt0MoTt27ND169fNttWrV+vUqVNW45o3b64zZ87oyy+/tKrhdqfh36p9+/ZKS0vThAkTMvXduHHDrOvSpUuZZlozwmp2zgw4c+aM1V3wExMT9cknn6hmzZry8fExa4mOjs7yGF++fFk3btz4x/fJrpdeekljxozRe++9d9sxvr6+qlmzpiIiIqy+PwcOHNDatWvNn5uccnNzy/L7DQCwP2a6AQA2U65cOS1dulQvvPCCKlWqpK5du6pq1aq6fv26tm/frmXLlpnPB65Ro4bCw8O1YMECXb58WU899ZR+/PFHRUREqE2bNmrUqJFNa3N1dVVkZKTCw8NVu3Ztff/99/r222/15ptv3vHGWJMmTdLGjRtVu3Zt9erVS5UrV9bFixe1Z88erVu3ThcvXjT33dPTU/Pnz1exYsXk5uam2rVrKzAwUP/5z38UFhamKlWqqHv37nrwwQd1+vRpbdy4Ue7u7lq1apWkmzdCi4yMVIMGDfTqq6/qxo0bmj17tqpUqaJ9+/bdcf+uXLmiunXrqk6dOmrWrJn8/f11+fJlrVy5Ulu3blWbNm1Uq1atf6z1pZde0pdffqlmzZqpffv2OnbsmD777LNMj5jq1auX5syZo65du2r37t3y9fXVp59+qiJFivzj9+Kpp55Snz59NHHiRMXGxqpp06ZycnLSkSNHtGzZMs2cOVPPPfecIiIiNG/ePD377LMqV66c/vrrL3300Udyd3fPVvh85JFH1LNnT+3cuVPe3t5auHCh4uPjtWjRInPMkCFD9M0336hly5bq1q2bgoKClJycrP379+vLL7/U77//rpIlS/7je2VHQECAxo4d+4/jpk6dqrCwMAUHB6tnz57mI8M8PDyytX5WgoKCtG7dOk2fPl1+fn4KDAw0bzoIALCzXLtvOgAg3/r111+NXr16GWXKlDGcnZ2NYsWKGfXq1TNmz55tXLt2zRyXmppqjBs3zggMDDScnJwMf39/Y8SIEVZjDOP/Hr30d5KMvn37WrVlPNpp6tSpZlt4eLjh5uZmHDt2zGjatKlRpEgRw9vb2xgzZoyRlpaWaZu3PjLMMAwjPj7e6Nu3r+Hv7284OTkZPj4+RuPGjY0FCxZYjfv666+NypUrG46OjpkeybV3716jbdu2RokSJQwXFxcjICDAaN++vbF+/XqrbWzevNkICgoynJ2djbJlyxrz5883H+t0J6mpqcZHH31ktGnTxggICDBcXFyMIkWKGLVq1TKmTp1qpKSkZLvW9957z3jwwQcNFxcXo169esauXbsyPTLMMAzjxIkTxjPPPGMUKVLEKFmypDFgwADzsV93emRYhgULFhhBQUFG4cKFjWLFihnVqlUzhg4dapw5c8YwDMPYs2eP0bFjR6N06dKGi4uLUapUKaNly5bGrl277ngsDOP/PjNr1qwxqlevbri4uBgVK1Y0li1blmnsX3/9ZYwYMcIoX7684ezsbJQsWdKoW7euMW3aNOP69euGYWT9ucpuDXeS1SPDDMMw1q1bZ9SrV88oXLiw4e7ubrRq1cr4+eefrcZkfC5ufeTdrds8fvy42fbLL78YTz75pFG4cGFDkvn4sJxsAwDw71gMgztkAADyt27duunLL7/M8vRu5E9lypRR1apVtXr16twuBQBQwHFNNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCdd0AwAAAABgJ8x0AwAAAABgJ4RuAAAAAADsxDG3C8gr0tPTdebMGRUrVkwWiyW3ywEAAAAA5CLDMPTXX3/Jz89PDg63n88mdGfTmTNn5O/vn9tlAAAAAADuI6dOndJDDz10235CdzYVK1ZM0s0D6u7unsvVAAAAAAByU2Jiovz9/c2seDuE7mzKOKXc3d2d0A0AAAAAkKR/vPyYG6kBAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAHAPbNmyRa1atZKfn58sFotWrlyZacyhQ4f0zDPPyMPDQ25ubnr88cd18uRJs3/BggVq2LCh3N3dZbFYdPny5Uzb2LNnj5o0aSJPT0+VKFFCvXv3VlJSkh33DAAA3AmhGwCAeyA5OVk1atTQ3Llzs+w/duyY6tevr4oVK2rTpk3at2+fRo0aJVdXV3PMlStX1KxZM7355ptZbuPMmTMKCQlR+fLlFRMTo8jISB08eFDdunWzxy4BAIBssBiGYeR2EXlBYmKiPDw8lJCQIHd399wuBwCQh1ksFn311Vdq06aN2dahQwc5OTnp008//cf1N23apEaNGunSpUvy9PQ02xcsWKBRo0bp7NmzcnC4+Xf1/fv3q3r16jpy5IjKly9v610BAKDAym5GZKYbAIBclp6erm+//VaPPPKIQkNDVapUKdWuXTvLU9DvJCUlRc7OzmbglqTChQtLkrZt22bLkgEAQDYRugEAyGXnzp1TUlKSJk2apGbNmmnt2rV69tln1bZtW23evDnb23n66acVFxenqVOn6vr167p06ZKGDx8uSTp79qy9ygcAAHdA6AYAIJelp6dLklq3bq1BgwapZs2aGj58uFq2bKn58+dneztVqlRRRESE3nvvPRUpUkQ+Pj4KDAyUt7e31ew3AAC4d/gNDABALitZsqQcHR1VuXJlq/ZKlSpZ3b08Ozp16qS4uDidPn1aFy5c0NixY3X+/HmVLVvWliUDAIBscsztAgAAKOicnZ31+OOP6/Dhw1btv/76qwICAv7VNr29vSVJCxculKurq5o0aXLXdQIAgJwjdAMAcA8kJSXp6NGj5vLx48cVGxsrLy8vlS5dWkOGDNELL7ygJ598Uo0aNVJkZKRWrVqlTZs2mevExcUpLi7O3M7+/ftVrFgxlS5dWl5eXpKkOXPmqG7duipatKiioqI0ZMgQTZo0yeou5wAA4N7hkWHZxCPDAAB3I+MxX38XHh6uxYsXS7o5Kz1x4kT98ccfqlChgsaNG6fWrVubY8eOHatx48Zl2saiRYvMZ3F37dpV3377rZKSklSxYkW98cYb6tKli132CQCAgiy7GZHQnU2EbgAAAABABp7TDQAAAABALiN0AwAAAABgJ9xIDQCAf2PzrtyuwL6eeiy3KwAAIF/I1ZnuLVu2qFWrVvLz85PFYtHKlSszjTl06JCeeeYZeXh4yM3NTY8//rjVM0uvXbumvn37qkSJEipatKjatWun+Ph4q22cPHlSLVq0UJEiRVSqVCkNGTJEN27csPfuAQAAAAAKuFwN3cnJyapRo4bmzp2bZf+xY8dUv359VaxYUZs2bdK+ffs0atQoubq6mmMGDRqkVatWadmyZdq8ebPOnDmjtm3bmv1paWlq0aKFrl+/ru3btysiIkKLFy/W6NGj7b5/AAAAAICC7b65e7nFYtFXX32lNm3amG0dOnSQk5OTPv300yzXSUhI0AMPPKClS5fqueeekyT98ssvqlSpkqKjo1WnTh19//33atmypc6cOSNvb29J0vz58zVs2DCdP39ezs7O2aqPu5cDAKxwejkAAAVanr97eXp6ur799ls98sgjCg0NValSpVS7dm2rU9B3796t1NRUhYSEmG0VK1ZU6dKlFR0dLUmKjo5WtWrVzMAtSaGhoUpMTNTBgwdv+/4pKSlKTEy0egEAAAAAkBP3beg+d+6ckpKSNGnSJDVr1kxr167Vs88+q7Zt22rz5s2SpLi4ODk7O8vT09NqXW9vb8XFxZljbg3cGf0ZfbczceJEeXh4mC9/f38b7h0AAAAAoCC4b0N3enq6JKl169YaNGiQatasqeHDh6tly5aaP3++3d9/xIgRSkhIMF+nTp2y+3sC97N/uvFht27dZLFYrF7NmjWzGlOmTJlMYyZNmmT2b9q0Sa1bt5avr6/c3NxUs2ZNLVmy5F7sHgAAAGAX9+0jw0qWLClHR0dVrlzZqr1SpUratm2bJMnHx0fXr1/X5cuXrWa74+Pj5ePjY4758ccfrbaRcXfzjDFZcXFxkYuLiy12BcgXMm582KNHD6ubFd6qWbNmWrRokbmc1c/Q+PHj1atXL3O5WLFi5tfbt29X9erVNWzYMHl7e2v16tXq2rWrPDw81LJlSxvuDQAAAHBv3Leh29nZWY8//rgOHz5s1f7rr78qICBAkhQUFCQnJyetX79e7dq1kyQdPnxYJ0+eVHBwsCQpODhY77zzjs6dO6dSpUpJkqKiouTu7p4p0AO4vbCwMIWFhd1xjIuLyx3/mCXdDNm3G/Pmm29aLQ8YMEBr167VihUrCN0AAADIk3L19PKkpCTFxsYqNjZWknT8+HHFxsaaz+EeMmSIvvjiC3300Uc6evSo5syZo1WrVunVV1+VJHl4eKhnz54aPHiwNm7cqN27d6t79+4KDg5WnTp1JElNmzZV5cqV1aVLF/30009as2aNRo4cqb59+zKTDdjYpk2bVKpUKVWoUEGvvPKKLly4kGnMpEmTVKJECdWqVUtTp07VjRs37rjNhIQEeXl52atkAAAAwK5ydaZ7165datSokbk8ePBgSVJ4eLgWL16sZ599VvPnz9fEiRP12muvqUKFClq+fLnq169vrvP+++/LwcFB7dq1U0pKikJDQzVv3jyzv1ChQlq9erVeeeUVBQcHy83NTeHh4Ro/fvy921GgAGjWrJnatm2rwMBAHTt2TG+++abCwsIUHR2tQoUKSZJee+01Pfroo/Ly8tL27ds1YsQInT17VtOnT89ym//73/+0c+dOffjhh/dyVwAAAACbuW+e032/4zndwP+xWCz66quv1KZNm9uO+e2331SuXDmtW7dOjRs3znLMwoUL1adPHyUlJWU682Tjxo1q2bKlPvjgA3Xt2tWW5QO2wXO6AQAo0PL8c7oB5G1ly5ZVyZIldfTo0duOqV27tm7cuKHff//dqn3z5s1q1aqV3n//fQI3AAAA8jRCNwC7+OOPP3ThwgX5+vredkxsbKwcHBzMmxxKN68Lb9GihSZPnqzevXvfi1IBAAAAu7lv714O4P6SlJRkNWudceNDLy8veXl5ady4cWrXrp18fHx07NgxDR06VOXLl1doaKgkKTo6WjExMWrUqJGKFSum6OhoDRo0SC+++KKKFy8u6f9OKR8wYIDatWunuLg4STefZsDN1AAAAJAXcU13NnFNNwq6TZs2Wd34MEN4eLg++OADtWnTRnv37tXly5fl5+enpk2basKECfL29pYk7dmzR6+++qp++eUXpaSkKDAwUF26dNHgwYPN67m7deumiIiITO/x1FNPadOmTXbdPyDHuKYbAIACLbsZkdCdTYRuAIAVQjcAAAUaN1IDAAAAACCXEboBAAAAALATbqQGFFAzL83M7RLsakDxAbldAgAAAMBMNwAAAAAA9kLoBgAAAADATgjdBdyWLVvUqlUr+fn5yWKxaOXKlbcd+/LLL8tisWjGjBlW7Xv27FGTJk3k6empEiVKqHfv3kpKSspyGxcuXNBDDz0ki8Wiy5cv225HAAAAAOA+ROgu4JKTk1WjRg3NnTv3juO++uor7dixQ35+flbtZ86cUUhIiMqXL6+YmBhFRkbq4MGD6tatW5bb6dmzp6pXr26r8gEAAADgvsaN1Aq4sLAwhYWF3XHM6dOn1b9/f61Zs0YtWrSw6lu9erWcnJw0d+5cOTjc/BvO/PnzVb16dR09elTly5c3x37wwQe6fPmyRo8ere+//972OwMAAAAA9xlmunFH6enp6tKli4YMGaIqVapk6k9JSZGzs7MZuCWpcOHCkqRt27aZbT///LPGjx+vTz75xGosAAAAAORnpB/c0eTJk+Xo6KjXXnsty/6nn35acXFxmjp1qq5fv65Lly5p+PDhkqSzZ89KuhnMO3bsqKlTp6p06dL3rHYAAAAAyG2EbtzW7t27NXPmTC1evFgWiyXLMVWqVFFERITee+89FSlSRD4+PgoMDJS3t7c5oz1ixAhVqlRJL7744r0sHwAAAAByHaEbt7V161adO3dOpUuXlqOjoxwdHXXixAm9/vrrKlOmjDmuU6dOiouL0+nTp3XhwgWNHTtW58+fV9myZSVJGzZs0LJly8xtNG7cWJJUsmRJjRkzJjd2DQAAAADuCW6khtvq0qWLQkJCrNpCQ0PVpUsXde/ePdN4b29vSdLChQvl6uqqJk2aSJKWL1+uq1evmuN27typHj16aOvWrSpXrpwd9wAAAAAAchehu4BLSkrS0aNHzeXjx48rNjZWXl5eKl26tEqUKGE13snJST4+PqpQoYLZNmfOHNWtW1dFixZVVFSUhgwZokmTJsnT01OSMgXrP//8U5JUqVIlcwwAAAAA5EeE7gJu165datSokbk8ePBgSVJ4eLgWL16crW38+OOPGjNmjJKSklSxYkV9+OGH6tKliz3KBQAAAIA8hdBdwDVs2FCGYWR7/O+//56p7ZNPPrHrewIAAABAXsWN1AAAAAAAsBNCNwAAAAAAdsLp5fnMpL1/5nYJdjO8VsncLgEAAAAAcoSZbgAAAAAA7ITQDQAAAACAnRC6AQAAAACwE0I3AAAAAAB2QugGAAAAAMBOCN0AAAAAANgJoRsAAAAAADshdAMAAAAAYCeEbgAAAAAA7ITQDQCwuS1btqhVq1by8/OTxWLRypUrbzv25ZdflsVi0YwZM6za33nnHdWtW1dFihSRp6dnlutaLJZMr88//9x2OwIAAHCXCN0AAJtLTk5WjRo1NHfu3DuO++qrr7Rjxw75+fll6rt+/bqef/55vfLKK3fcxqJFi3T27Fnz1aZNm7spHQAAwKYcc7sAAED+ExYWprCwsDuOOX36tPr37681a9aoRYsWmfrHjRsnSVq8ePEdt+Pp6SkfH59/XSsAAIA9MdMNALjn0tPT1aVLFw0ZMkRVqlS5q2317dtXJUuW1BNPPKGFCxfKMAwbVQkAAHD3mOkGANxzkydPlqOjo1577bW72s748eP19NNPq0iRIlq7dq1effVVJSUl3fV2AQAAbIXQDQC4p3bv3q2ZM2dqz549slgsd7WtUaNGmV/XqlVLycnJmjp1KqEbAADcNzi9HABwT23dulXnzp1T6dKl5ejoKEdHR504cUKvv/66ypQpc1fbrl27tv744w+lpKTYplgAAIC7xEw3AOCe6tKli0JCQqzaQkND1aVLF3Xv3v2uth0bG6vixYvLxcXlrrYDAABgK4RuAIDNJSUl6ejRo+by8ePHFRsbKy8vL5UuXVolSpSwGu/k5CQfHx9VqFDBbDt58qQuXryokydPKi0tTbGxsZKk8uXLq2jRolq1apXi4+NVp04dubq6KioqSu+++67eeOONe7KPAAAA2UHoBgDY3K5du9SoUSNzefDgwZKk8PDwf3wEWIbRo0crIiLCXK5Vq5YkaePGjWrYsKGcnJw0d+5cDRo0SIZhqHz58po+fbp69eplux0BAAC4S4RuAIDNNWzYMEeP7vr9998ztS1evPiOAb1Zs2Zq1qzZv6gOAADg3uFGagAAAAAA2AmhGwAAAAAAO8nV08u3bNmiqVOnavfu3Tp79qy++uortWnTJsuxL7/8sj788EO9//77GjhwoNl+8eJF9e/fX6tWrZKDg4PatWunmTNnqmjRouaYffv2qW/fvtq5c6ceeOAB9e/fX0OHDrXz3gFA/rHi8NncLsGu2lbwze0SAABAPpWrM93JycmqUaOG5s6de8dxX331lXbs2CE/P79MfZ07d9bBgwcVFRWl1atXa8uWLerdu7fZn5iYqKZNmyogIEC7d+/W1KlTNXbsWC1YsMDm+wMAAAAAwK1ydaY7LCxMYWFhdxxz+vRp9e/fX2vWrFGLFi2s+g4dOqTIyEjt3LlTjz32mCRp9uzZat68uaZNmyY/Pz8tWbJE169f18KFC+Xs7KwqVaooNjZW06dPtwrnAAAAAADY2n19TXd6erq6dOmiIUOGqEqVKpn6o6Oj5enpaQZuSQoJCZGDg4NiYmLMMU8++aScnZ3NMaGhoTp8+LAuXbp02/dOSUlRYmKi1QsAANjWli1b1KpVK/n5+clisWjlypVW/WPHjlXFihXl5uam4sWLKyQkxPwdf6tvv/1WtWvXVuHChVW8ePFMl6udPHlSLVq0UJEiRVSqVCkNGTJEN27csOOeAQBw030duidPnixHR0e99tprWfbHxcWpVKlSVm2Ojo7y8vJSXFycOcbb29tqTMZyxpisTJw4UR4eHubL39//bnYFAABk4Z8uNXvkkUc0Z84c7d+/X9u2bVOZMmXUtGlTnT9/3hyzfPlydenSRd27d9dPP/2kH374QZ06dTL709LS1KJFC12/fl3bt29XRESEFi9erNGjR9t9/wAAuG+f0717927NnDlTe/bskcViuefvP2LECA0ePNhcTkxMJHgDAGBj/3Sp2a3hWZKmT5+ujz/+WPv27VPjxo1148YNDRgwQFOnTlXPnj3NcZUrVza/Xrt2rX7++WetW7dO3t7eqlmzpiZMmKBhw4Zp7NixVmfDAQBga/ftTPfWrVt17tw5lS5dWo6OjnJ0dNSJEyf0+uuvq0yZMpIkHx8fnTt3zmq9Gzdu6OLFi/Lx8THHxMfHW43JWM4YkxUXFxe5u7tbvQAAQO65fv26FixYIA8PD9WoUUOStGfPHp0+fVoODg6qVauWfH19FRYWpgMHDpjrRUdHq1q1alZnvoWGhioxMVEHDx685/sBAChY7tvQ3aVLF+3bt0+xsbHmy8/PT0OGDNGaNWskScHBwbp8+bJ2795trrdhwwalp6erdu3a5pgtW7YoNTXVHBMVFaUKFSqoePHi93anAABAjq1evVpFixaVq6ur3n//fUVFRalkyZKSpN9++03SzWu/R44cqdWrV6t48eJq2LChLl68KOnfX2oGAIAt5GroTkpKMgO1JB0/flyxsbE6efKkSpQooapVq1q9nJyc5OPjowoVKkiSKlWqpGbNmqlXr1768ccf9cMPP6hfv37q0KGD+XixTp06ydnZWT179tTBgwf1xRdfaObMmVanjgMAgPtXo0aNFBsbq+3bt6tZs2Zq3769eaZbenq6JOmtt95Su3btFBQUpEWLFslisWjZsmW5WTYAAJJyOXTv2rVLtWrVUq1atSRJgwcPVq1atXJ0Y5MlS5aoYsWKaty4sZo3b6769etbPYPbw8NDa9eu1fHjxxUUFKTXX39do0eP5nFhAADkEW5ubipfvrzq1Kmjjz/+WI6Ojvr4448lSb6+vpKsr+F2cXFR2bJldfLkSUn//lIzAABsIVdvpNawYUMZhpHt8b///numNi8vLy1duvSO61WvXl1bt27NaXkAAOA+lJ6erpSUFElSUFCQXFxcdPjwYdWvX1+SlJqaqt9//10BAQGSbl5q9s477+jcuXPmU0+ioqLk7u5uFdYBALCH+/bu5QAAIP9LSkrS0aNHzeWMS828vLxUokQJvfPOO3rmmWfk6+urP//8U3PnztXp06f1/PPPS5Lc3d318ssva8yYMfL391dAQICmTp0qSeaYpk2bqnLlyurSpYumTJmiuLg4jRw5Un379pWLi8u932kAQIFC6AYAALlm165datSokbmccc+V8PBwzZ8/X7/88osiIiL0559/qkSJEnr88ce1detWValSxVxn6tSpcnR0VJcuXXT16lXVrl1bGzZsMG+YWqhQIa1evVqvvPKKgoOD5ebmpvDwcI0fP/7e7iwAoEC6b+9eDgB5wZYtW9SqVSv5+fnJYrFo5cqVVv1jx45VxYoV5ebmpuLFiyskJEQxMTFm/++//66ePXsqMDBQhQsXVrly5TRmzBhdv349y/c7evSoihUrJk9PTzvuFXDvZFxq9vfX4sWL5erqqhUrVuj06dNKSUnRmTNn9PXXX+vxxx+32oaTk5OmTZum+Ph4JSYmKioqyiqUS1JAQIC+++47XblyRefPn9e0adPk6MjcAwDA/gjdAHAXkpOTVaNGDc2dOzfL/kceeURz5szR/v37tW3bNpUpU0ZNmzbV+fPnJUm//PKL0tPT9eGHH+rgwYN6//33NX/+fL355puZtpWamqqOHTuqQYMGdt0nAAAA2A5/4gWAuxAWFqawsLDb9nfq1Mlqefr06fr444+1b98+NW7cWM2aNVOzZs3M/rJly+rw4cP64IMPNG3aNKt1R44caT6tYfv27bbdEQAAANgFM90AcI9cv35dCxYskIeHh2rUqHHbcQkJCfLy8rJq27Bhg5YtW3bbGXXg/mHJ5y8AAHKGmW4AsLPVq1erQ4cOunLlinx9fRUVFaWSJUtmOfbo0aOaPXu21Sz3hQsX1K1bN3322Wdyd3e/V2UDAADABpjpBgA7a9SokWJjY7V9+3Y1a9ZM7du317lz5zKNO336tJo1a6bnn39evXr1Mtt79eqlTp066cknn7yXZQMAAMAGCN0AYGdubm4qX7686tSpo48//liOjo76+OOPrcacOXNGjRo1Ut26dbVgwQKrvg0bNph3WnZ0dFTPnj2VkJAgR0dHLVy48F7uCgAAAHKI08sB4B5LT09XSkqKuXz69Gk1atRIQUFBWrRokRwcrP8eGh0drbS0NHP566+/1uTJk7V9+3Y9+OCD96xuAAAA5ByhGwDuQlJSko4ePWouHz9+XLGxsfLy8lKJEiX0zjvv6JlnnpGvr6/+/PNPzZ07V6dPn9bzzz8v6WbgbtiwoQICAjRt2jTzUWKS5OPjI0mqVKmS1Xvu2rVLDg4Oqlq16j3YQwAAANwNQjcA3IVdu3apUaNG5vLgwYMlSeHh4Zo/f75++eUXRURE6M8//1SJEiX0+OOPa+vWrapSpYokKSoqSkePHtXRo0f10EMPWW3bMIx7tyMAAACwC0I3ANyFhg0b3jEcr1ix4o7rd+vWTd26dcvRe/6bdQAAAJA7uJEaAAAAAAB2QugGAAAAAMBOOL0cAG611JLbFdhXJ64TBwAAuJeY6QYAAAAAwE4I3cDfbNmyRa1atZKfn58sFotWrlxp9qWmpmrYsGGqVq2a3Nzc5Ofnp65du+rMmTPmmE2bNslisWT52rlzpzmmdevW8vX1lZubm2rWrKklS5bc610FAAAAYGeEbuBvkpOTVaNGDc2dOzdT35UrV7Rnzx6NGjVKe/bs0YoVK3T48GE988wz5pi6devq7NmzVq+XXnpJgYGBeuyxxyRJ27dvV/Xq1bV8+XLt27dP3bt3V9euXbV69ep7tp8AAAAA7I9ruoG/CQsLU1hYWJZ9Hh4eioqKsmqbM2eOnnjiCZ08eVKlS5eWs7OzfHx8zP7U1FR9/fXX6t+/vyyWm9cLv/nmm1bbGDBggNauXasVK1aoZcuWNt4jAAAAALmFmW7gLiUkJMhiscjT0zPL/m+++UYXLlxQ9+7d/3E7Xl5edqgQAAAAQG4hdAN34dq1axo2bJg6duwod3f3LMd8/PHHCg0N1UMPPXTb7fzvf//Tzp07/zGYAwAAAMhbOL0c+JdSU1PVvn17GYahDz74IMsxf/zxh9asWaP//e9/t93Oxo0b1b17d3300UeqUqWKvcoFAAAAkAsI3cC/kBG4T5w4oQ0bNtx2lnvRokUqUaKE1Y3WbrV582a1atVK77//vrp27WrPkgEAAADkAkI3kEMZgfvIkSPauHGjSpQokeU4wzC0aNEide3aVU5OTpn6N23apJYtW2ry5Mnq3bu3vcsGAAAAkAsI3cDfJCUl6ejRo+by8ePHFRsbKy8vL/n6+uq5557Tnj17tHr1aqWlpSkuLk6S5OXlJWdnZ3O9DRs26Pjx43rppZcyvcfGjRvVsmVLDRgwQO3atTO34ezszM3UAAAAgHyEG6kBf7Nr1y7VqlVLtWrVkiQNHjxYtWrV0ujRo3X69Gl98803+uOPP1SzZk35+vqar+3bt1tt5+OPP1bdunVVsWLFTO8RERGhK1euaOLEiVbbaNu27T3ZRwAAAAD3BjPdwN80bNhQhmHctv9OfbdaunTpbfsWL16sxYsX57Q0AAAAAHkMM90AAAAAANgJoRsAAOA+s2XLFrVq1Up+fn6yWCxauXKl2Zeamqphw4apWrVqcnNzk5+fn7p27aozZ85YbeOZZ55R6dKl5erqKl9fX3Xp0iXTmH379qlBgwZydXWVv7+/pkyZci92DwAKFE4vR76XOu713C7BrpzGvJfbJQAAbCw5OVk1atRQjx49Mt3v48qVK9qzZ49GjRqlGjVq6NKlSxowYICeeeYZ7dq1yxzXqFEjvfnmm/L19dXp06f1xhtv6LnnnjPvQZKYmKimTZsqJCRE8+fP1/79+9WjRw95enryVA0AsCFCNwAAwH0mLCxMYWFhWfZ5eHgoKirKqm3OnDl64okndPLkSZUuXVqSNGjQILM/ICBAw4cPV5s2bZSamionJyctWbJE169f18KFC+Xs7KwqVaooNjZW06dPJ3QDgA1xejkAAEAel5CQIIvFIk9Pzyz7L168qCVLlqhu3bpycnKSJEVHR+vJJ5+0etxlaGioDh8+rEuXLt2LsgGgQCB0AwAA5GHXrl3TsGHD1LFjR7m7u1v1DRs2TG5ubipRooROnjypr7/+2uyLi4uTt7e31fiM5bi4OPsXDgAFBKEbAAAgj0pNTVX79u1lGIY++OCDTP1DhgzR3r17tXbtWhUqVEhdu3bN9qMvAQC2wTXdAAAAeVBG4D5x4oQ2bNiQaZZbkkqWLKmSJUvqkUceUaVKleTv768dO3YoODhYPj4+io+Ptxqfsezj43NP9gEACgJmugEAAPKYjMB95MgRrVu3TiVKlPjHddLT0yVJKSkpkqTg4GBt2bJFqamp5pioqChVqFBBxYsXt0/hAFAAEboBAADuM0lJSYqNjVVsbKwk6fjx44qNjdXJkyeVmpqq5557Trt27dKSJUuUlpamuLg4xcXF6fr165KkmJgYzZkzR7GxseZMeMeOHVWuXDkFBwdLkjp16iRnZ2f17NlTBw8e1BdffKGZM2dq8ODBubXbAJAvcXo5AADAfWbXrl1q1KiRuZwRhMPDwzV27Fh98803kqSaNWtarbdx40Y1bNhQRYoU0YoVKzRmzBglJyfL19dXzZo108iRI+Xi4iLp5qPH1q5dq759+yooKEglS5bU6NGjeVwYANgYoRsAAOA+07Bhwzve8OyfboZWrVo1bdiw4R/fp3r16tq6dWuO6wMAZB+nlwMAAAAAYCeEbgAAAAAA7ITTywEAAOwsYdy43C7BrjzGjMntEgDgvsVMNwAAAAAAdkLoBgAAAADATgjdAAAAAADYSa6G7i1btqhVq1by8/OTxWLRypUrzb7U1FQNGzZM1apVk5ubm/z8/NS1a1edOXPGahsXL15U586d5e7uLk9PT/Xs2VNJSUlWY/bt26cGDRrI1dVV/v7+mjJlyr3YPQAAAABAAZeroTs5OVk1atTQ3LlzM/VduXJFe/bs0ahRo7Rnzx6tWLFChw8f1jPPPGM1rnPnzjp48KCioqK0evVqbdmyRb179zb7ExMT1bRpUwUEBGj37t2aOnWqxo4dqwULFth9/wAAAAAABVuO714eERGhkiVLqkWLFpKkoUOHasGCBapcubL++9//KiAgINvbCgsLU1hYWJZ9Hh4eioqKsmqbM2eOnnjiCZ08eVKlS5fWoUOHFBkZqZ07d+qxxx6TJM2ePVvNmzfXtGnT5OfnpyVLluj69etauHChnJ2dVaVKFcXGxmr69OlW4RwAAAAAAFvL8Uz3u+++q8KFC0uSoqOjNXfuXE2ZMkUlS5bUoEGDbF7grRISEmSxWOTp6Wm+v6enpxm4JSkkJEQODg6KiYkxxzz55JNydnY2x4SGhurw4cO6dOmSXesFAAAAABRsOZ7pPnXqlMqXLy9JWrlypdq1a6fevXurXr16atiwoa3rM127dk3Dhg1Tx44d5e7uLkmKi4tTqVKlrMY5OjrKy8tLcXFx5pjAwECrMd7e3mZf8eLFs3y/lJQUpaSkmMuJiYk22xcAAAAAQMGQ45nuokWL6sKFC5KktWvXqkmTJpIkV1dXXb161bbV/X+pqalq3769DMPQBx98YJf3+LuJEyfKw8PDfPn7+9+T9wUAAAAA5B85Dt1NmjTRSy+9pJdeekm//vqrmjdvLkk6ePCgypQpY+v6zMB94sQJRUVFmbPckuTj46Nz585Zjb9x44YuXrwoHx8fc0x8fLzVmIzljDFZGTFihBISEszXqVOnbLVLAAAA+Bfu9OQbSVqxYoWaNm2qEiVKyGKxKDY2NtM2GjZsKIvFYvV6+eWXzf6ffvpJHTt2lL+/vwoXLqxKlSpp5syZdt4zAPlZjkP33LlzFRwcrPPnz2v58uUqUaKEJGn37t3q2LGjTYvLCNxHjhzRunXrzPfKEBwcrMuXL2v37t1m24YNG5Senq7atWubY7Zs2aLU1FRzTFRUlCpUqHDbU8slycXFRe7u7lYvAAAA5J47Pfkmo79+/fqaPHnyHbfTq1cvnT171nzd+jjZ3bt3q1SpUvrss8908OBBvfXWWxoxYoTmzJlj030BUHDk+JpuT0/PLP/RGTduXI7fPCkpSUePHjWXjx8/rtjYWHl5ecnX11fPPfec9uzZo9WrVystLc28TtvLy0vOzs6qVKmSmjVrpl69emn+/PlKTU1Vv3791KFDB/n5+UmSOnXqpHHjxqlnz54aNmyYDhw4oJkzZ+r999/Pcb0AAADIPXd68o0kdenSRZL0+++/33E7RYoUue0Zjz169LBaLlu2rKKjo7VixQr169cvZwUDgP7lc7q3bt2qF198UXXr1tXp06clSZ9++qm2bduWo+3s2rVLtWrVUq1atSRJgwcPVq1atTR69GidPn1a33zzjf744w/VrFlTvr6+5mv79u3mNpYsWaKKFSuqcePGat68uerXr2/1DG4PDw+tXbtWx48fV1BQkF5//XWNHj2ax4UBAAAUUEuWLFHJkiVVtWpVjRgxQleuXLnj+ISEBHl5ed2j6gDkNzme6V6+fLm6dOmizp07a8+ePeYdvhMSEvTuu+/qu+++y/a2GjZsKMMwbtt/p74MXl5eWrp06R3HVK9eXVu3bs12XQAAAMifOnXqpICAAPn5+Wnfvn0aNmyYDh8+rBUrVmQ5fvv27friiy/07bff3uNKAeQXOQ7db7/9tubPn6+uXbvq888/N9vr1aunt99+26bFAQAAALZ069mO1apVk6+vrxo3bqxjx46pXLlyVmMPHDig1q1ba8yYMWratOm9LhVAPpHj08sPHz6sJ598MlO7h4eHLl++bIuaAAAAgHsi4+a7t95nSJJ+/vlnNW7cWL1799bIkSNzozQA+USOQ7ePj0+mf5Qkadu2bSpbtqxNigIAAADuhYzHivn6+pptBw8eVKNGjRQeHq533nknlyoDkF/k+PTyXr16acCAAVq4cKEsFovOnDmj6OhovfHGGxo1apQ9agQAAADu+OSb0qVL6+LFizp58qTOnDkj6eYZmtLNSSMfHx8dO3ZMS5cuVfPmzVWiRAnt27dPgwYN0pNPPqnq1atLunlK+dNPP63Q0FANHjzYfHpOoUKF9MADD9zjPQaQH+Q4dA8fPlzp6elq3Lixrly5oieffFIuLi5644031L9/f3vUCAAAAGjXrl1q1KiRuTx48GBJUnh4uBYvXqxvvvlG3bt3N/s7dOggSRozZozGjh0rZ2dnrVu3TjNmzFBycrL8/f3Vrl07q9PHv/zyS50/f16fffaZPvvsM7M9ICDgHx9FBgBZyXHotlgseuuttzRkyBAdPXpUSUlJqly5sooWLWqP+gAAAABJ//zkm27duqlbt2637ff399fmzZvv+B5jx47V2LFj/2WFAJBZjkN3BmdnZ1WuXNmWtQAAAAAAkK9kK3S3bdtWixcvlru7u9q2bXvHsbd7xiEAAAAAAAVNtkK3h4eHLBaL+TUAAABwtw4cOJDbJdhV1apVc7sEAPeBbIXuRYsWZfk1AAAAAAC4vRw/pxsAAAAAAGRPtma6a9WqZZ5e/k/27NlzVwUBAAAAAJBfZCt0t2nTxvz62rVrmjdvnipXrqzg4GBJ0o4dO3Tw4EG9+uqrdikSAAAAAIC8KFuhe8yYMebXL730kl577TVNmDAh05hTp07ZtjoAAAAAAPKwHF/TvWzZMnXt2jVT+4svvqjly5fbpCgAAAAAAPKDHIfuwoUL64cffsjU/sMPP8jV1dUmRQEAAAAAbGvLli1q1aqV/Pz8ZLFYtHLlSqt+wzA0evRo+fr6qnDhwgoJCdGRI0esxvz6669q3bq1SpYsKXd3d9WvX18bN240+3/66Sd17NhR/v7+Kly4sCpVqqSZM2fei927b2Xr9PJbDRw4UK+88or27NmjJ554QpIUExOjhQsXatSoUTYvEAAAAABw95KTk1WjRg316NFDbdu2zdQ/ZcoUzZo1SxEREQoMDNSoUaMUGhqqn3/+2ZxgbdmypR5++GFt2LBBhQsX1owZM9SyZUsdO3ZMPj4+2r17t0qVKqXPPvtM/v7+2r59u3r37q1ChQqpX79+93qX7ws5Dt3Dhw9X2bJlNXPmTH322WeSpEqVKmnRokVq3769zQsEAAAAANy9sLAwhYWFZdlnGIZmzJihkSNHqnXr1pKkTz75RN7e3lq5cqU6dOigP//8U0eOHNHHH3+s6tWrS5ImTZqkefPm6cCBA/Lx8VGPHj2stlu2bFlFR0drxYoVhO6caN++PQEbAAAAAPKJ48ePKy4uTiEhIWabh4eHateurejoaHXo0EElSpRQhQoV9Mknn+jRRx+Vi4uLPvzwQ5UqVUpBQUG33XZCQoK8vLzuxW7cl/5V6AYAAAAA5B9xcXGSJG9vb6t2b29vs89isWjdunVq06aNihUrJgcHB5UqVUqRkZEqXrx4ltvdvn27vvjiC3377bf23YH7WI5vpObg4KBChQrd9gUAAAAAyH8Mw1Dfvn1VqlQpbd26VT/++KPatGmjVq1a6ezZs5nGHzhwQK1bt9aYMWPUtGnTXKj4/pDjme6vvvrKajk1NVV79+5VRESExo0bZ7PCAAAAAAD3ho+PjyQpPj5evr6+Znt8fLxq1qwpSdqwYYNWr16tS5cuyd3dXZI0b948RUVFKSIiQsOHDzfX+/nnn9W4cWP17t1bI0eOvHc7ch/K8Ux369atrV7PPfec3nnnHU2ZMkXffPONPWoEAAAAkAVbPAKqTJkyslgsVq9JkyZZjVmzZo3q1KmjYsWK6YEHHlC7du30+++/23nvcC8FBgbKx8dH69evN9sSExMVExOj4OBgSdKVK1ck3Tz7+VYODg5KT083lw8ePKhGjRopPDxc77zzzj2o/v6W49B9O3Xq1LH6BgEAAACwr4xHQM2dOzfL/oxHQM2fP18xMTFyc3NTaGiorl27ZjVu/PjxOnv2rPnq37+/2Xf8+HG1bt1aTz/9tGJjY7VmzRr9+eefWT5yCve3pKQkxcbGKjY2VtLN721sbKxOnjwpi8WigQMH6u2339Y333yj/fv3q2vXrvLz81ObNm0kScHBwSpevLjCw8P1008/6ddff9WQIUN0/PhxtWjRQtLNU8obNWqkpk2bavDgwYqLi1NcXJzOnz+fS3ud+2xyI7WrV69q1qxZevDBB22xOQAAAADZcLePgMpQrFgx8/Tiv9u9e7fS0tL09ttvmzOcb7zxhlq3bq3U1FQ5OTnZeK9gL7t27VKjRo3M5cGDB0uSwsPDtXjxYg0dOlTJycnq3bu3Ll++rPr16ysyMtJ8RnfJkiUVGRmpt956S08//bRSU1NVpUoVff3116pRo4Yk6csvv9T58+f12WefmY+YlqSAgIACe3ZEjkN38eLFZbFYzGXDMPTXX3+pSJEiVgcVAAAAQO7JziOgMkyaNEkTJkxQ6dKl1alTJw0aNEiOjjejQlBQkBwcHLRo0SJ169ZNSUlJ+vTTTxUSEkLgzmMaNmwowzBu22+xWDR+/HiNHz/+tmMee+wxrVmz5rb9Y8eO1dixY++mzHwnx6H7/ffftwrdDg4OeuCBB1S7du3b3iYeAAAAwL2VnUdASdJrr72mRx99VF5eXtq+fbtGjBihs2fPavr06ZJuXuu7du1atW/fXn369FFaWpqCg4P13Xff3budAfKwHIfup59+Wv7+/lbBO8PJkydVunRpmxQGAAAAwP4yTjGWpOrVq8vZ2Vl9+vTRxIkT5eLiori4OPXq1Uvh4eHq2LGj/vrrL40ePVrPPfecoqKisswFAP5PjkN3YGCgzp49q1KlSlm1X7hwQYGBgUpLS7NZcQAAAAD+new8AiortWvX1o0bN/T777+rQoUKmjt3rjw8PDRlyhRzzGeffSZ/f3/FxMSoTp06dtsH/INf8vkfPCre/lT4vCTHdy+/3TUASUlJ5gX2AAAAAHJXdh4BlZXY2Fg5ODiYk2xXrlzJ9IioQoUKSZLVY6IAZC3bM90Zp51YLBaNHj1aRYoUMfvS0tIUExNzx7+YAQAAALCtpKQkHT161FzOeASUl5eXSpcubT4C6uGHH1ZgYKBGjRpl9Qio6OhoxcTEqFGjRipWrJiio6M1aNAgvfjii+b9mlq0aKH3339f48ePN08vf/PNNxUQEKBatWrlxm4DeUq2Q/fevXsl3Zzp3r9/v5ydnc0+Z2dn1ahRQ2+88YbtKwQAAACQpbt9BJSLi4s+//xzjR07VikpKQoMDNSgQYOsrvN++umntXTpUk2ZMkVTpkxRkSJFFBwcrMjISBUuXPje7jCQB2U7dG/cuFGS1L17d82cOVPu7u52KwoAAADAP7vbR0A9+uij2rFjxz++T4cOHaweMQYg+3J8I7VFixZZLZ84cULJycmqWLFipms9AAAAAAAoyLKdkhcuXGg+qy9D7969VbZsWVWrVk1Vq1bVqVOnbF4gAAAAAAB5VbZnuhcsWKA+ffqYy5GRkVq0aJE++eQTVapUSf369dO4ceP0n//8xy6FAgAAAAXB2bOpuV2C3fj6OuV2CcA9l+3QfeTIET322GPm8tdff63WrVurc+fOkqR3331X3bt3t32FAAAAAADkUdk+vfzq1atWN0/bvn27nnzySXO5bNmyiouLs211AAAAAADkYdkO3QEBAdq9e7ck6c8//9TBgwdVr149sz8uLk4eHh62rxAAAAAAgDwq26eXh4eHq2/fvjp48KA2bNigihUrKigoyOzfvn27qlatapciAQAAAADIi7IduocOHaorV65oxYoV8vHx0bJly6z6f/jhB3Xs2NHmBQIAAAAAkFdlO3Q7ODho/PjxGj9+fJb9fw/hAAAAAAAUdNm+phsAAAAAAOQMoRsAAAAAADshdAMAAAAAYCeEbgAAAAAA7ITQDQAAAACAnWTr7uWDBw/O9ganT5+e7bFbtmzR1KlTtXv3bp09e1ZfffWV2rRpY/YbhqExY8boo48+0uXLl1WvXj198MEHevjhh80xFy9eVP/+/bVq1So5ODioXbt2mjlzpooWLWqO2bdvn/r27audO3fqgQceUP/+/TV06NBs1wkAAAAAwL+RrdC9d+9eq+U9e/boxo0bqlChgiTp119/VaFChRQUFJSjN09OTlaNGjXUo0cPtW3bNlP/lClTNGvWLEVERCgwMFCjRo1SaGiofv75Z7m6ukqSOnfurLNnzyoqKkqpqanq3r27evfuraVLl0qSEhMT1bRpU4WEhGj+/Pnav3+/evToIU9PT/Xu3TtH9QIAAAAAkBPZCt0bN240v54+fbqKFSumiIgIFS9eXJJ06dIlde/eXQ0aNMjRm4eFhSksLCzLPsMwNGPGDI0cOVKtW7eWJH3yySfy9vbWypUr1aFDBx06dEiRkZHauXOnHnvsMUnS7Nmz1bx5c02bNk1+fn5asmSJrl+/roULF8rZ2VlVqlRRbGyspk+fTugGAAAAANhVjq/pfu+99zRx4kQzcEtS8eLF9fbbb+u9996zWWHHjx9XXFycQkJCzDYPDw/Vrl1b0dHRkqTo6Gh5enqagVuSQkJC5ODgoJiYGHPMk08+KWdnZ3NMaGioDh8+rEuXLt32/VNSUpSYmGj1AgAAAAAgJ3IcuhMTE3X+/PlM7efPn9dff/1lk6IkKS4uTpLk7e1t1e7t7W32xcXFqVSpUlb9jo6O8vLyshqT1TZufY+sTJw4UR4eHubL39//7nYIAAAAAFDg5Dh0P/vss+revbtWrFihP/74Q3/88YeWL1+unj17Znlddl41YsQIJSQkmK9Tp07ldkkAAAAAgDwmW9d032r+/Pl644031KlTJ6Wmpt7ciKOjevbsqalTp9qsMB8fH0lSfHy8fH19zfb4+HjVrFnTHHPu3Dmr9W7cuKGLFy+a6/v4+Cg+Pt5qTMZyxpisuLi4yMXF5a73AwAAAABQcOV4prtIkSKaN2+eLly4oL1792rv3r26ePGi5s2bJzc3N5sVFhgYKB8fH61fv95sS0xMVExMjIKDgyVJwcHBunz5snbv3m2O2bBhg9LT01W7dm1zzJYtW8w/EEhSVFSUKlSoYHVdOgAAAAAAtpbj0J3h7NmzOnv2rB5++GG5ubnJMIwcbyMpKUmxsbGKjY2VdPPmabGxsTp58qQsFosGDhyot99+W998843279+vrl27ys/Pz3yWd6VKldSsWTP16tVLP/74o3744Qf169dPHTp0kJ+fnySpU6dOcnZ2Vs+ePXXw4EF98cUXmjlzZo6ePQ4AAAAAwL+R49PLL1y4oPbt22vjxo2yWCw6cuSIypYtq549e6p48eI5uoP5rl271KhRI3M5IwiHh4dr8eLFGjp0qJKTk9W7d29dvnxZ9evXV2RkpPmMbklasmSJ+vXrp8aNG8vBwUHt2rXTrFmzzH4PDw+tXbtWffv2VVBQkEqWLKnRo0fzuDAAAAAAgN3lOHQPGjRITk5OOnnypCpVqmS2v/DCCxo8eHCOQnfDhg3vOENusVg0fvx4jR8//rZjvLy8tHTp0ju+T/Xq1bV169Zs1wUAAAAAgC3kOHSvXbtWa9as0UMPPWTV/vDDD+vEiRM2KwwAAAAAgLwux9d0Jycnq0iRIpnaL168yN2+AQAAAAC4RY5Dd4MGDfTJJ5+YyxaLRenp6ZoyZYrV9dkAAAAAABR0OT69fMqUKWrcuLF27dql69eva+jQoTp48KAuXryoH374wR41AgAAAACQJ+V4prtq1ar69ddfVb9+fbVu3VrJyclq27at9u7dq3LlytmjRgAAAAAA8qQcz3SfPHlS/v7+euutt7LsK126tE0KAwAAAAAgr8vxTHdgYKDOnz+fqf3ChQsKDAy0SVEAAAAAYEt//fWXBg4cqICAABUuXFh169bVzp07zX7DMDR69Gj5+vqqcOHCCgkJ0ZEjR6y2sWfPHjVp0kSenp4qUaKEevfuraSkpHu9K8hjchy6DcOQxWLJ1J6UlCRXV1ebFAUAAAAAtvTSSy8pKipKn376qfbv36+mTZsqJCREp0+flnTz3lWzZs3S/PnzFRMTIzc3N4WGhuratWuSpDNnzigkJETly5dXTEyMIiMjdfDgQXXr1i0X9wp5QbZPLx88eLCkm3crHzVqlNVjw9LS0hQTE6OaNWvavEAAAAAAuBtXr17V8uXL9fXXX+vJJ5+UJI0dO1arVq3SBx98oAkTJmjGjBkaOXKkWrduLUn65JNP5O3trZUrV6pDhw5avXq1nJycNHfuXDk43Jy7nD9/vqpXr66jR4+qfPnyubZ/uL9lO3Tv3btX0s2Z7v3798vZ2dnsc3Z2Vo0aNfTGG2/YvkIAAAAAuAs3btxQWlpapjNzCxcurG3btun48eOKi4tTSEiI2efh4aHatWsrOjpaHTp0UEpKipydnc3AnbG+JG3bto3QjdvKdujeuHGjJKl79+6aOXOm3N3d7VYUAAAAANhKsWLFFBwcrAkTJqhSpUry9vbWf//7X0VHR6t8+fKKi4uTJHl7e1ut5+3tbfY9/fTTGjx4sKZOnaoBAwYoOTlZw4cPlySdPXv23u4Q8pQcX9O9aNEiubu76+jRo1qzZo2uXr0q6eYMOAAAAADcjz799FMZhqEHH3xQLi4umjVrljp27Gg1c30nVapUUUREhN577z0VKVJEPj4+CgwMlLe3d7a3gYIpx5+OixcvqnHjxnrkkUfUvHlz8686PXv21Ouvv27zAgEAAADgbpUrV06bN29WUlKSTp06pR9//FGpqakqW7asfHx8JEnx8fFW68THx5t9ktSpUyfFxcXp9OnTunDhgsaOHavz58+rbNmy93RfkLfkOHQPHDhQTk5OOnnypNXN1F544QVFRkbatDgAAAAAsCU3Nzf5+vrq0qVLWrNmjVq3bq3AwED5+Pho/fr15rjExETFxMQoODg40za8vb1VtGhRffHFF3J1dVWTJk3u5S4gj8n2Nd0Z1q5dqzVr1uihhx6yan/44Yd14sQJmxUGAAAAALayZs0aGYahChUq6OjRoxoyZIgqVqyo7t27y2KxaODAgXr77bf18MMPKzAwUKNGjZKfn5/atGljbmPOnDmqW7euihYtqqioKA0ZMkSTJk2Sp6dnru0X7n85Dt3JyclWM9wZLl68KBcXF5sUBQAAAAC2lJCQoBEjRuiPP/6Ql5eX2rVrp3feeUdOTk6SpKFDhyo5OVm9e/fW5cuXVb9+fUVGRlrd8fzHH3/UmDFjlJSUpIoVK+rDDz9Uly5dcmuXkEfkOHQ3aNBAn3zyiSZMmCDp5nO709PTNWXKFDVq1MjmBQIAAADA3Wrfvr3at29/236LxaLx48dr/Pjxtx3zySef2KM05HM5Dt1TpkxR48aNtWvXLl2/fl1Dhw7VwYMHdfHiRf3www/2qBEAAAAAgDwpxzdSq1q1qn799VfVr19frVu3VnJystq2bau9e/eqXLly9qgRAAAAAIA8Kccz3ZLk4eGht956y9a1AAAAAEAmgauW5XYJdnW81fO5XQLsKFuhe9++fdneYPXq1f91MQAAAAAA5CfZCt01a9aUxWKRYRh3HGexWJSWlmaTwgAAAAAAyOuyFbqPHz9u7zoAAAAAAMh3shW6AwIC7F0HAAAAAAD5zr+6kdrhw4c1e/ZsHTp0SJJUqVIl9e/fXxUqVLBpcQAAAAAA5GU5fmTY8uXLVbVqVe3evVs1atRQjRo1tGfPHlWtWlXLly+3R40AAAAAAORJOZ7pHjp0qEaMGKHx48dbtY8ZM0ZDhw5Vu3btbFYcAAAAAAB5WY5nus+ePauuXbtman/xxRd19uxZmxQFAAAAAEB+kOPQ3bBhQ23dujVT+7Zt29SgQQObFAUAAAAAQH6Q49PLn3nmGQ0bNky7d+9WnTp1JEk7duzQsmXLNG7cOH3zzTdWYwEAAAAAKKhyHLpfffVVSdK8efM0b968LPskyWKxKC0t7S7LAwAAAAAg78px6E5PT7dHHQAAAAAA5Ds5vqYbAAAAAABkT45nuiVp586d2rhxo86dO5dp5nv69Ok2KQwAAAAAgLwux6H73Xff1ciRI1WhQgV5e3vLYrGYfbd+DQAAAABAQZfj0D1z5kwtXLhQ3bp1s0M5AAAAAADkHzm+ptvBwUH16tWzRy0AAAAAAOQrOQ7dgwYN0ty5c+1RCwAAAAAA+UqOTy9/44031KJFC5UrV06VK1eWk5OTVf+KFStsVhwAAAAAAHlZjkP3a6+9po0bN6pRo0YqUaIEN08DAAAAAOA2chy6IyIitHz5crVo0cIe9QAAAAAAkG/k+JpuLy8vlStXzh61AAAAAACQr+Q4dI8dO1ZjxozRlStX7FEPAAAAAAD5Ro5PL581a5aOHTsmb29vlSlTJtON1Pbs2WOz4gAAAAAAyMtyHLrbtGljhzIAAAAAAMh/chy6x4wZY486AAAAAADId3J8TXeG3bt367PPPtNnn32mvXv32rImU1pamkaNGqXAwEAVLlxY5cqV04QJE2QYhjnGMAyNHj1avr6+Kly4sEJCQnTkyBGr7Vy8eFGdO3eWu7u7PD091bNnTyUlJdmlZgAAAAAAMuR4pvvcuXPq0KGDNm3aJE9PT0nS5cuX1ahRI33++ed64IEHbFbc5MmT9cEHHygiIkJVqlTRrl271L17d3l4eOi1116TJE2ZMkWzZs1SRESEAgMDNWrUKIWGhurnn3+Wq6urJKlz5846e/asoqKilJqaqu7du6t3795aunSpzWoFAAAAAODvcjzT3b9/f/311186ePCgLl68qIsXL+rAgQNKTEw0g7CtbN++Xa1bt1aLFi1UpkwZPffcc2ratKl+/PFHSTdnuWfMmKGRI0eqdevWql69uj755BOdOXNGK1eulCQdOnRIkZGR+s9//qPatWurfv36mj17tj7//HOdOXPGpvUCAAAAAHCrHIfuyMhIzZs3T5UqVTLbKleurLlz5+r777+3aXF169bV+vXr9euvv0qSfvrpJ23btk1hYWGSpOPHjysuLk4hISHmOh4eHqpdu7aio6MlSdHR0fL09NRjjz1mjgkJCZGDg4NiYmJsWi8AAAAAALfK8enl6enpmR4TJklOTk5KT0+3SVEZhg8frsTERFWsWFGFChVSWlqa3nnnHXXu3FmSFBcXJ0ny9va2Ws/b29vsi4uLU6lSpaz6HR0d5eXlZY7JSkpKilJSUszlxMREm+wTAAAAAKDgyPFM99NPP60BAwZYnZp9+vRpDRo0SI0bN7Zpcf/73/+0ZMkSLV26VHv27FFERISmTZumiIgIm75PViZOnCgPDw/z5e/vb/f3BAAAAADkLzkO3XPmzFFiYqLKlCmjcuXKqVy5cgoMDFRiYqJmz55t0+KGDBmi4cOHq0OHDqpWrZq6dOmiQYMGaeLEiZIkHx8fSVJ8fLzVevHx8Wafj4+Pzp07Z9V/48YNXbx40RyTlREjRighIcF8nTp1ypa7BgAAAAAoAHJ8erm/v7/27NmjdevW6ZdffpEkVapUyeq6alu5cuWKHBys/y5QqFAh8zT2wMBA+fj4aP369apZs6akm6eBx8TE6JVXXpEkBQcH6/Lly9q9e7eCgoIkSRs2bFB6erpq16592/d2cXGRi4uLzfcJAAAAAFBw5Dh0S5LFYlGTJk3UpEkTW9djpVWrVnrnnXdUunRpValSRXv37tX06dPVo0cPs46BAwfq7bff1sMPP2w+MszPz09t2rSRdPMPAs2aNVOvXr00f/58paamql+/furQoYP8/PzsWj8AAAAAoGDL9unlGzZsUOXKlbO8oVhCQoKqVKmirVu32rS42bNn67nnntOrr76qSpUq6Y033lCfPn00YcIEc8zQoUPVv39/9e7dW48//riSkpIUGRlpPqNbkpYsWaKKFSuqcePGat68uerXr68FCxbYtFYAAAAAAP4u2zPdM2bMUK9eveTu7p6pz8PDQ3369NH06dPVoEEDmxVXrFgxzZgxQzNmzLjtGIvFovHjx2v8+PG3HePl5aWlS5farC4AAAAAALIj2zPdP/30k5o1a3bb/qZNm2r37t02KQoAAAAAgPwg26E7Pj4+y+dzZ3B0dNT58+dtUhQAAAAAAPlBtkP3gw8+qAMHDty2f9++ffL19bVJUQAAAAAA5AfZDt3NmzfXqFGjdO3atUx9V69e1ZgxY9SyZUubFgcAAAAAQF6W7RupjRw5UitWrNAjjzyifv36qUKFCpKkX375RXPnzlVaWpreeustuxUKAAAAAEBek+3Q7e3tre3bt+uVV17RiBEjZBiGpJt3Dw8NDdXcuXPl7e1tt0IBAAAAAMhrsh26JSkgIEDfffedLl26pKNHj8owDD388MMqXry4veoDAAAAACDPylHozlC8eHE9/vjjtq4FAAAAAIB8Jds3UgMAAAAAADlD6AYAAAAAwE4I3QAAAAAA2Em2Qvejjz6qS5cuSZLGjx+vK1eu2LUoAAAAAADyg2yF7kOHDik5OVmSNG7cOCUlJdm1KAAAAAAA8oNs3b28Zs2a6t69u+rXry/DMDRt2jQVLVo0y7GjR4+2aYEAAAAAAORV2Qrdixcv1pgxY7R69WpZLBZ9//33cnTMvKrFYiF0AwAAAADw/2UrdFeoUEGff/65JMnBwUHr169XqVKl7FoYAAAAAAB5XbZC963S09PtUQcAAAAAAPlOjkO3JB07dkwzZszQoUOHJEmVK1fWgAEDVK5cOZsWBwAAAABAXpbj53SvWbNGlStX1o8//qjq1aurevXqiomJUZUqVRQVFWWPGgEAAAAAyJNyPNM9fPhwDRo0SJMmTcrUPmzYMDVp0sRmxQEAAAAAkJfleKb70KFD6tmzZ6b2Hj166Oeff7ZJUQAAAAAA5Ac5Dt0PPPCAYmNjM7XHxsZyR3MAAAAAAG6R49PLe/Xqpd69e+u3335T3bp1JUk//PCDJk+erMGDB9u8QAAAAAAA8qoch+5Ro0apWLFieu+99zRixAhJkp+fn8aOHavXXnvN5gUCAAAAAJBX5Th0WywWDRo0SIMGDdJff/0lSSpWrJjNCwMAAAAAIK/7V8/pzkDYBgAAAADg9nJ8IzUAAAAAAJA9hG4AAAAAAOyE0A0AAAAAgJ3kKHSnpqaqcePGOnLkiL3qAQAAAAAg38hR6HZyctK+ffvsVQsAAAAAAPlKjk8vf/HFF/Xxxx/boxYAAAAAAPKVHD8y7MaNG1q4cKHWrVunoKAgubm5WfVPnz7dZsUBAAAAAJCX5Th0HzhwQI8++qgk6ddff7Xqs1gstqkKAAAAAIB8IMehe+PGjfaoAwAAAACAfOdfPzLs6NGjWrNmja5evSpJMgzDZkUBAAAAAJAf5Dh0X7hwQY0bN9Yjjzyi5s2b6+zZs5Kknj176vXXX7d5gQAAAAAA5FU5Dt2DBg2Sk5OTTp48qSJFipjtL7zwgiIjI21aHAAAAAAAeVmOr+leu3at1qxZo4ceesiq/eGHH9aJEydsVhgAAAAAAHldjme6k5OTrWa4M1y8eFEuLi42KQoAAAAAgPwgx6G7QYMG+uSTT8xli8Wi9PR0TZkyRY0aNbJpcQAAAAAA5GU5Pr18ypQpaty4sXbt2qXr169r6NChOnjwoC5evKgffvjBHjUCAAAAAJAn5Ximu2rVqvr1119Vv359tW7dWsnJyWrbtq327t2rcuXK2aNGAAAAAADypBzPdEuSh4eH3nrrLVvXAgAAAABAvvKvQvelS5f08ccf69ChQ5KkypUrq3v37vLy8rJpcQAAAAAA5GU5Pr18y5YtKlOmjGbNmqVLly7p0qVLmjVrlgIDA7VlyxZ71AgAAAAAQJ6U45nuvn376oUXXtAHH3ygQoUKSZLS0tL06quvqm/fvtq/f7/NiwQAAAAAIC/K8Uz30aNH9frrr5uBW5IKFSqkwYMH6+jRozYtTpJOnz6tF198USVKlFDhwoVVrVo17dq1y+w3DEOjR4+Wr6+vChcurJCQEB05csRqGxcvXlTnzp3l7u4uT09P9ezZU0lJSTavFQAAAACAW+U4dD/66KPmtdy3OnTokGrUqGGTojJcunRJ9erVk5OTk77//nv9/PPPeu+991S8eHFzzJQpUzRr1izNnz9fMTExcnNzU2hoqK5du2aO6dy5sw4ePKioqCitXr1aW7ZsUe/evW1aKwAAAAAAf5et08v37dtnfv3aa69pwIABOnr0qOrUqSNJ2rFjh+bOnatJkybZtLjJkyfL399fixYtMtsCAwPNrw3D0IwZMzRy5Ei1bt1akvTJJ5/I29tbK1euVIcOHXTo0CFFRkZq586deuyxxyRJs2fPVvPmzTVt2jT5+fnZtGYAAAAAADJkK3TXrFlTFotFhmGYbUOHDs00rlOnTnrhhRdsVtw333yj0NBQPf/889q8ebMefPBBvfrqq+rVq5ck6fjx44qLi1NISIi5joeHh2rXrq3o6Gh16NBB0dHR8vT0NAO3JIWEhMjBwUExMTF69tlns3zvlJQUpaSkmMuJiYk22y8AAAAAQMGQrdB9/Phxe9eRpd9++00ffPCBBg8erDfffFM7d+7Ua6+9JmdnZ4WHhysuLk6S5O3tbbWet7e32RcXF6dSpUpZ9Ts6OsrLy8sck5WJEydq3LhxNt4jAAAAAEBBkq3QHRAQYO86spSenq7HHntM7777riSpVq1aOnDggObPn6/w8HC7vveIESM0ePBgczkxMVH+/v52fU8AAAAAQP6S40eGSdKZM2e0bds2nTt3Tunp6VZ9r732mk0KkyRfX19VrlzZqq1SpUpavny5JMnHx0eSFB8fL19fX3NMfHy8atasaY45d+6c1TZu3LihixcvmutnxcXFRS4uLrbYDQAAAABAAZXj0L148WL16dNHzs7OKlGihCwWi9lnsVhsGrrr1aunw4cPW7X9+uuv5sx7YGCgfHx8tH79ejNkJyYmKiYmRq+88ookKTg4WJcvX9bu3bsVFBQkSdqwYYPS09NVu3Ztm9UKAAAAAMDf5Th0jxo1SqNHj9aIESPk4JDjJ47lyKBBg1S3bl29++67at++vX788UctWLBACxYskHQz5A8cOFBvv/22Hn74YQUGBmrUqFHy8/NTmzZtJN2cGW/WrJl69eql+fPnKzU1Vf369VOHDh24czkAAAAAwK5yHLqvXLmiDh062D1wS9Ljjz+ur776SiNGjND48eMVGBioGTNmqHPnzuaYoUOHKjk5Wb1799bly5dVv359RUZGytXV1RyzZMkS9evXT40bN5aDg4PatWunWbNm2b1+AAAAAEDBluPQ3bNnTy1btkzDhw+3Rz2ZtGzZUi1btrxtv8Vi0fjx4zV+/PjbjvHy8tLSpUvtUR4AAAAAALeV49A9ceJEtWzZUpGRkapWrZqcnJys+qdPn26z4gAAAAAAyMv+Vehes2aNKlSoIEmZbqQGAAAAAABuynHofu+997Rw4UJ169bNDuUAAAAAAJB/5PhuaC4uLqpXr549agEAAAAAIF/JcegeMGCAZs+ebY9aAAAAAADIV3J8evmPP/6oDRs2aPXq1apSpUqmG6mtWLHCZsUBAAAAAJCX5Th0e3p6qm3btvaoBQAAAACAfCXHoXvRokX2qAMAAAAAgHwnx9d0AwAAAACA7MnxTHdgYOAdn8f922+/3VVBAAAAAADkFzkO3QMHDrRaTk1N1d69exUZGakhQ4bYqi4AAAAAAPK8HIfuAQMGZNk+d+5c7dq1664LAgAAAAAgv7DZNd1hYWFavny5rTYHAAAAAECeZ7PQ/eWXX8rLy8tWmwMAAAAAIM/L8enltWrVsrqRmmEYiouL0/nz5zVv3jybFgcAAAAAQF6W49Ddpk0bq2UHBwc98MADatiwoSpWrGirugAAAAAAyPNyHLrHjBljjzoAAAAAAMh3bHZNNwAAAAAAsJbtmW4HBwera7mzYrFYdOPGjbsuCgAAAACA/CDbofurr766bV90dLRmzZql9PR0mxQFAAAAAEB+kO3Q3bp160xthw8f1vDhw7Vq1Sp17txZ48ePt2lxAAAAAADkZf/qmu4zZ86oV69eqlatmm7cuKHY2FhFREQoICDA1vUBAAAAAJBn5Sh0JyQkaNiwYSpfvrwOHjyo9evXa9WqVapataq96gMAAAAAIM/K9unlU6ZM0eTJk+Xj46P//ve/WZ5uDgAAAAAA/k+2Q/fw4cNVuHBhlS9fXhEREYqIiMhy3IoVK2xWHAAAAAAAeVm2Q3fXrl3/8ZFhAAAAAADg/2Q7dC9evNiOZQAAAAAAkP/8q7uXAwAAAACAf0boBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYSZ4K3ZMmTZLFYtHAgQPNtmvXrqlv374qUaKEihYtqnbt2ik+Pt5qvZMnT6pFixYqUqSISpUqpSFDhujGjRv3uHoAAAAAQEGTZ0L3zp079eGHH6p69epW7YMGDdKqVau0bNkybd68WWfOnFHbtm3N/rS0NLVo0ULXr1/X9u3bFRERocWLF2v06NH3ehcAAAAAAAVMngjdSUlJ6ty5sz766CMVL17cbE9ISNDHH3+s6dOn6+mnn1ZQUJAWLVqk7du3a8eOHZKktWvX6ueff9Znn32mmjVrKiwsTBMmTNDcuXN1/fr13NolAAAAAEABkCdCd9++fdWiRQuFhIRYte/evVupqalW7RUrVlTp0qUVHR0tSYqOjla1atXk7e1tjgkNDVViYqIOHjx4b3YAAAAAAFAgOeZ2Af/k888/1549e7Rz585MfXFxcXJ2dpanp6dVu7e3t+Li4swxtwbujP6MvttJSUlRSkqKuZyYmPhvdwEAAAAAUEDd1zPdp06d0oABA7RkyRK5urre0/eeOHGiPDw8zJe/v/89fX8AAAAAQN53X4fu3bt369y5c3r00Ufl6OgoR0dHbd68WbNmzZKjo6O8vb11/fp1Xb582Wq9+Ph4+fj4SJJ8fHwy3c08YzljTFZGjBihhIQE83Xq1Cnb7hwAAAAAIN+7r0N348aNtX//fsXGxpqvxx57TJ07dza/dnJy0vr16811Dh8+rJMnTyo4OFiSFBwcrP379+vcuXPmmKioKLm7u6ty5cq3fW8XFxe5u7tbvQAAAAAAyIn7+pruYsWKqWrVqlZtbm5uKlGihNnes2dPDR48WF5eXnJ3d1f//v0VHBysOnXqSJKaNm2qypUrq0uXLpoyZYri4uI0cuRI9e3bVy4uLvd8nwAAAAAABcd9Hbqz4/3335eDg4PatWunlJQUhYaGat68eWZ/oUKFtHr1ar3yyisKDg6Wm5ubwsPDNX78+FysGgAAAABQEOS50L1p0yarZVdXV82dO1dz58697ToBAQH67rvv7FwZAAAAAADW7utrugEAAAAAyMsI3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAAAAALATQjcAAAAAAHZC6AYAAAAAwE4I3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAAAAALATQjcAAAAAAHZC6AYAAAAAwE4I3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAAAAALATQjcAAAAAAHZC6AYAAAAAwE4I3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAAAAALATQjcAAAAAAHZC6AYAAAAAwE4I3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAAAAALATQjcAAAAAAHZC6AYAAAAAwE4I3QAAAAAA2AmhGwAAAAAAOyF0AwAAAABgJ4RuAAAAAADshNANAAAAAICd3Pehe+LEiXr88cdVrFgxlSpVSm3atNHhw4etxly7dk19+/ZViRIlVLRoUbVr107x8fFWY06ePKkWLVqoSJEiKlWqlIYMGaIbN27cy10BAAAAABQw933o3rx5s/r27asdO3YoKipKqampatq0qZKTk80xgwYN0qpVq7Rs2TJt3rxZZ86cUdu2bc3+tLQ0tWjRQtevX9f27dsVERGhxYsXa/To0bmxSwAAAACAAsIxtwv4J5GRkVbLixcvVqlSpbR79249+eSTSkhI0Mcff6ylS5fq6aefliQtWrRIlSpV0o4dO1SnTh2tXbtWP//8s9atWydvb2/VrFlTEyZM0LBhwzR27Fg5Ozvnxq4BAAAAAPK5+36m++8SEhIkSV5eXpKk3bt3KzU1VSEhIeaYihUrqnTp0oqOjpYkRUdHq1q1avL29jbHhIaGKjExUQcPHryH1QMAAAAACpL7fqb7Vunp6Ro4cKDq1aunqlWrSpLi4uLk7OwsT09Pq7He3t6Ki4szx9wauDP6M/qykpKSopSUFHM5MTHRVrsBAAAAACgg8tRMd9++fXXgwAF9/vnndn+viRMnysPDw3z5+/vb/T0BAAAAAPlLngnd/fr10+rVq7Vx40Y99NBDZruPj4+uX7+uy5cvW42Pj4+Xj4+POebvdzPPWM4Y83cjRoxQQkKC+Tp16pQN9wYAAAAAUBDc96HbMAz169dPX331lTZs2KDAwECr/qCgIDk5OWn9+vVm2+HDh3Xy5EkFBwdLkoKDg7V//36dO3fOHBMVFSV3d3dVrlw5y/d1cXGRu7u71QsAAAAAgJy476/p7tu3r5YuXaqvv/5axYoVM6/B9vDwUOHCheXh4aGePXtq8ODB8vLykru7u/r376/g4GDVqVNHktS0aVNVrlxZXbp00ZQpUxQXF6eRI0eqb9++cnFxyc3dAwAAAADkY/d96P7ggw8kSQ0bNrRqX7Rokbp16yZJev/99+Xg4KB27dopJSVFoaGhmjdvnjm2UKFCWr16tV555RUFBwfLzc1N4eHhGj9+/L3aDQAAAABAAXTfh27DMP5xjKurq+bOnau5c+fedkxAQIC+++47W5YGAAAAAMAd3ffXdAMAAAAAkFcRugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnhG4AAAAAAOyE0A0AAAAAgJ0QugEAAAAAsBNCNwAAAAAAdkLoBgAAAADATgjdAAAAAADYCaEbAAAAAAA7IXQDAAAAAGAnBSp0z507V2XKlJGrq6tq166tH3/8MbdLAgAAAADkYwUmdH/xxRcaPHiwxowZoz179qhGjRoKDQ3VuXPncrs0AAAAAEA+VWBC9/Tp09WrVy91795dlStX1vz581WkSBEtXLgwt0sDAAAAAORTjrldwL1w/fp17d69WyNGjDDbHBwcFBISoujo6CzXSUlJUUpKirmckJAgSUpMTLRvsXfpWtJfuV2C3SQmOv+r9VKvpfzzoDzM6V9+Jq8lXrNxJfeXxEL/8mf1im3ruO/8y8/LlXz8b4skJSa65Xyl5CTbF3I/uc9/3+Wef3dcEq/l739zLf/y85KUlL9/jv7t/xv/+ivVxpXcP9zcnP7VeulX8vcv6H+dMfL3j9B9/7so4/tmGMYdx1mMfxqRD5w5c0YPPvigtm/fruDgYLN96NCh2rx5s2JiYjKtM3bsWI0bN+5elgkAAAAAyGNOnTqlhx566Lb9BWKm+98YMWKEBg8ebC6np6fr4sWLKlGihCwWSy5Wdv9ITEyUv7+/Tp06JXd399wu577AMckaxyVrHJescVwy45hkjeOSNY5L1jgumXFMssZxyRrHJTPDMPTXX3/Jz8/vjuMKROguWbKkChUqpPj4eKv2+Ph4+fj4ZLmOi4uLXFxcrNo8PT3tVWKe5u7uzg/e33BMssZxyRrHJWscl8w4JlnjuGSN45I1jktmHJOscVyyxnGx5uHh8Y9jCsSN1JydnRUUFKT169ebbenp6Vq/fr3V6eYAAAAAANhSgZjplqTBgwcrPDxcjz32mJ544gnNmDFDycnJ6t69e26XBgAAAADIpwpM6H7hhRd0/vx5jR49WnFxcapZs6YiIyPl7e2d26XlWS4uLhozZkym0/ALMo5J1jguWeO4ZI3jkhnHJGscl6xxXLLGccmMY5I1jkvWOC7/XoG4ezkAAAAAALmhQFzTDQAAAABAbiB0AwAAAABgJ4RuAAAAAADshNANAAAAAICdELoBAECetG/fPt24cSO3ywAA4I4I3QCQy9LT03O7hPseD9rIfAwK+jEZP368atasqc2bNystLS23y7lv3fo5KeifGfwzPiOAfRC68a/cLiTwjzWyg8+JNQeHm/8Ujx49Wj/88EMuV3N/slgskqSkpKRcriR3pKenm8fg+vXrkv7vmBRUo0ePVtOmTdWtWzdt3LiR4H0bGZ8TwzBksVj4I5/4Q+ftpKWlmZ+Xffv26fLly7lb0H2G/7vgbhC6kWOGYZghYfbs2erfv7/69Omjc+fOFfj/BGbgF3r2bN26Vdu3b8/tMnLNrZ+Tr776Su+8844KFSqUixXd36ZMmaIRI0bkdhn33K3/5k6bNk3dunVT69atFRsbawbwgiY1NVWSFBkZqYoVKyo8PJzg/Te3/vvy+eefq1WrVrpx44YcHBwK9O+o9PR08+dp27Zt2rFjh2JiYnK5qtz3+++/q3HjxpKklStXKiwsTMeOHcvlqu4vFotFO3bs0LJlyyQRwqX/OwYXLlzI5Uruf4Ru5Mitsy1jxozR6NGjdf78ea1bt05PPPFEgZ+lu3btmqT/m7ncu3evli1bpu+++06nTp0yxxXUf6gz9ttisWj9+vV66qmndPHiRfM/0AVNxufkv//9r86cOaP58+erTp06uVzV/atkyZL6/PPPdejQodwu5Z659d/cSZMm6e2339YDDzygEydOqGnTplq2bJmSk5Nzucp7Kz09XU5OTuZyVFSUKlWqRPC+xa3BcsOGDdqwYYMiIyPVt2/fAh28b/0D1uDBg/Xss8+qXbt2CgsLU48ePXT27NlcrjD3JCcn648//lCFChXUtm1bTZ06VUFBQbld1n3DMAylpaVp5MiRioiIkMTZRhlnz3z77bdq06aNIiMjc7uk+xqhGzmS8cvq3LlzOnHihNauXavPP/9chw8fVpUqVfT8889r69atuVxl7nj33Xc1bNgw/fnnn5Ju/qU4ODhYb7/9ttq0aaNOnTpp5syZkgruP9QZ+3369GkdO3ZM77zzjlq2bClHR8dcriz3HD16VMOHD1f//v31119/SRI3hlLW1y83aNBAjzzyiKKjoyWpQISrjH9zT5w4oePHj2vVqlWaOXOmYmNj1aJFCw0ZMkQrVqwoUME745h8++235mdh3bp1BO9bZByj119/XUOHDpWDg4OCgoL0zTffqFu3bgUyeGcEBEnatWuXVq1apVWrVun777/XF198oW+++Ua9e/cuUD9Lt6pSpYoGDhyoI0eOKCAgQJ06dZLEmXu3KlSokN59913t2LFDK1asyO1ycp3FYtHXX3+t559/Xi1btpSHh0dul3R/M4Ac+s9//mO4u7sbjz32mPHLL79Y9TVv3tzw8/Mztm7dmkvV5Z4PP/zQsFgsxptvvmkcOnTIqF27tjF//nzjypUrxoEDB4y+ffsajz76qDFr1qzcLjVXnThxwrBYLIa7u7sxefLk3C7nnktPT7davnr1qrFy5UqjevXqRlBQkNl+48aNe13afSkpKclquV+/fkZgYKBx9erVXKro3vv0008Ni8ViVKxY0di5c6dVX/fu3Q0/Pz/j008/NRITE3Opwnvvl19+Mby9vY3w8HCrY9K4cWPDz8/PWLduXYH/GVq7dq1RsmRJY/v27YZhGEZaWpoxffp0o2bNmsaLL75opKammu0Fyccff2x06tTJePnll63aDx8+bBQtWtQYPnx4LlWWOzJ+J12/ft3Ytm2b8d577xm1atUyatSoYSQkJBiGYZiflYLm77+v09LSjMuXLxudOnUyXnnlFSM9Pb3A/fzcKj4+3ggKCjImTZpk1f7344abCN3Isfj4eKNx48aGo6OjsW3bNsMwrH9pt2rVyrBYLEZsbGxulZhrMv5zPGjQIKNt27ZGfHy82Xf8+HGjT58+RqNGjYzz58/nYpW5b/78+Yazs7PRvXt348qVK7ldzj3z91/OKSkphmHc/M/Od999ZwQEBBiNGzc2+wt6aPjwww+N5557zli3bp1x/fp1wzAM48KFC0ZQUJAxb948wzDy5y/3rP4T17p1a8NisRiffPKJeSwy9OzZ07BYLMb3339/r0q857L6Pv/vf/8zqlatavTo0cMqeIeEhBj+/v7G6tWrC/R/iD/77DPDz8/P+PPPP822xMREY/To0UaRIkWMl156yfws5cefo6zExcUZHTt2NIoXL248++yzZvu1a9cMwzCMqVOnGjVr1jQuXLhQII5Jxj5GRUUZb731lrF3717DMAxj3759RvXq1Y3q1atb/eEzKirKuHz5cm6UmmtiYmKM5cuXW7VFREQYhQsXNvbt22cYRsH5+fm7I0eOGA8++KA50Zaenl5gj0V2ELpxR7f7D8u5c+eMJ554wqhUqZJx5MgRwzCs/9F54403ClRguHXfIyIiDIvFYhQqVMjYtWuX1bhdu3YZFovF2Lhx4z2u8P7zwQcfGBaLpUDOdk+ePNl49tlnjTp16hjz5s0zfv/9d8MwDOO7774zHnnkEaNp06bm2IIcGqZOnWp07tzZcHZ2Njp16mTMmvX/2rv3gJrS9Q/gzyJJI+WuIk27lChFYXTlIJFSKJkikUEuOXMOGpeZzriGHPeYhME0ucS4jYaccalcEklITEpkdkkkt9T390e/vc7ewjHnqD32fj7/0Fp759nLWu9+n/d91rtWobKyEn5+fvD391d2eLXu4MGD4iwlALi5uaFNmzY4evRojfZ1wYIFatHmymbeZHbv3o2OHTsiODgYFy5cELfb2NjA09OzrsNTmjd1dE+ePAkLCwv88ssvCtvz8/NhaGiIDh06YOzYsSp93ryp/UxLS0NQUBAaNGiA7du3K+xbt24drK2tUVZWVlchKt2ePXugpaWF+fPnK0yWZGZmiol3WloaZs6cCWNjYxQUFCgx2rpTVVWFBw8eYNSoURAEAYGBgdi2bZu4f/jw4fDz86tRjaVO8vLyYGxsjK1bt4rbZNdcYmIiDh48qKzQ/pQ46WZvJf9ldfnyZaSnpys0tkVFRejWrRs6der0xsQbUN+Zuvj4eAiCgIkTJ6KwsFDcXlRUhI4dO9boBKkq2fmQmZmJpKQk7N27V2H/6tWrIQgCIiMjVXp0VP5a+vrrr9GsWTNMmzYNY8eORbNmzTBy5EhxgObQoUOwtLSEra2tssJVincNLpw4cQLTp0+HoaEhPDw8xJndAwcO1GGEdeu/LZ9WtTY3JSUF2dnZAIAVK1Zg8uTJyM3NVXjNzp070bJlSwQGBiok3uo4YLV48WKcOHECQPWsbteuXeHh4YHMzEzxNbdu3cKwYcPw7bffwtbWVqxYUzXy///5+fm4cuWKuC03NxejRo0SE4by8nLcv38fffv2hbu7u0p/H8m7evUqjI2NsWHDhjfuz87ORo8ePdCuXTuYmJjUmEhQB+Xl5Th79iwGDhwIGxsbdO3aFUePHsXcuXPh7u4u9n9Vnfw1IbuOnjx5AldXV/Tu3RtXrlxReH1YWBjc3d3VelDidZx0szeS/7KaO3cuTExMYGJigsaNG2Pz5s0oKSkBABQXF8POzg7W1ta4du2assJVCvkymps3b+LMmTNITk4Wy9RiY2MhCALGjx+PU6dOITc3F+Hh4dDT00N+fr4yQ68TsmOTkJCAtm3bwsrKCnp6eujfvz8uX74snmOrV69Gw4YNERERocxw60ReXh5mzZqFpKQkcVtiYiK6deuGoKAglJeX49mzZ9i1axf8/f3VJmmQ/5z79+/H1q1bxU6g/P2GDx48wLRp0+Dj4wNBEPDFF1/UeP/Hisuna8rNzUWPHj0wePBgFBYWIjY2Fs2bN0d4eLhYHSLzzTffQE9PD8OHD0dWVpa4XdUGId7l8ePH8PT0RL169cREOisrCwYGBujfvz+WL1+OY8eOoW/fvvD390dJSQl0dHQQFRWl5Mg/PPnrae7cubC2toa+vj66du2KZcuWoby8HFevXhVnMY2MjBAUFARnZ2dxvQhVvbbk+y4///wzOnTooDCQ9aa2KDU1Fffv36+rEJVG9tmvX7+OxMREnD9/XpxsKikpwZUrV+Dt7Y1evXqhR48e4jo+qk7+NoSwsDD069cP0dHRuH//PvLz86Gvr4/+/ftjzZo1OHDgACZNmgRdXV2FwT7GSTf7DyIiIqCvry/OzAYEBKBJkyaIjIzEw4cPAVQn3kZGRggICFBipHVP1gjt2bMHFhYWMDU1Rc+ePWFtbS3eyy27x1sQBAwfPhxOTk7iPVPq4OjRo2jatCliYmIAAOnp6RAEAX369MGFCxfEYxgZGYlmzZrhwYMHygy3Vv30008QBAGtWrVSSLqB6o6PpqameNuB/KI1qtrxk5H/fDNnzoSBgQF69eqFli1bws3NDenp6TWOwdOnT7Fy5UpoaWmp3GAfl08r2rhxI3r37g0/Pz+UlZUhPj4ebdq0wcyZMxUShRUrVsDFxQWjR49W+WtGRvY55ZOk/Px8jBo1CpqamuKM97Vr1zBs2DBYWFhAIpHAxcVFXEvjs88+w48//lj3wdeRhQsXonXr1jh06BBevXqFv/zlL2jfvj0yMjIAVA9KBAcHw9TUVGHwQTZ4rkqePn2K58+fIy8vT/z/3717N1q3bi3epy3/3ZOSkoKzZ88qJVZlkF1Hu3fvhqGhIYyNjdG+fXuYm5vXWBw4MTERixcvRuvWrcVzSdUlJCRAR0cHEyZMwNy5c2FoaIj+/fvjxYsXyMnJgZeXF8zNzSGRSODo6KiW6zr9J5x0MwXypXyZmZno27evWMK5b98+NG3aVFzQJzIyUlygpbS0VOVnFGQdnPLycnHbiRMn0LhxY2zYsAEvXrzAgQMHIAgCoqKiFGZ6BUHAP/7xD5VfgCQ3Nxc//fQTgOpFwsLCwvD1118DAH777TeYmJggKCgIJiYm6NmzJ9LS0sTjKqueUBWyzyX78+7duwgNDYUgCNiyZQsAxQ5Op06dsHTp0roP9E9i+fLlMDAwEMsX4+LiIAgCnJyckJ6eLl5P8gmGk5PTR78mAJdPv5n8//PmzZvh4OAAPz8/PH78GHFxcdDX18eMGTNw9uxZvHz5Ej4+Pti1a5f4PlU+Nq+TDVbKPvudO3cQEBAATU1NnDx5EgBQVlaGBw8eIC8vT3xfeHg4DAwMapxvHzP5ZLm0tBSurq74/vvvAVSv5q6joyNW0cj6LBkZGQgJCUHHjh1r3AKlKq5evQofHx907twZGhoasLGxQUREBH7//Xe0aNECYWFhNd4TFhaGRYsW1Vi4URXJvovPnj0LHR0dREdHo6CgAL/++isCAgKgpaWlsL6GjLosBJufnw9ra2usX78eQHVbo6OjgxkzZojX0cuXL/H48WMUFBSo1ZM0/ghOuplIVsrn6emJW7du4fnz54iJicGLFy9w8uRJGBgYYPXq1QAAX19f6OnpYd68eQoXl6om3rIOXFpaGiQSidhJWbJkCUJDQwFUN0pGRkbizwDEL6vt27fj6tWrdRt0Hbt79y5atGiBjh07YseOHQCqOzlZWVl4+PAh7O3tMW7cOADA8ePHIQgCunXrppKjoXFxcRgzZgyys7MV7mcqLCzEqFGj0KhRI4XZ7kePHsHExATR0dHKCFcpEhMTERcXB6C6czxhwgRxUaM9e/ZAT08Py5cvh0QigZOTE9LS0mqUPdrb24uDOh8jLp9+t3cl3rt27YKVlRXatGmDDh06oFOnTmLHWV3uxwWq1w/R1tYWKz5knz0vLw9eXl7Q1tZWGKgBgIsXL2Lw4MEwMDBAenp6ncdcWxITExEZGSnOzpaWlsLW1hZSqRS//PILGjduLCYNT58+RXR0tDjgdenSJYwfPx6tW7fGvn37lPYZasPly5ehq6uL0NBQxMTEICEhAV5eXqhfvz6GDh2KHTt2oHnz5ggNDcWdO3eQlZUl3gqnapVEr7t9+7Z4zbx69QoxMTHo3bu3wqBdYWEhRo4cCVtb2xpPnlGXtiY/Px+2trZ48uQJbty4AUNDQ4SEhIj7U1NTa1RpsZo46WYKNm7ciD59+sDX1xd37twRt4eEhGDMmDFiEjl58mTY2trCwcFB5RsdWeN76dIl6OjoKIwIh4SEYOzYsbh79y7atm2L8ePHi8dj165dWLZsmUp3iuX961//Qr169WBvbw9PT08xoQKqZ/vt7OzEBUcOHz4MT09P2Nra4tatW8oKuVY8evQIEokELVu2hJWVFcaOHYvNmzeL+8vLy+Hv7w8tLS1MmzYNS5YsgYeHBzp37qw2z0I9ffo0BEGAnZ2dOECTlJSE+/fv4+LFi5BIJFi5ciUA4Pvvv4cgCLC0tBQ7yED1jETDhg0/+tI+Lp9+t7cl3iUlJbhx4wZ++OEHREdHi9eOqre3r1fQnDlzBm5ubvj0009x/fp1hX07d+4Ub2+SPdpIZu3ateLrVUFsbCwMDQ0xceJEhfUPevXqBScnJzRp0kS8zQmoHpRwcXFRKK1PS0vDlClTcPPmzTqNvTZJpVLY2trWePa4VCrFmjVroKOjAw8PD+zfvx9t2rSBgYEBJBIJzM3NVWpA5k2eP3+Onj17wtjYWGxnoqKi0LRpU/H2Sdn2gwcPol27dio/CAFU91GKiopw/PhxFBQUoLS0FAUFBTA0NMTx48chkUgQEhIitjMZGRkYMWKEyp8vHwIn3QxAzY6Nk5MTfH19xU6us7Ozwgyut7c3Ll269MaST1Ui36hoa2vXWDBj/fr1GDZsGPT19cVZ3KqqKrx8+RITJ05EWFiY2pQfAUBwcDBsbGwwdOhQ9O7dWyzrW79+PQwNDcUFSb766ivMmzdPJTvIr169Qnh4OKKjo3HhwgUsXboUenp68Pf3F0v1ioqKMH36dAiCgGHDhiE+Pl4si1SHxHvfvn0QBAHOzs4YPHiwQsd31apV6NOnD6RSKYDqdRFCQ0MxYsQIhfPl4cOHCk8G+Nhw+fT7kz9WsbGxcHR0hJ+fH3777TeF/arYnsiTr6CRf6TVxYsX4e7uXiMpOHXqFMaPH4+oqCiVblfi4uKgra2N+Ph4cbZNdk4cOnQIFhYWcHJyEl//5MkTDBw4EK6urjXOGVW7lzs9PR2dO3dGZmam+FllbcfDhw8xf/586Ojo4MiRIygqKsLRo0eRkpLyUbet76uqqgqnTp1C586dYWNjg6qqKty6dQuWlpaIiooSE2+gehV3ExMTlb/HPTs7G6NGjYKFhQW0tLSgq6uLkSNHIjMzEzNmzBD7LPLCw8Nhb2+Pe/fuKSnqjwcn3Uz0eifQxcUFvr6+KC4uxpo1a1CvXj34+/vD1tYWlpaWalPKl5+fjxYtWsDX11dh+4YNG+Dv7w8rKyu0bNlSvN+nrKwMX331FfT19VVqJuFdZB2VQ4cOISgoCImJifDx8YGzszP27t2Lhw8fwtDQEBKJBA4ODtDV1VXpBeUOHz4MHR0dcRb22bNnmDt3rlhSv2TJEhw+fBjTp09H48aNkZycDED1OnzvEhgYCBcXF/j4+CjcdxkeHo4OHTqgsLAQjx49goeHB9asWSO+T5USKy6ffn+vJ97Ozs4ICAhQqMhSZW+qoImNjRX3Z2dni89xP3bsGLKysuDt7Y2JEyeKr1HFxFsqlcLV1VWhjQCqv4fT09Nx6NAhLFq0CJaWlrCzs4O3tzccHR1hbW0tVu6pUpvyus2bN0NLS0v8+fW249atW9DV1cWiRYvqOrQ/hcrKSqSmpsLc3Bz29vYAgNmzZ8PKygqRkZG4f/8+ysrKMHPmTJiamoqL5KqijIwM6OvrY8KECdiyZQuuXbuGmTNnQiKRwMLCAkuXLsWoUaNgamqKo0ePYvfu3Zg+fTp0dHRU8jbB2sBJN1PweidQNqNQWFiIDRs2wNfXF1988YVafFnJ5ObmiiXTssewLFy4ENra2rhy5QoKCgpgbGyMrl27okOHDnB3d4e+vr7Kl9rk5+cjISFBYZtUKoWFhQXWrFkDqVQKHx8fODg44MCBA/j999/xt7/9DeHh4Sp/fzsATJo0CZMmTRJ/trS0xJAhQ/Dll19iwIABEAQBixcvRkBAAPT09MSVy1WdbGBh+/btCAkJwZkzZ+Dj4wMnJyfxPNHX14e+vj5MTExgZWWl0gv5cPn0+5M/Vps2bUKPHj2wadOmGvtU0dsqaEaMGIHIyEhUVFQgKysL48ePhyAIkEgk6NKli3jtqOrxkUqlsLS0VFgAbd26dRg2bBgEQYCZmRmsra2RmpqKKVOmYNq0aVi2bJl4PaniQIS8U6dOQUtLC7t3737ra2xtbcXb5lT1PJEpLCxEamqqwraXL1/i7Nmz+PTTT+Hs7Ayg+jFznTt3hpaWFnr27ImWLVuqdJ9OVs0ZHh5e45qIi4tD9+7d0aNHD3z33XcYM2YMdHV1YWVlhb59+370t3jVJU66WQ1vK+WTPaNRVpqk6l9W8m7cuIEBAwbA09MTISEhaNWqFRITE8X9hYWFiIuLQ3h4OHbs2CGWPaqq/Px8NG/eHIIgYODAgYiPjxdvRdi/fz+cnJwglUrFFVNdXV2xa9cuJUddt2JiYuDg4ICSkhJx/QNZ6eOdO3cQHx+PiooKPHnyBF5eXjA0NFTZWxGOHz+ucD8lANy7dw+GhoaIjY1FYWEhfHx84OjoiIMHD6KkpASrVq3CunXr1KJzzOXT70/+WA0aNAheXl7KC6aOvauCxt7eHkuWLMH169eRkZGB1NRU8XxR5WtHKpWibdu2GDduHJKSkjB06FBYWVlh4sSJSExMxM6dO2FqaooVK1bUeK86XE937txBq1at4OnpqbA4o/xTQ3r16oVt27YpK8Q6I99vcXV1RXh4OJKSksTv5XPnzsHKygoODg4Aqvt1mzZtQkJCQo2FLVWJrJpz+PDh4raqqiqFdiM6OhrNmzfHxo0bAQA5OTl48uQJr1L+B3HSzd7o9U6gk5MTAgMDxVI+VR8NfZPs7Gz069cPjRo1wrJly8TtqtyheZvbt2/Dzs4On332Gbp27Ypx48ahffv22LBhA+Lj4+Hh4YHDhw8DqH4Oat++feHh4aF2q1va29tDEAS4uLi89RnkFRUVKC4uxt27d+s4urohW6leEAS4ublh/fr1yMzMBFA9gj548GCUlZXhypUrGDp0KFxcXMTF1WTUoXOs7uXTf4TsWE2aNAkjRozAixcvlBxR3XlXBU2/fv0gCAK2bt0q7leHa+fYsWPQ1dWFiYkJunTpgqSkJPFxpiUlJbCxscGcOXOUHKXy7NmzB5qamggMDMSVK1cU9s2ZMwfGxsYqnVTK3L59GzY2NjA3N4ednR1Gjx4NLS0t2NjYIDAwEPHx8di5cyckEgn69eunNv1c+WrO159HLn8MHB0d4e3tDUA92pXawEk3eyt1LuV7m5s3b6J///5wd3dXaJzU8XjcuHEDPj4+GDJkCBISErB37164urpiyJAhEAQBPXr0EDvD169fV6vkQXY+bNu2DZ07dxafPa2O50lOTg6cnZ3Rp08fuLq6YsqUKWjevDn++c9/IioqCn369BGvpaysLLi6uios2qhOuM19f0VFRXBwcBAHcNTFuypoCgoKEBcXp5YDwVKp9I0VZiUlJXB2dhafza2OXr16hejoaGhoaMDc3BzBwcGYPXs2Ro4ciaZNm6p02fTrcnJy4O3tDS8vL5w5cwZ5eXmIi4uDg4MDunfvDm1tbVhZWUEQBAwZMgSAerS9smpONze3t/ZtXV1d8fnnnysjPJUhAAAx9hYASBAEIiLy8PAgDQ0N2rdvn3KDUrKcnByaOnUqAaC5c+eSg4ODskNSmuzsbJo+fTpVVlbS6tWrydDQkDIzM2nBggXk5+dHAQEBCueQurl79y7Z29vT1KlTadasWcoOR2lu3LhB4eHhVFFRQVOnTqXKykrauHEjPXv2jI4cOUJeXl60e/duql+/Pt2+fZuMjIyoXr16yg5bKbjNfX/Pnz8nLS0tZYdR57p3705paWnk7OxMCQkJ1KxZsxqvefXqFWloaCghuj+PoqIiGjNmDBUXF1NycjLVr19f2SEp1dmzZykyMpKys7NJT0+PunTpQlOmTCELCwtlh1ansrOzadq0aVRVVUULFiwge3t7IiIqLS2lAwcO0PXr1+nnn3+mTZs2ka2trZKjrTtv69tWVVXRvXv3aPz48eTn50ejR49W637d/4KTbvYfyS6u0NBQKikpoa1bt5Kmpqayw1KqnJwc+utf/0rFxcW0YsUK6tmzp7JDUpqcnByaPHkyERHNmzdPrQch3mT16tUUERFBJ0+eJEtLS2WHozTZ2dkUFhZGVVVVtHLlSjIzM6Ps7GyKioqiKVOmUJcuXRS+yKuqqtQ+8eY2l8mTnRfbt2+nJUuW0JYtW6hbt27cAX5NcXExxcTE0OnTp0kqlVJycjI1aNCAKisr1T7xrqyspHr16pEgCGrdxubk5NCUKVOIiCg8PJxcXFwU9qvroJV84j1nzhxydHQkIqJZs2bRkSNH6ODBg9S2bVslR/nxUs+rjf0hgiBQcXExZWRk0OzZs7nzR0RmZma0dOlSatu2LRkYGCg7HKUyMzOjNWvWUL169ejbb7+l06dPKzukP5WBAwfSoEGD1G424XXm5ua0atUqIiKaNm0apaSkkKWlJcXExFCXLl2oqqpKIXFQ184gEbe57M1k10fv3r3pwYMHdPToUYXtrFpBQQElJyeTqakppaSkUIMGDejVq1dqn3ATkZhwE6n3eWNmZkarV68mQRBo0aJFlJKSorBfHRNuourjsmrVKhIEgebPn08XL16kyMhIWrt2LW3dupUT7v8Rz3Sz96aupXzv8vLlS+4Q/z+e/X872UwUz7T8eySdiGj27NniSDqridtc9jZcQfNupaWlpKury+0ueyfut7yZ7LicO3eOHj58SKmpqdStWzdlh/XRU9+pBPaHceevJk64/41n/99ONqPAHb9/j6TXr1+fpk+fTpcvX1Z2SH9a3Oayt+EKmnfT09MjQRAIALe77K243/JmZmZmtGzZMurZsyddvHiRE+4PhGe6GWMfFM/+s/dx7do1iomJoaVLl6p1KTlj/y2uoGHsw+B+y5tVVFRQgwYNlB2GyuCkmzHGmFKp84I+jDHGGFN9nHQzxhhjjDHGGGO1hKcWGGOMMcYYY4yxWsJJN2OMMcYYY4wxVks46WaMMcYYY4wxxmoJJ92MMcYYY4wxxlgt4aSbMcYYY4wxxhirJZx0M8YYY4wxxhhjtYSTbsYYY4zVCUEQaN++fcoOgzHGGKtTnHQzxhhjKi4oKIgEQaAJEybU2BcaGkqCIFBQUNAH+/e++eYbsrGx+WC/jzHGGPuYcdLNGGOMqYF27drRjz/+SM+ePRO3PX/+nH744QcyMjJSYmSMMcaYauOkmzHGGFMDXbt2pXbt2lFCQoK4LSEhgYyMjMjW1lbc9uLFC5o6dSq1atWKtLS0yNHRkc6fPy/u//XXX0kQBEpKSiI7OzvS1tamXr16UXZ2NhERbdmyhSIiIigjI4MEQSBBEGjLli3i+4uLi8nb25u0tbXJzMyM9u/fX/sfnjHGGFMiTroZY4wxNREcHEybN28Wf46NjaUxY8YovGbGjBm0Z88e2rp1K6Wnp5OpqSm5ublRSUmJwutmz55Ny5cvp7S0NNLQ0KDg4GAiIvLz86Mvv/ySOnXqRIWFhVRYWEh+fn7i+yIiIsjX15cuX75MAwcOpM8//7zG72aMMcZUCSfdjDHGmJoICAig06dPU15eHuXl5VFycjIFBASI+8vLy2n9+vW0dOlScnd3J0tLS/ruu++oUaNGtGnTJoXftWDBAnJxcSFLS0uaNWsWpaSk0PPnz6lRo0bUuHFj0tDQoDZt2lCbNm2oUaNG4vuCgoLI39+fTE1NaeHChfTkyRM6d+5cnR0DxhhjrK5pKDsAxhhjjNWNli1b0qBBg2jLli0EgAYNGkQtWrQQ99+6dYsqKirIwcFB3NagQQPq3r07Xbt2TeF3WVtbi3/X19cnIiKpVPof7w+Xf98nn3xCTZo0IalU+j99LsYYY+zPjJNuxhhjTI0EBwfT5MmTiYho7dq1//XvadCggfh3QRCIiKiqquoPvU/23vd5H2OMMfax4vJyxhhjTI0MGDCAXr58SRUVFeTm5qawTyKRkKamJiUnJ4vbKioq6Pz582Rpafne/4ampiZVVlZ+sJgZY4yxjxnPdDPGGGNqpH79+mKpeP369RX2ffLJJzRx4kT6+9//Ts2aNSMjIyOKjIykp0+f0tixY9/73zA2Nqbc3Fy6dOkStW3blnR0dKhhw4Yf9HMwxhhjHwtOuhljjDE106RJk7fuW7x4MVVVVVFgYCCVlZWRnZ0dJSYmUtOmTd/79w8dOpQSEhKod+/eVFpaSps3b6agoKAPEDljjDH28REAQNlBMMYYY4wxxhhjqojv6WaMMcYYY4wxxmoJJ92MMcYYY4wxxlgt4aSbMcYYY4wxxhirJZx0M8YYY4wxxhhjtYSTbsYYY4wxxhhjrJZw0s0YY4wxxhhjjNUSTroZY4wxxhhjjLFawkk3Y4wxxhhjjDFWSzjpZowxxhhjjDHGagkn3YwxxhhjjDHGWC3hpJsxxhhjjDHGGKslnHQzxhhjjDHGGGO15P8Aq8mIrOZ5dBgAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Extract months and counts from the result\n",
    "months, counts = zip(*result)\n",
    "\n",
    "# Define all months\n",
    "all_months = ['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec']\n",
    "\n",
    "# Create a dictionary to hold counts for each month\n",
    "counts_dict = dict(zip(months, counts))\n",
    "\n",
    "# Fill in counts for missing months\n",
    "complete_counts = [counts_dict.get(month, 0) for month in all_months]\n",
    "\n",
    "# Define custom colors for each bar\n",
    "custom_colors = ['skyblue', 'salmon', 'lightgreen', 'orange', 'lightblue', 'pink', 'yellow', 'lightcoral', 'lightgray', 'lavender', 'lightseagreen', 'gold']\n",
    "\n",
    "# Create a bar plot with custom colors\n",
    "plt.figure(figsize=(10, 6))\n",
    "bars = plt.bar(all_months, complete_counts, color=custom_colors)\n",
    "\n",
    "# Add labels and title\n",
    "plt.xlabel('Month')\n",
    "plt.ylabel('Number of Completed Studies')\n",
    "plt.title('Completed Studies per Month')\n",
    "\n",
    "# Rotate x-axis labels for better readability\n",
    "plt.xticks(rotation=45)\n",
    "\n",
    "# Add value labels on top of each bar\n",
    "for bar, count in zip(bars, complete_counts):\n",
    "    plt.text(bar.get_x() + bar.get_width() / 2, bar.get_height(), count, ha='center', va='bottom')\n",
    "\n",
    "# Display the plot\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "ee9d528e-5c72-46f0-a614-9602834bbb54",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#Further Analysis\n",
    "#Plot the number of Terminated studies in 2023"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "e56c6142-4759-4d27-bd32-8b70f03138f3",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('01', 150),\n",
       " ('02', 146),\n",
       " ('03', 164),\n",
       " ('04', 118),\n",
       " ('05', 142),\n",
       " ('06', 127),\n",
       " ('07', 115),\n",
       " ('08', 114),\n",
       " ('09', 103),\n",
       " ('10', 99),\n",
       " ('11', 99),\n",
       " ('12', 83)]"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "year = '2023'\n",
    "Terminated_Studies = clinicaltrial_2023rdd2 \\\n",
    "    .map(lambda col: (col[3], col[-1])) \\\n",
    "    .filter(lambda x: x[0] == 'TERMINATED') \\\n",
    "    .map(lambda x: x[1]) \\\n",
    "    .filter(lambda x: x.split('-')[0] == year) \\\n",
    "    .map(lambda x: (x.split('-')[1], 1)) \\\n",
    "    .reduceByKey(lambda x, y: x + y) \\\n",
    "    .sortByKey()\n",
    "Terminated_Studies.collect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "9cc14710-ab07-4e26-9223-02f0252d31aa",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Changed months after applying changer function:\n['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec']\n"
     ]
    }
   ],
   "source": [
    "def changer(month):\n",
    "    month_dict = {'01': 'Jan', '02': 'Feb', '03': 'Mar', '04': 'Apr', '05': 'May', '06': 'Jun', '07': 'Jul', '08': 'Aug', '09': 'Sep', '10': 'Oct', '11': 'Nov', '12': 'Dec'}\n",
    "    return month_dict.get(month, None)\n",
    "\n",
    "changed_months = Terminated_Studies.map(lambda x: changer(x[0])).collect()\n",
    "\n",
    "print(\"Changed months after applying changer function:\")\n",
    "print(changed_months)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "dbdd09f3-c99c-4063-82a4-60ea2f0caca9",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Terminated_Studies_final:\n[('Apr', 118), ('Aug', 114), ('Dec', 83), ('Feb', 146), ('Jan', 150), ('Jul', 115), ('Jun', 127), ('Mar', 164), ('May', 142), ('Nov', 99), ('Oct', 99), ('Sep', 103)]\n"
     ]
    }
   ],
   "source": [
    "# Apply changer function and filter out None values\n",
    "Terminated_Studies_final = Terminated_Studies.map(lambda x: (changer(x[0]), x[1])) \\\n",
    "    .filter(lambda x: x[0] is not None) \\\n",
    "    .sortBy(lambda x: x[0], ascending=True) \\\n",
    "    .map(lambda x: (x[0], x[1]))\n",
    "\n",
    "# Collect the sorted months along with the counts into a list\n",
    "results = Terminated_Studies_final.collect()\n",
    "\n",
    "# Print the final result\n",
    "print(\"Terminated_Studies_final:\")\n",
    "print(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "cf2471d6-ad98-4d80-8f92-9fe8f431ef9f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Extract months and counts from the result\n",
    "months, counts = zip(*results)\n",
    "\n",
    "# Define all months\n",
    "all_months = ['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec']\n",
    "\n",
    "# Create a dictionary to hold counts for each month\n",
    "counts_dict = dict(zip(months, counts))\n",
    "\n",
    "# Fill in counts for missing months\n",
    "complete_counts = [counts_dict.get(month, 0) for month in all_months]\n",
    "\n",
    "# Define custom colors for each bar\n",
    "custom_colors = ['skyblue', 'salmon', 'lightgreen', 'orange', 'lightblue', 'pink', 'yellow', 'lightcoral', 'lightgray', 'lavender', 'lightseagreen', 'gold']\n",
    "\n",
    "# Create a bar plot with custom colors\n",
    "plt.figure(figsize=(6, 4))\n",
    "bars = plt.bar(all_months, complete_counts, color=custom_colors)\n",
    "\n",
    "# Add labels and title\n",
    "plt.xlabel('Month')\n",
    "plt.ylabel('Number of Terminated Studies')\n",
    "plt.title('Terminated Studies per Month')\n",
    "\n",
    "# Rotate x-axis labels for better readability\n",
    "plt.xticks(rotation=45)\n",
    "\n",
    "# Add value labels on top of each bar\n",
    "for bar, count in zip(bars, complete_counts):\n",
    "    plt.text(bar.get_x() + bar.get_width() / 2, bar.get_height(), count, ha='center', va='bottom')\n",
    "\n",
    "# Display the plot\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  }
 ],
 "metadata": {
  "application/vnd.databricks.v1+notebook": {
   "dashboards": [],
   "language": "python",
   "notebookMetadata": {
    "mostRecentlyExecutedCommandWithImplicitDF": {
     "commandId": 1524222412942187,
     "dataframes": [
      "_sqldf"
     ]
    },
    "pythonIndentUnit": 4
   },
   "notebookName": "Clinical_trial_2023_RDD",
   "widgets": {}
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
